



















Sodium Picosulfate Hydrate**Sodium Risedronate Hydrate****Spiramycin Acetate**




Spironolactone**Sulindac****Sulpiride**




Sultiamine**Tacalcitol Hydrate****Tamoxifen Citrate**




Tamsulosin Hydrochloride**Tegafur****Telmisartan**




Temocapril Hydrochloride**Terbinafine Hydrochloride****Terbutaline Sulfate**




Testosterone Propionate**Tetracaine Hydrochloride****Tetracycline Hydrochloride**




Theophylline**Thiamine Chloride Hydrochloride****Thiamylal Sodium**




Tiapride Hydrochloride**Timepidium Bromide Hydrate****Timolol Maleate**




Tinidazole**Tipepidine Hibenzate****Tizanidine Hydrochloride**




Tocopherol Nicotinate**Todralazine Hydrochloride Hydrate****Tofisopam**




Tolazamide**Tolnaftate****Tosufloxacin Tosilate Hydrate**




Tranilast**Trapidil****Trepibutone**




Triamcinolone Acetonide**Triamterene****Trichlormethiazide**




Trimebutine Maleate**Trimetazidine Hydrochloride****Trimetoquinol Hydrochloride Hydrate**



Troxipide**Tulobuterol****Tulobuterol Hydrochloride**

L-Tyrosine**Ubenimex****Ulinastatin**

Urapidil**Valaciclovir Hydrochloride****Valsartan**

Vancomycin Hydrochloride**Verapamil Hydrochloride****Vinblastine Sulfate**

Vincristine Sulfate**Voriconazole****Warfarin Potassium**

Zaltoprofen**Zolpidem Tartrate**

General Information

GENERAL INFORMATION

G1 Physics and Chemistry

Near Infrared Spectrometry

Near infrared spectrometry (NIR) is one of spectroscopic methods used to qualitatively and quantitatively evaluate substances from analysis of data obtained by determining their absorption spectrum of light in the near-infrared range.

The near-infrared range lies between the visible light and infrared light, typically of wavelengths (wave numbers) between 750 and 2500 nm ($13,333 - 4000 \text{ cm}^{-1}$). The absorption of near-infrared light occurs due to harmonic overtones from normal vibration or combination tones in the infrared range (4000 to 400 cm^{-1}), primarily absorption of O-H, N-H, C-H and S-H that involve hydrogen atoms, in particular. For instance the asymmetrical stretching vibration of N-H occurs in the vicinity of 3400 cm^{-1} , but the absorption due to the first harmonic overtone occurs in the vicinity of 6600 cm^{-1} (wavelength 1515 nm), which is near double 3400 cm^{-1} .

Absorption in the near-infrared range is far weaker than absorption due to normal vibration that occurs in the infrared range. Furthermore, in comparison with visible light, near-infrared light has longer wavelength, which makes it possible for the light to penetrate to a depth of several mm into solid specimens including fine particles. This method is often utilized as a nondestructive analysis, as changes occurring with absorbed light spectrum (transmitted light or reflected light) in this process provide physical and chemical information pertaining to specimens.

Conventional spectrometry, such as calibration curve method, is used as a method for analyzing near-infrared absorption spectrum whenever applicable. Ordinarily, however, chemometrics methods are used for analysis. Chemometrics ordinarily involve quantification of chemical data, as well as numerical and statistical procedures for computerization of information. Chemometrics for near-infrared spectrometry includes various types of multivariate analysis such as multiple regression analysis, to perform qualitative or quantitative evaluation of active substances.

Near-infrared spectrometry is used as a rapid and nondestructive method of analysis that replaces conventional and established analysis methods for water determinations or substance verifications. It is necessary to perform a comparison test to evaluate this method against an existing analysis method, to verify that this method is equivalent to such existing analysis method, before using this analysis method as a quality evaluation test method in routine tests.

Applications of near-infrared spectrometry in the pharmaceutical field include qualitative or quantitative evaluation of ingredients, additives or water contents of active substances or preparations. Furthermore, near-infrared spectrometry can also be used for evaluation of physical conditions of substances, such as crystal forms, crystallinity, particle diameters. It is also possible to perform spectrometry on samples that are located in a remote location away from equipment main units, without sampling, by using optical fibers. It can therefore be used as an effective means

to perform pharmaceutical manufacturing process control online (or in-line).

1. Equipment

Near-infrared spectrophotometers can either be a distributed near-infrared spectrophotometer or a Fourier transform near-infrared spectrophotometer¹⁾. Interference filter-type near-infrared spectrophotometers that use interference filter in the spectrometry section are also available, however, this type of equipment is hardly used in the field of pharmaceutical quality control.

1.1. Distributed near-infrared spectrophotometer

This equipment is comprised of light source section, sample section, spectrometry section, photometry section, signal processing section, data processing section, display-record-output section. Halogen lamps, tungsten lamps, light emitting diodes and other such devices that can emit high intensity near-infrared light in a stable manner are used in the light source section. The sample section is comprised of a sample cell and a sample holder. Equipment that have an optical fiber section that is comprised of optical fibers and a collimator are equipped with a function for transmitting light to sample section, which is remotely located away from the spectrophotometer main unit. Quartz is ordinarily used as material for optical fibers.

The spectrometry section is intended to extract light of required wavelength, using dispersive devices and is comprised of slits, mirrors and dispersive devices. Potential dispersive devices include prisms, diffraction grating, acousto-optical tunable filters (AOTF), or liquid crystal tunable filters (LCTF). The photometry section is comprised of detectors and amplifiers. Sensors include semiconductor detectors (silicon, lead sulfide, indium-gallium-arsenic, indium-antimony), as well as photomultiplier tubes. Detecting methods that use semiconductor detectors generally perform detections with single elements, but there are also occasions where arraytype detectors that use multiple elements are used. Such detectors are capable of simultaneously detecting multiple wavelengths (wave numbers). The signal processing section separates signals required for measurements from output signals fed by amplifiers and then outputs such isolated signals. The data processing section performs data conversions and spectral analysis, etc. The display-record-output section outputs data, analysis results and data processing results to a printer.

1.2. Fourier transform near-infrared spectrophotometer

The configuration of the equipment is fundamentally same as that of the distributed-type equipment described in Section 1.1., except for the spectrometry section and the signal processing section.

The spectrometry section is comprised of interferometers, sampling signal generators, detectors, amplifiers, A/D conversion devices, etc. Interferometers include Michelson interferometers, transect interferometers and polarization interferometers. The signal processing section is equipped with functions that are required for spectrometer, as well as a function for translating acquired interference waveform (interferogram) into absorption spectrum by Fourier transformation.

2. Determination

There are three types of measurement methods that are

used with near-infrared spectrometry: transmittance method, diffuse reflectance method and transmittance reflectance method. The section of measurement methods relies on the shape of samples and applications. The transmittance method or diffuse reflectance method is used for solid samples, including fine particles. The transmittance method or transmittance reflectance method is used for liquid samples.

2.1. Transmittance method

The degree of decay for incident light intensity as the light from a light source passes through a sample, is represented as transmittance rate T (%) or absorbance A with the transmittance method. A sample is placed in the light path between a light source and a detector, the arrangement of which is ordinarily same as that of the spectroscopic method.

$$T = 100t$$

$$t = I/I_0 = 10^{-\alpha c l}$$

I_0 : Incident light intensity

I : Transmitted light intensity

α : Absorptivity

c : Solution concentration

l : Layer length (sample thickness)

$$A = -\log t = \log (1/t) = \log (I_0/I) = \alpha c l$$

This method is applied for taking measurements of samples that are liquids and solutions. Quartz glass cells and flow cells are used, with the layer length of 1 – 5 mm along. Furthermore, this method can also be applied for taking measurements of samples that are solids, including fine particles. It is also known as diffuse transmittance method. Selecting appropriate layer length is critical for this method, since the transmitted light intensity varies depending on grain sizes and surface condition of samples.

2.2. Diffuse reflectance method

The ratio of the reflection light intensity I , emitted from the sample in a wide reflectance range and a control reflection light intensity I_r emitted from surface of a substance, is expressed as reflectance R (%) with the diffuse reflectance method. The near-infrared light penetrates to a depth of several mm into solid samples, including fine particles. In that process, transmission, refraction, reflection and dispersion are repeated, and diffusion takes place, but a portion of the diffused light is emitted again from the surface of the sample and captured by a detector. The spectrum for the diffuse reflectance absorbance (A_r) can ordinarily be obtained by plotting logarithm of inverse numbers for reflectance ($1/r$) against wavelengths (wave numbers).

$$R = 100r$$

$$r = I/I_r$$

I : Reflection light intensity of light, diffuse reflected off the sample

I_r : Control reflection light intensity of light emitted from surface of reference substance

$$A_r = \log (1/r) = \log (I_r/I)$$

The intensity of diffuse reflectance spectrum can also be expressed with the Kubelka-Munk (K-M) function. The K-M function is derived, based on the existence of a sample with sufficient thickness, and expressed in terms of light scattering coefficient, which is determined by absorptivity, grain size, shape and fill condition (compression).

This method is applied to solid samples, including fine particles, and requires a diffuse reflector.

2.3. Transmittance reflectance method

The transmittance reflectance method is a combination of

the transmittance method and reflectance method. A mirror is used to re-reflect a light that has passed through a sample in order to take a measurement of transmittance reflectance rate, T^* (%). Light path must be twice the thickness of the sample. On the other hand, the light reflected by a mirror and being introduced into a detector is used as the control light. When this method is applied to suspended samples, however, a metal plate or a ceramic reflector with rough surface that causes diffuse reflectance is used instead of a mirror.

Transmittance reflectance absorbance (A^*) is obtained by the following formula with this method:

$$T^* = 100t^*$$

$$t^* = I/I_T$$

I : Intensity of transmitted and reflected light, in cases where a sample is placed

I_T : Intensity of reflected light, in cases where is no sample

$$A^* = \log (1/t^*)$$

This is a method that is applied to solid samples, including fine particles, as well as liquids and suspended samples. The thickness of a sample must be adjusted when applying this method to a solid sample. Ordinarily adjustment is made by setting absorbance to 0.1 – 2 (transmittance of 79 – 1%), which provides the best linearity and SN ratio of detector. A cell with appropriate layer length, according to the grain size of the fine particle, must be selected when applying the method to a fine particle sample.

3. Factors that affect spectrum

Following items must be considered as factors that can affect spectrum when applying near-infrared spectrometry, particularly when conducting quantitative analysis.

(i) Sample temperature: A significant change (wavelength shift, for example) can occur when the temperature varies by a several degree (°C). Care must be taken, particularly when the sample is a solution or contains water.

(ii) Water or residual solvent: Water or residual solvent contents of a sample, as well as water (humidity) in the environment wherein measurements are taken, can significantly affect absorption band of the near-infrared range.

(iii) Sample thickness: The thickness of a sample is a factor for spectral changes and therefore needs to be controlled at a certain thickness. A sample may be considered to be of adequate thickness for the diffuse reflectance method, however, if the thickness is less than a certain amount, for example, the sample may have to be placed on a support plate with high reflectance to take measurements by the transmittance reflectance method.

(iv) Fill condition of sample: The condition of sample fill can potentially affect spectrum, when taking measurements of samples that are solids or fine particles. Care must be taken with filling samples in a cell, to ensure that a certain amount is filled through a specific procedure.

(v) Optical characteristics of samples: When a sample is physically, chemically or optically uneven, relatively large beam size must be used, multiple samples must be used, measurements must be taken at multiple points on the same samples, or a sample must be pulverized to ensure averaging of sample. Grain size, fill condition, as well as roughness of surface can also affect fine particle samples.

(vi) Crystal forms: Variations in crystal structures (crystal forms) can also affect spectrum. In cases where multiple crystal forms exist, it is necessary to have consideration for characteristics of samples to be considered and care must be taken to ensure that even standard samples for calibration

curve method have diversified distributions similar to that of samples that are subject to analysis.

(vii) Temporal changes in characteristics of samples: Samples can potentially undergo chemical, physical or optical property changes, due to passing of time or storage after sampling, and such changes affect spectrum in a subtle manner. For instance even with identical samples, if elapsed times differ, then their characteristics of near-infrared spectrum can vary significantly. In creating calibration curves, therefore, the samples to be used must be prepared with adequate considerations for reducing the time to be measured, such as the measurement is carried out offline in a laboratory or online in manufacturing process (or inline).

4. Control of equipment performance^{2,3)}

4.1. Accuracy of wavelengths (wave numbers)

The accuracy of wavelengths (wave numbers) of an equipment is derived from the deviation of substances for which peak absorption wavelengths (wave numbers) have been defined, such as polystyrene, mixture of rare earth oxides (dysprosium, holmium and erbium; 1:1:1) or steam, from the figures indicated on the equipment. Tolerance figures in the vicinity of 3 peaks are ordinarily set in the following manner, though appropriate tolerance figures can be set, depending on the intended purpose:

$$\begin{aligned} 1200 &\pm 1 \text{ nm} (8300 \pm 8 \text{ cm}^{-1}) \\ 1600 &\pm 1 \text{ nm} (6250 \pm 4 \text{ cm}^{-1}) \\ 2000 &\pm 1.5 \text{ nm} (5000 \pm 4 \text{ cm}^{-1}) \end{aligned}$$

Since the location of absorption peaks vary, depending on the substance used as reference, absorption peaks of wavelengths (wave numbers) that are closest to the above 3 peaks are selected for suitability evaluations. A mixture of rare earth oxides, for instance, would indicate characteristic absorption peaks at 1261 nm, 1681 nm and 1971 nm.

Absorption peaks at 1155 nm, 1417 nm, 1649 nm, 2352 nm (layer length: 1.0 nm) can be used, when taking measurements with transmittance method that involve the use of dichloromethane as reference. The absorption peak of steam at 7306.7 cm⁻¹ can be used with a Fourier transformation-type spectrophotometer, as its wave number resolution ability is high.

Other substances can also be used as reference, so long as their adequacy for the purpose can be verified.

4.2. Spectroscopic linearity

Appropriate standard plates, such as plate-shaped polymer impregnated with varying concentrations of carbon (Carbon-doped polymer standards), can be used to evaluate spectroscopic linearity. In order to verify linearity, however, standard plates with no less than 4 levels of concentration within the reflectance of 10 – 90% must be used. When measurements are expected to be taken with absorbance of no less than 1.0, it is necessary to add standard plates with reflectance of either 2% or 5% or both.

In order to plot absorbance (A_{OBS}) of such standard plates at locations in the vicinity of wavelengths 1200 nm, 1600 nm and 2000 nm against absorbance (A_{REF}) assigned to each standard plate, verifications must be made to ensure that the gradient of linearity obtained are ordinarily within the range 1.0 ± 0.05 for each of these wavelengths and 0 ± 0.05 for ordinate intercept. Depending on the intended purpose, appropriate tolerance figures can be set.

4.3. Spectrophotometric noise

The spectrophotometric noise of the equipment can be checked using appropriate reflectance standard plates, such as white-colored reflecting ceramic tiles or reflective thermoplastic resin (such as polytetrafluoroethylene).

4.3.1. High flux noise

Spectrophotometric noise is evaluated by using standard plates with high reflectance, such as reflectance of 99%. Standard plates are used to take measurements for both samples and control samples. Generally, the average value obtained from calculation of mean square root (RMS) of noise for each 100 nm segments in the wavelength range of 1200 – 2200 nm ordinarily must not be more than 0.3×10^{-3} and individual values must not exceed 0.8×10^{-3} . Depending on the intended purpose, appropriate tolerance figures can be set.

$$RMS = \{1/N \cdot \sum (A_i - A_m)^2\}^{1/2}$$

N : Number of measurement points per segment

A_i : Absorbance at each measurement point of segment

A_m : Average absorbance for segment

4.3.2. Low flux noise

Spectrophotometric noise is evaluated by using standard plates with low reflectance, such as reflectance of 10%, when the amount of light is low. In such cases, light source, optical system, detector and electronic circuit systems all have some impact on noise. Similar to the cases of high flux noise, generally, the average value obtained from calculation of RMS for each 100 nm segments in the wavelength range of 1200 – 2200 nm ordinarily must not be more than 1.0×10^{-3} and individual values must not exceed 2.0×10^{-3} . Depending on the intended purpose, appropriate tolerance figures can be set.

5. Application of qualitative or quantitative analysis

Unlike in the infrared range, mainly harmonic overtones and combinations manifest as spectrum in the near-infrared range. Such absorbance spectrums are often observed as overlay of absorption bands of functional groups and atomic groups. The near-infrared spectrometry, therefore, differs from conventional analysis methods that correspond to each application, by preparing model analysis methods using methodologies of chemometrics, such as multivariate analysis.

Characteristics of near-infrared absorption spectrum must be emphasized and effects of complexities of spectrums, as well as overlay of absorption bands must be reduced by performing mathematical preprocesses, such as primary or secondary spectral differentiation processes or normalizations, which becomes one of vital procedures in establishing analysis methods that use methodologies of chemometrics. While there are many chemometrics methodologies and mathematical preprocessing methods for data, appropriate combinations must be selected that suit the purposes of intended analysis.

Evaluation of validity based on analysis parameters is ordinarily required for the analysis validation when establishing a near-infrared analysis method. Selection of parameters that are appropriate for applications must be made for its intended use. Furthermore, following issues must be considered, in conformity with attributes of the near-infrared spectrometry.

(i) Whether or not wavelengths (wave numbers) intended for the particular analysis method, are suitable for evaluation of characteristics of a sample in performing analysis under given conditions.

(ii) Whether or not the method is adequately robust to deal with variables such as handling of samples (for instance fill condition for fine particle samples, etc.) and configuration matrix.

(iii) Whether or not about the same level of accuracy or precision can be obtained, in comparison with the existing

and established analysis methods, which are available as standards.

(iv) Sustaining and managing performance of an analysis method, once established, are critical. Continuous and systematic maintenance and inspection work must therefore be implemented. Furthermore, it must be determined whether or not appropriate evaluation procedures are available to deal with change controls or implementation of re-validation on changes made in manufacturing processes or raw materials, as well as changes arising from replacement of major components in equipment.

(v) Whether or not there are appropriate evaluation procedures in place to verify validity of transferring implementation of an analysis, which presupposed the use of a specific equipment, from such originally intended equipment to another equipment (model transfer) for the purpose of sharing the analysis method.

5.1. Qualitative analysis

Qualitative analysis, such as verification of substances, is performed after preparing a reference library that includes inter-lot variations within tolerance range and chemometrics methodologies, such as multivariate analysis, have been established. Minute quality characteristic variations between lots can also be established by using this method.

Furthermore, multivariate analysis includes direct analysis methods that consider wavelengths (wave numbers) and absorption as variables, such as wavelength correlation method, residual sum of squares, range sum of squares, along with factor analysis method, cluster analysis method, discriminant analysis method, as well as SIMCA (Soft independent modeling of class analogy).

It is also possible to consider the overall near-infrared absorption spectrum as a single pattern and to identify parameters obtained by applying multivariate analysis methods or characteristic wavelength (wave number) peaks of the sample substance as indices for monitoring, for the purpose of manufacturing process control for active substances or preparations.

5.2. Quantitative analysis

Quantitative analysis uses spectrums of sample groups and analysis values obtained through the existing and established analysis methods, to obtain quantitative models with methodologies of chemometrics. These are used to calculate concentrations of individual ingredients and material values of samples being measured, using conversion formulas. Chemometrics methodologies for obtaining quantitative models include multiple regression analysis method, main ingredient regression analysis method and PLS (Partial least squares) regression analysis method.

In cases where the composition of a sample is simple, concentrations of ingredients in the sample that are subject to analysis can be calculated, by plotting a calibration curve using the absorbance of a specific wavelength (wave number) or the correlating relationship between the parameters and concentration, using samples for preparation of calibration curves with known concentrations (calibration curve method).

References

- 1) General Rules for Near-infrared Spectrophotometric Analysis, JIS K 0134 (2002), Japanese Industrial Standards
- 2) Near-Infrared Spectrophotometry, 2.2.40, European Pharmacopoeia 5.0 (2005)
- 3) Near-Infrared Spectrophotometry, <1119>, US Pharmacopoeia 30 (2007)

pH Test for Gastrointestinal Medicine

In this test, medicine for the stomach and bowels, which is said to control stomach acid, is stirred in a fixed amount of the 0.1 mol/L hydrochloric acid for a fixed duration, and the pH value of this solution is measured. The pH value of a stomach medicine will be based on the dose and the dosage of the medicine (when the dosage varies, a minimum dosage is used) and expressed in the pH value obtained from the test performed by the following procedure.

1. Preparation of Sample

Solid medicine which conforms to the general regulations for medicine (the powdered medicine section) can be used as a sample. When the medicine is in separate packages, the content of 20 or more packages is accurately weighed to calculate the average mass for one dose and mixed evenly to make a sample. For granules and similar types in separate packages, among the solid medicine which does not conform to the general regulations for medicine (the powdered medicine section), the content of 20 or more packages is accurately weighed to calculate the average mass for one dose and is then powdered to make sample. For granules and similar types not in separate packages, among solid medicine which does not conform to the general regulations for medicine (the powdered medicine section), 20 doses or more are powdered to make a sample. For capsules and tablets, 20 doses or more are weighed accurately to calculate the average mass for one dose or average mass and then powdered to make a sample.

Liquid medicine is generously mixed to make a sample.

2. Procedure

Put 50 mL of the 0.1 mol/L hydrochloric acid with the molarity coefficient adjusted to 1.000, or equivalent 0.1 mol/L hydrochloric acid with its volume accurately measured in a 100-mL beaker. Stir this solution with a magnetic stirrer and a magnetic stirrer rotator (35 mm length, 8 mm diameter) at the speed of about 300 revolutions per minute. While stirring, add the accurately weighed one-dose sample. After 10 minutes, measure the pH value of the solution using the pH Determination. The solution temperature should be maintained at $37 \pm 2^\circ\text{C}$ throughout this operation.

System Suitability

In order to ensure the reliability on the results of drug analyses, it is essential to verify that the test method to be applied to the test, including the method prescribed in the Japanese Pharmacopoeia (JP), can give the results adequate for its intended use using the analytical system in the laboratory in which the test is to be performed, then to carry out system suitability testing for confirming that the analytical system maintains the state suitable for the quality test.

1. Definition and role of system suitability

“System Suitability” is the concept for ensuring that the performance of the analytical system is as suitable for the analysis of the drug as was at the time when the verification of the test method was performed using the system. Usually, system suitability testing should be carried out at every series of drug analysis. The test procedures and acceptance criteria of system suitability testing must be prescribed in the test methods of drugs. The results of drug analyses are not ac-

ceptable unless the requirements of system suitability have been met.

System suitability testing is an integral part of test methods using analytical instruments, and based on the concept that the equipments, electronic data processing systems, analytical operations, samples to be analyzed and operators constitute an integral system that can be evaluated, when the test procedures and acceptance criteria of system suitability testing are prescribed in the test methods.

2. Points to consider in setting system suitability

Parameters of system suitability testing to be prescribed in the test method depend on the intended use and type of analytical method. Since system suitability testing is to be carried out in a routine manner, it is preferable to select the parameters necessary for ensuring that the analytical system maintains the state suitable for the analysis of the drug and to prescribe its test procedure able to carry out easily and rapidly.

For example, in the case of quantitative purity tests using liquid chromatography or gas chromatography, the evaluation of parameters such as "System performance" (to confirm the ability to analyze target substance specifically), "System repeatability" (to confirm that the degree of variation in the analytical results of target substance in replicate injections is within the allowable limit) and "Test for required detectability" (to confirm the linearity of chromatographic response around the specification limit) are usually required.

The followings are supplements to the section of system suitability prescribed in "Liquid Chromatography".

2.1. System repeatability of HPLC and GC

2.1.1. Allowable limit of system repeatability

It is described in the section of system suitability in "Liquid Chromatography" that "In principle, total number of replicate injections should be 6", and "The allowable limit of "System repeatability" should be set at an appropriate level based on the data when suitability of the method for the evaluation of quality of the drug was verified, and the precision necessary for the quality test".

Based on the above description, an allowable limit of system repeatability for 6 replicate injections should be set in consideration with the following descriptions. However, in the case that the test method prescribed in the JP monograph is used for the test, the allowable limit of system repeatability prescribed in the monograph should be applied.

(i) Assay for drug substance (for drug substance with the content nearby 100%): An adequate allowable limit should be set at the level that the chromatographic system is able to give the precision suitable for the evaluation of variation in the content of active ingredient within and among the batches of drug substance. For example, the allowable limit of "not more than 1.0%" is usually recommended for the drug substances whose width of content specification are not more than 5%, as is in the case of content specification of 98.0 – 102.0% which is often observed in the assay using liquid chromatography.

(ii) Assay for drug products: An adequate allowable limit should be set considering the width of content specification of the drug product and the allowable limit prescribed in the assay of drug substance (when the drug product is analyzed by a method with the same chromatographic conditions as those used for the analysis of drug substance).

(iii) Purity test for related substances: An adequate allowable limit should be set considering the concentration of active ingredients in the solution used for the system suitability testing. In the case that a solution with active ingredi-

ent concentration of 0.5 – 1.0% is used for the test of system repeatability, an allowable limit of "not more than 2.0%" is usually recommended.

Recommendations for allowable limits described above should not be applicable to gas chromatography.

2.1.2. Method for decreasing the number of replicate injections without losing the quality of system repeatability testing

It is described in the section of system suitability in "Liquid Chromatography" that "In principle, total number of replicate injections should be 6. However, in the case that a long time is necessary for one analysis, such as the analysis using the gradient method, or the analysis of samples containing late eluting components, it may be acceptable to decrease the number of replicate injections by adopting new allowable limit of "System repeatability" which can guarantee a level of "System repeatability" equivalent to that at 6 replicate injections."

In consideration of the above description, a method for decreasing the number of replicate injections without losing the quality of system repeatability testing is adopted. One can set the test for system repeatability with reduced number of replicate injections by utilizing this method, if necessary, and can also apply it as an alternative for the method prescribed in a monograph.

The following table shows the allowable limits to be attained in the test at 3 – 5 replicate injections ($n = 3 – 5$) to keep the quality test equivalent to that of test at $n = 6$.

However, it should be kept in mind that since decrease in the number of replicate injections results in increase in the weight of each injection, it becomes more important to perform the test by the experienced operator, and to maintain the equipment in a suitable state.

3. Points to consider at the change of analytical system (Change control of analytical system)

When the test method and analytical system verified is continuously used for the quality test without any change, it is sufficient to confirm the compliance to the requirements of system suitability at every series of drug analysis.

However, when the test is performed for a long period, a situation in which some changes in the analytical system are inevitable, may occur. These changes don't affect the quality of the product itself, but they affect the scale in the evaluation of product quality. If the change in the analytical system may induce a significant deviation of the scale, it may lead to the acceptance of products with inadequate quality and/or the rejection of products with adequate quality. Thus, at the time of change in the analytical system, it is necessary to check whether the change is appropriate or not, to avoid the deviation of the scale in the evaluation of product quality.

In the case of the change of test method, it is required to perform an adequate validation depending on the extent of the change.

On the other hand, in the case of the change of analytical system in a laboratory, such as renewal of apparatus or column of liquid chromatography, and the change of operator, it is necessary to perform at least system suitability testing using the system after change, and to confirm that the equivalency of the results before and after change.

In the case that equivalent results would not be obtained after change, for example, when a renewal of column of liquid chromatograph may induce a significant change of elution pattern, such as the reversal of elution order between target ingredient of the test and substance for checking resolution, it is required to perform a revalidation of the analytical system for the test using new column, since it is uncertain

Table Allowable limits to be attained in the test at 3 – 5 replicate injections ($n = 3 – 5$) to keep the quality of test equivalent to that of test at $n = 6^*$

		Allowable limit (RSD)					
Allowable limit prescribed in the test of $n = 6$		1%	2%	3%	4%	5%	10%
Allowable limit to be attained	$n = 5$	0.88%	1.76%	2.64%	3.52%	4.40%	8.81%
	$n = 4$	0.72%	1.43%	2.15%	2.86%	3.58%	7.16%
	$n = 3$	0.47%	0.95%	1.42%	1.89%	2.37%	4.73%

* The probability for inadequate analytical systems to meet the requirements of system suitability testing, is supposed to be 5%.

whether the specificity and/or other validation characteristics necessary for estimating target ingredient is kept or not.

Test for Trace Amounts of Aluminum in Total Parenteral Nutrition (TPN) Solutions

Total parenteral nutrition solutions (TPNs) are nutrient preparations for intravenous injection. Since toxic effects to the central nervous system, bone, etc. due to trace amounts of aluminum have recently been reported in several countries, testing methods for trace amounts of aluminum contaminating TPNs are required for the official standard. The following three analytical methods are available: High-Performance Liquid Chromatography using a fluorescence photometric detector (HPLC with fluorescence detection), Inductivity Coupled Plasma-Atomic Emission Spectrometry (ICP-AES method), Inductivity Coupled Plasma-Mass Spectrometry (ICP-MS method). Detection sensitivity by HPLC with fluorescence detection is about 1 $\mu\text{g/L}$ (ppb), while ICP-AES fitted with special apparatus and ICP-MS have higher sensitivity.

Since TPNs are nutrient preparations, they contain many nutrients such as sugars, amino acids, electrolytes, etc., in various compositions. Thus, care is needed in the selection of a suitable analytical method, because these coexisting components may affect the measurement of trace amounts of aluminum.

In view of the general availability of HPLC apparatus, the present general information describes procedures for the determination of trace levels of aluminum in TPNs by means of HPLC with a fluorescence photometric detector, using two kinds of fluorescent chelating agents, i.e., Quinolinol complexing method, Lumogallion complexing method.

1. Quinolinol complexing method

After forming a complex of aluminum ion in the sample solution with quinolinol, the assay for aluminum by HPLC fitted with a fluorescence photometer is performed.

1.1. Preparation of sample solution

Pipet 1 mL of the sample (TPNs) exactly, and after adding 10 μL of water for aluminum test, make up the sample solution to 10 mL exactly by adding the mobile phase.

1.2. Preparation of a series of standard solutions for calibration curve

Pipet 1 mL of water for aluminum test exactly, and after adding 10 μL each of standard solutions of aluminum (1)–(5), make up the standard solutions for calibration curve to

10 mL (Aluminum concentration: 0, 1.25, 2.5, 5.0, and 10.0 ppb).

1.3. Standard testing method

Pipet 0.1 mL each of the sample solution and standard solutions, and perform the test by HPLC under the following conditions. Calculate the aluminum content in the sample solution using a calibration curve method.

Operating conditions—

Detector: A fluorescence photometer (excitation wavelength: 380 nm, emission wavelength: 520 nm)

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with phenylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of 8-quinolinol in acetonitrile (3 in 100) and diluted 0.5 mol/L ammonium acetate TS (2 in 5) (1:1).

Flow rate: Adjust so that the retention time of aluminum/8-quinolinol complex is about 9 minutes.

System suitability—

The correlation coefficient of the calibration curve, which is prepared using a series of standard solutions, is not less than 0.99.

Furthermore there is an alternative method, in which the chelating agent 8-quinolinol is not included in the mobile phase. In this method also, aluminum is detected as a complex with 8-quinolinol in the sample solution by using HPLC fitted with a fluorescence photometer. But it is necessary to form a more stable aluminum/8-quinolinol complex in the sample solution, because the chelating agent is not included in the mobile phase. Further, since the analytical wavelength for the fluorescence detection is different from that in the standard method, excitation WL: 370 nm, emission WL: 504 nm, the detection sensitivity is different. Thus, it is appropriate to obtain the calibration curve between 0 – 25 ppb of aluminum. Other than the above-mentioned differences, the size of column, column temperature, and the mobile phase are also different from those used in the standard method, so suitable analytical conditions should be established for performing precise and reproducible examinations of trace amounts of aluminum in the sample specimen.

2. Lumogallion complexing method

After forming a complex of aluminum ion in the sample specimen with the fluorescent reagent of lumogallion, the solution is examined by HPLC fitted with a fluorescence photometer.

2.1. Preparation of sample solution

Pipet 70 μL of the sample specimen (TPN) exactly, add

0.15 mL of lumogallion hydrochloric acid TS and 0.6 mL of buffer solution for aluminum test (pH 7.2) exactly, then mix the solution. After this solution has been allowed to stand for 4 hours at 40°C, it can be used for the measurement as a sample solution.

2.2. Preparation of a series of standard solutions for calibration curve

Pipet 1 mL each of standard aluminum solutions (1) – (5) exactly, and add diluted nitric acid for aluminum test (1 in 100) to make exactly 100 mL. Pipet 70 μ L each of these solutions exactly, and add exactly 0.15 mL of lumogallion hydrochloric acid TS and exactly 0.6 mL of buffer solution for aluminum test (pH 7.2) then allow to stand for 4 hours at 40°C to make a series of standard solutions for obtaining the calibration curve (Aluminum: 0, 1.07, 2.13, 4.27, and 8.54 ppb).

2.3. Standard examination method

Take 0.1 mL each of the sample solution and standard aluminum solutions for the calibration curve, and perform HPLC analysis under the following conditions. Calculate the aluminum content in the sample solution by using a calibration curve method.

Operating conditions—

Detector: A fluorescence photometer(excitation wavelength 505 nm, emission wavelength 574 nm)

Column: A stainless steel column 6.0 mm in inside diameter and 10 cm in length, packed with octylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Take 100 mL of 2-propanol, and add a diluted 1 mol/L acetic acid-sodium acetate buffer solution of pH 5.0 (1 in 10) to make 1000 mL.

Flow rate: Adjust so that the retention time of aluminum/lumogallion complex is about 5 minutes.

System suitability—

The correlation coefficient of the calibration curve, which is prepared using a series of standard solutions, is not less than 0.99.

3. Notes

(i) Regarding water, solvents, reagents, vessels and other tools used for the examination, select those not contaminated with aluminum. Further, keep the testing environment clean and free from dust in the testing room.

(ii) Before the measurement, it is necessary to confirm that the characteristic properties of the sample do not affect the formation of the complex.

(iii) Reference substances of river water for analysis of trace elements, distributed by the Japan Society for Analytical Chemistry, contain certified amounts of aluminum: JSAC 0301-1 and JSAC 0302 (a known amount of aluminum is artificially added to JSAC 0301-1).

4. Standard Solutions, Reagents and Test Solutions

Other than the standard solutions, reagents and test solutions specified in the Japanese Pharmacopoeia, those described below can be used in this test.

(i) ***N,N-Bis(2-hydroxyethyl)-2-aminoethane sulfonic acid*** $C_6H_{15}NO_5S$ White crystals or powder.

(ii) **Hydrochloric acid for aluminum test** Same as the reagent *Hydrochloric acid*. Further, it contains not more than 1 ppb of aluminum.

(iii) **Lumogallion** [5-Chloro-2-hydroxy-3-(2,4-dihydroxyphenylazo)benzenesulfonic acid] $C_{12}H_9ClN_2O_6S$ Red-brown to dark brown powder. Further, it contains not more than 1 ppm of aluminum.

(iv) **Lumogallion hydrochloric acid TS** Dissolve 0.86 g

of lumogallion in 300 mL of 2-propanol, and add 350 mL of diluted *Hydrochloric acid for aluminum test* (9 in 50) and *Water for aluminum test* to make 1000 mL exactly.

(v) **Nitric acid for aluminum test** Same as the reagent *Nitric acid*. Further, it contains not more than 1 ppb of aluminum.

(vi) **pH buffer solution for aluminum test (pH 7.2)** Dissolve 106.6 g of *N,N-bis(2-hydroxyethyl)-2-aminoethane sulfonic acid* in 800 mL of *Water for aluminum test*, adjust the pH 7.2 by using *Tetramethylammonium hydroxide aqueous solution*, and add *Water for aluminum test* to make 1000 mL.

(vii) **Standard aluminum solution** Pipet a constant volume each of *Water for aluminum test* or the *Standard aluminum stock solution*, dilute and adjust the aluminum concentration to 0, 1.25, 2.5, 5.0, and 10 ppm by using diluted *Nitric acid for aluminum test* (1 in 100), to make Standard aluminum solutions (1) – (5).

(viii) **Tetramethylammonium hydroxide TS** $[(CH_3)_4NOH]$ It is a 25% aqueous solution, prepared for aluminum test. Further, it contains not more than 1 ppb of aluminum.

(ix) **Water for aluminum test** It contains not more than 1 ppb of aluminum.

Validation of Analytical Procedures

The validation of an analytical procedure is the process of confirming that the analytical procedure employed for a test of pharmaceutics is suitable for its intended use. In other word, the validation of an analytical procedure requires us to demonstrate scientifically that risks in decision by testing caused by errors from analytical steps are acceptably small. The performance of an analytical procedure is established by various kinds of validation characteristics. The validity of a proposed analytical procedure can be shown by demonstrating experimentally that the validation characteristics of the analytical procedure satisfy the standards set up according to the acceptable limits of testing.

When an analytical procedure is to be newly carried in the Japanese Pharmacopoeia, when a test carried in the Japanese Pharmacopoeia is to be revised, and when the test carried in the Japanese Pharmacopoeia is to be replaced with a new test according to regulations in general notices, analytical procedures employed for these tests should be validated according to this document.

1. Required data for analytical procedures to be carried in the Japanese Pharmacopoeia

1.1. Outline

This section should provide a brief explanation of the principle of a proposed analytical procedure, identify the necessity of the analytical procedure and its advantage compared with other procedures, and summarize the validation. When an analytical procedure is revised, the limitation of the current analytical procedure and the advantage offered by the new analytical procedure should be described.

1.2. Analytical procedure

This section should contain a complete description of the analytical procedure to enable skilled persons to evaluate correctly the analytical procedure and replicate it if necessary. Analytical procedures include all important operating procedures for performing analyses, the preparation of standard samples, reagents and test solutions, precautions, procedures to verify system suitability (e.g. the verification of the separating performance of a chromatographic sys-

tem), formulas to obtain results, the number of replications and so forth. Any instruments and apparatus that are not stated in the Japanese Pharmacopoeia should be described in detail. The physical, chemical or biological characteristics of any new reference standards should be clarified and their testing methods should be established.

1.3. Data showing the validity of analytical procedures

This section should provide complete data showing the validity of the analytical procedures. This includes the experimental designs to determine the validation characteristics, experimental data, calculation results and results of hypothesis tests.

2. Validation characteristics

The definition of typical validation characteristics to be assessed in validation of analytical procedures and examples of assessing procedures are given below.

The terminology and definitions of the validation characteristics may possibly vary depending upon the fields to which analytical procedures are applied. The terminology and definitions shown in this document are established for the purpose of the Japanese Pharmacopoeia. Typical methods for assessing the validation characteristics are shown in the item of assessment. Various kinds of methods to determine the validation characteristics have been proposed and any methods that are widely accepted will be accepted for the present purpose. However, since values of the validation characteristics may possibly depend upon methods of determination, it is required to present the methods of determining the validation characteristics, the data and calculation methods in sufficient detail.

Although robustness is not listed as a validation characteristic, it should be considered during the development of analytical procedures. Studying the robustness may help to improve analytical procedures and to establish appropriate analytical conditions including precautions.

2.1. Accuracy/Trueness

2.1.1. Definition

The accuracy is a measure of the bias of observed values obtained by an analytical procedure. The accuracy is expressed as the difference between the average value obtained from a large series of observed values and the true value.

2.1.2. Assessment

The estimate of accuracy of an analytical method is expressed as the difference between the total mean of observed values obtained during investigation of the reproducibility and the true value. The theoretical value is used as the true value (e.g., in the case of titration methods, etc.). When there is no theoretical value or it is difficult to obtain a theoretical value even though it exists, a certified value or a consensus value may be used as the true value. When an analytical procedure for a drug product is considered, the observed value of the standard solution of the drug substance may be used as the consensus value.

It may be inferred from specificity data that an analytical procedure is unbiased.

The estimate of accuracy and a 95% confidence interval of the accuracy should be calculated using the standard error based on the reproducibility (intermediate precision). It should be confirmed that the confidence interval includes zero or that the upper or lower confidence limits are within the range of the accuracy required of the analytical procedure.

2.2. Precision

2.2.1. Definition

The precision is a measure of the closeness of agreement between observed values obtained independently from multi-

ple samplings of a homogenous sample and is expressed as the variance, standard deviation or relative standard deviation (coefficient of variation) of observed values.

The precision should be considered at three levels with different repetition conditions; repeatability, intermediate precision and reproducibility.

(i) Repeatability/Intra-assay precision

The repeatability expresses the precision of observed values obtained from multiple samplings of a homogenous sample over a short time interval within a laboratory, by the same analyst, using the same apparatus and instruments, lots of reagents and so forth (repeatability conditions).

(ii) Intermediate precision

The intermediate precision expresses the precision of observed values obtained from multiple samplings of a homogenous sample by changing a part of or all of the operating conditions including analysts, experimental dates, apparatus and instruments and lots of reagents within a laboratory (intermediate precision condition).

(iii) Reproducibility

The reproducibility expresses the precision of observed values obtained from multiple samplings of a homogenous sample in different laboratories (reproducibility condition).

2.2.2. Assessment

A sufficient volume of a homogenous sample should be prepared before studying the precision. The solution is assumed to be homogenous. When it is difficult to obtain a homogenous sample, the following samples may be used as homogenous samples; e.g., a large amount of drug products or mixture of drug substance and vehicles that are crushed and mixed well until they can be assumed to be homogenous.

Suitable experimental designs such as one-way layout may be employed when more than one level of precision is to be investigated simultaneously. A sufficient number of repetitions, levels of operating conditions and laboratories should be employed. Sources of variations affecting analytical results should be evaluated as thoroughly as possible through the validation.

It is required to show the variance, standard deviation and relative standard deviation (coefficient of variation) of each level of precision. The 90% confidence interval of the variance and corresponding intervals of the standard deviation and relative standard deviation should also be established. The validity of the proposed analytical procedure for its intended use may be confirmed by comparing obtained values with the required values of the analytical procedure. Whether the proposed analytical procedure is acceptable may normally be decided based on the reproducibility.

2.3. Specificity

2.3.1. Definition

The specificity is the ability of an analytical procedure to measure accurately an analyte in the presence of components that may be expected to be present in the sample matrix. The specificity is a measure of discriminating ability. Lack of specificity of an analytical procedure may be compensated by other supporting analytical procedures.

2.3.2. Assessment

It should be confirmed that the proposed analytical procedure can identify an analyte or that it can accurately measure the amount or concentration of an analyte in a sample. The method to confirm the specificity depends very much upon the purpose of the analytical procedure. For example, the specificity may be assessed by comparing analytical results obtained from a sample containing the analyte only with results obtained from samples containing excipients, related substances or degradation products, and including or excluding the analyte. If reference standards of impurities are un-

available, samples that are expected to contain impurities or degradation products may be used (e.g. samples after accelerated or stress tests).

2.4. Detection limit

2.4.1. Definition

The detection limit is the lowest amount or concentration of the analyte in a sample that is detectable, but not necessarily quantifiable.

2.4.2. Assessment

The detection limit should be normally determined so that producer's and consumer's risks are less than 5%. The detection limit may be calculated using the standard deviation of responses of blank samples or samples containing an analyte close to the detection limit and the slope of the calibration curve close to the detection limit. The following equation is an example to determine the detection limit using the standard deviation of responses of blank samples and the slope of the calibration curve.

$$DL = 3.3\sigma/slope$$

DL: detection limit

σ : the standard deviation of responses of blank samples

slope: slope of the calibration curve

The noise level may be used as the standard deviation of responses of blank samples in chromatographic methods. It should be ensured that the detection limit of the analytical procedure is lower than the specified limit for testing.

2.5. Quantitation limit

2.5.1. Definition

The quantitation limit is the lowest amount or concentration of the analyte in a sample that can be determined. The precision expressed as the relative standard deviation of samples containing an analyte at the quantitation limit is usually 10%.

2.5.2. Assessment

The quantitation limit may be calculated using the standard deviation of responses of blank samples or samples containing an analyte close to the quantitation limit and the slope of the calibration curve close to the quantitation limit. The following equation is an example to determine the quantitation limit using the standard deviation of responses of blank samples and the slope of the calibration curve.

$$QL = 10\sigma/slope$$

QL: quantitation limit

σ : the standard deviation of responses of blank samples

slope: slope of the calibration curve

The noise level may be used as the standard deviation of responses of blank samples in chromatographic methods. It should be ensured that the quantitation limit of the analytical procedure is lower than the specified limit for testing.

2.6. Linearity

2.6.1. Definition

The linearity is the ability of an analytical procedure to elicit responses linearly related to the amount or concentration of an analyte in samples. A well-defined mathematical transformation may sometimes be necessary to obtain a linear relationship.

2.6.2. Assessment

Responses are obtained after analyzing samples with various amounts or concentrations of an analyte according to described operating procedures. The linearity may be evaluated in terms of the correlation coefficient, and the slope and y-intercept of the regression line. It may be also helpful for evaluating the linearity to plot residual errors from the regression line against the amount or concentration and to

confirm that there is no particular tendency in the graph. Samples with five different amounts or concentrations of an analyte should be usually investigated.

2.7. Range

2.7.1. Definition

The range for the validation of analytical procedures is the interval between the lower and upper limits of the amount or concentration of an analyte providing sufficient accuracy and precision. The range for the validation of analytical procedures for an analytical procedure with linearity is the interval between the lower and upper limits providing sufficient accuracy, precision and linearity.

2.7.2. Assessment

When the range for the validation of analytical procedures is investigated, 80 to 120% of specified limits of testing should be usually considered. The accuracy, precision and linearity should be evaluated using samples containing the lower and upper limits and in the middle of the range.

3. Categories of tests employing analytical procedures

Tests covered with this document are roughly classified into three categories shown below according to their purposes. The table lists the normally required validation characteristics to be evaluated in the validation of analytical procedures used in these tests. This list should be considered to represent typical validation characteristics. A different approach to validating analytical procedures should be considered depending upon the characteristics of analytical procedures and their intended use.

(i) Type I Identification. Tests for identifying major components in pharmaceuticals according to their characteristics.

(ii) Type II Impurity tests. Tests for determination of impurities in pharmaceuticals.

(iii) Type III Tests for assaying drug substances, active ingredients, and major components in pharmaceuticals. (Additives such as stabilizing agents and preservatives are included in major components.) Tests for determining performance of pharmaceuticals, such as dissolution testing.

Table Lists of validation characteristics required to be evaluated in tests of each type

Type of test Validation characteristics	Type I	Type II		Type III
		Quantitation test	Limit test	
Accuracy/Trueness	—	+	—	+
Precision				
Repeatability	—	+	—	+
Intermediate precision	—	—*	—	—*
Reproducibility	—	+*	—	+*
Specificity**	+	+	+	+
Detection limit	—	—	+	—
Quantitation limit	—	+	—	—
Linearity	—	+	—	+
Range	—	+	—	+

— Usually need not to be evaluated.

+ Usually need to be evaluated.

* Either intermediate precision or reproducibility should be evaluated depending upon circumstances in which analytical procedures or tests are performed. The latter should be normally evaluated in the validation of analytical procedures proposed to be included in the Japanese Pharmacopoeia.

** The lack of the specificity of an analytical procedure may be compensated by other relevant analytical procedures

4. Terminology used in the validation of analytical procedures

(i) Analytical procedure: This document covers analytical procedures applied to identification, and ones that provides responses depending upon the amount or concentration of analytes in samples.

(ii) Laboratory: The laboratory means an experimental room or facility where tests are performed. In this document different laboratories are expected to perform an analytical procedure using different analysts, different experimental apparatus and instruments, different lots of reagents and so forth.

(iii) Number of replications: The number of replications is one that is described in analytical procedures. An observed value is often obtained by more than one measurement in order to achieve good precision of analytical procedures. Analytical procedures including the number of replications should be validated. This is different from repetition in the validation of analytical procedures to obtain accuracy or precision.

(iv) Observed value: The value of a characteristic obtained as the result of performing an analytical procedure.

(v) Consumer's risk: This is the probability that products out of the specification of tests are decided to be accepted after testing. It is usually expressed as β , and is called the probability of type II error or the probability of false negative in impurity tests.

(vi) Producer's risk: This is the probability that products satisfying the specification of tests are decided to be rejected after testing. It is usually expressed as α , and is called the probability of type I error or the probability of false positive in impurity tests.

(vii) Robustness: The robustness is a measure of the capacity to remain unaffected by small but deliberate variations in analytical conditions. The stability of observed values may be studied by changing various analytical conditions within suitable ranges including pH values of solutions, reaction temperature, reaction time or amount of reagents added. When observed values are unstable, the analytical procedure should be improved. Results of studying robustness may be reflected in the developed analytical procedure as precautions or significant digits describing analytical conditions.

(viii) Test: Tests mean various tests described in general tests and official monographs in the Japanese Pharmacopoeia such as impurity tests and assay. They includes sampling methods, specification limits and analytical procedures.

G2 Solid-state Properties

Laser Diffraction Measurement of Particle Size

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

The laser light diffraction technique used for the determination of particle-size distribution is based on the analysis of the diffraction pattern produced when particles are exposed to a beam of monochromatic light. Historically, the early laser diffraction instruments only used scattering at small angles. However, the technique has since been broadened to include laser light scattering in a wider range and application

of the Mie theory, in addition to the Fraunhofer approximation and anomalous diffraction.

The technique cannot distinguish between scattering by single particles and scattering by clusters of primary particles, i.e. by agglomerates or aggregates. As most particulate samples contain agglomerates or aggregates and as the focus of interest is generally on the size distribution of primary particles, the clusters are usually dispersed into primary particles before measurement.

For non-spherical particles, an equivalent sphere-size distribution is obtained because the technique assumes spherical particles in its optical model. The resulting particle-size distribution may differ from those obtained by methods based on other physical principles (e.g. sedimentation, sieving).

This chapter provides guidance for the measurement of size distributions of particles in different dispersed systems, for example, powders, sprays, aerosols, suspensions, emulsions, and gas bubbles in liquids, through analysis of their angular light-scattering patterns. It does not address specific requirements of particle-size measurement of specific products.

1. Principle

A representative sample, dispersed at an adequate concentration in a suitable liquid or gas, is passed through a beam of monochromatic light, usually a laser. The light scattered by the particles at various angles is measured by a multi-element detector. Numerical values representing the scattering pattern are then recorded for subsequent analysis. These scattering pattern values are then transformed, using an appropriate optical model and mathematical procedure, to yield the proportion of total volume to a discrete number of size classes, forming a volumetric particle-size distribution.

2. Instrument

The instrument is located in an environment where it is not affected by electrical noise, mechanical vibrations, temperature fluctuations, humidity or direct bright light. An example of a set-up of a laser light diffraction instrument is given in Fig. 1. Other equipment may be used.

The instrument comprises a laser light source, beam processing optics, a sample measurement region (or cell), a Fourier lens, and a multi-element detector for measuring the scattered light pattern. A data system is also required for deconvolution of the scattering data into a volumetric size distribution and associated data analysis and reporting.

The particles can enter the laser beam in 2 positions. In the conventional case the particles enter the parallel beam before the collecting lens and within its working distance. In so-called reversed Fourier optics the particles enter behind the collecting lens and thus, in a converging beam. The advantage of the conventional set-up is that a reasonable path length for the sample is allowed within the working distance of the lens. The second set-up allows only small path lengths but enables measurement of scattered light at larger angles, which is useful when submicron particles are present.

The interaction of the incident light beam and the ensemble of dispersed particles results in a scattering pattern with different light intensities at various angles. The total angular intensity distribution, consisting of both direct and scattered light, is then focused onto a multi-element detector by a lens or a series of lenses. These lenses create a scattering pattern that, within limits, does not depend on the location of the particles in the light beam. Hence, the continuous angular intensity distribution is converted into a discrete spatial intensity distribution on a set of detector elements.

It is assumed that the measured scattering pattern of the particle ensemble is identical to the sum of the patterns from

all individual single scattering particles presented in random relative positions. Note that only a limited angular range of scattered light is collected by the lens(es) and, therefore, by the detector.

3. Development of the method

The measurement of particle size by laser diffraction can give reproducible data, even in the sub-micron region, provided the instrument used and the sample tested are carefully controlled to limit variability of the test conditions (e.g. dispersion medium, method of preparation of the sample dispersion).

Traditionally, the measurement of particle size using laser diffraction has been limited to particles in the range of approximately $0.1\text{ }\mu\text{m}$ to 3 mm . Because of recent advances in lens and equipment design, newer instruments are capable of exceeding this range routinely. With the validation report the user demonstrates the applicability of the method for its intended use.

3.1. Sampling

The sampling technique must be adequate to obtain a representative sample of a suitable volume for the particle-size measurement. Sample splitting techniques such as rotating riffler or the cone and quartering method may be applied.

3.2. Evaluation of the dispersion procedure

Inspect the sample to be analyzed, visually or with the aid of a microscope, to estimate its size range and particle shape. The dispersion procedure must be adjusted to the purpose of the measurement. The purpose may be such that it is preferable to deagglomerate clusters into primary particles as far as possible, or it may be desirable to retain clusters as intact as possible. In this sense, the particles of interest may be either primary particles or clusters.

For the development of a method it is highly advisable to check that comminution of the particles does not occur, and conversely, that dispersion of particles or clusters is satisfactory. This can usually be done by changing the dispersing energy and monitoring the change of the particle-size distribution. The measured size distribution must not change significantly when the sample is well dispersed and the particles are neither fragile nor soluble. Moreover, if the manufacturing process (e.g. crystallization, milling) of the material has changed, the applicability of the method must be verified (e.g. by microscopic comparison).

Sprays, aerosols and gas bubbles in a liquid should be measured directly, provided that their concentration is adequate, because sampling or dilution generally alters the particle-size distribution.

In other cases (such as emulsions, pastes and powders), representative samples may be dispersed in suitable liquids. Dispersing aids (wetting agents, stabilizers) and/or mechanical forces (e.g. agitation, sonication) are often applied for deagglomeration or deaggregation of clusters and stabilization of the dispersion. For these liquid dispersions, a recirculating system is most commonly used, consisting of an optical measuring cell, a dispersion bath usually equipped with stirrer and ultrasonic elements, a pump, and tubing. Non-recirculating, stirred cells are useful when only small amounts of a sample are available or when special dispersion liquids are used.

Dry powders can also be converted into aerosols through the use of suitable dry powder dispersers, which apply mechanical force for deagglomeration or deaggregation. Generally, the dispersers use the energy of compressed gas or the differential pressure of a vacuum to disperse the particles to an aerosol, which is blown through the measuring zone,

usually into the inlet of a vacuum unit that collects the particles. However, for free flowing, coarser particles or granules the effect of gravity may be sufficient to disperse the particles adequately.

If the maximum particle size of the sample exceeds the measuring range of the instrument, the material that is too coarse can be removed by sieving and the mass and percentage of removed material are reported. However, after pre-sieving, note that the sample is no longer representative, unless otherwise proven.

3.3. Optimization of the liquid dispersion

Liquids, surfactants, and dispersing aids used to disperse powders must:

- (i) be transparent at the laser wavelength and practically free from air bubbles or particles;
- (ii) have a refractive index that differs from that of the test material;
- (iii) be non-solvent of the test material (pure liquid or pre-filtered, saturated solution);
- (iv) not alter the size of the test materials (e.g. by solubility, solubility enhancement, or recrystallization effects);
- (v) favor easily formation and stability of the dispersion;
- (vi) be compatible with the materials used in the instrument (such as O-rings, gaskets, tubing, etc.);
- (vii) possess a suitable viscosity to facilitate recirculation, stirring and filtration.

Surfactants and/or dispersing aids are often used to wet the particles and to stabilize the dispersion. For weak acids and weak bases, buffering of the dispersing medium at low or high pH respectively can assist in identifying a suitable dispersant.

A preliminary check of the dispersion quality can be performed by visual or microscopic inspection. It is also possible to take fractional samples out of a well-mixed stock dispersion. Such stock dispersions are formed by adding a liquid to the sample while mixing it with, for example, a glass rod, a spatula or a vortex mixer. Care must be taken to ensure the transfer of a representative sample and that settling of larger particles does not occur. Therefore a sample paste is prepared or sampling is carried out quickly from a suspension maintained under agitation.

3.4. Optimization of the gas dispersion

For sprays and dry powder dispersions, a compressed gas free from oil, water and particles may be used. To remove such materials from the compressed gas, a dryer with a filter can be used. Any vacuum unit should be located away from the measurement zone, so that its output does not disturb the measurement.

3.5. Determination of the concentration range

In order to produce an acceptable signal-to-noise ratio in the detector, the particle concentration in the dispersion must exceed a minimum level. Likewise, it must be below a maximum level in order to avoid multiple scattering. The concentration range is influenced by the width of the laser beam, the path length of the measurement zone, the optical properties of the particles, and the sensitivity of the detector elements.

In view of the above, measurements must be performed at different particle concentrations to determine the appropriate concentration range for any typical sample of material. (Note: in different instruments, particle concentrations are usually represented by differently scaled and differently named numbers, e.g. obscuration, optical concentration, proportional number of total mass).

3.6. Determination of the measuring time

The time of measurement, the reading time of the detector and the acquisition frequency is determined experimentally




Fig. 1 Example of a set-up of a laser light diffraction instrument

in accordance with the required precision. Generally, the time for measurement permits a large number of detector scans or sweeps at short time intervals.

3.7. Selection of an appropriate optical model

Most instruments use either the Fraunhofer or the Mie theory, though other approximation theories are sometimes applied for calculation of the scattering matrix. The choice of the theoretical model depends on the intended application and the different assumptions (size, absorbance, refractive index, roughness, crystal orientation, mixture, etc.) made for the test material. If the refractive index values (real and imaginary parts for the used wavelength) are not exactly known, then the Fraunhofer approximation or the Mie theory with a realistic estimate of the refractive index can be used. The former has the advantages that it is simple and it does not need refractive index values; the latter usually provides less-biased particle-size distributions for small particles. For instance, if the Fraunhofer model is used for samples containing an appreciable amount of small, transparent particles, a significantly larger amount of small particles may be calculated. In order to obtain traceable results, it is essential to document the refractive index values used, since small differences in the values assumed for the real and imaginary part of the complex refractive index may cause significant differences in the resulting particle-size distributions. Small values of the imaginary part of the refractive index (about $0.01 - 0.1i$) are often applied to allow the correction of the absorbance for the surface roughness of the particles. It should be noted, in general, that the optical properties of the substance to be tested, as well as the structure (e.g. shape, surface roughness and porosity) bear upon the final result.

3.8. Validation

Typically, the validity of a procedure may be assessed by the evaluation of its specificity, linearity, range, accuracy, precision and robustness. In particle-size analysis by laser light diffraction, specificity as defined by ICH is not applicable as it is not possible to discriminate different components into a sample, as is neither possible to discriminate between agglomerates from dispersed particles unless properly complemented by microscopic techniques. Exploring a linear relationship between concentration and response, or a mathematical model for interpolation, is not applicable to this procedure. Rather than evaluating linearity, this method requires the definition of a concentration range within which the result of the measurements does not vary significantly. Concentrations below that range produce an error due to a poor signal to noise ratio, while concentrations above that range produce an error due to multiple scattering. The range

depends mostly in the instrument hardware. Accuracy should be confirmed through an appropriate instrument qualification and comparison with microscopy, while precision may be assessed by means of a repeatability determination.

The attainable repeatability of the method mainly depends on the characteristics of the material (milled/not milled, robust/fragile, width of its size distribution, etc.), whereas the required repeatability depends on the purpose of the measurement. Mandatory limits cannot be specified in this chapter, as repeatabilities (different sample preparations) may vary appreciably from one substance to another. However, it is good practice to aim at acceptance criteria for repeatability such as $RSD\ (\%) \leq 10\% [n = 6]$ for any central value of the distribution (e.g. for x_{50}). Values at the sides of the distribution (e.g. x_{10} and x_{90}) are oriented towards less stringent acceptance criteria such as $RSD \leq 15\% [n = 6]$. Below $10\ \mu m$, these values must be doubled. Robustness may be tested during the selection and optimization of the dispersion media and forces. The change of the particle-size distribution.

4. Measurement

4.1. Precautions

- (i) never look into the direct path of the laser beam or its reflections;
- (ii) earth all instrument components to prevent ignition of solvents or dust explosions;
- (iii) check the instrument set-up (e.g. warm-up, required measuring range and lens, appropriate working distance, position of the detector, no direct bright daylight);
- (iv) in the case of wet dispersions, avoid air bubbles, evaporation of liquid, schlieren or other inhomogeneities in the dispersion; similarly, avoid improper mass-flow from the disperser or turbulent air-flow in the case of dry dispersions; such effects can cause erroneous particle-size distributions.

4.2. Measurement of the light scattering of dispersed sample(s)

After proper alignment of the optical part of the instrument, a blank measurement of the particle-free dispersion medium must be performed using the same method as that used for the measurement of the sample. The background signal must be below an appropriate threshold. The detector data are saved in order to subtract them later from the data obtained with the sample. The sample dispersion is measured according to the developed method.

For each detector element, an average signal is calculated,

sometimes together with its standard deviation. The magnitude of the signal from each detector element depends upon the detection area, the light intensity and the quantum efficiency. The co-ordinates (size and position) of the detector elements together with the focal distance of the lens determine the range of scattering angles for each element. Most instruments also measure the intensity of the central (unscattered) laser beam. The ratio of the intensity of a dispersed sample to that in its absence (the blank measurement) indicates the proportion of scattered light and hence the particle concentration.

4.3. Conversion of scattering pattern into particle-size distribution

This deconvolution step is the inverse of the calculation of a scattering pattern for a given particle-size distribution. The assumption of spherical particle shape is particularly important as most algorithms use the mathematical solution for scattering from spherical particles. Furthermore, the measured data always contain some random and systematic errors, which may vitiate the size distributions. Several mathematical procedures have been developed for use in the available instruments. They contain some weighting of deviations between measured and calculated scattering patterns (e.g. least squares), some constraints (e.g. non-negativity for amounts of particles), and/or some smoothing of the size distribution curve.

The algorithms used are specific to each make and model of equipment, and are proprietary. The differences in the algorithms between different instruments may give rise to differences in the calculated particle-size distributions.

4.4. Replicates

The number of replicate measurements (with individual sample preparations) to be performed, depends on the required measurement precision. It is recommended to set this number in a substance-specific method.

5. Reporting of results

The particle-size distribution data are usually reported as cumulative undersize distribution and/or as density distribution by volume. The symbol x is used to denote the particle size, which in turn is defined as the diameter of a volume-equivalent sphere. $Q_3(x)$ denotes the volume fraction undersize at the particle size x . In a graphical representation, x is plotted on the abscissa and the dependent variable Q_3 on the ordinate. Most common characteristic values are calculated from the particle-size distribution by interpolation. The particle sizes at the undersize values of 10%, 50%, and 90% (denoted as x_{10} , x_{50} , and x_{90} respectively) are frequently used. x_{50} is also known as the median particle size. It is recognized that the symbol d is also widely used to designate the particle size, thus the symbol x may be replaced by d .

Moreover, sufficient information must be documented about the sample, the sample preparation, the dispersion conditions, and the cell type. As the results depend on the particular instrument, data analysis program, and optical model used, these details must also be documented.

6. Control of the instrument performance

Use the instrument according to the manufacturer's instructions and carry out the prescribed qualifications at an appropriate frequency, according to the use of the instrument and substances to be tested.

6.1. Calibration

Laser diffraction systems, although assuming idealized properties of the particles, are based on first principles of laser light scattering. Thus, calibration in the strict sense is not required. However, it is still necessary to confirm that the instrument is operating correctly. This can be undertaken

using any certified reference material that is acceptable in industrial practice. The entire measurement procedure is examined, including sample collection, sample dispersion, sample transport through the measuring zone, measurement, and the deconvolution procedure. It is essential that the total operational procedure is fully described.

The preferred certified reference materials consist of spherical particles of a known distribution. They must be certified as to the mass-percentage size distribution by an absolute technique, if available, and used in conjunction with an agreed, detailed operation procedure. It is essential that the real and imaginary parts of the complex refractive index of the material are indicated if the Mie theory is applied in data analysis. The representation of the particle-size distribution by volume will equal that of the distribution by mass, provided that the density of the particles is the same for all size fractions.

The response of a laser diffraction instrument is considered to meet the requirements if the mean value of x_{50} from at least 3 independent measurements does not deviate by more than 3% from the certified range of values of the certified reference material. The mean values for x_{10} and x_{90} must not deviate by more than 5% from the certified range of values. Below 10 μm , these values must be doubled.

Although the use of materials consisting of spherical particles is preferable, non-spherical particles may also be employed. Preferably, these particles have certified or typical values from laser diffraction analysis performed according to an agreed, detailed operating procedure. The use of reference values from methods other than laser diffraction may cause a significant bias. The reason for this bias is that the different principles inherent in the various methods may lead to different sphere-equivalent diameters for the same non-spherical particle.

Although the use of certified reference materials is preferred, other well-defined reference materials may also be employed. They consist of substances of typical composition and particle-size distribution for a specified class of substances. Their particle-size distribution has proven to be stable over time. The results must comply with previously determined data, with the same precision and bias as for the certified reference material.

6.2. Qualification of the system

In addition to the calibration, the performance of the instrument must be qualified at regular time intervals or as frequently as appropriate. This can be undertaken using any suitable reference material as mentioned in the previous paragraph.

The qualification of the system is based on the concept that the equipment, electronics, software and analytical operations constitute an integral system, which can be evaluated as an entity. Thus the entire measurement procedure is examined, including sample collection, sample dispersion, sample transport through the measuring zone, and the measurement and deconvolution procedure. It is essential that the total operational procedure is fully described.

In general, unless otherwise specified in the individual monograph, the response of a laser diffraction instrument is considered to meet the requirements if the x_{50} value does not deviate by more than 10% from the range of values of the reference material. If optionally the values at the sides of the distribution are evaluated (e.g. x_{10} and x_{90}), then these values must not deviate by more than 15% from the certified range of values. Below 10 μm , these values must be doubled.

Note 1: For calibration of the instrument stricter requirements are laid down in 6.1. Calibration.

Note 2: Laser Diffraction Measurement of Particle Size complies with ISO13320-1 (1999) and 9276-1 (1998).

Measurement of the Diameter of Particles Dispersed in Liquid by Dynamic Light Scattering

This method is used for measuring average particle diameter and particle diameter distribution of submicron-sized particles dispersed in a liquid by means of dynamic light scattering.

The average particle diameter and the particle diameter distribution obtained by this method are important characteristics mainly of colloidal dispersion formulations, such as emulsion injections, suspension injections, and liposome formulations.

There are two ways of analyzing the detected signals in dynamic light scattering: photon correlation spectroscopy and frequency analysis. Dynamic light scattering is applied to the analysis of particles whose diameters range from nm scale to approximately 1 μm or particles free from the influence of sedimentation.

1. Principle

When particles in Brownian motion in solution or in suspension are irradiated with laser light, scattered light from the particles fluctuates depending on their diffusion coefficients. The intensity of the scattered light from larger particles fluctuates more slowly, because the larger particles move more slowly. On the other hand, the intensity of the scattered light from smaller particles fluctuates more rapidly, because they move faster.

In dynamic light scattering measurements, the particle diameter is determined by applying the Stokes-Einstein equation to analysis of the detected fluctuations of scattered light intensity, which reflect the diffusion coefficient of the particles.

$$d = \frac{kT}{3\pi\eta D} \times 10^{12}$$

d: Particle diameter (nm)

k: Boltzmann constant ($1.38 \times 10^{-23} \text{ J}\cdot\text{K}^{-1}$)

T: Absolute temperature (K)

\eta: Viscosity (mPa·s)

D: Diffusion coefficient ($\text{m}^2\cdot\text{s}^{-1}$)

In photon correlation spectroscopy, the time-dependent changes (fluctuation) in the scattered light intensity, namely the observed signals of the scattered light intensity, are transmitted to the correlator. The average particle diameter and the polydispersity index are obtained from the autocorrelation function of the scattered light intensity, which is calculated based on the data processed by the correlator.

In frequency analysis, the average particle diameter and




Fig. 1 Schematic illustration of the measurement principle

the polydispersity index are obtained from the frequency power spectrum, which is the Fourier transform of the frequency components included in the signals of the scattered light intensity.

Major terms used in this method are as follows.

(i) Average particle diameter: dynamic light scattering harmonic intensity-weighted arithmetic averaged particle diameter, whose unit is nanometer (nm).

(ii) Polydispersity index: dimensionless indicator of the broadness of the particle diameter distribution.

(iii) Scattering volume: observation volume defined by the light-receiving optics and the incident laser light. This value may be given in the specifications of the instrument. Its order of magnitude is typically 10^{-12} m^3 .

(iv) Count rate: number of the photon pulses per second detected in the light-receiving optics in photon correlation spectroscopy. This value is proportional to the detected scattered light intensity. The unit is cps (count per second).

(v) Signal of scattered light fluctuation: signal detected by the light-receiving optics in the frequency analysis. The signal is proportional to the scattered light intensity, and includes frequency components depending on the distribution of the particle diameter.

2. Apparatus

2.1. Constitution of the apparatus

The measuring apparatus generally consists mainly of a laser, sample holder, light-receiving optics and detector, and correlator or spectrum analyzer. There are two types of optical detection according to the optical arrangements: (a) homodyne detection in which only the scattered light is measured, and (b) heterodyne detection in which the scattered light and a portion of the incident light are measured simultaneously.

(i) Laser: a monochromatic laser polarized with its electric field component perpendicular to the plane formed by the incident light and light-receiving optical axes (vertical polarization).

(ii) Sample holder: a holder whose temperature can be measured and controlled within an accuracy of $\pm 0.3^\circ\text{C}$.

(iii) Measuring cell: a rectangular or cylindrical cell made of optical glass or optical plastic, which can be placed in the sample holder. The cell is integrated with the sample holder in some apparatus.

(iv) Light-receiving optics and detector: light optics and detector which capture the scattered light from the sample at a single scattering angle between 90° to 180° and convert the captured light to a photon pulse (digitized signal). In the case that a polarization analyzer is included, it shall be positioned so that the transmittance of the vertically polarized light is maximized.

(v) Correlator: a device which calculates the autocorrelation function from the number of photon pulses in a certain time.




Fig. 2 Different optical arrangements of the apparatus

(vi) Spectrum analyzer: a device which calculates the frequency power spectrum by performing Fourier transformation of the frequency components present in the scattered light fluctuation signals.

(vii) Computation unit: data processor for determining the particle diameter distribution from the autocorrelation function obtained by the correlator or from the frequency power spectrum. Some computation units also function as a correlator or spectrum analyzer.

2.2. Validation and reproducibility of the instrument

Because the particle diameter obtained by dynamic light scattering is not a relative value calculated using standard particles but an absolute value based on a fundamental principle, calibration of the value is unnecessary.

However, it is necessary to confirm the performance of the instrument by using particles with certified diameter, when the instrument is first installed or if abnormal performance is suspected. In addition, it is desirable to confirm the proper performance of the instrument at least every year thereafter.

As standard particles of known diameter, polystyrene latex particles with a narrow distribution of diameter shall be used, whose average particle size is certified to be approximately 100 nm as determined by dynamic light scattering. The measured average diameter of these particles must be within 2% of the stated diameter range, and the relative standard deviation must be less than 2%. In addition, the measured polydispersity index must be less than 0.1.

3. Measurement

3.1. Choice of the dispersion liquid

The dispersion liquid shall fulfill all of the following requirements.

- (i) It shall be non-absorbing at the wavelength of the laser.
- (ii) It shall not cause damage such as corrosion to the materials of the instrument.
- (iii) It shall not dissolve, swell or coagulate the particles.
- (iv) It shall have a refractive index different from that of the particulate material.
- (v) Its refractive index and viscosity shall be known within an accuracy of 0.5%.
- (vi) It shall be clean enough not to interfere with the measurements.

3.2. Cleaning the measuring cell

The degree of cell washing required depends on the conditions of the measurement.

When an individually packaged clean disposable cell is used, cleaning by blowing off dust with compressed clean air is sufficient. When a cell is intended to be washed rigorously, the cell is fully rinsed beforehand with water to remove water-rinsable adhesion substances and is washed with a nonabrasive detergent.

3.3. Sample preparation

It is necessary to prepare a sample whose concentration is within an appropriate range to eliminate the influence of the multiple scattering of light. In addition, it is important to remove dust, which may affect the measurement, and to prevent their re-introduction during the preparation.

When the sample is shaken, dust-laden air is entrapped in the sample and air is dissolved in the solvent. The invisible small air bubbles scatter light more strongly than do the sample particles to be measured. It is necessary not to shake the sample violently after preparation, but to swirl it gently. A homogeneous sample solution can be prepared quickly by adding diluent to the concentrated sample droplet rather than dropping the sample droplet into the diluent.

3.4. Measurement procedure

- 1) Switch the instrument on and allow it to warm up. A period of approximately 30 minutes is typically required for stabilizing the laser intensity and bringing the sample holder to the desired temperature.
- 2) Choose the appropriate dispersion liquid, and record the count rate or the amplitude of the signals of scattered light fluctuation from the dispersion liquid.
- 3) Place the sample containing the dispersed particles in the instrument, and wait until temperature equilibrium is established between the sample and the sample holder. It is desirable to control and measure the temperature within an accuracy of $\pm 0.3^{\circ}\text{C}$.
- 4) Perform a preliminary measurement of the sample, and set the particle concentration within the appropriate range based on 5.2.
- 5) Perform the measurement with the appropriate measuring time and number of integrations.
- 6) Record the average particle diameter and the polydispersity index for each measurement.
- 7) If the measured values are dependent on the particle concentration, adopt the extrapolated infinite dilution values of the average particle diameter and the polydispersity index (or the measured values at the lowest particle concentration).
- 8) Confirm that no significant sedimentation has occurred in the sample at the end of the measurement. The presence of sediment indicates that the sample may have aggregated or precipitated, or that the sample may be unsuitable for measurement by dynamic light scattering.
- 9) Perform the measurement for each sample at least three times.

3.5. Repeatability

The repeatability of the determination of the average particle diameter, evaluated in terms of relative standard deviation, must be less than 5%.

4. Data analysis

The dispersion that is the target for the measurement is irradiated with the laser light. Phases of the light scattered by each particle fluctuate because the dispersed particles are in Brownian motion. The observed scattered intensity, which is the sum of the scattered light (result of interference), fluctuates along the time axis. Analyzing the fluctuation of the scattered light intensity as a function of time provides information on the motion of the dispersed particles.

Analysis by photon correlation spectroscopy is performed using the autocorrelation function of the scattered light intensity. This autocorrelation function depend only on the time difference (correlation time) and is independent of the time at which the measurement is started. For a large number of monodisperse particles in Brownian motion in a scattering volume, the autocorrelation function of the scattered light intensity is basically an exponential decay function of the correlation time. Polydispersity index is a parameter indicating the distribution of the decay constant, and is also a scale indicating the broadness of the distribution of particle diameter.

Frequency analysis is performed using the frequency power spectrum calculated from the scattered light intensity. The amplitude of the frequency power spectrum is proportional to the scattered light intensity and the concentration of the sample, and the characteristic frequency is inversely proportional to the particle diameter. The decay constant and the characteristic frequency are related to the translational diffusion coefficient of homogeneous spherical particles in Brown-

nian motion. The diffusion constant of the spherical particles dispersed in the dispersion liquid is related to the particle diameter according to the Stokes-Einstein equation in the absence of inter-particle interaction. The polydispersity index determined by frequency analysis is a measure of the broadness of the particle diameter distribution calculated from the particle diameter distribution based on the scattered light intensity, and might differ from the polydispersity index determined by photon correlation spectroscopy.

Records of data shall include the average particle diameter and polydispersity index, and in addition, shall also state the principle of measurement (photon correlation spectroscopy or frequency analysis), optical configuration (homodyne or heterodyne), observation angle, temperature of the sample, refractive index and viscosity of the dispersion liquid, measuring time or number of integrations, and sample concentration.

5. Points to note regarding the measurement

5.1. Shape of particles

The particles are assumed to be homogeneous and spherical in the data analysis of dynamic light scattering.

5.2. Particle concentration

For measurement, it is necessary to prepare a sample whose concentration falls in the range satisfying the following conditions.

(i) The sample consists of dispersion liquid and particles well-dispersed in the liquid.

(ii) The range of the particle concentration is determined so that consistent results can be obtained in particle diameter measurements. The range is determined beforehand based on measurements of systematically diluted samples.

5.3. Purification of the dispersion liquid

Scattered light signals from the dispersion liquid used for sample dilution must normally be undetected or very weak. If the situations described in cases (i) or (ii) below are found, particulate substances are likely to have become mixed in the sample, and in such cases the dispersion liquid shall be further purified (by filtration, distillation, and so on) before use. The lower limit of the particle concentration is determined mainly so that scattered light from the dispersion liquid and contaminating substances will not affect the measurement. When water is chosen as the dispersion liquid, use of fresh distilled water (prepared by quartz-glass distillation) or desalinated and filtered (pore size 0.2 μm) water is recommended.

(i) Large fluctuations of the count rate or of the amplitude of the scattered light fluctuation signals, accompanied by abnormally strong signals, are recorded.

(ii) Light spots appear in the path of the laser light in the sample.

5.4. Others

(i) When particles are highly charged with electricity, long-range interactions between the particles may affect the measurement result, and in such cases, a small amount of salt (for example, sodium chloride: around 10⁻² mol/L) may be added to the dispersion liquid to reduce the effect.

(ii) Traceable polystyrene latex particles for use in the validation of the instrument are commercially available.

Reference

- 1) JIS Z8826: 2005 Particle size analysis—Photon correlation spectroscopy
- 2) ISO 13321: 1996 Particle size analysis—Photon correlation spectroscopy
- 3) ISO 22412: 2008 Particle size analysis—Dynamic light scattering (DLS)

Powder Fineness

This classification is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

A simple descriptive classification of powder fineness is provided in this chapter. Sieving is most suitable where a majority of the particles are larger than about 75 μm , although it can be used for some powders having smaller particle sizes where the method can be validated. Light diffraction is also a widely used technique for measuring the size of a wide range of particles.

Where the cumulative distribution has been determined by analytical sieving or by application of other methods, particle size may be characterized in the following manner:

- x_{90} : Particle size corresponding to 90% of the cumulative undersize distribution
- x_{50} : Median particle size (ie: 50% of the particles are smaller and 50% of the particles are larger)
- x_{10} : Particle size corresponding to 10% of the cumulative undersize distribution

It is recognized that the symbol d is also widely used to designate these values. Therefore, the symbols d_{90} , d_{50} , d_{10} may be used.

The following parameters may be defined based on the cumulative distribution.

$Q_r(x)$: cumulative distribution of particles with a dimension less than or equal to x where the subscript r reflects the distribution type

r	Distribution type
0	Number
1	Length
2	Area
3	Volume

Therefore, by definition:

$$Q_r(x) = 0.90 \text{ when } x = x_{90}$$

$$Q_r(x) = 0.50 \text{ when } x = x_{50}$$

$$Q_r(x) = 0.10 \text{ when } x = x_{10}$$

An alternative but less informative method of classifying powder fineness is by use of the descriptive terms in the following table.

Classification of powders by fineness		
Descriptive term	x_{50} (μm)	Cumulative distribution by volume basis, $Q_3(x)$
Coarse	> 355	$Q_3(355) < 0.50$
Moderately fine	180–355	$Q_3(180) < 0.50$ and $Q_3(355) \geq 0.50$
Fine	125–180	$Q_3(125) < 0.50$ and $Q_3(180) \geq 0.50$
Very fine	≤ 125	$Q_3(125) \geq 0.50$

Powder Flow

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia.

The widespread use of powders in the pharmaceutical industry has generated a variety of methods for characterizing powder flow. Not surprisingly, scores of references appear in the pharmaceutical literature, attempting to correlate the various measures of powder flow to manufacturing properties. The development of such a variety of test methods was inevitable; powder behavior is multifaceted and thus complicates the effort to characterize powder flow. The purpose of this chapter is to review the methods for characterizing powder flow that have appeared most frequently in the pharmaceutical literature. In addition, while it is clear that no single and simple test method can adequately characterize the flow properties of pharmaceutical powders, this chapter proposes the standardization of test methods that may be valuable during pharmaceutical development.

Four commonly reported methods for testing powder flow are (1) angle of repose, (2) compressibility index or Hausner ratio, (3) flow rate through an orifice, and (4) shear cell. In addition, numerous variations of each of these basic methods are available. Given the number of test methods and variations, standardizing the test methodology, where possible, would be advantageous.

With this goal in mind, the most frequently used methods are discussed below. Important experimental considerations are identified and recommendations are made regarding standardization of the methods. In general, any method of measuring powder flow should be practical, useful, reproducible, sensitive, and yield meaningful results. It bears repeating that no one simple powder flow method will adequately or completely characterize the wide range of flow properties experienced in the pharmaceutical industry. An appropriate strategy may well be the use of multiple standardized test methods to characterize the various aspects of powder flow as needed by the pharmaceutical scientist.

1. Angle of repose

The angle of repose has been used in several branches of science to characterize the flow properties of solids. Angle of repose is a characteristic related to interparticulate friction, or resistance to movement between particles. Angle of repose test results are reported to be very dependent upon the method used. Experimental difficulties arise due to segregation of material and consolidation or aeration of the powder as the cone is formed. Despite its difficulties, the method continues to be used in the pharmaceutical industry, and a number of examples demonstrating its value in predicting manufacturing problems appear in the literature.

The angle of repose is the constant, three-dimensional angle (relative to the horizontal base) assumed by a cone-like pile of material formed by any of several different methods (described briefly below).

1.1. Basic methods for angle of repose

A variety of angle of repose test methods are reported in the literature. The most common methods for determining the static angle of repose can be classified based on two important experimental variables:

- (i) The height of the "funnel" through which the powder passes may be fixed relative to the base, or the height may be varied as the pile forms.
- (ii) The base upon which the pile forms may be of fixed diameter or the diameter of the powder cone may be allowed to vary as the pile forms.

1.2. Variations in angle of repose methods

In addition to the above methods, variations of them have been used to some extent.

(i) Drained angle of repose: This is determined by allowing an excess quantity of material positioned above a fixed diameter base to "drain" from the container. Formation of a cone of powder on the fixed diameter base allows determination of the drained angle of repose.

(ii) Dynamic angle of repose: This is determined by filling a cylinder (with a clear, flat cover on one end) and rotating it at a specified speed. The dynamic angle of repose is the angle (relative to the horizontal) formed by the flowing powder. The internal angle of kinetic friction is defined by the plane separating those particles sliding down the top layer of the powder and those particles that are rotating with the drum (with roughened surface).

1.3. Angle of repose general scale of flowability

While there is some variation in the qualitative description of powder flow using the angle of repose, much of the pharmaceutical literature appears to be consistent with the classification by Carr¹⁾, which is shown in Table 1. There are examples of formulations with an angle of repose in the range of 40 to 50 degrees that manufactured satisfactorily. When the angle of repose exceeds 50 degrees, the flow is rarely acceptable for manufacturing purposes.

Table 1 Flow properties and corresponding angles of repose¹⁾

Flow property	Counter measure to prevent crosslink	Angle of repose (degrees)
Excellent		25 – 30
Good		31 – 35
Fair	aid not needed	36 – 40
Passable	may hang up	41 – 45
Poor	most agitate, vibrate	46 – 55
Very poor		56 – 65
Very, very poor		> 66

1.4. Experimental considerations for angle of repose

Angle of repose is not an intrinsic property of the powder, that is to say, it is very much dependent upon the method used to form the cone of powder. On this subject, the existing literature raises these important considerations:

(i) The peak of the cone of powder can be distorted by the impact of powder from above. By carefully building the powder cone, the distortion caused by impact can be minimized.

(ii) The nature of the base upon which the powder cone is formed influences the angle of repose. It is recommended that the powder cone be formed on a "common base", which can be achieved by forming the cone of powder on a layer of powder. This can be done by using a base of fixed diameter with a protruding outer edge to retain a layer of powder upon which the cone is formed.

1.5. Recommended procedure for angle of repose

Form the angle of repose on a fixed base with a retaining lip to retain a layer of powder on the base. The base should be free of vibration. Vary the height of the funnel to carefully build up a symmetrical cone of powder. Care should be taken to prevent vibration as the funnel is moved. The funnel height should be maintained approximately 2 – 4 cm from the top of the powder pile as it is being formed in order to minimize the impact of falling powder on the tip of the

cone. If a symmetrical cone of powder cannot be successfully or reproducibly prepared, this method is not appropriate. Determine the angle of repose by measuring the height of the cone of powder and calculating the angle of repose, α , from the following equation:

$$\tan \alpha = \text{height}/(\text{diameter of base} \times 0.5)$$

2. Compressibility index and Hausner ratio

In recent years the compressibility index and the closely related Hausner ratio have become the simple, fast and popular methods of predicting powder flow characteristics. The compressibility index has been proposed as an indirect measure of bulk density, size and shape, surface area, moisture content, and cohesiveness of materials because all of these can influence the observed compressibility index. The compressibility index and the Hausner ratio are determined by measuring both the bulk volume and tapped volume of a powder.

2.1. Basic methods for compressibility index and Hausner ratio

While there are some variations in the method of determining the compressibility index and Hausner ratio, the basic procedure is to measure (1) the unsettled apparent volume, V_o , and (2) the final tapped volume, V_f , of the powder after tapping the material until no further volume changes occur. The compressibility index and the Hausner ratio are calculated as follows:

$$\text{Compressibility Index} = (V_o - V_f)/V_o \times 100$$

$$\text{Hausner Ratio} = V_o/V_f$$

Alternatively, the compressibility index and Hausner ratio may be calculated using measured values for bulk density (ρ_{bulk}) and tapped density (ρ_{tapped}) as follows:

$$\text{Compressibility Index} = (\rho_{\text{tapped}} - \rho_{\text{bulk}})/\rho_{\text{tapped}} \times 100$$

$$\text{Hausner Ratio} = \rho_{\text{tapped}}/\rho_{\text{bulk}}$$

In a variation of these methods, the rate of consolidation is sometimes measured rather than, or in addition to, the change in volume that occurs on tapping. For the compressibility index and the Hausner ratio, the generally accepted scale of flowability is given in Table 2.

Table 2 Scale of flowability¹⁾

Compressibility index (%)	Flow character	Hausner ratio
≤ 10	Excellent	1.00 – 1.11
11 – 15	Good	1.12 – 1.18
16 – 20	Fair	1.19 – 1.25
21 – 25	Passable	1.26 – 1.34
26 – 31	Poor	1.35 – 1.45
32 – 37	Very poor	1.46 – 1.59
> 38	Very, very poor	> 1.60

2.2. Experimental considerations for the compressibility index and Hausner ratio

Compressibility index and Hausner ratio are not intrinsic properties of the powder, that is to say, they are dependent upon the methodology used. The existing literature points out several important considerations affecting the determination of the (1) unsettled apparent volume, V_o , (2) the final tapped volume, V_f , (3) the bulk density, ρ_{bulk} , and (4) the tapped density, ρ_{tapped} :

- (i) The diameter of the cylinder used
- (ii) The number of times the powder is tapped to achieve

the tapped density

- (iii) The mass of material used in the test
- (iv) Rotation of the sample during tapping

2.3. Recommended procedure for compressibility index and Hausner ratio

Use a 250-mL volumetric cylinder with a test sample weight of 100 g. Smaller weights and volumes may be used, but variations in the method should be described with the results. An average of three determinations is recommended.

3. Flow through an orifice

The flow rate of a material depends upon many factors, some of which are particle-related and some related to the process. Monitoring the rate of flow of material through an orifice has been proposed as a better measure of powder flowability. Of particular significance is the utility of monitoring flow continuously since pulsating flow patterns have been observed even for free flowing materials. Changes in flow rate as the container empties can also be observed. Empirical equations relating flow rate to the diameter of the opening, particle size, and particle density have been determined. However, determining the flow rate through an orifice is useful only with free-flowing materials.

The flow rate through an orifice is generally measured as the mass per time flowing from any of a number of types of containers (cylinders, funnels, hoppers). Measurement of the flow rate can be in discrete increments or continuous.

3.1. Basic methods for flow through an orifice

There are a variety of methods described in the literature. The most common for determining the flow rate through an orifice can be classified based on three important experimental variables:

(1) The type of container used to contain the powder. Common containers are cylinders, funnels and hoppers from production equipment.

(2) The size and shape of the orifice used. The orifice diameter and shape are critical factors in determining powder flow rate.

(3) The method of measuring powder flow rate. Flow rate can be measured continuously using an electronic balance and with some sort of recording device (strip chart recorder, computer). It can also be measured in discrete samples (for example, the time it takes for 100 g of powder to pass through the orifice to the nearest tenth of a second or the amount of powder passing through the orifice in 10 seconds to the nearest tenth of a gram).

3.2. Variations in methods for flow through an orifice

Either mass flow rate or volume flow rate can be determined. Mass flow rate is the easier of the methods, but it biases the results in favor of high-density materials. Since die fill is volumetric, determining volume flow rate may be preferable. A vibrator is occasionally attached to facilitate flow from the container, however, this appears to complicate interpretation of results. A moving orifice device has been proposed to more closely simulate rotary press conditions. The minimum diameter orifice through which powder flows can also be identified.

3.3. General scale of flowability for flow through an orifice

No general scale is available because flow rate is critically dependent on the method used to measure it. Comparison between published results is difficult.

3.4. Experimental considerations for flow through an orifice

Flow rate through an orifice is not an intrinsic property of the powder. It is very much dependent upon the methodology used. The existing literature points out several important

considerations affecting these methods:

- (i) The diameter and shape of the orifice
- (ii) The type of container material (metal, glass, plastic)
- (iii) The diameter and height of the powder bed.

3.5. Recommended procedure for flow through an orifice

Flow rate through an orifice can be used only for materials that have some capacity to flow. It is not useful for cohesive materials. Provided that the height of the powder bed (the 'head' of powder) is much greater than the diameter of the orifice, the flow rate is virtually independent of the powder head. Use a cylinder as the container because the cylinder material should have little effect on flow. This configuration results in flow rate being determined by the movement of powder over powder rather than powder along the wall of the container. Powder flow rate often increases when the height of the powder column is less than two times the diameter of the column. The orifice should be circular and the cylinder should be free of vibration. General guidelines for dimensions of the cylinder are as follows:

- (i) Diameter of opening > 6 times the diameter of the particles
- (ii) Diameter of the cylinder > 2 times the diameter of the opening

Use of a hopper as the container may be appropriate and representative of flow in a production situation. It is not advisable to use a funnel, particularly one with a stem, because flow rate will be determined by the size and length of the stem as well as the friction between the stem and the powder. A truncated cone may be appropriate, but flow will be influenced by the powder—wall friction coefficient, thus, selection of an appropriate construction material is important.

For the opening in the cylinder, use a flat-faced bottom plate with the option to vary orifice diameter to provide maximum flexibility and better ensure a powder-over-powder flow pattern. Rate measurement can be either discrete or continuous. Continuous measurement using an electronic balance can more effectively detect momentary flow rate variations.

4. Shear cell methods

In an effort to put powder flow studies and hopper design on a more fundamental basis, a variety of powder shear testers and methods that permit more thorough and precisely defined assessment of powder flow properties have been developed. Shear cell methodology has been used extensively in the study of pharmaceutical materials. From these methods, a wide variety of parameters can be obtained, including the yield loci representing the shear stress-shear strain relationship, the angle of internal friction, the unconfined yield strength, the tensile strength, and a variety of derived parameters such as the flow factor and other flowability indices. Because of the ability to more precisely control experimental parameters, flow properties can also be determined as a function of consolidation load, time, and other environmental conditions. The methods have been successfully used to determine critical hopper and bin parameters.

4.1. Basic methods for shear cell

One type of shear cell is the cylindrical shear cell which is split horizontally, forming a shear plane between the lower stationary base and the upper movable portion of the shear cell ring. After powder bed consolidation in the shear cell (using a well-defined procedure), the force necessary to shear the powder bed by moving the upper ring is determined. Annular shear cell designs offer some advantages over the cylindrical shear cell design, including the need for less material. A disadvantage, however, is that because of its design,

the powder bed is not sheared as uniformly because material on the outside of the annulus is sheared more than material in the inner region. A third type of shear cell (plate-type) consists of a thin sandwich of powder between a lower stationary rough surface and an upper rough surface that is moveable.

All of the shear cell methods have their advantages and disadvantages, but a detailed review is beyond the scope of this chapter. As with the other methods for characterizing powder flow, many variations are described in the literature. A significant advantage of shear cell methodology in general is a greater degree of experimental control. The methodology generally is rather time-consuming and requires significant amounts of material and a well-trained operator.

4.2. Recommendations for shear cell

The many existing shear cell configurations and test methods provide a wealth of data and can be used very effectively to characterize powder flow. They are also helpful in the design of equipment such as hoppers and bins.

Because of the diversity of available equipment and experimental procedures, no specific recommendations regarding methodology are presented in this chapter. It is recommended that the results of powder flow characterization using shear cell methodology include a complete description of equipment and methodology used.

References

- 1) Carr R.L.: Evaluating flow properties of solids. *Chem. Eng.* 1965; 72: 163–168.

Solid and Particle Densities

Density of a solid or a powder as a state of aggregation has different definitions depending on the way of including of the interparticulate and intraparticulate voids that exist between the particles or inside the powder. Different figures are obtained in each case, and there are different practical meanings. Generally, there are three levels of definitions of the solid or powder density.

(1) Crystal density: It is assumed that the system is homogeneous with no intraparticulate void. Crystal density is also called true density.

(2) Particle density: The sealed pores or the experimentally non-accessible open pores is also included as a part of the volumes of the solid or the powder.

(3) Bulk density: The interparticulate void formed in the powder bed is also included as a part of the volumes of the solid or the powder. Bulk density is also called apparent density. Generally, the powder densities at loose packing and at tapping are defined as the bulk density and the tapped density, respectively.

Generally, the densities of liquid or gas are affected only by temperature and pressure, but the solid or powder density is affected by the state of aggregation of the molecules or the particles. Therefore, the solid or powder densities naturally vary depending on crystal structure or crystallinity of the substance concerned, and also varies depending on the method of preparation or handling if the sample is amorphous form or partially amorphous. Consequently, even in a case that two solids or powders are chemically identical, it may be possible that the different figures of density are obtained if their crystal structures are different. As the solid or powder particle densities are important physical properties for the powdered pharmaceutical drugs or the powdered raw materials of drugs, the Japanese Pharmacopoeia specifies

each density determination as “Powder Particle Density Determination” for the particle density and as “Determination of Bulk and Tapped Densities” for the bulk density.

The solid or powder densities are expressed in mass per unit volume (kg/m^3), and generally expressed in g/cm^3 ($1 \text{ g}/\text{cm}^3 = 1000 \text{ kg}/\text{m}^3$).

Crystal Density

The crystal density of a substance is the average mass per unit volume, exclusive of all voids that are not a fundamental part of the molecular packing arrangement. It is an intrinsic property concerning the specific crystal structure of the substance, and is not affected by the method of determination. The crystal density can be determined either by calculation or by simple measurement.

- A. The calculated crystal density is obtained using:
 - 1) For example, the crystallographic data (volume and composition of the unit cell) obtained by indexing the perfect crystal X-ray diffraction data from single crystal or the powder X-ray diffraction data.
 - 2) Molecular mass of the substance.
- B. The measured crystal density is obtained as the mass to volume ratio after measuring the single crystal mass and volume.

Particle Density

The particle density takes account both the crystal density and the intraparticulate porosity (sealed and/or experimentally non-accessible open pores) as a part of the particle volume. The particle density depends on the value of the volume determined, and the volume in turn depends on the method of measurement. Particle density can be determined either by gas displacement pycnometry or mercury porosimetry, but the Japanese Pharmacopoeia specifies the pycnometry as the “Powder Particle Density Determination”.

- A. The pycnometric density is obtained by assuming that the volume of the gas displaced, which is measured with the gas displacement pycnometer, is equivalent to that of a known mass of the powder. In pycnometric density measurements, any volume with the open pores accessible to the gas is not included as a part of volume of the powder, but the sealed pores or pores inaccessible to the gas is included as a part of the volume of the powder. Due to the high diffusivity of helium which can penetrate to most open pores, it is recommendable as the measurement gas of particle density. Therefore, the pycnometric particle density of a finely milled powder is generally not very different from the crystal density. Hence, the particle density by this method is the best estimate of the true density of an amorphous or partially crystalline sample, and can be widely used for manufacturing control of the processed pharmaceutical powder samples.
- B. The mercury porosimetric density is also called granular density. This method also includes the sealed pores as a part of the volumes of the solid or the powder, but excludes the volume only from the open pores larger than some size limit. This pore size limit or minimal access diameter depends on the maximal mercury intrusion pressure applied during the measurement and under normal operating pressure, the mercury does not penetrate the finest pores accessible to helium. Since this method is capable of measuring the density which corresponds to the pore size limit at each mercury intrusion pressure, the various granular densities can be obtained from one sample.

Bulk Density and Tapped Density

The bulk density of a powder includes the contribution of interparticulate void volume as a part of the volume of the powder. Therefore, the bulk density depends on both the powder particle density and the space arrangement of particles in the power bed. Further, since the slightest disturbance of the bed may result in variation of the space arrangement, it is often very difficult to determine the bulk density with good reproducibility. Therefore, it is essential to specify how the determination was made upon reporting the bulk density.

The Japanese Pharmacopoeia specifies “Determination of Bulk and Tapped Densities”.

- A. The bulk density is determined by measuring the apparent volume of a known mass of powder sample that has been passed through a screen in a graduated cylinder (constant mass method). Separately, the Pharmacopoeia specifies the method of determining bulk density by measuring the mass of powder in a vessel having a known volume (constant volume method).
- B. The tapped density is obtained by mechanically tapping a measuring cylinder containing a powder sample. After determining the initial bulk volume, carry out tapping under a fixed measurement condition (tapping rate and drop height), and the measurement is carried out repeatedly until the bulk volume variation obtained at consecutive two measurements is within an acceptable range (constant mass method). Separately, the Pharmacopoeia specifies the method of determining the tapped density by measuring the mass of a fixed volume of the tapped powder (constant volume method).

G3 Biotechnological/Biological Products

Amino Acid Analysis

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia.

Amino acid analysis refers to the methodology used to determine the amino acid composition or content of proteins, peptides, and other pharmaceutical preparations. Proteins and peptides are macromolecules consisting of covalently bonded amino acid residues organized as a linear polymer. The sequence of the amino acids in a protein or peptide determines the properties of the molecule. Proteins are considered large molecules that commonly exist as folded structures with a specific conformation, while peptides are smaller and may consist of only a few amino acids. Amino acid analysis can be used to quantify protein and peptides, to determine the identity of proteins or peptides based on their amino acid composition, to support protein and peptide structure analysis, to evaluate fragmentation strategies for peptide mapping, and to detect atypical amino acids that might be present in a protein or peptide. It is necessary to hydrolyze a protein/peptide to its individual amino acid constituents before amino acid analysis. Following protein/peptide hydrolysis, the amino acid analysis procedure can be the same as that practiced for free amino acids in other pharmaceutical preparations. The amino acid constituents of the test sample are typically derivatized for analysis.

Apparatus

Methods used for amino acid analysis are usually based on

a chromatographic separation of the amino acids present in the test sample. Current techniques take advantage of the automated chromatographic instrumentation designed for analytical methodologies. An amino acid analysis instrument will typically be a low-pressure or high-pressure liquid chromatograph capable of generating mobile phase gradients that separate the amino acid analytes on a chromatographic column. The instrument must have postcolumn derivatization capability, unless the sample is analyzed using precolumn derivatization. The detector is usually an ultraviolet-visible or fluorescence detector depending on the derivatization method used. A recording device (e.g., integrator) is used for transforming the analog signal from the detector and for quantitation. It is preferred that instrumentation be dedicated particularly for amino acid analysis.

General Precautions

Background contamination is always a concern for the analyst in performing amino acid analysis. High purity reagents are necessary (e.g., low purity hydrochloric acid can contribute to glycine contamination). Analytical reagents are changed routinely every few weeks using only high-pressure liquid chromatography (HPLC) grade solvents. Potential microbial contamination and foreign material that might be present in the solvents are reduced by filtering solvents before use, keeping solvent reservoirs covered, and not placing amino acid analysis instrumentation in direct sunlight.

Laboratory practices can determine the quality of the amino acid analysis. Place the instrumentation in a low traffic area of the laboratory. Keep the laboratory clean. Clean and calibrate pipets according to a maintenance schedule. Keep pipet tips in a covered box; the analysts may not handle pipet tips with their hands. The analysts may wear powder-free latex or equivalent gloves. Limit the number of times a test sample vial is opened and closed because dust can contribute to elevated levels of glycine, serine, and alanine.

A well-maintained instrument is necessary for acceptable amino acid analysis results. If the instrument is used on a routine basis, it is to be checked daily for leaks, detector and lamp stability, and the ability of the column to maintain resolution of the individual amino acids. Clean or replace all instrument filters and other maintenance items on a routine schedule.

Reference Standard Material

Acceptable amino acid standards are commercially available for amino acid analysis and typically consist of an aqueous mixture of amino acids. When determining amino acid composition, protein or peptide standards are analyzed with the test material as a control to demonstrate the integrity of the entire procedure. Highly purified bovine serum albumin has been used as a protein standard for this purpose.

Calibration of Instrumentation

Calibration of amino acid analysis instrumentation typically involves analyzing the amino acid standard, which consists of a mixture of amino acids at a number of concentrations, to determine the response factor and range of analysis for each amino acid. The concentration of each amino acid in the standard is known. In the calibration procedure, the analyst dilutes the amino acid standard to several different analyte levels within the expected linear range of the amino acid analysis technique. Then, replicates at each of the different analyte levels can be analyzed. Peak areas obtained for each amino acid are plotted versus the known concentration for each of the amino acids in the standard dilution. These results will allow the analyst to determine the range of

amino acid concentrations where the peak area of a given amino acid is an approximately linear function of the amino acid concentration. It is important that the analyst prepare the samples for amino acid analysis so that they are within the analytical limits (e.g., linear working range) of the technique employed in order to obtain accurate and repeatable results.

Four to six amino acid standard levels are analyzed to determine a response factor for each amino acid. The response factor is calculated as the average peak area or peak height per nmol of amino acid present in the standard. A calibration file consisting of the response factor for each amino acid is prepared and used to calculate the concentration of each amino acid present in the test sample. This calculation involves dividing the peak area corresponding to a given amino acid by the response factor for that amino acid to give the nmol of the amino acid. For routine analysis, a single-point calibration may be sufficient; however, the calibration file is updated frequently and tested by the analysis of analytical controls to ensure its integrity.

Repeatability

Consistent high quality amino acid analysis results from an analytical laboratory require attention to the repeatability of the assay. During analysis of the chromatographic separation of the amino acids or their derivatives, numerous peaks can be observed on the chromatogram that correspond to the amino acids. The large number of peaks makes it necessary to have an amino acid analysis system that can repeatedly identify the peaks based on retention time and integrate the peak areas for quantitation. A typical repeatability evaluation involves preparing a standard amino acid solution and analyzing many replicates (i.e., six analyses or more) of the same standard solution. The relative standard deviation (RSD) is determined for the retention time and integrated peak area of each amino acid. An evaluation of the repeatability is expanded to include multiple assays conducted over several days by different analysts. Multiple assays include the preparation of standard dilutions from starting materials to determine the variation due to sample handling. Often the amino acid composition of a standard protein (e.g., bovine serum albumin) is analyzed as part of the repeatability evaluation. By evaluating the replicate variation (i.e., RSD), the laboratory can establish analytical limits to ensure that the analyses from the laboratory are under control. It is desirable to establish the lowest practical variation limits to ensure the best results. Areas to focus on to lower the variability of the amino acid analysis include sample preparation, high background spectral interference due to quality of reagents and/or laboratory practices, instrument performance and maintenance, data analysis and interpretation, and analyst performance and habits. All parameters involved are fully investigated in the scope of the validation work.

Sample Preparation

Accurate results from amino acid analysis require purified protein and peptide samples. Buffer components (e.g., salts, urea, detergents) can interfere with the amino acid analysis and are removed from the sample before analysis. Methods that utilize postcolumn derivatization of the amino acids are generally not affected by buffer components to the extent seen with precolumn derivatization methods. It is desirable to limit the number of sample manipulations to reduce potential background contamination, to improve analyte recovery, and to reduce labor. Common techniques used to remove buffer components from protein samples include the following methods: (1) injecting the protein sample onto a reversed-phase HPLC system, eluting the protein with a

volatile solvent containing a sufficient organic component, and drying the sample in a vacuum centrifuge; (2) dialysis against a volatile buffer or water; (3) centrifugal ultrafiltration for buffer replacement with a volatile buffer or water; (4) precipitating the protein from the buffer using an organic solvent (e.g., acetone); and (5) gel filtration.

Internal Standards

It is recommended that an internal standard be used to monitor physical and chemical losses and variations during amino acid analysis. An accurately known amount of internal standard can be added to a protein solution prior to hydrolysis. The recovery of the internal standard gives the general recovery of the amino acids of the protein solution. Free amino acids, however, do not behave in the same way as protein-bound amino acids during hydrolysis because their rates of release or destruction are variable. Therefore, the use of an internal standard to correct for losses during hydrolysis may give unreliable results. It will be necessary to take this point under consideration when interpreting the results. Internal standards can also be added to the mixture of amino acids after hydrolysis to correct for differences in sample application and changes in reagent stability and flow rates. Ideally, an internal standard is an unnaturally occurring primary amino acid that is commercially available and inexpensive. It should also be stable during hydrolysis, its response factor should be linear with concentration, and it needs to elute with a unique retention time without overlapping other amino acids. Commonly used amino acid standards include norleucine, nitrotyrosine, and α -aminobutyric acid.

Protein Hydrolysis

Hydrolysis of protein and peptide samples is necessary for amino acid analysis of these molecules. The glassware used for hydrolysis must be very clean to avoid erroneous results. Glove powders and fingerprints on hydrolysis tubes may cause contamination. To clean glass hydrolysis tubes, boil tubes for 1 hour in 1 mol/L hydrochloric acid or soak tubes in concentrated nitric acid or in a mixture of concentrated hydrochloric acid and concentrated nitric acid (1:1). Clean hydrolysis tubes are rinsed with high-purity water followed by a rinse with HPLC grade methanol, dried overnight in an oven, and stored covered until use. Alternatively, pyrolysis of clean glassware at 500°C for 4 hours may also be used to eliminate contamination from hydrolysis tubes. Adequate disposable laboratory material can also be used.

Acid hydrolysis is the most common method for hydrolyzing a protein sample before amino acid analysis. The acid hydrolysis technique can contribute to the variation of the analysis due to complete or partial destruction of several amino acids. Tryptophan is destroyed; serine and threonine are partially destroyed; methionine might undergo oxidation; and cysteine is typically recovered as cystine (but cystine recovery is usually poor because of partial destruction or reduction to cysteine). Application of adequate vacuum (\leq less than 200 μ m of mercury or 26.7 Pa) or introduction of an inert gas (argon) in the headspace of the reaction vessel can reduce the level of oxidative destruction. In peptide bonds involving isoleucine and valine the amido bonds of Ile-Ile, Val-Val, Ile-Val, and Val-Ile are partially cleaved; and asparagine and glutamine are deamidated, resulting in aspartic acid and glutamic acid, respectively. The loss of tryptophan, asparagine, and glutamine during an acid hydrolysis limits quantitation to 17 amino acids. Some of the hydrolysis techniques described are used to address these concerns. Some of the hydrolysis techniques described (i.e., *Methods 4-11*) may cause modifications to other amino

acids. Therefore, the benefits of using a given hydrolysis technique are weighed against the concerns with the technique and are tested adequately before employing a method other than acid hydrolysis.

A time-course study (i.e., amino acid analysis at acid hydrolysis times of 24, 48, and 72 hours) is often employed to analyze the starting concentration of amino acids that are partially destroyed or slow to cleave. By plotting the observed concentration of labile amino acids (i.e., serine and threonine) versus hydrolysis time, the line can be extrapolated to the origin to determine the starting concentration of these amino acids. Time-course hydrolysis studies are also used with amino acids that are slow to cleave (e.g., isoleucine and valine). During the hydrolysis time course, the analyst will observe a plateau in these residues. The level of this plateau is taken as the residue concentration. If the hydrolysis time is too long, the residue concentration of the sample will begin to decrease, indicating destruction by the hydrolysis conditions.

An acceptable alternative to the time-course study is to subject an amino acid calibration standard to the same hydrolysis conditions as the test sample. The amino acid in free form may not completely represent the rate of destruction of labile amino acids within a peptide or protein during the hydrolysis. This is especially true for peptide bonds that are slow to cleave (e.g., Ile-Val bonds). However, this technique will allow the analyst to account for some residue destruction. Microwave acid hydrolysis has been used and is rapid but requires special equipment as well as special precautions. The optimal conditions for microwave hydrolysis must be investigated for each individual protein/peptide sample. The microwave hydrolysis technique typically requires only a few minutes, but even a deviation of one minute may give inadequate results (e.g., incomplete hydrolysis or destruction of labile amino acids). Complete proteolysis, using a mixture of proteases, has been used but can be complicated, requires the proper controls, and is typically more applicable to peptides than proteins.

Note: During initial analyses of an unknown protein, experiments with various hydrolysis time and temperature conditions are conducted to determine the optimal conditions.

Method 1

Acid hydrolysis using hydrochloric acid containing phenol is the most common procedure used for protein/peptide hydrolysis preceding amino acid analysis. The addition of phenol to the reaction prevents the halogenation of tyrosine.

Hydrolysis Solution 6 mol/L hydrochloric acid containing 0.1% to 1.0% of phenol.

Procedure—

Liquid Phase Hydrolysis Place the protein or peptide sample in a hydrolysis tube, and dry. [Note: The sample is dried so that water in the sample will not dilute the acid used for the hydrolysis.] Add 200 μ L of *Hydrolysis Solution* per 500 μ g of lyophilized protein. Freeze the sample tube in a dry ice-acetone bath, and flame seal in vacuum. Samples are typically hydrolyzed at 110°C for 24 hours in vacuum or inert atmosphere to prevent oxidation. Longer hydrolysis times (e.g., 48 and 72 hours) are investigated if there is a concern that the protein is not completely hydrolyzed.

Vapor Phase Hydrolysis This is one of the most common acid hydrolysis procedures, and it is preferred for microanalysis when only small amounts of the sample are available. Contamination of the sample from the acid reagent is also minimized by using vapor phase hydrolysis. Place vials containing the dried samples in a vessel that contains an appropriate amount of *Hydrolysis Solution*. The *Hydrolysis*

Solution does not come in contact with the test sample. Apply an inert atmosphere or vacuum (\leq less than 200 μm of mercury or 26.7 Pa) to the headspace of the vessel, and heat to about 110°C for a 24-hour hydrolysis time. Acid vapor hydrolyzes the dried sample. Any condensation of the acid in the sample vials is minimized. After hydrolysis, dry the test sample in vacuum to remove any residual acid.

Method 2

Tryptophan oxidation during hydrolysis is decreased by using mercaptoethanesulfonic acid (MESA) as the reducing acid.

Hydrolysis Solution 2.5 mol/L MESA solution.

Vapor Phase Hydrolysis About 1 to 100 μg of the protein/peptide under test is dried in a hydrolysis tube. The hydrolysis tube is placed in a larger tube with about 200 μL of the *Hydrolysis Solution*. The larger tube is sealed in vacuum (about 50 μm of mercury or 6.7 Pa) to vaporize the *Hydrolysis Solution*. The hydrolysis tube is heated to 170°C to 185°C for about 12.5 minutes. After hydrolysis, the hydrolysis tube is dried in vacuum for 15 minutes to remove the residual acid.

Method 3

Tryptophan oxidation during hydrolysis is prevented by using thioglycolic acid (TGA) as the reducing acid.

Hydrolysis Solution A solution containing 7 mol/L hydrochloric acid, 10% of trifluoroacetic acid, 20% of thioglycolic acid, and 1% of phenol.

Vapor Phase Hydrolysis About 10 to 50 μg of the protein/peptide under test is dried in a sample tube. The sample tube is placed in a larger tube with about 200 μL of the *Hydrolysis Solution*. The larger tube is sealed in vacuum (about 50 μm of mercury or 6.7 Pa) to vaporize the TGA. The sample tube is heated to 166°C for about 15 to 30 minutes. After hydrolysis, the sample tube is dried in vacuum for 5 minutes to remove the residual acid. Recovery of tryptophan by this method may be dependent on the amount of sample present.

Method 4

Cysteine-cystine and methionine oxidation is performed with formic acid before the protein hydrolysis.

Oxidation Solution The formic acid is prepared fresh by mixing formic acid and 30 percent hydrogen peroxide (9:1), and incubated at room temperature for 1 hour.

Procedure The protein/peptide sample is dissolved in 20 μL of formic acid, and heated at 50°C for 5 minutes; then 100 μL of the *Oxidation Solution* is added. The oxidation is allowed to proceed for 10 to 30 minutes. In this reaction, cysteine is converted to cysteic acid and methionine is converted to methionine sulfone. The excess reagent is removed from the sample in a vacuum centrifuge. This technique may cause modifications to tyrosine residues in the presence of halides. The oxidized protein can then be acid hydrolyzed using *Method 1* or *Method 2*.

Method 5

Cysteine-cystine oxidation is accomplished during the liquid phase hydrolysis with sodium azide.

Hydrolysis Solution 6 mol/L hydrochloric acid containing 0.2% of phenol, to which is added sodium azide to obtain a final concentration of 0.2% (w/v). The added phenol prevents halogenation of tyrosine.

Liquid Phase Hydrolysis The protein/peptide hydrolysis is conducted at about 110°C for 24 hours. During the hydrolysis, the cysteine-cystine present in the sample is converted to cysteic acid by the sodium azide present in the *Hydrolysis Solution*. This technique allows better tyrosine

recovery than *Method 4*, but it is not quantitative for methionine. Methionine is converted to a mixture of the parent methionine and its two oxidative products, methionine sulfoxide and methionine sulfone.

Method 6

Cysteine-cystine oxidation is accomplished with dimethyl sulfoxide (DMSO).

Hydrolysis Solution 6 mol/L hydrochloric acid containing 0.1% to 1.0% of phenol, to which DMSO is added to obtain a final concentration of 2% (v/v).

Vapor Phase Hydrolysis The protein/peptide hydrolysis is conducted at about 110°C for 24 hours. During the hydrolysis, the cysteine-cystine present in the sample is converted to cysteic acid by the DMSO present in the *Hydrolysis Solution*. As an approach to limit variability and compensate for partial destruction, it is recommended to evaluate the cysteic acid recovery from oxidative hydrolyses of standard proteins containing 1 to 8 mol of cysteine. The response factors from protein/peptide hydrolysates are typically about 30% lower than those for nonhydrolyzed cysteic acid standards. Because histidine, methionine, tyrosine, and tryptophan are also modified, a complete compositional analysis is not obtained with this technique.

Method 7

Cysteine-cystine reduction and alkylation is accomplished by a vapor phase pyridylethylation reaction.

Reducing Solution Transfer 83.3 μL of pyridine, 16.7 μL of 4-vinylpyridine, 16.7 μL of tributylphosphine, and 83.3 μL of water to a suitable container, and mix.

Procedure Add the protein/peptide (between 1 and 100 μg) to a hydrolysis tube, and place in a larger tube. Transfer the *Reducing Solution* to the large tube, seal in vacuum (about 50 μm of mercury or 6.7 Pa), and incubate at about 100°C for 5 minutes. Then remove the inner hydrolysis tube, and dry it in a vacuum desiccator for 15 minutes to remove residual reagents. The pyridylethylated protein/peptide can then be acid hydrolyzed using previously described procedures. The pyridylethylation reaction is performed simultaneously with a protein standard sample containing 1 to 8 mol of cysteine to improve accuracy in the pyridylethylcysteine recovery. Longer incubation times for the pyridylethylation reaction can cause modifications to the α -amino terminal group and the ϵ -amino group of lysine in the protein.

Method 8

Cysteine-cystine reduction and alkylation is accomplished by a liquid phase pyridylethylation reaction.

Stock Solutions Prepare and filter three solutions: 1 mol/L Tris hydrochloride (pH 8.5) containing 4 mmol/L disodium dihydrogen ethylenediamine tetraacetate (*Stock Solution A*), 8 mol/L guanidine hydrochloride (*Stock Solution B*), and 10% of 2-mercaptopethanol in water (*Stock Solution C*).

Reducing Solution Prepare a mixture of *Stock Solution B* and *Stock Solution A* (3:1) to obtain a buffered solution of 6 mol/L guanidine hydrochloride in 0.25 mol/L Tris hydrochloride.

Procedure Dissolve about 10 μg of the test sample in 50 μL of the *Reducing Solution*, and add about 2.5 μL of *Stock Solution C*. Store under nitrogen or argon for 2 hours at room temperature in the dark. To achieve the pyridylethylation reaction, add about 2 μL of 4-vinylpyridine to the protein solution, and incubate for an additional 2 hours at room temperature in the dark. The protein/peptide is desalted by collecting the protein/peptide fraction from a reversed-phase

HPLC separation. The collected sample can be dried in a vacuum centrifuge before acid hydrolysis.

Method 9

Cysteine-cystine reduction and alkylation is accomplished by a liquid phase carboxymethylation reaction.

Stock Solutions Prepare as directed for *Method 8*.

Carboxymethylation Solution Prepare a solution containing 100 mg of iodoacetamide per mL of ethanol (95).

Buffer Solution Use the *Reducing Solution*, prepared as directed for *Method 8*.

Procedure Dissolve the test sample in 50 μ L of the *Buffer Solution*, and add about 2.5 μ L of *Stock Solution C*. Store under nitrogen or argon for 2 hours at room temperature in the dark. Add the *Carboxymethylation Solution* in a ratio 1.5 fold per total theoretical content of thiols, and incubate for an additional 30 minutes at room temperature in the dark. [Note: If the thiol content of the protein is unknown, then add 5 μ L of 100 mmol/L iodoacetamide for every 20 nmol of protein present.] The reaction is stopped by adding excess of 2-mercaptoethanol. The protein/peptide is desalted by collecting the protein/peptide fraction from a reversed-phase HPLC separation. The collected sample can be dried in a vacuum centrifuge before acid hydrolysis. The S-carboxyamidomethyl-cysteine formed will be converted to S-carboxymethylcysteine during acid hydrolysis.

Method 10

Cysteine-cystine is reacted with dithiodiglycolic acid or dithiodipropionic acid to produce a mixed disulfide. [Note: The choice of dithiodiglycolic acid or dithiodipropionic acid depends on the required resolution of the amino acid analysis method.]

Reducing Solution A solution containing 10 mg of dithiodiglycolic acid (or dithiodipropionic acid) per mL of 0.2 mol/L sodium hydroxide.

Procedure Transfer about 20 μ g of the test sample to a hydrolysis tube, and add 5 μ L of the *Reducing Solution*. Add 10 μ L of isopropyl alcohol, and then remove all of the sample liquid by vacuum centrifugation. The sample is then hydrolyzed using *Method 1*. This method has the advantage that other amino acid residues are not derivatized by side reactions, and the sample does not need to be desalted prior to hydrolysis.

Method 11

Asparagine and glutamine are converted to aspartic acid and glutamic acid, respectively, during acid hydrolysis. Asparagine and aspartic acid residues are added and represented by *Asx*, while glutamine and glutamic acid residues are added and represented by *Glx*. Proteins/peptides can be reacted with bis(1,1-trifluoroacetoxy)iodobenzene (BTI) to convert the asparagine and glutamine residues to diaminopropionic acid and diaminobutyric acid residues, respectively, upon acid hydrolysis. These conversions allow the analyst to determine the asparagine and glutamine content of a protein/peptide in the presence of aspartic acid and glutamic acid residues.

Reducing Solutions Prepare and filter three solutions: a solution of 10 mmol/L trifluoroacetic acid (*Solution A*), a solution of 5 mol/L guanidine hydrochloride and 10 mmol/L trifluoroacetic acid (*Solution B*), and a freshly prepared solution of *N,N*-dimethylformamide containing 36 mg of BTI per mL (*Solution C*).

Procedure In a clean hydrolysis tube, transfer about 200 μ g of the test sample, and add 2 mL of *Solution A* or *Solution B* and 2 mL of *Solution C*. Seal the hydrolysis tube in vacuum. Heat the sample at 60°C for 4 hours in the dark.

The sample is then dialyzed with water to remove the excess reagents. Extract the dialyzed sample three times with equal volumes of *n*-butyl acetate, and then lyophilize. The protein can then be acid hydrolyzed using previously described procedures. The α,β -diaminopropionic and α,γ -diaminobutyric acid residues do not typically resolve from the lysine residues upon ion-exchange chromatography based on amino acid analysis. Therefore, when using ion-exchange as the mode of amino acid separation, the asparagine and glutamine contents are the quantitative difference in the aspartic acid and glutamic acid content assayed with underivatized and BTI-derivatized acid hydrolysis. [Note: The threonine, methionine, cysteine, tyrosine, and histidine assayed content can be altered by BTI derivatization; a hydrolysis without BTI will have to be performed if the analyst is interested in the composition of these other amino acid residues of the protein/peptide.]

Methodologies of Amino Acid Analysis General Principles

Many amino acid analysis techniques exist, and the choice of any one technique often depends on the sensitivity required from the assay. In general, about one-half of the amino acid analysis techniques employed rely on the separation of the free amino acids by ion-exchange chromatography followed by postcolumn derivatization (e.g., with ninhydrin or *o*-phthalaldehyde). Postcolumn detection techniques can be used with samples that contain small amounts of buffer components, such as salts and urea, and generally require between 5 and 10 μ g of protein sample per analysis. The remaining amino acid techniques typically involve pre-column derivatization of the free amino acids (e.g., phenyl isothiocyanate; 6-aminoquinolyl-*N*-hydroxysuccinimidyl carbamate or *o*-phthalaldehyde; (dimethylamino)azobenzenesulfonyl chloride; 9-fluorenylmethylchloroformate; and, 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole) followed by reversed-phase HPLC. Precolumn derivatization techniques are very sensitive and usually require between 0.5 and 1.0 μ g of protein sample per analysis but may be influenced by buffer salts in the samples. Precolumn derivatization techniques may also result in multiple derivatives of a given amino acid, which complicates the result interpretation. Postcolumn derivatization techniques are generally influenced less by performance variation of the assay than precolumn derivatization techniques.

The following *Methods* may be used for quantitative amino acid analysis. Instruments and reagents for these procedures are available commercially. Furthermore, many modifications of these methodologies exist with different reagent preparations, reaction procedures, chromatographic systems, etc. Specific parameters may vary according to the exact equipment and procedure used. Many laboratories will utilize more than one amino acid analysis technique to exploit the advantages offered by each. In each of these *Methods*, the analog signal is visualized by means of a data acquisition system, and the peak areas are integrated for quantification purposes.

Method 1—Postcolumn Ninhydrin Detection General Principle

Ion-exchange chromatography with postcolumn ninhydrin detection is one of the most common methods employed for quantitative amino acid analysis. As a rule, a Li-based cation-exchange system is employed for the analysis of the more complex physiological samples, and the faster Na-based cation-exchange system is used for the more simplistic amino acid mixtures obtained with protein hydrolysates (typically containing 17 amino acid components). Separation of the amino acids on an ion-exchange column is accom-

plished through a combination of changes in pH and cation strength. A temperature gradient is often employed to enhance separation.

When the amino acid reacts with ninhydrin, the reactant has characteristic purple or yellow color. Amino acids, except imino acid, give a purple color, and show the maximum absorption at 570 nm. The imino acids such as proline give a yellow color, and show the maximum absorption at 440 nm. The postcolumn reaction between ninhydrin and amino acid eluted from column is monitored at 440 and 570 nm, and the chromatogram obtained is used for the determination of amino acid composition.

Detection limit is considered to be 10 pmol for most of the amino acid derivatives, but 50 pmol for proline. Response linearity is obtained in the range of 20 to 500 pmol with correlation coefficients exceeding 0.999. To obtain good composition data, samples larger than 1 μ g before hydrolysis are best suited for this amino acid analysis of protein/peptide.

Method 2—Postcolumn OPA Fluorometric Detection General Principle

o-Phthalaldehyde (OPA) reacts with primary amines in the presence of thiol compound, to form highly fluorescent isoindole products. This reaction is utilized for the postcolumn derivatization in analysis of amino acids by ion-exchange chromatography. The rule of the separation is the same as *Method 1*. Instruments and reagents for this form of amino acid analysis are available commercially. Many modifications of this methodology exist.

Although OPA does not react with secondary amines (imino acids such as proline) to form fluorescent substances, the oxidation with sodium hypochlorite allows secondary amines to react with OPA. The procedure employs a strongly acidic cation-exchange column for separation of free amino acids followed by postcolumn oxidation with sodium hypochlorite and postcolumn derivatization using OPA and thiol compound such as *N*-acetyl-L-cysteine and 2-mercaptopethanol. The derivatization of primary amino acids are not noticeably affected by the continuous supply of sodium hypochlorite.

Separation of the amino acids on an ion-exchange column is accomplished through a combination of changes in pH and cation strength. After postcolumn derivatization of eluted amino acids with OPA, the reactant passes through the fluorometric detector. Fluorescence intensity of OPA-derivatized amino acids are monitored with an excitation wavelength of 348 nm and an emission wavelength of 450 nm.

Detection limit is considered to be a few tens of picomole level for most of the amino acid derivatives. Response linearity is obtained in the range of a few picomole level to a few tens of nanomole level. To obtain good compositional data, the starting with greater than 500 ng of sample before hydrolysis is best suited for the amino acid analysis of protein/peptide.

Method 3—Precolumn PITC Derivatization General Principle

Phenylisothiocyanate (PITC) reacts with amino acids to form phenylthiocarbamyl (PTC) derivatives which can be detected with high sensitivity at 245 nm. Therefore, precolumn derivatization of amino acids with PITC followed by a reversed-phase HPLC separation with UV detection is used to analyze the amino acid composition.

After the reagent is removed under vacuum, the derivatized amino acids can be stored dry and frozen for several weeks with no significant degradation. If the solution for injection is kept cold, no noticeable loss in chromatographic

response occurs after three days.

Separation of the PTC-amino acids on a reversed-phase HPLC with ODS column is accomplished through a combination of changes in concentrations of acetonitrile and buffer ionic strength. PTC-amino acids eluted from the column are monitored at 254 nm.

Detection limit is considered to be 1 pmol for most of the amino acid derivatives. Response linearity is obtained in the range of 20 to 500 pmol with correlation coefficients exceeding 0.999. To obtain good compositional data, samples larger than 500 ng of protein/peptide before hydrolysis is best suited for this amino acid analysis of proteins/peptides.

Method 4—Precolumn AQC Derivatization General Principle

Precolumn derivatization of amino acids with 6-aminoquinolyl-*N*-hydroxysuccinimidyl carbamate (AQC) followed by reversed-phase HPLC separation with fluorometric detection is used.

AQC reacts with amino acids to form stable, fluorescent unsymmetric urea derivatives (AQC-amino acids) which are readily amenable to analysis by reversed-phase HPLC. Therefore, precolumn derivatization of amino acids with AQC followed by reversed-phase HPLC separation is used to analyze the amino acid composition.

Separation of the AQC-amino acids on an ODS column is accomplished through a combination of changes in concentrations of acetonitrile and salt. Selective fluorescence detection of the derivatives with excitation wavelength at 250 nm and emission wavelength at 395 nm allows for the direct injection of the reaction mixture with no significant interference from the only major fluorescent reagent by-product, 6-aminoquinoline. Excess reagent is rapidly hydrolyzed ($t_{1/2} < 15$ seconds) to yield 6-aminoquinoline, *N*-hydroxysuccinimide and carbon dioxide, and after 1 minute no further derivatization can take place.

Peak areas for AQC-amino acids are essentially unchanged for at least 1 week at room temperature, and the derivatives have more than sufficient stability to allow for overnight automated chromatographic analysis.

Detection limit is considered to be ranging from ca. 40 to 320 fmol for each amino acid, except for Cys. Detection limit for Cys is approximately 800 fmol. Response linearity is obtained in the range of 2.5 to 200 μ mol/L with correlation coefficients exceeding 0.999. Good compositional data could be obtained from the analysis of derivatized protein hydrolysates containing as little as 30 ng of protein/peptide.

Method 5—Precolumn OPA Derivatization General Principle

Precolumn derivatization of amino acids with *o*-phthalaldehyde (OPA) followed by reversed-phase HPLC separation with fluorometric detection is used. This technique does not detect amino acids that exist as secondary amines (e.g., proline).

OPA in conjunction with a thiol reagent reacts with primary amine groups to form highly fluorescent isoindole products. 2-Mercaptoethanol or 3-mercaptopropionic acid can be used as thiol. OPA itself does not fluoresce and consequently produces no interfering peaks. In addition, its solubility and stability in aqueous solution, along with the rapid kinetics for the reaction, make it amenable to automated derivatization and analysis using an autosampler to mix the sample with the reagent. However, lack of reactivity with secondary amino acids has been a predominant drawback. This method does not detect amino acids that exist as secondary amines (e.g., proline). To compensate for this

drawback, this technique may be combined with another technique described in *Method 7* or *Method 8*.

Precolumn derivatization of amino acids with OPA is followed by a reversed-phase HPLC separation. Because of the instability of the OPA-amino acid derivative, HPLC separation and analysis are performed immediately following derivatization. The liquid chromatograph is equipped with a fluorometric detector for the detection of derivatized amino acids. Fluorescence intensity of OPA-derivatized amino acids is monitored with an excitation wavelength of 348 nm and an emission wavelength of 450 nm.

Detection limits as low as 50 fmol via fluorescence have been reported, although the practical limit of analysis remains at 1 pmol.

Method 6—Precolumn DABS-Cl Derivatization General Principle

Precolumn derivatization of amino acids with (dimethylamino)azobenzenesulfonyl chloride (DABS-Cl) followed by reversed-phase HPLC separation with visible light detection is used.

DABS-Cl is a chromophoric reagent employed for the labeling of amino acids. Amino acids labeled with DABS-Cl (DABS-amino acids) are highly stable and show the maximum absorption at 436 nm.

DABS-amino acids, all 19 naturally occurring amino acids derivatives, can be separated on an ODS column of a reversed-phase HPLC by employing gradient systems consisting of acetonitrile and aqueous buffer mixture. Separated DABS-amino acids eluted from the column are detected at 436 nm in the visible region.

This *Method* can analyze the imino acids such as proline together with the amino acids at the same degree of sensitivity. DABS-Cl derivatization method permits the simultaneous quantification of tryptophan residues by previous hydrolysis of the protein/peptide with sulfonic acids such as mercaptoethanesulfonic acid, *p*-toluenesulfonic acid or methanesulfonic acid described under *Method 2* in "Protein Hydrolysis". The other acid-labile residues, asparagine and glutamine, can also be analysed by previous conversion into diaminopropionic acid and diaminobutyric acid, respectively, by treatment of protein/peptide with BTI described under *Method 11* in "Protein Hydrolysis".

The non-proteinogenic amino acid, norleucine cannot be used as internal standard in this method, as this compound is eluted in a chromatographic region crowded with peaks of primary amino acids. Nitrotyrosine can be used as an internal standard, because it is eluted in a clean region.

Detection limit of DABS-amino acid is about 1 pmol. As little as 2 to 5 pmol of an individual DABS-amino acid can be quantitatively analysed with reliability, and only 10 to 30 ng of the dabsylated protein hydrolysate is required for each analysis.

Method 7—Precolumn FMOC-Cl Derivatization General Principle

Precolumn derivatization of amino acids with 9-fluorenylmethyl chloroformate (FMOC-Cl) followed by reversed-phase HPLC separation with fluorometric detection is used.

FMOC-Cl reacts with both primary and secondary amino acids to form highly fluorescent products. The reaction of FMOC-Cl with amino acid proceeds under mild conditions in aqueous solution and is completed in 30 seconds. The derivatives are stable, only the histidine derivative showing any breakdown. Although FMOC-Cl is fluorescent itself, the reagent excess and fluorescent side-products can be eliminated without loss of FMOC-amino acids.

FMOC-amino acids are separated by a reversed-phase HPLC using an ODS column. The separation is carried out by gradient elution varied linearly from a mixture of acetonitrile methanol and acetic acid buffer (10:40:50) to a mixture of acetonitrile and acetic acid buffer (50:50), and 20 amino acid derivatives are separated in 20 minutes. Each derivative eluted from the column is monitored by a fluorometric detector set at an excitation wavelength of 260 nm and an emission wavelength of 313 nm.

The detection limit is in the low fmol range. A linearity range of 0.1 to 50 μ mol/L is obtained for most of the amino acids.

Method 8—Precolumn NBD-F Derivatization General Principle

Precolumn derivatization of amino acids with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-F) followed by reversed-phase HPLC separation with fluorometric detection is used.

NBD-F reacts with both primary and secondary amino acids to form highly fluorescent products. Amino acids are derivatized with NBD-F by heating to 60°C for 5 minutes.

NBD-amino acid derivatives are separated on an ODS column of a reversed-phase HPLC by employing gradient elution system consisting of acetonitrile and aqueous buffer mixture, and 17 amino acid derivatives are separated in 35 minutes. ϵ -Aminocaproic acid can be used as an internal standard, because it is eluted in a clean chromatographic region. Each derivative eluted from the column is monitored by a fluorometric detector set at an excitation wavelength of 480 nm and an emission wavelength of 530 nm.

The sensitivity of this method is almost the same as for precolumn OPA derivatization method (*Method 5*), excluding proline to which OPA is not reactive, and might be advantageous for NBD-F against OPA. The detection limit for each amino acid is about 10 fmol. Profile analysis was achieved for about 1.5 μ g of protein hydrolysates in the final precolumn labeling reaction mixture for HPLC.

Data Calculation and Analysis

When determining the amino acid content of a protein/peptide hydrolysate, it should be noted that the acid hydrolysis step destroys tryptophan and cysteine. Serine and threonine are partially destroyed by acid hydrolysis, while isoleucine and valine residues may be only partially cleaved. Methionine can undergo oxidation during acid hydrolysis, and some amino acids (e.g., glycine and serine) are common contaminants. Application of adequate vacuum (≤ 0.0267 kPa) or introduction of inert gas (argon) in the headspace of the reaction vessel during vapor phase hydrolysis can reduce the level of oxidative destruction. Therefore, the quantitative results obtained for cysteine, tryptophan, threonine, isoleucine, valine, methionine, glycine, and serine from a protein/peptide hydrolysate may be variable and may warrant further investigation and consideration.

Calculations

Amino Acid Mole Percent This is the number of specific amino acid residues per 100 residues in a protein. This result may be useful for evaluating amino acid analysis data when the molecular weight of the protein under investigation is unknown. This information can be used to corroborate the identity of a protein/peptide and has other applications. Carefully identify and integrate the peaks obtained as directed for each *Procedure*. Calculate the mole percent for each amino acid present in the test sample by the formula:

$$100r_U/r,$$

in which r_U is the peak response, in nmol, of the amino acid

under test; and r is the sum of peak responses, in nmol, for all amino acids present in the test sample. Comparison of the mole percent of the amino acids under test to data from known proteins can help establish or corroborate the identity of the sample protein.

Unknown Protein Samples This data analysis technique can be used to estimate the protein concentration of an unknown protein sample using the amino acid analysis data. Calculate the mass, in μg , of each recovered amino acid by the formula:

$$mM_W/1000,$$

in which m is the recovered quantity, in nmol, of the amino acid under test; and M_W is the average molecular weight for that amino acid, corrected for the weight of the water molecule that was eliminated during peptide bond formation. The sum of the masses of the recovered amino acids will give an estimate of the total mass of the protein analyzed after appropriate correction for partially and completely destroyed amino acids. If the molecular weight of the unknown protein is available (i.e., by SDS-PAGE analysis or mass spectroscopy), the amino acid composition of the unknown protein can be predicted. Calculate the number of residues of each amino acid by the formula:

$$m/(1000M/M_{WT}),$$

in which m is the recovered quantity, in nmol, of the amino acid under test; M is the total mass, in μg , of the protein; and M_{WT} is the molecular weight of the unknown protein.

Known Protein Samples This data analysis technique can be used to investigate the amino acid composition and protein concentration of a protein sample of known molecular weight and amino acid composition using the amino acid analysis data. When the composition of the protein being analyzed is known, one can exploit the fact that some amino acids are recovered well, while other amino acid recoveries may be compromised because of complete or partial destruction (e.g., tryptophan, cysteine, threonine, serine, methionine), incomplete bond cleavage (i.e., for isoleucine and valine) and free amino acid contamination (i.e., by glycine and serine).

Because those amino acids that are recovered best represent the protein, these amino acids are chosen to quantify the amount of protein. Well-recovered amino acids are, typically, aspartate-asparagine, glutamate-glutamine, alanine, leucine, phenylalanine, lysine, and arginine. This list can be modified based on experience with one's own analysis system. Divide the quantity, in nmol, of each of the well-recovered amino acids by the expected number of residues for that amino acid to obtain the protein content based on each well-recovered amino acid. Average the protein content results calculated. The protein content determined for each of the well-recovered amino acids should be evenly distributed about the mean. Discard protein content values for those amino acids that have an unacceptable deviation from the mean. Typically \geq greater than 5% variation from the mean is considered unacceptable. Recalculate the mean protein content from the remaining values to obtain the protein content of the sample. Divide the content of each amino acid by the calculated mean protein content to determine the amino acid composition of the sample by analysis.

Calculate the relative compositional error, in percentage, by the formula:

$$100m/m_S,$$

in which m is the experimentally determined quantity, in

nmol per amino acid residue, of the amino acid under test; and m_S is the known residue value for that amino acid. The average relative compositional error is the average of the absolute values of the relative compositional errors of the individual amino acids, typically excluding tryptophan and cysteine from this calculation. The average relative compositional error can provide important information on the stability of analysis run over time. The agreement in the amino acid composition between the protein sample and the known composition can be used to corroborate the identity and purity of the protein in the sample.

Basic Requirements for Viral Safety of Biotechnological/Biological Products listed in Japanese Pharmacopoeia

Introduction

The primary role of specification of biotechnological/biological products listed in Japanese Pharmacopoeia (JP) is not only for securing quality control or consistency of the quality but also for assuring their efficacy and safety. In the meantime, the requirements to assure quality and safety of drugs have come to be quite strict recently, and a rigid attitude addressing safety assurance is expected for biotechnological/biological products. The key points for quality and safety assurance of biotechnological/biological products are selection and appropriate evaluation of source material, appropriate evaluation of manufacturing process and maintenance of manufacturing consistency, and control of specific physical properties of the products. Now, how to assure quality and safety of such drugs within a scope of JP has come to be questioned. This General Information describes what sorts of approaches are available to overcome these issues.

It is desired that quality and safety assurance of JP listed products are achieved by state-of-the-art methods and concepts which reflect progress of science and accumulation of experiences. This General Information challenges to show the highest level of current scientific speculation. It is expected that this information will contribute to promotion of scientific understanding of quality and safety assurance of not only JP listed products but also the other biotechnological/biological products and to promotion of active discussion of each Official Monograph in JP.

1. Fundamental measures to ensure viral safety of JP listed biotechnological/biological products

The biotechnological/biological product JP includes the products derived from living tissue and body fluid (urine, blood, etc.) of mammals, etc. Protein drugs derived from cell lines of human or animal origin (e.g., recombinant DNA drug, cell culture drug) are also included. The fundamental measures required for comprehensive viral safety of JP listed biotechnological/biological products are as follows: 1) acquaintance of possible virus contamination (source of contamination); 2) careful examination of eligibility of raw materials and their sources, e.g. human/animal, and thorough analysis and screening of the sample chosen as a substrate for drug production (e.g., pooled body fluid, cell bank, etc.) to determine any virus contamination and determination of type and nature of the virus, if contaminated; 3) evaluation to determine virus titer and virus-like particles hazardous to human, if exists; 4) selection of production related material

(e.g., reagent, immune antibody column) free from infectious or pathogenic virus; 5) performance of virus free test at an appropriate stage of manufacturing including the final product, if necessary; 6) adoption of effective viral clearance method in the manufacturing process to remove/inactivate virus. Combined method sometimes achieves higher level of clearance; 7) development of a deliberate viral clearance scheme; 8) performance of the test to evaluate viral removal and inactivation. It is considered that the stepwise and supplemental adoption of the said measures will contribute to ensure viral safety and its improvement.

2. Safety assurance measures described in the Official Monograph and this General Information

As mentioned in above 1, this General Information describes, in package, points to be concerned with and concrete information on the measures taken for viral safety of JP listed products. Except where any specific caution is provided in Official Monograph of a product in question, Official Monograph provides in general that “Any raw material, substrate for drug production and production related material used for production of drug should be derived from healthy animals and should be shown to be free of latent virus which is infectious or pathogenic to human”, “Cell line and culture method well evaluated in aspects of appropriateness and rationality on viral safety are used for production, and the presence of infectious or pathogenic latent virus to human in process related materials derived from living organisms should be denied”. and “biotechnological/biological drug should be produced through a manufacturing process which is capable of removing infectious or pathogenic virus”, etc., to raise awareness on viral safety and on necessity to conduct test and process evaluation for viral safety.

3. Items and contents described in this General Information

As for viral safety of protein drug derived from cell line of human or animal origin, there is a Notice in Japan entitled “Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin” (Iyakushin No. 329 issued on February 22, 2000 by Director, Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare) to reflect the internationally harmonized ICH Guideline, and as for blood plasma protein fraction preparations, there is a document entitled “Guideline for ensuring viral safety of blood plasma protein fraction preparations”. This General Information for ensuring viral safety of JP listed biotechnological/biological products has been written, referencing the contents of those guidelines, to cover general points and their details to be concerned for ensuring viral safety of not only JP listed biotechnological/biological products but also all products which would be listed in JP in future, i.e., biological products derived from living tissue and body fluid, such as urine, and protein drugs derived from cell line of human or animal origin (Table 1).

3.1. Purpose

The purpose of this document is to propose the comprehensive concepts of the measures to be taken for ensuring viral safety of biotechnological/biological products derived from living tissue or body fluid of mammals, etc. and of protein drugs derived from cell lines of human or animal origin. That is to say, this document describes the measures and the points of concern on the items, such as ① consideration of the source of virus contamination; ② appropriate evaluation on eligibility at selecting the raw material and on qualification of its source, e.g. human or animal; ③ virus test, and its analysis and evaluation at a stage of cell sub-

Table 1 Items described in General Information for viral safety assurance of JP listed biotechnological/biological products

I. Introduction

1. Fundamental measures to ensure viral safety of JP listed biotechnological/biological products
2. Safety assurance measures described in the Official Monograph and this General Information
3. Items and contents described in this General Information

II. General Matters

1. Purpose
2. Background
3. Unknown risk on the measures taken for ensuring viral safety
4. Applicable range
5. Possible viral contamination to a JP listed biotechnological/biological product (source of virus contamination)
6. Basis for ensuring viral safety
7. Limit of virus test
8. Roles of viral clearance studies

III. Raw material/substrate for drug production

1. Issues relating to animal species and its region as a source of raw material substrate for drug production and countermeasures to be taken thereto
2. Qualification evaluation test on human or animal as a source of raw material/substrate for drug production

IV. Points of concern with respect to manufacturing and virus testing

1. Virus test conducted in advance of purification process
2. Virus test as an acceptance test of an intermediate material, etc.
3. Virus test on a final product

V. Process evaluation on viral clearance

1. Rationale, objective and general items to be concerned with respect to viral clearance process evaluation
2. Selection of virus
3. Design of viral clearance studies
4. Interpretation of viral clearance studies
 - 1) Evaluation of viral clearance factor
 - 2) Calculation of viral clearance index
 - 3) Interpretation of results and items to be concerned at evaluation

VI. Statistics

1. Statistical considerations for assessing virus assays
2. Reproducibility and confidence limit of viral clearance studies

VII. Re-evaluation of viral clearance

VIII. Measurement for viral clearance studies

1. Measurement of virus infective titer
2. Testing by nucleic-acid amplification test (NAT)

IX. Reporting and preservation

X. Others

strate for drug production; ④ appropriate evaluation to choose product related materials derived from living organisms (e.g. reagent, immune antibody column, etc.); ⑤ conduct of necessary virus test on the product at an appropriate stage of manufacturing; ⑥ development of viral clearance test scheme; ⑦ performance and evaluation of viral clearance test. This document is also purposed to comprehensively describe in details that supplemental and combining adoption of the said measures will contribute to secure viral

safety and its improvement.

3.2. Background

One of the most important issues to be cautioned for safety of a biological product, which is directly derived from human or animal, or of a protein drug, which is derived from cell line of human or animal origin (recombinant DNA derived product, cell culture derived product, etc.), is a risk of virus contamination. Virus contamination may cause serious situation at clinical use once it occurs. Virus contamination may be from a raw material or from a cell substrate for drug production, or may be from an adventitious factor introduced to the manufacturing process.

JP listed biological drugs or protein drugs derived from cell line have achieved drastic contribution to the medical society, and to date, there has not been any evidence of any safety problem on them caused by virus. But, social requirement of health hazard prevention is strong, and it is now very important to prevent accidental incidence, taking security measures carefully supported by scientific rationality. It is always great concern among the persons involved that under what sort of viewpoint and to what extent we have to pursue for ensuring viral safety of a biotechnological/biological product. Before discussing these issues, two fundamental points have to be reconfirmed. One is that; we have to consider scientific, medical, and social profiles a drug has. In other words, "Medicine is a social asset which is utilized in medical practice paying attention to the risk and benefit from the standpoints of science and society". It is the destination and the mission of the medical/pharmaceutical society to realize prompt and stable supply of such a social asset, drug, among the medical work front to bring gospel to the patients.

The other is that; issue of viral safety is independent from safety of the components of a drug per se (narrow sense of safety). It is important to consider that this is the matter of general safety of drug (broad sense of safety). In case of a drug which has been used for a long time in the medical front, such as a JP listed product, its broad sense of safety is considered to have been established epidemiologically, and its usage past records have a great meaning. However, different from safety of drug per se (its components), taking into account any possibility of virus contamination, we have to say that only the results accumulated can not always assure viral safety of a drug used in future. Accordingly, the basis for securing broad sense of viral safety of JP listed biotechnological/biological products is to pay every attention to the measures to take for prevention, while evaluating the accumulated results.

Adopting strict regulations and conducting tests at maximum level to the extent theoretically considered may be the ways off assuring safety, but applying such way generally, without sufficient scientific review of the ways and evaluation of usage results, causes excessive requirement of regulation and test not having scientific rationality. As the results, effective and prompt supply of an important drug, already having enough accumulation of experiences, to the medical work front will be hampered, and the drug, a social asset, may not to be utilized effectively. Medicine is a sword used in medical field having double-edge named effectiveness and safety. Effectiveness and safety factors have to be derived as the fruits of leading edge of science, and relatively evaluated on a balance sheet of usefulness. Usefulness evaluation should not be unbalanced in a way that too much emphasis is placed on safety concern without back-up of appropriate scientific rationality. A drug can play an important role as a social asset only when well balanced appropriate scientific usefulness evaluation in addition to social concern of the age

are given. In other words, drug is a common asset utilized by society for medication as a fruit of science of the age, and the key point of its utilization lies on a balance of risk and benefit produced from scientific and social evaluation. So, those factors have to be taken into account when target and pursuance levels for ensuring viral safety of a JP listed biotechnological/biological product are reviewed.

And, in general, the risk and benefit of drugs should be considered with the relative comparison to alternative drugs or medical treatment. The usefulness of certain drug should be reviewed finally after the competitive assessment on the risk and benefit on the alternative drugs, relevant drugs and/or alternative medical treatment.

Under such background, the purpose of this article is to describe the scientific and rational measures to be taken for ensuring viral safety of JP listed biotechnological/biological products. Giving scientific and rational measures mean that; appropriate and effective measures, elaborated from the current scientific level, are given to the issues assumable under the current scientific knowledge. In other words, possible contaminant virus is assumed to have the natures of genus, morph, particle size, physical/chemical properties, etc. which are within the range of knowledge of existing virology, and is those assumed to exist in human and animal, tissue and body fluid, which are the source of biotechnological/biological product, reagent, material, additives, etc. Accordingly, viral clearance studies using a detection method which target those viruses have to be designed.

3.3. Unknown risk on the measures taken for ensuring viral safety

There are known and unknown risks.

It is easy to determine a test method and an evaluation standard on the known risk, which exists in the drug per se (pharmaceutical component) or inevitably exists due to a quality threshold, and quantification of such risk is possible. In other words, it is easy to evaluate the known risk on a balance sheet in relation to the benefit, and we can say that valuation even in this respect has been established to some extent.

On the other hand, as for the unknown risk which is inevitable for ensuring viral safety, the subject of the risk can not be defined and quantitative concept is hard to introduce, and, therefore, taking a counter measure and evaluating its effect are not so easy. Therefore, this is the subject to be challenged calling upon wisdom of the related parties among the society of drug.

Talking about the unknown risk, there are view points that say "It is risky because it is unknown." and "What are the unknowns, and how do we cope with them in ensuring safety?".

The view of "It is risky because it is unknown." is already nothing but a sort of evaluation result, and directly connects to a final decision if it can be used as a drug. Such evaluation/decision has to be made based upon a rational, scientific or social judgment.

For example, in the case that "In a manufacturing process of drug, virus, virus-like particle or retrovirus was detected, but its identification could not be confirmed, and, therefore, its risk can not be denied.", the evaluation of "It is risky because it is unknown." is scientifically rational and reasonable. On the other hand, however, if we reach a decision of "It is risky because it is unknown." due to the reason that "In a manufacturing process of drug, virus, virus-like particle or retrovirus was not detected, but there is a 'concern' that something unknown may exist.", it can not be said that such evaluation is based upon a rational, scientific or social judgment. It goes without saying that the utmost care has to

be taken for viral safety, but the substance of 'concern' has to be at least clearly explainable. Otherwise, the 'concern' may result in causing contradiction in the meaningful mission to utilize a social asset, drug, in medical practice.

From scientific view point, we should not be narrow minded by saying "it is risky" because "there is a 'concern' that something unknown may exists", but challenge to clarify the subject of "What is unknown, and how to cope with it for ensuring safety" using wisdom. What is important at the time is to define "what is unknown" based upon current scientific knowledge. Only through this way, is it possible for us to elaborate the measures for ensuring safety.

Once we chase up the substance of unknown risk for viral safety without premises of "what is unknown", "unknown" will be an endless question because it theoretically remains unresolved forever. If this kind of approach is taken, the issue and the measure can not be scientifically connected to each other, which will result in the excessive requirement of regulation and of test to be conducted. Yet, it is unlikely that the measure which has no relation with science will be effective to the subject of "What is unknown is unknown."

For example, "what is unknown" at the "evaluation of a purification process which can completely clear up every virus that contaminated in a manufacturing process" should be the subject of "what sort of existing virus that contaminated is unknown", not on the subject of "what sort of virus that exist in the world is unknown. In the former subject, the premise of the study is based on all the knowledge on viruses including DNA/RNA-virus, virus with/without envelope, particle size, physical/chemical properties, etc. The premise is that the virus contaminated should be within range of existing wisdom and knowledge of virus such as species, type, nature, etc., even though the virus that contaminated is unknown. Under such premise, when evaluation is made on a purification process to decide its capability of clearing a derived virus, which is within the range of existing wisdom and learning, specific viral clearance studies designed to combine a few model viruses with different natures, such as type of nucleic acid, with/without envelope, particle size, physical/chemical properties, etc., would be enough to simulate every sort of the virus already known, and will be a "good measure for ensuring safety".

The issue of "the sort of viruses that exist in the world is unknown" may be a future study item, but it is not an appropriate subject for the viral clearance test. Further, even if the subject of "unknown viruses, which have a particle size smaller than that of currently known viruses, may exists" or "unknown viruses, which have special physical/chemical properties that can not be matched to any of the currently known viruses, may exists" is set up as an armchair theory, any experimental work can not be pursued under the current scientific level, since such virus model is not available. Further, any viral clearance test performed by using the currently available methods and technologies will be meaningless "for ensuring safety", since particle size or natures of such speculated virus are unknown. Likewise, any counter measures can not be taken on the subject of "unknown virus, which can not be detected by currently available screening method, may exist", and conducting any virus detection test at any stage will be useless "for ensuring safety".

The requirement of regulations or tests excessively over scientific rationality will raise human, economical and temporal burden to the pharmaceutical companies, and will adversely affect prompt, effective and economical supply of a drug to the medical front. As drug is a sort of social asset, which has to be scientifically evaluated, how to assure maximization of its safety by means of scientifically rational ap-

proach at minimum human, economical and time resources is important.

It is also important to reconfirm that achievement of those issues is on the premise that appropriate measures are taken on the supply source of drugs. For example, in a case of "In a manufacturing process of drug, virus, virus-like particle or retrovirus was not detected, but there is a 'concern' that something unknown may exist.", appropriateness of the test, which resulted in the judgment that "virus, virus-like particle or retrovirus was not detected in a process of drug production", should be a prerequisite premise when judged by science standard at the time. If there is any question on the premise, it is quite natural that the question of "there is a 'concern' that unknown something may exist." will be effective.

3.4. Applicable range

This General Information is on JP listed biological products, derived from living tissue or body fluid, and protein drugs, derived from human or animal cell line, that in Japan. In the case of protein drugs derived from human or animal cell line, the products developed and approved after enforcement of the Notice Iyakushin No. 329 entitled "Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin" should have been treated under the Notice, and it is inevitable that some products approved before the Notice might not have been sufficiently treated. It is expected that such biodrug will be sufficiently examined to meet such General Information before being listed in JP. On the other hand, blood preparations listed in the biological products standard and covered by "Guideline for securing safety of blood plasma protein fraction preparations against virus", are out of the scope of this General Information. Further, in case of a relatively lower molecular biogenous substance, such as amino acid, saccharide and glycerin, and of gelatin, which is even classified as infectious or pathogenic polymer, there are cases that viral contamination can not be considered due to its manufacturing or purification process, and that potent viral inactivation/removal procedure that can not be applied to protein, can be used, and, therefore, it is considered reasonable to omit such substances from the subject for application. However, some part of this General Information may be used as reference. Further, a comprehensive assurance measure for viral safety is recommendable on a biotechnological/biological product not listed in JP using this document as a reference so long as it is similar to the biotechnological/biological product JP.

3.5. Possible viral contamination to a JP listed biotechnological/biological product (source of virus contamination)

Promoting awareness of virus contamination to a JP listed biotechnological/biological product (source of virus contamination) and citing countermeasure are important for eradicating any possible virus contamination and raising probability of safety assurance. Many biotechnological/biological products are produced from a "substrate" which is derived from human or animal tissue, body fluid, etc. as an origin/raw material, and in purification or pharmaceutical processing of such products column materials or additives, which are living organism origin, are occasionally used. Accordingly, enough safety measures should be taken against diffusion of the contaminant virus. Further, as mentioned in Notice Iyakushin No. 329, any protein drug derived from cell lines of human or animal origin should be carefully examined with respect to the risk of virus contamination through the cell line, the cell substrate for drug production, and through the manufacturing process applied thereafter.

"Substrate for drug production" is defined as a starting

material which is at a stage where it is deemed to be in a position to ensure quality/safety of an active substance. The "substrate for drug production" is sometimes tissue, body fluid, etc. of human or animal *per se* and pooled material such as urine, and sometimes a material after some treatment. In many cases, it is considered rational that starting point of full-scale test, evaluation and control should be at the stage of "substrate for drug production". The more strict levels of test, evaluation and control achieved at the stage of "substrate for drug production" can more rationalize evaluation and control of the raw material or individual level of upper stream. On the contrary, strict evaluation and control of the raw material or individual level at an upper stream stage can rationalize tests, evaluation or quality control at the stage of "substrate for drug production".

The measures taken for ensuring viral safety on a biotechnological/biological product currently listed in JP can be assumed from the provisions of manufacturing method, specification and test methods of each preparation. However, unitary principles or information with respect to the measures to be taken for ensuring viral safety, totally reviewing the entire process up to the final product rationally and comprehensively, including source/raw material/substrate, purification process, etc. have not been clarified. The most important thing for ensuring viral safety is to take thorough measures to eliminate the risk of virus contamination at any stage of source animal, raw material and substrate. Although not the cases of a biotechnological/biological product, known examples of a virus contamination from a raw material/substrate for drug production in old times are Hepatitis A Virus (HAV) or Hepatitis C Virus (HCV) contamination in blood protein fraction preparations. It is also well known that Human Immunodeficiency Virus (HIV) infection caused by blood plasma protein fraction preparations occurred in 1980s. The aim of this General Information is to show concrete guidelines for comprehensive viral safety assurance of the JP listed biotechnological/biological products. The pathogenic infectious viruses, currently known to contaminate to raw materials, etc. of drug and have to be cautioned, are HIV, HAV, Hepatitis B Virus (HBV), HCV, Human T-Lymphotropic Virus (HTLV-I/II), Human Parvovirus B19, Cytomegalovirus (CMV), etc. Biotechnological/biological products produced from raw material/cell substrate derived from tissue or body fluid of human or animal origin always have a risk of contamination of pathogenic or other latent virus. Therefore, safety measures should be thoroughly taken. There is also the case that a material, other than the biological component such as raw material/substrate, causes virus contamination. Using enzymatic or monoclonal antibody column or using albumin etc. as a stabilizer, is the example of the case, in which caution has to be taken on risk of virus contamination from the source animal or cell. Further, there is a possibility of contamination from environment or personnel in charge of production or at handling of the product. So, caution has to be taken on these respects as well.

In case of protein drugs derived from cell line of human or animal origin, there may be cases where latent or persistent infectious viruses (e.g., herpesvirus) or endogenous retroviruses exist in the cell. Further, adventitious viruses may be introduced through the routes such as: 1) derivation of a cell line from an infected animal; 2) use of a virus to drive a cell line; 3) use of a contaminated biological reagent (e.g., animal serum components); 4) contamination during cell handling. In the manufacturing process of drug, an adventitious virus may contaminate the final product through the routes, such as 1) contamination through a reagent of living

being origin, such as serum component, which is used for culturing, etc.; 2) use of a virus for introduction of a specific gene expression to code an objective protein; 3) contamination through a reagent used for purification such as monoclonal antibody affinity column; 4) contamination through an additive used for formulation production; 5) contamination at handling of cell and culture media, etc. It is reported that monitoring of cell culture parameter may be helpful for early detection of an adventitious viral contamination.

3.6. Basis for ensuring viral safety

Viral safety of a biotechnological/biological product produced from a raw material/substrate, which derived from tissue, body fluid, cell line, etc. of human or animal origin, can be achieved by supplemental and appropriate adoption of the following plural methods.

- (1) Acquaintance of possible virus contamination (source of contamination).
- (2) Careful examination of eligibility of the raw material and its source, i.e., human or animal, thorough analysis and screening of the sample chosen as the substrate for drug production to determine virus contamination and through examination of the type of virus and its nature, if contaminated.
- (3) Evaluation to determine hazardous properties of the virus or virus-like particle to human, if exists.
- (4) Choosing a product related material of living organism origin (e.g., reagent, immune anti-body column, etc.) which is free from infectious or pathogenic virus.
- (5) Conduct virus free test at an appropriate stage of manufacturing including the final product, if necessary.
- (6) Adoption of an effective method to remove/inactivate the virus in the manufacturing process for viral clearance. Combined processes sometimes achieve higher level of viral clearance.
- (7) Develop a deliberate viral clearance scheme.
- (8) Conduct test and evaluation to confirm removal/inactivation of the virus.

Manufacturer is responsible for explaining rationality of the way of approach adopted among the comprehensive strategy for viral safety on each product and its manufacturing process. At the time, the approach described in this General Information shall be applicable as far as possible.

3.7. Limit of virus test

Virus test has to be conducted to define existence of virus, but it should be noted that virus test alone can not reach a conclusion of inexistence of virus nor sufficient to secure safety of the product. Examples of a virus not being detected are as follows: 1) Due to statistical reason, there is an inherent quantitative limit, such as detection sensitivity at lower concentration depends upon the sample size. 2) Generally, every virus test has a detection limit, and any negative result of a virus test can not completely deny existence of a virus. 3) A virus test applied is not always appropriate in terms of specificity or sensitivity for detection of a virus which exists in the tissue or body fluid of human or animal origin.

Virus testing method is improved as science and technology progress, and it is important to apply scientifically the most advanced technology at the time of testing so that it can be possible to raise the assurance level of virus detection. It should be noted, however, that the limit as mentioned above can not always be completely overcome. Further, risk of virus contamination in a manufacturing process can not be completely denied, and, therefore, it is necessary to elaborate the countermeasure taken these effects into account.

Reliable assurance of viral free final product can not be

obtained only by negative test results on the raw material/substrate for drug production or on the product in general, it is also necessary to demonstrate inactivation/removal capability of the purification process.

3.8. Roles of viral clearance studies

Under the premises as mentioned in the preceding clause that there is a limit of a virus test, that there is a possibility of existence of latent virus in a raw material/substrate for drug production and that there is a risk of entry of a non-endogenous virus in a manufacturing process, one of the important measures for viral safety is how to remove or inactivate the virus, which exists in a raw material, etc. and can not be detected, or the virus, which is contingently contaminated in a manufacturing process. The purpose of viral clearance study is to experimentally evaluate the viral removal/inactivation capability of a step that mounted in a manufacturing process. So, it is necessary to conduct an experimental scale spike test using an appropriate virus that is selected by taking account the properties, such as particle size, shape, with or without envelope, type of nucleic acid (DNA type, RNA type), heat and chemical treatment tolerance, etc., with an aim to determine removal/inactivation capability of the virus that can not be detected in a raw material or contingently contaminated.

As mentioned above, the role of viral clearance study is to speculate removal/inactivation capability of a process through a model test, and it contributes to give scientific basis to assure that a biotechnological/biological product of human or animal origin has reached an acceptable level in aspect of viral safety.

At a viral clearance study, it is necessary to adopt an appropriate approach method which is definitive and rational and can assure viral safety of a final product, taking into consideration the source and the properties of the raw material/substrate as well as the manufacturing process.

4. Raw material/substrate for drug production

4.1. Issues relating to animal species and its region as a source of raw material/substrate for drug production and countermeasures to be taken thereto

For manufacturing JP listed biotechnological/biological products, which require measures for viral safety, a raw material/substrate derived mainly from human, bovine, swine or equine is used, and it is obvious that such human and animal has to be healthy nature. A wild animal should be avoided, and it is recommended to use animals derived from a colony controlled by an appropriate SPF (Specific Pathogen-Free) condition and bred under a well designed hygienic control, including appropriate control for prevention of microbial contamination and contamination monitoring system. If a meat standard for food is available, an animal meeting this standard has to be used. The type of virus to be concerned about depend on animal species, but it may be possible to narrow down the virus for investigation by means of examining the hygiene control, applicability of a meat standard for food, etc. On the other hand, even with the animals of the same species, a different approach may be necessary depending upon the region where the specimen for a raw material/substrate is taken. For example, in case of obtaining raw material/substrate from blood or other specific region, it is necessary to be aware of the risk level, virus multiplication risk, etc. which may specifically exists depending upon its region. Such approach may be different from those applied to body waste such as urine, milk, etc. as a source of raw material/substrate. Further, caution has to be taken on transmissible spongiform encephalopathy (TSE) when pituitary gland, etc. is used as a raw material. This

report does not include detailed explanation on TSE, but recommendations are to use raw material derived from 1) animals originated in the countries (area) where incidence of TSE has not been reported; 2) animals not infected by TSE; or 3) species of animal which has not been reported on TSE. It is recommended to discuss the matters concerned with TSE with the regulatory authority if there is any unclear point.

Followings are the raw material/substrate used for manufacturing biotechnological/biological products in Japan.

(1) Biological products derived from human

Blood plasma, placenta, urine, etc. derived from human are used as the sources of raw material of biotechnological/biological product. As for these raw materials, there are two cases: 1) Appropriateness can be confirmed by interview or by examination of the individual who supplies each raw material, and 2) Such sufficient interview or examination of the individual can not be made due to type of raw material. In case that sufficient examination of individual level is not possible, it is necessary to perform the test to deny virus contamination at an appropriate manufacturing stage, for example, the stage to decide it as a substrate for drug production.

(2) Biological products derived from animal besides human

Heparin, gonadotropin, etc. are manufactured from blood plasma or from various organs of bovine, swine and equine.

(3) Protein drug derived from cell line of human or animal origin

In the case of protein drugs derived from cell line of human or animal origin, a cell line of human or animal is the raw material per se, and the substrate for drug production is a cell bank prepared from cloned cell line (master cell bank or working cell bank). Examination at cell bank level is considered enough for viral safety qualification, but it goes without saying that the more appropriate and rational qualification evaluation test of cell bank can be realized when more information is available on the virus of the source animal or on prehistory of driving the cell line, the base of cell bank.

4.2. Qualification evaluation test on human or animal as a source of raw material/substrate for drug production

(1) Biological products derived from human

Body fluid etc. obtained from healthy human must be used for biological products production. Further, in case that interview or examination of the individual, who supplies the raw material, can be possible and is necessary, interview under an appropriate protocol and a serologic test well evaluated in aspects of specificity, sensitivity and accuracy have to be performed, so that only the raw material, which is denied latent HBV, HCV and HIV, will be used. In addition to the above, it is necessary to test for gene of HBV, HCV and HIV by a nucleic amplification test (NAT) well evaluated in aspects of specificity, sensitivity and accuracy.

In case of the raw material (e.g., urine), which can not be tested over the general medical examination of the individual who supplies the material, or of the raw material which is irrational to conduct individual test, the pooled raw material, as the substrate for drug production, has to be conducted at least to deny existence of HBV, HCV and HIV, using a method well evaluated in aspects of specificity, sensitivity and accuracy, such as the antigen test or NAT.

(2) Biological products derived from animal besides human

The animal used for manufacturing biological product has to be under appropriate health control, and has to be confirmed of its health by various tests. Further, it is necessary that the population, to which the animal belongs, has been

under an appropriate breeding condition, and that no abnormal individual has been observed in the population. Further, it is necessary to demonstrate information or scientific basis which can deny known causes infection or disease to human, or to deny such animal inherent latent virus by serologic test or by nucleic amplification test (NAT). The infectious virus that is known to be common between human and animal, and known to cause infection in each animal are tentatively listed in Table 2. It is necessary that the table is completed under careful examination, and denial of all of them, by means of tests on individual animal, tissue, body fluid, etc. as a raw material, or on pooled raw material (as a direct substrate for drug production), is not always necessary. Table 2 can be used as reference information, in addition to the other information, such as; source of animal, health condition, health and breeding control, conformity to the meat standard for food, etc., to elaborate to which virus what kind of test has to be performed, and for which virus it is not always necessary to test for, etc. It is important to clarify and record the basis of choosing the virus and the test conducted thereof.

(3) Protein drug derived from cell line of human or animal origin

It is important to conduct thorough investigation on latent endogenous and non-endogenous virus contamination in a master cell bank (MCB), which is the cell substrate for drug production, in accordance with the Notice Iyakushin No. 329 entitled "Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin". Further, it is necessary to conduct an appropriate adventitious virus test (e.g., *in vitro* and *in vivo* test) and a latent endogenous virus test on the cell at the limit of *in vitro* cell age (CAL) for drug production. Each WCB as a starting cell substrate for drug production should be tested for adventitious virus either by direct testing or by analysis of cells at the CAL, initiated from the WCB. When appropriate non-endogenous virus tests have been performed on the MCB and cells cultured up to or beyond the CAL have been derived from the WCB and used for testing for the presence of adventitious viruses, similar tests need not be performed on the initial WCB.

5. Points of concern with respect to manufacturing and virus testing

To ensure viral safety of a biological product derived from tissue, body fluid etc. of human or animal origin, it is necessary to exclude any possibility of virus contamination from a raw material, such as tissue and body fluid, or a substrate, paying attention to the source of virus contamination as mentioned in above 3.5, and to adopt appropriate manufacturing conditions and technologies in addition to enhancement of manufacturing environment, so that virus contamination in the course of process and handling and from operators, facilities and environment can be minimized.

In addition to the above, effective virus test and viral inactivation/removal technology, which are reflected by rapid progress of science, have to be introduced. Adoption of two or more steps with different principles is recommended for virus inactivation/removal process. Further, it is important to minimize any possible virus derivation by using a reagent, which quality is equivalent to that of a drug. Examples of virus inactivation/removal processes are ① heating (It is reported that almost viruses are inactivated by heating at 55 – 60°C for 30 minutes with exceptions of hepatitis virus, etc. and that dry heating at 60°C for 10 – 24 hours is effective in case of the products of blood or urine origin.), ② treatment with organic solvent/surfactant (S/D treatment),

③ membrane filtration (15 – 50 nm), ④ acid treatment, ⑤ irradiation (γ -irradiation, etc.), ⑥ treatment with column chromatograph (e.g. affinity chromatography, ion-exchange chromatography), ⑦ fractionation (e.g. organic solvent or ammonium sulfate fractionation), ⑧ extraction.

5.1. Virus test conducted in advance of purification process

(1) Biological products derived from human

In many cases, samples for virus test before purification process are body fluid or tissue of individual collected as a raw material, or its pooled material or extraction as a substrate. As mentioned in 4.2 (1), it is necessary to deny latent HBV, HCV and HIV by the test evaluated enough in aspects of specificity, sensitivity and accuracy. Even in a case that a non-purified bulk before purification process is produced from a substrate, it is not always necessary to conduct virus test again at the stage before purification, so long as the presence of any latent virus can be denied at the stage of substrate by an appropriate virus test, with cases where the non-purified bulk is made from the substrate by adding any reagent etc. of living organisms origin are an exception.

(2) Biological products derived from animal besides human

Similar to (1) above, samples for virus test before purification process are, in many cases, body fluid or tissue of individual collected as a raw material, or its pooled material or extraction as a substrate. In these cases, it is necessary to have a data, which can deny latent virus of probable cause of human infection or disease as mentioned in the above 4.2 (2), or to have a result of serologic test or nucleic amplification test (NAT) evaluated enough in aspects of specificity, sensitivity and accuracy. The concept, which is applied to a case that non-purified bulk before purification process is produced from substrate, is the same as those provided in the above 4.2 (1).

(3) Protein drug derived from cell line of human or animal origin

Generally, substrate in this case is cell bank, and the sample for testing before purification process is a harvested cell after cell culturing or unprocessed bulk which consists of single or pooled complex culture broth. The unprocessed bulk may be sometimes culture broth without cell. Denial of latent virus, which is determined by virus test at a MCB or WCB level, does not always deny latent virus in unprocessed bulk after culturing. Further, it is noted that the viral test at the CAL is meaningful as a validation but can not guarantee definite assurance of latent virus denial, since the test is generally performed only once. In case of using a serum or a component of blood origin in a culture medium, definite denial of latent virus at the level of unprocessed bulk can not be assured so long as the viral test has not been conducted on each lot at the CAL, since lot renewal can be a variable factor on viral contamination.

A representative sample of the unprocessed bulk, removed from the production reactor prior to further processing, represents one of the most suitable levels at which the possibility of adventitious virus contamination can be determined with a high probability of detection. Appropriate testing for viruses should be performed at the unprocessed bulk level unless virus testing is made more sensitive by initial partial processing (e.g., unprocessed bulk may be toxic in test cell cultures, whereas partially processed bulk may not be toxic). In certain instances it may be more appropriate to test a mixture consisting of both intact and disrupted cells and their cell culture supernatants removed from the production reactor prior to further processing.

In case of unprocessed bulk, it is required to conduct virus test on at least 3 lots obtained from pilot scale or commercial

Table 2 Infectious viruses known to be common between human and animal and known to cause infection to each animal

	bovine	swine	sheep	goat	equine
Cowpox virus	◎				
Paravaccinia virus	◎	◎	◎	◎	
Murray valley encephalitis virus	◎	◎			
Louping ill virus	◎	◎	◎	◎	
Wesselsbron virus			◎		
Foot-and-mouth disease virus	◎	◎			
Japanese encephalitis virus		◎			
Vesicular stomatitis virus		◎			
Bovine papular stomatitis virus	◎				
Orf virus			◎		
Borna disease virus			◎		◎
Rabies virus	◎	◎	◎	◎	◎
Influenza virus		◎			
Hepatitis E virus		◎			
Encephalomyocarditis virus	◎	◎			
Rotavirus	◎				
Eastern equine encephalitis virus					◎
Western equine encephalitis virus					◎
Venezuelan equine encephalitis virus					◎
Morbillivirus					◎
Hendra virus					◎
Nipah virus		◎			
Transmissible gastroenteritis virus		◎			
Porcine respiratory coronavirus		◎			
Porcine epidemic diarrhea virus		◎			
Hemagglutinating encephalomyelitis virus		◎			
Porcine respiratory and reproductive syndrome virus		◎			
Hog cholera virus		◎			

Parainfluenza virus Type 3		◎		
Talfan/Teschen disease virus		◎		
Reovirus		◎		
Endogenous retrovirus		◎		
Porcine adenovirus		◎		
Porcine circovirus		◎		
Porcine parvovirus		◎		
Porcine poxvirus		◎		
Porcine cytomegalovirus		◎		
Pseudorabies virus		◎		
Russian spring-summer encephalitis virus			◎	◎
Rift Valley fever virus			◎	◎
Crimean-Congo hemorrhagic fever virus (Nairovirus)	◎		◎	◎
Torovirus	◎			

scale production. It is recommended that manufacturers develop programs for the ongoing assessment of adventitious viruses in production batches. The scope, extent and frequency of virus testing on the unprocessed bulk should be determined by taking several points into consideration including the nature of the cell lines used to produce the desired products, the results and extent of virus tests performed during the qualification of the cell lines, the cultivation method, raw material sources and results of viral clearance studies. Screening *in vitro* tests, using one or several cell lines, are generally employed to test unprocessed bulk. If appropriate, a NAT test or other suitable methods may be used.

Generally, harvest material in which adventitious virus has been detected should not be used to manufacture the product. If any adventitious viruses are detected at this level, the process should be carefully checked to determine the cause of the contamination, and appropriate actions taken.

5.2. Virus test as an acceptance test of an intermediate material, etc.

When a biological product is manufactured from tissue, body fluid etc. of human or animal origin, there are cases that an intermediate material, partially processed as a raw material or substrate by outside manufacturer, is purchased and used for manufacturing. In such case, if any test to meet this General Information has been conducted by such outside manufacturer, it is necessary for the manufacturer of the biological product, who purchased the intermediate material, to examine what sort of virus test has to be conducted as acceptance tests, and to keep record on the basis of rationality including the details of the test conducted.

On the other hand, if no test to meet this General Information has been conducted by such outside manufacturer of the raw material, all necessary virus free test has to be conducted to meet this General Information on the intermediate material regarding it as the direct substrate for drug production.

5.3. Virus test on a final product

Virus tests to be conducted on a final product (or on a product to reach the final product) has to be defined under comprehensive consideration of the type of raw material or substrate, the result of virus test conducted on raw material/substrate, the result of evaluation on viral removal/inactivation process, any possibility of virus contamination in the manufacturing process, etc. Comprehensive viral safety assurance can only be achieved by appropriate selection of the raw material/substrate, an appropriate virus test conducted on the raw material/substrate/intermediate material, the virus test conducted at an appropriate stage of manufacturing, an appropriate viral clearance test, etc. However, there are cases of having specific backgrounds, such as 1) use of the raw material derived from unspecified individual human, 2) possible existence of virus at window period, 3) specific detection limit of virus test, etc. and in these cases, virus contamination to the final product may occur if there is any deficiency on the manufacturing process (e.g., damage of membrane filter) or any mix-up of the raw materials, etc. To avoid such accidental virus contamination, it may be recommended to conduct nucleic amplification test (NAT) on the final product focusing on the most risky virus among those that may possibly to exist in the raw material.

6. Process evaluation on viral clearance

6.1. Rationale, objective and general items to be concerned with respect to viral clearance process evaluation

Evaluation of a viral inactivation/removal process is important for ensuring safety of a biological product derived from tissue or body fluid of human or animal origin. Conducting evaluation on viral clearance is to assure, even to some extent, elimination of the virus, which may exist in a raw material, etc. or may be derived to the process due to unexpected situation. Viral clearance studies should be made by a carefully designed appropriate method, and has to be rationally evaluated.

The objective of viral clearance studies is to assess process step(s) that can be considered to be effective in inactivating/removing viruses and to estimate quantitatively the overall level of virus reduction obtained by the process. This should be achieved by the deliberate addition ("spiking") of significant amounts of a virus at different manufacturing/purification steps and demonstrating its removal or inactivation during the subsequent steps. It is not necessary to evaluate or characterize every step of a manufacturing process if adequate clearance is demonstrated by the use of fewer steps. It should be borne in mind that other steps in the process may have an indirect effect on the viral inactivation/removal achieved. Manufacturers should explain and justify the approach used in studies for evaluating viral clearance.

The reduction of virus infectivity may be achieved by removal of virus particles or by inactivation of viral infectivity. For each production step assessed, the possible mechanism of loss of viral infectivity should be described with regard to whether it is due to inactivation or removal. For inactivation steps, the study should be planned in such a way that samples are taken at different times and an inactivation curve constructed.

6.2. Selection of virus

To obtain broad range of information of viral inactivation/removal, it is desirable that a model virus used for viral clearance studies should be chosen from the viruses with broad range of characteristics in aspects of DNA/RNA, with or without envelope, particle size, significant resistance to physical/chemical treatment, etc. and it is necessary to combine about 3 model viruses to cover these characteristics.

At choice of a model virus, there are also the ways to choose a virus closely related to or having the same characteristics of the virus known to exist in the raw material. In such case, it is in principle recommendable to choose a virus which demonstrates a higher resistance to inactivation/removal treatment if two or more candidate viruses are available for choice. Further, a virus which can grow at a high titer is desirable for choice, although this may not always be possible. In addition to the above, choosing a virus, which will provide effective and reliable assay result at each step, is necessary, since sample condition to be tested at each step of a production process may influence the detection sensitivity. Consideration should also be given to health hazard which may pose to the personnel performing the clearance studies.

For the other items taken for consideration at choice of virus, the Notice, Iyakushin No. 329 can be used as a reference. Examples of the virus which have been used for viral clearance studies are shown in Table 3 which was derived from Iyakushin No. 329. However, the Notice, Iyakushin No. 329, is on viral safety of a product derived cell line of human or animal origin, and a more appropriate model virus has to be chosen taking into account the origin/raw material of biological products.

6.3. Design of viral clearance studies

The purpose of viral clearance studies is to quantitatively evaluate removal or inactivation capability of a process, in which a virus is intentionally spiked to a specific step of a manufacturing process.

Following are the precautions to be taken at planning viral clearance studies.

(1) Care should be taken in preparing the high-titer virus to avoid aggregation which may enhance physical removal and decrease inactivation thus distorting the correlation with actual production.

(2) Virus detection method gives great influence to viral clearance factor. Accordingly, it is advisable to gain detection sensitivity of the methods available in advance, and use a method with a detection sensitivity as high as possible. Quantitative infectivity assays should have adequate sensitivity and reproducibility in each manufacturing process, and should be performed with sufficient replicates to ensure adequate statistical validity of the result. Quantitative assays not associated with infectivity may be used if justified. Appropriate virus controls should be included in all infectivity assays to ensure the sensitivity of the method. Also, the statistics of sampling virus when at low concentrations (for example, number of virus is 1-1000/L) should be considered.

(3) Viral clearance studies are performed in a miniature size system that simulates the actual production process of the biotechnological/biological product used by the manufacturer. It is inappropriate to introduce any virus into a production facility because of GMP constraints. Therefore, viral clearance studies should be conducted in a separate laboratory equipped for virological work and performed by staff with virological expertise in conjunction with production personnel involved in designing and preparing a scaled-down version of the purification process. The viral clearance studies should be performed under the basic concept of GLP.

(4) Each factor on a viral clearance study of a process, which is performed in miniature size, should reflect that of actual manufacturing as far as possible, and its rationality should be clarified. In case of chromatograph process, length of column bed, linear velocity, ratio of bed volume per velocity (in other words, contact time), buffer, type of column packing, pH, temperature, protein concentration, salt concentration and concentration of the objective

Table 3 Example of viruses which have been used for viral clearance studies

Virus	Family	Genus	Natural host	Genome	Env	Size (nm)	Shape	Resistance
Vesicular Stomatitis Virus	Rhabdo	Vesiculovirus	Equine Bovine	RNA	yes	70 × 150	Bullet	Low
Parainfluenza Virus	Paramyxo	Type 1,3 Respirovirus Type 2,4 Rubulavirus	Various	RNA	yes	100 – 200+	Pleo-Spher	Low
MuLV	Retro	Type C oncovirus	Mouse	RNA	yes	80 – 110	Spherical	Low
Sindbis Virus	Toga	Alphavirus	Human	RNA	yes	60 – 70	Spherical	Low
BVDV	Flavi	Pestivirus	Bovine	RNA	yes	50 – 70	Pleo-Spher	Low
Pseudorabies Virus	Herpes	Varicellovirus	Swine	DNA	yes	120 – 200	Spherical	Med
Poliovirus Sabin Type 1	Picorna	Enterovirus	Human	RNA	no	25 – 30	Icosahedral	Med
Encephalomyocarditis Virus	Picorna	Cardiovirus	Mouse	RNA	no	25 – 30	Icosahedral	Med
Reovirus Type 3	Reo	Orthoreovirus	Various kind	RNA	no	60 – 80	Spherical	Med
SV 40	Papova	Polyomavirus	Monkey	DNA	no	40 – 50	Icosahedral	Very high
Parvovirus: canine, porcine	Parvo	Parvovirus	Canine Porcine	DNA	no	18 – 24	Icosahedral	Very high

product are all correspondent to those of the actual production. Further, similarity of elution profile should be achieved. For the other process, similar concept should be applied. If there is any factor which can not reflect the actual production, its effect to the result should be examined.

(5) It is desirable that two or more inactivation/removal processes of different principles are selected and examined.

(6) As for the process which is expected to inactivate/remove virus, each step should be evaluated in aspect of clearance capability, and carefully determined if it is the stage of inactivation, removal or their combination for designing the test. Generally, in viral clearance test, a virus is spiked in each step which is the object of the test, and after passing through the process in question, the reduction level of infectivity is evaluated. But, in some case, it is accepted that a high potential virus is spiked at a step of the process, and virus concentration of each succeeding step is carefully monitored. When removal of virus is made by separation or fractionation, it is desirable to investigate how the virus is separated or fractionated (mass balance).

(7) For assessment of viral inactivation, unprocessed crude material or intermediate material should be spiked with infectious virus and the reduction factor calculated. It should be recognized that virus inactivation is not a simple, first order reaction and is usually more complex, with a fast "phase 1" and a slow "phase 2". The study should, therefore, be planned in such a way that samples are taken at different times and an inactivation curve constructed. It is recommended that studies for inactivation include at least one time point less than the minimum exposure time and greater than zero, in addition to the minimum exposure time. The reproducible clearance should be demonstrated in at least two independent studies. When there is a possibility that the virus is a human pathogen, it is very important that the effective inactivation process is designed and additional data are obtained. The initial virus load should be determined from the virus which can be detected in the spiked starting material. If this is not possible, the initial virus load may be calculated from the titer of the spiking virus prepara-

tion. Where inactivation is too rapid to plot an inactivation curve using process conditions, appropriate controls should be performed to demonstrate that infectivity is indeed lost by inactivation.

(8) If antibody against virus exists in an unprocessed material, caution should be taken at clearance studies, since it may affect the behavior of virus at viral removal or inactivation process.

(9) Virus spiked in unprocessed material should be sufficient enough to evaluate viral removal or inactivation capability of the process. However, the virus "spike" to be added to the unprocessed material should be as small as possible in comparison with the sample volume of the unprocessed material so as not to cause characteristic change of the material by addition of the virus nor to cause behavioral change of the protein in the material.

(10) It is desirable that the virus in the sample is subject for quantitative determination without applying ultracentrifuge, dialysis, storage, etc. as far as possible. However, there may be a case that any handling before quantitative test, such as remove procedure of inhibitor or toxic substance, storage for a period to realize test at a time, etc., is inevitable. If any manipulation, such as dilution, concentration, filtration, dialysis, storage, etc., is applied for preparation of the sample for testing, a parallel control test, which passes through a similar manipulation, should be conducted to assess infectivity variance at the manipulation.

(11) Buffers and product (desired protein or other component contained therein) should be evaluated independently for toxicity or interference in assays used to determine the virus titer, as these components may adversely affect the indicator cells. If the solutions are toxic to the indicator cells, dilution, adjustment of the pH, or dialysis of the buffer containing spiked virus might be necessary. If the product itself has anti-viral activity, the clearance study may need to be performed without the product in a "mock" run, although omitting the product or substituting a similar protein that does not have anti-viral activity could affect the behaviour of the virus in some production steps.

(12) Many purification schemes use the same or similar buffers or columns, repetitively. The effects of this approach should be taken into account when analyzing the data. The effectiveness of virus elimination by a particular process may vary with the stage in manufacture at which it is used.

(13) Overall reduction factors may be underestimated where production conditions or buffers are too cytotoxic or virucidal and should be discussed on a case-by-case basis. Overall reduction factors may also be overestimated due to inherent limitations or inadequate design of viral clearance studies.

(14) It has to be noted that clearance capability of viral removal/inactivation process may vary depending upon the type of virus. The viral removal/inactivation process, which displays viral clearance by specific principle or mechanism, may be quite effective to the virus, which meets such mechanism of action, but not effective to the other type of viruses. For example, S/D (Solvent/Detergent) treatment is generally effective to the virus with lipid membrane, but not effective to the non-enveloped virus. Further, some virus is resistant to the general heating process (55 – 60°C, 30 minutes). When clearance is expected for such virus, introduction of a further severe condition or process, which has different principle or mechanism, is necessary. Virus removal by membrane filtration, which is different from S/D or heat treatment in aspect of principle, is effective to a broad range of virus that can not pass through the membrane. Affinity chromatography process, which specifically absorbs the objective protein, can thoroughly wash out the materials other than the objective protein including virus etc. and is generally effective for viral removal. Separation/fractionation of a virus from an objective protein is sometimes very difficult, but there are not so rare that ion exchange chromatography, ethanol fractionation, etc. is effective for clearance of a virus which can not be sufficiently inactivated or removed by the other process.

(15) Effective clearance may be achieved by any of the following: multiple inactivation steps, multiple complementary separation steps, or combinations of inactivation and separation steps. Separation methods may be dependent on the extremely specific physico-chemical properties of a virus which influence its interaction with gel matrices and precipitation properties. However, despite these potential variables, effective removal can be obtained by a combination of complementary separation steps or combinations of inactivation and separation steps. Well designed separation steps, such as chromatographic procedures, filtration steps and extractions, can be also effective virus removal steps provided that they are performed under appropriately controlled conditions.

(16) An effective virus removal step should give reproducible reduction of virus load shown by at least two independent studies.

(17) Over time and after repeated use, the ability of chromatography columns and other devices used in the purification scheme to clear virus may vary. Some estimate of the stability of the viral clearance after several uses may provide support for repeated use of such columns.

(18) The Notice, Iyakushin No. 329, would be used as a reference when viral clearance studies on biological products are designed.

6.4. Interpretation of viral clearance studies

6.4.1. Evaluation on viral clearance factor

Viral clearance factor is a logarithm of reduction ratio of viral amount (infectious titer) between each step applied for viral clearance of a manufacturing process. Total viral clearance factor throughout the process is sum of the viral clear-

ance factor of each step appropriately evaluated.

Whether each and total viral clearance factor obtained are acceptable or should not be evaluated in aspects of every virus that can be realistically anticipated to derive into the raw material or the manufacturing process, and its rationality should be shown.

In case that existence of any viral particle is recognized in a substrate for drug production, e.g., a substrate of rodent origin for biodrug production, it is important not only to demonstrate removal or inactivation of such virus, but also to demonstrate that the purification process has enough capability over the required level to assure safety of the final product at an appropriate level. The virus amount removed or inactivated in a manufacturing process should be compared with the virus amount assumed to exist in the substrate etc. used for manufacturing drug, and for this purpose, it is necessary to obtain the virus amount in the raw materials/substrate, etc. Such figure can be obtained by measuring infectious titer or by the other method such as transmission electron microscope (TEM). For evaluation of overall process, a virus amount, far larger than that assumed to exist in the amount of the raw materials/substrate which is equivalent to single administration of the final product, has to be removed. It is quite rare that existence of virus can be assumed in a substrate for drug production, with the exception of the substrate of rodent origin, and such suspicious raw material/substrate should not be used for manufacturing drug with a special exceptional case that the drug in question is not available from the other process and is clinically indispensable, and that the information including infectious properties of the virus particle assumed to exist has been clarified. Any virus contaminations in the substrates used for production of biotechnological/biological products are usually denied by some tests or examinations. In such case, a specific virus that can possibly contaminate may be used as a model. However, in general, it would be necessary to perform a viral clearance test by choosing a combination of appropriate model viruses that can show the capability for clearance of a wide variety of viruses in the process, as indicated in 6.2. In this case, a common numerical goal cannot be established on the viral clearance. Therefore, the validity of viral clearance factor of the process should be taken into account, considering various information on factual possibility of virus contaminations of the substrates and others, detection sensitivity of the virus free test, and other cases in publications.

6.4.2. Calculation of viral clearance index

Viral clearance factor, “ R ”, for viral removal/inactivation process can be calculated by the following formula.

$$R = \log[(V_1 \times T_1)/(V_2 \times T_2)]$$

In which

R : Logarithm of reduction ratio

V_1 : Sample volume of the unprocessed material

T_1 : Virus amount (titer) of the unprocessed material

V_2 : Sample volume of the processed material

T_2 : Virus amount (titer) of the processed material

At the calculation of viral clearance factor, it is recommended to use the virus titer detected in the sample preparation of the unprocessed material after addition of virus, not the viral titer added to the sample preparation wherever possible. If this is not possible, loaded virus amount is calculated from virus titer of the solution used for spike.

6.4.3. Interpretation of results and items to be concerned at evaluation

At the interpretation and the evaluation of the data on ef-

fectiveness of viral inactivation/removal process, there are various factors to be comprehensively taken into account, such as ① appropriateness of the virus used for the test, ② design of the viral clearance studies, ③ virus reduction ratio shown in logarithm, ④ time dependence of inactivation, ⑤ factors/items which give influence to the inactivation/removal process, ⑥ sensitivity limit of virus assay method, ⑦ possible effect of the inactivation/removal process which is specific to certain class of viruses.

Additional items to be concerned at appropriate interpretation and evaluation of the viral clearance data are as follows:

(1) Behavior of virus used to the test

At interpretation of the viral clearance results, it is necessary to recognize that clearance mechanism may differ depending upon the virus used for the test. Virus used for a test is generally produced in tissue culture, but behavior of the virus prepared in the tissue culture may be different from that of the native virus. Examples are possible differences of purity and degree of aggregation between the native and the cultured viruses. Further, change of surface properties of a virus, e.g., addition of a sucrose chain which is ascribed to specific nature of a separation process, may give effect to the separation. These matters should be also considered at interpretation of the results.

(2) Design of test

Viral clearance test should have been designed taking into account variation factors of the manufacturing process and scaling down, but there still remain some variance from actual production scale. It is necessary to consider such variance at the interpretation of the data and limitation of the test.

(3) Acceptability of viral reduction data

Total viral clearance factor is expressed as a sum of logarithm of reduction ratio obtained at each step. The summation of the reduction factor of multiple steps, particularly of steps with little reduction (e.g., below 1 log₁₀), may overestimate viral removal/inactivation capability of the overall process. Therefore, virus titer of the order of 1 log₁₀ or less has to be ignored unless justified. Further, viral clearance factor achieved by repeated use of the same or similar method should be ignored for calculation unless justified.

(4) Time dependence of inactivation

Inactivation of virus infectivity frequently shows biphasic curve, which consists of a rapid initial phase and subsequent slow phase. It is possible that a virus not inactivated in a step may be more resistant to the subsequent step. For example, if an inactivated virus forms coagulation, it may be resistant to any chemical treatment and heating.

(5) Evaluation of viral reduction ratio shown in logarithm

Viral clearance factor shown in logarithm of reduction ratio of virus titer can demonstrate drastic reduction of residual infectious virus, but there is a limit that infectious titer can never be reduced to zero. For example, reduction in infectivity of a preparation containing 8 log₁₀ infectious unit per mL by a factor of 8 log₁₀ leaves zero log₁₀ per mL or one infectious unit per mL, taking into account the detection limit of assay.

(6) Variable factor of manufacturing process

Minor variance of a variation factor of a manufacturing process, e.g., contact time of a spiked sample to a buffer or a column, will sometimes give influence to viral removal or inactivation effect. In such case, it may be necessary to investigate to what extent such variance of the factor has given influence to the process concerned in aspect of viral inactivation.

(7) Existence of anti-viral antiserum

Anti-viral antiserum that exists in the sample preparation used for a test may affect sensitivity of distribution or inactivation of a virus, which may result in not only defusing the virus titer but complicating interpretation of the test result. So, existence of anti-viral antiserum is one of the important variable factors.

(8) Introduction of a new process for removal/inactivation

Viral clearance is an important factor for securing safety of drug. In case that an achievement level of infective clearance of a process is considered insufficient, a process which is characterized by inactivation/removal mechanism to meet the purpose or an inactivation/removal process which can mutually complement to the existence process has to be introduced.

(9) Limit of viral clearance studies

Viral clearance studies are useful for contributing to the assurance that an acceptable level of safety in the final product is achieved but do not by themselves establish safety. However, a number of factors in the design and execution of viral clearance studies may lead to an incorrect estimate of the ability of the process to remove virus infectivity, as described above.

7. Statistics

The viral clearance studies should include the use of statistical analysis of the data to evaluate the results. The study results should be statistically valid to support the conclusions reached.

7.1. Statistical considerations for assessing virus assays

Virus titrations suffer the problems of variation common to all biological assay systems. Assessment of the accuracy of the virus titrations and reduction factors derived from them and the validity of the assays should be performed to define the reliability of a study. The objective of statistical evaluation is to establish that the study has been carried out to an acceptable level of virological competence.

Assay

1. Assay methods may be either semiquantitative or quantitative. Both semiquantitative and quantitative assays are amenable to statistical evaluation.

2. Variation can arise within an assay as a result of dilution errors, statistical effects and differences within the assay system which are either unknown or difficult to control. These effects are likely to be greater when different assay runs are compared (between-assay variation) than when results within a single assay run are compared (within-assay variation).

3. The 95% confidence limits for results of within-assay variation normally should be on the order of $\pm 0.5 \log_{10}$ of the mean. Within-assay variation can be assessed by standard textbook methods. Between-assay variation can be monitored by the inclusion of a reference preparation, the estimate of whose potency should be within approximately 0.5 log₁₀ of the mean estimate established in the laboratory for the assay to be acceptable. Assays with lower precision may be acceptable with appropriate justification.

7.2. Reproducibility and confidence limit of viral clearance studies

An effective virus inactivation/removal step should give reproducible reduction of virus load shown by at least two independent studies. The 95% confidence limits for the reduction factor observed should be calculated wherever possible in studies of viral clearance. If the 95% confidence limits for the viral assays of the starting material are $\pm s$, and for the viral assays of the material after the step are $\pm a$, the 95% confidence limits for the reduction factor are

$\pm \sqrt{s^2 + a^2}$.

8. Re-evaluation of viral clearance

Whenever significant changes in the production or purification process are made, the effect of that change, both direct and indirect, on viral clearance should be re-evaluated as needed. Changes in process steps may also change the extent of viral clearance.

9. Measurement for viral clearance studies

9.1. Measurement of virus infective titer

Assay methods may be either semiquantitative or quantitative. Semiquantitative methods include infectivity assays in animals or in cultured cell infections dose (CCID) assays, in which the animal or cell culture is scored as either infected or not. Infectivity titers are then measured by the proportion of animals or culture infected. In quantitative methods, the infectivity measured varies continuously with the virus input. Quantitative methods include plaque assays where each plaque counted corresponds to a single infectious unit. Both quantal and quantitative assays are amenable to statistical evaluation.

9.2. Testing by nucleic-acid-amplification test (NAT)

NAT can detect individual or pooled raw material/cell substrate or virus genome at a high sensitivity even in a stage that serum test on each virus is negative. Further, it can detect HBV or HCV gene, which can not be measured in culture system. Window period can be drastically shortened at the test on HBV, HCV and HIV, and the method is expected to contribute as an effective measure for ensuring viral safety. However, depending upon a choice of primer, there may be a case that not all the subtype of objective virus can be detected by this method, and, therefore, it is recommendable to evaluate, in advance, if subtype of a broad range can be detected.

NAT will be an effective evaluation method for virus removal capability for viral clearance. However, in case of viral inactivation process, viral inactivation obtained by this method may be underrated, since there is a case that inactivated virus still shows positive on nucleic acid. Further, at introduction of NAT, cautions should be taken on rationality of detection sensitivity, choice of a standard which is used as run-control, quality assurance and maintenance of a reagent used for primer, interpretation of positive and negative results, etc.

10. Reporting and preservation

All the items relating to virus test and viral clearance studies should be reported and preserved.

11. Others

The Notice, Iyakushin No. 329, should be used as a reference at virus test and viral clearance studies.

Conclusion

As mentioned at the Introduction, assurance of quality/safety etc. of JP listed drugs should be achieved by state-of-the-art methods and concepts reflecting the progress of science and accumulation of experiences.

The basis for ensuring viral safety of JP listed biotechnological/biological products is detailed in this General Information. What is discussed here is that an almost equal level of measures are required for both development of new drugs and for existing products as well, which means that similar level of concerns should be paid on both existing and new products in aspect of viral safety. This document is intended to introduce a basic concept that quality and safety assurance of JP listed product should be based upon the most advanced methods and concepts. This document has been writ-

ten to cover all conceivable cases, which can be applied to all biotechnological/biological products. Therefore, there may be cases that it is not so rational to pursue virus tests and viral clearance studies in accordance with this document on each product, which has been used for a long time without any safety issue. So, it will be necessary to elaborate the most rational ways under a case-by-case principle taking into due consideration source, origin, type, manufacturing process, characteristics, usages at clinical stage, accumulation of the past usage record, etc. relating to such biotechnological/biological products.

Capillary Electrophoresis

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia.

Capillary electrophoresis is a physical method of analysis based on the migration, inside a capillary, of charged analytes dissolved in an electrolyte solution, under the influence of a direct-current electric field.

The migration velocity of an analyte under an electric field of intensity E , is determined by the electrophoretic mobility of the analyte and the electroosmotic mobility of the buffer inside the capillary. The electrophoretic mobility of a solute (μ_{ep}) depends on the characteristics of the solute (electric charge, molecular size and shape) and those of the buffer in which the migration takes place (type and ionic strength of the electrolyte, pH, viscosity and additives). The electrophoretic velocity (v_{ep}) of a solute, assuming a spherical shape, is given by the equation:

$$v_{ep} = \mu_{ep}E = \left(\frac{q}{6\pi\eta r} \right) \left(\frac{V}{L} \right)$$

q : Effective charge of the solute,

η : Viscosity of the electrolyte solution,

r : Stoke's radius of the solute,

V : Applied voltage,

L : Total length of the capillary.

When an electric field is applied through the capillary filled with buffer, a flow of solvent is generated inside the capillary, called electroosmotic flow. The velocity of the electroosmotic flow depends on the electroosmotic mobility (μ_{eo}) which in turn depends on the charge density on the capillary internal wall and the buffer characteristics. The electroosmotic velocity (v_{eo}) is given by the equation:

$$v_{eo} = \mu_{eo}E = \left(\frac{\epsilon\zeta}{\eta} \right) \left(\frac{V}{L} \right)$$

ϵ : Dielectric constant of the buffer,

ζ : Zeta potential of the capillary surface.

The velocity of the solute (v) is given by:

$$v = v_{ep} + v_{eo}$$

The electrophoretic mobility of the analyte and the electroosmotic mobility may act in the same direction or in opposite directions, depending on the charge of the solute. In normal capillary electrophoresis, anions will migrate in the opposite direction to the electroosmotic flow and their velocities will be smaller than the electroosmotic velocity. Cations will migrate in the same direction as the electroosmotic flow and their velocities will be greater than the electroosmotic velocity. Under conditions in which there is a fast electroosmotic velocity with respect to the electrophoretic velocity of the solutes, both cations and anions can be separated in the

same run.

The time (t) taken by the solute to migrate the distance (l) from the injection end of the capillary to the detection point (capillary effective length) is given by the expression:

$$t = \frac{l}{v_{\text{ep}} + v_{\text{eo}}} = \frac{l \times L}{(\mu_{\text{ep}} + \mu_{\text{eo}})V}$$

In general, uncoated fused-silica capillaries above pH 3 have negative charge due to ionized silanol groups in the inner wall. Consequently, the electroosmotic flow is from anode to cathode. The electroosmotic flow must remain constant from run to run if good reproducibility is to be obtained in the migration velocity of the solutes. For some applications, it may be necessary to reduce or suppress the electroosmotic flow by modifying the inner wall of the capillary or by changing the concentration, composition and/or pH of the buffer solution.

After the introduction of the sample into the capillary, each analyte ion of the sample migrates within the background electrolyte as an independent zone, according to its electrophoretic mobility. Zone dispersion, that is the spreading of each solute band, results from different phenomena. Under ideal conditions the sole contribution to the solute-zone broadening is molecular diffusion of the solute along the capillary (longitudinal diffusion). In this ideal case the efficiency of the zone, expressed as the number of theoretical plates (N), is given by:

$$N = \frac{(\mu_{\text{ep}} + \mu_{\text{eo}}) \times V \times l}{2 \times D \times L}$$

D : Molecular diffusion coefficient of the solute in the buffer.

In practice, other phenomena such as heat dissipation, sample adsorption onto the capillary wall, mismatched conductivity between sample and buffer, length of the injection plug, detector cell size and unlevelled buffer reservoirs can also significantly contribute to band dispersion.

Separation between two bands (expressed as the resolution, R_s) can be obtained by modifying the electrophoretic mobility of the analytes, the electroosmotic mobility induced in the capillary and by increasing the efficiency for the band of each analyte, according to the equation:

$$R_s = \frac{\sqrt{N}(\mu_{\text{epb}} - \mu_{\text{epa}})}{4(\bar{\mu}_{\text{ep}} + \mu_{\text{eo}})}$$

μ_{epa} and μ_{epb} : Electrophoretic mobilities of the two analytes separated,

$\bar{\mu}_{\text{ep}}$: Mean electrophoretic mobility of the two analytes

$$\bar{\mu}_{\text{ep}} = \frac{1}{2}(\mu_{\text{epb}} + \mu_{\text{epa}}).$$

Apparatus

An apparatus for capillary electrophoresis is composed of:

- (1) a high-voltage, controllable direct-current power supply,
- (2) two buffer reservoirs, held at the same level, containing the prescribed anodic and cathodic solutions,
- (3) two electrode assemblies (the cathode and the anode), immersed in the buffer reservoirs and connected to the power supply,
- (4) a separation capillary (usually made of fused-silica) which, when used with some specific types of detectors, has an optical viewing window aligned with the detector. The ends of the capillary are placed in the buffer reservoirs. The capillary is filled with the solution prescribed in the monograph,
- (5) a suitable injection system,

(6) a detector able to monitor the amount of substances of interest passing through a segment of the separation capillary at a given time. It is usually based on absorption spectrophotometry (UV and visible) or fluorometry, but conductimetric, amperometric or mass spectrometric detection can be useful for specific applications. Indirect detection is an alternative method used to detect non-UV-absorbing and non-fluorescent compounds,

(7) a thermostatic system able to maintain a constant temperature inside the capillary is recommended to obtain a good separation reproducibility,

(8) a recorder and a suitable integrator or a computer.

The definition of the injection process and its automation are critical for precise quantitative analysis. Modes of injection include gravity, pressure or vacuum injection and electrokinetic injection. The amount of each sample component introduced electrokinetically depends on its electrophoretic mobility, leading to possible discrimination using this injection mode.

Use the capillary, the buffer solutions, the preconditioning method, the sample solution and the migration conditions prescribed in the monograph of the considered substance. The employed electrolytic solution is filtered to remove particles and degassed to avoid bubble formation that could interfere with the detection system or interrupt the electrical contact in the capillary during the separation run. A rigorous rinsing procedure should be developed for each analytical method to achieve reproducible migration times of the solutes.

1. Capillary Zone Electrophoresis

In capillary zone electrophoresis, analytes are separated in a capillary containing only buffer without any anticonvective medium. With this technique, separation takes place because the different components of the sample migrate as discrete bands with different velocities. The velocity of each band depends on the electrophoretic mobility of the solute and the electroosmotic flow in the capillary (see General Principles). Coated capillaries can be used to increase the separation capacity of those substances adsorbing on fused-silica surfaces.

Using this mode of capillary electrophoresis, the analysis of both small ($M_r < 2000$) and large molecules ($2000 < M_r < 100,000$) can be accomplished. Due to the high efficiency achieved in capillary zone electrophoresis, separation of molecules having only minute differences in their charge-to-mass ratio can be effected. This separation mode also allows the separation of chiral compounds by addition of chiral selectors to the separation buffer.

Optimization

Optimization of the separation is a complex process where several separation parameters can play a major role. The main factors to be considered in the development of separations are instrumental and electrolytic solution parameters.

Instrumental parameters

(1) *Voltage*: A Joule heating plot is useful in optimizing the applied voltage and column temperature. Separation time is inversely proportional to applied voltage. However, an increase in the voltage used can cause excessive heat production, giving rise to temperature and, as a result thereof, viscosity gradients in the buffer inside the capillary. This effect causes band broadening and decreases resolution.

(2) *Polarity*: Electrode polarity can be normal (anode at the inlet and cathode at the outlet) and the electroosmotic flow will move toward the cathode. If the electrode polarity is reversed, the electroosmotic flow is away from the outlet and only charged analytes with electroosmotic mobilities

greater than the electroosmotic flow will pass to the outlet.

(3) *Temperature*: The main effect of temperature is observed on buffer viscosity and electrical conductivity, and therefore on migration velocity. In some cases, an increase in capillary temperature can cause a conformational change in proteins, modifying their migration time and the efficiency of the separation.

(4) *Capillary*: The dimensions of the capillary (length and internal diameter) contribute to analysis time, efficiency of separations and load capacity. Increasing total length can decrease the electric fields (working at constant voltage), and increasing both effective length and total length increase migration time. For a given buffer and electric field, heat dissipation, and hence sample band-broadening, depend on the internal diameter of the capillary. The latter also affects the detection limit, depending on the sample volume injected and the detection system employed.

Since the adsorption of the sample components on the capillary wall limits efficiency, methods to avoid these interactions should be considered in the development of a separation method. In the specific case of proteins, several strategies have been devised to avoid adsorption on the capillary wall. Some of these strategies (use of extreme pH and adsorption of positively charged buffer additives) only require modification of the buffer composition to prevent protein adsorption. In other strategies, the internal wall of the capillary is coated with a polymer, covalently bonded to the silica, that prevents interaction between the proteins and the negatively charged silica surface. For this purpose, ready-to-use capillaries with coatings consisting of neutral-hydrophilic, cationic and anionic polymers are available.

Electrolytic solution parameters

(1) *Buffer type and concentration*: Suitable buffers for capillary electrophoresis have an appropriate buffer capacity in the pH range of choice and low mobility to minimize current generation.

Matching buffer-ion mobility to solute mobility, whenever possible, is important for minimizing band distortion. The type of sample solvent used is also important to achieve on-column sample focusing, which increases separation efficiency and improves detection.

An increase in buffer concentration (for a given pH) decreases electroosmotic flow and solute velocity.

(2) *Buffer pH*: The pH of the buffer can affect separation by modifying the charge of the analyte or additives, and by changing the electroosmotic flow. In protein and peptide separation, changing the pH of the buffer from above to below the isoelectric point (pI) changes the net charge of the solute from negative to positive. An increase in the buffer pH generally increases the electroosmotic flow.

(3) *Organic solvents*: Organic modifiers (methanol, acetonitrile, etc.) may be added to the aqueous buffer to increase the solubility of the solute or other additives and/or to affect the degree of ionization of the sample components. The addition of these organic modifiers to the buffer generally causes a decrease in the electroosmotic flow.

(4) *Additives for chiral separations*: For the separation of optical isomers, a chiral selector is added to the separation buffer. The most commonly used chiral selectors are cyclodextrins, but crown ethers, polysaccharides and proteins may also be used. Since chiral recognition is governed by the different interactions between the chiral selector and each of the enantiomers, the resolution achieved for the chiral compounds depends largely on the type of chiral selector used. In this regard, for the development of a given separation it may be useful to test cyclodextrins having a different cavity size (α -, β -, or γ -cyclodextrin) or modified cyclodextrins with

neutral (methyl, ethyl, hydroxyalkyl, etc.) or ionizable (aminomethyl, carboxymethyl, sulfobutyl ether, etc.) groups. When using modified cyclodextrins, batch-to-batch variations in the degree of substitution of the cyclodextrins must be taken into account since it will influence the selectivity. Other factors controlling the resolution in chiral separations are concentration of chiral selector, composition and pH of the buffer and temperature. The use of organic additives, such as methanol or urea can also modify the resolution achieved.

2. Capillary Gel Electrophoresis

In capillary gel electrophoresis, separation takes place inside a capillary filled with a gel that acts as a molecular sieve. Molecules with similar charge-to-mass ratios are separated according to molecular size since smaller molecules move more freely through the network of the gel and therefore migrate faster than larger molecules. Different biological macromolecules (for example, proteins and DNA fragments), which often have similar charge-to-mass ratios, can thus be separated according to their molecular mass by capillary gel electrophoresis.

Characteristics of Gels

Two types of gels are used in capillary electrophoresis: permanently coated gels and dynamically coated gels. Permanently coated gels, such as cross-linked polyacrylamide, are prepared inside the capillary by polymerization of the monomers. They are usually bonded to the fused-silica wall and cannot be removed without destroying the capillary. If the gels are used for protein analysis under reducing conditions, the separation buffer usually contains sodium dodecyl sulfate and the samples are denatured by heating a mixture of sodium dodecyl sulfate and 2-mercaptoethanol or dithiothreitol before injection. When non-reducing conditions are used (for example, analysis of an intact antibody), 2-mercaptoethanol and dithiothreitol are not used. Separation in cross-linked gels can be optimized by modifying the separation buffer (as indicated in the capillary zone electrophoresis section) and controlling the gel porosity during the gel preparation. For cross-linked polyacrylamide gels, the porosity can be modified by changing the concentration of acrylamide and/or the proportion of cross-linker. As a rule, a decrease in the porosity of the gel leads to a decrease in the mobility of the solutes. Due to the rigidity of these gels, only electrokinetic injection can be used.

Dynamically coated gels are hydrophilic polymers, such as linear polyacrylamide, cellulose derivatives, dextran, etc., which can be dissolved in aqueous separation buffers giving rise to a separation medium that also acts as a molecular sieve. These separation media are easier to prepare than cross-linked polymers. They can be prepared in a vial and filled by pressure in a wall-coated capillary (with no electroosmotic flow). Replacing the gel before every injection generally improves the separation reproducibility. The porosity of the gels can be increased by using polymers of higher molecular mass (at a given polymer concentration) or by decreasing the polymer concentration (for a given polymer molecular mass). A reduction in the gel porosity leads to a decrease in the mobility of the solute for the same buffer. Since the dissolution of these polymers in the buffer gives low viscosity solutions, both hydrodynamic and electrokinetic injection techniques can be used.

3. Capillary Isoelectric Focusing

In isoelectric focusing, the molecules migrate under the influence of the electric field, so long as they are charged, in a pH gradient generated by ampholytes having pI values in a wide range (poly-aminocarboxylic acids), dissolved in the

separation buffer.

The three basic steps of isoelectric focusing are loading, focusing and mobilization.

(1) Loading step: Two methods may be employed:

- (i) loading in one step: the sample is mixed with ampholytes and introduced into the capillary either by pressure or vacuum;
 - (ii) sequential loading: a leading buffer, then the ampholytes, then the sample mixed with ampholytes, again ampholytes alone and finally the terminating buffer are introduced into the capillary. The volume of the sample must be small enough not to modify the pH gradient.
- (2) Focusing step: When the voltage is applied, ampholytes migrate toward the cathode or the anode, according to their net charge, thus creating a pH gradient from anode (lower pH) to cathode (higher pH). During this step the components to be separated migrate until they reach a pH corresponding to their isoelectric point (pI) and the current drops to very low values.
- (3) Mobilization step: If mobilization is required for detection, use one of the following methods. Three methods are available:

- (i) in the first method, mobilization is accomplished during the focusing step under the effect of the electroosmotic flow; the electroosmotic flow must be small enough to allow the focusing of the components;
- (ii) in the second method, mobilization is accomplished by applying positive pressure after the focusing step;
- (iii) in the third method, mobilization is achieved after the focusing step by adding salts to the cathode reservoir or the anode reservoir (depending on the direction chosen for mobilization) in order to alter the pH in the capillary when the voltage is applied. As the pH is changed, the proteins and ampholytes are mobilized in the direction of the reservoir which contains the added salts and pass the detector.

The separation achieved, expressed as ΔpI , depends on the pH gradient (dpH/dx), the number of ampholytes having different pI values, the molecular diffusion coefficient (D), the intensity of the electric field (E) and the variation of the electrophoretic mobility of the analyte with the pH ($-d\mu/dpH$):

$$\Delta pI = 3 \sqrt{\frac{D(dpH/dx)}{E(-d\mu/dpH)}}$$

Optimization

The main parameters to be considered in the development of separations are:

(1) Voltage: Capillary isoelectric focusing utilises very high electric fields, 300 V/cm to 1000 V/cm in the focusing step.

(2) Capillary: The electroosmotic flow must be reduced or suppressed depending on the mobilization strategy (see above). Coated capillaries tend to reduce the electroosmotic flow.

(3) Solutions: The anode buffer reservoir is filled with a solution with a pH lower than the pI of the most acidic ampholyte and the cathode reservoir is filled with a solution with a pH higher than the pI of the most basic ampholyte. Phosphoric acid for the anode and sodium hydroxide for the cathode are frequently used.

Addition of a polymer, such as methylcellulose, in the ampholyte solution tends to suppress convective forces (if any) and electroosmotic flow by increasing the viscosity. Com-

mercial ampholytes are available covering many pH ranges and may be mixed if necessary to obtain an expanded pH range. Broad pH ranges are used to estimate the isoelectric point whereas narrower ranges are employed to improve accuracy. Calibration can be done by correlating migration time with isoelectric point for a series of protein markers.

During the focusing step precipitation of proteins at their isoelectric point can be prevented, if necessary, using buffer additives such as glycerol, surfactants, urea or zwitterionic buffers. However, depending on the concentration, urea denatures proteins.

4. Micellar Electrokinetic Chromatography (MEKC)

In micellar electrokinetic chromatography, separation takes place in an electrolyte solution which contains a surfactant at a concentration above the critical micellar concentration (cmc). The solute molecules are distributed between the aqueous buffer and the pseudo-stationary phase composed of micelles, according to the partition coefficient of the solute. The technique can therefore be considered as a hybrid of electrophoresis and chromatography. It is a technique that can be used for the separation of both neutral and charged solutes, maintaining the efficiency, speed and instrumental suitability of capillary electrophoresis. One of the most widely used surfactants in MEKC is the anionic surfactant sodium dodecyl sulfate, although other surfactants, for example cationic surfactants such as cetyltrimethylammonium salts, are also used.

The separation mechanism is as follows. At neutral and alkaline pH, a strong electroosmotic flow is generated and moves the separation buffer ions in the direction of the cathode. If sodium dodecyl sulfate is employed as the surfactant, the electrophoretic migration of the anionic micelle is in the opposite direction, towards the anode. As a result, the overall micelle migration velocity is slowed down compared to the bulk flow of the electrolytic solution. In the case of neutral solutes, since the analyte can partition between the micelle and the aqueous buffer, and has no electrophoretic mobility, the analyte migration velocity will depend only on the partition coefficient between the micelle and the aqueous buffer. In the electropherogram, the peaks corresponding to each uncharged solute are always between that of the electroosmotic flow marker and that of the micelle (the time elapsed between these two peaks is called the separation window). For electrically charged solutes, the migration velocity depends on both the partition coefficient of the solute between the micelle and the aqueous buffer, and on the electrophoretic mobility of the solute in the absence of micelle.

Since the mechanism in MEKC of neutral and weakly ionized solutes is essentially chromatographic, migration of the solute and resolution can be rationalized in terms of the retention factor of the solute (k'), also referred to as mass distribution ratio (D_m), which is the ratio of the number of moles of solute in the micelle to those in the mobile phase. For a neutral compound, k' is given by:

$$k' = \frac{t_R - t_0}{t_0 \left(1 - \frac{t_R}{t_{mc}} \right)} = K \frac{V_S}{V_M}$$

t_R : Migration time of the solute,

t_0 : Analysis time of an unretained solute (determined by injecting an electroosmotic flow marker which does not enter the micelle, for instance methanol),

t_{mc} : Micelle migration time (measured by injecting a micelle marker, such as Sudan III, which migrates while continuously associated in the micelle),

K : Partition coefficient of the solute,

V_S : Volume of the micellar phase,

V_M : Volume of the mobile phase.

Likewise, the resolution between two closely-migrating solutes (R_S) is given by:

$$R_S = \frac{\sqrt{N}}{4} \times \frac{\alpha - 1}{\alpha} \times \frac{k'_b}{k'_a + 1} \times \frac{1 - \left(\frac{t_0}{t_{mc}} \right)}{1 + \left(\frac{t_0}{t_{mc}} \right) k'_a}$$

N : Number of theoretical plates for one of the solutes,

α : Selectivity,

k'_a and k'_b : Retention factors for both solutes, respectively ($k'_b > k'_a$).

Similar, but not identical, equations give k' and R_S values for electrically charged solutes.

Optimization

The main parameters to be considered in the development of separations by MEKC are instrumental and electrolytic solution parameters.

Instrumental parameters

(1) *Voltage*: Separation time is inversely proportional to applied voltage. However, an increase in voltage can cause excessive heat production that gives rise to temperature gradients and viscosity gradients of the buffer in the cross-section of the capillary. This effect can be significant with high conductivity buffers such as those containing micelles. Poor heat dissipation causes band broadening and decreases resolution.

(2) *Temperature*: Variations in capillary temperature affect the partition coefficient of the solute between the buffer and the micelles, the critical micellar concentration and the viscosity of the buffer. These parameters contribute to the migration time of the solutes. The use of a good cooling system improves the reproducibility of the migration time for the solutes.

(3) *Capillary*: As in capillary zone electrophoresis, the dimensions of the capillary (length and internal diameter) contribute to analysis time and efficiency of separations. Increasing both effective length and total length can decrease the electric fields (working at constant voltage), increase migration time and improve the separation efficiency. The internal diameter controls heat dissipation (for a given buffer and electric field) and consequently the sample band broadening.

Electrolytic solution parameters

(1) *Surfactant type and concentration*: The type of surfactant, in the same way as the stationary phase in chromatography, affects the resolution since it modifies separation selectivity. Also, the $\log k'$ of a neutral compound increases linearly with the concentration of surfactant in the mobile phase. Since resolution in MEKC reaches a maximum when k' approaches the value of $\sqrt{t_m/t_0}$, modifying the concentration of surfactant in the mobile phase changes the resolution obtained.

(2) *Buffer pH*: Although pH does not modify the partition coefficient of non-ionized solutes, it can modify the electroosmotic flow in uncoated capillaries. A decrease in the buffer pH decreases the electroosmotic flow and therefore increases the resolution of the neutral solutes in MEKC, resulting in a longer analysis time.

(3) *Organic solvents*: To improve MEKC separation of hydrophobic compounds, organic modifiers (methanol, propanol, acetonitrile, etc.) can be added to the electrolytic solution. The addition of these modifiers usually decreases migration time and the selectivity of the separation. Since the addition of organic modifiers affects the critical micellar

concentration, a given surfactant concentration can be used only within a certain percentage of organic modifier before the micellization is inhibited or adversely affected, resulting in the absence of micelles and, therefore, in the absence of partition. The dissociation of micelles in the presence of a high content of organic solvent does not always mean that the separation will no longer be possible; in some cases the hydrophobic interaction between the ionic surfactant monomer and the neutral solutes forms solvophobic complexes that can be separated electrophoretically.

(4) *Additives for chiral separations*: For the separation of enantiomers using MEKC, a chiral selector is included in the micellar system, either covalently bound to the surfactant or added to the micellar separation electrolyte. Micelles that have a moiety with chiral discrimination properties include salts of *N*-dodecanoyl-L-amino acids, bile salts, etc. Chiral resolution can also be achieved using chiral discriminators, such as cyclodextrins, added to the electrolytic solutions which contain micellized achiral surfactants.

(5) *Other additives*: Several strategies can be carried out to modify selectivity, by adding chemicals to the buffer. The addition of several types of cyclodextrins to the buffer can also be used to reduce the interaction of hydrophobic solutes with the micelle, thus increasing the selectivity for this type of compound.

The addition of substances able to modify solute-micelle interactions by adsorption on the latter, is used to improve the selectivity of the separations in MEKC. These additives may be a second surfactant (ionic or non-ionic) which gives rise to mixed micelles or metallic cations which dissolve in the micelle and form co-ordination complexes with the solutes.

Quantification

Peak areas must be divided by the corresponding migration time to give the corrected area in order to:

- (1) compensate for the shift in migration time from run to run, thus reducing the variation of the response,
- (2) compensate for the different responses of sample constituents with different migration times.

Where an internal standard is used, verify that no peak of the substance to be examined is masked by that of the internal standard.

Calculations

From the values obtained, calculate the content of the component or components being examined. When prescribed, the percentage content of one or more components of the sample to be examined is calculated by determining the corrected area(s) of the peak(s) as a percentage of the total of the corrected areas of all peaks, excluding those due to solvents or any added reagents (normalization procedure). The use of an automatic integration system (integrator or data acquisition and processing system) is recommended.

System Suitability

In order to check the behavior of the capillary electrophoresis system, system suitability parameters are used. The choice of these parameters depends on the mode of capillary electrophoresis used. They are: retention factor (k') (only for micellar electrokinetic chromatography), apparent number of theoretical plates (N), symmetry factor (A_S) and resolution (R_S). In previous sections, the theoretical expressions for N and R_S have been described, but more practical equations that allow these parameters to be calculated from the electropherograms are given below.

Apparent Number of Theoretical Plates

The apparent number of theoretical plates (N) may be calculated using the expression:

$$N = 5.54 \left(\frac{t_R}{w_h} \right)^2$$

t_R : Migration time or distance along the baseline from the point of injection to the perpendicular dropped from the maximum of the peak corresponding to the component,

w_h : Width of the peak at half-height.

Resolution

The resolution (R_S) between peaks of similar height of two components may be calculated using the expression:

$$R_S = \frac{1.18(t_{R2} - t_{R1})}{w_{h1} + w_{h2}}$$

$$t_{R2} > t_{R1}$$

t_{R1} and t_{R2} : Migration times or distances along the baseline from the point of injection to the perpendiculars dropped from the maxima of two adjacent peaks,

w_{h1} and w_{h2} : Peak widths at half-height.

When appropriate, the resolution may be calculated by measuring the height of the valley (H_v) between two partly resolved peaks in a standard preparation and the height of the smaller peak (H_p) and calculating the peak-to-valley ratio:

$$p/v = \frac{H_p}{H_v}$$

Symmetry Factor

The symmetry factor (A_S) of a peak may be calculated using the expression:

$$A_S = \frac{w_{0.05}}{2d}$$

$w_{0.05}$: Width of the peak at one-twentieth of the peak height,

d : Distance between the perpendicular dropped from the peak maximum and the leading edge of the peak at one-twentieth of the peak height.

Tests for area repeatability (standard deviation of areas or of the area/migration-time ratio) and for migration time repeatability (standard deviation of migration time) are introduced as suitability parameters. Migration time repeatability provides a test for the suitability of the capillary washing procedures. An alternative practice to avoid the lack of repeatability of the migration time is to use migration time relative to an internal standard.

A test for the verification of the signal-to-noise ratio for a standard preparation (or the determination of the limit of quantification) may also be useful for the determination of related substances.

Signal-to-noise Ratio

The detection limit and the quantification limit are equivalent to signal-to-noise ratios of 3 and 10, respectively. The signal-to-noise ratio (S/N) is calculated using the expression:

$$S/N = \frac{2H}{h}$$

H : Height of the peak corresponding to the component concerned, in the electropherogram obtained with the prescribed reference solution, measured from the maximum of the peak to the extrapolated baseline of the signal observed over a distance equal to twenty times the width at half-height,

h : Range of the background in an electropherogram obtained after injection of a blank, observed over a distance equal to twenty times the width at the half-height of the peak in the electropherogram obtained with the prescribed reference solution and, if possible, situated equally around the place where this peak would be found.

Isoelectric Focusing

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia. The parts of the text that are not harmonized are marked with symbols (♦ ◆).

General Principles

Isoelectric focusing (IEF) is a method of electrophoresis that separates proteins according to their isoelectric point. Separation is carried out in a slab of polyacrylamide or agarose gel that contains a mixture of amphoteric electrolytes (ampholytes). When subjected to an electric field, the ampholytes migrate in the gel to create a pH gradient. In some cases gels containing an immobilized pH gradient, prepared by incorporating weak acids and bases to specific regions of the gel network during the preparation of the gel, are used. When the applied proteins reach the gel fraction that has a pH that is the same as their isoelectric point (pI), their charge is neutralized and migration ceases. Gradients can be made over various ranges of pH, according to the mixture of ampholytes chosen.

Theoretical Aspects

When a protein is at the position of its isoelectric point, it has no net charge and cannot be moved in a gel matrix by the electric field. It may, however, move from that position by diffusion. The pH gradient forces a protein to remain in its isoelectric point position, thus concentrating it; this concentrating effect is called "focusing". Increasing the applied voltage or reducing the sample load result in improved separation of bands. The applied voltage is limited by the heat generated, which must be dissipated. The use of thin gels and an efficient cooling plate controlled by a thermostatic circulator prevents the burning of the gel whilst allowing sharp focusing. The separation R is estimated by determining the minimum pI difference (ΔpI), which is necessary to separate 2 neighboring bands:

$$R: \Delta pI = 3 \sqrt{\frac{D(dpH/dx)}{E(-d\mu/dpH)}}$$

D : Diffusion coefficient of the protein

dpH/dx : pH gradient

E : Intensity of the electric field, in volts per centimeter

$-d\mu/dpH$: Variation of the solute mobility with the pH in the region close to the pI

Since D and $-d\mu/dpH$ for a given protein cannot be altered, the separation can be improved by using a narrower pH range and by increasing the intensity of the electric field. Resolution between protein bands on an IEF gel prepared with carrier ampholytes can be quite good. Improvements in resolution may be achieved by using immobilized pH gradients where the buffering species, which are analogous to carrier ampholytes, are copolymerized within the gel matrix. Proteins exhibiting pIs differing by as little as 0.02 pH units may be resolved using a gel prepared with carrier ampholytes while immobilized pH gradients can resolve proteins differing by approximately 0.001 pH units.

Practical Aspects

Special attention must be paid to sample characteristics and/or preparation. Having salt in the sample can be problematic and it is best to prepare the sample, if possible, in deionized water or 2 per cent ampholytes, using dialysis or gel filtration if necessary.

The time required for completion of focusing in thin-layer polyacrylamide gels is determined by placing a colored protein (e.g. hemoglobin) at different positions on the gel surface and by applying the electric field: the steady state is reached when all applications give an identical band pattern. In some protocols the completion of the focusing is indicated by the time elapsed after the sample application.

The IEF gel can be used as an identity test when the migration pattern on the gel is compared to a suitable standard preparation and IEF calibration proteins, the IEF gel can be used as a limit test when the density of a band on IEF is compared subjectively with the density of bands appearing in a standard preparation, or it can be used as a quantitative test when the density is measured using a densitometer or similar instrumentation to determine the relative concentration of protein in the bands subject to validation.

Apparatus

An apparatus for IEF consists of:

- a controllable generator for constant potential, current and power. Potentials of 2500 V have been used and are considered optimal under a given set of operating conditions. Supply of up to 30 W of constant power is recommended,
- a rigid plastic IEF chamber that contains a cooled plate, of suitable material, to support the gel,
- a plastic cover with platinum electrodes that are connected to the gel by means of paper wicks of suitable width, length and thickness, impregnated with solutions of anodic and cathodic electrolytes.

Isoelectric Focusing in Polyacrylamide Gels: Detailed Procedure

The following method is a detailed description of an IEF procedure in thick polyacrylamide slab gels, which is used unless otherwise stated in the monograph.

Preparation of the Gels

Mould The mould (see Figure) is composed of a glass plate (A) on which a polyester film (B) is placed to facilitate handling of the gel, one or more spacers (C), a second glass plate (D) and clamps to hold the structure together.

7.5% Polyacrylamide gel Dissolve 29.1 g of acrylamide and 0.9 g of *N,N'*-methylenebisacrylamide in 100 mL of water. To 2.5 volumes of this solution, add the mixture of ampholytes specified in the monograph and dilute to 10 volumes with water. Mix carefully and degas the solution.

Preparation of the mould Place the polyester film on the lower glass plate, apply the spacer, place the second glass plate and fit the clamps. Place 7.5% polyacrylamide gel prepared before use on a magnetic stirrer, and add 0.25 volumes of a solution of ammonium persulfate (1 in 10) and 0.25 volumes of *N,N,N',N'*-tetramethylethylenediamine. Immediately fill the space between the glass plates of the mould with the solution.

Method

Dismantle the mould and, making use of the polyester film, transfer the gel onto the cooled support, wetted with a few millilitres of a suitable liquid, taking care to avoid forming air bubbles. Prepare the test solutions and reference solutions as specified in the monograph. Place strips of paper for sample application, about 10 mm × 5 mm in size, on the gel




Figure. Mould

and impregnate each with the prescribed amount of the test and reference solutions. Also apply the prescribed quantity of a solution of proteins with known isoelectric points as pH markers to calibrate the gel. In some protocols the gel has pre-cast slots where a solution of the sample is applied instead of using impregnated paper strips. Cut 2 strips of paper to the length of the gel and impregnate them with the electrolyte solutions: acid for the anode and alkaline for the cathode. The compositions of the anode and cathode solutions are given in the monograph. Apply these paper wicks to each side of the gel several millimetres from the edge. Fit the cover so that the electrodes are in contact with the wicks (respecting the anodic and cathodic poles). Proceed with the isoelectric focusing by applying the electrical parameters described in the monograph. Switch off the current when the migration of the mixture of standard proteins has stabilized. Using forceps, remove the sample application strips and the 2 electrode wicks. Immerse the gel in fixing solution for isoelectric focusing in polyacrylamide gel. Incubate with gentle shaking at room temperature for 30 minutes. Drain off the solution and add 200 mL of destaining solution. Incubate with shaking for 1 hour. Drain the gel, add coomassie staining TS. Incubate for 30 minutes. Destain the gel by passive diffusion with destaining solution until the bands are well visualized against a clear background. Locate the position and intensity of the bands in the electropherogram as prescribed in the monograph.

Variations to the Detailed Procedure (Subject to Validation)

Where reference to the general method on isoelectric focusing is made, variations in methodology or procedure may be made subject to validation. These include:

- (1) the use of commercially available pre-cast gels and of commercial staining and destaining kits,
- (2) the use of immobilized pH gradients,
- (3) the use of rod gels,
- (4) the use of gel cassettes of different dimensions, including ultra-thin (0.2 mm) gels,
- (5) variations in the sample application procedure, including different sample volumes or the use of sample application masks or wicks other than paper,
- (6) the use of alternate running conditions, including variations in the electric field depending on gel dimensions and equipment, and the use of fixed migration times rather than subjective interpretation of band stability,
- (7) the inclusion of a pre-focusing step,
- (8) the use of automated instrumentation,
- (9) the use of agarose gels.

Validation of Iso-Electric Focusing Procedures

Where alternative methods to the detailed procedure are employed they must be validated. The following criteria may be used to validate the separation:

- (1) formation of a stable pH gradient of desired characteristics, assessed for example using colored pH markers of known isoelectric points,
- (2) comparison with the electropherogram provided with the chemical reference substance for the preparation to be examined,
- (3) any other validation criteria as prescribed in the monograph.

Specified Variations to the General Method

Variations to the general method required for the analysis of specific substances may be specified in detail in monographs. These include:

- (1) the addition of urea in the gel (3 mol/L concentration is often satisfactory to keep protein in solution but up to 8 mol/L can be used): some proteins precipitate at their isoelectric point. In this case, urea is included in the gel formulation to keep the protein in solution. If urea is used, only fresh solutions should be used to prevent carbamylation of the protein,
- (2) the use of alternative staining methods,
- (3) the use of gel additives such as non-ionic detergents (e.g. octylglucoside) or zwitterionic detergents (e.g., 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) or 3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO)), and the addition of ampholyte to the sample, to prevent proteins from aggregating or precipitating.

Points to Consider

Samples can be applied to any area on the gel, but to protect the proteins from extreme pH environments samples should not be applied close to either electrode. During method development the analyst can try applying the protein in 3 positions on the gel (i.e. middle and both ends); the pattern of a protein applied at opposite ends of the gel may not be identical.

A phenomenon known as cathodic drift, where the pH gradient decays over time, may occur if a gel is focused too long. Although not well understood, electroendoosmosis and absorption of carbon dioxide may be factors that lead to cathodic drift. Cathodic drift is observed as focused protein migrating off the cathode end of the gel. Immobilized pH gradients may be used to address this problem.

Efficient cooling (approximately 4°C) of the bed that the gel lies on during focusing is important. High field strengths used during isoelectric focusing can lead to overheating and affect the quality of the focused gel.

Reagents and Solutions—

Fixing solution for isoelectric focusing in polyacrylamide gel Dissolve 35 g of 5-sulfosalicylic acid dihydrate and 100 g of trichloroacetic acid in water to make 1000 mL.

♦**Coomassie staining TS** Dissolve 125 mg of coomassie brilliant blue R-250 in 100 mL of a mixture of water, methanol and acetic acid (100) (5:4:1), and filter.

Destaining solution A mixture of water, methanol and acetic acid (100) (5:4:1).♦

Mass Spectrometry of Peptides and Proteins

Mass spectrometry (MS) is based on the ionization of molecules and separation of the electrically charged ions according to the dimensionless quantity, m/z value, which is obtained by dividing the relative mass (m) of the ion to uni-




Fig. 1 Schematic diagram of mass spectrometry (MS) and tandem mass spectrometry (MS/MS)

fied atomic mass unit by the charge number (z) of the ion. The unified atomic mass unit is defined as one twelfth of the mass of ground state ^{12}C and used to express the mass of atom, molecule and ion. The results are expressed as a mass spectrum with m/z values of the ions on the x-axis and signal intensity of the ions on the y-axis. The mass of the molecule is calculated from the m/z values and z . Tandem mass spectrometry (MS/MS) is based on the fragmentation of the precursor ion selected in the first stage mass analysis and measurement of the product ions in the second stage mass analysis. This technique provides useful information for structural analysis of the molecule. Information obtained in MS is qualitative and is sometimes used for qualification. MS and MS/MS are useful for measuring masses of peptides and proteins and for confirming amino acid sequences and post-translational modifications. Both methods are therefore used for identification of pharmaceutical peptides and proteins.

1. Instrument

A mass spectrometer is composed of an ion source, an analyzer, an ion detector, and a data system (Fig. 1). A peptide and protein sample introduced into the ion source is ionized by soft-ionization methods, such as matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI). The charged and gas phased ions are sorted according to the m/z ratio under a vacuum in the analyzer, which may be a quadrupole, time-of-flight, ion trap or Fourier transform ion cyclotron resonance analyzer. The ion flux collected in the detector is converted to an electric signal. Then the signal is recorded as a mass spectrum. MS/MS is carried out by using two mass spectrometers connected in series, an ion-trap mass spectrometer and Fourier transform ion cyclotron resonance mass spectrometer. The precursor ions are generally fragmented by collision-induced dissociation, post-source decay, electron capture dissociation, etc.

2. Analytical mode

2.1. MS

There are two useful modes for MS:

(1) Total ion monitoring

The signals of the entire ion are acquired over the chosen range of m/z value. This mode provides information on the masses of the molecule of interest and different species.

(2) Selected ion monitoring

The signals of the ion at chosen m/z value are acquired. This mode is useful for the sensitive measurement of the chosen molecule.

2.2. MS/MS

There are four essential modes for MS/MS:

(1) Product ion analysis

The signals of all the product ions produced from the precursor at chosen m/z value are acquired. This mode provides structural information on the substrates and various co-existing species.

(2) Precursor ion scan mode

The signals of the precursor that yields the product ion at chosen m/z value are monitored. This mode is used for sorting the molecules containing a component of interest.

(3) Constant neutral loss scan mode

The signals of the precursor that loses the fragment at chosen m/z value are monitored. This mode is useful to sort the molecules containing a component of interest.

(4) Selected reaction monitoring

The signals of product ions at chosen m/z value that are produced from the precursor at chosen m/z value are monitored. This mode allows for sensitive and selective measurement and is used for quantification of a molecule in a complex mixture.

3. Analytical procedure**3.1. MS**

In advance, it should be confirmed if the detectability and the difference between the calculated mass and observed mass meet the criteria stated in the monograph by mass measuring using a test solution specified in the system suitability in the monograph. If they do not meet the criteria, the system should be optimized by adjustment of the voltage of the ion source, analyzer and detector, as well as by calibration using appropriate mass calibrator. MS is performed according to the sample preparation and operating conditions indicated in the monograph. The general procedure is described as follows.

(1) Matrix-assisted laser desorption/ionization (MALDI)

A desalted peptide and protein sample is dissolved in an appropriate solvent, e.g., an aqueous solution of trifluoroacetic acid. A suitable matrix, such as α -ciano-4-hydroxycinnamic acid, 2,5-dihydroxybenzoic acid, or sinapic acid, is dissolved in an aqueous solution containing acetonitrile and trifluoroacetic acid. A mixture of sample solution and matrix solution is deposited on a sample plate and dried. The sample on the plate is set in the ion source, and ionized by a laser beam at suitable intensity.

(2) Electrospray ionization (ESI)

A desalted peptide and protein sample is dissolved in a suitable solvent, such as an aqueous solution containing acetic acid and methanol or acetonitrile. The sample solution is sprayed through a needle tip and held at a potential of several kilovolts. The sample is introduced by using a syringe or HPLC.

3.2. MS/MS

System suitability is tested by MS/MS of the test sample specified in the monograph. The detectability and system performance should be confirmed based on the detection of the product ions specified in the monograph. The sample is ionized in the same way as for MS, and the chosen precursor is fragmented by the suitable conditions specified in the monograph. The signals are recorded as a mass spectrum. A peptide containing disulfide bonds is generally reduced by dithiothreitol, 2-mercaptopethanol and tris(2-carboxyethyl) phosphine. The reduced peptides are derivatized with monoiodoacetic acid, iodoacetamide, and 4-vinylpyridine.

4. Identification test**4.1. Mass of the molecule**

The monoisotopic mass of the peptide is preferably acquired. If the monoisotopic mass is not detectable, the average mass is calculated from the top of the ion peak.

Deconvolution is effective for calculating the average mass of multiply-charged ions from proteins. The mass should meet the criteria specified in the monograph.

4.2. Amino acid sequence

After measuring the mass of the sample peptide, the presence of the specified product ions that arise from the selected precursor is confirmed according to the conditions indicated in the monograph. Digestion of sample proteins with a suitable enzyme followed by MS/MS is sometimes effective for sequencing of the high-molecular weight proteins which provide insufficient product ions. Details of the digestion procedure are provided in the section on peptide mapping.

5. Glossary**Ion-trap (IT)**

Ion-trap refers to the quadrupole ion trap mass analyzer in a restricted sense. Ions stored in the analyzer by applying radio frequency voltage to ring electrodes are separated by subsequent ejection of the ions from the analyzer by varying the voltage on the ring electrodes. This allows multiple stage MS in which a selected ion is repeatedly trapped, fragmented and ejected.

Electrospray ionization (ESI)

The sample in solution is sprayed through a needle tip and held at high-voltage at atmospheric pressure. The sample is ionized by a formation of charged liquid droplets. High-molecular mass proteins are detected as multiply-charged ions. The analyzer can be connected with HPLC.

Quadrupole (Q)

The analyzer is composed of four parallel electrodes which have a hyperboloidal or corresponding cross-section. The ions transmitted to the analyzer are separated by varying the potential of direct and radio frequency components applied to the rods so that the filter for sorting the m/z values of ions is changed.

Collision-induced dissociation (CID)

When an ion collides with a neutral atom or molecule (He, Ar, N_2 and so on), some of the translational energy of the collision is converted into internal energy, thereby causing dissociation. The terms low-energy CID and high-energy CID refer to those CIDs for which the translational energy of the precursor ions is lower than 1000 eV and higher than 1000 eV, respectively.

Electron capture dissociation (ECD)

Multiply-charged positive ions interact with low energy electrons producing charge-reduced radical ions, which readily dissociate. This method is primarily used for MS/MS in FT-ICR MS or IT MS.

Time-of-flight (TOF)

The ionized sample is accelerated at high-voltage and separated based on the time required for an ion to travel to the detector. There are two types of analyzer, a linear type in which ions travel linearly from the ion source to the detector, and a reflectron type where ions are inverted by a reflectron. The latter type allows high-resolution measurement by correction of the variation in the initial energy of ions.

Fourier transform ion cyclotron resonance (FT-ICR)

The analyzer is based on the principle that the cyclotron frequency of the ions in a magnetic field is inversely proportional to its m/z value. Ions are excited to a larger radius orbit using radio frequency energy and their image current is detected on receiver plates. The resulting data are devolved by applying a Fourier transform to give a mass spectrum.

Post-source decay (PSD)

Metastable ion decay occurs by excess internal energy and collision with residual gas during ion acceleration out of the MALDI ion source and prior to reaching the detector. This method is used for MS/MS by using MALDI-TOF MS with a reflectron mode.

Matrix-assisted laser desorption/ionization (MALDI)

The sample, which is mixed with a suitable matrix and deposited on a target plate, is ionized by irradiation with nanosecond laser pulses. Proteins, carbohydrates, oligonucleotides, and lipids can be ionized without any dissociation. Singly-charged ions are mainly detected.

Monosaccharide Analysis and Oligosaccharide Analysis/ Oligosaccharide Profiling

Glycosylation analysis is a method to confirm the consistency of the oligosaccharides attached to glycoprotein drug substance, product or material. When oligosaccharides attached to the glycoprotein affect efficacy and safety or the possibility cannot be denied, oligosaccharides are considered as critical quality attribute, and strategy should be designed in order to ensure the consistency of glycosylation. One of the strategies is glycosylation analysis, which involves 1) analysis of released monosaccharides (monosaccharide analysis), 2) analysis of released oligosaccharides (oligosaccharide analysis/oligosaccharide profiling), 3) analysis of glycopeptides (glycopeptide analysis), and 4) analysis of intact glycoprotein (glycoform analysis). These methods provide monosaccharide compositions, oligosaccharide identities and distribution in whole glycoprotein, site-specific glycosylation identities and distribution, and overall glycosylation characteristics and distribution of glycoprotein, respectively. In the setting specification of glycosylation analysis, proper methods should be selected and used alone or in combination, in consideration of the relationship between the oligosaccharide structures and functions, such as biological activity, pharmacodynamics, pharmacokinetics, immunogenicity, stability, and solubility. Glycosylation consistency may be ensured not only by oligosaccharide analysis but also at manufacturing process. Glycosylation analysis can be also used as in-process test, and as method to confirm glycosylation consistency during process development. Methods and general consideration of monosaccharide analysis and oligosaccharide analysis/oligosaccharide profiling are described below. For glycopeptide analysis, General Test <2.62> Mass Spectrometry, and General Information Peptide Mapping and Mass Spectrometry of Peptides and Proteins would be helpful, and for glycoform analysis, General Information Isoelectric Focusing and Capillary Electrophoresis, and General Test <2.62> Mass Spectrometry would be helpful.

1. Monosaccharide analysis

Monosaccharides are released by cleavage of glycosidic bond using acid hydrolysis, exoglycosidase or methanolysis. Released monosaccharides are dried and purified if needed, and then analyzed using liquid chromatography, gas chromatography, or capillary electrophoresis. Internal standard method or absolute calibration method are used for quantitative measurement. The analytical results are typically expressed as molar ratio of individual monosaccharides to glycoprotein.

1.1. Isolation and purification of glycoprotein

Monosaccharide analysis is generally performed after glycoprotein is isolated and purified in an appropriate manner, because excipients and salts may affect hydrolysis, derivatization of monosaccharides, and chromatographic separation. When purification of the glycoprotein is required, the procedure is specified in the specific monograph.

1.2. Release of monosaccharide

1.2.1. Acid hydrolysis

Acid hydrolysis is the most common procedure to release neutral and amino sugars. In general, monosaccharides may be released by acid hydrolysis of glycosidic bond under conditions such as 2 to 7 mol/L trifluoroacetic acid at about 100°C. Since amino sugar residue directly attached to protein is difficult to release, for accurate quantification of amino sugars, acid hydrolysis should be performed separately under conditions such as 2 to 6 mol/L hydrochloride at 100°C. Because hydrolysis rate is dependent on the identity of the monosaccharide, the anomeric configuration, and position of the glycosidic linkage, it is recommended that release and degradation of individual monosaccharides are confirmed by time-course study. Because N-acetyl groups of amino sugars are removed under acid hydrolysis conditions, re-N-acetylation may be performed if needed. Since sialic acid is labile, sialic acids are released separately under conditions such as 0.1 mol/L hydrochloride, 0.1 mol/L sulfuric acid, or 2 mol/L acetic acid at 80°C.

1.2.2. Enzymatic treatment

Exoglycosidase digestion is also used for release of sialic acids from glycoprotein. Typically, sialidases with broad specificity, such as those derived from *Arthrobacter ureafaciens* or *Clostridium perfringens* are used. Digestion conditions should be optimized in consideration of the identity of sialic acids, linkage, O-acetylation and others. Other enzymes with high specificity may be used to distinguish different types of linkage.

1.2.3. Methanolysis

Dried sample is heated under methanolic hydrogen chloride. Monosaccharides are released as methyl glycosides. Degradation of released monosaccharides is low compared to acid hydrolysis.

1.3. Quantification of the released monosaccharides

1.3.1. High-pH anion-exchange chromatography with pulsed amperometric detection

Acid is removed from the hydrolysate if needed. Monosaccharides can be separated and quantified without derivatization using high-pH anion-exchange chromatography with pulsed amperometric detection. Monosaccharides have about 12 to 14 of acid dissociation constant (pKa). They are ionized under high pH conditions (pH 12 to 13), and can be separated by strong anion-exchange chromatography using polymer-based stationary phase containing quaternary ammonium groups. Amperometric detection is a method to detect electrochemically active ions by measuring the current when analyte is oxidized or reduced at electrodes. Sugar is ionized at high pH and can be selectively detected by amperometry. Because oxidized products of sugars foul the electrodes and reduce the signals, pulsed amperometry, where electrode surface is cleaned by changing positive and negative potentials after data acquisition, is used. Since amino acids are also detectable by amperometry, it is noted that analysis may be interfered in the case of the glycoprotein with low oligosaccharide contents. This analytical method can be used for oligosaccharide analysis as well as for analysis of neutral and amino sugars, and sialic acids.

1.3.2. Derivatization and liquid chromatography

(1) Neutral and amino sugars

Monosaccharides obtained by acid hydrolysis are treated to remove the acid, re-N-acetylated if needed, then reductively aminated with 2-aminobenzoic acid, 2-aminopyridine, or ethyl-4-aminobenzoate, or derivatized with 3-methyl-1-phenyl-5-pyrazolone. Impurities derived from reagents may interfere the analysis, attention should be paid to the purity of the reagents used. To prevent excessive reagents to affect test results, derivatized monosaccharides are purified if needed. The derivatized monosaccharides may be separated using reversed-phase chromatography, or anion-exchange chromatography with formation of borate complex. Separated monosaccharides are detected by fluorometric or ultraviolet detector. Underivatized monosaccharides may be separated by ion-exchange chromatography, post-column derivatization using such as arginine, and then detected.

(2) Sialic acid

Released sialic acids by mild acid hydrolysis or sialidase digestion are derivatized with 1,2-diamino-4,5-methylenedioxybenzen or 1,2-phenylenediamine, which react with α -keto acid specifically. This reaction proceed in acidic conditions, thus acid hydrolysate can be used for derivatization without removal of the acid. Derivatized sialic acids are separated by reversed-phase chromatography and detected by fluorometric detector.

1.3.3. Gas chromatography

There are several methods for gas chromatography; monosaccharides obtained by methanolysis are re-N-acetylated and trimethylsilylated (trimethylsilyl derivatives), and the monosaccharides obtained by acid hydrolysis are reduced and then acetylated (alditol acetate derivatives). The former can quantitate sialic acids simultaneously without degradation, but each sugar gives several peaks due to α - and β -anomers and isomers, and chromatogram becomes complex.

Methylation analysis provides the structural information or the glycosidic linkage of individual monosaccharides. After all hydroxy groups in the oligosaccharide are methylated, permethylated oligosaccharide is subject to acid hydrolysis and resultant partially methylated monosaccharides are reduced and acetylated. Partially methylated alditol acetates are separated and quantified using gas chromatography.

1.4. Acceptance criteria

Confirmation of compliance of the test material is typically achieved by demonstrating that contents of individual monosaccharides per protein are within a specified range. In order to set acceptance criteria properly, it is needed to consider the relationship between characteristics of glycosylation, and efficacy and safety.

1.5. Monosaccharide reference materials

Monosaccharides to be analyzed are often used as reference materials for monosaccharide analysis. In this case, monosaccharide reference material mixture is prepared as mixing each monosaccharide equally, or at similar ratio expected in test substance.

1.6. System suitability

The solution for system suitability test should be prepared properly using monosaccharide reference materials. It may be difficult to separate each monosaccharide completely due to its similar physical property. Acceptance criteria should be set properly.

2. Oligosaccharide analysis/oligosaccharide profiling

Oligosaccharides are released from glycoprotein by enzymatic or chemical treatment, and then released oligosaccharides are analyzed or profiled by liquid chromatography <2.01>, capillary electrophoresis, mass spectrometry <2.62>, or combination of them. Analysis result is obtained as oligosaccharide profile, which provides the information on the identity and the distribution of oligosaccharide.

2.1. Separation and purification of glycoprotein

Interfering substance, such as excipients, salts and surfactant, are removed if needed. When purification of the glycoprotein is required, the procedure is specified in the specific monograph.

2.2. Release and isolation of oligosaccharides


Release of N-linked oligosaccharides from glycoprotein is performed by enzymatic treatment or hydrazinolysis. Release of O-linked oligosaccharides is performed by alkali β -elimination, hydrazinolysis, and O-glycanase digestion. The releasing conditions must be optimized in order to release and recover all oligosaccharides attached to the glycoprotein reproducibly, independent of their structure and their individual position in the protein. Table 1 give a non-exhaustive list of enzymatic cleavage agents and their specificity. Released oligosaccharides may be purified prop-

Table 1 Examples of enzymatic cleavage agents


Enzyme	Specificity
N-linked oligosaccharide release Peptide- N^4 -(N -acetyl- β -D-glucosaminyl) asparagine amidase (EC 3.5.1.52)	Hydrolysis of peptide- N^4 -(N -acetyl- β -D-glucosaminyl) asparagine residue in which the glucosamine residue may be further glycosylated, to yield a (substituted) N -acetyl- β -D-glucosaminylamine and a peptide containing an aspartate residue
—Peptide N-glycosidase F (PNGase F)	Release of N-linked oligosaccharides but no release of N-linked oligosaccharides containing (α 1,3)-linked core fucose
—Peptide N-glycosidase A	Release of N-linked oligosaccharides including those containing (α 1,3)-linked core fucose
Mannosyl-glycoprotein endo- β -N-acetylglucosaminidase (EC 3.2.1.96)	Endohydrolysis of the N,N' -diacetylchitobiosyl unit in high-mannose glycopeptides/glycoproteins containing the—[Man(GlcNAc) ₂]Asn structure [Man(GlcNAc) ₂]Asn
—Endo- β -N-acetylglucosaminidase F (endo F)	Release of high-mannose, hybrid, and complex oligosaccharides
—Endo- β -N-acetylglucosaminidase H (endo H)	Release of high-mannose and hybrid oligosaccharides
O-linked oligosaccharide release Glycopeptide α -N-acetylgalactosaminidase (EC 3.2.1.97)*	Release of D-galactose-(α 1,3)- N -acetylgalactosamine α -linked to serine/threonine residue

* This enzyme has limited usage because of its high substrate specificity.

[High-mannose type]




[Hybrid type]




[Complex type]

Bi-antennary



Tetra-antennary



Fuc : L-Fucose GlcNAc : N-Acetyl-D-glucosamine
 Gal : D-Galactose LacNAc : N-Acetyl-lactosamine
 GalNAc : N-Acetyl-D-galactosamine Man : D-Mannose
 Glc : D-Glucose Neu5Ac : N-Acetylneurameric acid

Fig. Common types of N-linked oligosaccharides

erly if needed.

2.2.1. Enzymatic release

For the release of N-linked oligosaccharides, peptide N-glycosidase F (PNGase F) derived from *Flavobacterium meningosepticum* or peptide N-glycosidase A (PNGase A) derived from almonds are available. These enzymes hydrolyze the amide bond between asparagine residue and N-acetyl-glucosamine residue at reducing end of oligosaccharides to produce glycosylamine derivative and aspartic acid residue. Glycosylamine derivative is subsequently hydrolyzed non-enzymatically under weak acidic conditions to ammonia and free oligosaccharide. O-glycanase from *Diplococcus pneumoniae* is available to release O-linked oligosaccharides, but specificity of this enzyme is too narrow.

2.2.1.1. PNGase F digestion

PNase F has an optimum pH 7 to 9. Glycoprotein is treated directly or under presence of reducing agent, surfactant, and/or denaturing agent. Glycoprotein may be

treated with PNGase F after reduced and alkylated, or after digested into glycopeptides. Glycoproteins from some insect cells and plants may have a (α1,3)-linked fucose attached to the proximal GlcNAc of the core chitobiose, and N-linked oligosaccharides containing this structure are not released by this enzyme.

2.2.1.2. PNGase A digestion

PNase A has an optimum pH 4 to 6. Since this enzyme is difficult to release oligosaccharides directly from whole glycoprotein, glycoprotein sample is digested with proteolytic agent, such as endoprotease, and then glycopeptides are treated with this enzyme to release oligosaccharides.

2.2.2. Chemical cleavage

2.2.2.1. Hydrazinolysis

Well-dried glycoprotein is added anhydrous hydrazine and heated. Hydrazine cleaves glycosylamine linkage between oligosaccharide and peptide as well as peptide bond. With careful control of reaction conditions, selective release of N-

Table 2 Examples of derivatizing agents and suitable analytical techniques.

Agent	Structure	Acronym	Analytical techniques	Fluorescent or UV detection
2-Aminobenzoic acid		2-AA	LC, CE, MS	Ex: 360 nm, Em: 425 nm Ex: 325 nm, Em: 405 nm
2-Aminobenzamide		2-AB	LC, MS	Ex: 330 nm, Em: 420 nm
2-Aminopyridine		2-AP	LC, MS	Ex: 310 nm, Em: 380 nm Ex: 320 nm, Em: 400 nm
Trisodium 8-aminopyrene-1,3,6-trisulfonic salt		APTS	CE	Ex: 488 nm, Em: 520 nm
3-methyl-1-phenyl-5-pyrazolone		PMP	LC, MS	UV 245 nm

linked oligosaccharide and/or O-linked oligosaccharides can be achieved. Because de-N-acetylation of amino sugar and sialic acid in oligosaccharides also occurs, amino groups are re-N-acetylated after removing hydrazine. Attention should be paid to the possibility of loss of sialic acid, and successive degradation from reducing end of released O-linked oligosaccharides (peeling reaction).

2.2.2.2. Alkali β -elimination

Heating glycoprotein under alkaline conditions results in release of O-linked oligosaccharides. To prevent peeling reactions, reaction is conducted in the presence of a reducing agent, such as sodium tetrahydroborate. It is noted that reducing end of obtained O-linked oligosaccharides is already reduced, thus, cannot be derivatized. There is a method to release the oligosaccharides and simultaneously to derivatize with 3-methyl-1-phenyl-5-pyrazolone.

2.3. Analysis of released oligosaccharides

Oligosaccharides are analyzed directly or after derivatized. Table 2 gives a non-exhaustive list of commonly used fluorescent labels and suitable analytical techniques. Analysis method is needed to separate and detect individual oligosaccharides or family of oligosaccharides with the structure which affects efficacy and safety.

2.3.1. Liquid chromatography <2.01>

2.3.1.1. Derivatization and liquid chromatography/fluorometric or UV detection

Profiling of derivatized oligosaccharides by liquid chromatography is the most common methods. Oligosaccharides derivatized with 2-aminobenzamide, 2-aminobenzoic acid, 2-aminopyridine or others are separated by hydrophilic interaction, reversed-phase, ion-exchange, or mixed-mode chromatography, and then detected by fluorometry. Oligosaccharides derivatized with 3-methyl-1-phenyl-5-pyrazolone are separated by reversed-phase chromatography, and then detected by UV spectrometry. Hydrophilic interaction liquid chromatography separates oligosaccharides on the basis of hydrophilicity (i.e. size, the number of sialic acid, ...). Reversed-phase chromatography separates oligosaccharides on the basis of hydrophobicity (i.e. type of oligosaccharide, branching, number of sialic acid, ...). Ion-exchange chromatography separates oligosaccharides on the basis of number of charges. Mix mode of ion-exchange and

hydrophilic interaction separates oligosaccharides on the basis of structure as well as number of charges.

2.3.1.2. High-pH anion-exchange chromatography/pulsed amperometric detection

Released oligosaccharides are separated by strong anion-exchange chromatography using polymer-based stationary phase containing quaternary ammonium groups, and detected by pulsed amperometry. This method can separate and detect sialo-oligosaccharides according to the number of sialic acids and linkage differences. This method has often been used for profiling of sialo-oligosaccharides because of no need of derivatization (no loss of sialic acid and no loss of oligosaccharides during procedure) and high resolution. Because response factors of individual oligosaccharides are not equal, relative peak response does not directly reflect the molar ratio of individual oligosaccharides.

2.3.2. Capillary electrophoresis

Derivatized oligosaccharides are separated by capillary zone electrophoresis using appropriate electrolyte buffer, and then detected by laser-induced fluorometric detector. Oligosaccharide is separated based on the sample properties such as charge, size, or shape. In general, capillary is used with the inner wall surface modified using neutral polymers covalently or dynamically in order to prevent electroosmotic flow. Derivatizing agent, and pH and additives of the electrolyte buffer are selected to achieve good separation. Capillary electrophoresis has high resolution separations and requires small amounts of sample.

2.3.3. Mass spectrometry <2.62>

Mass spectrometry is used for underivatized oligosaccharides as well as derivatized oligosaccharides. Monosaccharide compositions of oligosaccharides can be deduced from observed molecular mass of oligosaccharides. For ionization methods for oligosaccharides, soft ionization techniques, such as electrospray ionization and matrix-assisted laser desorption/ionization are used. It is noted that oligosaccharides containing sialic acid are susceptible to loss of sialic acid during mass spectrometry.

2.4. Assignment or identification of the peak

Identification of the oligosaccharides attached to the glycoprotein is important for test method development and evaluation of oligosaccharide profile. In general, structure

Table 3 Examples of exoglycosidases and endoglycosidase useful for structure assignment.

Enzyme	Origin	Specificity
Exo- α -sialidase (EC 3.2.1.18)	<i>Arthrobacter ureafaciens</i> <i>Vibrio cholerae</i> <i>Clostridium perfringens</i> <i>Newcastle disease virus</i> <i>Streptococcus pneumoniae</i>	α 2-3,6,8,9 α 2-3,6,8 α 2-3,6,8 α 2-3 α 2-3
β -Galactosidase (EC 3.2.1.23)	Bovine testes <i>Streptomyces pneumoniae</i>	β 1-3,4 β 1-4
α -L-Fucosidase (EC 3.2.1.51)	Almond meal <i>Xanthomonas sp.</i>	α 1-3 α 1-3,4
α -Mannosidase (EC 3.5.1.24)	Bovine kidney Jack Bean	α 1-2,3,4,6 α 1-2,3,6
α -Galactosidase (EC 3.2.1.22)	Green coffee beans	α 1-3,4,6
Keratan-sulfate endo- β -galactosidase (EC 3.2.1.103)	<i>Bacteroides fragilis</i>	β 1-3,4/poly LacNAc

of oligosaccharides may be deduced based on the molecular mass determined by mass spectrometry, the pattern of fragment ions obtained by tandem mass spectrometry, sensitivity to exoglycosidases or endoglycosidases with high specificity, comparison of chromatogram or electropherogram with well-characterized oligosaccharide standards, methylation analysis, and knowledge on the oligosaccharide patterns biosynthesized in the used cell line. Table 3 give a non-exhaustive list of exoglycosidases and endoglycosidases for structural assignment. During routine application, the identity of oligosaccharide peaks may be confirmed by comparison with oligosaccharide profile obtained from the reference material.

2.5. Acceptance criteria

Oligosaccharide profile obtained from the test material is compared with that obtained in parallel using reference material, and then peak position and response ratio of individual oligosaccharides are comparable. Or peak ratio of individual oligosaccharide to total response (peak area percentage method) or relative peak response meets the acceptance criteria. In order to set specification properly, it is important to identify the oligosaccharide structure to be controlled in consideration of the relationship between oligosaccharide structure, and efficacy and safety.

2.6. Reference materials

It is important that reference material has been validated for glycosylation analysis.

2.7. System suitability

System suitability is developed depending on the purpose of oligosaccharide test. Acceptance criteria, e.g. presence of specific peaks, resolution between two adjacent peaks, the number of detectable peaks, and/or conformance to reference oligosaccharide profile may be set for oligosaccharide profile, obtained from standard material, or well-characterized glycoprotein with similar property by treating similarly. Otherwise, oligosaccharide reference material, e.g. oligosaccharide standard prepared from the substance being tested and demonstrated to be suitable, or system suitability oligosaccharide marker, is similarly treated. Similar acceptance criteria described above may be set for obtained oligosaccharide profile.

Mycoplasma Testing for Cell Substrates used for the Production of Biotechnological/Biological Products

This document describes the currently available methods of mycoplasma testing that should be performed for cell substrates that are used in the manufacture of biotechnological/biological products.

Methods suggested for detection of mycoplasma are, A. culture method, B. indicator cell culture method, and C. nucleic acid amplification test (NAT) method.

Mycoplasma testing should be performed on the master cell bank (MCB) and the working cell bank (WCB), as well as on the cell cultures used during the manufacturing process of the product. For the assessment of these cells, mycoplasma testing should be performed using both methods A and B. Note that method C may be used as an alternative to methods A and/or B (one or both of other methods) after suitable validation.

Prior to mycoplasma testing by methods A or B, the sample should be tested to detect the presence of any factors inhibiting the growth of mycoplasma. If such growth-inhibiting factors are detected, they should be neutralized or eliminated by an appropriate method, such as centrifugation or cell passage.

If the test will be performed within 24 hours of obtaining the sample, the sample should be stored at 2–8°C. If more than 24 hours will elapse before the test is performed, the sample should be stored at –60°C or lower.

If mycoplasma is detected, additional testing to identify the species may be helpful in determining the source of contamination.

A. Culture Method

1. Culture Medium

Both agar plates and broth are used. Each batch of agar and broth medium should be free of antibiotics except for penicillin. Refer to the Minimum Requirements for Biological Products regarding selection of the culture media. Other culture media may be used if they fulfill the requirements described in the following section 2.

2. Suitability of Culture Medium

Each batch of medium should be examined for mycoplasma growth-promoting properties. To demonstrate the capacity of the media to detect known mycoplasma, each test should include control cultures of at least two known species or strains of mycoplasma, one of which should be a dextrose fermenter (i.e., *Mycoplasma pneumoniae* ATCC 15531, NBRC 14401 or equivalent species or strains) and one of which should be an arginine hydrolyser (i.e., *Mycoplasma orale* ATCC 23714, NBRC 14477 or equivalent species or strains). The mycoplasma strains used for the positive control tests should be those with a low number of passages obtained from an official or suitably accredited agency, and handled appropriately. Inoculate the culture medium with 100 colony-forming units (CFU) or 100 color-changing units (CCU) or less.

3. Culture and Observation

1) Inoculate no less than 0.2 mL of test sample (cell suspension) in evenly distributed amounts over the surface of each of two or more agar plates. After the surfaces of the inoculated plates are dried, the plates should be incubated in an atmosphere of nitrogen containing 5–10% carbon diox-

ide and adequate humidity at 35 – 37°C for no less than 14 days.

2) Inoculate no less than 10 mL of the test sample (cell suspension) into each of one or more vessels containing 100 mL of broth medium, and incubate at 35 – 37°C.

If the culture medium for the sample cells contains any growth-inhibiting factors, such as antibiotics, these factors should be removed. Refer to the Validation tests for growth-inhibiting factors described in the Minimum Requirements for Biological Products for the detection of growth-inhibiting factors.

3) Subculture 0.2 mL of broth culture from each vessel on the 3rd, 7th, and 14th days of incubation onto two or more agar plates. Observe the broth media every 2 or 3 days and if a color change occurs, subculture. The plates should be incubated in nitrogen containing 5 – 10% carbon dioxide and adequate humidity at 35 – 37°C for no less than 14 days.

4) Examination of all plates for mycoplasma colonies should be done microscopically on the 7th and 14th day at 100 times magnification or greater.

B. Indicator Cell Culture Method

Using Vero cell culture substrate, pretest the suitability of the method using an inoculum of 100 CFU or 100 CCU or less of *Mycoplasma hyorhinis* (ATCC 29052, ATCC 17981, NBRC 14858 or equivalent species or strains) and *M. orale* (ATCC 23714, NBRC 14477 or equivalent species or strains).

Indicator cell substrate equivalent to Vero cells and suitable mycoplasma strains may be acceptable if data demonstrate at least equal sensitivity for the detection of known mycoplasma contaminants. The mycoplasma strains should be those with a low number of passages obtained from an official or suitably accredited agency, and handled appropriately, and the unit of inoculation should be determined before use. The cell substrate used should be obtained from a qualified cell bank and certified to be mycoplasma free. The acquired cells should be carefully cultured and propagated, and sufficient volumes of seed stock should be prepared with the proper precautions to avoid mycoplasma contamination. The stock should be tested for mycoplasma contamination using at least one of the methods described in this document, then frozen for storage. For each test a new container from the stock should be thawed and used within 6 passages.

Indicator cell cultures should be grown on cover slips submerged in culture dishes or equivalent containers for one day. Inoculate no less than 1 mL of the test sample (cell culture supernatant) into two or more of the culture dishes.

The test should include a negative (non-infected) control and two positive mycoplasma controls, such as *M. hyorhinis* (ATCC 29052, ATCC 17981, NBRC 14858 or equivalent species or strains) and *M. orale* (ATCC 23714, NBRC 14477 or equivalent species or strains). Use an inoculum of 100 CFU or 100 CCU or less for the positive controls.

Incubate the cell cultures for 3 – 6 days at 35 – 38°C in an atmosphere of air containing 5% carbon dioxide.

Examine the cell cultures after fixation for the presence of mycoplasma by epifluorescence microscopy (400 to 600 times magnification or greater) using a DNA-binding fluorochrome, such as bisbenzimide or an equivalent stain. Compare the microscopical appearance of the test cultures with that of the negative and positive controls.

Procedure

1) Aseptically place a sterilized glass cover slip into each cell culture dish (35 mm diameter).

2) Prepare Vero cell suspension in Eagle's minimum essential medium containing 10% fetal calf serum at a concentration of 1×10^4 cells per mL. The fetal calf serum

should be tested and confirmed to be free from mycoplasma prior to use.

3) Inoculate aliquots of 2 mL of the Vero cell suspension into each culture dish. Ensure that the cover slips are completely submerged, and not floating on the surface of the culture medium. Incubate the cultures at 35 – 38°C in an atmosphere of air containing 5% carbon dioxide for one day, so that the cells are attached to the glass cover slip.

4) Replace 2 mL of the culture medium with fresh medium, then add 0.5 mL of the test sample (cell culture supernatant) to each of two or more culture dishes. Perform the same procedure for the positive (2 types of mycoplasmas, such as *M. hyorhinis* (ATCC 29052, ATCC 17981, NBRC 14858 or equivalent species or strains) and *M. orale* (ATCC 23714, NBRC 14477 or equivalent species or strains) and negative controls.

5) Incubate the cultures for 3 – 6 days at 35 – 38°C in an atmosphere of air containing 5% carbon dioxide.

6) Remove the culture medium from the culture dishes, and add 2 mL of a mixture of acetic acid (100) and methanol (1:3) (fixative) to each dish; then, allow them to stand for 5 minutes.

7) Remove the fixative from each dish, then add the same amount of fixative again, and leave the dishes to stand for 10 minutes.

8) Remove the fixative and then completely air-dry all the dishes.

9) Add 2 mL of bisbenzimide fluorochrome staining solution to each culture dish. Cover the dishes and let them stand at room temperature for 30 minutes.

10) Aspirate the staining solution and rinse each dish with 2 mL of distilled water 3 times. Take out the glass cover slips and dry them.

11) Mount each cover slip with a drop of a mounting fluid. Blot off surplus mounting fluid from the edges of the cover slips.

12) Examine by epifluorescence microscopy at 400 to 600 times magnification or greater.

13) Compare the microscopic appearance of the test sample with that of the negative and positive controls.

14) The test result is judged to be positive if there are more than 5 cells per 1000 (0.5%) that have minute fluorescent spots that appear to surround, but are outside, the cell nucleus.

C. Nucleic Acid Amplification Test (NAT)

Nucleic acid amplification test (NAT) is a detection method of genes or mRNA transcribed from genes of target cells or viruses by enzymatic amplification with specific primers for target nucleic acid sequences, and the amplified products are detected by several ways. When NAT is used for detection of mycoplasma, high sensitivity detection is expected for the presence or absence of the target sequence derived from mycoplasma by amplification of nucleic acid extracted from a test sample (cell suspension or cell culture supernatant) with specific primers/probes. NAT indicates the presence of a target sequence and not necessarily the presence of viable mycoplasmas.

A number of different NAT methods are available. This general information does not prescribe a particular method. NAT method applied should be validated for sufficient sensitivity, specificity, and robustness of results that remain unaffected by small variations in extraction method parameters or in composition of the reaction mix. Any NAT method is available if the specificity and the sensitivity is properly validated as described in this section. Where a commercial kit is used, certain elements of the validation may be carried out

by the manufacturer and information provided to the user. However, it should be remembered that the different results might be obtained by user depending on the instrument used and the target cells tested. The user should confirm the manufacturer's validation results by own facilities. Especially, when the target cell substrate is different from cells validated by manufacturer, detection limit and reproducibility of the kit should be confirmed with the cells of interest. When the user's extraction method or instruments used for detection etc. are different from the method or the instrument specified by manufacturer, the employed method or the instrument should be validated.

In addition, when the information on the primers/probes or the kit reagents may not be available from the manufacturer, countermeasure is required to obtain the information from the manufacturer about the modification of the kit production when modified. If the composition of the kit reagents is modified, user should confirm that the detection limit and the detection accuracy of the modified kit for target mycoplasma is comparable to the previous one, as needed. On the other hand, appropriate alternative method should be considered, since the production of the kit may be discontinued.

Basically, cell suspension but not cell culture supernatant will be used as a test sample, since mycoplasma contaminated in cell culture mainly growth in cell-dependent manner. When cell culture supernatant is used as test samples, validation is required that the method employed is able to fully detect the mycoplasma contamination in cell cultures.

NAT may be used instead of methods A and/or B, after suitable validation described below, and the validation revealed sufficient sensitivity for all of the listed mycoplasma species.

In order to increase the detection sensitivity of nucleic acid derived from infectious mycoplasma, it is possible to perform NAT after enrichment of mycoplasma that may be present in test samples by culturing with Vero cells. In this case, again, validation is required to show sufficient sensitivity for all of the listed mycoplasma species.

C-1. Mycoplasma testing by NAT

The tests should include both a positive control (run control) (such as *M. hyorhinis* (ATCC 17981, NBRC 14858 or equivalent species or strains) of 100 CFU or 100 CCU or less) and a negative control. The mycoplasma strains used for the positive control tests should be those within a low number of passages obtained from an official or suitably accredited agency, and handled appropriately. The unit of inoculation should be determined before use. When cell suspension is used as a test sample, preliminary test is required for the effect of cellular nucleic acid to NAT with the cells confirmed to be mycoplasma-free as a negative control, and confirm that no positive signals are obtained from the negative control. The test result is judged to pass the test if no mycoplasma sequences are amplified from the test sample.

C-2. Precautions for the test

Because NAT enables the detection of trace amounts of nucleic acid, false positive results may be obtained by contamination of the facilities, instruments and reagents etc. with amplified products. To prevent the risk of contamination, wherever possible, each step of the storage and preparation of reagents, the extraction of nucleic acid, the amplification of nucleic acid, and the detection of amplified products should be performed in separate facilities or equipments with special precautions for handling. To exclude false-positive results by contamination of carry-over amplified products, Uracil-N-glycosylase (UNG) procedure may be available. To exclude the false-negative results by low efficiency of

extraction or interfering substances for NAT in test samples, simultaneous detection of house-keeping genes of the test cells as internal control is recommended.

On the other hand, if automatic closed system from extraction to amplification is used to prevent cross-contamination, segregation of the area is not always required. However, measures to prevent contamination are required when disposing the amplified products from the automatic system.

C-3. Validation of NAT for the detection of mycoplasmas

NAT methods for the detection of target sequences are either qualitative or quantitative tests. To detect mycoplasma contamination of cell substrates, qualitative tests are adequate and may be considered to be limit tests. This section describes methods to validate qualitative NAT analytical procedures for assessing mycoplasma contamination. These validation methods may also be applicable for quantitative NAT with optimal cut-off point.

The most important parameters for validation of the analytical procedure are the specificity and the detection limit. In addition, the robustness of the analytical procedure should be evaluated. Note that for the purpose of this document, validation of NAT method is defined as the complete procedure from extraction of nucleic acid to detection of the amplified products.

Where commercial kits are used for a part or all of the analytical procedure, documented full validation data already covered by the kit manufacturer can replace validation data by the user, and a full validation by the user is unnecessary. Nevertheless, the performance of the kit with respect to its intended use and user's test system should be demonstrated by the user (e.g. specificity, detection limit).

NAT may be used as:

- a test for in-process control purposes;
- an alternative method to replace methods A and/or B.

This section will thus separate these 2 objectives by presenting first a guideline for the validation of the NAT themselves, and second, a guideline for a comparability study between NAT and methods A or B.

Mycoplasma reference strains evaluated for concentration either in CFUs or equivalent copies are required at various stages during validation of specificity or detection limit of NAT. During routine application of the test, mycoplasma reference strains or the test sample calibrated for concentration using reference strains are used as positive controls. In the test, mycoplasma or mycoplasma nucleic acid (e.g. plasmid) may be used as a positive control. Mycoplasma is required for validation of the procedure including extraction efficiency.

1) Evaluation parameters

Three parameters should be evaluated: specificity, detection limit, and robustness.

2) Specificity

Specificity of NAT is the ability to unequivocally detect target nucleic acid in the presence of test samples that may be expected to be present. The specificity of NAT is dependent on the choice of primers/probes and the strictness of the test conditions (both of the amplification and the detection steps).

It is important to use primers/probes by choosing nucleic acid sequences that are specific and well conserved for a wide range of mycoplasmas (the bacterial class *Mollicutes* such as the genus *Mycoplasma* and related genera such as *Ureaplasma*, *Spiroplasma*, *Acholeplasma* etc.). The ability of NAT to detect a large panel of mycoplasma species should be demonstrated by experimental results using reference mycoplasmas described in 3), and evaluated only by the the-

oretical analysis of primers/probes comparing with databases is not recommended.

3) Detection limit

The detection limit of an individual analytical procedure is the lowest amount of target nucleic acid in a sample that can be detected but not necessarily quantitated as an exact value. For establishment of the detection limit, a positive cut-off point should be determined for the nucleic acid amplification analytical procedure. The positive cut-off point is the target sequence copies per volume of sample that can be detected in 95% of test runs. This positive cut-off point is influenced by the nucleic acid sequences of target mycoplasma in the individual samples being tested and by factors such as enzyme efficiency, and can result in different 95% cut-off values for individual analytical test runs. To determine the positive cut-off point, a dilution series of characterized and calibrated (either in CFUs or nucleic acid copies) mycoplasma reference strains or international standards should be tested on different days to examine variation between test runs.

For validation of the limit of detection, the following species should be used. These species represent an optimal selection in terms of the frequency of occurrence as contaminants of mammalian culture cells used for production of biotechnological/biological products, phylogenetic relationships, and animal-derived components used during culture and production processes. Note that the list is only for validation of NAT and not for used as positive run control in routine tests.

- *Acholeplasma laidlawii* (ATCC 23206, NBRC 14400 or equivalent strains)
- *Mycoplasma arginini* (ATCC 23838 or equivalent strains)
- *Mycoplasma fermentans* (ATCC 19989, NBRC 14854 or equivalent strains)
- *Mycoplasma hyorhinis* (ATCC 17981, NBRC 14858 or equivalent strains)
- *Mycoplasma orale* (ATCC 23714, NBRC 14477 or equivalent strains)
- *Mycoplasma pneumoniae* (ATCC 15531, NBRC 14401 or equivalent strains)
- *Mycoplasma salivarium* (ATCC 23064, NBRC 14478 or equivalent strains)

Where there is use of insect or plant cells during production, mycoplasma strains derived from insect or plant (e.g. *Spiroplasma citri*) should be tested in addition to the above list. Where there is use of or exposure to avian cells or materials during production, mycoplasma species derived from avian should be tested whether avian mycoplasmas (e.g. *Mycoplasma synoviae*) can be detected.

For establishment of the detection limit, appropriate dilution series (10-fold or 10^{0.5}-fold dilution) should be prepared from the undiluted mycoplasma evaluated for concentration (CFU etc.), and performed NAT for each dilution. Based on the dilution factor that shows the limit of the detection, a positive cut-off point should be determined as the minimum number of CFUs of target sequences in the test sample. In case amplified products are separated by electrophoresis and the positive band is detected by fluorescent staining, confirmation is required whether no positive band is appeared from the test sample of mycoplasma-free cells. Detection using quantitative real-time PCR requires to set an adequate cut-off point of amplification cycles, and the setting of the cut-off point should be validated. Since extraction efficiency of nucleic acid from the test sample affects the detection sensitivity, detection of mycoplasma in cell suspension should be evaluated.

For each mycoplasma reference strain described above, at

least 3 independent 10-fold dilution series should be tested, with a sufficient number of replicates at each dilution to give a total number of 24 test results for each dilution, to enable a statistical analysis of the results. For example, a laboratory may test 3 dilution series on different days with 8 replicates for each dilution, 4 dilution series on different days with 6 replicates for each dilution, or 6 dilution series on different days with 4 replicates for each dilution. In order to keep the number of dilutions at a manageable level, a preliminary test should be performed to obtain a preliminary value for the positive cut-off point (i.e. the highest dilution giving a positive signal). The range of dilutions can then be chosen around the determined preliminary cut-off point. The concentration of mycoplasmas (CFUs, etc.) that can be detected in 95% of test runs can then be calculated using an appropriate statistical evaluation. These results may also serve to evaluate the variability of the analytical procedure.

4) Robustness

The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters, and provides an indication of its reliability during normal usage.

The evaluation of robustness should be considered during the development phase. It should show the reliability of the analytical procedure with respect to deliberate variations in method parameters. For NAT, small variations in the method parameters can be crucial. However, the robustness of the method can be demonstrated during its development when small variations in the concentrations of reagents (e.g. MgCl₂, primers, and deoxyribonucleotides) are tested. Modifications of extraction kits or extraction procedures as well as different thermal cycler types may also be evaluated.

5) Use of NAT instead of methods A and/or B

NAT may be used instead of methods A (culture method) and/or B (indicator cell culture method). In this case, a comparability study should be carried out. This comparability study should include mainly a comparison of the respective detection limits of the NAT and methods A and/or B. However, specificity (mycoplasma panel detected, putative false positive results) should also be considered.

For the detection limit, acceptability criteria are defined as follows:

- if the alternative method is proposed to replace method A (the culture method), the NAT system should be shown to detect 10 CFU/mL for each mycoplasma test species described in 3).
- if the alternative method is proposed to replace method B (the indicator cell culture method), the NAT system should be shown to detect 100 CFU/mL for each mycoplasma test species described in 3).

For both cases, suitable standards calibrated for the number of CFUs may be used for establishing that these acceptability criteria are reached.

One of the following 2 strategies can be used to perform this comparability study:

- perform the NAT alternative method in parallel with the methods A or B to evaluate simultaneously the detection limit of both methods using the same samples of calibrated strains with CFUs.

- compare the performance of the NAT alternative method using previously obtained data from methods A or B. In this case, calibration of CFUs of reference strains used for both validations as well as their stabilities should be described carefully.

Alternatively, comparability of detection limit may be demonstrated by detection of nucleic acid copies or etc. of mycoplasma in test samples. In this case, the relation be-

tween CFUs and nucleic acid copies for the reference preparations should be previously established.

6) Controls

- Internal controls: For validation, internal controls are useful to confirm appropriate amplification without effect of inhibitory substances derived from test samples. Internal controls are also necessary for routine verification of extraction and absence of inhibition to NAT. The internal control may contain the primer binding-site, or some other suitable sequence may be used. It is preferably added to the test material before isolating the nucleic acid and therefore acts as an overall control for extraction, reverse transcription, amplification, and detection. Cellular genes derived from test samples may also be used as the internal control.

- External controls: The external positive control contains a defined number of target-sequence copies or CFUs from one or more suitable species of mycoplasma chosen from those used during validation of the test conditions. One of the positive controls is set close to the positive cut-off point to demonstrate that the expected sensitivity is achieved. The external negative control contains no target sequence but does not necessarily represent the same matrix as the test article.

7) Interpretation of results

The primers/probes used may also amplify non-mycoplasma nucleic acid, leading to false-positive results. Procedures are established at the time of validation for dealing with confirmation of positive results, where necessary.

C-4 Method of cultivating mycoplasma with Vero cells

- Use at least two cell culture dishes for each of the test sample, positive control and negative control.

- Into each cell culture dish (35 mm diameter), inoculate 2 mL of the Vero cell suspension (1×10^4 cells per mL) in Eagle's minimum essential medium containing 10% fetal calf serum (tested in advance using the NAT method to verify that it does not contain any detectable mycoplasma DNA). Incubate the cultures at 35 – 38°C in an atmosphere of air containing 5% carbon dioxide for one day.

- Replace the culture media with fresh media, and add 0.5 mL of the test sample (cell culture supernatant) to each of two or more Vero cell culture dishes. Perform the same procedure for the positive (such as 100 CFU or 100 CCU or less of *M. hyorhinis* (ATCC 17981, NBRC 14858 or equivalent species or strains)) and negative controls.

- Incubate the Vero cell culture dishes for the test sample, positive and negative controls for 3 – 6 days at 35 – 38°C in an atmosphere of air containing 5% carbon dioxide.

Peptide Mapping

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia.

Peptide mapping is an identity test for proteins, especially those obtained by r-DNA technology. It involves the chemical or enzymatic treatment of a protein, resulting in the formation of peptide fragments, followed by separation and identification of the fragments in a reproducible manner. It is a powerful test that is capable of identifying single amino acid changes resulting from events such as errors in the reading of complementary DNA (cDNA) sequences or point mutations. Peptide mapping is a comparative procedure because the information obtained, compared to a reference standard or reference material similarly treated, confirms the primary structure of the protein, is capable of detecting whether alterations in structure have occurred, and demonstrates process consistency and genetic stability. Each protein

presents unique characteristics which must be well understood so that the scientific and analytical approaches permit validated development of a peptide map that provides sufficient specificity.

This chapter provides detailed assistance in the application of peptide mapping and its validation to characterize the desired protein product, to evaluate the stability of the expression construct of cells used for recombinant DNA products, to evaluate the consistency of the overall process and to assess product stability as well as to ensure the identity of the protein product, or to detect the presence of protein variant.

1. Peptide Map

Peptide mapping is not a general method, but involves developing specific maps for each unique protein. Although the technology is evolving rapidly, there are certain methods that are generally accepted. Variations of these methods will be indicated, when appropriate, in specific monographs.

A peptide map may be viewed as a fingerprint of a protein and is the end product of several chemical processes that provide a comprehensive understanding of the protein being analyzed. Four major steps are necessary for the development of the procedure: isolation and purification of the protein, if the protein is part of a formulation; selective cleavage of the peptide bonds; chromatographic separation of the peptides; and analysis and identification of the peptides. A test sample is digested and assayed in parallel with a reference standard or a reference material. Complete cleavage of peptide bonds is more likely to occur when enzymes such as endoproteases (e.g., trypsin) are used, instead of chemical cleavage reagents. A map should contain enough peptides to be meaningful. On the other hand, if there are too many fragments, the map might lose its specificity because many proteins will then have the same profiles.

2. Isolation and Purification

Isolation and purification are necessary for analysis of bulk drugs or dosage forms containing interfering excipients and carrier proteins and, when required, will be specified in the monograph. Quantitative recovery of protein from the dosage form should be validated.

3. Selective Cleavage of Peptide Bonds

The selection of the approach used for the cleavage of peptide bonds will depend on the protein under test. This selection process involves determination of the type of cleavage to be employed —enzymatic or chemical— and the type of cleavage agent within the chosen category. Several cleavage agents and their specificity are shown in Table 1. This list is not all-inclusive and will be expanded as other cleavage agents are identified.

3.1. Pretreatment of Sample

Depending on the size or the configuration of the protein, different approaches in the pretreatment of samples can be used. For monoclonal antibodies, the heavy and light chains will need to be separated before mapping. If trypsin is used as a cleavage agent for proteins with a molecular mass greater than 100,000 Da, lysine residues must be protected by citraconylation or maleylation; otherwise, too many peptides will be generated.

3.2. Pretreatment of the Cleavage Agent

Pretreatment of cleavage agents —especially enzymatic agents— might be necessary for purification purposes to ensure reproducibility of the map. For example, trypsin used as a cleavage agent will have to be treated with tosyl-L-phenylalanine chloromethyl ketone to inactivate chymotrypsin. Other methods, such as purification of trypsin by HPLC

Table 1 Examples of cleavage agents

Type	Agent	Specificity
Enzymatic	Trypsin (EC 3.4.21.4)	C-terminal side of Arg and Lys
	Chymotrypsin (EC 3.4.21.1)	C-terminal side of hydrophobic residues (e.g., Leu, Met, Ala, aromatics)
	Pepsin (EC 3.4.23.1 & 2)	Nonspecific digest
	Lysyl endopeptidase (Lys-C endopeptidase) (EC 3.4.21.50)	C-terminal side of Lys
	Glutamyl endopeptidase (from <i>S. aureus</i> strain V8) (EC 3.4.21.19)	C-terminal side of Glu and Asp
	Peptidyl-Asp metallo endopeptidase (Endoproteinase Asp-N) (EC 3.24.33)	N-terminal side of Asp
	Clostripain (EC 3.4.22.8)	C-terminal side of Arg
Chemical	Cyanogen bromide	C-terminal side of Met
	2-Nitro-5-thio-cyanobenzoic acid	N-terminal side of Cys
	<i>o</i> -Iodosobenzoic acid	C-terminal side of Trp and Tyr
	Dilute acid	Asp and Pro
	BNPS-skatole	Trp

or immobilization of enzyme on a gel support, have been successfully used when only a small amount of protein is available.

3.3. Pretreatment of the Protein

Under certain conditions, it might be necessary to concentrate the sample or to separate the protein from added substances and stabilizers used in formulation of the product, if these interfere with the mapping procedure. Physical procedures used for pretreatment can include ultrafiltration, column chromatography, and lyophilization. Other pretreatments, such as the addition of chaotropic agents (e.g., urea) can be used to unfold the protein prior to mapping. To allow the enzyme to have full access to cleavage sites and permit some unfolding of the protein, it is often necessary to reduce and alkylate the disulfide bonds prior to digestion.

Digestion with trypsin can introduce ambiguities in the tryptic map due to side reactions occurring during the digestion reaction, such as nonspecific cleavage, deamidation, disulfide isomerization, oxidation of methionine residues, or formation of pyroglutamic groups created from the deamidation of glutamine at the N-terminal side of a peptide. Furthermore, peaks may be produced by autohydrolysis of trypsin. Their intensities depend on the ratio of trypsin to protein. To avoid autohydrolysis, solutions of proteases may be prepared at a pH that is not optimal (e.g., at pH 5 for trypsin), which would mean that the enzyme would not become active until diluted with the digest buffer.

3.4. Establishment of Optimal Digestion Conditions

Factors that affect the completeness and effectiveness of digestion of proteins are those that could affect any chemical or enzymatic reactions.

(i) pH: The pH of the digestion mixture is empirically

determined to ensure the optimal performance of the given cleavage agent. For example, when using cyanogen bromide as a cleavage agent, a highly acidic environment (e.g., pH 2, formic acid) is necessary; however, when using trypsin as a cleavage agent, a slightly alkaline environment (pH 8) is optimal. As a general rule, the pH of the reaction milieu should not alter the chemical integrity of the protein during the digestion and should not change during the course of the fragmentation reaction.

(ii) Temperature: A temperature between 25°C and 37°C is adequate for most digestions. The temperature used is intended to minimize chemical side reactions. The type of protein under test will dictate the temperature of the reaction milieu, because some proteins are more susceptible to denaturation as the temperature of the reaction increases. For example, digestion of recombinant bovine somatotropin is conducted at 4°C, because at higher temperatures it will precipitate during digestion.

(iii) Time: If sufficient sample is available, a time course study is considered in order to determine the optimum time to obtain a reproducible map and avoid incomplete digestion. Time of digestion varies from 2 to 30 hours. The reaction is stopped by the addition of an acid which does not interfere in the tryptic map or by freezing.

(iv) Amount of Cleavage Agent: Although excessive amounts of cleavage agent are used to accomplish a reasonably rapid digestion time (i.e., 6 to 20 hours), the amount of cleavage agent is minimized to avoid its contribution to the chromatographic map pattern. A protein to protease ratio between 20:1 and 200:1 is generally used. It is recommended that the cleavage agent can be added in two or more stages to optimize cleavage. Nonetheless, the final reaction volume remains small enough to facilitate the next step in peptide mapping—the separation step. To sort out digestion artifacts that might be interfering with the subsequent analysis, a blank determination is performed, using a digestion control with all the reagents, except the test protein.

4. Chromatographic Separation

Many techniques are used to separate peptides for mapping. The selection of a technique depends on the protein being mapped. Techniques that have been successfully used for separation of peptides are shown in Table 2. In this section, a most widely used reverse-phase high performance liquid chromatography (RP-HPLC) is described as one of the procedures of chromatographic separation.

The purity of solvents and mobile phases is a critical factor in HPLC separation. HPLC-grade solvents and water that are commercially available are recommended for RP-HPLC. Dissolved gases present a problem in gradient systems where the solubility of the gas in a solvent may be less in a mixture than in a single solvent. Vacuum degassing and agitation by sonication are often used as useful degassing procedures. When solid particles in the solvents are drawn into the HPLC system, they can damage the sealing of pump valves or clog the top of the chromatographic column. Both pre- and post-pump filtration is also recommended.

4.1. Chromatographic Column

The selection of a chromatographic column is empirically determined for each protein. Columns with 100 Å or 300 Å pore size with silica support can give optimal separation. For smaller peptides, octylsilane chemically bonded to totally porous silica articles, 3 to 10 µm in diameter (L7) and octadecylsilane chemically bonded to porous silica or ceramic micro-particles, 3 to 10 µm in diameter (L1) column packings are more efficient than the butyl silane chemically bonded to totally porous silica particles, 5 to 10 µm in diameter

Table 2 Techniques used for the separation of peptides

Reverse-Phase High Performance Liquid Chromatography (RP-HPLC)
Ion-Exchange Chromatography (IEC)
Hydrophobic Interaction Chromatography (HIC)
Polyacrylamide Gel Electrophoresis (PAGE), nondenaturing
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Capillary Electrophoresis (CE)
Paper Chromatography-High Voltage (PCHV)
High-Voltage Paper Electrophoresis (HVPE)

(L26) packing.

4.2. Solvent

The most commonly used solvent is water with acetonitrile as the organic modifier to which less than 0.1% trifluoroacetic acid is added. If necessary, add isopropyl alcohol or n-propyl alcohol to solubilize the digest components, provided that the addition does not unduly increase the viscosity of the components.

4.3. Mobile Phase

Buffered mobile phases containing phosphate are used to provide some flexibility in the selection of pH conditions, since shifts of pH in the 3.0 to 5.0 range enhance the separation of peptides containing acidic residues (e.g., glutamic and aspartic acids). Sodium or potassium phosphates, ammonium acetate, phosphoric acid, and a pH between 2 and 7 (or higher for polymer-based supports) have also been used with acetonitrile gradients. Acetonitrile containing trifluoroacetic acid is used quite often.

4.4. Gradient Selection

Gradients can be linear, nonlinear, or include step functions. A shallow gradient is recommended in order to separate complex mixtures. Gradients are optimized to provide clear resolution of one or two peaks that will become "marker" peaks for the test.

4.5. Isocratic Selection

Isocratic HPLC systems using a single mobile phase are used on the basis of their convenience of use and improved detector responses. Optimal composition of a mobile phase to obtain clear resolution of each peak is sometimes difficult to establish. Mobile phases for which slight changes in component ratios or in pH significantly affect retention times of peaks in peptide maps should not be used in isocratic HPLC systems.

4.6. Other Parameters

Temperature control of the column is usually necessary to achieve good reproducibility. The flow rates for the mobile phases range from 0.1 to 2.0 mL per minute, and the detection of peptides is performed with a UV detector at 200 to 230 nm. Other methods of detection have been used (e.g., postcolumn derivatization), but they are not as robust or versatile as UV detection.

4.7. Validation

This section provides an experimental means for measuring the overall performance of the test method. The acceptance criteria for system suitability depend on the identification of critical test parameters that affect data interpretation and acceptance. These critical parameters are also criteria that monitor peptide digestion and peptide analysis. An indicator that the desired digestion endpoint was achieved is by the comparison with a reference standard or reference material, which is treated exactly as the article under test. The use of a reference standard or reference material in parallel with the protein under test is critical in the development and es-

tablishment of system suitability limits. In addition a specimen chromatogram should be included with the reference standard or reference material for additional comparison purposes. Other indicators may include visual inspection of protein or peptide solubility, the absence of intact protein, or measurement of responses of a digestion-dependent peptide. The critical system suitability parameters for peptide analysis will depend on the particular mode of peptide separation and detection and on the data analysis requirements.

When peptide mapping is used as an identification test, the system suitability requirements for the identified peptides covers selectivity and precision. In this case, as well as when identification of variant protein is done, the identification of the primary structure of the peptide fragments in the peptide map provides both a verification of the known primary structure and the identification of protein variants by comparison with the peptide map of the reference standard/reference material for the specified protein. The use of a digested reference standard or reference material for a given protein in the determination of peptide resolution is the method of choice. For an analysis of a variant protein, a characterized mixture of a variant and a reference standard or reference material can be used, especially if the variant peptide is located in a less-resolved region of the map. The index of pattern consistency can be simply the number of major peptides detected. Peptide pattern consistency can be best defined by the resolution of peptide peaks. Chromatographic parameters —such as peak-to-peak resolution, maximum peak width, peak area, peak tailing factors, and column efficiency— may be used to define peptide resolution. Depending on the protein under test and the method of separation used, single peptide or multiple peptide resolution requirements may be necessary.

The replicate analysis of the digest of the reference standard or reference material for the protein under test yields measures of precision and quantitative recovery. Recovery of the identified peptides is generally ascertained by the use of internal or external peptide standards. The precision is expressed as the relative standard deviation (RSD). Differences in the recovery and precision of the identified peptides are expected; therefore, the system suitability limits will have to be established for both the recovery and the precision of the identified peptides. These limits are unique for a given protein and will be specified in the individual monograph.

Visual comparison of the relative retention times, the peak responses (the peak area or the peak height), the number of peaks, and the overall elution pattern is completed initially. It is then complemented and supported by mathematical analysis of the peak response ratios and by the chromatographic profile of a 1:1 (v/v) mixture of sample and reference standard or reference material digest. If all peaks in the sample digest and in the reference standard or reference material digest have the same relative retention times and peaks response ratios, then the identity of the sample under test is confirmed.

If peaks that initially eluted with significantly different relative retention times are then observed as single peaks in the 1:1 mixture, the initial difference would be an indication of system variability. However, if separate peaks are observed in the 1:1 mixture, this would be evidence of the nonequivalence of the peptides in each peak. If a peak in the 1:1 mixture is significantly broader than the corresponding peak in the sample and reference standard or reference material digest, it may indicate the presence of different peptides. The use of computer-aided pattern recognition software for the analysis of peptide mapping data has been proposed and applied, but issues related to the validation of the computer

software preclude its use in a compendial test in the near future. Other automated approaches have been used that employ mathematical formulas, models, and pattern recognition. Such approaches are, for example, the automated identification of compounds by IR spectroscopy and the application of diode-array UV spectral analysis for identification of peptides. These methods have limitations due to inadequate resolutions, co-elution of fragments, or absolute peak response differences between reference standard or reference material and sample fragments.

The numerical comparison of the retention times and peak areas or peak heights can be done for a selected group of relevant peaks that have been correctly identified in the peptide maps. Peak areas can be calculated using one peak showing relatively small variation as an internal reference, keeping in mind that peak area integration is sensitive to baseline variation and likely to introduce error in the analysis. Alternatively, the percentage of each peptide peak height relative to the sum of all peak heights can be calculated for the sample under test. The percentage is then compared to that of the corresponding peak of the reference standard/reference material. The possibility of auto-hydrolysis of trypsin is monitored by producing a blank peptide map, that is, the peptide map obtained when a blank solution is treated with trypsin.

The minimum requirement for the qualification of peptide mapping is an approved test procedure that includes system suitability as a test control. In general, early in the regulatory process, qualification of peptide mapping for a protein is sufficient. As the regulatory approval process for the protein progresses, additional qualifications of the test can include a partial validation of the analytical procedure to provide assurance that the method will perform as intended in the development of a peptide map for the specified protein.

5. Analysis and Identification of Peptides

This section gives guidance on the use of peptide mapping during development in support of regulatory applications.

The use of a peptide map as a qualitative tool does not require the complete characterization of the individual peptide peaks. However, validation of peptide mapping in support of regulatory applications requires rigorous characterization of each of the individual peaks in the peptide map. Methods to characterize peaks range from N-terminal sequencing of each peak followed by amino acid analysis to the use of mass spectroscopy (MS).

For characterization purposes, when N-terminal sequencing and amino acids analysis are used, the analytical separation is scaled up. Since scale-up might affect the resolution of peptide peaks, it is necessary, using empirical data, to assure that there is no loss of resolution due to scale-up. Eluates corresponding to specific peptide peaks are collected, vacuum-concentrated, and chromatographed again, if necessary. Amino acid analysis of fragments may be limited by the peptide size. If the N-terminus is blocked, it may need to be cleared before sequencing. C-terminal sequencing of proteins in combination with carboxypeptidase digestion and MALDI-TOF MS can also be used for characterization purposes.

The use of MS for characterization of peptide fragments is by direct infusion of isolated peptides or by the use of on-line LC-MS for structure analysis. In general, it includes electrospray and MALDI-TOF MS analyzer as well as fast atom bombardment (FAB). Tandem MS has also been used to sequence a modified protein and to determine the type of amino acid modification that has occurred. The comparison of mass spectra of the digests before and after reduction pro-

vides a method to assign the disulfide bonds to the various sulphydryl-containing peptides.

If regions of the primary structure are not clearly demonstrated by the peptide map, it might be necessary to develop a secondary peptide map. The goal of a validated method of characterization of a protein through peptide mapping is to reconcile and account for at least 95% of the theoretical composition of the protein structure.

Qualification of Animals as Origin of Animal-derived Medicinal Products provided in the General Notices of Japanese Pharmacopoeia and Other Standards

Introduction

The Official Gazette issued on March 29, 2002 announced that General Notices of the Japanese Pharmacopoeia and other standards were amended to add a provision that "When a drug product or a drug substance which is used to manufacture a drug product, is manufactured from a raw material of animal origin, the animal in question should be in principle a healthy subject, if not otherwise provided."

The Notice Iyaku-hatsu No. 0329001, which was issued on the same date, provided that "Healthy subject herein provided is the animal which does not cause any disease or any infection to human being at an appropriate production process and use of the drug product, and as for the oral or external drug for example, the animal, as its raw material of animal origin, should be confirmed at this stage to meet the Food Standard. It has to be noted that this standard of healthy subject has to be revised timely taking into account the up-to-date information with respect to the amphixenosis infections common between human beings and animals."

This General Information describes safety assurance against infection associated with the use of drugs, which are manufactured from raw materials of animal origin, to follow up the Notice as mentioned above.

1. Basic concept

When drugs derived from raw materials of animal origin including human are used, it is important to take into account any possibility that communicable disease agents such as virus may cause infectious disease or any possible hazards to patients. In such case, it goes without saying that the primary subject that has to be considered is the absence of any infectious agents such as virus in the raw materials of animal origin including human as the source of the drug. More important point is whether there is any possibility of transmission of infectious agents when the drugs containing such infectious agents are administered to patient. The eligibility of animals including human, as the source of raw materials of drugs, in other words "the subject which is free from any disease or transmission of infectious agents that is infectious to human being at an appropriate production process and use of the drug product" is that "The drug should be entirely free from any risk of infections by means of whole procedures which include evaluation of appropriateness of the animals including human as the source of their raw materials, establishment of appropriate production processes and their appropriate control, and strict adherence to the clinical indications of the final product."

2. Animals including human as the source of raw materials of drugs

The most clear and appropriate preventive measures against infection to human being due to administration of drugs which are derived from animals including human are to assure the absence of any infectious agents such as virus in its raw materials or an appropriate critical raw material by either of the following: (1) the use of raw materials of healthy animal origin, which are proved to be free from communicable disease agents to human, or (2) the use of appropriate critical raw materials (e.g., cell substrate, blood plasma, pooled urine after some treatments) for drug production, which are proved to be free from communicable disease agents after certain appropriate processing on raw materials of animal origin.

As for raw materials of drugs of human origin, cell, tissue, blood, placenta, urine, etc. are used. Whenever it is possible for each donor of such raw materials to be asked or inspected about his (her) health condition, the appropriateness as a donor should be confirmed at this stage from the standpoint of safety concerning communicable disease agents such as virus.

For example, "Basic concept on handling and use of a drug product, etc. which is derived from cell/tissue" (Attachment 1 of the Notice Iyaku-Hatsu No. 1314 dated December 26, 2000) issued by the Director-General of the Medicinal Safety Bureau, Ministry of Health and Welfare, states that since the cell/tissue supplied by a human donor comes to be applied to patients without processing through any sufficient inactivation or removal of communicable disease agents, the selection and qualification criteria on such donor has to be established. These criteria are to be composed with the respect to the check items on the case history and the physical conditions as well as the test items on the various transmission of infectious agents through cell/tissue, and that the appropriateness of these criteria has to be clarified. Hepatitis Type-B (HBV), Hepatitis Type-C (HCV), Human Immune Deficiency Viral infections (HIV), Adult T-Cell Leukemia and Parvovirus B19 Infections should be denied through the interview to the donor and the tests (serologic test, nucleic-acid amplification test, etc.). Further, if necessary, Cytomegalovirus infection and EB Virus infection should be denied by tests. "Infections caused by bacteria such as *Treponema pallidum*, *Chlamydia*, *Gonococci*, *Tubercle bacillus*, etc.", "septicemia and its suspicious case", "vicious tumor", "serious metabolic or endocrine-related disorders", "collagenosis and haematological disorder", "hepatic disease" and "dementia (transmissible spongiform encephalopathies and its suspicious case)" should be checked on the case history or by the interview, etc. and the experience of being transfused or/and transplanted should be checked to confirm eligibility as a donor. The most appropriate check items and test methods then available are to be used, which need to be reconsidered at appropriate timing taking into account the updated knowledge and the progress of the science and the technologies. At screening of a donor, reexaminations has to be made at appropriate timing using the eligible check items and the test methods taking into account the window period (Initial period after infection, in which antibody against bacteria, fungi or virus is not detected.)

In the case of plasma derivatives produced from the donated blood in Japan, the donor should be checked by means of self-assessed report about health conditions, and a serologic check and a nucleic acid amplification test (NAT) on mini pooled plasma targeted for HBV, HCV and HIV should be performed at the stage of donated blood. Further,

the plasma material for fractionation should be stored 4 months in minimum so that the arrangement could be taken based on the information available after collection of the blood and the blood infusion to exclude the possibility of using any critical raw material which might cause infection to patients.

On the other hand, as for the materials such as urine which are taken from the unspecified number of the donors and come to be critical raw materials for drug production after some treatments, it is unrealistic and not practical to conduct the tests of virus infection, etc. on the individual donor. Consequently, appropriate tests such as virus test has to be performed on such critical raw materials for drug production.

In the case of the animals besides human, the wild ones should be excluded. Only the animals, which are raised under well sanitarily controlled conditions taken to prevent bacterial contamination or under the effective bacterial pollution monitoring systems, have to be used, and it is recommended that the animals from a colony appropriately controlled under specific pathogen-free (SPF) environment are to be used as far as possible. Further, for the animals regulated under the Food Standard, only the animals that met this standard should be used. It should be confirmed by appropriate tests that the animals were free from pathogen, if necessary.

The concrete measures to avoid transmittance or spread of infectivity of prion, which is considered to be the pathogen of transmissible spongiform encephalopathies (TSEs), as far as possible are the followings: ① avoidance of use of animals, which are raised in the areas where high incidence or high risk of TSEs (Scrapie in sheep and goat, bovine spongiform encephalopathies (BSE) in cattle, chronic wasting disease (CWD) in deer, new type of Creutzfeldt-Jacob-Disease (CJD) in human, etc.) is reported, and humans, who have stayed long time (more than 6 months) in such areas, as raw materials or related substances of drugs; ② avoidance of use of any substances that are derived from the individual infected with scrapie, BSE, CJD, etc.; ③ avoidance of using a material derived from organ, tissue and cell, etc. of high risk of TSEs; and ④ taking appropriate measures basing on the information collected, which includes incidence of TSEs, the results of epidemiological investigation and the experimental research on prion, and incidence of tardive infection on donors after collecting raw materials, etc.

3. Human or animal cells which are used as critical raw materials for drug production

Cell substrates derived from humans or animals are used for drug production. In such case, it is desirable that the humans or the animals, which are the origins of the cell substrates, are healthy subjects. However, it is considered practical that viral safety of the drugs derived from the cell substrates are evaluated on the cells, which are so called critical raw materials for production of such drugs. In such case, the safety should be confirmed through the test and analysis on established cell bank thoroughly with respect to virus etc., as far as possible. The items and the methods of the tests that have been followed in this case are described in detail in the Notice of Japanese version on the internationally accepted ICH Guideline entitled "Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin" (Iyakushin No. 329 issued on February 22, 2000 by Director, Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare). In the meantime, it is important how to handle the cell in case that any virus has been detected under the

cell level tests. This Notice describes how to cope with this situation as follows: "It is recognised that some cell lines used for the manufacture of product will contain endogenous retroviruses, other viruses or viral sequences. In such circumstances, the action plan recommended for manufacturer is described in Section V (Rationale and action plan for viral clearance studies and virus tests on purified bulk) of the Notice. The acceptability of cell lines containing viruses other than endogenous retroviruses will be considered on an individual basis by the regulatory authorities, by taking into account a risk/benefit analysis based on the benefit of the product and its intended clinical use, the nature of the contaminating viruses, their potential for infecting humans or for causing disease in humans, the purification process for the product (e.g., viral clearance evaluation data), and the extent of the virus tests conducted on the purified bulk." For example, it is well known that Type A-, R- and C-endogenous particles like retrovirus are observed in the cells of the rodents used most often for drug production. It is also known that they are not infectious to human and is not dangerous, and CHO cells are generally used for drug production. The established cell lines (e.g., NAMALWA Cell, BALL-1 Cell, etc.) derived from cancer patients are sometimes used, but through the thorough virus tests, etc., their safety are confirmed. The established cell lines are assumed to be safer than the primary cultured cells which are hard to conduct the thorough virus test.

4. Establishment and control of appropriate production process and adherence to the clinical indication of final product for safety assurance

Safety assurance against potential infections at only the level of animals that are source of raw materials of drugs is limited. Further, "health of animal" can not be defined univocally, and the various factors have to be taken into account. The final goal of this subject is to protect human from any infectious disease caused by drugs. Achieving this goal, the establishment and control of appropriate production processes of each drug and the adherence to the clinical indications of the final product are important.

As mentioned above, the rodent cells used most often for the production of the drugs are known to have endogenous retrovirus-like particles sometimes. The reason why such cells can be used for the production of the drugs is that multiple measures are applied for safety in the purification stages which include appropriate inactivation or removal processes. There are cases in which the production procedure involves intentional use of a virus or a microorganism. In this case, relevant measures capable of removing or inactivating of such virus or microorganism are appropriately incorporated in the purification process, so that the risk of infection to human can be fully denied and its safety can be assured when it is used as a drug. Further, even in the case that it is difficult to clarify the risk of contamination of the infectious agents or that the raw material are contaminated by viruses etc., the raw material in question may be used for the production of drugs so long as appropriate inactivation or removal processes are introduced, their effectiveness can be confirmed and the safety can be assured by appropriate control of the manufacturing processes under GMP, etc.

5. Conclusion

The qualification of animals including human, as the source of raw materials of drugs, in other words "the subject which does not cause any infectious diseases to human being at an appropriate production process and use of the drug product" is that "the drug has to be entirely free from any risk of infections by means of whole procedures which in-

clude evaluation of appropriateness of the animal including human as the source of their raw materials, establishment of appropriate production processes and their appropriate control, and strict adherence to the clinical indication of the final product."

To cope with this subject, the advanced scientific measures, which actually reflect the updated knowledge and progress of the science and the technology about infectious diseases in human and infection of animal origin, have to be taken into account timely.

SDS-Polyacrylamide Gel Electrophoresis

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia.

Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)—Uniform Percentage Gels

Polyacrylamide gel electrophoresis is used for the qualitative characterisation of proteins in biological preparations, for control of purity and for quantitative determinations.

Analytical gel electrophoresis is an appropriate method with which to identify and to assess the homogeneity of proteins in pharmaceutical preparations. The method is routinely used for the estimation of protein subunit molecular masses and for determination of the subunit compositions of purified proteins.

Ready-to-use gels and reagents are commercially available and can be used instead of those described in this text, provided that they give equivalent results and that they meet the validity requirements given below under Validation of the test.

1. Characteristics of Polyacrylamide Gels

The sieving properties of polyacrylamide gels are established by the three-dimensional network of fibres and pores which is formed as the bifunctional bisacrylamide cross-links adjacent polyacrylamide chains. Polymerisation is usually catalysed by a free radical-generating system composed of ammonium persulfate and *N,N,N',N'*-tetramethylethylene-diamine (TEMED).

As the acrylamide concentration of a gel increases, its effective pore size decreases. The effective pore size of a gel is operationally defined by its sieving properties; that is, by the resistance it imparts to the migration of macromolecules. There are limits on the acrylamide concentrations that can be used. At high acrylamide concentrations, gels break much more easily and are difficult to handle. As the pore size of a gel decreases, the migration rate of a protein through the gel decreases. By adjusting the pore size of a gel, through manipulating the acrylamide concentration, the resolution of the method can be optimised for a given protein product. Thus, a given gel is physically characterised by its respective composition of acrylamide and bisacrylamide.

In addition to the composition of the gel, the state of the protein is an important component to the electrophoretic mobility. In the case of proteins, the electrophoretic mobility is dependent on the pK value of the charged groups and the size of the molecule. It is influenced by the type, the concentration and the pH of the buffer, by the temperature and the field strength, and by the nature of the support material.

2. Denaturing Polyacrylamide Gel Electrophoresis

The method cited as an example is limited to the analysis of monomeric polypeptides with a mass range of 14,000 to

100,000 daltons. It is possible to extend this mass range by various techniques (e.g. gradient gels, particular buffer system). For instance, tricine sodium dodecyl sulfate (SDS) gels, using tricine as the trailing ion in the electrophoresis running buffer (instead of glycine as in the method described here), can separate very small proteins and peptides under 10,000–15,000 daltons.

Denaturing polyacrylamide gel electrophoresis using glycine SDS (SDS-PAGE) is the most common mode of electrophoresis used in assessing the pharmaceutical quality of protein products and will be the focus of the example method. Typically, analytical electrophoresis of proteins is carried out in polyacrylamide gels under conditions that ensure dissociation of the proteins into their individual polypeptide subunits and that minimise aggregation. Most commonly, the strongly anionic detergent SDS is used in combination with heat to dissociate the proteins before they are loaded on the gel. The denatured polypeptides bind to SDS, become negatively charged and exhibit a consistent charge-to-mass ratio regardless of protein type. Because the amount of SDS bound is almost always proportional to the molecular mass of the polypeptide and is independent of its sequence, SDS-polypeptide complexes migrate through polyacrylamide gels with mobilities dependent on the size of the polypeptide.

The electrophoretic mobilities of the resultant detergent-polypeptide complexes all assume the same functional relationship to their molecular masses. SDS complexes will migrate toward the anode in a predictable manner, with low molecular mass complexes migrating faster than larger ones. The molecular mass of a protein can therefore be estimated from its relative mobility in calibrated SDS-PAGE and the intensity of a single band relative to other undesired bands in such a gel can be a measure of purity.

Modifications to the polypeptide backbone, such as N- or O-linked glycosylation, can change the apparent molecular mass of a protein since SDS does not bind to a carbohydrate moiety in a manner similar to a polypeptide; therefore, a consistent charge-to-mass ratio is not maintained.

Depending on the extent of glycosylation and other post-translational modifications, the apparent molecular mass of proteins may not be a true reflection of the mass of the polypeptide chain.

2.1. Reducing conditions

Polypeptide subunits and three-dimensional structure are often maintained in proteins by the presence of disulfide bonds. A goal of SDS-PAGE analysis under reducing conditions is to disrupt this structure by reducing disulfide bonds. Complete denaturation and dissociation of proteins by treatment with 2-mercaptoethanol (2-ME) or dithiothreitol (DTT) will result in unfolding of the polypeptide backbone and subsequent complexation with SDS. Using these conditions, the molecular mass of the polypeptide subunits can reasonably be calculated by linear regression (or, more closely, by non linear regression) in the presence of suitable molecular mass standards.

2.2. Non-reducing conditions

For some analyses, complete dissociation of the protein into subunit peptides is not desirable. In the absence of treatment with reducing agents such as 2-ME or DTT, disulfide covalent bonds remain intact, preserving the oligomeric form of the protein. Oligomeric SDS-protein complexes migrate more slowly than their SDS-polypeptide subunits. In addition, non-reduced proteins may not be completely saturated with SDS and, hence, may not bind the detergent in a constant mass ratio. Moreover, intra-chain disulphide bonds constrain the molecular shape, usually in such a way as to

reduce the Stokes radius of the molecule, thereby reducing the apparent molecular mass M_r . This makes molecular mass determinations of these molecules by SDS-PAGE less straightforward than analyses of fully denatured polypeptides, since it is necessary that both standards and unknown proteins be in similar configurations for valid comparisons.

3. Characteristics of Discontinuous Buffer System Gel Electrophoresis

The most popular electrophoretic method for the characterisation of complex mixtures of proteins uses a discontinuous buffer system involving two contiguous, but distinct gels: a resolving or separating (lower) gel and a stacking (upper) gel. The two gels are cast with different porosities, pH, and ionic strengths. In addition, different mobile ions are used in the gel and electrode buffers. The buffer discontinuity acts to concentrate large volume samples in the stacking gel, resulting in improved resolution. When power is applied, a voltage drop develops across the sample solution which drives the proteins into the stacking gel. Glycinate ions from the electrode buffer follow the proteins into the stacking gel. A moving boundary region is rapidly formed with the highly mobile chloride ions in the front and the relatively slow glycinate ions in the rear. A localised high-voltage gradient forms between the leading and trailing ion fronts, causing the SDS-protein complexes to form into a thin zone (stack) and migrate between the chloride and glycinate phases. Within broad limits, regardless of the height of the applied sample, all SDS-proteins condense into a very narrow region and enter the resolving gel as a well-defined, thin zone of high protein density. The large-pore stacking gel does not retard the migration of most proteins and serves mainly as an anti-convective medium. At the interface of the stacking and resolving gels, the proteins undergo a sharp increase in retardation due to the restrictive pore size of the resolving gel and the buffer discontinuity, which also contributes to focusing of the proteins. Once in the resolving gel, proteins continue to be slowed by the sieving of the matrix. The glycinate ions overtake the proteins, which then move in a space of uniform pH formed by the 2-amino-2-hydroxymethyl-1,3-propanediol and glycine. Molecular sieving causes the SDS-polypeptide complexes to separate on the basis of their molecular masses.

4. Preparing Vertical Discontinuous Buffer SDS Polyacrylamide Gels

This section describes the preparation of gels using particular instrumentation. This does not apply to pre-cast gels. For pre-cast gels or any other commercially available equipment, the manufacturer's instructions must be used for guidance.

The use of commercial reagents that have been purified in solution is recommended. When this is not the case and where the purity of the reagents used is not sufficient, a pre-treatment is applied. For instance, any solution sufficiently impure to require filtration must also be deionised with a mixed bed (anion/cation exchange) resin to remove acrylic acid and other charged degradation products. When stored according to recommendations, acrylamide/bisacrylamide solutions and solid persulfate are stable for long periods.

4.1. Assembling the gel moulding cassette

Clean the two glass plates (size: e.g. 10 cm × 8 cm), the polytetrafluoroethylene comb, the two spacers and the silicone rubber tubing (diameter e.g. 0.6 mm × 35 cm) with mild detergent and rinse extensively with water, followed by dehydrated alcohol, and allow the plates to dry at room temperature. Lubricate the spacers and the tubing with non-silicone grease. Apply the spacers along each of the two short

sides of the glass plate 2 mm away from the edges and 2 mm away from the long side corresponding to the bottom of the gel. Begin to lay the tubing on the glass plate by using one spacer as a guide. Carefully twist the tubing at the bottom of the spacer and follow the long side of the glass plate. While holding the tubing with one finger along the long side twist again the tubing and lay it on the second short side of the glass plate, using the spacer as a guide. Place the second glass plate in perfect alignment and hold the mould together by hand pressure. Apply two clamps on each of the two short sides of the mould. Carefully apply four clamps on the longer side of the gel mould thus forming the bottom of the gel mould. Verify that the tubing is running along the edge of the glass plates and has not been extruded while placing the clamps. The gel mould is now ready for pouring the gel.

4.2. Preparation of the gel

In a discontinuous buffer SDS polyacrylamide gel, it is recommended to pour the resolving gel, let the gel set, and then pour the stacking gel since the composition of the two gels in acrylamide-bisacrylamide, buffer and pH are different.

4.2.1. Preparation of the resolving gel

In a conical flask, prepare the appropriate volume of solution containing the desired concentration of acrylamide for the resolving gel, using the values given in Table 1. Mix the components in the order shown. Where appropriate, before adding the ammonium persulfate solution and the TEMED, filter the solution if necessary under vacuum through a cellulose acetate membrane (pore diameter 0.45 µm). Keep the solution under vacuum, while swirling the filtration unit, until no more bubbles are formed in the solution. Add appropriate amounts of ammonium persulfate solution and TEMED as indicated in Table 1, swirl and pour immediately into the gap between the two glass plates of the mould. Leave sufficient space for the stacking gel (the length of the teeth of the comb plus 1 cm). Using a tapered glass pipette, carefully overlay the solution with water-saturated isobutanol. Leave the gel in a vertical position at room temperature to allow polymerisation.

4.2.2. Preparation of the stacking gel

After polymerisation is complete (about 30 min), pour off the isobutanol and wash the top of the gel several times with water to remove the isobutanol overlay and any unpolymerised acrylamide. Drain as much fluid as possible from the top of the gel, and then remove any remaining water with the edge of a paper towel.

In a conical flask, prepare the appropriate volume of solution containing the desired concentration of acrylamide, using the values given in Table 2. Mix the components in the order shown. Where appropriate, before adding the ammonium persulfate solution and the TEMED, filter the solution if necessary under vacuum through a cellulose acetate membrane (pore diameter: 0.45 µm). Keep the solution under vacuum, while swirling the filtration unit, until no more bubbles are formed in the solution. Add appropriate amounts of ammonium persulfate solution and TEMED as indicated in Table 2. Swirl and pour immediately into the gap between the two glass plates of the mould directly onto the surface of the polymerised resolving gel. Immediately insert a clean polytetrafluoroethylene comb into the stacking gel solution, being careful to avoid trapping air bubbles. Add more stacking gel solution to fill the spaces of the comb completely. Leave the gel in a vertical position and allow to polymerise at room temperature.

4.3. Preparation of the sample

Unless otherwise specified in the specific monograph the samples can be prepared as follows:

Sample solution (non-reducing conditions). Mix equal volumes of: a mixture comprising water plus the preparation or the reference solutions, and concentrated SDS-PAGE sample buffer.

Sample solution (reducing conditions). Mix equal volumes of: a mixture comprising water plus the preparation or the reference solutions, and concentrated SDS-PAGE sample buffer for reducing conditions containing 2-ME (or DTT) as reducing agent.

The concentration prescribed in the monograph can vary depending on the protein and staining method.

Sample treatment: keep for 5 min in a boiling water bath or in a block heater set at 100°C, then chill. (Note that temperature and time may vary in the monograph since protein cleavage may occur during the heat treatment.)

4.4. Mounting the gel in the electrophoresis apparatus and electrophoretic separation

After polymerisation is complete (about 30 min), remove the polytetrafluoroethylene comb carefully. Rinse the wells immediately with water or with the SDS-PAGE running buffer to remove any unpolymerised acrylamide. If necessary, straighten the teeth of the stacking gel with a blunt hypodermic needle attached to a syringe. Remove the clamps on one short side, carefully pull out the tubing and replace the clamps. Proceed similarly on the other short side. Remove the tubing from the bottom part of the gel. Mount the gel in the electrophoresis apparatus. Add the electrophoresis buffers to the top and bottom reservoirs. Remove any bubbles that become trapped at the bottom of the gel between the glass plates. This is best done with a bent hypodermic needle attached to a syringe. Never pre-run the gel before loading the samples, since this will destroy the discontinuity of the buffer systems. Before loading the sample carefully rinse each well with SDS-PAGE running buffer. Prepare the test and reference solutions in the recommended sample buffer and treat as specified in the individual monograph. Apply the appropriate volume of each solution to the stacking gel wells. Start the electrophoresis using the conditions recommended by the manufacturer of the equipment. Manufacturers of SDS-PAGE equipment may provide gels of different surface area and thickness and electrophoresis running time and current/voltage may vary in order to achieve optimal separation. Check that the dye front is moving into the resolving gel. When the dye is near the bottom of the gel, stop the electrophoresis. Remove the gel assembly from the apparatus and carefully separate the glass plates. Remove the spacers, cut off and discard the stacking gel and immediately proceed with staining.

4.5. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)—Gradient concentration gels

Gradient gels (resolving gels) are prepared with an increasing concentration of acrylamide from the top to the bottom. Preparation of gradient gels requires a gradient forming apparatus. Ready-to-use gradient gels are commercially available with specific recommended protocols.

Gradient gels offer some advantages over fixed concentration gels. Some proteins which co-migrate on fixed concentration gels can be resolved within gradient gels. During electrophoresis the proteins migrate until the pore size stops further progress and therefore a stacking effect occurs, resulting in sharper bands. Per the table below, gradient gels also allow separation of a wider range of proteins molecular masses than on a single fixed concentration gel.

The table below gives suggested compositions of the linear gradient, relating the range of acrylamide concentrations to the appropriate protein molecular ranges. Note that other gradient shapes (e.g. concave) can be prepared for specific

applications.

Acrylamide (%)	Protein range (kDa)
5–15	20–250
5–20	10–200
10–20	10–150
8–20	8–150

Gradient gels are also used for molecular mass determination and protein purity determination.

4.6. Detection of proteins in gels

Coomassie and silver staining are the most common protein staining methods and are described in more detail below. Several other commercial stains, detection methods and commercial kits are available. For example, fluorescent stains are visualised using a fluorescent imager and often provide a linear response over a wide range of protein concentrations, often several orders of magnitude depending on the protein.

Coomassie staining has a protein detection level of approximately 1 to 10 µg of protein per band. Silver staining is the most sensitive method for staining proteins in gels and a band containing 10 ng to 100 ng can be detected. These figures are considered robust in the context of these gels. Improved sensitivity of one or two orders of magnitude has sometimes been reported in the literature.

Coomassie staining responds in a more linear manner than silver staining; however the response and range depend on the protein and development time. Both Coomassie and silver staining can be less reproducible if staining is stopped in a subjective manner, i.e. when the staining is deemed satisfactory. Wide dynamic ranges of reference proteins are very important to use since they help assess the intra-experimental sensitivity and linearity. All gel staining steps are done while wearing gloves, at room temperature, with gentle shaking (e.g. on an orbital shaker platform) and using any convenient container.

4.6.1. Coomassie staining

Immerse the gel in a large excess of Coomassie staining solution and allow to stand for at least 1 h. Remove the staining solution.

Destain the gel with a large excess of destaining solution. Change the destaining solution several times, until the stained protein bands are clearly distinguishable on a clear background. The more thoroughly the gel is destained, the smaller is the amount of protein that can be detected by the method. Destaining can be speeded up by including a few grams of anion-exchange resin or a small sponge in the destaining solution.

The acid-alcohol solutions used in this procedure do not completely fix proteins in the gel. This can lead to losses of some low-molecular-mass proteins during the staining and destaining of thin gels. Permanent fixation is obtainable by allowing the gel to stand in a mixture of 1 volume of trichloroacetic acid, 4 volumes of methanol and 5 volumes of water for 1 h before it is immersed in the Coomassie staining solution.

4.6.2. Silver staining

Immerse the gel in a large excess of fixing solution and allow to stand for 1 h. Remove the fixing solution, add fresh fixing solution and incubate either for at least 1 h or overnight, if convenient. Discard the fixing solution and wash the gel in a large excess of water for 1 h. Soak the gel for 15 min in a 1% V/V solution of glutaraldehyde. Wash the gel twice for 15 min in a large excess of water. Soak the gel in

fresh silver nitrate reagent for 15 min, in darkness. Wash the gel three times for 5 min in a large excess of water. Immerse the gel for about 1 min in developer solution until satisfactory staining has been obtained. Stop the development by incubation in the blocking solution for 15 min. Rinse the gel with water.

4.7. Recording of the results

Gels are photographed or scanned while they are still wet or after an appropriate drying procedure. Currently, “gel scanning” systems with data analysis software are commercially available to photograph and analyse the wet gel immediately.

Depending on the staining method used, gels are treated in a slightly different way. For Coomassie staining, after the destaining step, allow the gel to stand in a 100 g/L solution of glycerol for at least 2 h (overnight incubation is possible). For silver staining, add to the final rinsing a step of 5 min in a 20 g/L solution of glycerol.

Drying of stained SDS Polyacrylamide gels is one of the methods to have permanent documentation. This method frequently results in the “cracking of gel” during drying between cellulose films.

Immerse two sheets of porous cellulose film in water and incubate for 5 min to 10 min. Place one of the sheets on a drying frame. Carefully lift the gel and place it on the cellulose film. Remove any trapped air bubbles and pour a few millilitres of water around the edges of the gel. Place the second sheet on top and remove any trapped air bubbles. Complete the assembly of the drying frame. Place in an oven or leave at room temperature until dry.

4.8. Molecular mass determination

Molecular masses of proteins are determined by comparison of their mobilities with those of several marker proteins of known molecular weight. Mixtures of pre-stained and unstained proteins with precisely known molecular masses blended for uniform staining are available for calibrating gels. They are available in various molecular mass ranges. Concentrated stock solutions of proteins of known molecular mass are diluted in the appropriate sample buffer and loaded on the same gel as the protein sample to be studied.

Immediately after the gel has been run, the position of the bromophenol blue tracking dye is marked to identify the leading edge of the electrophoretic ion front. This can be done by cutting notches in the edges of the gel or by inserting a needle soaked in India ink into the gel at the dye front. After staining, measure the migration distances of each protein band (markers and unknowns) from the top of the resolving gel. Divide the migration distance of each protein by the distance travelled by the tracking dye. The normalised migration distances are referred to as the relative mobilities of the proteins (relative to the dye front), or *Rf*. Construct a plot of the logarithm of the relative molecular masses (*M_r*) of the protein standards as a function of the *Rf* values. Unknown molecular masses can be estimated by linear regression analysis (more accurately by non-linear regression analysis) or interpolation from the curves of $\log M_r$ against *Rf* if the values obtained for the unknown samples are positioned along the approximately linear part of the graph.

4.9. Validation of the test

The test is not valid unless the target resolution range of the gel has been demonstrated by the distribution of appropriate molecular mass markers e.g. across 80% of the length of the gel. The separation obtained for the expected proteins must show a linear relationship between the logarithm of the molecular mass and the *Rf*. If the plot has a sigmoidal shape then only data from the linear region of the curve can be used in the calculations. Additional validation

Table 1 Preparation of resolving gel

Solution components	Component volumes (mL) per gel mould volume of							
	5 mL	10 mL	15 mL	20 mL	25 mL	30 mL	40 mL	50 mL
6% Acrylamide								
Water	2.6	5.3	7.9	10.6	13.2	15.9	21.2	26.5
Acrylamide solution ⁽¹⁾	1.0	2.0	3.0	4.0	5.0	6.0	8.0	10.0
1.5 M Tris (pH 8.8) ⁽²⁾	1.3	2.5	3.8	5.0	6.3	7.5	10.0	12.5
100 g/L SDS ⁽³⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
100 g/L APS ⁽⁴⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
TEMED ⁽⁵⁾	0.004	0.008	0.012	0.016	0.02	0.024	0.032	0.04
8% Acrylamide								
Water	2.3	4.6	6.9	9.3	11.5	13.9	18.5	23.2
Acrylamide solution ⁽¹⁾	1.3	2.7	4.0	5.3	6.7	8.0	10.7	13.3
1.5 M Tris (pH 8.8) ⁽²⁾	1.3	2.5	3.8	5.0	6.3	7.5	10.0	12.5
100 g/L SDS ⁽³⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
100 g/L APS ⁽⁴⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
TEMED ⁽⁵⁾	0.003	0.006	0.009	0.012	0.015	0.018	0.024	0.03
10% Acrylamide								
Water	1.9	4.0	5.9	7.9	9.9	11.9	15.9	19.8
Acrylamide solution ⁽¹⁾	1.7	3.3	5.0	6.7	8.3	10.0	13.3	16.7
1.5 M Tris (pH 8.8) ⁽²⁾	1.3	2.5	3.8	5.0	6.3	7.5	10.0	12.5
100 g/L SDS ⁽³⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
100 g/L APS ⁽⁴⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
TEMED ⁽⁵⁾	0.002	0.004	0.006	0.008	0.01	0.012	0.016	0.02
12% Acrylamide								
Water	1.6	3.3	4.9	6.6	8.2	9.9	13.2	16.5
Acrylamide solution ⁽¹⁾	2.0	4.0	6.0	8.0	10.0	12.0	16.0	20.0
1.5 M Tris (pH 8.8) ⁽²⁾	1.3	2.5	3.8	5.0	6.3	7.5	10.0	12.5
100 g/L SDS ⁽³⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
100 g/L APS ⁽⁴⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
TEMED ⁽⁵⁾	0.002	0.004	0.006	0.008	0.01	0.012	0.016	0.02
14% Acrylamide								
Water	1.4	2.7	3.9	5.3	6.6	8.0	10.6	13.8
Acrylamide solution ⁽¹⁾	2.3	4.6	7.0	9.3	11.6	13.9	18.6	23.2
1.5 M Tris (pH 8.8) ⁽²⁾	1.2	2.5	3.6	5.0	6.3	7.5	10.0	12.5
100 g/L SDS ⁽³⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
100 g/L APS ⁽⁴⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
TEMED ⁽⁵⁾	0.002	0.004	0.006	0.008	0.01	0.012	0.016	0.02
15% Acrylamide								
Water	1.1	2.3	3.4	4.6	5.7	6.9	9.2	11.5
Acrylamide solution ⁽¹⁾	2.5	5.0	7.5	10.0	12.5	15.0	20.0	25.0
1.5 M Tris (pH 8.8) ⁽²⁾	1.3	2.5	3.8	5.0	6.3	7.5	10.0	12.5
100 g/L SDS ⁽³⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
100 g/L APS ⁽⁴⁾	0.05	0.1	0.15	0.2	0.25	0.3	0.4	0.5
TEMED ⁽⁵⁾	0.002	0.004	0.006	0.008	0.01	0.012	0.016	0.02

(1) Acrylamide solution: 30% acrylamide/bisacrylamide (29:1) solution.

(2) 1.5 M Tris (pH 8.8): 1.5 M tris-hydrochloride buffer solution (pH 8.8).

(3) 100 g/L SDS: a 100 g/L solution of sodium dodecyl sulfate.

(4) 100 g/L APS: a 100 g/L solution of ammonium persulfate. Ammonium persulfate provides the free radicals that drive polymerization of acrylamide and bisacrylamide. Since ammonium persulfate solution decomposes rapidly, fresh solutions must be prepared daily.

(5) TEMED: *N,N,N',N'*-tetramethylethylenediamine.

requirements with respect to the test sample may be specified in individual monographs.

Sensitivity must also be validated. A reference protein control corresponding to the desired concentration limit that is run in parallel with the test samples can serve as a system suitability of the experiment.

4.10. Quantification of impurities

SDS-PAGE is often used as a limit test for impurities. When impurities are quantified by normalisation to the main band using an integrating densitometer or image analysis,

the responses must be validated for linearity. Note that depending on the detection method and protein as described in the introduction of the section "Detection of proteins in gels" the linear range can vary but can be assessed within each run by using one or more control samples containing an appropriate range of protein concentration.

Where the impurity limit is specified in the individual monograph, a reference solution corresponding to that level of impurity should be prepared by diluting the test solution. For example, where the limit is 5%, a reference solution

Table 2 Preparation of stacking gel

Solution components	Component volumes (mL) per gel mould volume of							
	1 mL	2 mL	3 mL	4 mL	5 mL	6 mL	8 mL	10 mL
Water	0.68	1.4	2.1	2.7	3.4	4.1	5.5	6.8
Acrylamide solution ⁽¹⁾	0.17	0.33	0.5	0.67	0.83	1.0	1.3	1.7
1.0 M Tris (pH 6.8) ⁽²⁾	0.13	0.25	0.38	0.5	0.63	0.75	1.0	1.25
100 g/L SDS ⁽³⁾	0.01	0.02	0.03	0.04	0.05	0.06	0.08	0.1
100 g/L APS ⁽⁴⁾	0.01	0.02	0.03	0.04	0.05	0.06	0.08	0.1
TEMED ⁽⁵⁾	0.001	0.002	0.003	0.004	0.005	0.006	0.008	0.01

(1) Acrylamide solution: 30% acrylamide/bisacrylamide (29:1) solution.

(2) 1.0 M Tris (pH 6.8): 1 M tris-hydrochloride buffer solution (pH 6.8).

(3) 100 g/L SDS: a 100 g/L solution of sodium dodecyl sulfate.

(4) 100 g/L APS: a 100 g/L solution of ammonium persulfate. Ammonium persulfate provides the free radicals that drive polymerization of acrylamide and bisacrylamide. Since ammonium persulfate solution decomposes rapidly, fresh solutions must be prepared daily.

(5) TEMED: *N,N,N',N'*-tetramethylethylenediamine.

would be a 1:20 dilution of the test solution. No impurity (any band other than the main band) in the electropherogram obtained with the test solution may be more intense than the main band obtained with the reference solution.

Under validated conditions impurities may be quantified by normalisation to the main band using an integrating densitometer or by image analysis.

5. Reagents

(i) 30% acrylamide/bisacrylamide (29:1) solution: Prepare a solution containing 290 g of acrylamide and 10 g of methylenebisacrylamide per litre of water. Filter.

(ii) SDS-PAGE running buffer: Dissolve 151.4 g of 2-amino-2-hydroxymethyl-1,3-propanediol, 721.0 g of glycine and 50.0 g of sodium dodecyl sulfate in water and dilute to 5000 mL with the same solvent. Immediately before use, dilute to 10 times its volume with water and mix. Measure the pH of the diluted solution. The pH is between 8.1 and 8.8.

(iii) SDS-PAGE sample buffer (concentrated): Dissolve 1.89 g of 2-amino-2-hydroxymethyl-1,3-propanediol, 5.0 g of sodium dodecyl sulfate and 50 mg of bromophenol blue in water. Add 25.0 mL of glycerol and dilute to 100 mL with water. Adjust the pH to 6.8 with hydrochloric acid, and dilute to 125 mL with water.

(iv) SDS-PAGE sample buffer for reducing conditions (concentrated): Dissolve 3.78 g of 2-amino-2-hydroxymethyl-1,3-propanediol, 10.0 g of sodium dodecyl sulfate and 100 mg of bromophenol blue in water. Add 50.0 mL of glycerol and dilute to 200 mL with water. Add 25.0 mL of 2-mercaptoethanol. Adjust to pH 6.8 with hydrochloric acid, and dilute to 250.0 mL with water. Alternatively, dithiothreitol may be used as reducing agent instead of 2-mercaptoethanol. In this case prepare the sample buffer as follows: dissolve 3.78 g of 2-amino-2-hydroxymethyl-1,3-propanediol, 10.0 g of sodium dodecyl sulfate and 100 mg of bromophenol blue in water. Add 50.0 mL of glycerol and dilute to 200 mL with water. Adjust to pH 6.8 with hydrochloric acid, and dilute to 250.0 mL with water. Immediately before use, add dithiothreitol to a final concentration of 100 mM.

(v) Coomassie staining solution: A 1.25 g/L solution of acid blue 83 in a mixture consisting of 1 volume of glacial acetic acid, 4 volumes of methanol and 5 volumes of water. Filter.

(vi) Developer solution: Dilute 2.5 mL of a 20 g/L solu-

tion of citric acid and 0.27 mL of formaldehyde to 500.0 mL with water.

(vii) Fixing solution: To 250 mL of methanol, add 0.27 mL of formaldehyde and dilute to 500.0 mL with water.

(viii) Silver nitrate reagent: To a mixture of 3 mL of concentrated ammonia and 40 mL of 1 M sodium hydroxide, add 8 mL of a 200 g/L solution of silver nitrate, dropwise, with stirring. Dilute to 200 mL with water.

(ix) Destaining solution: A mixture consisting of 1 volume of glacial acetic acid, 4 volumes of methanol and 5 volumes of water.

(x) 1.5 M tris-hydrochloride buffer solution (pH 8.8): Dissolve 90.8 g of 2-amino-2-hydroxymethyl-1,3-propanediol in 400 mL of water. Adjust the pH with hydrochloric acid and dilute to 500.0 mL with water.

(xi) Blocking solution: A 10% *V/V* solution of acetic acid.

Surface Plasmon Resonance

Surface plasmon resonance (SPR) optical detection is a method for detecting changes in mass on a sensor chip as changes in the angle at which the reflected light disappears by SPR. This method is used to analyze the binding specificity and binding affinity between substances, and to measure the concentration of analytes in samples.

The devices designed to measure interactions between substances by means of surface plasmon resonance usually adopt a prism-based Kretschmann configuration (Fig. 1). If polarized light is applied in a manner allowing total reflection on the metallic film surface of the sensor chip, an SPR signal (a reduction in intensity in a portion of the reflected light) is observed. The angle at which the SPR signal is produced varies depending on the mass placed on the sensor chip. Thus, the angle at which the SPR signal is produced is changed by binding or dissociation between the molecule immobilized on the sensor chip (the ligand) and the molecule added (the analyte) (Fig. 1). The results of measurement are in the form of a sensorgram presenting changes over time in the SPR signal-producing angle or the response unit (RU) converted from changes in the angle. If the thus-obtained binding and dissociation sensorgram is fitted to the theoretical curve, the ligand/analyte binding rate constant (k_a), dissociation rate constant (k_d) and dissociation constant (K_D) =




Fig. 1 Principle of SPR measurement (Kretschmann configuration)




Fig. 2 Example of an SPR sensorgram

k_d/k_a) can be determined. If the response of the analyte in a given sample is compared to the response of the analyte of known concentration, the analyte concentration in a given sample can be determined.

1. Instrument

The instrument usually used for SPR optical detection (a continuous flow system) consists of a light source, an optical detector, a fluid delivery system, a sensor chip insertion port and a data accumulating unit. A sensor chip conjugated with carboxymethyl dextran is usually employed. An appropriate sensor chip tailored to the characteristics of the molecule to be immobilized should be selected. If the sensor chip is set on the device, multiple flow cells are formed on the sensor chip surface, allowing the ligand to be immobilized on each flow cell.

2. Measurement

SPR optical detection is used for testing the binding specificity between the ligand and the analyte, analyzing the binding affinity between the ligand and the analyte, or measuring the analyte concentration. Usually, SPR signals are observed over time while applying the buffer solution to the flow cell and injecting the analyte, and a sensorgram illustrating the binding of the analyte to the ligand immobilized on the sensor chip is obtained. In kinetic analysis designed to analyze the binding affinity from the shape of the sensorgram, a running buffer free of the analyte is applied after the end of analyte injection in order to obtain a dissociation sensorgram. After measurement, a regeneration buffer is applied so that the analyte bound to the ligand can be removed completely (Fig. 2).

2.1. Sample and buffer solution

(1) Analyte solution

Depending on the objective of analysis and the affinity between the molecules to be measured, the sample is diluted to an optimal concentration with the running buffer to yield an analyte solution. If the sample contains insoluble contaminants, they need to be removed by an appropriate method such as centrifugation or filtration using a low protein adsorptive filter.

(2) Running buffer

A buffer appropriate for the ligand and analyte is selected. Addition of salts or detergents to the buffer can be useful in stabilizing the ligand and the analyte. If appropriate, the buffer is filtrated and degassed prior to use. If non-specific binding to the reference flow cell is observed at the time of analyte injection, the buffer needs to be optimized by changing its pH, ionic strength, or other conditions.

(3) Regeneration buffer

As regeneration solution, a buffer with low pH, high pH, or high ionic strength, or a buffer containing surfactants, nonpolar reagents, or chelating agents can be used. The type of buffer to be used varies depending on the material of the flow path of the device. Thus, it is necessary to check the chemical resistance of the device. The ideal setting for regeneration is the one under which complete dissociation of the bound analyte can be achieved without altering the nature of the ligand on the sensor chip surface. If the regeneration buffer is suitable, the baseline after regeneration returns to the baseline recorded before addition of the analyte and it is possible to avoid a reduction in the binding response during repeated measurement. If the setting for regeneration is inappropriate, the level of binding to the ligand decreases during the cycles of measurement, thus affecting the reproducibility of measurement. If the dissociation rate is sufficiently high, the flow of the buffer allows dissociation of the analyte from the ligand, thus making it unnecessary to apply the buffer for regeneration.

2.2. Preparation of the sensor chip used for the measurement

Two methods of binding the ligand to the sensor chip are available: a direct method (direct immobilization of the ligand), and a capture method (capture immobilization of the ligand). In both methods, it is essential to immobilize the ligand while retaining its biological activity and minimizing the impact on binding to the analyte. A ligand of high purity level must be used for the immobilization.

The amount of the ligand to be immobilized is determined with reference to the equation given below.

Ligand immobilization quantity

$$= \frac{\text{Required } R_{\max}}{\text{Valency of the ligand}} \times \frac{\text{molecular weight of the ligand}}{\text{molecular weight of the analyte}}$$

The R_{\max} (response in the case of maximal binding of the analyte to the ligand) needed for measurement is determined depending on the sensitivity of the instrument used. For analysis of binding affinity, R_{\max} needs to be low to avoid steric effects, aggregation and mass transport limitation (a condition under which the amount of analyte supplied serves as a rate-limiting factor for changes in the binding amount due to a shortage in the amount of analyte against the excess ligand). For measurement of the analyte concentration, high R_{\max} is desirable to induce a mass transport limitation which increases the dependency of the analyte-binding amount on the concentration and improves the linearity of the calibration curve.

Usually, a control flow cell free of bound ligand is prepared on the sensor chip and is used to detect nonspecific

bindings. The following can serve as the control flow cell: (1) an untreated flow cell, (2) a flow cell having undergone a chemical treatment identical to that for ligand immobilization, and (3) a flow cell having undergone immobilization of a ligand-like molecule having no potential for binding to the analyte. In the case that the ligand is immobilized by the capture method, a flow cell having undergone immobilization of the capturing molecule serves as the control flow cell.

If the immobilized ligand is stable, it is possible to store the sensor chip apart from the device. Such storage is used under conditions such as dry environments or immersion in a buffer solution at low temperature.

Ligand immobilization methods

(1) Direct method

The ligand is immobilized directly via the amino group, thiol group, carboxyl group, aldehyde group or hydroxyl group of the ligand, or via the hydrophobicity of the ligand. The sensor chip usually possesses a layer containing carboxyl groups, which can be used for immobilization. Thus, the ligand is immobilized by the covalent bond. In the case of direct immobilization, the surface often becomes inhomogeneous due to the lack of a uniform direction in the ligand.

(2) Capture method

A capturing molecule having the potential to bind to the ligand is immobilized on the sensor chip so that the ligand can be captured on the chip by binding to the capturing molecule. Capturing molecules include the antibody to the ligand, and antibody to the specific tag sequence allocated to the ligand. If the ligand is an antibody drug, protein A and protein G serve as capturing molecules. If the ligand is a biotinylated molecule, streptavidin is used as a capturing molecule. By the capture method, the direction in the ligand is likely to become uniform. It is important that dissociation of the ligand from the capturing molecule does not occur during measurement. If ligand capturing is performed at each cycle of measurement, there is no need to determine the conditions of regeneration for individual ligands, thus making it easy to set the conditions for measurement.

2.3. Setting the conditions for measurement

(1) Checking the baseline

Before starting the measurement, the stability of the baseline needs to be confirmed. If the baseline is not stable, stabilization should be attempted by the following procedures: administration of several infusions of buffer solution, high ion intensity solution or surfactant solution, application of buffer at a high flow rate, and repetition of the sequence of analyte binding and regeneration.

(2) Flow rate

For analysis of the binding affinity, it is necessary to set the flow rate high in order to suppress the mass transport limitation. For measurement of the analyte concentration, the flow rate must be set low to facilitate the mass transport limitation.

(3) Duration of the analysis

The time needed for analysis in each step (binding, dissociation, etc.) varies depending on the type of measurement. When specific binding is to be tested, the time for binding is set as the time allowing sufficient observation of changes in response. In the case of binding affinity analysis by means of kinetic analysis, a sufficient amount of time should be allowed for dissociation if the response involves slow dissociation. In the case of affinity analysis by means of steady state analysis, the time sufficient for the binding level to reach the equilibrium must be set. In the case of concentration measurement, the time will suffice if it covers the points of measurement capable of yielding an appropriate calibration

curve.

(4) Checking R_{\max}

If the R_{\max} measured exceeds the theoretical R_{\max} calculated from the molecular weight of the ligand and analyte together with the ligand immobilization quantity and the ligand's binding valency, the following reasons can be considered: inappropriate binding valency, analyte aggregation, or non-specific binding. In such cases, the conditions for measurement or analysis need to be modified.

(5) Checking the reproducibility of measurement

The reproducibility of measurement may be affected if the conditions for measurement are not optimal, and if the ligand is inactivated during repetition of the measuring cycle. Furthermore, if a sensor chip that has been kept stored is used, the reproducibility may be affected by the storage. When the conditions for measurement are set, close attention needs to be paid to reproducibility. The acceptable repeated number of measurements and the acceptable storage period should be set in advance.

2.4. Methods of measurement

2.4.1. Analysis of binding specificity

The analyte is added, and its binding to the ligand is tested on the basis of the binding responses. An appropriate control experiment should be carried out (e.g., demonstrating lack of binding of other analytes to the immobilized ligand), to confirm that the binding observed in the measurement was specific to the analyte.

2.4.2. Analysis of binding affinity

(1) Kinetic analysis

The analyte is injected and its binding is measured. Then, fluid free of the analyte is applied and dissociation of the analyte is measured. Thereafter, complete dissociation of the analyte is achieved by the regeneration step, followed by measurement of the next analyte solution. Another method is analysis of the binding affinity through successive application of analyte solutions at varying concentration levels without interposing a regeneration step. Usually, measurement is performed using the analyte at 5 or more concentrations (between 1/10 of K_D and $10 \times K_D$).

(2) Steady state analysis

If binding and dissociation take place rapidly, making kinetic analysis or model fitting difficult, steady state analysis is performed. The analyte injection is continued for a period of time until the analyte binding reaches equilibrium. The responses upon reaching equilibrium are recorded. Dissociation of the bound analyte is achieved by regeneration and the next analyte solution is measured. With this method, K_D is calculated as an analyte concentration which yields $1/2 R_{\max}$. Thus, the analyte concentration needs to be set so that binding to the ligand at the highest analyte concentration is close to saturation.

2.4.3. Measurement of concentration

If measurement is done under the conditions facilitating mass transport limitation, the linearity of the calibration curve is improved, allowing increased accuracy of measurement over a wide range. For this reason, the analyte is injected into the flow cell immobilized with a large amount of ligand, and binding is measured under this setting. Then, dissociation of the analyte is achieved by regeneration, and the next analyte solution is measured. A calibration curve is prepared from the results of measurement of the analyte at known concentration levels. Then, the analyte concentration is calculated. Another available method attempts to calculate the analyte concentration by making use of the proportional relationship between the analyte concentration and diffusion rate, without using a calibration curve.

3. Data analysis

When analysis is performed, the unnecessary part of the sensorgram (e.g., corresponding to capture of the ligand by the capturing molecule, and the regeneration step) is removed, and the response of the control flow cells is subtracted from the response of the ligand-bound flow cells. In addition, the sensorgram baseline is adjusted to 0. As needed, the sensorgram yielded by injection of the buffer for measurement alone is subtracted from the sensorgram yielded by analyte injection.

3.1. Analysis of binding affinity

(1) Kinetic analysis

Kinetic analysis is intended to calculate the parameters for the approximate formula (k_a , k_d , K_D , R_{max} , etc.) from the sensorgram with the use of the reaction rate equation derived from the ligand/analyte binding model. If the ligand binds to the analyte at a ratio of 1:1, the reaction rate equation for association phase is as follows:

$$dR/dt = k_a \times C \times (R_{max} - R) - k_d \times R$$

The reaction rate equation for the dissociation phase is as follows:

$$dR/dt = -k_d \times R$$

(C: analyte concentration; R: response).

A reaction rate equation involving a term corresponding to mass transport limitation or fluid effect can also be used.

The dissociation constant (K_D) serving as an indicator of binding affinity is defined as follows.

$$K_D = k_d/k_a$$

The reaction models employed for analysis of binding affinity include: ① a model of 1:1 ligand/analyte binding, ② a model of 2:1 ligand/analyte binding, like antigen/antibody binding, ③ a model of competitive binding of two analytes to the ligand, ④ a model of one analyte to the ligand possessing two binding sites of different affinity levels, and ⑤ a model of conformational change after 1:1 complex formation. A model theoretically considered as appropriate should be selected, with the results of other biochemical experiments being taken into account.

After the kinetic analysis, an evaluation is needed to determine the appropriateness of the fitting performed. This is accomplished by evaluating the residual plot between the sensorgram obtained and the theoretical curve, or statistical parameters such as χ^2 (mean squared residual, demonstrating the difference between the measured data and the calculated theoretical curve).

Poor fitting to the theoretical curve may be attributable to the following factors: (1) low purity of the reagent, (2) inappropriate method or density of immobilization, (3) inappropriate analyte concentration, (4) nonspecific binding, (5) reduced ligand activity, and (6) inappropriate selection of a reaction model. Thus, the conditions for measurement and the reaction model need to be reviewed. If the RI (refractive index) calculated as a response of the buffer components in the sample is excessively high during analysis of the data on reactions involving rapid binding/dissociation, fitting is performed by fixing the RI to 0. In the case of a poor fitting, the fit might be improved by setting the initial values close to the anticipated values of k_a and k_d .

(2) Steady state analysis

Steady state analysis is as follows. The response reaching equilibrium at each analyte concentration (Y axis) is plotted against the analyte concentration (X axis). Then, regression is performed using the following equation:

Steady state response equation:

$$\text{Equilibrium level at analyte concentration } R_{max} \\ = \text{analyte concentration} \times \frac{R_{max}}{\text{analyte concentration} + K_D}$$

In this way, the K_D shown by the response of $1/2 R_{max}$ is determined. The K_D calculated with this equation is the value when 1:1 ligand/analyte binding is assumed. If the actually measured response converges at R_{max} , good analysis is possible. However, if it is in a range lower than R_{max} , the analytical data are less reliable and it is desirable to repeat the measurement by expanding the range of measured concentrations to cover the higher concentration levels.

3.2. Measurement of concentration

From the sensorgram derived by injecting an analyte of known concentration, the slope of the sensorgram near the start of injection or the response at a certain time after starting the injection is determined and plotted against the analyte concentration. A calibration curve is prepared with an appropriate formula for approximation (e.g., the formula for 4-parameter logistic regression, linear regression). Then, the slope or the response is determined from measurement of the sample as an analyte, followed by calculation of the sample concentration from the calibration curve.

4. Application to various tests

4.1. Example of an application to the identification test

This test is aimed at confirming binding of the sample to the ligand by testing the specific binding as described in 2.4.1. To evaluate the system performance, measurement is performed on the reference material and a negative control (a substance distinguishable from the ligand in terms of the ligand-binding activity) to confirm the specificity of the binding.

4.2. Example of application to binding affinity test

This test is aimed at determining the K_D of the reference material and the sample, making use of the binding affinity analysis described in section 2.4.2. The criterion value related to the binding affinity may be set as the K_D or relative K_D (sample K_D /reference material K_D).

Regarding system suitability, the system performance and system repeatability are set. For example, concerning the system performance, it is confirmed that the ligand immobilization quantity is within the predetermined range; that the calculated K_D of known ligand-binding affinity samples is consistent with the order of affinity levels; and that χ^2 is not more than the predetermined level. System repeatability is confirmed by checking that the relative standard deviation for K_D during repeated measurement is not more than the predetermined level.

4.3. Example of application to measurement of specific activity based on the binding quantity to the target molecule

When specific activity is calculated with the quantity of binding to the target molecule, the measurement is performed using the concentration measuring method described in 2.4.3. On the basis of the calibration curve prepared from the reference material, the relative potency to the reference material is calculated using the data on the response of the sample solution, and then the potency is divided by the protein concentration to yield the specific activity.

Regarding system suitability, the system performance and system repeatability are confirmed. For example, concerning system performance, it is confirmed that the ligand immobilization quantity is within the predetermined range; and that the correlation coefficient or determination coefficient of the calibration curve is not less than the predetermined level. System repeatability is confirmed by checking that the

relative standard deviation of the response during repeated measurement is not more than the predetermined level.

Total Protein Assay

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia. The parts of the text that are not harmonized are marked with symbols (♦ ◆).

The following procedures are provided as illustrations of the determination of total protein content in pharmacopoeial preparations. Other techniques, such as HPLC, are also acceptable if total protein recovery is demonstrated. Many of the total protein assay methods described below can be performed successfully using kits from commercial sources.

Note: Where water is required, use distilled water.

Method 1 (UV method)

Protein in solution absorbs UV light at a wavelength of 280 nm, due to the presence of aromatic amino acids, mainly tyrosine and tryptophan. This property is the basis of this method. Protein determination at 280 nm is mainly a function of the tyrosine and tryptophan content of the protein. If the buffer used to dissolve the protein has a high absorbance relative to that of water, there is an interfering substance in the buffer. This interference can be compensated for when the spectrophotometer is adjusted to zero buffer absorbance. If the interference results in a large absorbance that challenges the limit of sensitivity of the spectrophotometer, the results may be compromised. Furthermore, at low concentrations protein can be absorbed onto the cuvette, thereby reducing the content in solution. This can be prevented by preparing samples at higher concentrations or by using a nonionic detergent in the preparation.

Note: Keep the Test Solution, the Standard Solution, and the buffer at the same temperature during testing.

Standard Solution Unless otherwise specified in the individual monograph, prepare a solution of the reference standard or reference material for the protein under test in the same buffer and at the same concentration as the Test Solution.

Test Solution Dissolve a suitable quantity of the protein under test in the appropriate buffer to obtain a solution having a concentration of 0.2 to 2 mg per mL.

Procedure Concomitantly determine the absorbances of the Standard Solution and the Test Solution in quartz cells at a wavelength of 280 nm, with a suitable spectrophotometer, using the buffer as the blank. To obtain accurate results, the response should be linear in the range of protein concentrations to be assayed.

Light-Scattering The accuracy of the UV spectroscopic determination of protein can be decreased by the scattering of light by the test specimen. If the proteins in solution exist as particles comparable in size to the wavelength of the measuring light (250 to 300 nm), scattering of the light beam results in an apparent increase in absorbance of the test specimen. To calculate the absorbance at 280 nm due to light-scattering, determine the absorbances of the Test Solution at wavelengths of 320, 325, 330, 335, 340, 345, and 350 nm. Using the linear regression method, plot the log of the observed absorbance versus the log of the wavelength, and determine the standard curve best fitting the plotted points. From the graph so obtained, extrapolate the absorbance value due to light-scattering at 280 nm. Subtract the absorbance from light-scattering from the total absorbance at 280 nm to obtain the absorbance value of the protein in solution.

Filtration with a filter having a 0.2- μ m porosity or clarification by centrifugation may be performed to reduce the effect of light-scattering, especially if the solution is noticeably turbid.

Calculations Calculate the concentration, C_U , of protein in the test specimen by the formula:

$$C_U = C_S (A_U/A_S),$$

in which C_S is the concentration of the Standard Solution; and A_U and A_S are the corrected absorbances of the Test Solution and the Standard Solution, respectively.

Method 2 (Lowry method)

This method, commonly referred to as the Lowry assay, is based on the reduction by protein of the phosphomolybdate-tungstic mixed acid chromogen in the Folin-Ciocalteu's phenol reagent, resulting in an absorbance maximum at 750 nm. The Folin-Ciocalteu's phenol reagent (Folin's TS) reacts primarily with tyrosine residues in the protein, which can lead to variation in the response of the assay to different proteins. Because the method is sensitive to interfering substances, a procedure for precipitation of the protein from the test specimen may be used. Where separation of interfering substances from the protein in the test specimen is necessary, proceed as directed below for Interfering Substances prior to preparation of the Test Solution. The effect of interfering substances can be minimized by dilution provided the concentration of the protein under test remains sufficient for accurate measurement. Variations of the Lowry test that are indicated in national regulatory documents¹⁾ can be substituted for the method described below.

Standard Solutions Unless otherwise specified in the individual monograph, dissolve the reference standard or reference material for the protein under test in the buffer used to prepare the Test Solution. Dilute portions of this solution with the same buffer to obtain not fewer than five Standard Solutions having concentrations between 5 and 100 μ g of protein per mL, the concentrations being evenly spaced.

Test Solution Dissolve a suitable quantity of the protein under test in the appropriate buffer to obtain a solution having a concentration within the range of the concentrations of the Standard Solutions. An appropriate buffer will produce a pH in the range of 10 to 10.5.

Blank Use the buffer used for the Test Solution and the Standard Solutions.

Reagents and Solutions—

Copper Sulfate Reagent Dissolve 100 mg of copper (II) sulfate pentahydrate and 200 mg of sodium tartrate dihydrate in water, dilute with water to 50 mL, and mix. Dissolve 10 g of anhydrous sodium carbonate in water to a final volume of 50 mL, and mix. Slowly pour the sodium carbonate solution into the copper sulfate solution with mixing. Prepare this solution fresh daily.

5% SDS TS Dissolve 5 g of sodium dodecyl sulfate in water, and dilute with water to 100 mL.

Alkaline Copper Reagent Prepare a mixture of 5% SDS TS, Copper Sulfate Reagent, and Sodium Hydroxide Solution (4 in 125) (2:1:1). This reagent may be stored at room temperature for up to 2 weeks.

Diluted Folin's TS Mix 10 mL of Folin's TS with 50 mL of water. Store in an amber bottle, at room temperature.

Procedure To 1 mL of each Standard Solution, the Test Solution, and the Blank, add 1 mL of Alkaline Copper Reagent, and mix. Allow to stand at room temperature for 10 minutes. Add 0.5 mL of the Diluted Folin's TS to each solution, and mix each tube immediately after the addition, and allow to stand at room temperature for 30 minutes. Deter-

mine the absorbances of the solutions from the Standard Solutions and the Test Solution at the wavelength of maximum absorbance at 750 nm, with a suitable spectrophotometer, using the solution from the Blank to set the instrument to zero.

Calculations [Note: The relationship of absorbance to protein concentration is nonlinear; however, if the standard curve concentration range is sufficiently small, it will approach linearity.] Using the linear regression method, plot the absorbances of the solutions from the Standard Solutions versus the protein concentrations, and determine the standard curve best fitting the plotted points. From the standard curve so obtained and the absorbance of the Test Solution, determine the concentration of protein in the Test Solution.

Interfering Substances In the following procedure, deoxycholate-trichloroacetic acid is added to a test specimen to remove interfering substances by precipitation of proteins before testing. This technique also can be used to concentrate proteins from a dilute solution.

Sodium Deoxycholate Reagent Prepare a solution of sodium deoxycholate in water having a concentration of 150 mg in 100 mL.

Trichloroacetic Acid Reagent Prepare a solution of trichloroacetic acid in water having a concentration of 72 g in 100 mL.

Procedure Add 0.1 mL of Sodium Deoxycholate Reagent to 1 mL of a solution of the protein under test. Mix on a vortex mixer, and allow to stand at room temperature for 10 minutes. Add 0.1 mL of Trichloroacetic Acid Reagent, and mix on a vortex mixer. Centrifuge at $3000 \times g$ for 30 minutes, decant the liquid, and remove any residual liquid with a pipet. Redissolve the protein pellet in 1 mL of Alkaline Copper Reagent. Proceed as directed for the Test Solution. [Note: Color development reaches a maximum in 20 to 30 minutes during incubation at room temperature, after which there is a gradual loss of color. Most interfering substances cause a lower color yield; however, some detergents cause a slight increase in color. A high salt concentration may cause a precipitate to form. Because different protein species may give different color response intensities, the standard protein and test protein should be the same.]

Method 3 (Bradford method)

This method, commonly referred to as the Bradford assay, is based on the absorption shift from 470 nm to 595 nm observed when Coomassie brilliant blue G-250 binds to protein. The Coomassie brilliant blue G-250 binds most readily to arginyl and lysyl residues in the protein, which can lead to variation in the response of the assay to different proteins.

Standard Solutions Unless otherwise specified in the individual monograph, dissolve the reference standard or the reference material for the protein under test in the buffer used to prepare the Test Solution. Dilute portions of this solution with the same buffer to obtain not fewer than five Standard Solutions having concentrations between 100 μ g and 1 mg of protein per mL, the concentrations being evenly spaced.

Test Solution Dissolve a suitable quantity of the protein under test in the appropriate buffer to obtain a solution having a concentration within the range of the concentrations of the Standard Solutions.

Blank Use the buffer used to prepare the Test Solution and the Standard Solutions.

Coomassie Reagent Dissolve 100 mg of Coomassie brilliant blue G-250² in 50 mL of ethanol (95). [Note: Not all dyes have the same brilliant blue G content, and different prod-

ucts may give different results.] Add 100 mL of phosphoric acid, dilute with water to 1000 mL, and mix. Filter the solution through filter paper (Whatman No.1 or equivalent), and store the filtered reagent in an amber bottle at room temperature. [Note: Slow precipitation of the dye will occur during storage of the reagent. Filter the reagent before use.]

Procedure Add 5 mL of the Coomassie Reagent to 100 μ L of each Standard Solution, the Test Solution, and the Blank, and mix by inversion. Avoid foaming, which will lead to poor reproducibility. Determine the absorbances of the solutions from the Standard Solutions and the Test Solution at 595 nm, with a suitable spectrophotometer, using the Blank to set the instrument to zero.

[Note: Do not use quartz (silica) spectrophotometer cells; the dye binds to this material. Because different protein species may give different color response intensities, the standard protein and test protein should be the same.] There are relatively few interfering substances, but detergents and ampholytes in the test specimen should be avoided. Highly alkaline specimens may interfere with the acidic reagent.

Calculations [Note: The relationship of absorbance to protein concentration is nonlinear; however, if the standard curve concentration range is sufficiently small, it will approach linearity.] Using the linear regression method, plot the absorbances of the solutions from the Standard Solutions versus the protein concentrations, and determine the standard curve best fitting the plotted points. From the standard curve so obtained and the absorbance of the Test Solution, determine the concentration of protein in the Test Solution.

Method 4 (Bicinchoninic acid method)

This method, commonly referred to as the bicinchoninic acid or BCA assay, is based on reduction of the cupric (Cu^{2+}) ion to cuprous (Cu^{+}) ion by protein. The bicinchoninic acid reagent is used to detect the cuprous ion. The method has few interfering substances. When interfering substances are present, their effect may be minimized by dilution, provided that the concentration of the protein under test remains sufficient for accurate measurement.

Standard Solutions Unless otherwise specified in the individual monograph, dissolve the reference standard or the reference material for the protein under test in the buffer used to prepare the Test Solution. Dilute portions of this solution with the same buffer to obtain not fewer than five Standard Solutions having concentrations between 10 and 1200 μ g of protein per mL, the concentrations being evenly spaced.

Test Solution Dissolve a suitable quantity of the protein under test in the appropriate buffer to obtain a solution having a concentration within the range of the concentrations of the Standard Solutions.

Blank Use the buffer used to prepare the Test Solution and the Standard Solutions.

Reagents and Solutions—

BCA Reagent Dissolve about 10 g of bicinchoninic acid, 20 g of sodium carbonate monohydrate, 1.6 g of sodium tartrate dihydrate, 4 g of sodium hydroxide, and 9.5 g of sodium hydrogen carbonate in water. Adjust, if necessary, with sodium hydroxide or sodium hydrogen carbonate to a pH of 11.25. Dilute with water to 1000 mL, and mix.

Copper Sulfate Reagent Dissolve about 2 g of copper (II) sulfate pentahydrate in water to a final volume of 50 mL.

Copper-BCA Reagent Mix 1 mL of Copper Sulfate Reagent and 50 mL of BCA Reagent.

Procedure Mix 0.1 mL of each Standard Solution, the Test Solution, and the Blank with 2 mL of the Copper-BCA Re-

gent. Incubate the solutions at 37°C for 30 minutes, note the time, and allow to come to room temperature. Within 60 minutes following the incubation time, determine the absorbances of the solutions from the Standard Solutions and the Test Solution in quartz cells at 562 nm, with a suitable spectrophotometer, using the Blank to set the instrument to zero. After the solutions are cooled to room temperature, the color intensity continues to increase gradually. If substances that will cause interference in the test are present, proceed as directed for Interfering Substances under Method 2. Because different protein species may give different color response intensities, the standard protein and test protein should be the same.

Calculations [Note: The relationship of absorbance to protein concentration is nonlinear; however, if the standard curve concentration range is sufficiently small, it will approach linearity.] Using the linear regression method, plot the absorbances of the solutions from the Standard Solutions versus the protein concentrations, and determine the standard curve best fitting the plotted points. From the standard curve so obtained and the absorbance of the Test Solution, determine the concentration of protein in the Test Solution.

Method 5 (Biuret method)

This method, commonly referred to as the Biuret assay, is based on the interaction of cupric (Cu^{2+}) ion with protein in an alkaline solution and the resultant development of absorbance at 545 nm.

Standard Solutions Unless otherwise specified in the individual monograph, prepare a solution of Albumin Human for which the protein content has been previously determined by nitrogen analysis (using the nitrogen-to-protein conversion factor of 6.25) or of the reference standard or reference material for the protein under test in sodium chloride solution (9 in 1000). Dilute portions of this solution with sodium chloride solution (9 in 1000) to obtain not fewer than three Standard Solutions having concentrations between 0.5 and 10 mg per mL, the concentrations being evenly spaced. [Note: Low responses may be observed if the sample under test has significantly different level of proline than that of Albumin Human. A different standard protein may be employed in such cases.]

Test Solution Prepare a solution of the test protein in sodium chloride solution (9 in 1000) having a concentration within the range of the concentrations of the Standard Solutions.

Blank Use sodium chloride solution (9 in 1000).

Biuret Reagent Dissolve about 3.46 g of copper (II) sulfate pentahydrate in 10 mL of water, with heating if necessary, and allow to cool (Solution A). Dissolve about 34.6 g of sodium citrate dihydrate and 20.0 g of anhydrous sodium carbonate in 80 mL of water, with heating if necessary, and allow to cool (Solution B). Mix Solutions A and B, and dilute with water to 200 mL. This Biuret Reagent is stable at room temperature for 6 months. Do not use the reagent if it develops turbidity or contains any precipitate.

Procedure To one volume of the Standard Solutions and a solution of the Test Solution add an equal volume of sodium hydroxide solution (6 in 100), and mix. Immediately add a volume of Biuret Reagent equivalent to 0.4 volume of the Test Solution, and mix. Allow to stand at a temperature between 15°C and 25°C for not less than 15 minutes. Within 90 minutes after the addition of the Biuret Reagent, determine the absorbances of the Standard Solutions and the solution from the Test Solution at the wavelength of maximum absorbance at 545 nm, with a suitable spectrophotometer,

using the Blank to set the instrument to zero. [Note: Any solution that develops turbidity or a precipitate is not acceptable for calculation of protein concentration.]

Calculations Using the least-squares linear regression method, plot the absorbances of the Standard Solutions versus the protein concentrations, and determine the standard curve best fitting the plotted points, and calculate the correlation coefficient for the line. [Note: Within the given range of the standards, the relationship of absorbance to protein concentration is approximately linear.] A suitable system is one that yields a line having a correlation coefficient of not less than 0.99. From the standard curve and the absorbance of the Test Solution, determine the concentration of protein in the test specimen, making any necessary correction.

Interfering Substances To minimize the effect of interfering substances, the protein can be precipitated from the initial test specimen as follows. Add 0.1 volume of 50% trichloroacetic acid to 1 volume of a solution of the test specimen, withdraw the supernatant layer, and dissolve the precipitate in a small volume of 0.5 mol/L sodium hydroxide TS. Use the solution so obtained to prepare the Test Solution.

Comments This test shows minimal difference between equivalent IgG and albumin samples. Addition of the sodium hydroxide and the Biuret Reagent as a combined reagent, insufficient mixing after the addition of the sodium hydroxide, or an extended time between the addition of the sodium hydroxide solution and the addition of the Biuret Reagent will give IgG samples a higher response than albumin samples. The trichloroacetic acid method used to minimize the effects of interfering substances also can be used to determine the protein content in test specimens at concentrations below 500 μ g per mL.

Method 6 (Fluorometric method)

This fluorometric method is based on the derivatization of the protein with *o*-phthalaldehyde (OPA), which reacts with the primary amines of the protein (i.e., NH₂-terminal amino acid and the ϵ -amino group of the lysine residues). The sensitivity of the test can be increased by hydrolyzing the protein before testing. Hydrolysis makes the α -amino group of the constituent amino acids of the protein available for reaction with the OPA reagent. The method requires very small quantities of the protein.

Primary amines, such as tris(hydroxymethyl)aminomethane and amino acid buffers, react with OPA and must be avoided or removed. Ammonia at high concentrations will react with OPA as well. The fluorescence obtained when amine reacts with OPA can be unstable. The use of automated procedures to standardize this procedure may improve the accuracy and precision of the test.

Standard Solutions Unless otherwise specified in the individual monograph, dissolve the reference standard or the reference material for the protein under test in the buffer used to prepare the Test Solution. Dilute portions of this solution with the same buffer to obtain not fewer than five Standard Solutions having concentrations between 10 and 200 μ g of protein per mL, the concentrations being evenly spaced.

Test Solution Dissolve a suitable quantity of the protein under test in the appropriate buffer to obtain a solution having a concentration within the range of the concentrations of the Standard Solutions.

Blank Use the buffer used to prepare the Test Solution and the Standard Solutions.

Reagents and Solutions—

Borate Buffer Dissolve about 61.83 g of boric acid in water, and adjust with potassium hydroxide to a pH of 10.4.

Dilute with water to 1000 mL, and mix.

Stock OPA Reagent Dissolve about 120 mg of *o*-phthalaldehyde in 1.5 mL of methanol, add 100 mL of Borate Buffer, and mix. Add 0.6 mL of polyoxyethylene (23) lauryl ether, and mix. This solution is stable at room temperature for at least 3 weeks.

OPA Reagent To 5 mL of Stock OPA Reagent add 15 μ L of 2-mercaptoethanol. Prepare at least 30 minutes prior to use. This reagent is stable for one day.

Procedure Adjust each of the Standard Solutions and the Test Solution to a pH between 8.0 and 10.5. Mix 10 μ L of the Test Solution and each of the Standard Solutions with 100 μ L of OPA Reagent, and allow to stand at room temperature for 15 minutes. Add 3 mL of 0.5 mol/L sodium hydroxide TS, and mix. Using a suitable fluorometer, determine the fluorescent intensities of solutions from the Standard Solutions and the Test Solution at an excitation wavelength of 340 nm and an emission wavelength between 440 and 455 nm. [Note: The fluorescence of an individual specimen is read only once because irradiation decreases the fluorescent intensity.]

Calculations The relationship of fluorescence to protein concentration is linear. Using the linear regression method, plot the fluorescent intensities of the solutions from the Standard Solutions versus the protein concentrations, and determine the standard curve best fitting the plotted points. From the standard curve so obtained and the fluorescent intensity of the Test Solution, determine the concentration of protein in the test specimen.

Method 7 (Nitrogen method)

This method is based on nitrogen analysis as a means of protein determination. Interference caused by the presence of other nitrogen-containing substances in the test protein can affect the determination of protein by this method. Nitrogen analysis techniques destroy the protein under test but are not limited to protein presentation in an aqueous environment.

Procedure A Determine the nitrogen content of the protein under test as directed elsewhere in the Pharmacopoeia. Commercial instrumentation is available for the Kjeldahl nitrogen assay.

Procedure B Commercial instrumentation is available for nitrogen analysis. Most nitrogen analysis instruments use pyrolysis (i.e., combustion of the sample in oxygen at temperatures approaching 1000°C), which produces nitric oxide (NO) and other oxides of nitrogen (NO_x) from the nitrogen present in the test protein. Some instruments convert the nitric oxides to nitrogen gas, which is quantified with a thermal conductivity detector. Other instruments mix nitric oxide (NO) with ozone (O₃) to produce excited nitrogen dioxide (NO₂) which emits light when it decays and can be quantified with a chemiluminescence detector. A protein reference standard or reference material that is relatively pure and is similar in composition to the test proteins is used to optimize the injection and pyrolysis parameters and to evaluate consistency in the analysis.

Calculations The protein concentration is calculated by dividing the nitrogen content of the sample by the known nitrogen content of the protein. The known nitrogen content of the protein can be determined from the chemical composition of the protein or by comparison with the nitrogen content of the appropriate reference standard or reference material.

- ♦1) Example: Minimum Requirements for Biological Products and individual monograph in JP.♦
- 2) Purity of the reagent is important.

G4 Microorganisms

Decision of Limit for Bacterial Endotoxins

The endotoxin limit for injections is to be decided as follows:

$$\text{Endotoxin limit} = K/M$$

where *K* is a threshold pyrogenic dose of endotoxin per kg body mass (EU/kg), and depending on the administration route, values for *K* are set as in the following table.

Intended route of administration	<i>K</i> (EU/kg)
Intravenous	5.0
Intravenous, for radiopharmaceuticals	2.5
Intraspinal	0.2

M is equal to the maximum bolus dose of product per kg body mass. When the product is to be injected at frequent intervals or infused continuously, *M* is the maximum total dose administered in a single hour period. *M* is expressed in mL/kg for products to be administered by volume, in mg/kg or mEq/kg for products to be administered by mass, and in Unit/kg for products to be administered by biological units. Notes:

- 1) For products to be administered by mass or by units, the endotoxin limit should be decided based on the labeled amount of the principal drug.
- 2) Sixty kg should be used as the average body mass of an adult when calculating the maximum adult dose per kg.
- 3) The pediatric dose per kg body mass should be used when this is higher than the adult dose.
- 4) The *K* values for the intravenous route are applicable to drugs to be administered by any route other than those shown in the table.

Disinfection and Decontamination Methods

This chapter describes procedures for reducing the number of microorganisms to a predetermined level using chemical agents during hygiene control of structures and facilities in clean areas or aseptic processing areas that require cleanliness control, as well as of personnel involved in manufacturing control and manufacturing operations in those areas, in pharmaceutical product manufacturing plants.

Appropriate action should be taken based on this chapter when performing microbiological tests specified in the monographs, when taking measures needed to prevent microbial contamination of products and materials used in the manufacture of pharmaceutical products, and when microbial control is needed in pharmacies.

1. Terms and Definitions

The terms used in this chapter are defined as follows.

- Microorganisms: Generally it is a term for bacteria, fungi, protozoa, viruses, and the like. In this chapter, the

term means bacteria and fungi.

- Disinfection: Generally it is a term for harmful microorganisms such as pathogens are removed, killed, or detoxified. In this chapter, the term means microorganisms on an object or in local areas such as the surface of an object are reduced.

- Decontamination: To reduce microorganisms in structures and facilities such as work space and work rooms to a predetermined microbial count level.

- Logarithmic reduction value: The difference in log values for microbial count before and after certain treatments.

- Disinfectant rotation: A disinfection program for when microorganisms that are resistant to a using disinfectant are discovered. In which a disinfectant with different efficacy is used until those microorganisms are no longer detected, or disinfectants with different mechanisms of action are alternately used for certain periods of time in turn. The effectiveness of this method should be evaluated before its implementation.

2. Disinfection Methods

This includes methods such as wiping, spraying, or immersion using chemical agents to reduce microorganisms on equipment, floors, walls, or containers that are carried into clean areas or aseptic processing areas, and the local surfaces such as the wrapping materials of environmental monitoring media. The disinfectants in Table 1 are commonly used, in single or in combination, upon due consideration of the nature of the surface to which the method is applied, such as corrosion by disinfectants, as well as the extent of contamination, such as the types and counts of microorganisms. Although this method does not kill or remove all microorganisms on an object or local surface, disinfectants of proven efficacy should be used when this method is employed. The effects of chemical agents used as disinfectants on microorganisms will differ depending on factors such as the applied concentration, temperature, contact time, and level of surface contamination. When using this method, attention should be paid to disinfectant expiration dates, microbial contamination, the effect of chemical residue on pharmaceutical product quality, and deterioration such as discoloration, deformation and corrosion of the materials being treated.

2.1. Disinfectants

Table 1 presents examples of commonly used disinfectants and their concentrations, and the microbial effects of these disinfectants. Disinfectants and concentrations proven to be safe and effective other than those shown here can also be used.

2.2. Evaluation Methods

When disinfection methods are applied to clean areas and aseptic processing areas, the effectiveness of the conditions should be checked upon due consideration of factors such as the disinfectant concentration, contact time, material of the surface being disinfected, and type of microorganisms that are to be reduced with the disinfectant. Examples of evaluation methods are provided below. Methods other than those shown in the examples may be used if they can be demonstrated to be scientifically appropriate.

2.2.1. Test Microorganism Suspension Method

The diluent that is actually used (purified water, tap water, etc.) should be used to adjust the disinfectant to the actually used concentration. Inoculate 1 mL of the prepared disinfectant with 10^5 to 10^6 CFU test microorganisms. Allow the disinfectant to take effect for the prescribed time (usually 5 to 15 minutes), then dilute or remove (filter) the disin-

Table 1 Types of disinfectants, concentrations, and mechanisms of action

Classification	Types of Disinfectant	Concentration	Mechanism of action
Oxidant	Peracetic acid	0.3 w/v%	Oxidizing action
	Hydrogen peroxide	3 w/v%	
	Sodium hypochlorite	0.02 to 0.05%	
Alcohol-based	Isopropanol	50 to 70%	Protein and nucleic acid denaturation
	Ethanol	76.9 to 81.4 vol%	
Surfactant-based	Benzalkonium chloride Benzethonium chloride	0.05 to 0.2%	Protein denaturation
	Alkyldiaminoethylglycine hydrochloride	0.05 to 0.5%	Cell membrane function impairment, protein coagulation/denaturation
Biguanide-based	Chlorhexidine gluconate	0.05 to 0.5%	Interruption of bacterial enzyme or alteration/disruption of cytoplasmic membrane

Table 2 Test microorganisms

Classification	Test microorganism
Bacteria	<i>Escherichia coli</i> ATCC 8739, NBRC 3972 <i>Staphylococcus aureus</i> ATCC 6538, NBRC 13276 <i>Pseudomonas aeruginosa</i> ATCC 9027, NBRC 13275 <i>Bacillus subtilis</i> ATCC 6633, NBRC 3134
Fungi	<i>Candida albicans</i> ATCC 10231, NBRC 1594 <i>Aspergillus brasiliensis</i> ATCC 16404, NBRC 9455

fectant. In the diluent or filtered wash solution, neutralize¹⁾ the disinfectant using a solution containing an inactivator such as lecithin, polysorbate 80, or sodium thiosulfate as needed. Count the number of the microorganisms used for inoculation and the number after disinfection under conditions meeting the requirements in Microbiological Examination of Non-sterile Products <4.05> I. 3.4 Suitability of the counting method in the presence of product. Calculate the logarithmic decrement from the test microorganism counts before and after disinfectant treatment. A 3 log or greater decrease in bacteria or fungi and a 2 log or greater decrease in spores will indicate that the disinfection of each target microorganism is effective. The required test microorganism species for evaluating efficacy should be selected with reference to Table 2. These test microorganisms should be used in the evaluation by being cultured and diluted under the conditions described in the Microbiological Examination of Non-sterile Products <4.05>. However, *Bacillus subtilis* should be used in the evaluation after a spore suspension has been pre-

Table 3 Examples of materials to be disinfected

Material	Example of application
Stainless steel	Workbenches, tanks, machines
Glass	Windows, screens
Polycarbonate	Screens, containers
Decorative calcium silicate board	Walls, ceiling
Epoxy resin coating	Floors
Vinyl chloride	Floors, curtains, vinyl bags
Rigid urethane rubber	Floors
Nitrile rubber	Gloves

pared with reference to Microbial Assay for Antibiotics <4.02>. Species that are suitable for the purpose of the test can be used.

2.2.2. Hard Surface Carrier Method

Prepare each type of surface material carrier (approximately 5 cm × 5 cm) in a quantity resulting in the appropriate precision. Inoculate a broad range of carriers with 10^5 to 10^6 CFU test microorganisms, allow to dry, and then add disinfectant dropwise in the actually used concentration. Allow the disinfectant to take effect for the prescribed time (usually 5 to 15 minutes), then collect the test microorganisms on the carriers by diluting in the collected solution. In the collected solution, neutralize¹⁾ the disinfectant using a solution containing an inactivator such as lecithin, polysorbate 80, or sodium thiosulfate as needed. The stomach method, shaking method, swab method, or the like can be used as the method of collection with reference to JIS T11737-1.²⁾ Count the number of the test microorganisms used for inoculation and the number of the recovered microorganisms under test conditions meeting the requirements in Microbiological Examination of Non-sterile Products <4.05> I. Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests, 3.4 Suitability of the counting method in the presence of product. Calculate the logarithmic decrement from the test microorganism counts before and after disinfectant treatment. Conditions showing the same results as the decreases specified in 2.2.1 Test Organism Suspension Method will indicate that the disinfection of each target microorganism is effective. In addition to the selection of the required test microorganism species for evaluating efficacy with reference to Table 2, one or two representative microorganisms which are frequently isolated in environmental monitoring should be added. Species that are suitable for the purpose of the test can be used. The test microorganisms should be cultured and diluted, etc., as specified in 2.2.1 Test Microorganism Suspension Method. Examples of various surface materials used in clean areas or aseptic processing areas are given in Table 3, but other materials can be added for evaluation as needed depending on the circumstances of actual use.

3. Decontamination Methods

In these methods, decontamination is achieved, for example, by vaporizing or spraying chemical agents to reduce the number of microorganisms to a predetermined level in isolators and RABS (restricted access barrier systems) employed in sterile pharmaceutical product manufacturing processes, or structures and facilities such as work spaces and work rooms in clean areas or aseptic processing areas.

When this method is applied to structures and facilities for manufacturing sterile pharmaceutical products, the efficacy of the decontaminants and decontamination conditions must

be validated, and worker safety must be ensured.

3.1. Decontaminants

Commonly used decontaminants are shown below. Decontaminants proven to be safe and effective other than those shown here can also be used.

3.1.1. Hydrogen Peroxide

Decontamination is achieved when hydrogen peroxide (30) is volatilized and allowed to spread. This is a method in which hydrogen peroxide that has been vaporized using a heater is allowed to spread inside an isolator or work room to kill microorganisms through the oxidative power of hydrogen peroxide. When a high degree of microbiological cleanliness must be achieved, as when decontaminating the interior of an isolator for sterilization operations, conditions should ensure a 6 log or greater decrease in the spores of the biological indicator, and when work rooms are decontaminated, conditions should ensure a 3 log or greater decrease. Although the method can be used at ambient temperature, the suitability of the method must be investigated beforehand because the potent oxidative power of hydrogen peroxide may cause deterioration such as discoloration, deformation, and corrosion of the materials exposed, depending on the nature of the materials, and the hydrogen peroxide itself may be degraded by the contact of the materials. If surfaces that are in contact with the product exist inside the isolator, it will be necessary to simultaneously decontaminate the interior and ensure the sterility assurance of the surfaces that are in contact with the product. In such cases, the pre-sterilization bioburden, parameters, utilities, and the like should be controlled in terms of the sterilization method with reference to the chapter "Sterilization Methods and Sterilization Indicators."

3.1.2. Peracetic Acid

Decontamination can be achieved, for example, when 0.2% peracetic acid aqueous solution is sprayed in the form of a mist and is allowed to spread. This method is used to clean work rooms, with conditions ensuring at least a 3 log decrease in the spores of the biological indicator. This is a method in which microorganisms are killed through the oxidative power of peracetic acid. Although the method can be used at ambient temperature, the suitability of the method must be investigated beforehand because the potent oxidative power of peracetic acid may result in deterioration such as discoloration, deformation, or corrosion of some materials.

3.1.3. Formaldehyde

Decontamination is achieved when formalin, an aqueous solution containing 36.0 to 38.0% formaldehyde, is vaporized by being heated, or when paraformaldehyde is sublimated by being heated, and allowed to spread. This is a method in which microorganisms are killed through the denaturation of protein by the aldehyde group (-CHO) in the formaldehyde molecule. This method is used to clean work rooms, with conditions ensuring at least a 3 log decrease in the spores of the biological indicator. As formaldehyde is harmful to the human body and has been designated a deleterious substance in the Poisonous and Deleterious Substances Control Act, it must be handled in work spaces equipped with a power exhaust device. It must also be detoxified when disposing of chemical waste.

3.2. Evaluation Methods

Methods using biological indicators to evaluate the effects of decontamination are generally used. Biological indicators that are resistant to decontaminants are commonly placed in various locations in structures and facilities such as work spaces and work rooms prior to decontamination. After decontamination, the biological indicators are commonly

collected and are cultured to check for survivor microorganisms. In addition to culturing, faster methods, for example, that are equal to or greater than culturing can be used. When the decontamination of an isolator with hydrogen peroxide needs to be verified by inactivating 6 log or greater spore count after the use of 10^6 CFU biological indicators, it is not necessary to demonstrate complete destruction of the spores in the isolator after decontamination. Decontamination conditions suitable for a 6 log reduction in spores can also be established by statistical analysis or a method for evaluating the effects of decontamination by collecting the biological indicator and counting the number of survivor microorganisms by culturing to calculate the logarithmic decrement of the biological indicator.

The spores of *Geobacillus stearothermophilus* ATCC 7953 and 12980 are known to be resistant to hydrogen peroxide and formaldehyde, and can thus be used as indicator organisms. As representative environmental microorganisms, the spores of *Bacillus atrophaeus* ATCC 9372 can also be used as a biological indicator for the decontamination of work rooms.

4. Points to Consider

4.1. Worker Safety

Disinfectants and decontaminants often have an effect on the human body. That is, they are toxic. Therefore, when they are used, the method and amounts used must be strictly observed, protective gear must be properly used as needed, and the residue level must be checked.

4.2. Selection of Disinfectants and Decontaminants Used in Pharmaceutical Product Manufacturing Environments

When selecting disinfectants and decontaminants to be used in pharmaceutical product manufacturing environments, the following should be taken into consideration to select the appropriate ones depending on the purpose for which they are being used. The following items (1) through (13) must also be taken into consideration in order to ensure safer and more appropriate use of disinfectants and decontaminant.

- (1) Type and number of microorganisms to be treated
- (2) Antimicrobial spectrum
- (3) Method of use, concentration, contact time, and expiration period of chemical agents
- (4) Method for preparing decontaminant, including sterilization, when used in aseptic processing areas
- (5) Suitability of materials being treated with disinfectants and decontaminants (such as extent of deterioration)
- (6) Effects in the presence of organic substances such as protein
- (7) Effective time duration
- (8) Effect on human body (safety)
- (9) Suitability with cleansers
- (10) Necessity of disinfectant rotation, and the method, if needed
- (11) Necessary procedures for preventing contamination of pharmaceutical products by chemical agents (such as method of inactivation and checking residue level)
- (12) Ease of waste disposal (neutralization, inactivation)
- (13) Environmental effects of waste disposal

References

- 1) US Pharmacopeia 37 (2014), <1072> DISINFECTANTS AND ANTISEPTICS
- 2) Japanese Industrial Standards JIS T 11737 – 1 (2013), Sterilization of medical devices—Microbiological methods, Part 1: Determination of a population of

microorganisms on products (ISO 11737 – 1: 2006)

Media Fill Test (Process Simulation)

The media fill test is one of the process validations employed to evaluate the propriety of the aseptic processing of pharmaceutical products using sterile media, etc. instead of actual products. Therefore, media fill should be conducted under conditions that simulate routine manufacturing procedures, e.g. filling and sealing, operating environment, processing operation, number of personnel involved, etc., and include permissible worst case conditions. Process simulation can be applied to the other aseptic manufacturing processes in addition to aseptic manufacturing processes for finished drug products such as “filling” and “sealing”.

1. Frequency of media fills

1.1. Initial performance qualification

Initial performance qualification should be conducted for each new facility, item of equipment, filling line, and container design (except for multiple sizes of the same container design), etc. As referring to Table 1, a sufficient number of units should be used to simulate aseptic manufacturing process. A minimum of three consecutive separate successful runs should be performed on each separate day. However, the action as shown in Table 1 may be performed at the time when the contamination is found.

1.2. Periodic performance requalification

1) As referring to Table 2, a sufficient number of units should be used to simulate aseptic manufacturing process. Media fill run should be conducted at least on semi-annual base for each shift and processing line. All personnel working in the critical processing area should be trained about aseptic processing and participate in a media fill run at least once a year.

2) When filling lines have not been used for over six months, conduct appropriate numbers of media fill runs in the same way as for the initial performance qualification prior to the use of the filling lines.

3) In cases of facility and equipment modification (interchanging standard parts may not require requalification),

Table 1 Initial performance qualification

Minimum number of simulations	Number of units filled per simulation	Contaminated units in any of the three simulations	Action
3	< 5000	≥ 1	Investigation, corrective measures, restart validation
3	5000 – 10000	1	Investigation, consideration of repeat of one media fill
		> 1	Investigation, corrective measures, restart validation
3	> 10000	1	Investigation
		> 1	Investigation, corrective measures, restart validation

Table 2 Periodic performance requalification

Minimum number of simulations	Number of units filled per simulation	Contaminated units	Action
Every half year	< 5000	1	Investigation, revalidation
		1	Investigation, consideration of repeat media fill
	5000 – 10000	> 1	Investigation, corrective measures, revalidation
		1	Investigation
	> 10000	> 1	Investigation, corrective measures, revalidation

major changes in personnel working in critical aseptic processing, anomalies in environmental monitoring results, or a product sterility test showing contaminated products, conduct appropriate numbers of media fill runs in the same way as for the initial performance qualification prior to the scheduled media fills.

2. Acceptance criteria of media fills

Both in initial performance qualification and periodic performance qualification, the target should be zero growth regardless of number of units filled per simulation. Where contaminated units are found, action shown in Tables 1 and 2 should be taken.

2.1. Investigation of positive units

Where contaminated units are found in media fill, an investigation should be conducted regarding the cause, taking into consideration the following points:

- 1) Microbial monitoring data
- 2) Particulate monitoring data
- 3) Personnel monitoring data (microbial monitoring data on gloves, gowns, etc. at the end of work)
- 4) Sterilization cycle data for media, commodities, equipment, etc.
- 5) Calibration data of sterilization equipment
- 6) Storage conditions of sterile commodities
- 7) HEPA filter evaluation (integrity tests, velocity, etc.)
- 8) Pre and post filter integrity test data (including filter housing assembly)
- 9) Air flow patterns and pressures
- 10) Unusual events that occurred during the media fill run
- 11) Characterization of contaminants
- 12) Hygienic control and training programs
- 13) Gowning procedures and training programs
- 14) Aseptic processing technique and training programs
- 15) Operator's health status (especially coughing, sneezing, etc., due to respiratory diseases)
- 16) Other factors that affect sterility

3. Data guidance for media fills

Each media fill run should be fully documented and the following information recorded:

- 1) Data and time of media fill
- 2) Identification of filling room and filling line used
- 3) Container/closure type and size
- 4) Volume filled per container

- 5) Filling speed
- 6) Filter type and integrity test result (in case of filtration)
- 7) Type of media filled
- 8) Number of units filled
- 9) Number of units not incubated and reason
- 10) Number of units incubated
- 11) Number of units positive
- 12) Incubation time and temperature
- 13) Procedures used to simulate any step of a normal production fill (e.g., mock lyophilization or substitution of vial headspace gas)
- 14) Microbiological monitoring data obtained during the media fill set-up and run
- 15) List of personnel who took part in the media fill
- 16) Growth promotion results of the media (in case of powder fill, an antimicrobial activity test for the powder is necessary)
- 17) Identification and characterization of the microorganisms from any positive units
- 18) Product(s) covered by the media fill
- 19) Investigation of runs with a positive unit or failed runs
- 20) Management review

4. Media fill procedures

Methods to validate aseptic processing of liquid, powder and freeze-dried products are described. Basically, it is possible to apply media fill procedures for liquid products to other dosage forms.

4.1. Media selection and growth promotion

Soybean-casein digest medium or other suitable media are used. When strains listed in the Microbiological Examination of Non-sterile Products <4.05> and, if necessary, one or two representative microorganisms which are frequently isolated in environmental monitoring are inoculated under the specified conditions, each strain should show obvious growth.

4.2. Sterile medium preparation

The medium is sterilized according to the pre-validated method.

4.3. Incubation and inspection of media filled units

Leaking or damaged units should be removed and recorded prior to incubation of media filled units. Units should be incubated at 20 – 35°C for not less than 14 days. The use of another temperature range should be justified. If two temperatures are used for incubation, the units are typically incubated for at least 7 days at each temperature starting with the lower temperature. Established temperature should be kept within $\pm 2.5^{\circ}\text{C}$. Observe the media filled units for growth of microorganisms on the last day of the incubation. Microorganisms in contaminated units should be followed to identification and characterization. For the identification of contaminants, "Rapid Identification of Microorganisms Based on Molecular Biological Method" shown in General Information or appropriate commercial kit for identification of microorganisms may be applicable.

A. Liquid products

Media fill procedure

Media fill should include normal facility/equipment operations and clean-up routines. Containers, closures, parts of the filling machine, trays, etc. are washed and sterilized according to the standard operating procedures. Media fills should be conducted under processing conditions that include "worst case" conditions, e.g., correction of line stoppage, repair or replacement of filling needles/tubes, replacement of on-line filters, permitted interventions, duration and

size of run, number of personnel involved, etc.

It is not necessary to put all worst-case scenarios in a single media fill run, but all worst-case scenarios should be evaluated intentionally. While advanced processing lines are highly automated, often operated at relatively high speeds, and are designed to limit operator intervention, there are processing lines showing frequent human interventions. Although the most accurate simulation model would be the full batch size and duration because it most closely simulates the actual production run, other appropriate models can be justified.

An appropriate volume of medium is filled into sterilized containers at a predetermined filling speed and the containers are sealed. The media are contacted with all interior surfaces in the containers by an appropriate method, and then incubated at the predetermined temperature.

B. Powder products

B.1 Powder selection and antimicrobial activity test

Actual products or placebo powder are used. In general, lactose monohydrate, D-mannitol, polyethylene glycol 6000, carboxymethyl cellulose salts or media powder, etc. are used as placebo powders. Prior to employing any of the powders, evaluate whether the powder has antimicrobial activity. Media powders are dissolved in water and other powders in liquid medium, and the solutions are inoculated with less than 100 CFU microorganisms of each kind, shown in 4.1, for the growth promotion test. If obvious growth appears in the medium incubated at the predetermined temperature for 5 days, the powder has no antimicrobial activity and is available for the media fill test.

B.2 Sterilization of powders

Powders are bagged in suitable containers (e.g. double heat-sealed polyethylene bags), and are subjected to radiation sterilization.

B.3 Sterility of filling powders

The powders must pass the Sterility Test. However, if the sterilization is fully validated, sterility testing of the powders can be omitted.

B.4 Media fill procedures

Choose a suitable procedure from among the following procedures.

1) Fill sterilized liquid media into containers by suitable methods, and then fill actual products or sterilized placebo powder with the powder filling machine. If sterilized powder media are used as a placebo powder, fill sterilized water instead of sterilized liquid media.

2) Distribute liquid media into containers, and then sterilize them in an autoclave. Remove the containers to the filling area, and then fill actual products or sterilized placebo powder into the containers with the powder filling machine.

3) Fill actual products or sterilized placebo powder into containers with the powder filling machine, and then fill sterilized liquid media into the containers by appropriate methods. If sterilized powder media are used as a placebo powder, fill sterilized water instead of sterilized liquid media.

C. Lyophilized products

In the case of lyophilized products, it may be impossible to conduct a media fill run in the same way as used for actual processing of lyophilized products. The process of freezing and lyophilization of the solution may kill contaminant organisms and change the characteristics of the media too. The use of inert gas as a blanket gas may inhibit the growth of aerobic bacteria and fungi. Therefore, in general, the actual freezing and lyophilization process should be avoided and air is used as the blanket gas. For products manufactured under

an anaerobic atmosphere, process simulation should be performed with the use of anaerobic growth media and the inert gas such as nitrogen gas.

Media fill procedures

Use the following method or other methods considered to be equivalent to these methods.

1) After filling of the media into containers by the filling machine, cap the containers loosely and collect them in pre-sterilized trays.

2) After placing the trays in the lyophilizer, close the chamber door, and conduct lyophilization according to the procedures for production operation. Hold them without freezing and boiling-over under weak vacuum for the predetermined time.

3) After the vacuum process, break the vacuum, and seal the stoppers.

4) Contact the media with all product contact surfaces in the containers by appropriate methods, and then cultivate them at the predetermined temperature.

References

ISO 13408-1 (2008): Aseptic processing of health care products: General requirements.

Microbial Attributes of Non-sterile Pharmaceutical Products

This chapter is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia. The parts of the text that are not harmonized are marked with symbols (♦ ◆).

The presence of certain micro-organisms in non-sterile preparations may have the potential to reduce or even inactivate the therapeutic activity of the product and has a potential to adversely affect the health of the patient. Manufacturers have therefore to ensure a low bioburden of finished dosage forms by implementing current guidelines on Good Manufacturing Practice during the manufacture, storage and distribution of pharmaceutical preparations. ♦ This chapter provides guidelines for acceptable limits of viable micro-organisms (bacteria and fungi) existing in raw materials and non-sterile pharmaceutical products.◆ Microbial examination of non-sterile products is performed according to the methods given in the Microbiological Examination of Non-sterile Products <4.05> on Microbiological Examination of Non-sterile Products: I. Microbial Enumeration Tests and II. Tests for Specified Micro-organisms. ♦ When these tests are carried out, a microbial control program must be established as an important part of the quality management system of the product. Personnel responsible for conducting the tests should have specialized training in microbiology, biosafety measures and in the interpretation of the testing results.◆

♦1. Definitions

(i) Non-sterile pharmaceutical products: Non-sterile drugs shown in monographs of the JP and non-sterile finished dosage forms.

(ii) Raw materials: All materials, including raw ingredients and excipients, used for the preparation of drugs, except for water and gases.

(iii) Bioburden: Number and type of viable micro-organisms existing in non-sterile pharmaceutical products.

(iv) Action levels: Established bioburden levels that require immediate follow-up and corrective action if they are exceeded.

(v) Alert levels: Established bioburden levels that give early warning of a potential drift from normal bioburden level, but which are not necessary grounds for definitive corrective action, though they may require follow-up investigation.

(vi) Quality management system: The procedures, operation methods and organizational structure of a manufacturer (including responsibilities, authorities and relationships between these) needed to implement quality management.

2. Scope

In general, Microbial Enumeration Tests is not applied to drugs containing viable micro-organisms as an active ingredient.

3. Sampling plan and frequency of testing

3.1. Sampling methods

Microbial contaminants are usually not uniformly distributed throughout the batches of non-sterile pharmaceutical products or raw materials. A biased sampling plan, therefore, cannot be used to estimate the real bioburden in the product. A sampling plan which can properly reflect the status of the product batch should be established on the basis of the bioburden data obtained by retrospective validation and/or concurrent validation. In general, a mixture of samples randomly taken from at least different three portions, almost the same amount for each portion, is used for the tests of the product. When the sampling is difficult in a clean area, special care is required during sampling to avoid introducing microbial contamination into the product or affecting the nature of the product bioburden. If it is confirmed that the product bioburden is stable for a certain period, as in the case of non-aqueous or dried products, it is not necessary to do the tests, immediately after the sampling.

3.2. Testing frequency

The frequency of the tests should be established on the basis of a variety of factors unless otherwise specified. These factors include:

- (i) Dosage forms of non-sterile pharmaceutical products (usage);
- (ii) Manufacturing processes;
- (iii) Manufacturing frequency;
- (iv) Characteristics of raw materials (natural raw material, synthetic compound, etc.);
- (v) Batch sizes;
- (vi) Variations in bioburden estimates (changes in batches, seasonal variations, etc.);
- (vii) Changes affecting the product bioburden (changes in manufacturing process, supplier of raw materials, batch number of raw materials, etc.);
- (viii) Others.

In general, the tests may be performed at a high frequency during the initial production of a drug to get information on the microbiological attributes of the product or raw materials used for the production. However, this frequency may be reduced as bioburden data are accumulated through retrospective validation and/or concurrent validation. For example, the tests may be performed at a frequency based on time (e.g., weekly, monthly or seasonally), or on alternate batches.

4. Microbial control program

When the "Microbiological Examination of Non-sterile Products <4.05>" is applied to a non-sterile pharmaceutical product, the methods for the recovery, cultivation and estimation of the bioburden from the product must be validated and a "Microbial control program" covering the items listed below must be prepared.

- (i) Subject pharmaceutical name (product name);
- (ii) Frequency of sampling and testing;
- (iii) Sampling methods (including responsible person, quantity, environment, etc. for sampling);
- (iv) Transfer methods of the samples to the testing area (including storage condition until the tests);
- (v) Treatment of the samples (recovery methods of microbial contaminants);
- (vi) Enumeration of viable micro-organisms (including testing quantity, culture media, growth-supporting test of the media, culturing methods, etc.);
- (vii) Detection of specified micro-organisms (including testing quantity, culture media, growth-supporting test of the media, culturing methods, etc.);
- (viii) Estimation of the number of and characterization of microbial contaminants;
- (ix) Establishment of "Microbial acceptance criteria" (including alert level and action level);
- (x) Actions to be taken when the levels exceed "Microbial acceptance criteria";
- (xi) Persons responsible for the testing and evaluation, etc.;
- (xii) Other necessary items.♦

5. Microbial acceptance criteria for non-sterile pharmaceutical products

By establishing "Microbial acceptance criteria" for non-sterile pharmaceutical products based upon the total aerobic microbial count (TAMC) and the total combined yeasts/moulds count (TYMC), ♦ it is possible to evaluate at the initial processing stage of the product whether the microbiological quality of the raw materials is adequate or not. Furthermore, it is then possible to implement appropriate corrective action as needed to maintain or improve the microbiological quality of the product.♦ The target limits of microbial levels for raw materials (synthetic compounds and minerals) are shown in Table 1.

♦In general, synthetic compounds have low bioburden levels due to the high temperatures, organic solvents, etc., used in their manufacturing processes. Raw materials originated from plants and animals in general have higher bioburdens than synthetic compounds.

The microbial quality of the water used in the processing of active ingredients or non-sterile pharmaceuticals may have a direct effect on the quality of the finished dosage form. This means it is necessary to keep the level of microbial contaminants in the water as low as possible.♦

Acceptance criteria for microbiological quality for non-sterile finished dosage forms are shown in Table 2. ♦These microbial limits are based primarily on the type of dosage form, water activity, and so on. For oral liquids and pharmaceutical products having a high water activity, in general, low microbial acceptance criteria are given.♦

Table 2 includes a list of specified micro-organisms for which acceptance criteria are set. The list is not necessarily

Table 1 Acceptance criteria for microbiological quality of non-sterile substances for pharmaceutical use

Substances for pharmaceutical use	Total Aerobic Microbial Count (CFU/g or CFU/mL)	Total Combined Yeasts/Moulds Count (CFU/g or CFU/mL)
	10^3	10^2

Table 2 Acceptance criteria for microbiological quality of non-sterile dosage forms

Route of administration	Total Aerobic Microbial Count (CFU/g or CFU/mL)	Total Combined Yeasts/Moulds Count (CFU/g or CFU/mL)	Specified Micro-organism
Non-aqueous preparations for oral use	10^3	10^2	Absence of <i>Escherichia coli</i> (1 g or 1 mL)
Aqueous preparations for oral use	10^2	10^1	Absence of <i>Escherichia coli</i> (1 g or 1 mL)
Rectal use	10^3	10^2	—
Oromucosal use	10^2	10^1	Absence of <i>Staphylococcus aureus</i> (1 g or 1 mL)
Gingival use			Absence of <i>Pseudomonas aeruginosa</i> (1 g or 1 mL)
Cutaneous use			Absence of <i>Pseudomonas aeruginosa</i> (1 g or 1 mL)
Nasal use			Absence of <i>Candida albicans</i> (1 g or 1 mL)
Auricular use			
Vaginal use	10^2	10^1	Absence of <i>Pseudomonas aeruginosa</i> (1 g or 1 mL)
			Absence of <i>Staphylococcus aureus</i> (1 g or 1 mL)
			Absence of <i>Candida albicans</i> (1 g or 1 mL)
Transdermal patches (limits for one patch including adhesive layer and backing)	10^2	10^1	Absence of <i>Staphylococcus aureus</i> (1 patch)
			Absence of <i>Pseudomonas aeruginosa</i> (1 patch)
Inhalation use (more rigorous requirements apply to liquid preparations for nebulization)	10^2	10^1	Absence of <i>Staphylococcus aureus</i> (1 g or 1 mL)
			Absence of <i>Pseudomonas aeruginosa</i> (1 g or 1 mL)
			Absence of bile-tolerant gram-negative bacteria (1g or 1 mL)

Table 3 Acceptance criteria for crude drugs and crude drug-containing preparations

	Total Aerobic Microbial Count (CFU/g or CFU/mL)	Total Combined Yeasts/Moulds Count (CFU/g or CFU/mL)	Specified Micro-organism
Category 1	Acceptance criterion: 10^7 Maximum limit: 50,000,000	Acceptance criterion: 10^5 Maximum limit: 500,000	Acceptance criterion for <i>Escherichia coli</i> : 10^3 (1 g or 1 mL) Absence of <i>Salmonella</i> (10 g or 10 mL)
Category 2	Acceptance criterion: 10^5 Maximum limit: 500,000	Acceptance criterion: 10^4 Maximum limit: 50,000	Acceptance criterion for bile-tolerant gram-negative bacteria: 10^4 (1 g or 1 mL) Absence of <i>Escherichia coli</i> (1 g or 1 mL) Absence of <i>Salmonella</i> (10 g or 10 mL)

exhaustive and for a given preparation it may be necessary to test for other micro-organisms depending on the nature of the starting materials and the manufacturing process.

If it has been shown that none of the prescribed tests will allow valid enumeration of micro-organisms at the level prescribed, a validated method with a limit of detection as close as possible to the indicated acceptance criterion is used.

In addition to the micro-organisms listed in Table 2, the significance of other micro-organisms recovered should be evaluated in terms of:

- the use of the product: hazard varies according to the route of administration (eye, nose, respiratory

- tract);
 - the nature of the product: does the product support growth, does it have adequate antimicrobial preservation?
 - the method of application;
 - the intended recipient: risk may differ for neonates, infants, the debilitated;
 - use of immunosuppressive agents, corticosteroids;
 - presence of disease, wounds, organ damage.
- Where warranted, a risk-based assessment of the relevant factors is conducted by personnel with specialized training in microbiology and the interpretation of microbiological data.

For raw materials, the assessment takes account of processing to which the product is subjected, the current technology of testing and the availability of materials of the desired quality. Acceptance criteria are based on individual results or on the average of replicate counts when replicate counts are performed (e.g. direct plating methods).

When an acceptance criterion for microbiological quality is prescribed it is interpreted as follows:

- 10^1 CFU: maximum acceptable count = 20,
- 10^2 CFU: maximum acceptable count = 200,
- 10^3 CFU: maximum acceptable count = 2000, and so forth.

♦6. Acceptance criteria for crude drugs and crude drug-containing preparations

Target limits of microbial contamination for crude drugs and crude drug-containing preparations are shown in Table 3. Category 1 includes crude drugs and crude drug preparations which are used for extraction by boiling water or to which boiling water is added before use. Category 2 includes crude drugs which are taken directly without extraction process and directly consumed crude drug preparations containing powdered crude drugs. In this guideline, bile-tolerant gram-negative bacteria, *Escherichia coli* and *Salmonella* are mentioned as specified micro-organisms, but other micro-organisms (such as certain species of *Bacillus cereus*, *Clostridia*, *Pseudomonas*, *Burkholderia*, *Staphylococcus aureus*, *Aspergillus* and *Enterobacter* species) are also necessary to be tested depending on the origin of raw materials for crude drugs or the preparation method of crude drug-containing preparations. The target limit of microbial contamination for the raw materials is to be set based on the risk assessment being taken into account the provided process of those materials or the desired quality specification for them.♦

Microbiological Environmental Monitoring Methods of Processing Areas for Sterile Pharmaceutical Products

This chapter describes the methods for the evaluation of air-cleanliness and the recommended limits for environmental microorganisms. The main purposes of this chapter are 1) to confirm that the designed cleanliness levels and microbial limits are attained and maintained in processing areas for sterile pharmaceutical products, and 2) to confirm that the number of particulates and microorganisms are appropriately controlled in the processing environment for sterile pharmaceuticals.

In reference to the evaluation methods and the recommended limits described in this chapter, a risk assessment should be performed for each manufacturing facility and acceptance criteria should be established based on the identified risks. Alternative measuring methods can be applied on rational grounds.

1. Definitions

For the purposes of this chapter, the following definitions apply:

- (i) Action level: An established number of objects to be monitored (and species of microorganisms, if appropriate) that requires immediate investigation and corrective action based on the investigation when exceeded.
- (ii) Alert level: An established number of objects to be monitored (and species of microorganisms, if appropriate)

that gives early warning of potential problems.

- (iii) Aseptic processing: Filling of sterile products and other operations performed under the environmental conditions in which air supply, materials, equipment, and personnel are regulated to control microbial and particulate contamination to acceptable levels.
- (iv) Aseptic processing area: The classified part of a facility in which air supply, materials, equipment, and personnel are highly regulated to control microbial and particulate contamination to acceptable levels. The area is classified into two categories: Grade A and Grade B.
- (v) Microorganisms: General term for bacteria, fungi, protozoa, viruses, etc. In this chapter, microorganisms indicate only bacteria and fungi.
- (vi) Shift: Scheduled period of work or production during which operations are conducted by a single or defined group of workers.
- (vii) Risk assessment: A series of processes including identification, analysis, and evaluation of hazards that may cause harm in accordance with ICH Q9, "Quality Risk Management." In this chapter, "harm" indicates contamination of products or manufacturing areas; "hazards" indicates possible causes of the contamination, such as personnel, environment, or operations carried out. Risk is expressed as a combination of the probable incidence and severity of the harm.
- (viii) Calibration: The act of establishing the relationship between values indicated by a measuring instrument and the values represented by a material measure, by comparison with the corresponding known values of a standard instrument or a standard reference material and of adjusting the accuracy of the measuring instrument for the proper use.
- (ix) At rest: The state in which production equipment is installed and operating, with no operating personnel present.
- (x) In operation: The state in which the installed equipment is functioning in the defined operating mode with the specified number of personnel working.

2. Processing areas

Processing areas refer to areas in which actions such as cultivation, extraction/purification, washing and drying of containers and stoppers, weighing of raw materials, preparation of solutions, sterilization, filling, sealing, and packaging are performed, including the gowning area.

The processing areas for sterile pharmaceutical products are maintained and controlled to prevent containers, raw materials, and in-process products from microbial and particulate contamination.

Personnel engaged in such activities in the areas should receive necessary training in hygiene, microbiology, manufacturing technology, and clothing.

2.1. Classification of processing areas

- (i) Grade A: A local area in which operational activities to prevent contamination risks of products at a high level are conducted. For pharmaceutical products prepared aseptically, the area is designed to preserve sterility of sterilized pharmaceutical products, containers, and closures that are exposed within it. In this area, manipulations of sterile materials prior to filling operation (e.g. aseptic connections, sterile ingredient additions), filling, and closing operations are conducted.
- (ii) Grade B: A multipurpose area in which operational activities to prevent contamination risks of products at a comparably high level are conducted. For pharmaceutical products prepared aseptically, the area is used as a route to load sterilized containers, raw materials, and in-process products that are stored to preserve sterility. Areas in which

personnel, equipment and apparatuses that directly come into aseptic processing areas exist are also classed as Grade B. In a general clean room, this is the surrounding environment for the Grade A area. When contamination risks of microorganisms derived from the environment are low, for example, where isolators are installed so that the levels of human intervention and exposure are low, the surrounding area does not necessarily qualify as Grade B.

(iii) Grades C, D: Areas to prevent contamination risks of products at a comparably low level. Activities conducted in such areas include operational activities of non-sterile containers, raw materials, and in-process products that are exposed to the surrounding environment, and cleaning of equipment and apparatuses for aseptic processing. When contamination risks of microorganisms derived from the environment are low, for example, where isolators are installed so that the levels of human intervention and the exposure are low, these areas can be used as the surrounding areas.

2.2. Environmental control level by processing area

Airborne particulates in areas used for processing of pharmaceutical products may be a key indicator to monitor performance of air-conditioning systems. They may act physically as a source of insoluble particulates in the products, and biologically as a carrier of microorganisms.

In areas used for the processing of pharmaceutical products, therefore, the number of airborne particulates, as well as the number of microorganisms, should be controlled within the specified limits. Air volume, airflow pattern, frequency of ventilation, and material and personnel flow are appropriately designed so that airborne particulates that exist in the areas can be effectively discharged.

The air-cleanliness and the recommended limits for en-

vironmental microorganisms for each grade area are shown in Table 1 and Table 2.

Compared with the classifications in ISO/DIS 14644-1 (2010), the maximum number of airborne particulates in Grade A, B, and C (in operation) are almost identical to those of ISO 5, ISO 7, and ISO 8, respectively.

When the number of sampling points is determined in order to classify manufacturing areas based on the defined cleanliness levels, Table 3 can be used as a reference. Sampling points that are evenly distributed throughout the area to be monitored should be selected. The height at which operational activities are conducted in the area should be also considered. Addition of sampling points can also be effective, based on the risks.

The sampling points specified in ISO/DIS 14644-1 (2010) are shown in Table 3.

Table 3 Minimum sampling points based on an area of clean rooms

Area of clean rooms (m ²) equal to or less than	Minimum sampling points
1	1
2	1
4	2
6	3
8	4
10	5
24	6
28	7
32	8
36	9
52	10
56	11
64	12
68	13
72	14
76	15
104	16
108	17
116	18
148	19
156	20
192	21
232	22
276	23
352	24
436	25
500	26

Table 1 Air-cleanliness

Grade	Maximum permitted number of airborne particulates (number/m ³)			
	at rest* ¹		in operation	
Size	≥0.5 μm	≥5.0 μm	≥0.5 μm	≥5.0 μm
A	3520	20	3520	20
B	3520	29	352000	2900
C	352000	2900	3520000	29000
D	3520000	29000* ²* ²

*¹ The number of particulates given in the table for the “at rest” condition should be achieved 15 – 20 minutes after the completion of operations.

*² The number will depend on the nature of the operation carried out.

Table 2 Recommended limits for environmental microorganisms (in operation)*¹

Grade	Airborne microorganisms		Microorganisms on surfaces	
	air sample (CFU/m ³)	settle plates* ² (CFU/plate)	contact plates	gloves
			(CFU/24 – 30 cm ²)	(CFU/5 fingers)
A	<1	<1	<1	<1
B	10	5	5	5
C	100	50	25
D	200	100	50

*¹ These are average values.

*² The exposure time of each plate should be less than four hours. Monitoring should be performed throughout operations.

For design qualification of Grade A area, a minimum sample volume of 1 m³ should be taken per measurement.

The monitoring of $\geq 5.0 \mu\text{m}$ airborne particulates and airborne microorganisms on settle plates are performed, if necessary.

3. Environmental monitoring program

For the manufacture of sterile pharmaceutical products, it is necessary to predict potential deterioration of the processing environment before it occurs and to prevent any adverse effect on the quality of products. The environmental monitoring program should include all necessary items to verify whether air-cleanliness in each production area is constantly maintained. The items included in the program should be determined in reference to Sections 3.1 to 3.6 in this chapter. An environmental monitoring program should be prepared for each facility. All personnel engaged in the environmental monitoring program should receive sufficient training in hygiene control, microbiology, measurement principles, measurement procedures, and gowning procedures.

3.1. Applicability

Microorganisms and airborne particulates should be monitored. Microorganisms to be monitored are bacteria and fungi, and airborne particulates to be monitored are those $\geq 0.5 \mu\text{m}$ in size.

3.2. Frequency of monitoring

In the processing areas used for sterile pharmaceutical products, monitoring of airborne particulates and microorganisms is required. The Grade A area, in which sterile products are in contact with environmental air, should be monitored during every operational shift. Recommended frequencies of monitoring during operation are given in Table 4. The frequencies are set for general and conventional aseptic processing. In individual cases, appropriate monitoring frequency should be determined based on the results of risk assessment. In particular, the risks of contamination of products should be considered when determining monitoring frequency of airborne microorganisms in Grade A and B areas. The monitoring frequency should be adequate for the assessment of potential effect. When high contamination risks of products are concerned, for example, where products are exposed to the environment for a long time or operational activities are frequently performed in a Grade A area, such areas should be more frequently monitored.

In contrast, in manufacturing operations in which isolator, RABS (Restricted Access Barrier System), or brow/

fill/seal units are used, monitoring frequency may be reduced due to lower contamination risks to the products from human and the environment.

3.3. Monitoring points

The items to be monitored include air, floors, walls, equipment surfaces, gloves, and gowns in the processing areas. When selecting monitoring points to be included in the environmental monitoring program, the following points should be included: the points where critical operations are performed, where a contamination risk is considered high, and points that represent the cleanliness levels of the manufacturing area.

Regular monitoring points in the manufacturing area should be determined based on the risk assessment and the data obtained in monitoring for cleanliness classification; e.g., the near vicinity (e.g. within 30 cm) of a site where products are exposed to the surrounding environment, a site that is prone to potential sources of contamination due to frequent human interventions and traffic or due to susceptibility to lower cleanliness levels, or a site regarded as worst-point based on the airflow analysis.

3.4. Monitoring methods

Appropriate methods should be selected according to the items to be monitored. Consideration should be given to potential contamination risks increased by interventions of personnel who are involved in sampling and disturbance of airflow during sampling.

For monitoring of airborne microorganisms, there are two types of microbial sampling methods: active sampling methods and passive sampling methods. Various types of culture medium and culture methods are available for different types of microorganisms to be monitored. For details, refer to Section 5, "Measurement of microorganisms" in this chapter.

3.5. Environmental control criteria

Establishment of an alert level for each item to be monitored can lead to early detection of performance degradation of facilities. It is also useful to control risks. In environmental monitoring, it is important to evaluate whether the specified cleanliness level for a monitored object is constantly maintained.

The measured values obtained by environmental monitoring are averaged. The contamination risks are evaluated based on the averaged values and should not be underestimated. In a case where bacteria are detected in a Grade A area, assessment of potential effect on the products should be carried out. Surfaces and personnel should be monitored

Table 4 Recommended Frequency of Environmental Monitoring

Grade	airborne particulates	airborne microorganisms	microorganisms on surfaces	
			instruments, walls etc.	gloves, gowns
A	In operation	For each shift	At the completion of each operation	At the completion of each operation
B	In operation	For each shift	At the completion of each operation	At the completion of each operation
C, D*	Areas in which products and containers are exposed to the surrounding environment	Once a month	Twice a week	Twice a week
	Other areas	Once a month	Once a week	Once a week

* When a contamination risk is low, for example, where products are not exposed to the surrounding environment, monitoring frequency may be reduced accordingly.

after the completion of critical operations.

Measurement of $\geq 5.0 \mu\text{m}$ airborne particulates in Grade A and B areas is useful for early detection of abnormalities in the environment. When $\geq 5.0 \mu\text{m}$ airborne particulates are continuously or frequently detected, even if the number is low, further investigation should be encouraged due to possible abnormalities that may have impact on the environment.

3.6. Evaluation of monitoring data and measures to be taken when the limit is exceeded

Environmental monitoring data should be evaluated both in the short-term and the long-term. The following items should be included in the evaluation:

- (i) Changes in numbers of microorganisms and airborne particulates over a period of time
- (ii) Changes in detected species of microorganisms
- (iii) Changes of monitoring points
- (iv) Review of the validity of alert and action levels
- (v) Review of frequency of positive results from each operator
- (vi) Changes that may impact the monitoring results during the monitoring periods

Trend analysis of environmental monitoring data will provide information required to predict potential deterioration of the manufacturing environment before it occurs and to determine its probable causes. Information that may impact the environment, such as monitoring location, date and time, product manufactured during the monitoring period, batch number, personnel in operation, is also important.

In the event of any deviation found in the environmental monitoring data, actions to be taken for the products manufactured and measures to be taken to recover the required cleanliness of the environment should be determined with consideration of the nature of activities performed at the time, distance between the product and the site where the deviation was found, and the severity of the deviation.

4. Measurement of particulates

For measurement of particulates, particle counters that can detect particulates of different sizes are used. In general, a particle counter is composed of an air suction pump, a sensor that discerns particle size from variations in the reflection of a laser beam, and a converter unit. When there is distance between a counter and a sampling point, sampling tubing is used. To measure distribution of particulates precisely, the inlet of the sampling probe is positioned parallel to airflow, and air is aspirated at the same velocity as the airflow.

For measurement of particulates, calibrated devices should be used. Consideration should be given to length, diameter of the tubing, and radii of any bends in the tubing, as well as to the device itself. Calibration items include flow rate, counting efficiency, false counts, and counting loss.

There are three types of methods for particulates monitoring; an independent particle counter is placed at individual monitoring point; a network of sequentially accessed monitoring points is connected by manifold to a single particle counter; or a combination of the two. In any method, the concentration of particulates in the predetermined particulate size range according to the cleanliness level of the area to be monitored should be indicated or recorded. When monitoring $\geq 5.0 \mu\text{m}$ particulates, a short length of sample tubing should be used, because of the relatively higher rate of precipitation of particulates of large size. For particulate monitoring, the selection of the monitoring system may take into account any health risks of operators presented by the materials used in the manufacturing operation (e.g. pathogens, radiopharmaceuticals, or strong sensitizers).

In general, continuous monitoring is recommended in a Grade A area. Sampling volumes that can be accurately converted to volume per m^3 should be applied.

5. Measurement of microorganisms

Measurement methods of microorganisms for environmental monitoring include active microbial sampling methods, measurement methods for microorganisms on surfaces, and settling plates. Various types of sampling devices and measurement methods are available for the sampling and measurement of microorganisms in the air and on surfaces. Appropriate samplers and measuring methodology should be selected according to the purpose of monitoring and the items to be monitored.

5.1. Measurement by cultivation

5.1.1. Active microbial sampling methods

Methods in which a fixed volume of air is aspirated and the number of microorganisms in the air sampled is counted. There are filtration-type sampling devices and impact-type sampling devices.

Both methods have advantages and disadvantages. Capabilities of an air sampling device (air sample volume capacity, performance of microorganism collection, etc.) should be confirmed before use. When a device is used in a Grade A area, the following points need to be confirmed before use: the device can effectively collect air; it is easily decontaminated or sterilized; it does not disturb unidirectional airflow.

An appropriate air sampling volume for active microbial measurement should be comprehensively determined on reasonable grounds, such as cleanliness level of the area to be monitored and monitoring frequency, etc. In a Grade A area, the air sample volume should be 1 m^3 at each sampling.

(i) Impact-type sampling method: When an impact-type sampling device is used, the speed at which the collected air strikes the culture medium surface must be sufficient to capture the microorganisms, but must not have an adverse effect on the collected microorganisms. The volume of air collected must not cause a significant change in the physical or chemical properties of the culture medium.

The most commonly used samplers are as follows: i) slit sampler, ii) Andersen sampler, iii) pinhole sampler, and iv) centrifugal sampler. Each sampler has specific characteristics. The slit sampler is a device to trap microorganisms in a known volume of air that is passed through a standardized slit. The air is impacted on a slowly revolving Petri dish containing a nutrient agar. The rotation rate of the Petri dish and the distance from the slit to the agar surface are adjustable, and it is possible to estimate the number of microorganisms in the air that passes through the device for a period of up to 1 hr. The Andersen sampler consists of a perforated cover and several Petri dishes containing a nutrient agar, and a known volume of air that is passed through the perforated cover impacts on the agar medium in the Petri dishes. The sampler is suitable for the determination of the distribution of size ranges of microorganism particulates in the air. The pinhole sampler resembles the slit sampler, but has pinholes in place of the slit. Microorganisms are collected by spraying a known volume of air through several pinholes onto agar medium in a slowly revolving Petri dish. The centrifugal sampler consists of a propeller that pulls a known volume of air into the device and then propels the air outward to impact on a tangentially placed nutrient agar strip. The sampler is portable and can be used anywhere, but the sampling volume of air is limited.

(ii) Filter-type sampling method: With the filter-type sampling devices, the desired volume of air can be collected by

appropriately changing the air intake rate or the filter size. However, care must be taken to ensure that sterility is maintained while the filter is placed in and removed from the holder. There are two types of filters: wet-type with gelatin filters and dry-type with membrane filters. With the dry-type filters, static electricity effects can make it impossible to quantitatively collect microorganisms on the filter.

5.1.2. Measurement methods for microorganisms on surfaces

The area to be surface-sampled should be designated according to the condition and shape of the object to be monitored.

(i) Contact plates: A contact plate is used with an appropriate contact surface and sufficient area. In principle, the recommended sampling area for equipment or apparatuses is 24 – 30 cm².

The culture medium surface should be brought into contact with the sampling site for several seconds by applying uniform pressure without circular or linear movement. After contact and removal, the plates are covered, and as soon as possible, incubated under appropriate culture conditions. After a contact plate has been used, the site to which the plate was applied must be wiped aseptically to remove any adherent culture medium.

(ii) Swabs: A sterilized, lint-free swab that is suitable for collecting microorganisms is premoistened with an appropriate rinse fluid, and then sampling is conducted by swabbing the defined sampling area in a slow circular movement or in closely parallel strokes while changing direction. After sampling, the swab is agitated in a specified amount of an appropriate sterilized rinse fluid, and the rinse fluid is assayed for viable organisms according to Section 4.05 of the Microbiological Examination of Non-sterile Products.

(iii) Adhesive sheets: An adhesive sheet for sampling is evenly applied to the surface of the item to be monitored and removed. This process should be repeated several times for one sampling area. Microorganisms captured on the adhesive sheet are counted in an appropriate manner. Ultrasonic treatment can be applied to recover microorganisms into solution.

5.1.3. Settling plates (passive microbial sampling method)

Petri dishes of a specified diameter (petri dishes 9 cm in diameter are commonly used) containing a suitable culture medium are placed at the measurement location, and the cover is removed. The plates are exposed for a specified time and the microorganisms deposited from the air onto the agar surface are enumerated after incubation. This method is not effective for quantitative monitoring of total airborne microorganisms, because it does not detect microorganisms that do not settle onto the surface of the culture media, and the settling velocity of aggregates of microorganisms is affected by air currents and disturbances in airflow. Although the results obtained by the settle plate method are only qualitative or semi-quantitative, this method is suitable for long-term evaluation of possible contamination of products or devices by airborne microorganisms.

Before using this method, it should be ensured that the growth of microorganisms is not inhibited due to dryness of the agar surface after lengthy exposure. The data obtained by settling plates can be useful when considered in combination with results from active sampling methods.

5.1.4. Cultivation

Culture conditions under which microorganisms can grow with high reproducibility should be applied in environmental monitoring. Growth promotion testing should be performed on all lots of prepared media. Inactivating agents may be used to negate or inhibit the effects of disinfectants or antibacterial agents that are used or manufactured in the area to be monitored.

Culture media and conditions will depend on types of target microorganisms. Examples of culture media and conditions are shown in Table 5. Liquid media as well as agar media listed in the table can be used according to the measurement method.

Media and extraction liquids should be sterilized in an appropriate manner.

In general, minimum incubation time is 5 days. If the counted number of colonies in shorter incubation time is reliable, the number may be adopted for viable count.

For detection of anaerobes, an appropriate culture medi-

Table 5 Media (examples)

Microorganisms to be detected	Media	Temperature and Incubation Time
Aerobes, Yeast and fungi	SCD agar medium SCDLP agar medium SCDL agar medium	25 – 30°C More than 5 days
Aerobes	SCD agar medium SCDLP agar medium SCDL agar medium	30 – 35°C More than 5 days
Yeast and fungi	SCD agar medium SCDLP agar medium SCDL agar medium Sabouraud glucose agar medium Potato dextrose agar medium Glucose peptone agar medium	20 – 25°C More than 5 days
Anaerobes	Reinforced clostridial agar medium SCD agar medium	30 – 35°C More than 5 days (under an anaerobic culture condition)
Extraction Liquids	Saline solution Phosphate buffered saline solution Phosphate buffered solution (pH 7.2) Buffered sodium chloride-peptone solution (pH 7.0) Peptone saline solution Peptone solution	

um and conditions should be applied.

(i) SCDF agar medium

Casein peptone	15.0 g
Soybean peptone	5.0 g
Sodium chloride	5.0 g
Lecithin	1.0 g
Polysorbate 80	7.0 g
Agar	15.0 g
Water	1000 mL

Adjust pH to 7.1 – 7.5 at 25°C after sterilization in an autoclave using a validated cycle.

(ii) SCDF agar medium

Casein peptone	15.0 g
Soybean peptone	5.0 g
Sodium chloride	5.0 g
Lecithin	1.0 g
Agar	15 g
Water	1000 mL

Adjust pH to 7.1 – 7.5 at 25°C after sterilization in an autoclave using a validated cycle.

(iii) Glucose peptone agar medium

Peptone	5.0 g
Yeast extract	2.0 g
Glucose	20.0 g
Magnesium sulfate heptahydrate	0.5 g
Potassium dihydrogen phosphate	1.0 g
Agar	15.0 g
Water	1000 mL

Adjust pH to 5.6 – 5.8 at 25°C after sterilization in an autoclave using a validated cycle.

(iv) Reinforced clostralid agar medium

Beef extract	10.0 g
Peptone	10.0 g
Yeast extract	3.0 g
Soluble starch	1.0 g
Dextrose monohydrate	5.0 g
Cystein hydrochloride	0.5 g
Sodium chloride	5.0 g
Sodium acetate	3.0 g
Agar	15.0 g
Water	1000 mL

Adjust pH to 6.6 – 7.0 at 25°C after sterilization in an autoclave using a validated cycle.

(v) Phosphate buffered saline

Potassium dihydrogen phosphate	0.0425 g
Sodium chloride	8.5 g
Water	1000 mL

(vi) Peptone saline

Peptone	1.0 g
Sodium chloride	8.5 g
Water	1000 mL

(vii) Peptone solution

Peptone	10.0 g
Sodium chloride	5.0 g
Water	1000 mL

5.1.5. Identification

Identification of microorganisms detected in Grade A and B areas to the species level is recommended. Genotypic methods are more accurate and precise than traditional biochemical and phenotypic techniques. These results can be used for investigations into contaminants found in sterility tests or process simulations. See “Rapid Identification Method of Microorganisms by Gene Analysis” for addition-

al information on gene analysis.

5.2. Rapid test methods

Rapid test methods can provide results in a shorter time compared with traditional culture methods.

In general, scientifically validated devices should be used for the following aspects of the identification process:

- (i) Collecting method (filtration, impact, adhesion, or air aspiration etc.)
- (ii) Detection signal (fluorescence, luminescence etc.)
- (iii) Detection device

In many cases, the detection thresholds in the rapid test methods are higher than those in traditional methods. Sufficient consideration should be given to qualification of equipment and calibration methods when introducing rapid test methods. In addition, as the measurement principles are different from those in cultural methods, acceptance criteria for each method should be established based on scientific rationale. The acceptance criteria for rapid test methods should be equivalent to or more stringent than those for traditional methods.

6. References

- (i) PIC/S GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICAL PRODUCTS ANNEXES: Annex 1-Manufacture of sterile medicinal products (March 2014)
- (ii) ISO/DIS 14644-1 (2010): Cleanrooms and associated controlled environments—Part 1: Classification of air cleanliness by particle concentration

Parametric Release of Terminally Sterilized Pharmaceutical Products

The pharmaceuticals and medical devices to which terminal sterilization can be applied generally must be sterilized so that a sterility assurance level of 10^{-6} or less is obtained. The sterility assurance level of 10^{-6} or less can be proven by using a sterilization process validation based on physical and microbiological methods, but cannot be proven by Sterility Tests <4.06>.

In Japan, parametric release has been required since 1997 for sterile medical devices that have been sterilized by methods such as moist-heat sterilization or ionizing radiation.¹⁾ The same sterilization validation, sterility assurance levels, and the like that are used for sterile medical devices have also been applied to sterile pharmaceutical products produced by terminal sterilization, but the use of parametric release is not widespread.

This chapter deals with the necessary requirements for the appropriate management of the critical sterilization parameters, including validation and routine control, of the sterilization process for “parametric release” ensuring a sterility assurance level of 10^{-6} or less in products, without performing the Sterility Tests <4.06> with low probability of contamination detection on products which have been subjected to terminal sterilization. At such times, the critical sterilization parameters to be controlled should be selected and validated according to the risk posed to product quality, and the selection should be based on the results of the sterilization process and a full understanding of microbial control during the manufacturing process. This will allow parametric release based on parameter control to be implemented.

Because of the limited experience with the actual adoption of parametric release for terminally sterilized pharmaceutical products in Japan, the adoption of parametric release may

tend to require unconventional sterilization equipment and techniques. In this chapter, these points have been sorted anew in order to recommend and expedite the adoption of parametric release.

For general matters such as process validation of manufacturing control and quality control of sterile pharmaceutical products, refer to the laws, notifications, administrative notices, and the like in which they are described in greater detail.

1. Definitions

The definitions of the terminology used in this chapter are provided below.

1.1. Parametric release: A release procedure based on an evaluation of information collected in the course of production, including critical parameters of the sterilization process (temperature, humidity, pressure, time, radiation dose, etc.), based on the results of validation and confirmation of compliance with GMP requirements, in lieu of release based on testing results of the final product.

1.2. Terminal sterilization: A process whereby a product is placed in a container and is then sterilized, and which permits the measurement and evaluation of quantifiable microbial lethality. The process should normally be carried out under conditions ensuring a sterility assurance level of 10^{-6} using, for example, which is a suitable sterilization indicator.

1.3. Sterility assurance level (SAL): Probability of a viable microorganism being present in a sterilized product, expressed as 10^{-n} .

1.4. Critical sterilization parameter: Physical parameters in the sterilization process, whose variability affects the sterility assurance level.

1.5. Sterilization indicator: Indicators are introduced into a loaded product that is to be sterilized for confirmation of the sterilization of the product to be sterilized or auxiliary use for each sterilization batch. Indicators include physical indicators (such as dosimeters), chemical indicators (CI), and biological indicators (BI).

1.6. F_0 value: Assume a value of 10°C for the Z value defined as the number of degrees of temperature required for a 10-fold change in the D value when the reference temperature is 121.1°C . The F_0 value indicates the time (minutes) required to give the equivalent lethality at T_b of the sterilization heat obtained by integrating the lethality rate (L) over an entire heating cycle.

$$L = \log^{-1} \frac{T_0 - T_b}{Z} = 10^{\frac{T_0 - T_b}{Z}}$$

T_0 : Temperature inside the chamber or inside the product to be sterilized

T_b : Reference temperature (121.1°C)

$$F_0 = \int_{t_0}^{t_1} L \, dt$$

$t_1 - t_0$ = Processing time (minutes)

1.7. Risk assessment: A systematic process for organizing information to support decisions on risk during the risk management process. The process consists of identifying hazards, and analyzing and assessing risks associated with exposure to such hazards. In this method, "harm" refers to terminally sterilized pharmaceutical products, including the integrity of container closure systems, that do not meet the desired sterility assurance level. Hazards refer to latent factors that give rise to such harm.

2. Release of sterilized product

Concepts such as sterilization validation, process control methods including critical sterilization parameters, and sterility assurance levels for parametrically released terminally sterilized pharmaceutical products are the same as for conventional terminally sterilized pharmaceutical products. The greatest difference is that release is not based on the results of sterility tests with low probability of decontamination detection. Parametric release is also based on records of critical sterilization parameters. A procedure for release based upon confirmation of sterilization within the permissible range of predefined critical sterilization parameters must be established and documented.

The sterility of parametrically released products should be confirmed with the inclusion of the following.

- 1) Batch production records must be checked.
- 2) The recorded results for critical sterilization parameters must be within permissible range.
- 3) Products must be sterilized in the specified loading format.
- 4) If sterilization indicators (such as BI or CI) are used, the results must be appropriate.
- 5) The bioburden of the product before sterilization must be within permissible range.
- 6) Microorganism evaluation data of the production environment must be within permissible range as needed.

If the results of examination and verification are out of permissible range, the product cannot be released, even if the sterility test results are acceptable.

3. Applicable sterilization methods and control points

In methods of sterilization applied to parametric release, the mechanism by which microorganisms are sterilized must be clearly defined, the critical control points must also be clearly specified, and the sterilization process must be able to be validated by appropriate physical and microbiological methods. In this chapter, the moist-heat sterilization and radiation (gamma ray radiation sterilization and electron beam radiation sterilization) in "Sterilization and Sterilization Indicators" are presented as basic sterilization methods, but other sterilization methods can also be used as long as they can control the critical sterilization parameters and can consistently ensure a sterility assurance level of 10^{-6} or less. Regulatory approval must be obtained to apply parametric release to approved terminally sterilized pharmaceutical products.

3.1. Moist-heat sterilization

Moist-heat sterilization includes widely used saturated steam sterilization and other types of moist-heat sterilization.

Critical sterilization parameters in this method are temperature, pressure, and exposure time at the specified temperature. Therefore, the temperature, pressure, and exposure time in routine sterilization process control should be continuously monitored and measured, and measuring equipment for that purpose should be included in the sterilization equipment specifications. The control points and control frequency for the critical sterilization parameters in moist-heat sterilization are provided as reference in Table 1.

3.2. Radiation

Radiation refers to methods of killing microorganisms through exposure to ionizing radiation. The types of ionizing radiation used are gamma-rays (γ -rays) emitted from a radioisotope such as ^{60}Co , or electron beams and bremsstrahlung (X-rays) generated from an electron accelerator. In the case of γ -rays, the cells are killed by secondarily-generated electrons, while in the case of the electron beam,

Table 1 Control points and control frequency for parametric release of terminally sterilized pharmaceutical products in moist-heat sterilization (reference)

Control point		Control frequency
Critical sterilization parameter	<ul style="list-style-type: none"> —Temperature (the validity of the control point should be pre-validated)* —Pressure in sterilization chamber* —Exposure time at specified temperature* —Heating history (usually indicated by F0 value) 	Each batch
Critical process characteristics	<ul style="list-style-type: none"> —Loading format of product being sterilized* —Vacuum deaeration profile (if applicable) 	Each batch
Quality of sterilization medium (for saturated steam)	<ul style="list-style-type: none"> —Degree of superheat —Dryness —Non-condensable gas concentration —Chemical purity (add to control points as needed) 	Recommended frequency: once or twice year
Quality of sterilization medium (for vapor-air mixture, hot water)	<ul style="list-style-type: none"> —Chemical purity (add to control points as needed) 	Recommended frequency: once or twice year
Common utilities	<ul style="list-style-type: none"> —Quality of the air introduced into the sterilization chamber to restore pressure, etc. (add to control points as needed) —Quality of water used for cooling (add to control points as needed) 	Recommended frequency: once or twice year
Sterilizer	<ul style="list-style-type: none"> —Calibration of critical instruments (thermometers, pressure gages, timers, recorders, etc.)* —Air-tightness of cans —Vacuum performance (add to control points as needed) —Temperature distribution in unloaded state —Other maintenance points that are necessary for machinery and equipment 	Recommended frequency: once or twice year

* Control requirements needed for any sterilization cycles for which parametric release is applicable

the cells are killed by electrons generated directly from the electron accelerator. For this reason, the processing time for electron beam sterilization is generally shorter than that for γ -ray sterilization; however, it is inferior to γ -rays in terms of penetration, therefore appropriate consideration must be paid to the density and thickness of the product being sterilized when choosing a method. In radiation, sterilization process control is mainly performed by measuring the dose, therefore the process is also called dosimetric release. The critical sterilization parameters, and the utilities and control devices that should be controlled in radiation sterilization are provided as reference in Table 2.

4. Sterilization validation

In order to adopt parametric release, critical sterilization parameters that can scientifically prove a sterility assurance

Table 2 Critical sterilization parameters, utilities, and control devices in radiation sterilization (reference)

	γ -ray radiation sterilization	Electron beam radiation sterilization
Critical sterilization parameters	<ul style="list-style-type: none"> —Absorbed dose —Loading pattern (density) of product being sterilized —Exposure time —Other requirements 	<ul style="list-style-type: none"> —Absorbed dose —Loading pattern (density) of product being sterilized —Electron beam characteristics (average electron beam current, electron energy, scan width) —Exposure time (conveyor speed or cycle time) —Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> —Dose measurement system —Others 	<ul style="list-style-type: none"> —Dose measurement device —Belt conveyor —Dose measurement system —Other

Table 3 ISO and JIS specifications related to sterilization²⁻¹²⁾

Sterilization	ISO specifications	JIS specifications
Radiation sterilization	ISO 11137-1: 2006 ISO 11137-2: 2006 ISO 11137-3: 2006	JIS T 0806-1: 2010 JIS T 0806-2: 2010 JIS T 0806-3: 2010
Moist heat sterilization	ISO 17665-1: 2006	JIS T 0816-1: 2010
CI	ISO 11140-1: 2005	JIS T 11140-1: 2013
BI	ISO 11138-1: 2006 ISO 11138-3: 2006	
Packaging materials	ISO 11607-1: 2006 ISO 11607-2: 2006	JIS T 0841-1: 2009 JIS T 0841-2: 2009
Microbiological tests	ISO 11737-1: 2006 ISO 11737-2: 2009	JIS T 11737-1: 2013 JIS T 11737-2: 2013

level of 10^{-6} or less and their permissible ranges should be determined by validation using qualified sterilization chambers and sterilizers. It should be checked on a routine basis that sterilization is being achieved under conditions meeting these permissible ranges, and the results should be regularly examined.

1) All equipment needed for sterilization must undergo design qualification (DQ), installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ).

2) In order to confirm that the equipment can be operated under typical sterilization conditions, OQ should be performed to check on temperature distribution, temperature uniformity, vacuum performance, and pressure regulating capacity in an unloaded state in the case of moist heat sterilization, and to check on dose uniformity, etc., in the case of radiation sterilization.

3) In terms of sterilization method and conditions, appropriate methods and parameters should be established in accordance with the properties of the product. Any of the following methods can be adopted to establish sterilization conditions. The ISO and JIS specifications in Table 3 should be used for reference when implementing sterilization validation.

— Half-cycle method

- Overkill method
 - Combination of bioburden and BI
 - Absolute bioburden method
 - In the case of radiation sterilization, methods based on ISO 11137-2 (JIS T 0806-2)
- 4) Heat permeability tests, BI challenge tests, and the like should be conducted in PQ to establish loading format and to identify whether hot spots and cold spots do and do not exist. Parameters demonstrating a sterility assurance level of 10^{-6} or less and their permissible ranges should be determined on the basis of the PQ results. PQ may also be performed after products or loading formats have been grouped according to the types and characteristics of the product to be sterilized, the size of sterilization batches, sterilization cycle characteristics, and the like.

5) In case permissible ranges of deviation, recording back-up conditions, and the like in sterilization cycles are set, adequate risk assessment should be performed to confirm its validity.

6) Periodic re-validation should normally be performed once a year. Periodic re-validation should be performed to confirm the efficacy of the parameters set for each sterilizer in view of the expected product or loading format. Re-validation may also be performed after grouping in the same manner as in PQ.

7) When changes potentially affecting product conformance or sterility assurance are made, sterilization validation should be performed in advance to show that a sterility assurance level of 10^{-6} or less can be proven even after the change. Changes that affect sterility assurance can include changes in the composition, volume, packaging configuration, and loading format of the pharmaceutical product to be sterilized, conditions for supplying the sterilization medium, and the sterilizer structure and bioburden.

5. Routine control

5.1. General requirements of routine control

1) Appropriate measures must be taken for the product to be sterilized in order to avoid cross-contamination of unsterilized and sterilized products.

2) Measures should be taken as needed to prevent recontamination of sterilized products.

3) Sterilization-related process control, maintenance, supply of gas, air, and water, etc., procedures and control points for confirming sterilization, and the like should be fully documented.

4) Based on the results of validation performed to establish terminal sterilization conditions, detailed procedures for implementing the sterilization process should be established, documented, and complied. These procedures should include the followings.

1. Critical sterilization parameters, control points, and their permissible ranges necessary for routine sterilization control
2. Methods and criteria for determining that the sterilization process meets these requirements
3. Procedural provisions for various records and their storage
4. Measures to be taken in the event of deviations
5. Loading format for each product (except for continuous sterilizers)
6. Confirmation that sterilization is initiated within the prescribed time range after the preparation of drug solution or after the filtration of drug solution, if filtration is also used
- 5) Periodic re-validation, maintenance, calibration, equipment test parameters, and the like should be documented

with detailed procedures and frequency.

6) Methods for detecting microorganisms that are strongly resistant to bioburden test methods and applicable sterilization methods should be established and documented.

7) Methods of action to take when microorganisms strongly resistant to applicable sterilization methods are isolated should be established and documented.

8) Sterilization indicators that are suitable for checking the process may be used. The specifications, efficacy, validity of methods of use and the like for using sterilization indicators should be validated and documented.

5.2. Methods of routine control

1) Routine control should be implemented for each sterilization batch in accordance with established procedures.

2) All data showing that the sterilization process was achieved within the specified permissible ranges should be recorded. The records should also be checked and approved by the persons responsible.

1. The date on which the sterilization process was carried out, and the times when the process was started and completed
2. The sterilization equipment that was used
3. The sterilization conditions that were adopted
4. Records of the history of physical parameters in the sterilization process
5. Sterilization criteria and results
6. Attributes and loading pattern of product to be sterilized
7. Names of personnel implementing the sterilization process

3) Appropriate action should be taken in accordance with established procedures for deviations from established procedures, alert levels, action levels, permissible ranges for parameters, and the like.

4) Records of the sterilization process and the maintenance of the sterilization process support system should be prepared and kept.

5) Equipment used in the control, measurement, and recording of critical sterilization parameters in the sterilization cycle should be calibrated, the calibration frequency and acceptable error should be established, and calibration should be performed with standard devices associated with formal standards. Control and measurement devices supporting the sterilization process should also be similarly handled.

6) Storage must not compromise the quality of sterilized products. Storage locations, methods, environments, times and the like should be predefined and appropriately controlled accordingly.

5.3. Microorganism control program

For sterile pharmaceutical products, it is important to understand, evaluate, and control the bioburden of the product before sterilization, the presence or absence of microbes that are heat-resistant to applicable sterilization methods, and the resistance of isolated microorganisms. That is, the bioburden test referred to here is intended to measure the bioburden count until before the start of sterilization using the Microbial Enumeration Tests in Microbiological Examination of Non-sterile Products <4.05> or an alternative method via a previously specified method and frequency, and, if needed, to survey the characteristics of isolated microorganisms to investigate the presence or absence of heat-resistant microbes or their resistance to the applicable sterilization method. A bioburden test of the product before sterilization should be conducted for each batch. However, if the overkill method is adopted, the bioburden test may be conducted at an appropriately

established frequency.

5.3.1. Microbial enumeration tests

This test should be conducted in view of the time from the adoption of the test until the start of the sterilization process for the applicable pharmaceutical product based on the Microbial Enumeration Tests in Microbiological Examination of Non-sterile Products <4.05>. A predetermined quantity of the applicable pharmaceutical product before sterilization should be tested. The test should be conducted by the membrane filter method using all specified sample units under aseptically controlled conditions. If it is difficult to use the entire sample or to conduct the test using the membrane filter method, another method should be used after clarification of the reasons.

5.3.2. Heat-resistant microorganism test

This is a screening test which should be conducted as needed to confirm the presence or absence of heat-resistant microorganisms (spores) in the product before sterilization. A predetermined quantity of the applicable pharmaceutical product before sterilization should be tested. The test should be conducted using all specified sample units under aseptically controlled conditions. Samples should be heated to between 80°C and 100°C for 10 to 15 minutes in a water bath. All of the sample should be tested by the membrane filter method. If it is difficult to use the entire sample or to conduct the test using the membrane filter method, another method should be used after clarification of the reasons. The culture conditions should be based on the Microbial Enumeration Tests in Microbiological Examination of Non-sterile Products <4.05>.

5.3.3. Identification of microbial species

Microorganisms isolated in the Microbial enumeration tests or heat-resistant microorganism test should be identified. Strongly sterilization-resistant microorganisms will be spore-forming, and it is essential that the spores can be accurately identified. Identification methods include methods based on phenotype, methods using simplified identification kits, and methods using the molecular structure or genetic information of microbial components (chemical classification, genetic analysis). The identification should at least reveal the genus, and information on the characteristics should be captured. The results of identification should be utilized for control purposes in sterilization resistance tests, estimation of routes of contamination, and bioburden reduction.

5.3.4. Sterilization resistance test

When heat-resistant microorganisms are isolated in the heat-resistant microorganism test, select an appropriate spore-forming medium to allow the microorganisms to form spores. A spore solution should be prepared using the spores to measure the *D* value (Z value, if needed) as an indicator of sterilization resistance in the product. The *D* value should be measured for the sterilization temperature of the product based on ISO11138 (as reference). If it is known in advance that a solution gives a value higher than the *D* value of the product, that solution may be used to measure the *D* value.

If it is difficult to measure the *D* value, the reasons should be clarified, a solution containing at least 10^6 spores per product should be prepared and heated for no more than half the sterilization time of the sterilization conditions for the product, and it should then be verified that the results of the membrane filter method in Part 5.1 of the Sterility Tests <4.06> (however, soybean casein digest medium should be used in the case of culturing) are negative, thereby ensuring that the sterility assurance lever of 10^{-6} or less has been met.

5.4. Sterilization indicators

BI, CI, dosimeters and the like are used as indices of sterility, and are used as a parameter to monitor the sterilization

process. When a BI, CI, or dosimeter is used for daily process control, an appropriate one that responds to critical parameters should be used. It must also be verified that the loading pattern on the product or simulated product is equal to or greater than that used for operation qualification

References

- 1) Medical Device Manufacturing Control and Quality Control Regulations, MHLW Ordinance No. 40, August 26, 1995.
- 2) JIS T 0806-1: 2010, Sterilization of healthcare products—Radiation—Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices (ISO11137-1: 2006 Sterilization of health care products—Radiation—Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices)
- 3) JIS T 0806-2: 2014, Sterilization of health care products—Radiation—Part 2: Establishing the sterilization dose (ISO11137-2: 2013 Sterilization of health care products—Radiation—Part 2: Establishing the sterilization dose)
- 4) JIS T 0806-3: 2010, Sterilization of health care products—Radiation—Part 3: Guidance on dosimetric aspects (ISO11137-3: 2006 Sterilization of health care products—Radiation—Part 3: Guidance on dosimetric aspects)
- 5) JIS T 0816-1: 2010, Sterilization of health care products—Moist heat—Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices (ISO17665-1: 2006 Sterilization of health care products—Moist heat—Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices)
- 6) JIS T 11140-1: 2013, Sterilization of health care products—Chemical indicators—Part 1: General requirements (ISO11140-1: 2014 Sterilization of health care products—Chemical indicators—Part 1: General requirements)
- 7) ISO11138-1: 2006 Sterilization of health care products—Biological indicators—Part 1: General requirements
- 8) ISO11138-3: 2006 Sterilization of health care products—Biological indicators—Part 3: Biological indicators for moist heat sterilization processes
- 9) JIS T 0841-1: 2009, Packaging for terminally sterilized medical devices—Part 1: Requirements for materials, sterile barrier systems and packaging systems (ISO11607-1: 2006 Packaging for terminally sterilized medical devices—Part 1: Requirements for materials, sterile barrier systems and packaging systems)
- 10) JIS T 0841-2: 2009, Packaging for terminally sterilized medical devices—Part 2: Validation requirements for forming, sealing and assembly processes (ISO11607-2: 2006 Packaging for terminally sterilized medical devices—Part 2: Validation requirements for forming, sealing and assembly processes)
- 11) JIS T 11737-1: 2013, Sterilization of medical devices—Microbiological methods—Part 1: Determination of a population of microorganisms on products (ISO11737-1: 2006 Sterilization of medical devices—Microbiological methods—Part 1: Determination of a population of microorganisms on products)
- 12) JIS T 11737-2: 2013, Sterilization of medical devices—Microbiological methods—Part 2: Tests of sterility performed in the definition, validation and maintenance

of a sterilization process (ISO11737-2: 2009 Sterilization of medical devices—Microbiological methods—Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process)

Preservatives-Effectiveness Tests

The purpose of the Preservatives-Effectiveness Tests is to assess microbiologically the preservative efficacy, either due to the action of product components themselves or any added preservative(s), for multi-dose containers^{1,2)}. The efficacy of the preservatives is assessed by direct inoculation and mixing of the test strains in the product, and determination of survival of the test strains with time.

Water activity in products plays an important role in the growth of microbial contaminant. In the case of article packaged in multiple-dose container, the degeneration change in quality could be occurred during use due to the microbial contamination, and if such contaminated product is used it could cause not only a decreasing in medical effect but also a hazard to the patient from infection. From these reasons, to the products packaged in multiple-dose containers addition of appropriate preservatives is permitted by General Rules for Preparations in the JP.

Preservatives must not be used solely to comply with GMP for drugs or to reduce viable aerobic (bacteria and yeasts/moulds) counts. In addition, preservatives show the toxicity depending on quantity. Therefore, preservatives must not be added to products in amounts which might jeopardize the safety of human beings, and consideration must be given to minimizing the amounts of preservative used. These tests are commonly used to verify that products maintain their preservative effectiveness at the design phase of formulation or in the case of periodic monitoring. Although these tests are not performed for lot release testing, antimicrobial action of the product itself or the efficacy of the preservative added to the product should be verified over the shelf life. Testing for antimicrobial preservative content should normally be performed at release. Under certain circumstances, in-process testing may suffice in lieu of release testing.

1. Products and their Categories

The products have been divided into two categories for these tests (Table 1). Category I products are those made with aqueous bases or vehicles, and having a water activity of not less than 0.6. Category II products are those made with nonaqueous bases or vehicles. Oil-in-water emulsions are considered Category I products, and water-in-oil emulsions Category II products.

2. Test Microorganisms, Growth Promotion Test and Suitability of the Counting Method

2.1. Preparation of test strains

Seed lot culture maintenance techniques (seed-lot systems) are used so that the viable micro-organisms used for inoculation are not more than 5 passages removed from the original master seed-lot. Grow each of the bacterial and fungal test strains separately as described in Table 2. The strains shown in Table 2 or those considered to be equivalent are used as the test microorganisms.

In addition to these strains designated as test microorganisms, it is desirable to use strains that might contaminate the product and grow on or in it, depending on its characteristics. It is desirable, for example, that *Zygosaccharomyces*

Table 1 Product categories

Category	Products
IA	<ul style="list-style-type: none"> · Injections · Sterile products made by dissolving or suspending in aqueous vehicles (ophthalmic preparations, ear preparations, nasal preparations, etc.)
IB	<ul style="list-style-type: none"> · Topically used non-sterile products made by dissolving or suspending in aqueous vehicles or by mixing with aqueous bases (ear preparations, nasal preparations, inhalations, including those applied to mucous membranes, etc.)
IC	<ul style="list-style-type: none"> · Preparations for oral administration other than antacids made by dissolving or suspending in aqueous vehicles or by mixing with aqueous bases and those applied to the oral cavity.
ID	<ul style="list-style-type: none"> · Antacids made with aqueous vehicles or bases
II	<ul style="list-style-type: none"> · All the dosage forms listed under Category I made with non-aqueous bases or vehicles

Table 2 Test microorganisms and culture conditions

Organism	Strain	Medium	Incubation temperature	Inoculum incubation time
<i>Escherichia coli</i>	ATCC 8739 NBRC 3972	Soybean-Casein Digest Medium Soybean-Casein Digest Agar Medium	30 – 35°C	18 – 24 hours
<i>Pseudomonas aeruginosa</i>	ATCC 9027 NBRC 13275	Soybean-Casein Digest Medium Soybean-Casein Digest Agar Medium	30 – 35°C	18 – 24 hours
<i>Staphylococcus aureus</i>	ATCC 6538 NBRC 13276	Soybean-Casein Digest Medium Soybean-Casein Digest Agar Medium	30 – 35°C	18 – 24 hours
<i>Candida albicans</i>	ATCC 10231 NBRC 1594	Fluid Sabouraud Glucose Medium Sabouraud Glucose Agar Medium	20 – 25°C	44 – 52 hours
<i>Aspergillus brasiliensis</i>	ATCC 16404 NBRC 9455	Sabouraud Glucose Agar Medium	20 – 25°C	6 – 10 days

rouxii (NCYC 381; IP 2021.92; NBRC 1960) is used for the products like as Syrups containing a high concentration of sugar. The test strains can be harvested by growth on solid agar or liquid media.

Cultures on agar media: Inoculate each of the five test strains on the surface of agar plates or agar slants. For growth of bacteria, use Soybean-Casein Digest Agar Medium, and for yeasts and moulds, use Sabouraud Glucose Agar Medium. Incubate bacterial cultures at 30°C to 35°C

for 18 to 24 hours, the culture of *Candida albicans* at 20°C to 25°C for 44 to 52 hours and the culture of *Aspergillus brasiliensis* at 20°C to 25°C for 6 to 10 days or until good sporulation is obtained. For the bacteria and *C. albicans*, harvest the cultured cells aseptically. Suspend the collected cells in physiological saline and adjust the viable cell count to about 10⁸ CFU/mL. In the case of *A. brasiliensis*, suspend the cultured cells in physiological saline containing 0.05 w/v% of polysorbate 80 and adjust the spore count to about 10⁸ CFU/mL. Filter, if needed, the spore suspension through a sterilized gauze or glass wool to remove hyphae. The medium components must be removed from all of the cells so prepared by centrifugation if needed. Use these suspensions as the inocula.

Liquid cultures: After cultivation each of the four strains except for *A. brasiliensis* in Soybean-Casein Digest Medium or in Fluid Sabouraud Glucose Medium, remove the medium by centrifugation. Wash the cells in physiological saline and resuspend them in the same solution with the viable cell count of the inoculum adjusted to about 10⁸ CFU/mL.

When strains other than the five listed above are cultured, select a culture medium suitable for growth of the strain concerned. The cell suspension may also be prepared by a method suitable for that strain. If it is not possible to inoculate the microbial suspensions into the test specimens within 2 hours after they have been prepared from the cultivations on agar media or in liquid media, keep them at 2 – 8°C and use within 24 hours. Usually, the spore of *A. brasiliensis* may be stored at 2 – 8°C for up to 7 days. Determine the viable cell count of the inocula immediately before use, and then calculate the theoretical viable cell count per mL or per gram of the product present just after inoculation.

2.2. Growth Promotion of the Media

An appropriate culture medium among Soybean-Casein Digest Ager Medium and Sabouraud Glucose Agar Medium is used for these tests. Other media also may be used if they have similar nutritive ingredients and growth-promoting properties for the microorganisms to be tested. The media to be used should be performed the growth promotion test using the strains specified in Table 2 or those considered to be equivalent. The incubation times are not more than 3 days for Soybean-Casein Digest Agar Medium, and not more than 5 days for Sabouraud Glucose Agar Medium.

By the agar media the colony counts should be obtained at least 50% of the standardized cell counts. For a freshly prepared inoculum, growth of the micro-organisms comparable to that previously obtained with a previously tested and approved batch of medium occurs.

2.3. Suitability of the Counting Method

Dilute 1 mL or 1 g of the product to be examined with 9 times its mass of physiological saline or other appropriate neutral diluting solution (10⁻¹ dilution), and prepare more two dilutions of this solution by serial 10-fold dilution (10⁻² and 10⁻³ dilutions). Add a suitable count of the test cells to each tube of these dilutions, mix, and inoculate them so as to yield less than 250 CFU/plate for bacteria and *C. albicans* (ideally 25 – 250 CFU) or less than 80 CFU/plate for *A. brasiliensis* (ideally 8 – 80 CFU). This plating should be performed minimally in duplicate (or more to minimize variability in the plate count estimate). A positive control for this procedure is to introduce the same inocula into saline and transfer similar volumes of saline to agar plates. A suitable recovery scheme is the one that provides at least 50% of this saline control count (averaged). In this case, the method is validated to verify its suitability in the presence of test specimen, and if the growth of the cells is inhibited an effective inactivator may be added in the buffer solution or liquid me-

dium to be used for dilution of the test specimen, as well as in the agar plate count medium. However, it is necessary to confirm that the inactivator has no effect on the growth of the microorganisms. When the occurrence of the preservative or the product itself affects determination of the viable cell count and there is no suitable inactivator available, calculate the viable cell counts by the Membrane filtration method in Microbiological Examination of Non-sterile Products <4.05>. In the case where any change is occurred in the test material or procedure or in the product to be examined which might give any effects to the test result, the validation must be performed for the test once again. In the validation study, if the cell recovery count is not less than 50% of the inoculated cell counts, the inoculated cell counts at 0 day may be used as the theoretical inoculate cell count. See 3.2 for more information to obtain suitable counting method for the Category II products.

3. Test Procedure

3.1. Category I products

Inject each of the cell suspensions aseptically into five containers containing the product and mix uniformly. Single-strain challenges rather than mixed cultures should be used. When it is difficult to inject the cell suspension into the container aseptically or the volume of the product in each container is too small to be tested, transfer aseptically a sufficient volume of the product into each of alternative sterile containers, and mix the inoculum. When the product is not sterile, incubate additional containers containing the uninoculated product as controls and calculate their viable cell counts. The volume of the suspension mixed in the product is 0.5 – 1.0% of the volume of the product. Generally, the cell suspension is inoculated and mixed so that the concentration of viable cells is 1 × 10⁵ to 1 × 10⁶ CFU per mL or per g of the product. For Category ID products (antacids) inoculate so that the final concentration of viable cells is 1 × 10³ to 1 × 10⁴ CFU per mL of the product. Incubate these inoculated containers at 20°C to 25°C with protection from light, and calculate the viable cell count of the test preparations at 0, 7 (Category IA only), 14 and 28 days. Record any marked changes (e.g., changes in color or the development of a bad odor or fungus) when observed in the test preparations during this time. Such changes should be considered when assessing the preservative efficacy of the product concerned. The sequential changes in the viable counts are expressed as changes in term of log reduction against the inoculated cell counts (CFU/mg or g). Determination of the viable cell counts is based, in principle, on the Plate-count methods (Pour-plate methods; Surface-spread method) or the Membrane filtration method in "Microbiological Examination of Non-sterile Products <4.05>". Alternative microbiological procedures, including an automated method, may be used for the products of Categories I and II, provided that they give a result equal to or better than that of the Pharmacopoeial methods³⁾.

3.2. Category II products

The procedures are the same as those described for Category I products, but special procedures and considerations are required for both uniform dispersion of the test microorganism in the product and determination of viable cell counts in the test preparations.

For semisolid ointment bases, heat the test preparation to 45°C to 50°C until it becomes oily, add the cell suspension and disperse the inoculum uniformly with a sterile glass rod or spatula. Surfactants may also be added to achieve uniform dispersion, but it is necessary to confirm that the surfactant added has no effect on survival or growth of the

Table 3 Interpretation criteria by product category

Category	Microorganisms	Interpretation criteria
IA	Bacteria	At 7 days: Not less than 1.0 log reduction from the initial count. At 14 days: Not less than 3.0 log reduction from the initial count. At 28 days: No increase from the 14 day's count.
	Yeasts/Moulds	At 7, 14 and 28 days: No increase from the initial count.
IB	Bacteria	At 14 days: Not less than 2.0 log reduction from the initial count. At 28 days: No increase from the 14 day's count.
	Yeasts/Moulds	At 14 and 28 days: No increase from the initial count.
IC	Bacteria	At 14 days: Not less than 1.0 log reduction from the initial count. At 28 days: No increase from the 14 day's count.
	Yeasts/Moulds	At 14 and 28 days: No increase from the initial count.
ID	Bacteria	At 14 and 28 days: No increase from the initial count.
	Yeasts/Moulds	At 14 and 28 days: No increase from the initial count.
II	Bacteria	At 14 and 28 days: No increase from the initial count.
	Yeasts/Moulds	At 14 and 28 days: No increase from the initial count.

test microorganisms and that it does not potentiate the preservative efficacy of the product. For determination of the viable cell count, a surfactant or emulsifier may be added to disperse the test preparations uniformly in the buffer solution or liquid medium. Sorbitan monooleate, polysorbate 80 or lecithin may be added to improve miscibility between the buffer solution or the liquid medium and semisolid ointments or oils in which test microorganisms were inoculated. These agents serve to inactivate or neutralize many of the most commonly used preservatives.

4. Interpretation

Interpret the preservative efficacy of the product according to Table 3. When the results described in Table 3 are obtained, the product examined is considered to be met the requirement of the test. There is a strong possibility of massive microbial contamination having occurred when microorganisms other than the inoculated ones are found in the sterile product to be examined, and caution is required in the test procedures and/or the control of the manufacturing process of the product. When the contamination level in a nonsterile product to be examined exceeds the microbial enumeration limit specified in "Microbial Attributes of Nonsterile Pharmaceutical Products" in General Information, caution is

also required in the test procedures and/or the control of the manufacturing process of the product. The statement "No increase from the initial count" means not more than 0.5 \log_{10} increase from the initial calculated count.

5. Culture Media

Culture media used for Preservatives Effectiveness Tests are described below. Other media may be used if they have similar nutritive ingredients and selective and growth-promoting properties for the microorganisms to be tested.

(i) Soybean-Casein Digest Medium

Casein peptone	17.0 g
Soybean peptone	3.0 g
Sodium chloride	5.0 g
Dipotassium hydrogen phosphate	2.5 g
Glucose monohydrate	2.5 g
Water	1000 mL

Adjust the pH so that after sterilization it is 7.1 – 7.5 at 25°C. Sterilize in an autoclave using a validated cycle.

(ii) Soybean-Casein Digest Agar Medium

Casein peptone	15.0 g
Soybean peptone	5.0 g
Sodium chloride	5.0 g
Agar	15.0 g
Water	1000 mL

Adjust the pH so that after sterilization it is 7.1 – 7.5 at 25°C. Sterilize in an autoclave using a validated cycle.

(iii) Sabouraud Glucose Agar Medium

Glucose	40.0 g
Peptone (animal tissue and casein 1:1)	10.0 g
Agar	15.0 g
Water	1000 mL

Adjust the pH so that after sterilization it is 5.4 – 5.8 at 25°C. Sterilize in an autoclave using a validated cycle.

(iv) Fluid Sabouraud Glucose Medium

Glucose	20.0 g
Peptone (animal tissue and casein 1:1)	10.0 g
Water	1000 mL

Adjust the pH so that after sterilization it is 5.4 – 5.8 at 25°C. Sterilize in an autoclave using a validated cycle.

6. References

- 1) European Pharmacopoeia. 8 (2014), 5.1.3. EFFICACY OF ANTIMICROBIAL PRESERVATION.
- 2) U.S. Pharmacopeia. 38 (2015), <51> ANTIMICROBIAL EFFECTIVENESS TESTING.
- 3) General Information "Rapid Microbial Methods"

Rapid Counting of Microbes using Fluorescent Staining

This chapter provides rapid methods using fluorescence staining for the quantitative estimation of viable microorganisms. Incubation on an agar medium has been widely used for quantitative estimation of viable microorganisms, but a number of environmental microorganisms of interest are not easy to grow in culture under usual conditions, thus new microbial detection methods based on fluorescence or luminescence have been developed. In the fluorescence staining method, microorganisms are stained with fluorescent dye, and can easily be detected and counted with various sorts of apparatus, such as a fluorescence microscope or flow cytometer. Methods are available to detect total microorganisms, including both dead and viable cells, or to

detect only cells with a specified bioactivity by choosing the dye reagent appropriately. Nucleic acid staining reagents, which bind with DNA or RNA, detect all cells containing nucleic acids, whether they are live or dead. This technique is the most fundamental for the fluorescence staining method. On the other hand, fluorescent vital staining methods target the respiratory activity of the microorganism and the activity of esterase, which is present universally in microorganisms. In the microcolony method, microcolonies in the early stage of colony formation are counted. The CFDA-DAPI double staining method and the microcolony method are described below. These methods can give higher counts than the other techniques, because these rapid and accurate techniques provide quantitative estimation of viable microorganisms based on a very specific definition of viability, which may be different from that implicit in other methods. The procedures of these methods described here may be changed as experience with the methods is accumulated. Therefore, other reagents, instruments and apparatus than those described here may also be used if there is a valid reason for so doing.

1. CFDA-DAPI double staining method

Fluorescein diacetate (FDA) reagents are generally used for the detection of microorganisms possessing esterase activity. These reagents are hydrolyzed by intracellular esterase, and the hydrolyzed dye exhibits green fluorescence under blue excitation light (about 490 nm). Modified FDAs such as carboxyfluorescein diacetate (CFDA) are used because of the low stainability of gramnegative bacteria with FDA. The principle of the CFDA-DAPI double staining method, which also employs a nucleic acid staining reagent, 4',6-diamidino-2-phenylindole (DAPI), is as follows. The nonpolar CFDA penetrates into the cells and is hydrolyzed to fluorescent carboxyfluorescein by intracellular esterase. The carboxyfluorescein is accumulated in the living cells due to its polarity, and therefore green fluorescence due to carboxyfluorescein occurs when cells possessing esterase activity are illuminated with blue excitation light. No fluorescent carboxyfluorescein is produced with dead cells, since they are unable to hydrolyze CFDA. On the other hand, DAPI binds preferentially to the adenine and thymine of DNA after penetration into both viable and dead microorganisms, and consequently all of the organisms containing DNA exhibit blue fluorescence under ultraviolet excitation light. Therefore, this double staining method enables to count specifically only live microorganisms possessing esterase activity under blue excitation light, and also to determine the total microbial count (viable and dead microorganisms) under ultraviolet excitation light.

1.1. Apparatus

1.1.1. Fluorescence microscope or fluorescence observation apparatus

Various types of apparatus for counting fluorescence-stained microorganisms are available. Appropriate filters are provided, depending on the fluorescent dye reagents used. A fluorescence microscope, laser microscope, flow cytometer, and various other types of apparatus may be used for fluorescence observation.

1.2. Instruments

- (i) Filtering equipment (funnels, suction flasks, suction pumps)
- (ii) Membrane filters (poresize: 0.2 μm); A suitable filter that can trap particles on the surface can be used such as polycarbonate filter, alumina filter, etc.
- (iii) Glass slide
- (iv) Cover glass
- (v) Ocular micrometer for counting (with 10 \times 10 grids)

1.3. Procedure

An example of the procedure using fluorescence microscope is described below.

1.3.1. Preparation of samples

Prepare samples by ensuring that microbes are dispersed evenly in the liquid (water or buffer solution).

1.3.2. Filtration

Set a membrane filter (poresize: 0.2 μm) on the funnel of the filtering equipment. Filter an appropriate amount of sample to trap microbes on the sample on the filter.

1.3.3. Staining

Pour sufficient amount of buffer solution for CFDA staining, mixed to provide final concentration of 150 $\mu\text{g}/\text{mL}$ of CFDA and 1 $\mu\text{g}/\text{mL}$ of DAPI, into the funnel of the filtering equipment and allow staining in room temperature for 3 minutes, then filter the liquid by suction. Pour sufficient amount of aseptic water in the funnel, filter by suction, and remove excess fluorescent reagent left on the filter. Thoroughly dry the filter.

1.3.4. Slide preparation

Put one drop of immersion oil for fluorescence microscope on the glass slide. Place the air dried filter over it, with the filtering side on the top. Then put one drop of immersion oil for fluorescence microscope on the surface of the filter, place a cover glass. Put another drop of immersion oil for fluorescence microscope on the cover glass when using an oilimmersion objective lens.

1.3.5. Counting

Observe and count under fluorescence microscope, with 1000 magnification. In case of CFDA-DAPI double staining method, count the microorganisms (with esterase activity) exhibiting green fluorescence under the blue excitation light first to avoid color fading by the ultraviolet light, then count the microorganisms (with DNA) exhibiting blue fluorescence under the ultraviolet excitation light in the same microscopic field. Count the organisms exhibiting fluorescence on more than 20 randomly selected fields among 100 grids observed through an ocular micrometer of the microscope, and calculate the total number of organisms using the following formula. The area of the microscopic field should be previously determined with the ocular and objective micrometers. The amount of the sample to be filtered must be adjusted so that the cell number per field is between 10 and 100. It might be necessary to reprepare the sample in certain instances. (In such case that the average count number is not more than 2 organisms per field, or where more than 5 fields are found which have no organism per field, it is assumed that the microorganism count is below the detection limit.)

Number of microbes (cells/mL)

$$= \{(\text{average number of microbes per visual field}) \times (\text{area of filtration})\} / \{(\text{amount of sample filtered}) \times (\text{area of one microscopic field})\}$$

1.4. Reagents and test solutions

(i) Aseptic water: Filter water through a membrane filter with 0.2 μm pore size to remove particles, then sterilize it by heating in an autoclave at 121°C for 15 minutes. Water for injection may be used.

(ii) CFDA solution, 10 mg/mL: Dissolve 50 mg of CFDA in dimethylsulfoxide to prepare a 5 mL solution. Store at -20°C in light shielded condition.

(iii) Buffer solution for CFDA staining: Dissolve 5 g of sodium chloride with 0.5 mL of 0.1 mol/L disodium dihydrogen ethylenediamine tetraacetate TS and diluted disodium hydrogen phosphate TS (1 in 3) to prepare 100 mL of solution. Add sodium dihydrogen phosphate dihydrate solution (1 in 64) to adjust the pH level to 8.5. Filter the solution

through a membrane filter with a pore size of $0.2\text{ }\mu\text{m}$.

(iv) DAPI solution, $10\text{ }\mu\text{g/mL}$: Dissolve 10 mg of DAPI in 100 mL of aseptic water. Dilute this solution 10 times with aseptic water and filter through a membrane filter with a pore size of $0.2\text{ }\mu\text{m}$. Store at 4°C in light shielded condition.

(v) Immersion oil for fluorescence microscope

2. Microcolony method

Microcolonies, which are in early stages of colony formation, are fluorescently stained, then observed and counted under fluorescence microscope or other suitable systems. This method enables to count the number of proliferative microorganisms, with short incubation time. In this method, the organisms are trapped on a membrane filter, the filter is incubated on a medium for a short time, and the microcolonies are counted. By this method, even colonies which are undetectable with the naked eye can be identified, so viable organisms can be counted rapidly and with high precision. Various nucleic acid staining reagents can be used for staining of microcolonies.

2.1. Apparatus

2.1.1. Fluorescence microscope or fluorescence observation apparatus

Various types of apparatus for counting fluorescence-stained microorganisms are available. Appropriate filters are provided, depending on the fluorescence dye reagents used. A fluorescence microscope, laser microscope and various other types of apparatus may be used for fluorescence observation.

2.2. Instruments

(i) Filtering equipment (funnels, suction flasks, suction pumps)

(ii) Membrane filters (pore size: $0.2\text{ }\mu\text{m}$); A suitable filter that can trap particles on the surface can be used such as polycarbonate filter, alumina filter, etc.

(iii) Glass slide

(iv) Cover glass

(v) Filter paper (No. 2)

(vi) Ocular micrometer for counting (with 10×10 grids)

2.3. Procedure

An example of the procedure using a fluorescence microscope is described below.

2.3.1. Preparation of samples

Prepare samples by ensuring that microbes are dispersed evenly in the liquid (water or buffer solution).

2.3.2. Filtration

Set a membrane filter (pore size: $0.2\text{ }\mu\text{m}$) on the funnel of the filtering equipment. Filter an appropriate amount of sample to trap microbes in the sample on the filter.

2.3.3. Incubation

Remove the filter from the filtering equipment and place it with filtering side facing up on a culture medium avoiding formation of air bubbles between the filter and the medium. Incubate at a suitable temperature for appropriate hours in a dark place. It should be noted that the appropriate incubation conditions (such as medium, incubation temperature and/or incubation time) are different, depending on the sample.

2.3.4. Fixation

Soak filter paper with an appropriate amount of neutral buffered formaldehyde test solution, then place the filter that has been removed from the culture medium on top with filtering side up, and allow to remain at room temperature for more than 30 minutes to fix the microcolonies.

2.3.5. Staining

Soak filter paper with an appropriate amount of staining solution (such as $1\text{ }\mu\text{g/mL}$ of DAPI, 2% polyox-

ethylene sorbitan monolaurate), then place the filter on top with filtering side up, and then leave at room temperature, light shielded for 10 minutes to stain microcolonies. Wash the filter by placing it with the filtering side facing up on top of a filter paper soaked with aseptic water for 1 minute. Thoroughly air dry the filter.

2.3.6. Slide preparation

Put one drop of immersion oil for fluorescence microscope on the slide glass. Place an air dried filter over it, with the filtering side on the top. Then, put one drop of immersion oil for fluorescence microscope on top, place a cover glass.

2.3.7. Counting

Count the organisms exhibiting fluorescence on more than 20 randomly selected fields among the 100 grids observed through an ocular micrometer of the microscope with 400 or 200 magnification, and calculate the total number of organisms using the following formula. The area of the microscopic field should be previously determined with the ocular and objective micrometers. In such case that the average count number is not more than 2 microcolonies per field, or where more than 5 fields are found which have no microcolony per field, it is assumed that the microorganism count is below the detection limit.

Number of microcolonies (cells/mL)

$$= \{(\text{average number of microcolonies per visual field}) \times (\text{area of filtration})\} / \{(\text{amount of sample filtered}) \times (\text{area of one microscopic field})\}$$

2.4. Reagents and test solutions

(i) Aseptic water: Filter water through a membrane filter with $0.2\text{ }\mu\text{m}$ pore size to remove particles, and sterilize it by heating in an autoclave at 121°C for 15 minutes. Water for injection may be used.

(ii) Staining solution: Dissolve 10 mg of DAPI in 100 mL of aseptic water. Dilute the solution 10 times with aseptic water and filter through a membrane filter with pore size of $0.2\text{ }\mu\text{m}$. Store at 4°C in light shielded condition. Dissolve polyoxyethylene sorbitan monolaurate to the final concentration of 2% , when using.

(iii) Neutral buffered formaldehyde solution (4w/v% formaldehyde solution; neutrally buffered).

(iv) Immersion oil for fluorescence microscope

Rapid Identification of Microorganisms Based on Molecular Biological Method

This chapter describes the methods for the identification or estimation of microorganisms (bacteria and fungi), found in in-process control tests or lot release tests of pharmaceutical products, at the species or genus level based on their DNA sequence homology. The identification of isolates found in the sterility test or aseptic processing can be helpful for investigating the causes of contamination. Furthermore, information on microorganisms found in raw materials used for pharmaceutical products, processing areas of pharmaceutical products, and so on is useful in designing measures to control the microbiological quality of drugs. For the identification of microorganisms, phenotypic analysis is widely used, based on morphological, physiological, and biochemical features and analysis of components. Commercial kits based on differences in phenotype patterns have been used for the identification of microorganisms, but are

not always applicable to microorganisms found in raw materials used for pharmaceutical products and in processing areas of pharmaceutical products. In general, the identification of microorganisms based on phenotypic analysis needs special knowledge and judgment is often subjective. It is considered that the evolutionary history of microorganisms (bacteria and fungi) is memorized in their ribosomal RNAs (rRNAs), so that systematic classification and identification of microorganisms in recent years have been based on the analysis of these sequences. This chapter presents a rapid method to identify or estimate microorganisms based on partial sequences of divergent regions of the 16S rRNA gene for bacteria and of the internal transcribed spacer 1 (ITS1) region located between 18S rRNA and 5.8S rRNA for fungi, followed by comparison of the sequences with those in the database. Methods described in this chapter do not take the place of usual other methods for the identification, and can be modified based on the examiner's experience, and on the available equipment or materials. Other gene regions besides those mentioned in this chapter can be used if appropriate.

1. Apparatuses

(i) DNA sequencer

Various types of sequencers used a gel board or capillary can be used.

(ii) DNA amplifier

To amplify target DNA and label amplified (PCR) products with sequencing reagents.

2. Procedures

The following procedures are described as an example.

2.1. Preparation of template DNA

It is important to use a pure cultivated bacterium or fungus for identification. In the case of colony samples, colonies are picked up with a sterilized toothpick (in the case of fungi, a small fragment of colony sample is picked up), and suspended in 0.3 mL of DNA releasing solution in a 1.5 mL centrifuge tube. In the case of culture fluid, a 0.5 mL portion of fluid is put in a 1.5 mL centrifuge tube and centrifuged at 10,000 rpm for 10 min. After removal of the supernatant, the pellet is suspended in 0.3 mL of DNA releasing solution, and then heated at 100°C for 10 min. In general, PCR can be run for bacteria and yeasts heated in DNA releasing solution. For fungi, DNA extraction from culture fluid is better because some of colony samples can disturb PCR reaction.

2.2. PCR

Add 2 μ L of template DNA in PCR reaction solution. Use 10F/800R primers (or 800F/1500R primers in the case to analyze also a latter part of 16S rRNA) for bacteria and ITS1F/ITS1R primers for fungi, and then perform 30 amplification cycles at 94°C for 30 sec, 55°C for 60 sec, and 72°C for 60 sec. DNA fragments are amplified about 800 bp in the case of bacteria and about 150 – 470 bp depending on the strain in the case of fungi. Include a negative control (water instead of the test solution) in the PCR.

2.3. Confirmation of PCR products

Mix 5 μ L of PCR product with 1 μ L of loading buffer solution, place it in a 1.5 w/v% agarose gel well, and carry out electrophoresis with TAE buffer solution (1-fold concentration). Carry out the electrophoresis together with appropriate DNA size markers. After the electrophoresis, observe PCR products on a trans-illuminator (312 nm) and confirm the presence of a single band of the targeted size. If multiple bands are observed, cut the targeted band out of the gel, and extract DNA by using appropriate commercial DNA extraction kit.

2.4. Purification of PCR products

Remove unincorporated PCR primers and deoxynucleoside triphosphates (dNTP) from PCR products by using appropriate purification methods.

2.5. Quantification of purified DNA

When purified DNA is measured by spectrophotometer, calculate 1 OD_{260 nm} as 50 μ g/mL.

2.6. Labeling of PCR products with sequencing reagents

Use an appropriate fluorescence-labeled sequencing reagent suitable for the available DNA sequencer or its program and label the PCR products according to the instructions provided with the reagent.

2.7. Purification of sequencing reagent-labeled PCR products

Transfer the product in 75 μ L of diluted ethanol (7 in 10) into a 1.5 mL centrifuge tube, keep in an ice bath for 20 min, and centrifuge at 15,000 rpm for 20 min. After removal of supernatant, add 250 μ L of diluted ethanol (7 in 10) to the precipitate and centrifuge at 15,000 rpm for 5 min. Remove the supernatant and dry the precipitate.

2.8. DNA homology analysis

Place sequencing reagent-labeled PCR products in the DNA sequencer and read the nucleotide sequences of the PCR products. Compare the partial nucleotide sequence with those in the BLAST database.

3. Judgment

If sequencing data show over 90% identity with a sequence in the database, in general, judgment may be made as follows.

- (i) In the case of bacteria, compare the nucleotides in the product obtained with the 10F primer (the 800F primer when 800F/1500R primers are used) with the BLAST database. Higher ranked species are judged as identified species or closely related species.
- (ii) In the case of fungi, compare sequencing data for the product obtained with the ITS1F primer with the BLAST database. Higher ranked species are judged as identified species or closely related species.

4. Reagents, Test Solutions

- (i) 0.5 mol/L Disodium dihydrogen ethylenediamine tetraacetate TS: Dissolve 18.6 g of disodium dihydrogen ethylenediamine tetraacetate dihydrate in water to make 100 mL.
- (ii) 1 mol/L Tris buffer solution (pH 8.0): Dissolve 24.2 g of 2-amino-2-hydroxymethyl-1,3-propanediol in a suitable amount of water, adjust the pH to 8.0 with 0.2 mol/L hydrochloric acid TS, and add water to make 200 mL.
- (iii) TE buffer solution: Mix 1.0 mL of 1 mol/L tris buffer solution (pH 8.0) and 0.2 mL of 0.5 mol/L disodium dihydrogen ethylenediamine tetraacetate TS, and add water to make 100 mL.
- (iv) DNA releasing solution: Divide TE buffer solution containing 1 vol% of polyoxyethylene (10) octylphenyl ether into small amounts and store frozen until use.

(v) PCR reaction solution

10-fold buffer solution*	5 μ L
dNTP mixture**	4 μ L
10 μ mol/L Sense primer	1 μ L
10 μ mol/L Anti-sense primer	1 μ L
Heat-resistant DNA polymerase (1 U/ μ L)	1 μ L
Water	36 μ L

* Being composed of 100 mmol/L 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride, pH 8.4, 500 mmol/L potassium chloride, 20 mmol/L magnesium chloride and 0.1 g/L gelatin.

** A solution containing 2.5 mmol/L each of dGTP (sodium 2'-deoxyguanosine 5'-triphosphate), dATP (sodium 2'-

deoxyadenosine 5'-triphosphate), dCTP (sodium 2'-deoxycytidine 5'-triphosphate) and dTTP (sodium 2'-deoxythymidine 5'-triphosphate). Adequate products containing these components as described above may be used.

(vi) Sequencing reagent: There are many kinds of sequencing methods, such as the dye-primer method for labeling of primer, the dye-terminator method for labeling of dNTP terminator and so on. Use an appropriate sequencing reagent kit for the apparatus and program to be used.

(vii) 50-Fold concentrated TAE buffer solution: Dissolve 242 g of 2-amino-2-hydroxymethyl-1,3-propanediol in 57.1 mL of acetic acid (100) and 100 mL of 0.5 mol/L disodium dihydrogen ethylenediamine tetraacetate TS, and add water to make 1000 mL.

(viii) 1-Fold concentrated TAE buffer solution: Diluted 50-fold concentrated TAE buffer solution (1 in 50) prepared before use is referred to as 1-fold concentrated TAE buffer solution.

(ix) Agarose gel: Mix 1.5 g of agarose, 2.0 mL of 50-fold concentrated TAE buffer solution, 10 μ L of a solution of ethidium bromide (3,8-diamino-5-ethyl-6-phenylphenanthridinium bromide) (1 in 100) and 100 mL of water. After dissolving the materials by heating, cool the solution to about 60°C, and prepare gels.

(x) Loading buffer solution (6-fold concentrated): Dissolve 0.25 g of bromophenol blue, 0.25 g of xylene cyanol FF and 1.63 g of disodium dihydrogen ethylenediamine tetraacetate dihydrate in 50 mL of water, and add 30 mL of glycerol and water to make 100 mL.

(xi) PCR primers

For	Primer
Bacteria	10F 5'-GTTTGATCCTGGCTCA-3'
	800R 5'-TACCAAGGGTATCTAATCC-3'
	800F 5'-GGATTAGATACCCTGGTA-3'
	1500R 5'-TACCTTGTACGACTT-3'
Fungi	ITS1F 5'-GTAACAAGGT(T/C)TCCGT-3'
	ITS1R 5'-CGTTCTTCATCGATG-3'

(xii) Polyoxyethylene(10)octylphenyl ether: A pale yellow, viscous liquid.

Rapid Microbial Methods

Advances in science and technology have provided new methods to perform high-precision measurements of bacterial physiological activities, intracellular components, and so on, and consequently new techniques for bacterial detection, enumeration and quantification have appeared. Since the 1980s it has become clear that the majority of bacteria in the natural environment have low growth ability in conventional culture media, and the detection, enumeration and identification of these bacteria are difficult by means of culture methods alone. The bacterial cell counts obtained vary from method to method, and it should be noted that it is difficult to obtain a reliable value even applied with a new method. Moreover, even if type strains exist for method validation, it is not easy to standardize the physiological activity.

Compared to the conventional methods, these new methods are not necessarily superior in every respect, but they usually offer greater speed and accuracy, and can be applied not only to bacteria, but also to fungi and viruses. Therefore, these new methods are very useful to improve the standards of microbial control in critical areas, and to decrease the risk of hazardous microbial contamination.

The conventional cultivation-based methods use colony formation or turbidity change due to cell growth as an indicator, whereas the new methods vary greatly as regards the detection target and the detection principle. The new methods may be more suitable for obtaining a comprehensive understanding of the microbial community, as well as for identifying specific microorganisms. Among these methods, phylogenetic analysis based on gene sequences has become popular, and the dramatic development of sequencing techniques in recent years now allows us to analyze the composition of the microbial community in a short time. In this information chapter, the principles of the new methods and their range of applicability are introduced, and key points in the usage of these methods are described.

1. Detection targets and principles

Name	Target	Principles of measurement	Examples of measurement device
1) Direct Method			
Solid phase cytometry	Microorganism	Directly detect the signals from the bacteria trapped onto a filter. The signals on their physiological activities can be obtained by choosing suitable dyes. Autofluorescence may also be used. To selectively detect specific bacteria, gene probe, antibody or fluorescent-labeled phage may be utilized. Various optical devices including a fluorescent microscope and laser microscope are used as detection/measurement apparatus.	Fluorescence microscope, Laser scanning cytometer, etc.
Flow cytometry	Microorganism	Directly detect the signals given by the bacteria passing through fluid or air. The signals on their physiological activities can be obtained by choosing suitable dyes. Autofluorescence may also be used. To selectively detect specific bacteria, gene probe, antibody or fluorescent-labeled phage may be utilized. Various optical devices are used as detection/measurement apparatus.	Flow cytometer, etc.
2) Indirect Method			
Immunological methods	Antigen	React the antigen of bacteria with the specific antibody, and detect the color or fluorescence visually or by a microplate reader. Immunochromatography is a simple and easy method for the purpose.	Immunochromatography, Micro plate reader, etc.
Nucleic acid amplification	Nucleic acid	Amplify a nucleic acid of microorganism by using the primers specific to the target microorganism, and analyze the amplified nucleic acid fragments. Quantitative determination is possible by performing of quantitative PCR.	Electrophoresis apparatus, Quantitative PCR
Bioluminescence/fluorescence	ATP, etc.	Measure ATP which is released from microorganisms on the basis of luminous or fluorescence phenomena occurred by enzyme reaction.	luminescence detector, fluorescence detector, etc.
Micro colony method	Growth (Micro colony)	Detect and count the micro colony that appears in early stage of colonization. The same culture conditions (medium composition, temperature, etc.) as the plate culture method can be used.	Fluorescence microscopy etc.
Impedance method	Growth (Electrical characteristic)	Utilize the change in electrical properties of medium due to the metabolites produced by the growth of microorganisms.	Electrodes
Gas measuring method	Growth (Gas production, etc.)	Utilize the change in amount of gases caused by CO ₂ production, O ₂ consumption, etc. with the growth of microorganisms.	Gas measuring instrument Color change of medium
Fatty acid profiles	Fatty acid	Utilize the fatty acid profile of cell components that differs depending on the taxonomic groups of microorganism.	Gas chromatography
Infrared spectroscopy	Cell component	Utilize the pattern of infrared spectrum obtained by infrared light irradiation to whole microorganism.	Fourier transformation infrared spectroscope
Mass spectrometry	Cell component	Measure the cell component by means of a mass spectrometer, and identify it by database.	Mass spectrometry
Genetic finger-printing method	DNA	Utilize the electrophoresis pattern of DNA fragments obtained by cleaving the DNA extracted from sample with a restriction enzyme. It can be identified by database. Analysis of community structure is possible by T-RFLP.	Electrophoresis apparatus
High throughput sequencing	Nucleic acid	Determine the sequence of nucleic acids extracted from bacteria exist in sample, and analyze the community structure phylogenetically.	Sequencer, etc.

2. Validation

To qualify introduced equipment, a standard component or strain, which represents the target of each method, should be utilized. That is, in direct measurement, type strains should be used, while in indirect measurement, standard components, etc., of the target bacteria are used.

To validate a protocol/procedure, it is required to demonstrate that the detection target is a suitable index/indicator for bacterial number or quantity. It is also important to state whether any special precautions are necessary in applying the protocol/procedure. When using a type strain, the result of validation should be equivalent to or better than that of the conventional method. However, because the detection principles of new methods are usually different from that of conventional methods, the correlation between them is not always required. For detection of environmental bacteria, it is important that the physiological state of the type strain should be maintained as close as possible to that of environmental bacteria, in order to obtain reliable results.

3. Applications and particular considerations:

New methods are expected to find application in a variety of fields. However, since their detection targets and detection protocols/procedures are different from the conventional methods, the resulting data may not show a good correlation with existing data. Although, it is important in principle that a new method should have an equal or greater capability than the conventional method, a new method may be used after verifying their validity, even in the absence of equivalence to conventional methods.

Because the new methods are rapid, product testing, environmental monitoring, bioburden evaluation, raw materials control, etc. can be performed in real-time, and this is highly advantageous for process control, allowing alert levels, action levels and so on to be set up based on trend analysis of the obtained data.

These new rapid methods may be applied to;

- Quality control of pharmaceutical manufacturing water
 - Microbial evaluation of processing areas
 - Sterility test
 - Microbial limit test
 - Antimicrobial and preservatives effectiveness test
 - Raw material acceptance test
- etc.

Sterilization and Sterilization Indicators

Sterilization refers to the destruction or removal of all forms of viable microorganisms in items. This reference information applies to cases where sterilization is required as well as the manufacture of sterile products. When sterilization is applicable, an appropriate sterilization method should be selected in accordance with the items being sterilized (such as products, or equipment, instrumentation, or materials that must be sterilized), including the packaging, after full consideration of the advantages and disadvantages of each sterilization method.

After installation of a sterilizer (including design and development of the sterilization process), an equipment maintenance and inspection program must be established based on qualification evaluation to ensure that the sterilization process is being properly performed as designed on the basis of sufficient scientific evidence. A quality system must also be established for manufacturing in general at manufac-

ting facilities where sterile pharmaceutical products are manufactured. For example, all operation potentially affecting quality, including sterility after sterilization, must be clearly identified, and any operating procedures that are needed to prevent microbial contamination of products must be established and properly enforced.

In order to establish sterilization conditions and ensure sterility after sterilization, the bioburden before sterilization of the items being sterilized must be evaluated periodically or on the basis of batches. For bioburden test method, refer to 4.05 Microbiological Examination of Non-sterile Products, etc.

Representative sterilization methods are presented in this reference information, but other sterilization methods can also be used, provided that they meet the following requirements and do not have any deleterious affect on the item being sterilized.

- The mechanism of sterilization is well established
- The critical physical parameters of the sterilization process are clear, controllable, and measurable
- The sterilization procedure can be performed effectively and reproducibly

1. Definitions

The terms used in this text are defined as follows.

- **Filter integrity test:** A non-destructive test which is demonstrated to correlates with the microbial removal performance data of filters.
- **Bioburden:** Population of viable microorganisms in an item to be sterilized.
- **D value:** The value represents exposure time (decimal reduction time) to achieve 90% reduction of a population of the test microorganism, and resulted that 10% of the original organisms remain.
- **F_H value:** The unit of lethality indicating the measure of the microbial inactivation capacity of a process in dry heat sterilization, expressed as the equivalent time (minutes) at 160°C for microbes with a z value (the number of degrees that are required for a 10-fold change in the D value) of 20°C.
- **F₀ value:** The unit of lethality indicating the measure of the microbial inactivation capacity of a process in moist heat sterilization, expressed as the equivalent time (minutes) at 121.1°C for microbes with a z value (the number of degrees that are required for a 10-fold change in the D value) of 10°C.
- **Sterility assurance level (SAL):** Probability of a single viable microorganism surviving in a product after sterilization, expressed as 10⁻ⁿ.
- **Dose of irradiation (absorbed dose):** Quantity of ionizing radiation energy imparted per unit mass of the item, expressed in units of gray (Gy).
- **Critical parameter:** A measureable parameter that is inherently essential to the sterilization process.
- **Loading pattern:** A specified combination of the numbers, orientation and distribution of the item(s) to be sterilized within the sterilization chamber or irradiation container.

2. Sterilization

2.1. Heat method

In the heat method, microorganisms are killed by heat.

2.1.1. Moist-heat sterilization

Moist-heat sterilization includes widely used saturated steam sterilization and other types of moist-heat sterilization. The control points, utilities, and control devices in moist-heat sterilization are provided as reference in Table 1.

Saturated steam sterilization is a method for killing microorganisms with high pressure saturated steam. Critical

Table 1 Control points, utilities, and control devices in moist-heat sterilization (reference)

	Saturated steam sterilization	Other types of moist-heat sterilization
Control point	<ul style="list-style-type: none"> Temperature profile (usually indicated by F_0 value) Temperature (drain or the like as needed) Pressure (in sterilizer) Exposure time at specified temperature Loading pattern of items being sterilized Steam quality (degree of superheat, dryness, non-condensable gas concentration, and chemical purity, as needed) Quality of air that is introduced to the sterilizer for vacuum break. Quality of cooling water Other requirements 	<ul style="list-style-type: none"> Temperature profile (usually indicated by F_0 value) Temperature (drain and the like as needed) Pressure, as needed (in sterilizer) Exposure time at specified temperature Loading pattern of item being sterilized Quality of air that is introduced to the sterilizer for vacuum break. Quality of cooling water Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> Steam Air introduced to the sterilizer for vacuum break Cooling water Temperature control device Pressure control device Time control device Other 	<ul style="list-style-type: none"> Steam Hot water Air introduced to the sterilizer for vacuum break Cooling water Temperature control device Pressure control device Time control device Conveyor for when a continuous sterilizer is used Other

Table 2 Control points, utilities, and control devices in dry-heat sterilization (reference)

	Batch-type dry heat sterilizer	Tunnel-type dry heat sterilizer
Control point	<ul style="list-style-type: none"> Temperature profile (usually indicated by F_H value) Temperature Exposure time at specified temperature Pressure differential between inside and outside of container Loading pattern of items being sterilized Quality of air (heating air, cooling air) Other requirements 	<ul style="list-style-type: none"> Temperature profile (usually indicated by F_H value) Temperature Belt speed (exposure time) Pressure differential between inside and outside of equipment Loading density Quality of air (heating air, cooling air) Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> Air (heating air, cooling air) Temperature control device Time control device Internal differential pressure gage HEPA filter Other 	<ul style="list-style-type: none"> Air (heating air, cooling air) Temperature control device Time control device Internal differential pressure gage HEPA filter Cooler (if needed) Other

parameters in this method are temperature, pressure, and exposure time at the specified temperature. Therefore, the temperature, pressure, and exposure time in routine sterilization process control should be continuously monitored and measured, and measuring equipment for that purpose should be included in the sterilization equipment specifications.

Other types of moist-heat sterilization may include steam pressurization cycles, water dispersion cycles, water immersion cycles, and the like, which are used when the items being sterilized is sterilized in a hermetically sealed container. Critical parameters in such methods are the temperature in the container and the exposure time at the specified temperature.

2.1.2. Dry-heat sterilization

Dry-heat sterilization is a method for destructing microorganisms with dry heated air. This method is usually conducted in a batch or continuous (tunnel-type) dry heat sterilizer. Attention must be paid to the cleanliness of the air that flows into the sterilizer in either case. The control points, utilities,

and control devices in dry-heat sterilization are provided as reference in Table 2. This method is suitable for when the item to be sterilized is highly heat-resistant, such as glass, ceramic or metal, or is thermo-stable, such as mineral oils, fatty oils, or solid pharmaceutical products.

Critical parameters in this method are temperature and the exposure time at the specified temperature (belt speed). Dry-heat sterilization requires higher temperatures and longer exposure times than does moist-heat sterilization even though the sterilization in both methods may be based on the same heating temperature. The temperature and exposure time in routine sterilization process control should be continuously monitored and measured, and measuring equipment for that purpose should be included in the sterilization equipment specifications.

2.1.3. Microwave sterilization

When substances to be sterilized such as chemical solutions are exposed to microwaves, the polar molecules of the substance being sterilized vibrate as they attempt to change

orientation due to the absorbed microwaves, and energy is released by the friction between the molecules. The method of killing microorganisms by the heat (microwave heat) generated at this time is called the microwave sterilization. A frequency of 2450 ± 50 MHz is ordinarily used.

Microwave devices are composed of a heating irradiation component which produces radiofrequency radiation to generate heat using a magnetron, a component for maintaining the sterilization temperature using an infrared heater or the like, and a cooling component for cooling the item being sterilized. Such devices continuously sterilize the item at ordinary pressure. The control points, utilities, and control devices in microwave sterilization are provided as reference in Table 3.

This method is applied to liquid products or products with high water content in hermetically sealed containers.

Critical parameters in this method include the temperature of the items being sterilized and processing time. Therefore, the temperature of the items being sterilized and the processing time in routine sterilization process control should be continuously monitored and measured, and measuring eq-

uipment for that purpose should be included in the sterilization equipment specifications.

Microwave heating characteristically allows rapid sterilization at high temperatures to be continuously carried out with excellent thermal efficiency and responsiveness. However, the ease of heat transfer in the items being sterilized sometimes makes it difficult to ensure uniform heating. Attention must also be paid to the pressure resistance and uniformity of the containers that are used because the heating takes place at ambient pressure, resulting in increases in internal pressure.

2.2. Gas method

The gas method kills microorganisms through contact with a sterilization gas or vapor. Microorganisms can be sterilized at lower temperatures than in heat methods, and the items being sterilized generally sustain little thermal damage. This method is therefore often applied to plastic containers and the like which are not very resistant to heat.

In the most common gas sterilization methods, adequate washing and drying are important to prevent contamination and moisture from compromising the sterilization effect. The sterilization effect may also be compromised if the gas is absorbed by the item being sterilized.

2.2.1. Ethylene oxide (EO) gas sterilization

EO gas sterilization kills microorganisms by altering the proteins and nucleic acids of microorganisms. Since EO gas is explosive, it is usually diluted 10 to 30% with carbon dioxide. EO gas is also a strongly reactive alkylating agent and therefore cannot be used to sterilize products which are likely to react with or absorb it.

The sterilization process consists of preconditioning, sterilization cycles, and aeration. EO gas is toxic (mutagenic, for example), and the substance being sterilized must therefore be aerated to ensure that the residual concentration of EO gas or other secondarily generated toxic gases (such as ethylene chlorohydrin) is at or below safe levels. Gas emissions must also be treated in compliance with regulations. The control points, utilities, and control devices in EO gas sterilization are provided as reference in Table 4.

Critical parameters in this method include temperature,

Table 3 Control points, utilities, and control devices in microwave sterilization (reference)

Control point	<ul style="list-style-type: none"> Temperature profile (usually indicated by F_0 value) Temperature Processing time Belt speed Configuration of items being sterilized Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> High frequency control device External heater (if needed) Cooler (if needed) Temperature monitoring device Time monitoring device Other

Table 4 Control points, utilities, and control devices in EO gas sterilization (reference)

Control point	<ul style="list-style-type: none"> Pressure increase, injection time, and final pressure for the injection of sterilization gas Temperature (in sterilizer and items being sterilized) Humidity EO gas concentration (gas concentration in sterilizer should be directly analyzed, but the following alternatives are acceptable when direct analysis is not feasible) <ul style="list-style-type: none"> i) Weight of gas used ii) Volume of gas used iii) Use of conversion formula based on initial reduced pressure and gas injection pressure Operating time (exposure time) Loading pattern of items being sterilized Biological indicator placement points and cultivation results Preconditioning conditions (temperature, humidity, time, etc.) Aeration conditions (temperature, time, etc.) Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> EO gas Injected vapor or water Air replaced after completion of sterilization Temperature control device Pressure control device Humidity control device Time control device Other

humidity, gas concentration (pressure), and time. Therefore, the temperature, humidity, gas concentration (pressure), and time in routine sterilization process control should be continuously monitored and measured, and measuring equipment for that purpose should be included in the sterilization equipment specifications.

2.2.2. Hydrogen peroxide sterilization

Sterilization with hydrogen peroxide is a method for killing microorganisms through the oxidative power of hydrogen peroxide or the oxidation caused by radicals that are produced upon the generation of hydrogen peroxide plasma. Although items can be sterilized at lower temperatures than in heat methods, this method is not suitable for the sterilization of objects that absorb hydrogen peroxides, such as cellulose-based disposable garment and membrane filters because the sterilization effect will be compromised. The control points, utilities, and control devices in hydrogen peroxide sterilization are provided as reference in Table 5.

Critical parameters in this method include the concentration, time, and temperature. The control of a radio frequency device is also important when substances are sterilized with the use of plasma. The residual moisture of the substance being sterilized and the humidity in the sterilization environment may affect sterilization and should therefore be controlled when necessary.

2.3. Radiation method

2.3.1. Radiation sterilization

Radiation sterilization includes γ -ray radiation for killing microorganisms through the exposure of the items that are to be sterilized to γ -rays emitted from ^{60}Co , and electron beam radiation for killing microorganisms through exposure to an electron beam emitted from an electron beam accelerator. To select this method of sterilization, it must first be ensured that it is compatible with the items to be sterilized, including whether the quality of the substance could potentially deteriorate.

In γ -ray radiation sterilization, microorganisms are killed by secondarily produced electrons, whereas in electron beam

radiation sterilization, microorganisms are directly killed by electrons. Although this kind of electron-based direct action is available, indirect action is also available, where sterilization is accomplished through the production of radicals and the like and damage to the DNA of microorganisms when γ -rays or electron beams react with water molecules.

Since sterilization can take place at room temperature, both methods can be applied to heat-labile items, and items can be sterilized while packaged because the radiation rays will penetrate the packaging. γ -Ray sterilization is suitable primarily for high density products such as metals, water, and powder because the penetration is better than that of electron beams. Electron beam radiation sterilization has a higher radiation dose per unit time (dose rate) compared with γ -rays and therefore has a shorter processing time. The control points, utilities, and control devices in radiation sterilization are provided as reference in Table 6.

2.4. Filtration method

The filtration method is a method for physically removing microorganisms in liquids or gas using a sterilization filter. It can therefore be applied to items that are unstable against heat or radiation. Filtration sterilization is for microorganisms which can be removed by a $0.2\text{ }\mu\text{m}$ membrane filter, and is not suitable for *Mycoplasma* spp., *Leptospira* spp., or viruses. The control points, utilities, and control devices in filtration sterilization are provided as reference in Table 7.

The critical parameters affecting the removal of microorganisms by the filter in liquid filtration sterilization include filtration time, filtration capacity, filtration flow rate, filtration differential pressure, and temperature. The critical parameters in gas filtration sterilization include filtration differential pressure and temperature. When a liquid is to be sterilized, the removal of microorganisms by a filter will be affected by the physical and chemical properties of the liquid that is undergoing filtration (such as viscosity, pH, and surfactant action). The microbial trapping performance of a sterilizing filter can generally be validated when a sterilizing filter challenged with more than 10^7 CFU microorganisms of

Table 5 Control points, utilities, and control devices in hydrogen peroxide sterilization (reference)

	Hydrogen peroxide sterilization	Hydrogen peroxide low temperature gas plasma sterilization
Control point	<ul style="list-style-type: none"> Concentration (the concentration in the sterilizer should be directly analyzed, but a method based on evidence of sterilizer performance uniformity in the chamber is an acceptable alternative when direct analysis is not feasible) Time Temperature Humidity Pressure Quality of hydrogen peroxide Consumption of hydrogen peroxide Residual moisture of substance being sterilized Loading pattern of items being sterilized Biological indicator placement points and cultivation results Chemical indicator placement points and results Other requirements 	<ul style="list-style-type: none"> Concentration (the concentration in the sterilizer should be directly analyzed, but a method based on evidence of sterilizer performance uniformity in the chamber is an acceptable alternative when direct analysis is not feasible) Time Temperature Humidity Pressure Quality of hydrogen peroxide Consumption of hydrogen peroxide Residual moisture of substance being sterilized Loading pattern of items being sterilized Biological indicator placement points and cultivation results Chemical indicator placement points and results Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> Hydrogen peroxide Pressure gauge Hydrogen peroxide injector Other 	<ul style="list-style-type: none"> Hydrogen peroxide Pressure gauge Hydrogen peroxide injector High frequency generator Other

Table 6 Control points, utilities, and control devices in radiation sterilization (reference)

	γ -Ray radiation sterilization	Electron beam radiation sterilization
Control point	<ul style="list-style-type: none"> • Absorbed dose • Loading pattern (density) of items being sterilized • Exposure time (conveyor speed or cycle time) • Other requirements 	<ul style="list-style-type: none"> • Absorbed dose • Loading pattern (density) of items being sterilized • Electron beam properties (mean electron beam current, electron beam energy, scanning width) • Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> • Belt conveyor • Dose measurement system • Other 	<ul style="list-style-type: none"> • Electron beam measurement device • Belt conveyor • Dose measurement system • Other

Table 7 Control points, utilities, and control devices in filtration sterilization (reference)

	Liquid filtration sterilization	Gas filtration sterilization
Control point	<ul style="list-style-type: none"> • Filtration time • Filtration capacity • Filtration flow rate • Filtration differential pressure • Temperature • Filter integrity • In cases involving multiple use: expiration period and number of times the filter can be used for sterilization • Other requirements 	<ul style="list-style-type: none"> • Filtration differential pressure • Temperature, if needed • Filter integrity • Expiration period • Number of sterilizations of times the filter can be used for sterilization • Direction of gas current (for bidirectional flow) • Other requirements
Utilities and control devices that should be controlled	<ul style="list-style-type: none"> • Pressure gage • Flow rate meter • Integrity tester • Other 	<ul style="list-style-type: none"> • Pressure gage • Flow rate meter • Integrity tester • Other

a strain of *Brevundimonas diminuta* (ATCC 19146, NBRC 14213), cultured under the appropriate conditions, per square centimeter of effective filter area, provides a sterile effluent.

The bioburden of liquids prior to filtration will affect filtration sterilization performance and should therefore be controlled.

3. Sterilization Indicators

3.1. Biological indicators (BI)

3.1.1. Introduction

A BI is an indicator prepared from the spores of a microorganism resistant to the specified sterilization process, and is used to develop and/or validate a sterilization process.

Indicators are classified based on configuration into the “paper strip type”, “the type that is inoculated on or into the surface of metal or the like”, “liquid type” and “the self-contained type in which a medium and paper strip are pre-encapsulated”. They are also classified by carrier, where one type comprises a carrier of paper, glass, stainless steel, plastic or the like that is inoculated with bacterial spores and packaged, and another type comprises the product or simulated product as the carrier, which is inoculated with bacterial spores. Typical examples of indicators by sterilization method are shown in Table 8.

3.1.2. Labeling of commercially available BI

Users of commercially available BI produced in accordance with ISO11138-1 must check the following information provided by the BI manufacturer to users.

- Traceability (microorganism, carrier, labeling, etc.)

- Species name
- Nominal bacterial spore count
- Resistance
- Method used
- Storage conditions (temperature, expiration date, etc.)
- Culture conditions (temperature, time, medium, etc.)
- Disposal method

Parameters determining BI performance include “species,” “resistance,” and “bacterial count.” Resistance varies, even for the same species, depending on the nature and configuration of the carrier or packaging, and evaluation must therefore include the packaging.

3.1.3. Control during use of commercially available BI

BI must be handled in accordance with the storage conditions, time to start of culture after sterilization, culturing conditions, disposal method, and the like provided by the BI manufacturer. Because the storage conditions in particular affect BI performance, precautions must be taken to prevent a BI from being allowed to stand for a long period of time until use after being removed from the packaging.

The BI should be set up to enable evaluation of the entire items being sterilized. The BI should be set up in places where the sterilization effect is expected to be low in any given method, such as cold spots in heat sterilization. Care should be taken to avoid damaging the BI packaging or carrier when recovered. Predetermined procedures for preventing microbial contamination should be in place in case bacteria are released or spread if the packaging does end up becoming damaged.

When using a BI that has been purchased, the user should

Table 8 List of typical indicators by sterilization method

Sterilization method	Species	Strain name	D value, etc. (reference)
Moist-heat sterilization	<i>Geobacillus stearothermophilus</i>	ATCC 7953, NBRC 13737	≥ 1.5 min (121°C)
Dry-heat sterilization	<i>Bacillus atrophaeus</i>	ATCC 9372, NBRC 13721	≥ 2.5 min (160°C)
EO gas sterilization	<i>Bacillus atrophaeus</i>	ATCC 9372, NBRC 13721	≥ 2.5 min (54°C) ≥ 12.5 min (30°C) Gas concentration: 600 mg/L ± 30 mg/L; relative humidity: 60% RH
Hydrogen peroxide sterilization	<i>Geobacillus stearothermophilus</i>	ATCC 12980, NBRC 12550 or ATCC 7953, NBRC 13737	—

measure the spore count or the like when received as needed to make sure there are no significant differences with the nominal count provided by the BI manufacturer.

3.1.4. Precautions for when sterilization indicators are prepared by the user

The following must be evaluated prior to use when users prepare indicators themselves using the bioburden collected from the items being sterilized or the manufacturing environment rather than purchasing a BI for use.

- Species name
- Bacterial spore count
- Resistance (D value at sterilization temperature or sterilization gas concentration)
- Storage conditions (temperature, expiration date, etc.)
- Culture conditions (temperature, incubation time, medium, etc.)

An evaluation program must be established to continuously show that the resistance of picked bacteria is the most resistant of the bioburden.

3.1.5. Precautions when commercially available BI are modified by users

When a BI that has been purchased is removed from the packaging and is used to inoculate an item such as drug solution or materials, the bacterial spore count or resistance will vary and must therefore be assessed prior to use.

ISO11138 or USP <55> can be used for reference for such evaluation. Resistance can be evaluated by using a biological indicator evaluation resistometer (BIER) or the capillary method with oil bath. When such self-assessment is unfeasible, a third-party testing facility can be used.

3.2. Chemical indicator (CI)

A CI is an indicator that chemically or physically changes due to exposure to heat, gas, radiation, or the like. Such indicators are produced by being applied to or printed on a piece of paper, for example. Because the principals involved in such changes will depend on the sterilization method, a CI that is suitable for the intended sterilization method must be used. CI is classified into the following six classes based on the intended application. The classes shown here are unrelated to level of performance.

A CI indicates the progress of a sterilization step or of a number of critical parameters, but is not used to assure sterilization effect or sterility and therefore cannot be used as an alternative to a BI.

Class 1: Process indicators

These are intended to distinguish whether an item being sterilized has passed through a sterilization step. They respond to one or more critical parameters.

Class 2: Indicators for use in specific tests

Table 9 Types of dosimeters

Type of radiation	Dosimeter
γ-ray	Dyed polymethyl methacrylate dosimeter Clear polymethyl methacrylate dosimeter Ceric-cerous dosimeter Alanine – EPR dosimeter
γ-ray, electron beam	Cellulose acetate dosimeter Radiochromic film dosimeter

These are used in tests of the exhaust capacity and vapor penetration of a vacuum-type high-pressure steam sterilizer as specified in the ISO11140 series. They correspond to the Bowie-Dick type.

Class 3: Single-variable indicators

These respond to only one critical parameter. They show exposure in a sterilization step based on a specified value for the designated parameter.

Class 4: Multi-variable indicators

These respond to two or more critical parameters. They show exposure in a sterilization step based on specified values for the designated parameters.

Class 5: Integrating indicators

These respond to all critical parameters. Their performance is equal to or greater than that required of BI in the ISO11138 series.

Class 6: Emulating indicators

These respond to all critical parameters of a specified sterilization cycle. The specifications are critical parameters of the designated sterilization step.

3.3. Dosimeter

3.3.1. Types of dosimeters

The dosimeter in a radiation process is an instrument or system which reads the absorbed dose based on changes caused by the absorption of the radiation, for which “reproducibility” and “response permitting radiation to be measured” are required. Most dosimeters are susceptible to environmental conditions (process parameters) such as temperature and dose rate before, during, and after exposure to the facilities being used, and caution is therefore required. The choice of dosimeter and calibration guidelines for radiation processes have been specified (ISO/ASTM 51261) as reference for the selection and use of dosimeters. Dosimeters for measuring the absorbed dose of radiation are shown in Table 9. γ-Ray dosimeters are not normally suitable for sterilization process control involving the use of electron

beams of less than 3 MeV energy.

3.3.2. Dosimeter use

Dosimeters are used when dose distribution is measured to determine the conditions of radiation and to evaluate the absorbed dose of an items being sterilized during ordinary radiation sterilization. In the former, dosimeters are set up in advance in the object being sterilized and are then recovered after radiation for measurement in the measurement system to find the absorbed dose at each location. The dosimeters should be arranged in a broad range of vertical and horizontal directions because it is necessary to determine the relationship between minimum/maximum exposure and the process parameters as well as to verify the appropriateness of the packaging configuration based on the variation in radiation penetration and dose. In the latter, there is no need to arrange the dosimeters in the locations characterized by the maximum or minimum dose in the object being sterilized. Control points where dosimeters are easily arranged and recovered should be selected, and the absorbed dose of the object being sterilized should be ensured based on the absorbed dose at the control points. Therefore, in the measurement of dose distribution, the quantitative relationship between the control points and the locations of maximum/minimum exposure should be determined, and the passing dose range at the control points should also be calculated.

Newly purchased dosimeters should be calibrated prior to use, and dosimeters should be calibrated every time a batch is changed and at least once a year.

4. Establishment of Sterilization Conditions

4.1. Half-cycle method

In the half-cycle method, a sterilization time twice as long as that required to inactivate all of the 10^6 CFU bacteria included in the BI is used, regardless of the bioburden count on the object being sterilized or the resistance of the test microorganisms to sterilization. This method is primarily used to establish the conditions of EO or other gas sterilization.

4.2. Overkill method

In the overkill method, a sterilization condition to achieve an SAL of 10^{-6} or better is used, regardless of bioburden count on the object being sterilized or the resistance of the test microorganisms to sterilization.

This means a level of sterilization of $12 D$ in steam sterilization. However, a level $\geq F_0 12$ is also referred to as the overkill method.

4.3. Combination of BI and bioburden method

In the combined bioburden/BI method, the maximum bioburden count is determined based on the results of extensive bioburden analysis, and the sterilization time (or radiation dose) is calculated using an appropriate commercially available BI with a test microorganism count \geq the maximum bioburden count based on the target SAL.

When this procedure is used, the bioburden count of the object being sterilized must be tested on a daily basis, and the resistance of the test microorganisms to sterilization must be periodically measured.

If the bioburden testing reveals a microorganism more resistant than the BI microorganism, it should be used as the indicator. The sterilization conditions must also be revised as needed.

$$\text{Sterilization time (or radiation dose)} = D \times \log (N_0/N)$$

D: *D* value of BI

N: Target sterility assurance level (SAL)

*N*₀: Maximum bioburden count in object being sterilized

4.4. Absolute bioburden method

In the absolute bioburden method, the sterilization resistance of the microorganisms found in the object being sterilized or environment is measured, and the sterilization conditions are determined, in the case of moist-heat sterilization, by employing the *D* value of the most resistant microorganism based on the bioburden count of the object being sterilized.

The bioburden count should be determined by extensive bioburden analysis. When this procedure is used, the microorganism count and the resistance of the detected microorganisms to sterilization must be assessed on a daily basis in routine bioburden control.

Radiation sterilization may be performed in accordance with ISO11137-2.

5. References

- ISO 11138-1 (2006): Sterilization of health care products-Biological indicators-Part1: General requirements
- ISO 11137-2 (2013): Sterilization of health care products-Radiation- Part2: Establishing the sterilization dose
- ISO/ASTM 51261 (2013): Guide for selection and calibration of dosimetry systems for radiation processing
- ISO 11140-1 (2014): Sterilization of health care products-Chemical indicators- Part1: General requirements
- USP 38 (2015) <55> BIOLOGICAL INDICATORS-RESISTANCE PERFORMANCE TEST

G5 Crude Drugs

Analytical Methods for Aflatoxins in Crude Drug and Crude Drug Preparations

Aflatoxins are carcinogenic secondary metabolites produced by some fungal strains¹⁾. They are found in agricultural products such as cereals, tree nuts and spices. Many countries including Japan have set regulatory limits on aflatoxins in foods^{2,3)}. Not only foods but also crude drug may be contaminated by aflatoxins because aflatoxin contamination in the ingredients of botanical products has been reported in some foreign countries⁴⁻⁶⁾. Therefore, aflatoxin testing in crude drug and preparations containing crude drugs as main ingredient (crude drug preparations) is required to be performed. In this connection, the regulatory limit for aflatoxins (sum of B₁, B₂, G₁ and G₂) has been set at 10 $\mu\text{g}/\text{kg}$ for all foods in Japan³⁾.

1. Summary

The methods based on HPLC with fluorescence detection and LC-MS are used for aflatoxins instrumental analysis⁷⁻¹⁰⁾. Aflatoxin standards should be handled with care because they are highly toxic compounds. (Refer to 4. Points to note) Simple measurement kits are also used for analysis of aflatoxin and some of them enable aflatoxin determination without using aflatoxin standards.

Aflatoxins are generally purified from the samples by cartridge-type columns such as immunoaffinity column and multifunctional column. An immunoaffinity column is useful for purification of aflatoxin from crude drug preparations, but in some cases, a multifunctional column is effective.

In this document, the analytical methods for aflatoxins using simple measurement kits, which are useful for screen-

ing, and HPLC with fluorescence detection are described. The methods should be selected according to the characteristics and aflatoxin contamination levels of the samples. Method optimization and validation are required to be performed. As references, an official method of Japan for aflatoxin analysis in food^{7,11)}, analytical methods described in European and US Pharmacopelia, and WHO guidelines can be used⁸⁻¹⁰⁾.

2. Analytical methods

2.1. An analytical method using a qualitative kit

The kit can detect the presence or absence of aflatoxin in the sample by using an antigen-antibody interaction. A kit for the detection of total aflatoxins can be used for qualitative test. The following method can be used for detecting aflatoxins in some extracts (Orengedokuto, Kakkonto, Shoseiryuto, Hachimijiogan, Goshajinkigan, Daiokanzoto and Mukoi-Daikenchuto) listed in Japanese Pharmacopoeia at cut-off levels of 4 ppb¹²⁾. In order to quantify aflatoxins in the positive samples, instrumental analysis is required to be done.

(i) Preparation for sample solution

Weigh accurately about 1 g of the powdered sample, add exactly 4 mL of a mixture of acetonitrile, water and methanol (6:4:1) and then shake for 30 minutes. After centrifugation, dilute exactly 2 mL of the supernatant to 50 mL with phosphate buffered saline (PBS) containing 4% of polysorbate 20. Apply the diluted extract to an immunoaffinity column, which is preequilibrated with PBS. Wash the column with 10 mL of PBS containing 0.01% of polysorbate 20 followed by 10 mL of water. Apply 1 mL of acetonitrile on the column and collect eluate. Wait 5 minutes and apply 2 mL of acetonitrile. Collect applied elution solvent. Evaporate the eluate to dryness under nitrogen. Dissolve the residue in exactly 0.5 mL of diluted methanol (7 in 10), and use this as the sample solution. In this method, 0.5 mL of the sample solution is equivalent to 0.5 g of the sample matrix.

(ii) Measurement and evaluation

Prepare the test strips, the microwells with the inner bottom covered by gold colloid, and the assay diluent attached with the kit. Add exactly 50 μ L of the assay diluent to each microwell. Dissolve the coating conjugate in the microwell by pipetting. Add exactly 50 μ L of sample extracts to each microwell and mix the content in each well by pipetting it up and down. Put one test strip into one well and allow the test strip to develop color for 5 minutes. Interpret test results from the lines formed in the test zone and the control zone. If the two lines are visible, this indicates the sample contains total aflatoxin less than 4 ppb (negative sample).

2.2. An instrumental method of analysis

Aflatoxins can be detected by a fluorescence detector because they are fluorescent substances. In order to enhance the fluorescent intensities of AFB₁ and AFG₁, the intensities of which are weak in polar solvents, a derivatization step is performed. Precolumn derivatization with trifluoroacetic acid and postcolumn derivatization with a photochemical reactor or an electrochemical cell are known. AFB₂ and AFG₂ are not derivatized by the above methods. The following method can be used for quantification of aflatoxins in some extracts listed in Japanese Pharmacopoeia¹²⁾. This method is an example and the other method can also be used.

(i) Preparation for sample solution

Weigh accurately about 1 g of the powdered sample and add exactly 4 mL of a mixture of acetonitrile, water and methanol (6:4:1) and then shake for 30 minutes. After centrifugation, dilute exactly 2 mL of the supernatant to 50 mL

with phosphate buffered saline (PBS) containing 4% of polysorbate 20. Apply the diluted extract to an immunoaffinity column, which is preequilibrated with PBS. Wash the column with 10 mL of PBS containing 0.01% of polysorbate 20 followed by 10 mL of water. Apply 1 mL of acetonitrile on the column and collect eluate. Wait 5 minutes and apply 2 mL of acetonitrile. Collect applied elution solvent. Evaporate the eluate to dryness under nitrogen. Redissolve the residue in exactly 0.5 mL of 70% methanol in water. In this method, 0.5 mL of the sample solution is equivalent to 0.5 g of the sample matrix.

(ii) Measurement and evaluation

Use an ODS column for separation. Aflatoxins can be detected by an HPLC equipped with a fluorescence detector because they are fluorescent (excitation $\lambda = 365$ nm, emission $\lambda = 430$ nm). Use trifluoroacetic acid (TFA) for derivatization of aflatoxins. Aflatoxins elute in the order of AFG_{2a} (a derivative of AFG₁), AFB_{2a} (a derivative of AFB₁), AFG₂ and AFB₂ when a mixture of acetonitrile, water and methanol (6:3:1) is used as a mobile solvent. Postcolumn derivatization with a photochemical reactor is useful when performing continuous monitoring of aflatoxins. In that case, aflatoxins elute in the order of AFG₂, AFG_{2a}, AFB₂ and AFB_{2a}. Prepare some standard solutions in which aflatoxins are present at the concentrations from 0.5 to 20 μ g/L, and verify linearity in the range.

3. Reagents and solutions

Some reagents and solutions prescribed in Japanese Pharmacopoeia and those listed below are used.

(i) PBS containing 0.01% or 4% of polysorbate 20 Dissolve 8.0 g of NaCl, 0.2 g of KCl, 2.9 g of Na₂HPO₄·12H₂O, 0.2 g of KH₂PO₄ and 0.1 g (0.01%) or 40 g (4%) of polysorbate 20 in 900 mL of water and adjust to pH 7.4 with 0.1 mol/L hydrochloric acid TS or dilute sodium hydroxide TS, and add water to make 1000 mL. Keep the solution at 2 – 8°C.

(ii) Aflatoxin solution Dilute the aflatoxin standard stock solution with acetonitrile or methanol. Use the commercially available standard stock solution which is precisely prepared in concentration.

4. Points to note

(i) Aflatoxins are highly cardiotoxic compounds, and sufficient caution is required when handling them. Especially in cases when handling a high concentration of aflatoxins, pay maximum attention. Wear a protect coat, gloves, a mask and goggles. All handling should be performed in a fume hood.

(ii) Soak the used labware in 0.5 – 1.0% sodium hypochlorite (NaClO) solution for more than 2 hours before discarding and washing it. Commercially available sodium hypochlorite solutions for disinfection or for food additive may also be used after adjusting the concentration.

(iii) Keep the aflatoxin solution in a dark and cool place. Keep the commercially available standard stock solution under specified conditions.

(iv) Aflatoxins may be absorbed by a glass vessel. In order to avoid absorption, using silanized glass vials may be effective. The vial should be washed with 20% acetonitrile and air-dried before use.

(v) Be cautious that there are no big air bubbles or cracks in the gel of the immunoaffinity column. If there are bubbles or cracks, remove them by applying pressure from the upper part of the column.

(vi) Confirm the performance of the immunoaffinity column by performing a spike and recovery test if necessary.

(vii) In case of using a multifunctional column for prepar-

ing the sample solution, it is necessary to assess its performance beforehand by performing a spike and recovery test.

5. References

- 1) IARC, IARC monographs on the evaluation of carino-genic risks to humans, Volume 82.
- 2) FAO, FAO food and nutrition paper 81, Worldwide regulations for mycotoxins in food and feed in 2003 (2004).
- 3) Notification No. 0331-6, Director of Food Safety Department, March 31, 2011.
- 4) Trucksess M., J. AOAC Int. 89 (3), 624 – 630 (2006).
- 5) Cavit Bircan, Int. J. Food Science and Technology 40, 929 – 934 (2005).
- 6) Halil Tosun and Recep Arslan, The Scientific World Journal (2013).
- 7) Notification No. 0816-2, Director of Food Safety Department, August 16, 2011.
- 8) European Pharmacopoeia 8.0 (2013), 2.8.18. Determination of aflatoxin B₁ in herbal drugs.
- 9) US Pharmacopeia 37 (2014), <561> Articles of botanical origin.
- 10) WHO, WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues (2007).
- 11) Notification No. 0816-7, Director of Inspection and Safety Division of Food Safety Department, August 16, 2011.
- 12) H. Sakuma, et al. Shoyakugaku Zasshi 68 (2), 53 – 57 (2014).

Aristolochic Acid

Aristolochic acid, which occurs in plants of *Aristolochiaceae*, is suspected to cause renal damage. It is also reported to be oncogenic (see References).

Aristolochic acid toxicity will not be a problem if crude drugs of the origin and parts designated in the JP are used, but there may be differences in crude drug nomenclature between different countries, and it is known that crude drug preparations not meeting the specifications of the JP are circulating in some countries. Consequently, when crude drugs or their preparations are used, it is important that the materials should not include any plant containing aristolochic acid.

Since Supplement I to JP14, the test for aristolochic acid I was added to the Purity under *Asiasarum Root*, which consists of the rhizome and root. Because the aerial part of the plant may contain aristolochic acid and may have been improperly contaminated in *Asiasarum Root*.

It is considered that *Akebia Stem*, *Sinomenium Stem* and *Saussurea Root* do not contain aristolochic acid, unless plants of origin other than that designated in the JP are used. However, contamination of aristolochic acid might occur, as mentioned above. In this case, the test described in the Purity under *Asiasarum Root* is useful for checking the presence of aristolochic acid.

References:

Drug & Medical Device Safety Information (No.161) (July, 2000).

New England Journal of Medicine (June 8, 2000).

Mutation Research 515, 63 – 72 (2002).

Notification for the Quantitative Marker Constituents of Crude Drugs and Crude Drug Preparations

One of the highly distinctive features of the crude drugs and preparations containing crude drugs as main ingredient (crude drug preparations) is the fact that they are multicomponent systems composed of a prodigious number of compounds. As an example, *glycyrrhiza*, one of the most important crude drugs worldwide has been demonstrated that they harbor more than 100 kinds of secondary metabolites, and this number could be counted up to more than 1000 when the intermediate occurred in the biosynthetic pathways were included. The whole members of the compounds are supposed to be integrated to reveal the effects of *glycyrrhiza*.

A wide diversity of constituents in the drugs made from botanical raw materials is fundamentally derived from a wide variety of secondary metabolites occurred in plants. However, there are more reasons for the diversity. The species of plants used as raw materials for drugs are specified in the approval documents of the drugs, though, a variation of their composition derived from the genetic variation of the plants will be produced since each botanical species includes a significant genetic divergence. The secondary metabolites of plants will be further differentiated in their quality and quantity according to the environmental factors such as soil (soil texture, water retentivity, pH, etc.) and weather (amount of precipitation, temperature, humidity, etc.) conditions. Also crude drugs are finally processed by excluding periderm, steaming, roasting, etc. and consequently the constituents are different according to the process method.

The stipulation on the quantitative values of marker constituents in crude drugs and crude drug preparations has very important implications for standardization of the quality of pharmaceutical natural products. The stipulations on crude drugs generally provide the minimum requisite amount of marker compounds. For example, *glycyrrhiza* of the Japanese Pharmacopoeia is ordered to contain not less than 2.0% of glycyrrhizic acid. Crude drugs are known to exhibit large difference in the content of secondary metabolites among individual plants that caused from multiple reasons described in the previous paragraph. It is reported that the glycyrrhizic acid content of *glycyrrhiza* in one plant can contain some 10 times the content of another plant when they are grown together in one farm field and harvested simultaneously. Accordingly, it is hard to standardize the ranges of content for marker constituents of crude drugs on a policy of the efficient use of natural resources for crude drugs. However, the crude drug preparations as finished products are required to contain a certain amount of active ingredients from a perspective of the reproducibility of medical treatments. Consequently, the marker constituents of the Kampo formulations and conventional crude drug preparations as the final stage of crude drug preparations are generally specified by the range of content values. Crude drugs containing different amount of marker constituents are appropriately blended to prepare the finished products with a particular amount of marker constituents.

It should be noted that the marker constituents of crude drugs for regulations include a variety of types. Followings are the examples of some different types. Sennosides, the marker constituents of senna leaf are the obvious active ingredients that accounts for the laxative effects of senna leaf to some extent. Other compounds of the anthraquinone-type found in senna leaf, such as rhein and aloe-emodin, are also

potent as laxative, though, because of their large difference in content in senna leaf, a medicinal effect of senna leaf can be standardized by managing the content of sennosides. However, sennosides are likely to be broken down into anthraquinones by heating and other factors that not only sennosides but also the increased rhein may be targeted for standardization in cases of the Kampo formula extracts including rhubarb, one of the sennoside-containing crude drugs, as a component. On the other hand, glycyrrhizic acid, a very famous bioactive component of *glycyrrhiza*, is an active ingredient that contributes to some parts of the medical effect of *glycyrrhiza*. Though, many components other than glycyrrhizic acid are also known to play a part in the medical effects of *glycyrrhiza*. Consequently, glycyrrhizic acid should be regarded as one of the multiple active ingredients of *glycyrrhiza* that being specified its content as a marker constituent. In other cases of the marker constituents that seemed to have less biological effects such as 10-hydroxy-2-(*E*)-decenoic acid in royal jelly or (*E*)-cinnamic acid in some extracts of Kampo formula, their content are standardized as a distinctive compound of each pharmaceutical product. Referring to the biosyntheses of natural products, the content of these compounds specified as marker constituents are unlikely to be independently changed to stand out from others. The specification values of crude drugs and crude drug preparations are stipulated in order to control the appropriate production process based on the strategy that every crude drug and crude drug preparation will be standardized to a certain level through the content control of marker constituents.

An instance of the relationship between the active ingredient and the marker compound of senna leaf may be a special case among crude drugs and pharmaceutical natural products made from crude drugs. The medicinal effects of the majority of crude drugs and pharmaceutical natural products made from crude drugs are achieved by the cooperative performance of their entire constituents. These drugs are standardized with the quantitative specification of particular constituents designated as the quantitative marker constituents, and this is owing to the fact that the standardization of every constituent consisting the multicomponent system is impossible. Taken all together, it requires particular consideration to the fact that the quantitative marker compounds specified for crude drugs and crude drug preparations are not directly same as the active ingredients in the chemical drugs that absolutely accounts for the medical effects of the drugs.

Purity Tests on Crude Drugs using Genetic Information

The first step in the quality assurance of natural products is the use of raw materials from the right part of the right origin (the right source). Therefore, it is clearly stated in Article 4 of the General Rules For Crude Drugs that the source of a crude drug is the approval or rejection criteria. There are various methods for differentiating the sources of crude drugs, such as morphological methods, organoleptic tests, and chemical methods, and appropriate methods for each are described in the individual monographs. Morphological methods, organoleptic tests, and chemical methods are discrimination methods for species that are based on the phenotypic characteristics of the crude drugs. On the other hand, together with recent progress in molecular biology techniques and the accumulation of genetic information on

plants, differentiating methods of crude drugs based on genotypes have been established. Unlike morphological and other methods that are based on phenotypic characteristics, the genotypic methods are not affected by environmental factors. Also, the methods have several advantages, such as specialized expertise and skill for classification are not needed, and objective results are easily obtained.

The evolution of living organisms is accomplished by genetic mutation, and differences among the nucleotide sequences of genes of closely related species reflect the strain relationships between the species. Based on this theory, in recent years methods that classify species phylogenetically using the nucleotide sequence of rDNA that codes for ribosomal RNA (rRNA) on the nuclear genome have been adopted. In the same way, the sequence of this rDNA is also most often used in the classification of higher plants based on the genotype. In particular, it is very easy to classify closely related species using the intergenic transcriber space (ITS) region of the rDNA region, since by comparison with the coded gene region nucleotide substitution is more often undertaken. Furthermore, since the genes on the nuclear genome originate from the parents' genome, there is an advantage that interspecies hybrids can be detected. Higher plants also have mitochondrial genes and chloroplastic genes. Although the genes on these genomes are also often used for classification, interspecies hybrids cannot be confirmed because the genes are normally uniparental inheritance.

The two methods presented here have been developed based on the reported identification methods of *Atractylodes Lancea* Rhizome and *Atractylodes Rhizome*^{1,2)} utilizing the gene sequence of the ITS of rDNA. Inter-laboratory validation study for purity test of *Atractylodes Rhizome* targeted for *Atractylodes Lancea* Rhizome have been completed. The plant sources for *Atractylodes Lancea* Rhizome stipulated in the individual monographs are *Atractylodes lancea* De Candolle or *A. chinensis* Koidzumi (*Compositae*), while those for *Atractylodes Rhizome* are *A. japonica* Koidzumi ex Kitamura or *A. ovata* De Candolle (*Compositae*). The approval or rejection of the source of *Atractylodes Lancea* Rhizome is, in principle, determined by the description of the crude drug, including microscopy, while that of *Atractylodes Rhizome* is determined by the description of the crude drug, including microscopy, together with color reaction, which is an identification test. In the above scientific paper, it was shown that these 4 plant species can be clearly classified by comparing the nucleotide sequences of the ITS mentioned above, and that the species can be easily classified without performing sequence analysis by performing PCR using a species specific primer set or by using a restriction enzyme which recognizes species specific sequence.

In validation studies, the simplicity of the test is given maximum consideration. We examined methods that observe PCR amplification bands using species specific primer sets (Mutant Allele Specific Amplification: Method 1) and that observe DNA fragments produced by restriction enzyme treatment of the PCR products, which are prepared using a primer set common to each plant source (PCR-Restriction Fragment Length Polymorphism: Method 2), and do not involve nucleotide sequence analyses. In these methods based on PCR, an extremely small amount of template DNA is amplified to billions to hundred-billions times. Therefore, when using them as identification tests for powdered crude drugs, the target DNA fragment can be observed even if the vast majority of the crude drug for analysis is not appropriate plant species and there is only a minute amount of powder from a crude drug derived from a suitable plant.

(Consequently, in identification tests, either a cut or a whole crude drug must be used, as long as one is careful to avoid contamination by powder originating from other crude drugs.) On the other hand, when used as a purity test, the form of the crude drug is irrelevant as long as the gene amplification is performed properly and the target gene is not polymorphic, so if DNA fragments of an inappropriate plant are confirmed in the purity test, regardless of the form of the crude drug, it becomes clear there is contamination by an inappropriate crude drug.

The methods shown here are reference information and at the present stage results obtained using the methods do not affect the approval or rejection of the crude drug in each monograph. Furthermore, by performing the sequence analysis outlined in the previous paper, it goes without saying that more accurate decision concerning the source species can be made.

1. DNA Amplification Equipment

DNA amplification equipment is used to amplify the DNA which is extracted from a crude drug and then purified. Since there are slight differences in the methods of temperature control, and so on depending on the equipment used, there may be differences in the intensity, etc. of the PCR amplification bands even if PCR is carried out under the stipulated conditions. Therefore, when judging results based solely on the presence or absence of PCR amplification bands as in 3. Methods 1, confirm that only proper amplification bands are obtained when performing PCR using DNA obtained from samples confirmed beforehand to be the source species. If proper amplification bands are not obtained, the PCR temperature conditions should be slightly adjusted. This equipment can be used for the restriction enzyme treatment in 4. Method 2.

2. General precautions

Crude drugs are different from fresh plants in that they are dried products and a certain amount of time has passed since they were harvested. Therefore, in many cases the DNA has undergone fragmentation. Furthermore, various substances that can block or interfere with the PCR reaction may be present in the plant. For these reasons, the extraction and purification of template DNA is the process that should receive the greatest amount of attention. In the case of Atractylodes crude drugs, the periderm should be removed using a clean scalpel or other clean instrument before pulverizing the sample because very often there are inhibitory substances present in the periderm.

3. Method 1 (Mutant Allele Specific Amplification Method)

Generally, this method is referred to as Mutant Allele Specific Amplification (MASA) or Amplification Refractory Mutation System (ARMS), and it provides nucleotide sequence information of sample-derived template DNA, based upon the presence or absence of DNA amplification in PCR using a species specific primer set.

3.1. Procedure

The following is an example procedure.

3.1.1. Preparation of template DNA

There are various methods with which to extract and purify DNA from the samples. It is recommended that commercially available DNA extraction kits be used when considering their advantages of not using any noxious reagents and not requiring any complicated purification procedures. In this case, attention should be paid to the final amount (concentration) of DNA obtained, and the initial amount of initial sample and the volume of liquid to elute the DNA need

to be controlled. When extraction and purification are performed using silica gel membrane type kits stipulated in notifications³⁾ related to inspection methods of the foods produced by recombinant DNA techniques, it is appropriate to use 200 mg of sample, 1 mL of AP1 buffer solution, 2 μ L of RNase A, and 325 μ L of AP2 buffer solution. Also, the most important things are that the supernatant loaded on the first column is clear and that there is no need to load 1 mL unreasonably. Furthermore, 50 μ L is an appropriate volume used in the final elution of the DNA, and normally the initial eluate is used as the DNA sample stock solution.

3.1.2. Confirmation of purity of DNA in DNA sample stock solution and assay of DNA

The purity of the DNA in the stock solution can be confirmed by the $OD_{260\text{ nm}}/OD_{280\text{ nm}}$ ratio using a spectrophotometer. A ratio of 1.5 indicates that the DNA has been adequately purified. The amount of DNA is calculated using $1\text{ OD}_{260\text{ nm}} = 50\text{ }\mu\text{g/mL}$. The measurement mentioned above is performed using appropriately diluted DNA sample stock solution. Based on the results obtained, dilute with water to the concentration needed for the subsequent PCR reactions, dispense the solution into micro tubes as the sample DNA solution, and if necessary store frozen at not over -20°C . The dispensed DNA sample is used immediately after thawing and any remaining solution should be discarded and not refrozen. If the concentration of the DNA sample stock solution does not reach the concentration stipulated in PCR, it is used as a DNA sample solution.

3.1.3. PCR

When a commercially available PCR enzyme mentioned in the above notification⁴⁾ is used, it is appropriate that 25 μ L of reaction mixture consisting of 2.5 μ L of the PCR buffer solution containing magnesium, dNTP (0.2 mmol/L), 5' and 3' primer (0.4 μ mol/L), Taq DNA polymerase (1.25 units), and 5 μ L of 10 ng/ μ L sample DNA solution (50 ng of DNA) is prepared on ice. Among them, the PCR buffer solution and dNTP are provided as adjuncts to the enzyme. When conducting purity tests on *Atractylodes Lancea* Rhizome in *Atractylodes* Rhizome, the primer sets used are C and D (C is positive with *A. lancea*, D is positive with *A. chinensis*) as described in the paper mentioned above (*J. Nat. Med.* 60, 149 – 156, 2006), however, when a combination of primer A and B is used, it is possible to confirm the source species of each of the respective specimens. In order to confirm that the DNA has been extracted correctly, the reaction solution containing the positive control primer (Pf and Pr) as shown below should be prepared. In addition, the negative control solutions which are not containing DNA sample or either of the primer sets should be prepared and simultaneously conduct PCR.

Pf: 5'-CAT TGT CGA AGC CTG CAC AGC A-3'

Pr: 5'-CGA TGC GTG AGC CGA GAT ATC C-3'

The PCR reaction is performed under the following conditions: starting the reaction at 95°C for 10 minutes, 30 cycles of 0.5 minutes at 95°C and 0.75 minutes at 68°C (69°C only when using the primer set C), terminate reaction at 72°C for 7 minutes, and store at 4°C . The resulting reaction mixture is used for the following process as PCR amplification reaction solution.

3.1.4. Agarose gel electrophoresis and detection of PCR products

After completion of the PCR reaction, mix 5 μ L of the PCR amplification reaction solution with an appropriate volume of gel loading buffer solution, add the mixture to the wells of 2 w/v% agarose gel, and then perform electrophoresis using 1-fold TAE buffer solution (refer to General Infor-

mation, Rapid Identification of Microorganisms Based on Molecular Biological Method). Run in parallel an appropriate DNA molecular mass standard. Electrophoresis is terminated when the bromophenol blue dye in the gel loading buffer has advanced to a point corresponding to 1/2 to 2/3 the length of the gel.

Stain the gel after electrophoresis when not using gel stained in advance with ethidium bromide. Place the gel that has undergone electrophoresis and staining in a gel image analyzer, irradiate with ultraviolet light (312 nm), and detected its electrophoresis pattern. Compare this to the DNA molecular mass standard and determine the absence or presence of the target amplification band.

3.2. Judgment

Confirm at first that a 305 bp band is found with the reaction solution to which the positive control primer set has been added, and confirm there are no bands in a solution with no primer sets and a solution with no sample DNA solution. Next, if a 226 bp band is confirmed when the primer set C is added or if a 200 bp band is confirmed when the primer set D is added, the sample is judged to be Atractylodes Lancea Rhizome (in the case of cut crude drug, contamination of Atractylodes Lancea Rhizome is observed) and it is rejected. The sample is judged not to be Atractylodes Lancea Rhizome (in the case of cut crude drug, there is no contamination of Atractylodes Lancea Rhizome) and the purity test is acceptable if a 305 bp band is confirmed with the positive control primer set, bands are not observed in reaction solution without primer and reaction solution without DNA sample solution, and a 226 bp band is not observed with the primer set C and a 200 bp band is not observed with the primer set D. If a band is not observed with the positive control primer, it is to be concluded that the DNA extraction failed and the procedure should be started over again from the DNA extraction step. If bands are confirmed in reaction solutions without primer sets or without DNA sample solution, it should be assumed that there was an error in the PCR procedure and therefore the procedure should be repeated again from the step 3.1.3. PCR.

4. Method 2 (PCR-Restriction Fragment Length Polymorphism)

Generally, this method is referred to as PCR-Restriction Fragment Length Polymorphism (RFLP), and it provides nucleotide sequence information of sample-derived template DNA, based upon the DNA fragment pattern produced by restriction enzyme treatment of the PCR products, which are amplified by using a primer set common to the DNA sequence of the objective plant.

The test is performed with 25 samples randomly taken from a lot, and each sample is designated with a number from 1 to 25. Differentiation of the sources is performed by individual PCR-RFLP measurement of the samples, and decision of the acceptability of the purity is dependent on how many nonconforming samples are present in the first 20 samples, taken in numerical order, for which judgment is possible as described below.

4.1. Procedure

The following is an example procedure.

4.1.1. Preparation of template DNA

There are various methods with which to extract and purify DNA from the samples. It is recommended that commercially available DNA extraction kits be used, when considering their advantages of not using noxious reagents and not requiring complicated purification procedures. Recently, PCR reagents that inhibit the effect of PCR enzyme-inhibiting substances present in samples have become com-

mercially available, and by using these reagents, it is possible to prepare the template DNA from the sample simply by incubating the sample with the DNA extraction reagent. Here, a recommended DNA preparing procedure using such PCR reagents is described for the convenience of experimenters.

Cut 20 mg of the sample into small pieces with a clean knife, add 400 μ L of the DNA extraction reagent, and incubate at 55°C overnight (16 – 18 hours). Then heat at 95°C for 5 minutes to inactivate the enzyme in the reagent. Centrifuge to precipitate the sample, and use 50 μ L of the supernatant liquid as the template DNA solution. The DNA solution prepared in this method can not be used for concentration measurement based on OD_{260 nm}, because it contains many foreign substances affecting OD₂₆₀ value from the sample.

The composition of the DNA extraction reagent is as follows:

2-Amino-2-hydroxymethyl-1,3-propanediol-hydrochloric acid (pH 8.0)	20 mmol/L
Ethylenediamine tetraacetate	5 mmol/L
Sodium chloride	400 mmol/L
Sodium dodecyl sulfate	0.3%
Proteinase K	200 μ g/mL

4.1.2. PCR

In the method using the PCR enzyme and PCR reagent as described²⁾, the reaction mixture is prepared on an ice bath in a total volume of 20 μ L of a solution containing 10.0 μ L of 2-fold concentrated PCR reagent, 5'- and 3'-primers (0.5 μ mol/L), Taq DNA polymerase (0.5 units) and 0.5 μ L of template DNA solution.

The PCR reaction is performed under the following conditions: 95°C for 10 minutes, 40 cycles of 95°C for 0.5 minute, 65°C for 0.25 minute, and 72°C for 0.25 minute and 72°C for 7 minutes. Store the solution at 4°C, and use this solution as the PCR amplified solution. A negative control (containing water instead of the template DNA solution) must be included in the procedure.

The sequence of each primer is as follows:

5'-primer: 5'-GGC ACA ACA CGT GCC AAG GAA AA-3'

3'-primer: 5'-CGA TGC GTG AGC CGA GAT ATC C-3'

4.1.3. Restriction enzyme treatment

The treatment is performed on individual reaction solutions using two enzymes, *Fau* I and *Msp* I. In the case of *Fau* I, to an appropriate amount of the reaction solution, composed of a reaction buffer containing 1.0 unit of enzyme, add 3.0 μ L of PCR products while cooling in an ice bath to make 15.0 μ L. In the case of *Msp* I, to an appropriate amount of the reaction solution, composed of a reaction buffer containing 20.0 units of enzyme, add 3.0 μ L of PCR products while cooling in an ice bath to make 15.0 μ L. Incubate these solutions at the temperature recommended by the manufacturer for 2 hours, and then inactivate the enzyme by heating at 72°C for 10 minutes. The negative control of the PCR reaction is also treated in the same manner.

4.1.4. Agarose gel electrophoresis and detection of DNA fragments

After the restriction enzyme treatment, mix the total amount of the reaction solution and an appropriate amount of the gel loading buffer solution, place it in a 4 w/v% agarose gel well, and carry out electrophoresis with 1-fold concentrated TAE buffer solution (see "Rapid Identification of Microorganisms Based on Molecular Biological Methods" under General Information). Carry out the electrophoresis together with appropriate DNA molecular mass standard. Stop the electrophoresis when the bromophenol

blue included in the loading buffer solution has moved about 2 cm from the well. The 4 w/v% agarose gel is sticky, difficult to prepare and hard to handle, so that it is better to use a commercially available precast gel.

After the electrophoresis, stain the gel, if it is not already stained, with ethidium bromide, and observe the gel on an illuminating device under ultraviolet light (312 nm) to confirm the electrophoretic pattern.

4.2. Judgment

4.2.1. Judgment of each sample

Confirm that no band is obtained with the negative control of the PCR, other than the primer dimer (about 40 bp) band. A sample treated with *Fau* I, showing bands of about 80 bp and 60 bp, or that treated with *Msp* I, showing bands of about 90 bp and 50 bp, is judged as *Atractylodes Lancea Rhizome*. A sample not showing any band other than a band at about 140 bp and the primer dimer band is judged as *Atractylodes Rhizome*. If a sample does not show any band other than the primer dimer band, it is considered that PCR products were not obtained, and judgment is impossible for the sample.

4.2.2. Judgment of the purity

Judgment of the purity is based on the result of the judgment of each sample. If there is no sample that is judged as *Atractylodes Lancea Rhizome* among 20 samples taken in order of the numbering, excluding any sample for which judgment is impossible, the lot is acceptable for purity. When there is one sample that is judged as *Atractylodes Lancea Rhizome* among the 20 samples, perform the same test with 25 newly taken samples from the lot, and if there is no sample that is judged as *Atractylodes Lancea Rhizome*, the lot is acceptable for purity. When there is a sample that is judged as *Atractylodes Lancea Rhizome* in the second test, or there is more than one sample that is judged as *Atractylodes Lancea Rhizome* in the first test, the lot is not acceptable for purity.

5. Reference

- 1) Y. Guo, *et al.*, *J. Nat. Med.* 60, 149 – 156 (2006).
- 2) K. Kondo, *et al.*, *J. Jpn. Bot.* 84, 356 – 359 (2009).
- 3) Notification No. 110, Director of Food Health Department, March 2001; Partial Amendment: Notification No. 0629002, 2.2.1.2, Director of Food Safety Department, June 2006.
- 4) Notification No. 0629002, 2.1.3.1.1, Director of Food Safety Department, June 2006.

Quantitative Analytical Technique Utilizing Nuclear Magnetic Resonance (NMR) Spectroscopy and its Application to Reagents in the Japanese Pharmacopoeia

1. Marker Compounds for the Assay of Crude Drugs in the JP and Establishment of Reference Substances for Quantitative Analyses

When the quantitative assay values are specified in the monographs of crude drugs and extracts of Kampo formulations in the JP, it is more difficult to establish and prepare their JP Reference Standards than those for synthetic chemical pharmaceutical substances, because the marker compounds for their assay are derived from natural sources.

Unlike the synthetic chemical pharmaceutical substances,

crude drugs and extracts of Kampo formulations are mixtures of a great deal of compounds. Although it is necessary to choose a substance contained at the level of 0.1% to several % in the crude drugs and the extracts of Kampo formulations as the marker compounds for their quantitative assay, the synthesis of such compounds is not so easy in most cases. Therefore, the marker compound would be separated from natural materials and be isolated to have sufficient purity. However, the preparation of the reference substance in such a way would require high economical cost and a great deal of effort. In addition, the composition of impurities contained in the reference substance prepared in such a way would be different batch by batch according to the difference of raw materials and their processes of extraction, isolation and purification. Accordingly, the difference among batches of reference materials is much larger than that of synthetic substances, and the control of their purity as the official reference standards is very difficult. Furthermore, in many cases of substances of natural origin, the greatest impurity would be water. For determining water contents precisely, it is necessary to use Karl Fischer method, and as the result, a large quantity of the valuable reference standard would be consumed.

Because there are such bottlenecks mentioned above in many cases of monographs of crude drugs and extracts of Kampo formulations, the establishment of the JP Reference Standard is difficult. Instead, reagents, which are commercially available or ready to put into the market, are designated as the reference substances for the quantitative assay, and the method and the content specification using the reagent are specified in monographs of crude drugs and extracts of Kampo formulations. In these cases, the specifications of their marker substances are defined in the section of Reagents and Test Solutions of the JP. However, in a strict sense, since the assay values obtained in this manner are not certified metrologically, the reliability of the analytical value obtained by using them is somewhat ambiguous.

2. Application of Quantitative NMR to Reference Substances Used in the Assay of Crude Drugs and Extracts of Kampo Formulations

The application of quantitative NMR can solve the issue on the purity of reagents derived from natural source. These reagents are used as the reference substances with metrological traceability, when the precise contents of these reagents are determined metrologically by using quantitative NMR based on the idea shown in 10.1 Principle of Quantitative Analytical Technique Utilizing Nuclear Magnetic Resonance (NMR) Spectroscopy under <5.01> Crude Drugs Test.

Currently, the quantitative NMR is being carried out for these reagents defined for the quantitative assay of crude drugs in the JP and a report in which the points to practically consider at determination of absolute purities of the reagents by using quantitative NMR are discussed has been published.¹⁾ In addition, a validation study of quantitative NMR has also been performed using the substances which will be used with high possibility as the reference substances for HPLC quantitative analysis. For the analyte compound having molecular mass of around 300, when about 10 mg of the compound was used for the quantitative NMR measurement, it was demonstrated that an accuracy of 2 significant digits for the determined value was achieved at the ordinary laboratory level, even when the error among the NMR instruments used was included.²⁾ Usually, the contents of marker compounds for the quantitative assay of crude drugs are several % at the maximum, and the minimum unit for the content specification is at the level of 0.1%. There-

fore, when variability of content in crude drugs is considered, the assurance of 2 significant digits for accuracy seems sufficient for the reference substances, which are used for the quantitative assay of crude drugs.

When discussion above is considered, the ambiguity of analytical values obtained by the use of the reagents derived from natural source as the reference substances for the quantitative assay of crude drugs can be avoided practically, by using the reagents certified by quantitative NMR as the reference substances in HPLC, etc., and by incorporating the certified purity of such reagent into the calculation of the quantitative value of the sample. For example, for Gardenia Fruit in the JP, the content of geniposide is specified at not less than 3.0% based on the HPLC analysis. The report cited above¹⁾ demonstrated that the absolute purity of geniposide used as the reference substance in the quantitative assay of Gardenia Fruit is determined to be about 92% by quantitative NMR. Therefore, in the case that the quantitative value of 3.0% in Gardenia Fruit sample is obtained as a result of HPLC analysis by using this reagent as the reference substance assuming its purity as 100%, the true value for the sample is evaluated to be 2.8% taking it into consideration of the absolute purity determined by quantitative NMR with the assurance of metrological traceability.

3. Supply of Certified Reagents by Using Quantitative NMR

Currently, in the accreditation system of the International Accreditation Japan (IA Japan), the National Institute of Technology and Evaluation (ASNITE), a feasibility study how the accreditation should be given to the organization which performs the assay certification of the reagents using calibrated NMR apparatus has been in progress. In addition, in the IA Japan, addition of "Quantitative NMR" to the test method categories is scheduled. Therefore, in the near future, the reagent manufacturers will become able to perform the assay certification of the reagent after having this accreditation. Under such situation, the user of the reagent would not be required to perform qualitative NMR individually to obtain the purity value with SI traceability. Furthermore, the inter-institutional errors (including inter-instrumental errors) would become negligible, and we will be able to carry out more precise and accurate quantitation assay of the sample by incorporating the labeled certified value on the reagent into the calculation of the quantitative value of the sample.

The certified reference materials (NMIJ CRM) to be used for the SI traceable metrological determination of the internal reference compounds are supplied from the National Metrology Institute of Japan, National Institute of Advanced Industrial Science and Technology (NMIJ AIST).

4. Management of Instrument Performance for Quantitative NMR

Quantitative NMR used to determine the purity of reagents for the JP, is an internal standard method that analyte compound and SI traceable reference material in a NMR tube are measured at the same time.³⁾ In this method, the number of nuclei are measured using NMR phenomenon, which means that the molar quantity of analyte compound in a sample solution is directly calibrated with a reference material.

In the management of instrument performance for quantitative NMR measurements, it should be confirmed that integral value of the targeted signals can be determined correctly within the spectrum where the signals are measured (in general, 0 – 10 ppm). The important point here is not to include the signals derived from impure substances in the

quantitative spectrum when integrate. Therefore, to manage instrument performance, a high-purity compound of already known purity (determined by quantitative NMR and not less than 99.0% is preferable) should be used. In addition, signals derived from simpler spin system should be selected and integrated, and the ratio of theoretical number of nuclei among signals should be accurate (for example, when each of the two signals is derived from 1H, the ratio of the integrated values of the both is 0.995 – 1.005).

Considering the excitation bandwidth of a NMR pulse, when an instrument of 800 MHz is used under the following conditions; center of spectrum window around 5 ppm, spectral width at 20 ppm (the conditions stipulated in assay using qNMR in the section of reagents), with a 90° pulse width of 10 microseconds, the excitation efficiency of the pulse in the range of 0 – 10 ppm, where signals of analyte compound are observed, is usually not less than 99.95%. Thus, the instrument, when probe is well tuned and shim is adjusted properly, can assure an accuracy of 2 significant digits at routine level of measurement. Furthermore, when an instrument of 400 MHz is used, similar excitation efficiency can be obtained up to 20 microseconds for 90° pulse width, so quantitative NMR can be measured sufficiently with a standard probe.

5. Reference

- 1) J. Hosoe, et al., Pharmaceutical and Medical Device Regulatory Science, 41, 960 – 970 (2010)
- 2) J. Hosoe, et al., Pharmaceutical and Medical Device Regulatory Science, 43, 182 – 193 (2012)
- 3) J. Hosoe, et al., Pharmaceutical and Medical Device Regulatory Science, 45, 243 – 250 (2014)

On the Scientific Names of Crude Drugs listed in the JP

The notation system of the scientific names for the original plants and animals of crude drugs listed in JP is not necessary the same as the taxonomic system used in the literature. The reason for this is that the JP is not an academic text, but an ordinance. The relationship between the scientific names used in the JP and those generally used taxonomically is indicated in the following table, to avoid misunderstanding by JP users owing to differences in the notation system.

Scientific Names used in the JP and Those being used Taxonomically

Crude Drug	Scientific names used in the JP = Scientific names being used taxonomically (Combined notation, Standard form for author or authors)	Family
Acacia アラビアゴム	Scientific names that are different from those written in JP but identical to them taxonomically or being regarded as identical, and typical sub-classified groups belonging to their species. The names marked with “*” are those being written together in JP. <i>Acacia senegal</i> Willdenow = <i>Acacia senegal</i> (L.) Willd.	<i>Leguminosae</i>
Achyranthes Root ゴシツ	Other species of the same genus <i>Achyranthes fauriei</i> Leveille et Vaniot = <i>Achyranthes fauriei</i> H. Lev. & Vaniot <i>Achyranthes bidentata</i> Blume	<i>Amaranthaceae</i>
Agar カンテン	<i>Gelidium elegans</i> Kuetzing Other species of the same genus Red seaweeds of several species	<i>Gelidiaceae</i>
Akebia Stem モクツウ	<i>Akebia quinata</i> Decaisne = <i>Akebia quinata</i> (Thunb. ex Houtt.) Decne. <i>Akebia trifoliata</i> Koidzumi = <i>Akebia trifoliata</i> (Thunb.) Koidz.	<i>Lardizabalaceae</i>
Alisma Tuber タクシャ	<i>Alisma orientale</i> Juzepczuk = <i>Alisma orientale</i> (Sam.) Juz. <i>Alisma plantago-aquatica</i> L. var. <i>orientale</i> Sam.	<i>Alismataceae</i>
Aloe アロエ	<i>Aloe ferox</i> Miller = <i>Aloe ferox</i> Mill. Hybrid between <i>Aloe ferox</i> Miller and <i>Aloe africana</i> Miller = <i>Aloe africana</i> Mill. Hybrid between <i>Aloe ferox</i> Miller and <i>Aloe spicata</i> Baker	<i>Liliaceae</i>
Alpinia Officinarum Rhizome リョウキョウ	<i>Alpinia officinarum</i> Hance	<i>Zingiberaceae</i>
Amomum Seed シュクシャ	<i>Amomum xanthioides</i> Wallich = <i>Amomum xanthioides</i> Wall. <i>Amomum villosum</i> Lour. var. <i>xanthioides</i> (Wall.) T. L. Wu et Senjen	<i>Zingiberaceae</i>
Anemarrhena Rhizome チモ	<i>Anemarrhena asphodeloides</i> Bunge	<i>Liliaceae</i>
Angelica Dahurica Root ビャクシ	<i>Angelica dahurica</i> Bentham et Hooker filius ex Franchet et Savatier = <i>Angelica dahurica</i> (Hoffm.) Benth. & Hook. f. ex Franch. & Sav.	<i>Umbelliferae</i>
Apricot Kernel キョウニン	<i>Prunus armeniaca</i> Linné = <i>Prunus armeniaca</i> L. <i>Prunus armeniaca</i> Linné var. <i>ansu</i> Maximowicz = <i>Prunus armeniaca</i> L. var. <i>ansu</i> Maxim. <i>Prunus sibirica</i> Linné = <i>Prunus sibirica</i> L.	<i>Rosaceae</i>
Aralia Rhizome ドクカツ	<i>Aralia cordata</i> Thunberg = <i>Aralia cordata</i> Thunb.	<i>Araliaceae</i>
Areca ビンロウジ	<i>Areca catechu</i> Linné = <i>Areca catechu</i> L.	<i>Palmae</i>

Artemisia Capillaris Flower インチンコウ	<i>Artemisia capillaris</i> Thunberg = <i>Artemisia capillaris</i> Thunb.	Compositae
Artemisia Leaf ガイヨウ	<i>Artemisia princeps</i> Pampanini = <i>Artemisia princeps</i> Pamp.	Compositae
	<i>Artemisia montana</i> Pampanini = <i>Artemisia montana</i> (Nakai) Pamp.	
Asiasarum Root サイシン	<i>Asiasarum sieboldii</i> F. Maekawa = <i>Asiasarum sieboldii</i> (Miq.) F. Maek.	Aristolochiaceae
	<i>Asarum sieboldii</i> Miq.	
	<i>Asarum sieboldii</i> Miq. var. <i>seoulense</i> Nakai	
	<i>Asiasarum heterotropoides</i> F. Maekawa var. <i>mandshuricum</i> F. Maekawa = <i>Asiasarum heterotropoides</i> (F. Schmidt) F. Maek. var. <i>mandshuricum</i> (Maxim.) F. Maek.	
	<i>Asarum heterotropoides</i> F. Schmidt var. <i>mandshuricum</i> (Maxim.) Kitag.	
Asparagus Root テンモンドウ	<i>Asparagus cochinchinensis</i> Merrill = <i>Asparagus cochinchinensis</i> (Lour.) Merr.	Liliaceae
Astragalus Root オウギ	<i>Astragalus membranaceus</i> Bunge = <i>Astragalus membranaceus</i> (Fisch.) Bunge	Leguminosae
	<i>Astragalus mongolicus</i> Bunge	
	<i>Astragalus membranaceus</i> (Fisch.) Bunge var. <i>mongolicus</i> (Bunge) Hsiao	
Atractylodes Lancea Rhizome ソウジュツ	<i>Atractylodes lancea</i> De Candolle = <i>Atractylodes lancea</i> (Thunb.) DC.	Compositae
	<i>Atractylodes chinensis</i> Koidzumi = <i>Atractylodes chinensis</i> (DC.) Koidz.	
	Hybrid between above species	
Atractylodes Rhizome ビャクジュツ	<i>Atractylodes japonica</i> Koidzumi ex Kitamura = <i>Atractylodes japonica</i> Koidz. ex Kitam.	Compositae
	<i>Atractylodes macrocephala</i> Koidzumi = <i>Atractylodes macrocephala</i> Koidz.	
	* <i>Atractylodes ovata</i> De Candolle = <i>Atractylodes ovata</i> (Thunb.) DC.	
Bear Bile ユウタン	<i>Ursus arctos</i> Linné = <i>Ursus arctos</i> L.	Ursidae
	Other animals of the related genus	
Bearberry Leaf ウワウルシ	<i>Arctostaphylos uva-ursi</i> Sprengel = <i>Arctostaphylos uva-ursi</i> (L.) Spreng.	Ericaceae
Beef Tallow 牛脂	<i>Bos taurus</i> Linné var. <i>domesticus</i> Gmelin = <i>Bos taurus</i> L. var. <i>domesticus</i> Gmelin	Bovidae
Yellow Beeswax ミツロウ	<i>Apis mellifera</i> Linné = <i>Apis mellifera</i> L.	Apidae
	<i>Apis cerana</i> Fabricius	
Belladonna Extract ペラドンナコン	<i>Atropa belladonna</i> Linné = <i>Atropa belladonna</i> L.	Solanaceae
Benincasa Seed トウガシ	<i>Benincasa cerifera</i> Savi	Cucurbitaceae
	<i>Benincasa hispida</i> (Thunb.) Cogn.	
	<i>Benincasa cerifera</i> Savi forma <i>emarginata</i> K. Kimura et Sugiyama = <i>Benincasa cerifera</i> Savi f. <i>emarginata</i> K. Kimura & Sugiyama	

Benzoin アンゾウコウ	<i>Styrax benzoin</i> Dryander = <i>Styrax benzoin</i> Dryand.	<i>Styracaceae</i>
	Other species of the same genus	
Bitter Cardamon ヤクチ	<i>Alpinia oxyphylla</i> Miquel = <i>Alpinia oxyphylla</i> Miq.	<i>Zingiberaceae</i>
Bitter Orange Peel トウヒ	<i>Citrus aurantium</i> Linné = <i>Citrus aurantium</i> L.	<i>Rutaceae</i>
	<i>Citrus aurantium</i> Linné var. <i>daidai</i> Makino = <i>Citrus aurantium</i> L. var. <i>daidai</i> Makino	
	<i>Citrus aurantium</i> L. 'Daidai'	
Brown Rice コウベイ	<i>Oryza sativa</i> Linné = <i>Oryza sativa</i> L.	<i>Gramineae</i>
Bupleurum Root サイコ	<i>Bupleurum falcatum</i> Linné = <i>Bupleurum falcatum</i> L.	<i>Umbelliferae</i>
	<i>Bupleurum chinense</i> DC. <i>Bupleurum scorzonerifolium</i> Willd.	
Burdock Fruit ゴボウシ	<i>Arctium lappa</i> Linné = <i>Arctium lappa</i> L.	<i>Compositae</i>
Cacao Butter カカオ脂	<i>Theobroma cacao</i> Linné = <i>Theobroma cacao</i> L.	<i>Sterculiaceae</i>
Calumba コロンボ	<i>Jateorhiza columba</i> Miers	<i>Menispermaceae</i>
Camellia Oil ツバキ油	<i>Camellia japonica</i> Linné = <i>Camellia japonica</i> L.	<i>Theaceae</i>
Capsicum トウガラシ	<i>Capsicum annuum</i> Linné = <i>Capsicum annuum</i> L.	<i>Solanaceae</i>
Cardamon ショウズク	<i>Elettaria cardamomum</i> Maton	<i>Zingiberaceae</i>
Carnauba Wax カルナウバロウ	<i>Copernicia cerifera</i> Martius = <i>Copernicia cerifera</i> Mart.	<i>Palmae</i>
Cassia Seed ケツメイシ	<i>Cassia obtusifolia</i> Linné = <i>Cassia obtusifolia</i> L.	<i>Leguminosae</i>
	<i>Cassia tora</i> Linné = <i>Cassia tora</i> L.	
Castor Oil ヒマシ油	<i>Ricinus communis</i> Linné = <i>Ricinus communis</i> L.	<i>Euphorbiaceae</i>
Catalpa Fruit キササゲ	<i>Catalpa ovata</i> G. Don	<i>Bignoniaceae</i>
	<i>Catalpa bungei</i> C. A. Meyer = <i>Catalpa bungei</i> C. A. Mey.	
Cherry Bark オウヒ	<i>Prunus jamasakura</i> Siebold ex Koidzumi = <i>Prunus jamasakura</i> Siebold ex Koidz.	<i>Rosaceae</i>
	<i>Prunus verecunda</i> Koehne = <i>Prunus verecunda</i> (Koidz.) Koehne	
Chrysanthemum Flower キクカ	<i>Chrysanthemum morifolium</i> Ramatuelle = <i>Chrysanthemum morifolium</i> Ramat.	<i>Compositae</i>
	<i>Chrysanthemum indicum</i> Linné = <i>Chrysanthemum indicum</i> L.	

Cimicifuga Rhizome ショウマ	<i>Cimicifuga simplex</i> Turczaninow = <i>Cimicifuga simplex</i> (DC.) Turcz.	Ranunculaceae
	<i>Cimicifuga dahurica</i> Maximowicz = <i>Cimicifuga dahurica</i> (Turcz.) Maxim.	
	<i>Cimisifuga heracleifolia</i> Komarov = <i>Cimisifuga heracleifolia</i> Kom.	
	<i>Cimicifuga foetida</i> Linné = <i>Cimicifuga foetida</i> L.	
Cinnamon Bark ケイヒ	<i>Cinnamomum cassia</i> Blume	Lauraceae
Cinnamon Oil ケイヒ油	<i>Cinnamomum cassia</i> Blume <i>Cinnamomum zeylanicum</i> Nees	Lauraceae
Cistanche Herb ニクジュヨウ	<i>Cistanche salsa</i> G. Beck = <i>Cistanche salsa</i> (C.A.Mey.) Beck <i>Cistanche deserticola</i> Y. C. Ma = <i>Cistanche deserticola</i> Ma <i>Cistanche tubulosa</i> Wight	Orobanchaceae
Citrus Unshiu Peel チンピ	<i>Citrus unshiu</i> Marcowicz = <i>Citrus unshiu</i> (Swingle) Marcow. <i>Citrus reticulata</i> Blanco 'Unshiu' <i>Citrus reticulata</i> Blanco	Rutaceae
Clematis Root イレイセン	<i>Clematis chinensis</i> Osbeck <i>Clematis mandshurica</i> Ruprecht = <i>Clematis mandshurica</i> Rupr. <i>Clematis hexapetala</i> Pallas = <i>Clematis hexapetala</i> Pall.	Ranunculaceae
Clove ショウジ Clove Oil ショウジ油	<i>Syzygium aromaticum</i> Merrill et Perry = <i>Syzygium aromaticum</i> (L.) Merr. & M. L. Perry * <i>Eugenia caryophyllata</i> Thunberg = <i>Eugenia caryophyllata</i> Thunb. <i>Eugenia caryophyllus</i> (Spreng.) Bullock & S. G. Harrison	Myrtaceae
Cnidium Monnier Fruit ジャショウシ	<i>Cnidium monnierii</i> Cusson = <i>Cnidium monnierii</i> (L.) Cusson	Umbelliferae
Cnidium Rhizome センキュウ	<i>Cnidium officinale</i> Makino	Umbelliferae
Coconut Oil ヤシ油	<i>Cocos nucifera</i> Linné = <i>Cocos nucifera</i> L.	Palmae
Codonopsis Root トウジン	<i>Codonopsis pilosula</i> Nannfeldt = <i>Codonopsis pilosula</i> Nannf. <i>Codonopsis tangshen</i> Oliver = <i>Codonopsis tangshen</i> Oliv.	Campanulaceae
Coix Seed ヨクイニン	<i>Coix lacryma-jobi</i> Linné var. <i>mayuen</i> Stapf = <i>Coix lacryma-jobi</i> L. var. <i>mayuen</i> (Rom. Caill.) Stapf	Gramineae
Condurango コンズランゴ	<i>Marsdenia condurango</i> Reichenbach filius = <i>Marsdenia condurango</i> Rchb. f.	Asclepiadaceae

Coptis Rhizome オウレン	<i>Coptis japonica</i> Makino = <i>Coptis japonica</i> (Thunb.) Makino	<i>Ranunculaceae</i>
	<i>Coptis japonica</i> (Thunb.) Makino var. <i>dissecta</i> (Yatabe) Nakai	
	<i>Coptis japonica</i> (Thunb.) Makino var. <i>japonica</i>	
	<i>Coptis japonica</i> (Thunb.) Makino var. <i>major</i> (Miq.) Satake	
	<i>Coptis chinensis</i> Franchet = <i>Coptis chinensis</i> Franch.	
Corn Oil トウモロコシ油	<i>Coptis deltoidea</i> C. Y. Cheng et Hsiao	<i>Gramineae</i>
	<i>Coptis teeta</i> Wallich = <i>Coptis teeta</i> Wall.	
	<i>Zea mays</i> Linné = <i>Zea mays</i> L.	
Cornus Fruit サンシュユ	<i>Cornus officinalis</i> Siebold et Zuccarini = <i>Cornus officinalis</i> Siebold & Zucc.	<i>Cornaceae</i>
Corydalis Tuber エンゴサク	<i>Corydalis turtschaninovii</i> Besser forma <i>yanhusuo</i> Y. H. Chou et C. C. Hsu = <i>Corydalis turtschaninovii</i> Besser f. <i>yanhusuo</i> (W. T. Wang) Y. H. Chou & C. C. Hsu	<i>Papaveraceae</i>
	<i>Corydalis yanhusuo</i> W. T. Wang	
Crataegus Fruit サンザシ	<i>Crataegus cuneata</i> Siebold et Zuccarini = <i>Crataegus cuneata</i> Siebold & Zucc.	<i>Rosaceae</i>
	<i>Crataegus pinnatifida</i> Bunge var. <i>major</i> N. E. Brown = <i>Crataegus pinnatifida</i> Bunge var. <i>major</i> N. E. Br.	
Cyperus Rhizome コウブシ	<i>Cyperus rotundus</i> Linné = <i>Cyperus rotundus</i> L.	<i>Cyperaceae</i>
Digenea マクリ	<i>Digenea simplex</i> C. Agardh = <i>Digenea simplex</i> (Wulfen) C. Agardh	<i>Rhodomelaceae</i>
Dioscorea Rhizome サンヤク	<i>Dioscorea japonica</i> Thunberg = <i>Dioscorea japonica</i> Thunb.	<i>Dioscoreaceae</i>
	<i>Dioscorea batatas</i> Decaisne = <i>Dioscorea batatas</i> Decne.	
	<i>Dioscorea opposita</i> Thunb.	
Dolichos Seed ヘンズ	<i>Dolichos lablab</i> Linné = <i>Dolichos lablab</i> L.	<i>Leguminosae</i>
Eleutherococcus Senticosus Rhizome シゴカ	<i>Eleutherococcus senticosus</i> Maximowicz = <i>Eleutherococcus senticosus</i> (Rupr. & Maxim.) Maxim.	<i>Araliaceae</i>
	* <i>Acanthopanax senticosus</i> Harms = <i>Acanthopanax senticosus</i> (Rupr. & Maxim.) Harms	
Ephedra Herb マオウ	<i>Ephedra sinica</i> Stapf	<i>Ephedraceae</i>
	<i>Ephedra intermedia</i> Schrenk et C. A. Meyer = <i>Ephedra intermedia</i> Schrenk & C. A. Mey.	
	<i>Ephedra equisetina</i> Bunge	

Epimedum Herb インヨウカク	<i>Epimedum pubescens</i> Maximowicz = <i>Epimedum pubescens</i> Maxim.	Berberidaceae
	<i>Epimedum brevicornu</i> Maximowicz = <i>Epimedum brevicornu</i> Maxim.	
	<i>Epimedum wushanense</i> T. S. Ying	
	<i>Epimedum sagittatum</i> Maximowicz = <i>Epimedum sagittatum</i> (Siebold & Zucc.) Maxim.	
	<i>Epimedum koreanum</i> Nakai	
	<i>Epimedum grandiflorum</i> Morren var. <i>thunbergianum</i> Nakai = <i>Epimedum grandiflorum</i> Morr. var. <i>thunbergianum</i> (Miq.) Nakai	
	<i>Epimedum sempervirens</i> Nakai	
Eucalyptus Oil ユーカリ油	<i>Eucalyptus globulus</i> Labillardiere = <i>Eucalyptus globulus</i> Labill.	Myrtaceae
	<i>Allied species</i>	
Eucommia Bark トチュウ	<i>Eucommia ulmoides</i> Oliver = <i>Eucommia ulmoides</i> Oliv.	Eucommiaceae
Evodia Fruit ゴシュユ	<i>Euodia ruticarpa</i> Hooker filius et Thomson = <i>Euodia ruticarpa</i> (A. Juss.) Hook. f. & Thomson	Rutaceae
	* <i>Evodia rutaecarpa</i> Bentham = <i>Evodia rutaecarpa</i> (A. Juss.) Benth. <i>Tetradium ruticarpum</i> (A. Juss.) Hartley	
	<i>Euodia officinalis</i> Dode	
	* <i>Evodia officinalis</i> Dode <i>Evodia rutaecarpa</i> (A. Juss.) Benth. var. <i>officinalis</i> (Dode) Huang	
	<i>Euodia bodinieri</i> Dode	
	* <i>Evodia bodinieri</i> Dode <i>Evodia rutaecarpa</i> (A. Juss.) Benth. var. <i>bodinieri</i> (Dode) Huang	
Fennel ウイキョウ	<i>Foeniculum vulgare</i> Miller = <i>Foeniculum vulgare</i> Mill.	Umbelliferae
Fennel Oil ウイキョウ油	<i>Foeniculum vulgare</i> Miller = <i>Foeniculum vulgare</i> Mill.	Umbelliferae
	<i>Illicium verum</i> Hooker filius = <i>Illicium verum</i> Hook. f.	Illiciaceae
Forsythia Fruit レンギョウ	<i>Forsythia suspensa</i> Vahl = <i>Forsythia suspensa</i> (Thunb.) Vahl	Oleaceae
Fritillaria Bulb バイモ	<i>Fritillaria verticillata</i> Willdenow var. <i>thunbergii</i> Baker = <i>Fritillaria verticillata</i> Willd. var. <i>thunbergii</i> (Miq.) Baker	Liliaceae
	<i>Fritillaria thunbergii</i> Miq.	
Gambir アセンヤク	<i>Uncaria gambir</i> Roxburgh = <i>Uncaria gambir</i> (Hunter) Roxb.	Rubiaceae
Gardenia Fruit サンシシ	<i>Gardenia jasminoides</i> Ellis <i>Gardenia jasminoides</i> Ellis f. <i>longicarpa</i> Z. W. Xie & Okada	Rubiaceae
Gastrodia Tuber テンマ	<i>Gastrodia elata</i> Blume	Orchidaceae
Gentian ゲンチアナ	<i>Gentiana lutea</i> Linné = <i>Gentiana lutea</i> L.	Gentianaceae

Geranium Herb ゲンノショウコ	<i>Geranium thunbergii</i> Siebold et Zuccarini = <i>Geranium thunbergii</i> Siebold & Zucc.	<i>Geraniaceae</i>
Ginger ショウキョウ	<i>Zingiber officinale</i> Roscoe	<i>Zingiberaceae</i>
Ginseng ニンジン	<i>Panax ginseng</i> C. A. Meyer = <i>Panax ginseng</i> C. A. Mey. * <i>Panax schinseng</i> Nees	<i>Araliaceae</i>
Glehnia Root ハマボウフウ	<i>Glehnia littoralis</i> Fr. Schmidt ex Miquel = <i>Glehnia littoralis</i> F. Schmidt ex Miq.	<i>Umbelliferae</i>
Glycyrrhiza カンゾウ	<i>Glycyrrhiza uralensis</i> Fischer = <i>Glycyrrhiza uralensis</i> Fisch.	<i>Leguminosae</i>
	<i>Glycyrrhiza glabra</i> Linné = <i>Glycyrrhiza glabra</i> L.	
Hedysarum Root シンギ	<i>Hedysarum polybotrys</i> Handel-Mazzetti = <i>Hedysarum polybotrys</i> Hand.-Mazz.	<i>Leguminosae</i>
Hemp Fruit マシニン	<i>Cannabis sativa</i> Linné = <i>Cannabis sativa</i> L.	<i>Moracea</i>
Honey ハチミツ	<i>Apis mellifera</i> Linné = <i>Apis mellifera</i> L.	<i>Apidae</i>
	<i>Apis cerana</i> Fabricius	
Houttuynia Herb ジュウヤク	<i>Houttuynia cordata</i> Thunberg = <i>Houttuynia cordata</i> Thunb.	<i>Saururaceae</i>
Immature Orange キジツ	<i>Citrus aurantium</i> Linné var. <i>daidai</i> Makino = <i>Citrus aurantium</i> L. var. <i>daidai</i> Makino	<i>Rutaceae</i>
	<i>Citrus aurantium</i> L. 'Daidai'	
	<i>Citrus natsudaidai</i> Hayata	
	<i>Citrus aurantium</i> Linné = <i>Citrus aurantium</i> L.	
	<i>Citrus aurantium</i> L. subsp. <i>hassaku</i> (Tanaka) Hiroe = <i>Citrus hassaku</i> hort. ex Tanaka	
Imperata Rhizome ボウコン	<i>Imperata cylindrica</i> Beauvois = <i>Imperata cylindrica</i> (L.) P. Beauv.	<i>Gramineae</i>
	<i>Imperata cylindrica</i> (L.) P. Beauv. var. <i>major</i> (Nees) C. E. Hubb.	
Ipecac トコン	<i>Cephaelis ipecacuanha</i> A. Richard = <i>Cephaelis ipecacuanha</i> (Brot.) A. Rich.	<i>Rubiaceae</i>
	<i>Cephaelis acuminata</i> Karsten = <i>Cephaelis acuminata</i> H. Karst.	
Japanese Angelica Root トウキ	<i>Angelica acutiloba</i> Kitagawa = <i>Angelica acutiloba</i> (Siebold & Zucc.) Kitag.	<i>Umbelliferae</i>
	<i>Angelica acutiloba</i> Kitagawa var. <i>sugiyamae</i> Hikino = <i>Angelica acutiloba</i> (Siebold & Zucc.) Kitag. var. <i>sugiyamae</i> Hikino	
Japanese Gentian リュウタン	<i>Gentiana scabra</i> Bunge	<i>Gentianaceae</i>
	<i>Gentiana scabra</i> Bunge var. <i>buergeri</i> (Miq.) Maxim.	
	<i>Gentiana manshurica</i> Kitagawa = <i>Gentiana manshurica</i> Kitag.	
	<i>Gentiana triflora</i> Pallas = <i>Gentiana triflora</i> Pall.	
	<i>Gentiana triflora</i> Pall. var. <i>japonica</i> Hara	

Japanese Valerian カノコソウ	<i>Valeriana fauriei</i> Briquet = <i>Valeriana fauriei</i> Briq. <i>Valeriana fauriei</i> Briq. f. <i>yezoensis</i> Hara	<i>Valerianaceae</i>
Japanese Zanthoxylum Peel サンショウ	<i>Zanthoxylum piperitum</i> De Candolle = <i>Zanthoxylum piperitum</i> (L.) DC. <i>Zanthoxylum piperitum</i> (L.) DC. f. <i>inerme</i> Makino	<i>Rutaceae</i>
Jujube Seed サンソウニン	<i>Zizyphus jujuba</i> Miller var. <i>spinosa</i> Hu ex H. F. Chou = <i>Zizyphus jujuba</i> Mill. var. <i>spinosa</i> (Bunge) Hu ex H. F. Chou	<i>Rhamnaceae</i>
Jujube タイソウ	<i>Zizyphus jujuba</i> Miller var. <i>inermis</i> Rehder = <i>Zizyphus jujuba</i> Mill. var. <i>inermis</i> (Bunge) Rehder	<i>Rhamnaceae</i>
Koi コウイ	<i>Zea mays</i> Linné = <i>Zea mays</i> L.	<i>Gramineae</i>
	<i>Manihot esculenta</i> Crantz	<i>Euphorbiaceae</i>
	<i>Solanum tuberosum</i> Linné = <i>Solanum tuberosum</i> L.	<i>Solanaceae</i>
	<i>Ipomoea batatas</i> Poiret = <i>Ipomoea batatas</i> (L.) Poir.	<i>Convolvulaceae</i>
	<i>Ipomoea batatas</i> (L.) Lam.	
	<i>Oryza sativa</i> Linné = <i>Oryza sativa</i> L.	<i>Gramineae</i>
	<i>Ovis aries</i> Linné = <i>Ovis aries</i> L.	<i>Bovidae</i>
Lard 豚脂	<i>Sus scrofa</i> Linné var. <i>domesticus</i> Gray = <i>Sus scrofa</i> L. var. <i>domesticus</i> Gray	<i>Suidae</i>
Leonurus Herb ヤクモソウ	<i>Leonurus japonicus</i> Houttuyn = <i>Leonurus japonicus</i> Houtt.	<i>Labiatae</i>
	<i>Leonurus sibiricus</i> Linné = <i>Leonurus sibiricus</i> L.	
Lilium Bulb ビャクゴウ	<i>Lilium lancifolium</i> Thunberg = <i>Lilium lancifolium</i> Thunb.	<i>Liliaceae</i>
	<i>Lilium brownii</i> F. E. Brown var. <i>colchesteri</i> Wilsohn = <i>Lilium brownii</i> F. E. Br. var. <i>colchesteri</i> (Van Houtte) E. H. Wilson ex Elwes	
	<i>Lilium brownii</i> F. E. Brown var. <i>viridulum</i> Baker	
	<i>Lilium brownii</i> F. E. Brown = <i>Lilium brownii</i> F. E. Br.	
	<i>Lilium pumilum</i> De Candolle = <i>Lilium pumilum</i> DC.	
Lindera Root ウヤク	<i>Lindera strychnifolia</i> Fernandez-Villar = <i>Lindera strychnifolia</i> (Siebold & Zucc.) Fern.-Vill.	<i>Lauraceae</i>
	<i>Lindera aggregata</i> (Sims) Kosterm.	
Lithospermum Root シコン	<i>Lithospermum erythrorhizon</i> Siebold et Zuccarini = <i>Lithospermum erythrorhizon</i> Siebold & Zucc.	<i>Boraginaceae</i>
Longan Aril リュウガンニク	<i>Euphoria longana</i> Lamarck = <i>Euphoria longana</i> Lam.	<i>Sapindaceae</i>
	<i>Dimocarpus longan</i> Lour.	
Lonicera Leaf and Stem ニンドウ	<i>Lonicera japonica</i> Thunberg = <i>Lonicera japonica</i> Thunb.	<i>Caprifoliaceae</i>

Loquat Leaf ビワヨウ	<i>Eriobotrya japonica</i> Lindley = <i>Eriobotrya japonica</i> (Thunb.) Lindl.	Rosaceae
Lycium Bark ジコッピ	<i>Lycium chinense</i> Miller = <i>Lycium chinense</i> Mill.	Solanaceae
	<i>Lycium barbarum</i> Linné = <i>Lycium barbarum</i> L.	
Lycium Fruit タコシ	<i>Lycium chinense</i> Miller = <i>Lycium chinense</i> Mill.	Solanaceae
	<i>Lycium barbarum</i> Linné = <i>Lycium barbarum</i> L.	
Magnolia Bark コウボク	<i>Magnolia obovata</i> Thunberg = <i>Magnolia obovata</i> Thunb.	Magnoliaceae
	* <i>Magnolia hypoleuca</i> Siebold et Zuccarini = <i>Magnolia hypoleuca</i> Siebold & Zucc.	
	<i>Magnolia officinalis</i> Rehder et Wilson = <i>Magnolia officinalis</i> Rehder & E. H. Wilson	
	<i>Magnolia officinalis</i> Rehder et Wilson var. <i>biloba</i> Rehder et Wilson = <i>Magnolia officinalis</i> Rehder & E. H. Wilson var. <i>biloba</i> Rehder & E. H. Wilson	
Magnolia Flower シンイ	<i>Magnolia salicifolia</i> Maximowicz = <i>Magnolia salicifolia</i> (Siebold & Zucc.) Maxim.	Magnoliaceae
	<i>Magnolia kobus</i> De Candolle = <i>Magnolia kobus</i> DC.	
	<i>Magnolia biondii</i> Pampanini = <i>Magnolia biondii</i> Pamp.	
	<i>Magnolia sprengeri</i> Pampanini = <i>Magnolia sprengeri</i> Pamp.	
	<i>Magnolia heptapeta</i> Dandy = <i>Magnolia heptapeta</i> (Buchoz) Dandy	
	* <i>Magnolia denudata</i> Desrousseaux = <i>Magnolia denudata</i> Desr.	
Mallotus Bark アカメガシワ	<i>Mallotus japonicus</i> Mueller Argoviensis = <i>Mallotus japonicus</i> (Thunb.) Müll. Arg.	Euphorbiaceae
Malt バクガ	<i>Hordeum vulgare</i> Linné = <i>Hordeum vulgare</i> L.	Gramineae
Mentha Herb ハッカ Mentha Oil ハッカ油	<i>Mentha arvensis</i> Linné var. <i>piperascens</i> Malinvaud = <i>Mentha arvensis</i> L. var. <i>piperascens</i> Malinv.	Labiatae
	<i>Mentha haplocalyx</i> Briq.	
	Hybrid originated from <i>Mentha arvensis</i> L. var. <i>piperascens</i> Malinv. as the mother species	
Moutan Bark ボタンピ	<i>Paeonia suffruticosa</i> Andrews * <i>Paeonia moutan</i> Sims	Paeoniaceae
Mulberry Bark ソウハクヒ	<i>Morus alba</i> Linné = <i>Morus alba</i> L.	Moraceae
Nelumbo Seed レンニク	<i>Nelumbo nucifera</i> Gaertner = <i>Nelumbo nucifera</i> Gaertn.	Nymphaeaceae
Notopterygium Rhizome キョウカツ	<i>Notopterygium incisum</i> Ting ex H. T. Chang	Umbelliferae
	<i>Notopterygium forbesii</i> Boissieu	

Nuphar Rhizome センコツ	<i>Nuphar japonicum</i> De Candolle = <i>Nuphar japonicum</i> DC.	<i>Nymphaeaceae</i>
Nutmeg ニクズク	<i>Myristica fragrans</i> Houttuyn = <i>Myristica fragrans</i> Houtt.	<i>Myristicaceae</i>
Nux Vomica ホミカ	<i>Strychnos nux-vomica</i> Linné = <i>Strychnos nux-vomica</i> L.	<i>Loganiaceae</i>
Olive Oil オリブ油	<i>Olea europaea</i> Linné = <i>Olea europaea</i> L.	<i>Oleaceae</i>
Ophiopogon Root バクモンドウ	<i>Ophiopogon japonicus</i> Ker-Gawler = <i>Ophiopogon japonicus</i> (L. f.) Ker Gawl.	<i>Liliaceae</i>
Orange Oil オレンジ油	<i>Citrus species</i>	<i>Rutaceae</i>
Oriental Bezoar ゴオウ	<i>Bos taurus</i> Linné var. <i>domesticus</i> Gmelin = <i>Bos taurus</i> L. var. <i>domesticus</i> Gmelin	<i>Bovidae</i>
Oyster Shell ボレイ	<i>Ostrea gigas</i> Thunberg = <i>Ostrea gigas</i> Thunb.	<i>Ostreidae</i>
Panax Japonicus Rhizome チクセツニンジン	<i>Panax japonicus</i> C. A. Meyer = <i>Panax japonicus</i> C. A. Mey.	<i>Araliaceae</i>
Peach Kernel トウニン	<i>Prunus persica</i> Batsch = <i>Prunus persica</i> (L.) Batsch	<i>Rosaceae</i>
	<i>Prunus persica</i> Batsch var. <i>davidiana</i> Maximowicz = <i>Prunus persica</i> (L.) Batsch var. <i>davidiana</i> (Carrière) Maxim.	
	<i>Prunus davidiana</i> (Carrière) Franch.	
Peanut Oil ラッカセイ油	<i>Arachis hypogaea</i> Linné = <i>Arachis hypogaea</i> L.	<i>Leguminosae</i>
Peony Root シャクヤク	<i>Paeonia lactiflora</i> Pallas = <i>Paeonia lactiflora</i> Pall.	<i>Paeoniaceae</i>
Perilla Herb ソヨウ	<i>Perilla frutescens</i> Britton var. <i>crispa</i> W. Deane = <i>Perilla frutescens</i> (L.) Britton var. <i>crispa</i> (Thunb.) W. Deane	<i>Labiatae</i>
Peucedanum Root ゼンコ	<i>Peucedanum praeruptorum</i> Dunn	<i>Umbelliferae</i>
	<i>Angelica decursiva</i> Franchet et Savatier = <i>Angelica decursiva</i> (Miq.) Franch. & Sav.	
	* <i>Peucedanum decursivum</i> Maximowicz = <i>Peucedanum decursivum</i> (Miq.) Maxim.	
Pharbitis Seed ケンゴシ	<i>Pharbitis nil</i> Choisy = <i>Pharbitis nil</i> (L.) Choisy	<i>Convolvulaceae</i>
Phellodendron Bark オウバク	<i>Phellodendron amurense</i> Ruprecht = <i>Phellodendron amurense</i> Rupr.	<i>Rutaceae</i>
	<i>Phellodendron amurense</i> Rupr. var. <i>sachalinense</i> F. Schmidt <i>Phellodendron amurense</i> Rupr. var. <i>japonicum</i> (Maxim.) Ohwi <i>Phellodendron amurense</i> Rupr. var. <i>lavallei</i> (Dode) Sprangue	
	<i>Phellodendron chinense</i> Schneider = <i>Phellodendron chinense</i> C. K. Schneid.	
Picrasma Wood ニガキ	<i>Picrasma quassoides</i> Bennet = <i>Picrasma quassoides</i> (D. Don) Benn.	<i>Simaroubaceae</i>
Pinellia Tuber ハンゲ	<i>Pinellia ternata</i> Breitenbach = <i>Pinellia ternata</i> (Thunb.) Breitenb.	<i>Araceae</i>
Plantago Herb シャゼンソウ	<i>Plantago asiatica</i> Linné = <i>Plantago asiatica</i> L.	<i>Plantaginaceae</i>

Plantago Seed シャゼンシ	<i>Plantago asiatica</i> Linné = <i>Plantago asiatica</i> L.	<i>Plantaginaceae</i>
Platycodon Root キキョウ	<i>latycodon grandiflorum</i> A. De Candolle = <i>Platycodon grandiflorum</i> (Jacq.) A. DC.	<i>Campanulaceae</i>
Pogostemon Herb カッコウ	<i>Pogostemon cablin</i> Bentham = <i>Pogostemon cablin</i> (Blanco) Benth.	<i>Labiatae</i>
Polygala Root オンジ	<i>Polygala tenuifolia</i> Willdenow = <i>Polygala tenuifolia</i> Willd.	<i>Polygalaceae</i>
Polygonatum Rhizome オウセイ	<i>Polygonatum falcatum</i> A. Gray	<i>Liliaceae</i>
	<i>Polygonatum sibiricum</i> Redouté	
	<i>Polygonatum kingianum</i> Collett et Hemsley = <i>Polygonatum kingianum</i> Collett & Hemsley	
	<i>Polygonatum cyrtonema</i> Hua	
Polygonum Root カシュウ	<i>Polygonum multiflorum</i> Thunberg = <i>Polygonum multiflorum</i> Thunb.	<i>Polygonaceae</i>
Polyporus Sclerotium チョレイ	<i>Polyporus umbellatus</i> Fries = <i>Polyporus umbellatus</i> (Pers.) Fries	<i>Polyporaceae</i>
Poria Sclerotium ブクリョウ	<i>Wolfiporia cocos</i> Ryvarden et Gilbertson = <i>Wolfiporia cocos</i> (Schw.) Ryv. & Gilbn.	<i>Polyporaceae</i>
	* <i>Poria cocos</i> Wolf = <i>Poria cocos</i> (Schw.) Wolf	
Powdered Opium アヘン末	<i>Papaver somniferum</i> Linné = <i>Papaver somniferum</i> L.	<i>Papaveraceae</i>
Prepared Glycyrrhiza シャカンゾウ	<i>Glycyrrhiza uralensis</i> Fischer = <i>Glycyrrhiza uralensis</i> Fisch.	<i>Leguminosae</i>
	<i>Glycyrrhiza glabra</i> Linné = <i>Glycyrrhiza glabra</i> L.	
Processed Aconite Root ブシ	<i>Aconitum carmichaeli</i> Debeaux	<i>Ranunculaceae</i>
	<i>Aconitum japonicum</i> Thunberg = <i>Aconitum japonicum</i> Thunb.	
Processed Ginger カンキョウ	<i>Zingiber officinale</i> Roscoe	<i>Zingiberaceae</i>
Prunella Spike カゴソウ	<i>Prunella vulgaris</i> Linné var. <i>lilacina</i> Nakai = <i>Prunella vulgaris</i> L. var. <i>lilacina</i> Nakai	<i>Labiatae</i>
Pueraria Root カッコン	<i>Pueraria lobata</i> Ohwi = <i>Pueraria lobata</i> (Willd.) Ohwi	<i>Leguminosae</i>
Quercus Bark ボクソク	<i>Quercus acutissima</i> Carruthers = <i>Quercus acutissima</i> Carruth.	<i>Fagaceae</i>
	<i>Quercus serrata</i> Murray	
	<i>Quercus mongholica</i> Fischer ex Ledebour var. <i>crispula</i> Ohashi = <i>Quercus mongholica</i> Fisch. ex Ledeb. var. <i>crispula</i> (Blume) Ohashi	
	<i>Quercus variabilis</i> Blume	
Rape Seed Oil ナタネ油	<i>Brassica campestris</i> Linné subsp. <i>napus</i> Hooker fil. et Anderson var. <i>nippo-oleifera</i> Makino = <i>Brassica campestris</i> L. subsp. <i>napus</i> Hook. f. et Anders. var. <i>nippo-oleifera</i> Makino	<i>Cruciferae</i>

Red Ginseng コウジン	<i>Panax ginseng</i> C. A. Meyer = <i>Panax ginseng</i> C. A. Mey. * <i>Panax schinseng</i> Nees	<i>Araliaceae</i>
Rehmannia Root ジオウ	<i>Rehmannia glutinosa</i> Liboschitz var. <i>purpurea</i> Makino = <i>Rehmannia glutinosa</i> Libosch. var. <i>purpurea</i> Makino	<i>Scrophulariaceae</i>
	<i>Rehmannia glutinosa</i> Liboschitz = <i>Rehmannia glutinosa</i> Libosch.	
Rhubarb ダイオウ	<i>Rheum palmatum</i> Linné = <i>Rheum palmatum</i> L.	<i>Polygonaceae</i>
	<i>Rheum tanguticum</i> Maximowicz = <i>Rheum tanguticum</i> Maxim.	
	<i>Rheum officinale</i> Baillon = <i>Rheum officinale</i> Baill.	
	<i>Rheum coreanum</i> Nakai	
	Hybrid between above species	
Rose Fruit エイジツ	<i>Rosa multiflora</i> Thunberg = <i>Rosa multiflora</i> Thunb.	<i>Rosaceae</i>
Rosin ロジン	Several plants of <i>Pinus</i> genus	<i>Pinaceae</i>
Royal Jelly ローヤルゼリー	<i>Apis mellifera</i> Linné = <i>Apis mellifera</i> L.	<i>Apidae</i>
	<i>Apis cerana</i> Fabricius	
Safflower コウカ	<i>Carthamus tinctorius</i> Linné = <i>Carthamus tinctorius</i> L.	<i>Compositae</i>
Saffron サフラン	<i>Crocus sativus</i> Linné = <i>Crocus sativus</i> L.	<i>Iridaceae</i>
Salvia Miltorrhiza Root タンジン	<i>Salvia miltorrhiza</i> Bunge	<i>Labiatae</i>
Saposhnikovia Root ボウフウ	<i>Saposhnikovia divaricata</i> Schischkin = <i>Saposhnikovia divaricata</i> (Turcz.) Schischk.	<i>Umbelliferae</i>
Sappan Wood ソボク	<i>Caesalpinia sappan</i> Linné = <i>Caesalpinia sappan</i> L.	<i>Leguminosae</i>
Saussurea Root モッコウ	<i>Saussurea lappa</i> Clarke = <i>Saussurea lappa</i> (Decne.) C. B. Clarke	<i>Compositae</i>
	<i>Aucklandia lappa</i> Decne.	
Schisandra Fruit ゴミシ	<i>Schisandra chinensis</i> Baillon = <i>Schisandra chinensis</i> (Turcz.) Baill.	<i>Schisandraceae</i>
Schizonepeta Spike ケイガイ	<i>Schizonepeta tenuifolia</i> Briquet = <i>Schizonepeta tenuifolia</i> Briq.	<i>Labiatae</i>
Scopolia Rhizome ロートコン	<i>Scopolia japonica</i> Maximowicz = <i>Scopolia japonica</i> Maxim.	<i>Solanaceae</i>
	<i>Scopolia carniolica</i> Jacquin = <i>Scopolia carniolica</i> Jacq.	
	<i>Scopolia parviflora</i> Nakai = <i>Scopolia parviflora</i> (Dunn) Nakai	
Scutellaria Root オウゴン	<i>Scutellaria baicalensis</i> Georgi	<i>Labiatae</i>

Senega セネガ	<i>Polygala senega</i> Linné = <i>Polygala senega</i> L.	<i>Polygalaceae</i>
	<i>Polygala senega</i> Linné var. <i>latifolia</i> Torrey et Gray = <i>Polygala senega</i> L. var. <i>latifolia</i> Torr. & A. Gray	
Senna Leaf センナ	<i>Cassia angustifolia</i> Vahl	<i>Leguminosae</i>
	<i>Cassia acutifolia</i> Delile	
Sesame ゴマ Sesame Oil ゴマ油	<i>Sesamum indicum</i> Linné = <i>Sesamum indicum</i> L.	<i>Pedaliaceae</i>
Sinomenium Stem ボウイ	<i>Sinomenium acutum</i> Rehder et Wilson = <i>Sinomenium acutum</i> (Thunb.) Rehder & E. H. Wilson	<i>Menispermaceae</i>
Smilax Rhizome サンキライ	<i>Smilax glabra</i> Roxburgh = <i>Smilax glabra</i> Roxb.	<i>Liliaceae</i>
Sophora Root クジン	<i>Sophora flavescens</i> Aiton	<i>Leguminosae</i>
Soybean Oil ダイズ油	<i>Glycine max</i> Merrill = <i>Glycine max</i> (L.) Merr.	<i>Leguminosae</i>
Sweet Hydrangea Leaf アマチャ	<i>Hydrangea macrophylla</i> Seringe var. <i>thunbergii</i> Makino = <i>Hydrangea macrophylla</i> (Thunb.) Ser. var. <i>thunbergii</i> (Siebold) Makino	<i>Saxifragaceae</i>
Swertia Herb センブリ	<i>Swertia japonica</i> Makino = <i>Swertia japonica</i> (Shult.) Makino	<i>Gentianaceae</i>
Toad Venom センソ	<i>Bufo bufo gargarizans</i> Cantor	<i>Bufoidae</i>
	<i>Bufo melanostictus</i> Schneider	
Tragacanth トラガント	<i>Astragalus gummifer</i> Labillardière = <i>Astragalus gummifer</i> Labill.	<i>Leguminosae</i>
Tribulus Fruit シツリシ	<i>Tribulus terrestris</i> Linné = <i>Tribulus terrestris</i> L.	<i>Zygophyllaceae</i>
Trichosanthes Root カロコン	<i>Trichosanthes kirilowii</i> Maximowicz = <i>Trichosanthes kirilowii</i> Maxim.	<i>Cucurbitaceae</i>
	<i>Trichosanthes kirilowii</i> Maximowicz var. <i>japonicum</i> Kitamura = <i>Trichosanthes kirilowii</i> Maxim. var. <i>japonicum</i> (Miq.) Kitam.	
	<i>Trichosanthes bracteata</i> Voigt = <i>Trichosanthes bracteata</i> (Lam.) Voigt	
Turmeric ウコン	<i>Curcuma longa</i> Linné = <i>Curcuma longa</i> L.	<i>Zingiberaceae</i>
Turpentine Oil テレピン油	Several plants of <i>Pinus</i> genus	<i>Pinaceae</i>
Uncaria Hook チョウトウコウ	<i>Uncaria rhynchophylla</i> Miquel = <i>Uncaria rhynchophylla</i> (Miq.) Miq.	<i>Rubiaceae</i>
	<i>Uncaria sinensis</i> Haviland = <i>Uncaria sinensis</i> (Oliv.) Havil.	
	<i>Uncaria macrophylla</i> Wallich = <i>Uncaria macrophylla</i> Wall.	

Wood Creosote 木クレオソート	Several plants of <i>Pinus</i> genus	<i>Pinaceae</i>
	Several plants of <i>Cryptomeria</i> genus	<i>Taxodiaceae</i>
	Several plants of <i>Fagus</i> genus	<i>Fagaceae</i>
	Several plants of <i>Afzelia</i> (<i>Intsia</i>) genus	<i>Leguminosae</i>
	Several plants of <i>Shorea</i> genus	<i>Dipterocarpaceae</i>
	Several plants of <i>Tectona</i> genus	<i>Verbenaceae</i>
Zedoary ガジュツ	<i>Curcuma zedoaria</i> Roscoe	<i>Zingiberaceae</i>

When "Other species of the same genus" is included as its original plants the scientific name is not written in Monograph, however, it is written in this table.

Reference

Terabayashi S. et al.: Pharmaceutical and Medical Device Regulatory Science, 41(5), 407 – 418 (2010).

Thin-layer Chromatography for Crude Drugs and Crude Drug Preparations

Thin-layer chromatography is a method to separate each component by developing with a mobile phase, using a thin-layer consisting of an appropriate stationary phase, and is used for identification, purity test, etc. of substances.

Thin-layer chromatography for crude drugs and preparations containing crude drugs as main ingredient (crude drug preparations) is used for identifying whether characteristic constituents or groups of constituents in crude drugs and extracts based on Kampo formulae are included or not.

1. Instruments and equipment:

Generally, the following instruments and equipment are used.

(i) Thin-layer plate: A smooth and uniformly thick glass plate is coated in advance with an uniform powder of carrier listed in Solid Supports/Column Packings for Chromatography <9.42>. It is classified into two types. The stationary phase of thin-layer chromatography plates (TLC plates) has a particle size of 10 – 15 μm , and that of high-performance thin-layer chromatography plates (HPTLC plates) has a particle size of 5 – 7 μm . In a case where separation requirements given that the quality of the chromatogram indicated in the individual monograph is ensured, it is possible to use a thin-layer plate with a preadsorbent zone which has been coated in advance and the home-made plate. Alternatively, such thin-layer plates are also available that use plate-like or sheeted hard aluminum and polyester for support medium instead of glass plate. Thin-layer plates are kept while avoiding humidity.

(ii) Application of samples: The sample solution(s) or standard solution(s) at the prescribed volume in the individual monograph, are applied with sample applicators of constant volume, which is generally a special capillary or microsyringe, at a position around 20 mm distance from the lower edge as a starting line of and release at least 10 mm from side to side edges of the thin-layer plate, in the form of circular spots (spot-like) of 2 – 6 mm in diameter or narrow linearly bands (band-shaped) of 4 – 10 mm in width with an appropriate interval of at least about 10 mm and then allowed to dry in air. In a case where separation requirements given that the quality of the chromatogram indicated in the individual monograph is ensured, it is possible to modify position of starting line and sample spots application

interval.

(iii) Chromatographic chamber: Generally, a chromatographic chamber made of inert, transparent material and having a lid is used: a flat-bottom or twin trough. Unless otherwise specified, attach a filter paper along with the inside wall of the chamber, and moisten the filter paper with the developing solvent. In the chamber, the developing solvent is placed up to about 10 mm in height from the bottom, seal the chamber closely, and allow it to stand for 1 hour at ordinary temperature. Place a thin-layer plate in the chamber so as only the upper end of the plate is touched to the wall of the chamber, seal the chamber closely, and perform the development at ordinary temperature. A chromatographic chamber shall be of a size appropriate for the thin-layer plate and the developing solvent to be poured into shall be of a volume not to immerse spot(s) or band(s) of samples applied to the thin-layer plate in advance.

(iv) Device for coloring: Glass mister sprayer or electric mister sprayer is used for spraying visualization reagent. Drying the thin-layer plate after development, visualization of components to be tested on the chromatogram is performed by evenly sprayed visualization reagent directly on the thin-layer plate to work the test reagent. The ways to discharge visualization reagent include air supply of compressed gas either by manually or electrically. Further, in case of a heating device, components to be tested which have been separated on the chromatogram are heated after spraying visualization reagent and derivatized for visualization. It is preferable to use a hot plate at a constant temperature to heat a thin-layer plate after spraying visualization reagent. In case of using a thermostatic oven, thin-layer plate is heated on the metal plate heated to a constant temperature in advance. A flat-bottom trough chamber, twin trough chamber and desiccator, could be used during the immersion visualization and the fumigation (exposure to reagent vapor) visualization.

(v) Detection device: It is a camera obscura equipped with visible light, ultraviolet light of wavelength 254 nm and 365 nm, and wide-range wavelength light, and corresponding filter, a dark box or room. The light source is required to meet the requirements for the tests prescribed in the individual monograph. Photographing device to be added to the detecting device is used for taking photographs to be recorded and requires adequate sensitivity, resolution and reproducibility enough to perform the tests.

(vi) Record of TLC images: TLC images are taken by a camera and recorded/stored in a format of film image or electronic image. Except for detection after exposure to ul-

traviolet radiation, it is preferable to take pictures of color samples for reference concurrently in case of recording color tones of chromatogram detected under a visible light. Further, it should be noted that color tones identified visually and those recorded are different in some cases when recording fluorescent spots caused by irradiation with a wavelength of 365 nm. It is also possible to use an image scanner with sufficient resolution to record chromatograms detected under visible light. A TLC scanning device is capable of detecting absorption of light or fluorescence of chromatogram and spots or bands of samples to be tested and recording absorption and fluorescence spectra corresponding to components to be tested.

(vii) TLC scanning device: The device measures absorption by ultraviolet or visible light or fluorescence by excitation light on a developed thin-layer plate and stores records of development patterns by converting them into chromatograms (peak information). Scanning data obtained from chromatograms is used for quantitative analyses.

2. Detection and visualization

Generally, pulling out a thin-layer plate and drying it after development, detection of spots separated on a chromatogram is visually confirmed under visible light directly or after visualized. It is detected as a spot in a form close to circle when applied in a circular form (spot-like) and as a linear band when applied in a narrow linear form (band-shaped). In case of components to be tested having ultraviolet absorptivity, detection is performed using a thin-layer plate containing fluorescent agent (fluorescent indicator) by ultraviolet irradiation with a dominant wavelength of 254 nm. While fluorescent indicator contained in the thin-layer plate emits greenish fluorescence excited by irradiation with a dominant wavelength of 254 nm, spots or bands of components to be tested reduce radiation light emission by absorbing irradiation light to reduce excitation of fluorescent indicator resulting in an observation as raspberry (dark purple) spots or bands. With a property to produce fluorescence on itself excited under ultraviolet irradiation, spots or bands of components to be tested produce fluorescence excited on the thin-layer plate by irradiation of ultraviolet with a dominant wavelength of 365 nm even without using fluorescent indicator. High illumination light source with stable radiation intensity at around 365 nm within the ultraviolet wavelength range includes lamps having a line spectrum with a narrow width at 365 nm and having a line spectrum at 366 nm (within a range from 364 to 367 nm) with more intense radiated signal. Even though light source and wavelength described in specification differs depending on the lamps to be used, light source lamp with a wavelength of 366 nm also includes a light source lamp with a wavelength of 365 nm making it possible to handle as a description of irradiation with a dominant ultraviolet wavelength of 365 nm.

Derivatization reaction based on spraying, immersion and fumigation of an appropriate coloring reagent visualizes spots or bands of components to be tested. In case of some visualization reagents, such derivatization reaction is further visualized by subsequent heating after spraying reagents. In some cases, characteristic fluorescence may be produced by irradiation with a dominant wavelength of 365 nm after spraying or after spraying and heating as well.

3. Operation methods

Generally, unless otherwise specified, operation method shall comply with the following methods. Prepared sample solution and standard solution which is prescribed in the individual monograph shall be applied on the starting line of a thin-layer plate by an indicated volume. Confirming that ap-

plied circular form or linear spots or bands are not immersed in the developing solvent and placing a thin-layer plate in a developing container, developments are initiated after closing the lid of the chromatographic chamber. Sending up the developing solvent to a required development distance, the thin-layer plate is taken out to be allowed to dry in air. In addition, starting line (starting point) and mobile phase front are marked before and after development. Then, based on visualization of chromatogram on the thin-layer plate, color tone or *Rf* value of circular spots or linear bands of components to be tested is determined (Fig. 1). *Rf* value is obtained by the following formula.

$$Rf = \frac{\text{Distance from starting line to center of spot or band}}{\text{Distance from starting line to mobile phase front}} \\ = \frac{b}{a}$$

Development operation and visualization shall be performed in an apparatus such as a draft chamber in which solvent vapor is efficiently removed with sufficient air ventilation.

4. Confirmation and purity test

When using this test method for an identification test, it is confirmed in general that color tone and *Rf* value of components to be tested in sample solution is equal to those in standard solution. In case of the identification test of multicomponent system sample solution, it is possible to confirm by color tone and *Rf* value of spots when components to be tested are recognized as a single spot clearly showing characteristic fluorescence and coloring. Alternatively, it is also possible to identify by the patterns of spots and bands. Moreover, this test method in combination with spectroscopic method (such as Ultraviolet-visible Spectrophotometry <2.24>, Nuclear Magnetic Resonance Spectrophotometry <2.21>) and Mass Spectrometry <2.62> makes it possible to perform further reliable confirmation.

In case of using this test method for purity test, a standard solution with a concentration corresponding to the limit of impurities in the sample solution is used in general, and purity is confirmed by whether any spot of components to be tested derived from sample solution is detected or whether the magnitude of the spot is lighter than that of standard solution.

5. Semi-quantitative and quantitative measurement

Presumptive quantitative measurement can be made by observation of spots or bands of identical *Rf* value and about equal magnitude obtained, respectively, with sample solution and standard solution or indicative component solu-




Fig. 1 Pattern diagram of TLC chromatogram

tion by applying the same volume, chromatographed on the same thin-layer plate. A visual comparison of the size or intensity of the spots or bands may serve for semi-quantitative estimation. Quantitative measurements are possible by means of densitometry.

6. Confirmation of suitability of lamp

Objectives of confirmation of suitability are sensitivity, resolution and reproducibility required for securing quality of chromatogram and satisfying separation requirements specified in the individual monograph. Confirmation of suitability in this test method is performed mainly for radiation intensity of line light source used for ultraviolet irradiation. In other words, the test is performed if specified spot (or band) is not recognized by irradiation with a wavelength of line light source specified in the individual monograph or specification of irradiation system was changed. Generally, in case of irradiation with a dominant wavelength of 254 nm to a thin-layer plate containing fluorescent agent, it is confirmed whether the thin-layer plate produce a green fluorescence. Alternatively, in case of irradiation with a dominant wavelength of 365 nm (366 nm), whether bluish white fluorescence is produced is confirmed by 2 μ L spotting the 0.5 μ g/mL scopoletin for thin-layer chromatography solution on a thin-layer plate.

In case of automated sample application equipment and TLC scanning device using densitometry, specifications of system suitability in Liquid Chromatography <2.01> is applied as required.

7. Point to consider regarding test conditions

Among tests prescribed in individual monograph, in identification tests using reagents of the Reference Standard or components to be tested (such as reagents for thin-layer chromatography), it is possible to modify developing temperature, developing distance, composition of developing solvent, developing rate, coloring reagent composition, heating temperature and duration of thin-layer plate within a range of better accuracy and precision than those prescribed is secured. However, such semi-quantitative identification tests are excluded that judgment criteria is based on size and strength of spots. On the other hand, in identification tests which do not use reagents of the Reference Standard or components to be tested, it is possible to modify developing distance, heating temperature and duration of thin-layer plate within a range where separation, *R*_f value and color tone prescribed in individual monograph is observed. Further, even in case of identification tests without specification for the Reference Standard or components to be tested, it is possible to make a confirmation based on conformity of color tone for reference and *R*_f value using the Reference Standard or components to be tested.

8. Reference

- 1) The Japanese Pharmacopoeia Sixteenth Edition/General Test Procedures/2. Physical Test Procedures/2.01 Liquid Chromatography/2.03 Thin-layer Chromatography
- 2) EP 8.0. 2.2.27/THIN-LAYER CHROMATOGRAPHY
- 3) USP 37 <621> CHROMATOGRAPHY, <201> THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST
- 4) CP 2010 A-42 Appendix VI VI B Thin-Layer Chromatography (English version)
- 5) Yukihiko Goda: Dispersion Observed in Fluorescence Spots on Thin-layer Chromatography during UV Lamp (long wave length) Use. The Japanese Journal of Pharmacognosy, 66, 63 (2012).

G6 Drug Formulation

Standard Procedure for Mechanical Calibration of Dissolution Apparatus

This chapter is intended to minimize sources of mechanical variability of apparatus which affect test results and assure the reproducibility of results, for Apparatus 1 (Basket method) and Apparatus 2 (Paddle method), and describes the standard procedure for the mechanical calibration of dissolution apparatus and the recommended specifications.

The validity of the mechanical calibration for qualification of dissolution test is confirmed on the meeting of international harmonization of pharmacopoeia about dissolution test, and subsequently, the standard practice for qualification of dissolution apparatus¹⁾ and the guidance of mechanical calibration²⁾ were issued in U.S.A.

Requirements for basic quality of materials and sizes, etc., to be required on dissolution test apparatus, and the suitability of the apparatus conform to the statements of Dissolution Test <6.10>. The tolerance of some parameters for the mechanical calibration described in this chapter may be specified strictly compared with that specified in Dissolution Test <6.10>. The below table shows the comparison of specified values of each calibration parameter. In order to minimize variability of test results by the mechanical calibration, it is recommended to apply this chapter.

Although qualification of dissolution test results by using Prednisone Tablet RS has been recommended in our country, since it cannot necessarily detect sources of mechanical variability of apparatus, the performance of the mechanical calibration is basically desirable. However the test appropriately performed by using Prednisone Tablet RS is valid for understanding overall factor including degassing state of a test solution and vibration of apparatus undetected by only the calibration of apparatus. Moreover a monitoring by a dissolved oxygen analyzer is valid for confirmation of degassing state of a test solution.

1. Setup of dissolution apparatus and periodic control

Mechanical calibration should be performed on purchase or receipt of dissolution apparatus, after move and after repair which can affect test results, and it is usually desirable to perform the calibration every year. If the instrument is not being used routinely, the mechanical calibration can be performed before performing the first dissolution test after the one year time interval.

2. Procedure of mechanical calibration

2.1. Instruments

Instruments for the mechanical calibration are runout gage, level, centering device and tachometer, etc., as generic ones and it is desirable to use the tools to be traceable to JIS (Japanese Industrial Standards), etc., wherever possible. In addition, special instruments for the mechanical calibration of dissolution apparatus are centering tool, depth gage, plastic ball, etc. Moreover, some dissolution apparatus require the special tools supplied by instrument manufacturers or incorporate automatic mechanical calibration devices within their equipment. These tools and devices may be used provided they follow the general principle of the below procedure.

Table Specified values of calibration parameters of Dissolution Test <6.10> and this chapter

Calibration Parameter	Dissolution Test <6.10>	This chapter
Shaft wobble	rotates smoothly without significant wobble that could affect the results	≤ 1.0 mm total runout
Shaft verticality	—	$\leq 0.5^\circ$ from vertical Bubble should be centered within the lines of the level.
Basket wobble	—	≤ 1.0 mm total runout
Vessel/Shaf t centering	≤ 2.0 mm from vertical	≤ 1.0 mm from centerline at upper position and lower position
Vessel verticality	—	$\leq 1.0^\circ$ from vertical
Basket and Paddle depth	25 ± 2 mm	25 ± 2 mm
Rotational speed	$\pm 4\%$ from the specified rate of rotation	$\pm 2\%$ or ± 2 rpm from the specified rate of rotation

2.2. Procedure

Perform the mechanical calibration of dissolution apparatus according to the below specified procedure. If each measured value does not meet the specification, repetitive adjustments and measurements may be necessary.

Confirm that the apparatus is horizontal on the installation table in advance. Also confirm the horizontality of the plate which fix the vessel (vessel plate) by placing a bubble level on the stage and confirming the bubble to be within the lines of the level.

2.2.1. Shaft Wobble

A runout gage is placed on top of the vessel plate, and positioned so that the gage probe touches the shaft about 2 cm above the top of the paddle blade or basket. The absolute value of the difference between the maximum and minimum readings is the wobble. The value of total wobble must not exceed 1.0 mm.

2.2.2. Shaft Verticality

Lower the drive unit to where it would be during an actual dissolution test. If necessary, the shaft verticality may be checked by raising the drive unit. Place an accurate bubble level on the front edge of each of the shafts. The bubble should be within the lines of the level. Rotate the level about 90° so that it touches the side of the shaft, and put it on the side of the shaft. The bubble should again be within the lines of the level.

A digital leveling device may also be used to determine the shaft verticality.

The shaft must be not more than 0.5° from vertical.

2.2.3. Basket Wobble

A runout gage is placed on top of the vessel plate and the drive unit is positioned so that the gage probe touches the bottom rim of the basket. The gage is placed so that the probe slightly presses in on the turning shaft. The value of total wobble must not exceed 1.0 mm.

2.2.4. Vessel Centering

Centering inside the vessel is measured by centering tools

for dissolution test apparatus or by an alternative procedure.

When measured by centering tools, two centering tools are used to center the paddle or basket shafts in the vessels and to align the vessels so that their sides are vertical.

As an example of the procedure for the paddle method, the bottom of one centering tool is placed 2 mm above the top of the paddle blade and the bottom of the second centering tool is clamped on the shaft 80 mm above the blade with the both probes positioned in the same direction towards the vessel wall. For the basket method, the bottom of one centering tool is placed 2 mm above the top of the basket and the bottom of the second centering tool is placed 60 mm above the top of the basket with the both probes positioned in the same direction towards the vessel wall. Carefully lower the shaft and centering tools into the vessels so that the paddle blade and the bottom of the basket is about 2.5 cm above the bottom of the vessel. Manually rotate the shaft slowly and check the centering at both levels. If the vessel is not centered at either level, adjust the vessel to center it.

An alternative procedure is to use a mechanical or digital centering device that centers the inside wall of the vessel around the shaft or a surrogate shaft. The centering is measured at two positions inside the vessel in the cylindrical portion, one just below the rim of the vessel and one just above the basket or the paddle in the bottom portion of the vessel.

The shaft must be centered within 1.0 mm from the center line.

2.2.5. Vessel Verticality

The vessel verticality can be calculated as the angle of the vertex of the triangle composed of the two points and the vertical line using the two centering measurements in 2.2.4 Vessel Centering and the difference in height between the two measurements. Or it can be determined using a digital leveling device placed on the inside wall of the vessel. The verticality should be determined at two positions 90° apart.

The vessel must be not more than 1.0° from vertical.

After each vessel has been centered and made vertical, each vessel must be positioned in the exact same position and same direction inside the vessel plate opening.

2.2.6. Basket and Paddle Depth

The actual distance between the bottom of the vessel and the bottom of the basket or paddle is determined. If the depth of the basket/paddle is adjustable, first a depth gage is used to determine the distance between the bottom of the paddle blade or basket and the inside bottom of the vessel. The depth gage is set at 25 mm and placed on the bottom of the vessel. After each shaft is raised into the apparatus drive module, the drive unit is then lowered to its operating position. The paddle or basket is then lowered into the vessel until it touches the top of the depth gage. Instead of a depth gage, sink a plastic ball with a diameter $25 \text{ mm} \pm 2 \text{ mm}$ on the bottom of the vessel and the paddle or basket can be lowered into the vessel until it touches the ball. The shafts are locked into this height. Usually the depth of basket and paddle is $25 \text{ mm} \pm 2 \text{ mm}$.

2.2.7. Rotational Speed

A tachometer is used to measure the rotational speed of the paddle or basket. The shafts should be rotating smoothly with a rate within a larger value of $\pm 2\%$ or ± 2 rpm of the specified rate.

3. References

- 1) ASTM E2503 – 13; Standard Practice for Qualification of Basket and Paddle Dissolution Apparatus (2013).
- 2) FDA Guidance for Industry: The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2—Current Good Manufacturing Practice (CGMP), U.S. Depart-

ment of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), January 2010.

Tablet Friability Test

This test is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia.


The Tablet Friability Test is a method to determine the friability of compressed uncoated tablets. The test procedure presented in this chapter is generally applicable to most compressed tablets. Measurement of tablets friability supplements other physical strength measurement, such as tablet crushing strength.

Use a drum, with an internal diameter between 283 and 291 mm and a depth between 36 and 40 mm, of transparent synthetic polymer with polished internal surfaces, and subject to minimum static build-up (see figure for a typical apparatus). One side of the drum is removable. The tablets are tumbled at each turn of the drum by a curved projection with an inside radius between 75.5 and 85.5 mm that extends from the middle of the drum to the outer wall. The outer diameter of the central ring is between 24.5 and 25.5 mm. The drum is attached to the horizontal axis of a device that rotates at 25 ± 1 rpm. Thus, at each turn the tablets roll or slide and fall onto the drum wall or onto each other.

For tablets with a unit mass equal to or less than 650 mg, take a sample of whole tablets n corresponding as near as possible to 6.5 g. For tablets with a unit mass of more than 650 mg, take a sample of 10 whole tablets. The tablets should be carefully dedusted prior to testing. Accurately weigh the tablet sample, and place the tablets in the drum. Rotate the drum 100 times, and remove the tablets. Remove any loose dust from the tablets as before, and accurately weigh.

Generally, the test is run once. If obviously cracked, cleaved, or broken tablets are present in the tablet sample after tumbling, the sample fails the test. If the results are difficult to interpret or if the mass loss is greater than the targeted value, the test should be repeated twice and the mean of the three tests determined. A maximum mean mass loss from the three samples of not more than 1.0% is considered acceptable for most products.

If tablet size or shape causes irregular tumbling, adjust the drum base so that the base forms an angle of about 10° with the horizontal and the tablets no longer bind together when lying next to each other, which prevents them from falling freely.



Effervescent tablets and chewable tablets may have different specifications as far as friability is concerned. In the case of hygroscopic tablets, an appropriate humidity-controlled environment is required for testing.

Drums with dual scooping projections, or apparatus with more than one drum, for the running of multiple samples at one time, are also permitted.

G7 Containers and Package

Basic Requirements and Terms for the Packaging of Pharmaceutical Products

This chapter describes the basic requirements for the packaging of pharmaceutical products as well as the terms and their definitions used for the packaging as taking into account the aspects in quality assurance of the pharmaceutical products and the point of view of international harmonization.¹⁾

In this chapter, the concept of packaging for pharmaceutical products, or packaging, includes putting or holding the drugs in container. In addition, the information presented as basic requirements shall be a central focus on packaging for drug products, as well as for ensuring quality on the transportation and storage of drug substances or additives.

1. Basic requirements of packaging for pharmaceutical products

For the packaging for pharmaceutical products, it is important to settle the requirements of the packaging based on the evaluation of the packaging suitability in the development stage so as to be able to ensure the quality standards of preparations defined over the shelf life of preparations. The suitability of packaging for pharmaceutical products must be maintained through the product life cycle on the basis of the requirements of packaging settled in the development stage.

For the packaging of drug products, it is also necessary to consider for the suitability for proper use and for ensuring safe application in addition to quality assurance. The stringency of the evaluation for suitability of packaging for preparations differs depending on the degree of the risk according to the route of administration, such as intravenous administration, oral administration, or dermal administration and the risk due to interaction between the products and the primary packaging according to injections, liquids and solutions, semi-solid or solid dosage forms.

1.1. Suitability evaluation and requirements of packaging in the design stage

The packaging suitability to be evaluated in the design stage includes protection, compatibility, safety, and performance.

The basic items to be evaluated as suitability are described in the course of the packaging design.

1.1.1. Safety of materials used for packaging

Leachables or migrants, such as the monomers of the polymer resins, additives or metal impurities, from the materials used for the primary packaging such as plastic or glass containers should not deteriorate drug safety. The amount of leachable or migratable chemical substances from the primary packaging materials to the contents must be sufficiently small from a safety perspective.

The primary packaging materials of the containers that are

in direct contact with the drugs should be used which quality such as on toxicity has been appropriately evaluated by the suppliers according to "Basic Requirements for Plastic Containers for Pharmaceutical Use and Rubber Closures for Containers for Aqueous Infusions" or the like. In the design stage, the information on quality evaluation of the packing materials are desirable to be obtained as far as possible from the suppliers.

1.1.2. Compatibility with the contents

The primary packaging must not reduce the quality of pharmaceutical products over the shelf life of preparations. The contents adsorbing onto the surface of primary packaging, or migrating inside of the materials, must not lead to a drug concentration change of more than a certain level. Moreover, the interaction between the contents and the materials must not lead to degradation of drugs.

The primary packaging should not be deformed, deteriorated, or degraded by the contents.

In the design stage, the compatibility of the primary packaging with the content is examined by the combination of individual candidate material and the content drugs, together with other evaluation items. And chose the applicable material based on the results of the study on the prototype primary packaging for complying with the essential requirements, i.e. the design specifications, for the issues about the protection from moisture and light, the sorption to and leaching from the primary packaging, etc., based on the data from the experiments and/or information from the scientific documentation. When selecting the primary packaging material, the suitability of the material for the secondary packaging is also to be evaluated as needed.

1.1.3. Protection by packaging

The packaging should be able to prevent loss, efflorescence, deliquescence, or evaporation of the contents and to protect the contents by the addition of moisture resistance, light shielding, or a gas barrier, depending on the characteristic of the contents. In the case of not being able to ensure the quality of the contents by the primary packaging alone, it should be ensured by the combination of multiple packaging materials, including the secondary packaging. Furthermore, the containers for injections or ophthalmic solutions are preferable to be made of a high transparency material, so that foreign matter contamination can be observed visually.

For pharmaceutical products susceptible to moisture such as by hydrolysis, the packaging used with desiccants or primary packaging materials with gas-barrier function can be moisture-proof packaging. For preparations susceptible to evaporation of water, gas-barrier materials for the primary packaging can be used. For the pharmaceutical products that are easily oxidized, the packaging with deoxidants or the low-gas-permeability materials can be used for the primary packaging to protect the pharmaceutical products from oxygen in the air.

Protection by the packaging should be evaluated in the packaging design stage, and finally confirmed by stability tests. Resistance to physical shock during transportation is also necessary to be verified.

1.1.4. Container integrity (microbial contamination prevention)

The packaging should be able to protect the contents from microbial contamination, depending on the characteristics of the content drug or dosage form, and especially for the containers used for sterile preparations, the integrity of primary packaging, through the tests such as the fitting compatibility tests for containers and closures, must be confirmed.

In the case of pharmaceutical products that must be sterilized, the primary packaging must meet the above-mentioned

suitability for safety, compatibility and protection even after the sterilization. There should not be any residue or generation of toxic substances of more than a certain safety level after the sterilization. In addition, the primary packaging should have a structure and/or material that must prevent any microbial contamination of the pharmaceutical products contained therein during storage and transportation after sterilization.

1.1.5. Packaging performance

The packaging design with consideration for discrimination, usability, and disposal should be performed.

With regard to discrimination, for example, a display should be considered for patients and even for aged patients so that the proper administration and use of the drugs can be ensured. An easy-to-understand display or container for preventing accidental misuse or a prank, such as tamper-resistant packaging and child-resistant packaging, is preferable.

With regard to usability, items such as easy handling of the drug in dispensing, easy dosaging for children, easy removal from the container when the drug is administered or used, successful administration, and preferable storage and portability should be considered for each preparation.

On packaging-related waste, the choice or determination of the containers must be considered for disposal, since paying attention to the effect of use of resources, following the Containers and Packaging Recycling Act and the rules of each local government, and striving to reduce wastes are required. In the primary packaging, the recycled packaging materials that are not assured for material composition must not be used.

1.1.6. Requirements of packaging

Based on the test methods and/or the evaluation techniques used for study of the packaging suitability in the design stage of pharmaceutical preparations, the necessary and sufficient items of the quality control for maintaining the packaging suitability are established. Generally, the requirements of packaging are composed of the control of the material quality, specifications and test methods, in-process tests, and the like.

1.2. Examples of suitability evaluation in the design stage of packaging for pharmaceutical products

The following are the examples of the suitability evaluation in the design stage.

1.2.1. Suitability evaluation of packaging to be used for solid oral dosage forms

For the suitability evaluation of the packaging for solid oral dosage forms, the following tests should be included.

- If bottles are used, the measurement of opening torques with selected stoppers should be performed.
- If PTP packaging or strip packaging is used, the moisture permeability test should be performed.

1.2.2. Suitability evaluation of containers to be used for injections

For the suitability evaluation of containers to be used for injections, the following tests should be included.

- The injections using ampules should perform pinhole tests, and the integrity must be confirmed.
- The injections using vials, rubber closures, or prefilled glass syringes, except ampules, should perform the fitting compatibility tests, and the integrity as a container must be confirmed.
- The plastic containers for pharmaceutical products used for injections (prefilled syringes, plastic bottles, plastic bags, etc.) should be verified as "tight containers in which microorganisms will not be contaminated" over the shelf life of preparations.

1.2.3. Suitability evaluation on metal impurities for a container closure system

If leaching of metal impurities from the primary packaging materials used for injections, liquids, or semi-solid preparations is suspected, it is necessary to confirm that the amount of metal impurities contained in preparations is sufficiently low from the viewpoint of safety using Atomic Absorption Spectrophotometry <2.23>, Inductively Coupled Plasma Emission Spectrometry and Inductively Coupled Plasma-Mass Spectrometry <2.63>, etc.

1.2.4. Suitability evaluation of kit products

If dispensing devices, such as prefilled syringes, injection cartridges, or metered-dose preparation for inhalation, are used, the accurate dose with reproducibility in conditions as close as possible to the product usage must be verified.

1.2.5. Suitability evaluation of light resistant packaging

If active substances are susceptible to the light and the formulation design alone cannot overcome the effect of light, the light resistant packaging including containers should be considered. A selection of an appropriate light resistant packaging must be verified using a photostability test and the like as severe tests.

1.3. Selection, change control, stability monitoring, etc. of the packaging materials in the packaging process development

To maintain appropriately the quality assurance of pharmaceutical products by packaging, the properness of the requirements of the packaging must be confirmed through the appropriate change control, stability monitoring and the like in the packaging process development and production stages, together with the suitability evaluation performed in the design stage.

For the primary packaging materials used in the manufacture of preparations, whether the quality of material is changed by the supplier must be appropriately managed. Therefore, all information, concerning the manufacturing process of containers including the information about substances added is desirable to be obtained.

The finally selected packaging for pharmaceutical products should be evaluated whether it meets the requirements as designed. If it does not meet the requirements, the packaging form or material must be changed through change control.

1.3.1. Selection or change of packaging materials in the packaging process development

The packaging materials should be selected in consideration of the manufacturability and the prevention capability of adhesion of foreign matters or insects in addition to meeting the requirements determined in the design stage. For the finally selected packaging, it should be verified to withstand against temperature change during storage and transportation, physical shock during transportation, and the like.

The suitability of the selected packaging materials shall be confirmed, using the applicable tests in the General Tests, 7. Test for Containers and Packing Materials. For the tests that are not described in the General Tests, set the applicable test and judge the suitability.

1.3.2. Stability monitoring, etc.

It must be confirmed that the packaging form does not adversely affect the stability of preparations through stability monitoring or reference sample stored. If the packaging is considered to affect the quality of stability of the preparations, the applicable packaging and management should be selected to ensuring quality, where the quality of the lots using this should be monitored, and the packaging should be improved through change control, if necessary.

1.4. Examples of quality control in the packaging process

of pharmaceutical products

To maintain the suitability of the packaging of pharmaceutical products, it must be confirmed by performing the test such as process control test before shipment that the packaging meets the requirements.

The following shows the examples.

1.4.1. Examples of solid oral dosage forms

The PTP packaged tablets must be confirmed whether the integrity of the seal as designed is secured in the airtight tests for PTP sheets (e.g. water pressure reduction tests).

1.4.2. Examples of injections

- Aqueous injections using ampules should be checked if it has no pinholes.
- The plastic containers for pharmaceutical products used for injections (prefilled syringes, plastic bottles, plastic bags, etc.) should be checked when they are shipped to the market if they have been produced as tight containers, as designed, where microorganisms are not contaminated.

2. Terms of packaging for pharmaceutical products

2.1. Basic terms

Primary packaging: Any packaging that is in direct contact with active substances, excipients, or preparations, and should not give a physical or chemical change to the contents. The primary packaging holds the quality of the pharmaceutical products and provides better performance including convenience.

For example, the primary packaging includes an ampule that is an “immediate container” for injections, and a PTP packaging which is an “inner bag” for tablets or capsules.

Outside container or outside wrapper: A container or wrapper that is used to contain or to wrap immediate containers or immediate wrappers for the pharmaceutical products for sale or distribution and has a legal label by ordinance²⁾ on it.

Tight container: A container that protects the contents from extraneous solids or liquids, from loss of the contents, and from efflorescence, deliquescence, or evaporation under ordinary or customary conditions of handling, shipment, and storage. Where a tight container is specified, it may be replaced by a hermetic container. (General Notices 43)

The tight container includes containers made of plastic resins as the examples of container and packaging often used (bottles, vials, syringes, blister (PTP) packaging, strip packaging, etc.).

Final packaging or marketed packaging: Any packaging that is for pharmaceutical products for sale or distribution and a form of the shipped products to the market by labeling as defined by ordinance^{2,3)}.

The final packaging may be used for irradiation when a radiation sterilization method is used.

Labeling and packaging materials⁴⁾: Product's containers, wrappers, and labeling including package insert.

Immediate wrapper: A container in which pharmaceutical products are contained directly (papers, clothes, plastics, and aluminum bags). It can be sold or distributed as it is by labeling as defined by ordinance³⁾. There is an inner bag as an example of immediate wrapper that it is not sold or distributed as it is and does not require a legal label by ordinance³⁾.

The immediate wrapper in which the pharmaceutical products are contained directly is also referred to as the primary packaging.

Immediate container: A solid container in which the drugs are directly contained (cans, bottles, ampules, vials, tubes, containers for eye drops, boxes, etc.). It can be sold or distributed as it is by labeling as defined by ordinance³⁾. In ad-

dition, the paper boxes will be the immediate container, if they use the PTP packaging as an inner bag like tablets.

The immediate container in which the drugs are contained directly is also referred to as a primary packaging.

Inner bag: For example, a plastic bag used under the wrapper for moisture-proof and light resistance and a drug bag that contains each single dose of powder. It is referred as a plastic bag, strip packaging, blister packaging (such as a PTP packaging), and a plastic container for suppositories. In addition, when the pharmaceutical products are contained directly in the inner bag, it corresponds to an immediate packaging, however, if it is not sold or distributed as it is, a legal label by ordinance³⁾ is not required.

The inner bag in which the drugs are contained directly is also referred to as a primary packaging.

Secondary packaging: Any packaging that is a single or multiple packaging to compensate for a primary packaging and is not in direct contact with active substances, excipients, or preparations. Any secondary packaging can keep the quality of pharmaceutical products and add performance, such as preventing errors and convenience in the use of pharmaceutical products.

Wrapper: A container or parcel made of soft materials such as paper, cloth, plastic, and aluminum bag. As examples of the wrapper for pharmaceutical products, there are medicine envelope, plastic bag, strip packaging, and blister packaging (such as a PTP packaging).

Labeling⁵⁾: A labeling defined by ordinance^{2,3)}, which is a product label and package insert.

Sealing: Sealing from which drugs cannot be taken out unless opened and does not allow its original state to be easily restored after being opened, according to ordinance.⁶⁾

Packaging⁷⁾: The appropriate materials, containers or wrappers to keep the quality of pharmaceutical products under ordinary or customary conditions of handling, shipment, storage, or usage, and techniques to hold the products in them, or a packaged state.

Hermetic container: A container that is impervious to air or any other gas under ordinary or customary conditions of handling, shipment, and storage. (General Notices 44)

For the injections, ampules, container closure systems, such as vials/rubber clousers, glass prefilled syringes may be used as this container. For the other dosage forms, blister (PTP) packaging with both sides of aluminum and metal extrusion tubes may be used as this container.

Well-closed container: A container that protects the contents from extraneous solids and from loss of the drug under ordinary or customary conditions of handling, shipment, and storage. Where a well-closed container is specified, it may be replaced by a tight container. (General Notices 42)

The well-closed container includes paper or plastic bags with one opening made of a flexible material, and cans with metal or plastic resins, etc., as the examples of often used.

Container: A device that holds drugs. The stopper or cap is included as a part of the container. The containers have no physical and chemical reactivity affecting the specified description and quality of the contents (General Notices⁴¹⁾.

As examples of the container for pharmaceutical products, there are cans, bottles, tubes, ampules, vials, and boxes.

Container closure system: A packaging form that consists of the materials used for a primary packaging that is in direct contact with active substances, excipients, or preparations and composed of other materials. A container closure system should be considered in combination with the contents, where the quality cannot be guaranteed with primary packaging alone, the materials used for a secondary packaging

should be included.

2.2. Terms of individual packaging or containers

Ampule: A container that is made of a clear or colored glass or plastic that encapsulates drug solution such as injections, or freeze-dried contents. The opening is usually sealed or welded.

Collapsible tube⁷⁾: A container that has a nozzle and cap at one end, and the other end is closed, having flexibility to extrude the contents of ointments. This includes metal tubes, plastic tubes, and laminated tubes, etc.

Syringe: A container that is composed of an external cylinder (barrel), a gasket, a pusher (plunger), and a top cap. This may include a needle. It is used for prefilled syringes.

Strip packaging⁷⁾: A packaging in which tablets, capsules, powder, and granules are directly tucked between two materials and bonded to the surrounding. It is also referred to as the SP packaging and corresponds to an inner bag or primary packaging as the pharmaceutical products are directly contained.

Vial: A container, a type of bottle, that is made of a clear or colored glass, or plastic used for injections. This is sealed with a rubber closure and aluminum cap.

PTP packaging⁷⁾ (Press through packaging): Any packaging that is a kind of a blister packaging, using collapsible materials such as aluminum foils to extrude the opening of the plastic forming products. This corresponds to an inner bag or primary packaging as the capsules or tablets are directly contained.

Pillow type packaging⁷⁾: Any packaging that is a kind of bag-shaped. For example, in which the vertical central portion is bonded and the top and bottom edges are sealed. Where the primary packaging alone is difficult to ensure quality, a secondary packaging, which consists of composite films laminated with aluminum foils for protection from moisture and lights, is often used.

Plastic bags: A soft container that uses polyethylene or polypropylene resins as single or composite materials, and which has one or more openings. This usually uses a rubber closure as a plug body. It is used as a large volume injection container such as parenteral infusions.

Blister packaging⁷⁾: Any packaging where plastic or aluminum foils are heat formed and given one or more pockets and the preparations are put therein, the opening is covered with plastic films, sheets, or aluminum foil, and the periphery to the substrate is bonded or fixed. It refers to the form that is carried out by peeling the film or foil as the preparations are removed, and used for capsules, tablets, prefilled syringes agent, kit products containing a plurality of ampules.

In addition, where the tables, etc. are directly contained, it corresponds to an inner bag or primary packaging.

Single-dose packages: Preparations in single-dose packages. For example, a strip packaging which contains powders or granules for a single dose corresponds to this.

2.3. Terms of packaging performance

Gas barrier packaging⁷⁾: Any packaging that gives the function of suppressing gas permeability aimed. This is a low-gas-permeability packaging.

Light resistant container and packaging: A container or packaging which prevents light permeability to protect if the light affects the quality of the contents under ordinary or customary conditions of handling, shipment, and storage. (General Notices 45)

In addition to colored containers to be used, the containers may be covered with shrink films.

Tamper-resistant packaging, tamper-proof packaging⁷⁾: Any packaging that is designed to prevent a risk if a person unin-

tentionally handles, or “plays a prank”.

Child-resistant packaging, childproof packaging⁷⁾: Any packaging that is intended for prevention of accidental ingestion by children and may be used for adults properly not to let children open it accidentally.

Moisture-proof packaging⁷⁾: Any packaging that uses a material with moisture-proof performance to protect the pharmaceutical products from the effects of moisture, if necessary, using desiccant to keep the inside dry.

3. Reference

- 1) FDA Guidance for Industry “Container Closure Systems for Packaging Human Drugs and Biologics”, May 1999.
- 2) November 25, 2014 enforcement, “The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices” provided in Article 51
- 3) “The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices” provided in Article 50
- 4) MHLW Ministerial Ordinance No. 179, “Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs” of December 24, 2004 provided in Article 2 Paragraph 2
- 5) PFSB/CND Notification No. 0830 - 1 Office Memorandum, ”Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs“ of August 30, 2013
- 6) “The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices” provided in Article 58
- 7) Japanese Industrial Standards JIS Z 0108: 2012 “Packaging-Vocabulary”

Basic Requirements for Plastic Containers for Pharmaceutical Use and Rubber Closures for Containers for Aqueous Infusions

In this chapter, there describe basic requirements for plastic containers for pharmaceutical use and rubber closures for containers for aqueous infusions, and the methods to evaluate the toxicity of containers at design stage.

Containers for pharmaceutical use should not have the properties to deteriorate the efficacy, safety or stability of the pharmaceutical products to be packed in the container. The compatibility of plastic containers with pharmaceutical products should be judged for each combination of container and the specific pharmaceutical product to be contained therein. Such judgment should be performed through verification that the container for the pharmaceutical preparation can comply with the essential requirements for the container, i.e., the design specifications, based on the data from the experiments on the prototype products of the container and/or information from scientific documentation, etc. In addition, such compatibility must be ensured based upon an appropriate quality assurance system.

1. Basic Requirements in Designing Containers for Pharmaceutical Use

Containers must not deteriorate the quality of the pharmaceutical products during storage. The concentration of the pharmaceuticals must not be decreased by more than a certain level due to the adsorption of the pharmaceuticals on

the surface of the container, the migration of the pharmaceuticals into the inside of the material of the container, or the loss of pharmaceuticals through the container. Also, the pharmaceutical products contained therein must not be degraded by an interaction with the material of the container.

The container should not be deformed, should not deteriorate and should not be degraded by the pharmaceutical products contained therein. Unacceptable loss of function of the container should not result from a possible high temperature or low temperature or their repetitions encountered during storage or transportation.

The leachable or migrants from the container should not deteriorate the efficacy or stability of the pharmaceutical products contained therein. In addition, the possible toxic hazards due to the leachable or migrants should not exceed a given level. Furthermore, the amounts of leachable or migratable chemical substances, such as monomers and additives, from the containers to the pharmaceutical products contained therein must be sufficiently small from the viewpoint of safety.

In the case of pharmaceutical products which must be sterilized, it is required to satisfy the above-mentioned essential requirements of the container after the sterilization, if there is a possibility that the quality of the container may change after the sterilization. There should not be any residue or generation of new toxic substances of more than certain risk level after the sterilization. In addition, the container should not have any inappropriate structure and/or material that might result in any bacterial contamination of the pharmaceutical products contained therein during storage and transportation after sterilization.

1.1. Plastic containers for pharmaceutical use

The plastic material used for the container should be of high quality. Therefore, recycled plastic materials, which are of unknown constitution, must not be used.

In the case of pharmaceutical products which are unstable to light, the container should provide a sufficient level of light shielding. In the case of pharmaceutical products which are easily oxidized, the container material should not allow the permeation of oxygen. In the case of aqueous pharmaceutical products and pharmaceutical products that must be kept dry, the container material should not allow the permeation of water vapor. In addition, it is necessary to pay attention to the permeability of solvents other than water through the container.

The container should have a certain level of physical properties such as hardness, flexibility, shock resistance, tensile strength, tear strength, bending strength, heat resistance and the like, in accordance with its intended usage. The container should be of a required level of transparency, when it is necessary to examine foreign insoluble matter and/or turbidity of the pharmaceutical products by visual observation.

Furthermore, in introducing a plastic container, it is desirable that proper disposal method after use is taken into consideration.

1.2. Rubber closures for containers for aqueous infusions

For the rubber closures for container, natural rubber, which has the possibility to cause an allergic response, or recycled rubber material that can not be guaranteed its material composition, should not be used.

As the closure systems, the appropriate materials should be used to prevent the permeation of oxygen, water vapor and solvents.

Further, the rubber closure should have a certain level of physical properties such as air tightness, hermetic seal, penetrability of a needle, coring-resistance and self-sealing

after penetration, in accordance with its intended usage.

2. Toxicity Evaluation of Container at Design Stage

For design verification, the toxicity of the container should be evaluated. For the toxicity evaluation, it is desirable to select appropriate test methods and acceptance criteria for the evaluation, and to explain the rationale for the selection clearly. The tests should be conducted using samples of the whole or a part of the prototype products of the container. If the container consists of plural parts of different materials, each part should be tested separately. Such materials as laminates, composites, and the like are regarded as a single material. To test containers made of such materials, it is recommended to expose the inner surface of the container, which is in contact with the pharmaceutical products contained therein, to the extraction media used in the tests as far as possible.

It is recommended to select the test items and the test methods for the evaluation of the toxicity of the containers, depending on their application site, in accordance with the standard test methods on medical devices and materials published in Japan, a notice entitled Basic Principle of Biological Safety Evaluation Required for Application for Approval to Market Medical Devices (MHLW Notification by Director, OMDE Yakusyokuki 0301 No.20 on March 1, 2012).

3. Test Results to be recorded per Production Unit for Plastic containers for pharmaceutical use and Rubber closures for containers for aqueous Infusions

3.1. Plastic containers for pharmaceutical use

At the commercial production phase, it is required to establish acceptance criteria on at least the test items listed below and to record the test results of each production unit of plastic containers for pharmaceutical products. In addition, it is desirable to explain the rationale for setting the acceptance criteria clearly. However, these requirements should not be applied to orally administered preparations except for liquid preparations.

(i) Combustion Tests: Residue on ignition, heavy metals. If necessary, the amounts of specified metals (lead, cadmium, etc.)

(ii) Extraction Tests: pH, UV spectrum, potassium permanganate-reducing substances, foaming test, residue on evaporation

(iii) Cytotoxicity Test

(iv) Any other tests necessary for the specific container for aqueous infusions.

3.2. Rubber closures for containers for aqueous infusions

At the commercial production phase of rubber closures, it is required to establish acceptance criteria on the test items that should be controlled other than those specified in the general chapter of <7.03> Test for Rubber Closure for Aqueous Infusions. And the test results of each production unit of rubber closures for containers for aqueous infusions should be recorded. In addition, it is desirable to explain the rationale for setting the acceptance criteria.

G8 Water

Quality Control of Water for Pharmaceutical Use

Water used for manufacturing pharmaceutical products and for cleaning their containers and equipments used in the manufacture of the products is referred to as "pharmaceutical water." For assuring the quality of pharmaceutical water consistently, it is important to verify through appropriate process validation of water processing system that water with the quality suitable for its intended use is produced and supplied, and to keep the quality of produced water through routine works for controlling the water processing system.

1. Types of Pharmaceutical Water

1.1. Water

The specification for "Water" is prescribed in the Japanese Pharmacopoeia (JP) monograph. It is required for *Water* to meet the Quality Standards for Drinking Water provided under the Article 4 of the Japanese Water Supply Law. In the case that *Water* is produced at individual facilities using well water or industrial water as source water, it is necessary for produced water to meet the Quality Standards for Drinking Water and an additional requirement for ammonium of "not more than 0.05 mg/L." Furthermore, when *Water* is to be used after storing for a period of time, it is necessary to prevent microbial proliferation.

Water is used as source water for *Purified Water* and *Water for Injection*. It is also used for manufacturing intermediates of active pharmaceutical ingredients (APIs), and for pre-washing of the equipments used in the manufacture of pharmaceutical products.

1.2. Purified Water

The specifications for "Purified Water" and "Purified Water in Containers" are prescribed in the JP monographs. *Purified Water* is prepared by distillation, ion-exchange, reverse osmosis (RO), ultrafiltration (UF) capable of removing microorganisms and substances with molecular masses of not less than approximately 6000, or a combination of these processes from *Water*, after applying some adequate pretreatments if necessary. For the production of *Purified Water*, appropriate control of microorganisms is required. Particularly, in the case that *Purified Water* is prepared by ion-exchange, RO or UF, it is necessary to apply the treatments adequate for preventing microbial proliferation, or to sanitize the system periodically.

When *Purified Water* is treated with chemical agents for sterilizing, preventing microbial proliferation, or maintaining the endotoxin level within an appropriate control range, a specification suitable for the intended use of treated water should be established individually, and a process control for keeping the quality of treated water in compliance with the specification thus established should be performed.

"*Purified Water in Containers*" is prepared from *Purified Water* by introducing it in a tight container.

1.3. Sterile Purified Water

The specification for "Sterile Purified Water in Containers" (its alternative name is *Sterile Purified Water*) is prescribed in the JP monograph.

Sterile Purified Water in Container is prepared from *Purified Water* by 1) introducing it into a hermetic container, sealing up the container, then sterilizing the product, or 2)

making it sterile by using a suitable method, introducing the sterilized water into a sterile hermetic container by applying aseptic manipulation, then sealing up the container.

Plastic containers for aqueous injections may be used in place of hermetic containers.

1.4. Water for Injection

The specifications for “*Water for Injection*” and “*Sterile Water for Injection in Containers*” are prescribed in the JP monographs. *Water for Injection* is prepared by distillation or reverse osmosis and/or ultrafiltration (RO/UF), either: from the water which is obtained by appropriate pretreatments such as ion exchange, RO, etc. on *Water*; or from *Purified Water*.

In the case of water processing systems based on distillation, it is necessary to take care for avoiding contamination of produced water by the impurities accompanied with the entrain.

In the case of water processing system based on RO/UF, it is required to provide water with equivalent quality to that prepared by distillation consistently, based on substantial process validation through long-term operation and elaborate routine control of the system. It is essential to ensure consistent production of water suitable for *Water for Injection* by the entire water processing system including pretreatment facilities, in any systems based on RO/UF. For the water supplied to the system, it is also required to keep the quality suitable as source water through adequate validation and routine control on the water.

For the water processing system based on RO/UF, routine control should be performed by analyzing water specimens, monitoring some quality attributes using in-line apparatus and checking the volume of water passed through the system. In addition, it is recommended to carry out periodical appearance observation and air-leak test on the membranes being currently used. It is also recommended to establish protocols for keeping the performance of membrane modules within appropriate control ranges and for estimating the timing to exchange the modules, through diagnosis on the degree of deterioration based on the results of tensile strength test on the used membrane modules, and visual observation on those modules whether any leakages of membranes have occurred or not, and to what extent they have occurred. Furthermore, it is desirable to establish the frequency of membrane exchange considering with its actual condition of use.

In the case that *Water for Injection* is stored in the water processing system temporarily, a stringent control for microorganisms and endotoxins should be taken. An acceptable criterion of lower than 0.25 EU/mL for endotoxins is specified in the JP monograph of *Water for Injection*.

“*Sterile Water for Injection in Container*” is prepared from *Water for Injection* by 1) introducing it into a hermetic container, sealing up the container, then sterilizing the product, or 2) making it sterile by using a suitable method, introducing the sterilized water into a sterile hermetic container by applying aseptic manipulation, then sealing up the container.

Plastic containers for aqueous injections may be used in place of hermetic containers.

2. Reverse Osmosis and/or Ultrafiltration (RO/UF)

RO/UF are the methods for refining water by using membrane modules based on either reverse osmosis or ultrafiltration, or the modules combining them, and used as the alternative methods for distillation in the production of *Purified Water* or *Water for Injection*.

When *Water for Injection* is produced by RO/UF, a water

processing system equipped with pretreatment facilities, facilities for producing *Water for Injection* and facilities for supplying *Water for Injection* is usually used. The pretreatment facilities are used to remove solid particles, dissolved salts and colloids in source water, and placed before the facilities for producing *Water for Injection* so as to reduce the load on the facilities for producing *Water for Injection*. They consist of apparatus properly selected from aggregation apparatus, precipitation-separation apparatus, filtration apparatus, chlorine sterilization apparatus, oxidation-reduction apparatus, residual chlorine-removing apparatus, precise filtration apparatus, reverse osmosis apparatus, ultrafiltration apparatus, ion exchange apparatus, etc., depending on the quality of source water. The facilities for producing *Water for Injection* consist of apparatus for supplying pretreated water, sterilization apparatus with ultraviolet rays, heat exchange apparatus, membrane modules, apparatus for cleaning and sterilizing the facilities, etc. The facilities for supplying *Water for Injection* consist of a reservoir tank for storing *Water for Injection* in the facilities temporarily, pipe lines, heat exchange apparatus, a pump for circulating *Water for Injection* in the facilities, pressure control apparatus, etc.

In the case that *Water for Injection* is stored in the water processing system temporarily, it should usually be circulated in a loop consisting of a reservoir tank and pipe line at a temperature not lower than 80°C for preventing microbial proliferation.

When *Purified Water* is produced by RO/UF, basic composition of water processing system is almost the same as that for *Water for Injection* described above.

When RO/UF is utilized for preparing pharmaceutical water, it is necessary to select the most appropriate combination of membrane modules in consideration of the quality of source water and the quality of produced water required for its intended use. When the ultrafiltration membrane is used to prepare *Purified Water* or *Water for Injection*, membrane modules capable of removing microorganisms and substances with molecular masses not less than approximately 6000 should be used.

3. Selection of Pharmaceutical Water

Depending on the intended use of pharmaceutical water, the water suitable for assuring the quality of final products without causing any trouble during their manufacturing processes, should be selected from the above 4 types (1.1 – 1.4) of pharmaceutical water specified in the JP. Table 1 exemplifies a protocol for such selection (in the case of pharmaceutical water used for the manufacture of active pharmaceutical ingredients and drug products).

Sterile Purified Water in Containers or *Water for Injection* (or *Sterile Water for Injection in Containers*) may be used in place of *Purified Water* (or *Purified Water in Containers*).

3.1. Drug Products

For the manufacture of sterile drug products such as Injections, for which endotoxins together with microorganisms should be severely controlled, *Water for Injection* (or *Sterile Water for Injection in Containers*) should be used. For the manufacture of sterile drug products such as Ophthalmic Preparations and Ophthalmic Ointments, for which contamination with microorganisms should be paid attention, *Purified Water* (or *Purified Water in Containers*), which viable count level is specified at low, can also be used.

For the manufacture of non-sterile drug products, water with a quality not lower than that of *Purified Water* (or *Purified Water in Containers*) should be used. For the Inha-

Table 1 An Exemplified Protocol for Selecting Pharmaceutical Water
(Water Used in the Manufacture of Drug Products or APIs)

Classification	Class of Pharmaceutical Water	Application	Remarks
Drug Product	<i>Water for Injection</i> or <i>Sterile Water for Injection in Containers</i>	Injections, Dialysis Agents (Peritoneal Dialysis Agents and Hemodialysis Agents)	For Hemodialysis Agents, unless otherwise specified, <i>Water for Injection</i> , <i>Water for Injection in Containers</i> , or water suitable for the dialysis.
	<i>Purified Water</i> or <i>Purified Water in Containers</i>	Ophthalmic Preparations, Ophthalmic Ointments, Inhalations, Ear Preparations, Nasal Preparations	For the sterile drug products, such as Ophthalmic Preparations and Ophthalmic Ointments, for which precautions should be taken against microbial contamination, <i>Purified Water</i> (or <i>Purified Water in Containers</i>) kept its viable counts at low levels may be used. For Inhalations, Ear Preparations and Nasal Preparations, <i>Purified Water</i> (or <i>Purified Water in Containers</i>) of which viable counts are controlled at an appropriate level should be used. However, for the Inhalation Liquid Preparations among Inhalations, <i>Purified Water</i> (or <i>Purified Water in Containers</i>) that vial count is strictly controlled should be used.
		Preparations for Oral Administration, Preparations for Oro-mucosal Application, Preparations for Rectal Application, Preparations for Vaginal Application, Preparations for Cutaneous Application, and Tinctures and Aromatic Waters among Preparations Related to Crude Drugs.	For Liquids and Solutions for Oral Administration, Syrups, Suppositories for Vaginal Use, Ointments, Creams and so on for which precautions should be taken against microbial contamination, <i>Purified Water</i> (or <i>Purified Water in Containers</i>) adequately controlled from microbiological viewpoints should be used, taking in mind the affection of containing preservatives.
	<i>Water</i>	Among Preparations Related to Crude Drugs: Extracts, Pills, Infusions and Decoctions, Teabags, Fluidextracts	The viable counts in crude drugs and the objective microbial limits of product should be considered in selecting water to be used.
Active Pharmaceutical Ingredient (API)	<i>Water for Injection</i> or <i>Sterile Water for Injection in Containers</i>	Sterile APIs	
	<i>Purified Water</i> or <i>Purified Water in Containers</i>	APIs	In the manufacture of APIs used for products to be rendered sterile in the formulation process and have no subsequent processes capable of removing endotoxins, <i>Purified Water</i> (or <i>Purified Water in Containers</i>) controlled endotoxins in an appropriate level should be used.
	<i>Water</i>	API Intermediates	

lations, Ear Preparations and Nasal Preparations, appropriately controlled *Purified Water* (or *Purified Water in Containers*) in vial count level should be used, and for Liquids and Solutions among Inhalations, strictly controlled *Purified Water* (or *Purified Water in Containers*) in vial count level should be used. For the Liquids and Solutions for Oral Administration, Syrups, Suppositories for Vaginal Use, Ointments and Creams, which require care against microbiological contamination, *Purified Water* (or *Purified Water in Containers*) adequately controlled from microbiological viewpoints should be used in consideration of the possible impacts of preservatives formulated in the drug products. For the manufacture of products containing crude drugs, it is recommended to select adequate type of water considering viable counts of the crude drugs used for manufacturing the

product and microbial limit required for the product.

Water used for pre-washing of containers or equipment surfaces that comes in direct contact with the drug products should have the quality not lower than that of *Water*. Water used for final rinsing should have an equivalent quality to that of water used for manufacturing drug products.

3.2. Active Pharmaceutical Ingredient (API)

Water used for manufacturing active pharmaceutical ingredient (API) should be selected in consideration of the characteristics of drug product for which the API is to be used, and its manufacturing process, so that the quality of the final drug product is assured.

Water used for manufacturing API or for cleaning containers or equipment surfaces that come in direct contact with the raw materials or API intermediates, should have the

quality not lower than that of *Water* adequately controlled from the chemical and microbiological viewpoints, even if the water is used at an earlier stage of synthetic or extraction process in the manufacture of API. Water used in the final purification process should have the quality equal to or higher than that of *Purified Water* (or *Purified Water in Containers*). Water used for final rinsing of containers or equipment surfaces that comes in direct contact with the APIs should have an equivalent quality to that of water used for manufacturing the APIs.

For manufacturing sterile API, *Sterile Purified Water in Containers* or *Water for Injection* (or *Sterile Water for Injection in Containers*) should be used. Similarly, for manufacturing APIs used for drug products where endotoxin control is required and there are no subsequent processes capable of removing endotoxins, *Water for Injection* (or *Sterile Water for Injection in Containers*), or *Purified Water* (or *Purified Water in Containers*) for which endotoxins are controlled at a low level, should be used.

4. Quality Control of Pharmaceutical Water

4.1. Outline

Verification that water with the quality required for its intended use has been produced by the pharmaceutical water processing system through substantial validation studies at an earlier stage of its operation, is the prerequisite for conducting quality control on pharmaceutical water in a routine and periodical manner. If this prerequisite is fulfilled, the following methods are applicable for quality control of pharmaceutical water.

For routine control, it is very useful to control quality of produced water based on the monitoring of electrical conductivity (conductivity) and total organic carbon (TOC). In addition, items to be monitored periodically, such as some specified impurities, viable counts, endotoxins, insoluble particulate matters, etc., should be determined according to the intended use of pharmaceutical water. The frequency of measurement should be determined considering with the variation in the quality of water to be monitored.

The following are points to consider in controlling the quality of produced water from microbiological and physicochemical (conductivity and TOC) viewpoints. It is necessary to monitor other items if necessary, and to confirm that they meet the specifications established individually.

4.2. Sampling

Monitoring should be conducted at an adequate frequency to ensure that the pharmaceutical water processing system is well-controlled and that water with acceptable quality is continuously produced and supplied. Specimens should be collected at the representative locations in the facilities for producing and supplying water, with particular care so that collected specimens reflect the operating condition of the pharmaceutical water processing system. An adequate protocol for the control of microorganisms at the sampling site should be established considering with the situation around the site.

Sampling frequency should be established based on the data from validation studies on the system. For microbiological monitoring, it is adequate to use the water specimens for the test within 2 hours after sampling. In the case that it is not possible to test within 2 hours, the specimens should be kept at 2 – 8°C and be used for the test within 12 hours.

4.3. Alert and Action Levels

In producing pharmaceutical water using a water processing system, microbiological and physicochemical monitoring is usually carried out to assure that water with required quality is being continuously produced when the

system is operating as it designed. The operating condition of the system can be estimated by the comparison of monitoring data thus obtained against the alert level, action level, other levels for controlling the system, and acceptance criteria specified for the water required for its intended use, and also by the trend analysis of monitoring data through plotting them in a control chart. In this manner, the alert level and action level are used for controlling the process of water production, and not used for judging pass/fail of produced water.

4.3.1. Definition of Alert Level

“Alert level” indicates that, when exceeded it, the system is threatening to deviate from its normal operating range. Alert levels are used for giving a warning, and exceeding them does not necessarily require a corrective action. Alert level is generally established either at a mean + 2 σ on the basis of past trend analysis, or at a level of 70% (50% for viable counts) of action level, whichever is lower.

4.3.2. Definition of Action Level

“Action level” indicates that, when exceeded it, the system has deviated from its normal operating range. Exceeding it indicates that corrective action must be taken to bring the system back within its normal operating range.

Alert and action levels should be established within the specified acceptance criteria of the water required for its intended use in consideration of available technologies and the quality required for the water. Consequently, exceeding an alert or action level does not necessarily indicate that the quality of produced water has become inadequate for its intended use.

4.4. Microbiological Monitoring

The main purpose of microbiological monitoring program for pharmaceutical water processing system is to foresee any microbiological quality deterioration of the produced water, and to prevent any adverse effects on the quality of pharmaceutical products. Consequently, detecting all of the microorganisms present in the water to be monitored may not be necessary. However it is required to adopt a monitoring technique able to detect a wide range of microorganisms, including slow growing microorganisms.

The following indicate incubation-based microbiological monitoring techniques for pharmaceutical water processing systems. To adopt a rapid microorganism detection technique, it is necessary to confirm in advance that the microbial counts obtained by such techniques are equivalent to those obtained by the incubation-based monitoring techniques.

4.4.1. Media and Incubation Conditions

There are many mesophilic bacteria of heterotrophic type that are adapted to poor nutrient water environments. Heterotrophic bacteria may form bio-films in many pharmaceutical water processing systems, and to cause quality deterioration of the produced water. Therefore, it is useful to monitor microbiological quality of water by using the R2A Agar Medium, which is excellent for growing bacteria of oligotrophic type.

Table 2 shows examples of measurement methods, minimum sample sizes, media, and incubation periods for estimating viable counts.

The media shown in Table 2 are as follows.

(i) Standard Agar Medium

Casein peptone	5.0 g
Yeast extract	2.5 g
Glucose	1.0 g
Agar	15.0 g
Water	1000 mL

Mix all the ingredients, and sterilize by heating in an autoclave at 121°C for 15 – 20 minutes. pH after sterilization

Table 2 Methods for Assessment of Viable Counts in Pharmaceutical Water

Method	Pharmaceutical Water		
	Water	Purified Water	Water for Injection
Measurement Method	Pour Plate Method or Membrane Filtration	Pour Plate Method or Membrane Filtration	Membrane Filtration
Minimum Sample Size	1.0 mL	1.0 mL	100 mL
Media	R2A Agar Medium Standard Agar Medium	R2A Agar Medium	R2A Agar Medium
Incubation Period	R2A Agar Medium: 4 – 7 days (or longer) Standard Agar Medium: 48 – 72 hours (or longer)	4 – 7 days (or longer)	4 – 7 days (or longer)
Incubation Temperature	R2A Agar Medium: 20 – 25°C or 30 – 35°C Standard Agar Medium: 30 – 35°C	20 – 25°C or 30 – 35°C	20 – 25°C or 30 – 35°C

zation: 6.9 – 7.1.

(ii) R2A Agar Medium

Peptone (casein and animal tissue)	0.5 g
Casamino acid	0.5 g
Yeast extract	0.5 g
Sodium pyruvate	0.3 g
Glucose	0.5 g
Magnesium sulfate heptahydrate	50 mg
Soluble starch	0.5 g
Dipotassium hydrogen phosphate	0.3 g
Agar	15.0 g
Water	1000 mL

Mix all the ingredients, and sterilize by heating in an autoclave at 121°C for 15 – 20 minutes. pH after sterilization: 7.1 – 7.3.

The following reagents should be used for preparing the R2A Agar Medium.

(i) Casamino acid Prepared for microbial test, by the acid hydrolysis of casein.

Loss on drying <2.41>: Not more than 8% (0.5 g, 105°C, constant mass).

Residue on ignition <2.44>: Not more than 55% (0.5 g).

Nitrogen content <1.08>: Not less than 7% (105°C, constant mass, after drying).

4.4.2. Media Growth Promotion Test

In the media growth promotion test with the R2A Agar Medium, use the strains listed below or other strains considered equivalent to these strains. Prior to the test, inoculate these strains into sterile purified water and starve them at 20 – 25°C for 3 days.

Methylobacterium extorquens: NBRC 15911

Pseudomonas fluorescens: NBRC 15842, ATCC 17386, etc.

Dilute the fluid containing the strain starved with sterile purified water to prepare a fluid containing about 5×10^1 – 2×10^2 CFU/mL of viable counts. When pipetting 1 mL of the diluted fluid onto the R2A Agar Medium and incubating at 20 – 25°C for 4 – 7 days, sufficient proliferation of the inoculated strain must be observed.

In the media growth promotion test with the Standard Agar Medium, use the strains listed below or other strains considered equivalent to these strains. Prepare the fluid containing the strain according to the procedure prescribed in the Microbiological Examination of Non-sterile Products

<4.05>. When pipetting 1 mL of the fluid onto the Standard Agar Medium and incubating at 30 – 35°C for 48 hours, sufficient proliferation of the inoculated strain must be observed.

Staphylococcus aureus: ATCC 6538, NCIMB 9518, CIP 4.83 or NBRC 13276

Pseudomonas aeruginosa: ATCC 9027, NCIMB 8626, CIP 82.118 or NBRC 13275

Colon bacillus (Escherichia coli): ATCC 8739, NCIMB 8545, CIP 53.126 or NBRC 3972

4.4.3. Action Levels for Microorganisms for Pharmaceutical Water Processing System

The following action levels are considered appropriate and generally applicable to pharmaceutical water processing systems.

Action Levels for viable counts in various types of pharmaceutical water

Water: 10^2 CFU/mL* (Acceptance criterion prescribed in the Quality Standards for Drinking Water provided under the Article 4 of the Water Supply Law)

Purified Water: 10^2 CFU/mL**

Water for Injection: 10^1 CFU/100 mL**

(*Viable counts obtained using the Standard Agar Medium, ** Viable counts obtained using the R2A Agar Medium)

Although the action level for *Purified Water* shown above is set at the same level as that for *Water*, it is recommended for each facility to perform a higher level of microbiological control of water processing system based on the action level established individually.

When actual counts in validation studies or routine control exceed the above action levels, it is necessary to isolate and identify the microorganisms present in the water, and to sanitize or disinfect the affected system.

4.5. Physicochemical Monitoring

Physicochemical monitoring of a pharmaceutical water processing system is usually performed using conductivity and TOC as the indicators for water quality. By monitoring conductivity, total amounts of inorganic salts present in the water can be estimated, and by monitoring TOC, total amount of organic compounds present in the water can be estimated. Normally, the *Conductivity Measurements* <2.51> and the *Test for Total Organic Carbon* <2.59> specified in the General Tests, Processes and Apparatus of the JP should

be applied to these physicochemical monitoring. However, since tests for monitoring are performed in the situations different from those for judging pass/fail to the acceptance criteria prescribed in the monographs, supplements necessary to cover the situations to which the JP general tests cannot be applied, are described below.

To adopt the monitoring using conductivity and TOC as the indicators for inorganic and organic impurities at individual facility, appropriate alert and action levels, and countermeasures against unexpected apparatus failures should be established for each indicator.

4.5.1. Monitoring of Conductivity as the Indicator for Inorganic Impurities

Measurement of conductivity for monitoring is usually conducted continuously using an in-line apparatus with a flow-through type or pipe-insertion type cell. Alternatively, offline batch testing may be performed using a dip type cell with water specimens taken at point-of-use sites or other appropriate locations of the pharmaceutical water processing system. For the operation control of a pharmaceutical water processing system, guides for judging whether it is adequate to continue the operation of the system or not based on the results from monitoring of conductivity, are shown below, both for the cases of monitoring at the standard temperature (20°C) by applying *Conductivity Measurements <2.51>* of the JP and monitoring at temperatures other than 20°C by applying <645> *WATER CONDUCTIVITY* of the United States Pharmacopeia (USP) with some modifications.

4.5.1.1. Monitoring of Conductivity by applying the *Conductivity Measurements <2.51>* of the JP

When the monitoring of the conductivity of *Purified Water* and *Water for Injection* is performed at the standard temperature (20°C), measure the conductivity after confirming that the measure temperature is within a range of 20 ± 1°C. In this case, the recommended allowable conductivity (action level) for *Purified Water* and *Water for Injection* is as follows.

- Action Level 1.1 $\mu\text{S}\cdot\text{cm}^{-1}$ (20°C)

Since the above allowable conductivity is established for in-line monitoring, an alternative action level may be used for the monitoring based on offline batch testing.

4.5.1.2. Monitoring of Conductivity by applying the <645> *WATER CONDUCTIVITY* of the USP with some modification

Usually, it is somewhat difficult to control the temperature exactly in in-line conductivity monitoring. Therefore, the following approach can be applied for the monitoring at temperatures other than the standard temperature (20°C) of the JP. This approach is based on the Stages 1 and 2 of the three-stage approach described in <645> *WATER CONDUCTIVITY* of the USP and in the monographs being associated with water for pharmaceutical use ("Purified Water", "Highly Purified Water" and "Water for Injections") of the European Pharmacopoeia (EP).

Stage 1 (In-line Measurement)

- Determine the temperature and the conductivity of the water specimens using a non-temperature-compensated conductivity reading.
- From the Table 3, find the temperature value equal to or just lower than the measured temperature. Adopt the corresponding conductivity value on this table as the allowable conductivity at the measured temperature.
- If the observed conductivity is not greater than the allowable conductivity adopted above, the water tested meets the requirement for monitoring conductivity. If the observed conductivity exceeds the allowable conduc-

Table 3 Stage 1 Allowable Conductivity for Different Temperatures*

Temperature (°C)	Allowable Conductivity ($\mu\text{S}\cdot\text{cm}^{-1}$)	Temperature (°C)	Allowable Conductivity ($\mu\text{S}\cdot\text{cm}^{-1}$)
0	0.6		
5	0.8	55	2.1
10	0.9	60	2.2
15	1.0	65	2.4
20	1.1	70	2.5
25	1.3	75	2.7
30	1.4	80	2.7
35	1.5	85	2.7
40	1.7	90	2.7
45	1.8	95	2.9
50	1.9	100	3.1

* Applicable only to non-temperature-compensated conductivity measurements.

tivity, proceed with Stage 2.

Stage 2 (Off-line Measurement)

- Measure the conductivity of the water specimen, by transferring it into a container and agitating it vigorously in order to attain equilibrium between the water specimen and the atmosphere on absorbing/desorbing carbon dioxide.
- Transfer a sufficient amount of water to be tested into a suitable container, and stir the water specimen. Adjust the temperature to $25 \pm 1^\circ\text{C}$, and begin agitating the water specimen vigorously, while observing the conductivity periodically. When the change in conductivity, due to the uptake of atmospheric carbon dioxide, becomes not greater than $0.1 \mu\text{S}\cdot\text{cm}^{-1}$ per 5 minutes, adopt the observed value as the conductivity (25°C) of the water specimen.
- If the conductivity of the water specimen at 25°C obtained above is not greater than $2.1 \mu\text{S}\cdot\text{cm}^{-1}$, the water tested meets the requirement for monitoring conductivity. If the observed value exceeds $2.1 \mu\text{S}\cdot\text{cm}^{-1}$, it should be judged that the water tested does not meet the requirement for monitoring conductivity.

4.5.2. Monitoring of TOC as the Indicator for Organic Impurities

The acceptance criterion of TOC is specified as "not greater than 0.50 mg/L (500 ppb)" in the monographs of *Purified Water* and *Water for Injection*. However it is recommended for each facility preparing pharmaceutical water to conduct operation control of pharmaceutical water processing system through TOC monitoring on produced water based on its own alert and action levels for TOC determined individually. The following are the recommended action levels for TOC.

- Action Level: $\leq 300 \text{ ppb}$ (in-line)
 $\leq 400 \text{ ppb}$ (off-line)

The Quality Standards for Drinking Water provided under the Article 4 of the Japanese Water Supply Law require that TOC should be "not greater than 3 mg/L (3 ppm)". Taking the above recommended action levels into consideration, it is also recommended for each facility to conduct quality control of source water through TOC monitoring based on its own alert and action levels for TOC determined individually.

The JP specifies the *Test for Total Organic Carbon <2.59>*, and normally, TOC measurement should be conducted using

an apparatus which meets the requirements described in the JP method. However, if a TOC apparatus conforms to the apparatus suitability test requirements described in “<643> TOTAL ORGANIC CARBON” of the USP, or those described in the “Methods of Analysis 2.2.44. TOTAL ORGANIC CARBON IN WATER FOR PHARMACEUTICAL USE” of the EP, the apparatus can be used for the monitoring of pharmaceutical water processing system, if sufficiently pure water not contaminated with ionic organic substances, or organic substances having nitrogen, sulfur, phosphorus or halogen atoms in their chemical structures, is used as the source water supplied to the system.

A TOC apparatus, characterized by calculating the amount of organic carbon from the difference in conductivity before and after the decomposition of organic substances without separating carbon dioxide from the sample solution, may be influenced negatively or positively, when applied to the water specimens containing ionic organic substances, or organic substances having nitrogen, sulfur, phosphorus or halogen atoms in their chemical structures. Therefore, the apparatus used for TOC monitoring should be selected appropriately in consideration of the purity of the water to be monitored and the contamination risk in the case of apparatus failure.

4.6. Storage of Water for Injection

In storing *Water for Injection* temporarily, adequate measures able to prevent microbial proliferation stringently, such as circulating it in a loop at a high temperature must be taken, and an appropriate storage time should also be established based on the validation studies, in consideration of the risks of contamination and quality deterioration.

5. Points to Consider for Assuring the Quality of Pharmaceutical Water in Containers

There are some specific points to consider for assuring the quality of pharmaceutical water in containers (*Purified Water in Containers*, *Sterile Purified Water in Containers* and *Sterile Water for Injection in Containers*), which are available as commercially products.

5.1. Methods for Preparing Sterile Pharmaceutical Water in Containers and Their Sterilization Validation

The following 2 different preparation methods are described in the monographs of *Sterile Purified Water in Containers* and *Sterile Water for Injection in Containers*.

- (i) Introduce *Purified Water* or *Water for Injection* into a hermetic container, seal up the container, then sterilize the product.
- (ii) Make *Purified Water* or *Water for Injection* sterile by using a suitable method, introduce the sterilized water into a sterile hermetic container by applying aseptic manipulation, then seal up the container.

For assuring the sterility of pharmaceutical water products, only the validation of final sterilization process is required in the case of preparation method (i), whereas validations of all the processes are indispensable in the case of preparation method (ii), since the latter is based on the idea to assure the sterility of pharmaceutical water products by “aseptically” introducing *Purified Water* (or *Water for Injection*) treated in advance with filtration sterilization, etc. into a sterile hermetic container, and sealing it up.

5.2. Deterioration of Water Quality during the Storage in Containers

5.2.1. Inorganic impurities (Conductivity as the indicator)

The conductivity of pharmaceutical water in containers may increase to some higher levels due to the absorption of carbon dioxide from the atmosphere at the time of its prepa-

ration and that passed through plastic layer of the containers during storage, and also due to ionic substances released from the containers, even if the conductivity of *Purified Water* or *Water for Injection* used for its production is maintained at the level not more than $1.0 \mu\text{S} \cdot \text{cm}^{-1}$. Particularly in the cases of pharmaceutical water products packed in small scale glass containers, it is necessary to pay attention to the change of conductivity during storage.

5.2.2. Organic impurities (Potassium Permanganate-reducing Substances or Total Organic Carbon (TOC) as the indicator)

JP specifies the classical test of potassium permanganate-reducing substances in the monographs of *Purified Water in Containers*, *Sterile Purified Water in Containers* and *Sterile Water for Injection in Containers* for controlling organic impurities in pharmaceutical water in containers. It forms a remarkable contrast to the specifications of *Purified Water* and *Water for Injection*, in which JP requires to control organic impurities in pharmaceutical water in bulk based on the test of TOC (acceptance criterion: not more than 0.5 mg/L (500 ppb)). This is because that it is considered difficult to establish the specification of pharmaceutical water in containers for organic impurities based on the test of TOC from the facts that there were many cases of remarkable increases in TOC values after storage of water in containers. Particularly in the cases of pharmaceutical water products packed in small scale plastic containers, it is necessary to pay attention to the increase of materials released from containers during storage.

The test of potassium permanganate-reducing substances is retained in the specifications of pharmaceutical water in containers, not as the most suitable method for the test of organic impurities present in the water in containers, but as a counter measure for performing the test of the water in containers with the same test method despite of the material (glass, polyethylene, polypropylene, etc.) and the size (0.5 – 2000 mL) of the containers, and the duration of storage. Therefore, it is recommended to adopt the test of TOC as the alternative for the test of potassium permanganate-reducing substances, and to perform quality control of pharmaceutical water in containers based on TOC measurements under the responsibility of each manufacturer, if possible.

In such cases, it is recommended to adopt the following values as the levels preferable to attain.

For products containing not more than 10 mL of water:

TOC not greater than 1500 ppb

For products containing more than 10 mL of water:

TOC not greater than 1000 ppb

As for the pharmaceutical water packed in the plastic containers made of polyethylene, polypropylene, etc., in addition to the concern for the release of materials such as monomer, oligomers, plasticizers, etc. from plastics, it is necessary to pay attention to the storage environment of the products to avoid the contaminations with low molecular volatile organics such as ethanol, or low molecular air pollutants such as nitrogen oxides, since these plastics have the properties of permeating various gases and water.

5.2.3. Microbial Limit (Total Aerobic Viable Counts)

For *Purified Water in Containers*, it is not required to assure the sterility, but it is necessary to produce it by using sanitary or aseptic processes in order to meet the acceptance criterion of “ 10^2 CFU/mL ” for total aerobic viable counts throughout the period of their storages. It is also necessary to take special care against microbial contamination during its circulation. In addition, it is recommended to use them as soon as possible after opening their seals.

The acceptance criterion of “10² CFU/mL” for total aerobic viable counts of *Purified Water in Container* is at the same level as the action level for viable counts in the production of *Purified Water* (in bulk). However, different from the case of microbiological monitoring of *Purified Water*, Soybean-Casein Digest Agar Medium is used for the test of total aerobic viable counts of *Purified Water in Containers* to detect microorganisms contaminated from the surroundings during its storage and circulation.

5.3. Points to consider in the case that commercially available products of pharmaceutical water in containers are used for the manufacture of pharmaceutical products

It is allowable to use commercially available products of pharmaceutical water in containers (*Purified Water in Containers*, *Sterile Purified Water in Containers* and *Sterile Water for Injection in Containers*) for the manufacture of pharmaceutical products and products for clinical trial, and for the tests of pharmaceutical products. In such cases, it is necessary to consider the following points.

- (i) When such products are used for manufacturing pharmaceutical products, it is recommended to use them soon after confirming their compliances to the requirements of JP monograph from the test results at the time of its receipt or those offered from the supplier of the products.
- (ii) In the case that such products are used for manufacturing pharmaceutical products, it is necessary to validate the process in which the water was used as a part of process validation of pharmaceutical products. In the case that they are used for manufacturing products for clinical trial, it is necessary to confirm that the water doesn't give any adverse effects on the quality of the products.
- (iii) The products of sterile pharmaceutical water in containers should be used only once after opening their seals, and it must be avoided to use them again after storage.
- (iv) It is recommended to prepare a standard operation practice (SOP) adequate for its intended use, considering that the contamination and quality deterioration of the water due to human and laboratory environmental origins might go on rapidly immediately after opening the product seal.

Water to be used in the Tests of Drugs

The water to be used in the tests of drugs is defined as “the water suitable for performing the relevant test” in the paragraph 21 under General Notices of the JP. Therefore, it is necessary to confirm that the water to be used in a test of a drug is suitable for the purpose of the relevant test before its use.

Unless otherwise specified in the individual test method, *Purified Water*, *Purified Water in Containers* or the water produced by an appropriate process, such as ion exchange or ultrafiltration, may be used for these purposes. Water produced for these purposes at other individual facilities may also be used.

Examples of the water for tests specified in General Tests in the JP are as follows:

- Water for ammonium limit test: <1.02> Ammonium Limit Test (Standard Ammonium Solution)
- Water used for measuring organic carbon (water for measurement): <2.59> Test for Total Organic Carbon

- Water for ICP analysis: <2.63> Inductively Coupled Plasma-Atomic Emission Spectrometry and Inductively Coupled Plasma-Mass Spectrometry
- Water for bacterial endotoxins test: <4.01> Bacterial Endotoxins Test
- Water for particulate matter test (for injections): <6.07> Insoluble Particulate Matter Test for Injections
- Water for particulate matter test (for ophthalmic solutions): <6.08> Insoluble Particulate Matter Test for Ophthalmic Solutions
- Water for particulate matter test (for plastic containers): <7.02> Test Methods for Plastic Containers

The water for tests specified in General Information in the JP is as follows:

- Water for aluminum test: Test for Trace Amounts of Aluminum in Total Parenteral Nutrition (TPN) Solutions

The term “water” described in the text concerning tests of drugs means “the water to be used in the tests of drugs” as defined in the paragraph 21 under General Notices.

G9 Reference Standards

Reference Standards and Reference Materials Specified in the Japanese Pharmacopoeia

Reference materials are materials that are used as standards in quantitative and qualitative measurement of drug products, calibration and accuracy confirmation of apparatus, and suitability tests of analytical systems. Reference standards specified in the Japanese Pharmacopoeia (JP) as described in the Reference Standards <9.01> are reference materials prepared to the specified quality necessary with regard to their intended use such as quality evaluation tests of drugs, and they are provided with public assurance that the substances have suitable quality for the specified use.

This chapter includes the definitions and explanations of basic terms regarding reference standards, and the particulars of the JP reference standards mainly used for chemical drugs, such as classification by use, requirements for establishment, required quality evaluation items, distribution and precautions for use. The descriptions show only basic policies, and therefore flexible management is required for practical application for the time being.

1. Basic terms of reference standards

- Reference materials: “The materials used as the standards” for determination of characteristic values of materials and substances. Reference materials are sufficiently homogeneous and stable with respect to one or more specified properties and are produced so that they are suitable for their intended use in measuring processes [JIS Q 0035:2008]. Reference materials for drug products are materials used as the standards in quantitative and qualitative measurements, calibration and accuracy confirmation of apparatus, and they are prepared so that they are suitable for their intended use.
- Reference standards: The reference materials prepared to a specified quality necessary with regard to their intended use, such as quality evaluation tests of drugs, and they are provided with public assurance that the substances have suitable quality for the specified use.

- JP reference standard: The reference standards specified in the Monographs or General Tests in the JP.
- Certified reference materials: The reference materials with one or more specified characteristic values determined by appropriate metrological procedure. Their qualities are guaranteed by a certificate that describes their characteristic values, uncertainties of the values, and metrological traceability [JIS Q 0035:2008].

2. Classification of the JP reference standards by use

JP reference standards include various types and are used for assays, identification, purity, calibration of apparatus, suitability tests of analytical systems, etc., and they are broadly classified by their use such as quantitative tests, qualitative tests, and calibration of apparatus. These reference standards are further subclassified according to their specific use, such as assays of active ingredients and indicator ingredients, assays of related substances, identification using spectral measurement or chromatography, calibration of apparatus used in tests, determinations and assays that are specified in the General Tests, and suitability tests for analytical systems.

2.1. Reference standards used for quantitative tests

2.1.1. Reference standards for assays of active ingredients etc.: Reference standards used for quantitative assays of products specified in the Monographs, such as chemical agents, antibiotics, additives, and biotechnological/biological products.

2.1.2. Reference standards for assays of indicator ingredients:

Reference standards used for quantitative assays of indicator ingredients of crude drugs specified in the Monographs.

2.1.3. Reference standards for assays of related substances: Reference standards used for quantitative assays of specific related substances in purity for products specified in the Monographs, such as chemical agents, antibiotics, additives, and biotechnological/biological products.

2.1.4. Other reference standards for assays:

Reference standards needed for quantitative assays specified in the General Tests.

2.2. Reference standards used for qualitative tests

2.2.1. Reference standards for identification:

Reference standards used for identification of products specified in the Monographs, such as chemical agents, antibiotics, additives, biotechnological/biological products, and crude drugs. These identification include the comparison of ultraviolet-visible absorption spectra, infrared absorption spectra, nuclear magnetic resonance spectra, retention time or *Rf* values in chromatography, and mobility in electrophoresis.

2.2.2. Reference standards for purity:

Reference standards used for identification of peaks or spots, or for limit tests of related substances, in purity of products specified in the Monographs, such as chemical agents, antibiotics, additives, biotechnological/biological products, and crude drugs.

2.3. Reference standards used for system suitability

2.3.1. Reference standards for system suitability:

Reference standards used for system suitability of products specified in the Monographs, such as chemical agents, antibiotics, additives, biotechnological/biological products, and crude drugs.

2.4. Reference standards used for calibration and suitability confirmation of apparatus

2.4.1. Reference standards for calibration of apparatus:

Reference standards used for secondary calibration of ap-

paratus that are specified in the General Tests.

2.4.2. Reference standards for suitability confirmation of apparatus:

Reference standards used in order to confirm that the measured values gained from an apparatus specified in the General Tests are within the defined range.

3. Names and uses of JP reference standards

JP reference standards are used for tests specified in the Monographs and General Tests, such as Assays, Identification, Purity, calibration of apparatus, and suitability tests of analytical systems. These reference standards include materials with only one specific use and materials with multiple uses. JP reference standards used for assays and quantitative determinations of active ingredients in uniformity of dosage units and dissolution are named in principle by attachment of the phrase "reference standard" to the material name. Reference standards used for quantitative tests can be used for other tests such as identification as the reference standards, if possible. Reference standards only used for uses other than quantitative tests are named by attachment of the name of their use. Some possible uses are shown below with examples in brackets.

- For identification (Montelukast Sodium RS for Identification)
- For purity (○○○ RS for Purity)
- For calibration of apparatus (Calcium Oxalate Monohydrate RS for Calibration of Apparatus)
- For system suitability (Montelukast RS for System Suitability)

4. Requirements for establishment of JP reference standards

The JP reference standards have been mainly used as standard substances for quantitative assays of active ingredients so far. On the other hand, the European Pharmacopoeia (Ph. Eur.) and the U.S. Pharmacopeia (USP) have been actively establishing reference standards or reference materials that have specific uses other than the use for quantitative assays of active ingredients. Such specified reference standards include standards for contaminants in purity, for suitability of analytical systems, and for identification. This situation requires JP to change its policy on the reference standards along with the international trends, however, careful deliberation is needed to establish new JP reference standards in consideration of the points shown below.

(1) To adopt a relative determination such as chromatography for a quantitative test, in principle, establish the reference standard for the assay or establish the reference materials indicated purity with metrological traceability as a reagent.

(2) To appoint a comparison method for an identification, such as comparison of ultraviolet-visible absorption spectra, infrared absorption spectra, or nuclear magnetic resonance spectra, comparison of retention time or *Rf* values in chromatography, or comparison of electrophoretic mobility, in principle, it is desirable to establish the reference standard for the identification unless the use of some reference standard for assays is applicable.

(3) In a purity where a specific related substance or contaminant is analyzed, it is recommended to establish the reference standard dedicated to the purity if the specific related substance or contaminant cannot be identified from the relative retention time of its peak on the chromatogram, and/or the limit cannot be specified by area normalization method or by comparison of the peaks with the sample solution and with the standard solution derived from the sample solution.

(4) Establish a reference standard for a suitability of an

analytical system, if the system suitability cannot be adequately evaluated by conventional JP methods (determination of the number of theoretical plates and the symmetry factor, etc.)

(5) If the continuous supply of the raw materials for the reference standard is uncertain, a reference standard for a related substance for a purity or a reference standard for a system suitability should not be established.

(6) When a material utilized as standard has the uses other than for quantitative assays and can be obtained as a certified reference material or as a reference material for other tests, that can be specify as the certified reference material and the reference material for other tests in the Reagents, Test Solutions <9.41> without establishing the materials as a JP reference standard.

(7) When a material utilized as standard has the uses other than for quantitative assay and can be obtained as a reagent, that can be specify the material in the Reagents, Test Solutions <9.41> establishing specifications and test methods according to its use, without establishing the material as a JP reference standard.

5. Quality evaluation items required for JP reference standards

Quality evaluation items required to establish a JP reference standard are shown below. The items are chosen mainly on the assumption that the materials are used as reference standards for chemical agents.

5.1. Quality evaluation items for reference standards used for quantitative assays

- (i) Description: color and shape
- (ii) Identification: establish a test method to identify or confirm the chemical structure.
- (i) Ultraviolet-visible absorption spectrum
- (ii) Infrared absorption spectrum
- (iii) Nuclear magnetic resonance spectrum (^1H)
- (iv) X-ray powder diffraction image[※](when the crystal form is specified)
- (v) Retention time or R_f value in chromatography[※](when chromatography is applicable to the identification)
- (vi) Counter ion[※]
- (iii) Purity
 - i) Related substances (total amount)
 - ii) Residual solvents
 - iii) Other contaminants[※]
- (iv) Characteristic values[※]
 - i) Specific rotation
 - ii) Melting point
- (v) Water/Loss on drying
- (vi) Residue on ignition[※]
- (vii) Purity determination by mass balance method: Regarding purity evaluation in mass balance method, calculate the purity (%) on the dried or anhydrous basis setting related substances, residue on ignition, residual solvent, and other contaminants as deductions.
- (viii) Assay (if possible, establish an absolute quantification method such as titration, etc.)

[Note] Quality evaluation items attached with[※] marks are items whose adoption should be considered taking into account the material's use as a reference standard.

5.2. Quality evaluation items for reference standards used for other than quantitative assays

Shown below are examples of quality evaluation items whose adoption should be considered taking into account the material's use as a reference standard.

- (i) Description: color and shape
- (ii) Identification: establish a test method to identify or

confirm the chemical structure.

- i) Ultraviolet-visible absorption spectrum
- ii) Infrared absorption spectrum
- iii) Nuclear magnetic resonance spectrum (^1H)
- iv) Mass spectrum
- v) X-ray powder diffraction image (when the crystal form is specified)
- vi) Retention time or R_f value in chromatography
- (iii) Purity
 - i) Related substances (total amount)
 - ii) Residual solvents
 - iii) Other contaminants
- (iv) Water/Loss on drying
- (v) Purity determination by mass balance method
- (vi) Tests related to the uses of the materials
 - i) A reference standard for system suitability used for peak identification needs identification of relative retention time of the peak under the same conditions to the test method that is specified in the Monographs.
 - ii) A reference standard for system suitability needs identification of the resolution under the same conditions to the test method that is specified in the Monographs.

6. Reference materials specified in the JP

Materials that correspond to reference materials are described in the Reagents, Test Solutions <9.41> in the JP. Such materials are shown as follows:

- Materials described as reagents for assays
- Materials used for identification that described as reagents for thin-layer chromatography (some materials do not correspond to reference materials)
- Materials specified as reagents for purity
- Materials described as specific related substances in the item of Related substances in Purity in the Monographs
- Reference materials specified by JIS

In the JP (except "Crude Drugs"), "reagents for assays" is specified as reference materials for assays of active ingredients in drug products, and some active ingredients with quality above a certain level are specified as reagents that are used as reference materials for identification of the active ingredients in drug products by thin-layer chromatography. However, these reference materials specified as reagents are not officially provided. Assays should be performed using reference standards, and it is considered appropriate that the "reagents for assays" described as reagents in the Reagents, Test Solutions <9.41> should be established as reference standards. Regarding new assay reagents that will be established for drug products except "Crude Drugs," there is a need to consider gradual establishment of these "reagents for assays" as reference standards.

On the other hand, it is difficult to establish reference standards for indicator ingredients of "Crude Drugs"; therefore, reference materials for assays of indicator ingredients are specified as reagents and quantitative NMR is included in specifications of the reagents so that a specification for assay with metrological traceability is established.

7. Precautions for the use of JP reference standards

7.1. JP reference standards are reference standards whose uses are specified in the Monographs and General Tests in the JP. Their detailed uses are described in the Monographs and their adequate qualities as reference standards are guaranteed when they are used for the described uses. Accordingly, their qualities for other uses are not guaranteed.

7.2. When a JP reference standard is used for a quantitative tests specified in the Monographs, if a correction coefficient is indicated on documents such as package in-

sert, multiply the standard amount by the correction coefficient to calculate the corrected amount for the use. If a correction coefficient is not indicated, do not correct the amount for use assuming that the purity of the reference standard is 100.0%.

7.3. If there is a description of "amount of the reference standard, calculated on the dried basis" or "amount of the reference standard, calculated on the anhydrous basis" in a calculation formula for an assay method in the Monographs, extra measurement of the loss on drying or the water content of the reference standard is required. If, however, the value of loss on drying or water content is indicated on document of the reference standard such as package insert, use of the indicated value is permitted.

7.4. JP reference standards have no established expiration date, therefore, obtain needed amount of a reference standard when it is needed, and then store the reference standard under specified conditions and use up it as quick as possible.

7.5. The quality of reference standards stored after unsealing of the packages are not guaranteed.

7.6. Normally, one packing unit of a reference standard contains the amount that enables several times of repeated test. However, some packages of reference standards whose raw material supply is scarce contain the amounts that enable only one-time test.

7.7. Information of JP reference standards necessary for the uses specified in the Monographs or General Tests is described on documents such as package inserts. However, their test results are not disclosed and certificates of analysis are not issued.

these concepts are useful for the management of any type of drugs.

Basic Concept

In recent years, the mainstream concept for quality of drugs is that their quality is assured by management of manufacturing process, including management of raw material and other materials, and quality tests of final products that are conducted mutually complementary.

1. Management of manufacturing process

1.1. Considerations of manufacturing process

Adequate design of manufacturing processes and knowledge of their capacity are important to establish manufacturing processes yielding drug substances or drug products that meet specifications and to manage the manufacturing processes, product quality, etc. appropriately and consistently.

From this standpoint, the limits for management of manufacturing processes should be based on information obtained from the entire process spanning the period from the early development through commercial scale production. The appropriateness of the limits also needs to be confirmed by evaluation, verification, review, and other examinations of manufacturing processes. In addition, the General Notices describes exception: for example, when an assurance that the level of an impurity is controlled within an allowable standard or an assurance that an impurity is effectively removed to below an accepted level by effective manufacturing process management is obtained, the purity test for the final product may be omitted, and in some cases, purity tests may be excluded from the specifications for the final product.

In-process tests are tests that may be performed during the manufacture of either the drug substance or drug product, rather than tests for the final product. In-process tests are performed for quality verification during manufacturing processes that are likely to influence product quality, or for confirmation of proper functioning of the manufacturing process. When proper management of manufacturing and quality is conducted, performing of in-process tests may allow omission of tests for the final product.

Usually in-process tests are properly designed according to the degree of the process's influence on quality, however, the use of internal action limits by the manufacturer to assess the consistency of the process at less critical steps is also important. Data obtained during development of the drug and during evaluation and verification to provide the basis for provisional action limits to be set for the manufacturing process, and these limits should be further refined based on additional manufacturing experience and data obtained after product approval.

1.2. Considerations of raw materials and other materials (starting materials, excipients, packaging materials, etc.)

The raw materials and other materials used in the production of drug substances (or drug products) should meet quality standards, appropriate for their intended use, and if necessary, appropriate setting of specifications is required. Especially, biological raw/source materials may require careful evaluation to establish the presence or the absence of deleterious endogenous or adventitious agents. Procedures that make use of affinity chromatography (for example, employing monoclonal antibodies), should be accompanied by appropriate measures to ensure that such process-related impurities or potential contaminants arising from their production and use do not compromise the quality and safety of the drug substance or drug product.

The quality of the excipients used in the drug product formulation (and in some cases, in the production of drug sub-

G10 Others

Basic Concepts for Quality Assurance of Drug Substances and Drug Products

Introduction

Quality of drug substances and products are generally assured through production and examination under appropriate Good Manufacturing Practice (GMP) control reflecting knowledge obtained from designing and developmental stages and manufacturing stage on management of raw materials and other materials, management of manufacturing process, specifications, etc. As shown in the General Notices, JP-listed drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the *Japanese Pharmacopoeia*. In addition to these, adherence to GMP, management of raw materials and other materials, and management of manufacturing process are fundamental factors required to assure the quality of JP-listed drugs in actual production.

The present chapter summarizes general concepts concerning measures for quality assurance of drug substances and products mainly aimed at chemicals, including chemically synthesized antibiotics and semisynthetic antibiotics, synthetic peptides, oligonucleotides, and biotechnological/biological products. Although radiopharmaceuticals, crude drugs, herbal products, and crude products of animal or plant origin are excluded from the subjects of the concepts,

stance), as well as the primary packaging materials, should be controlled with specifications established based on the characteristics of the drug. If specifications for a material are described by the JP, as a rule, at least the JP criteria should be satisfied. Concerning excipients not listed in the JP, appropriate specifications should be established individually.

2. Quality tests of products (specifications)

“A specification” is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria which are numerical limits, ranges, or other criteria for the tests described. Specifications of the JP are defined sets of quality attributes needed for determination of whether the use of a drug substance or a drug product is appropriate for the purpose. “Conformance to the specifications of the JP monograph” means that the JP listed drug substances and drug products, when tested according to the procedures described in general tests and drug monographs, will meet the all acceptance criteria except criteria of “Description” and “Containers and storage (for drug products)” in the JP monographs.

However, specifications of monographs for drug substance and drug product are one part of a total control strategy for assurance of the quality and consistency of the substances/products. Other control strategies include complete characterization of the drug in developmental stage (specifications are established based on the characterization), and management of manufacturing process and products' quality, such as evaluation, verification, and review of manufacturing process, and management of raw materials and other materials, that is to say, adherence to the GMP.

3. Periodic or Skip Testing

Periodic or skip testing is the performance of specified tests at release on preselected batches and/or at predetermined intervals, rather than on a batch-to-batch basis with the understanding that those batches not being tested still must meet all acceptance criteria established for that product. When this concept is applied, it is necessary to show its appropriateness and be approved previously by regulatory authority. This concept may be applicable to, for example, residual solvents and microbiological testing for solid oral dosage forms. It is recognized that only limited data may be available at the time of submission of an application. Implementation of this test should therefore generally be considered post-approval. When tested, any failure to meet acceptance criteria established for the periodic test should be handled by proper notification of the appropriate regulatory authorities. If these data demonstrate a need to restore routine testing, then batch-by-batch release testing should be reinstated.

4. Real time release testing and parametric release

Determination of the suitability for release can be based on the result of real time release testing instead of final product testing when approved by the regulatory authority. Real-time release testing is a type of tests to evaluate the quality of in-process or final products based on process data (including results of in-process testing and data on process parameters). Parametric release can be considered a type of real time release. One example of parametric release is to determine the suitability for release of terminally sterilized drug products based on the data on sterilizing process instead of the results of sterility testing. In this case, the release of each batch is based on satisfactory results from monitoring specific parameters, e.g., temperature, pressure, and time during the terminal sterilization phase(s) of drug

product manufacturing. Parametric release based on above parameters is more reliable in predicting sterility assurance than determination of suitability for release based on sterility testing using limited number of end-products.

Basic Concept of Quality Risk Management

Introduction

Quality Risk Management (QRM) is a crucial constituent of Pharmaceutical Quality System (PQS). PQS is a kind of the Quality System to control pharmaceutical quality in industries. Quality System is a basic concept of International Standards such as ISO 9001, ISO 14001, and ISO 27001. With its framework of maintenance and continuous improvement of business operation based on PDCA cycle (Plan → Do → Check → Act), PQS has been incorporated in ICH Q10 guideline as the basic philosophy. QRM is applicable to secure quality of every pharmaceuticals including drug substances, drug (medicinal) products, and biological and biotechnological products. Cooperating with a control strategy reflecting latest knowledge and understandings on products and manufacturing process, QRM contributes to realization and maintenance with consistent quality by responding flexibly and securely to risk regarding qualities.

Risks associated with the quality of pharmaceutical products are evaluated in the process of listing in Japanese Pharmacopoeia and the results are reflected in specifications of the individual monograph. However, the pharmaceuticals specified in the same monograph may each have different quality risk derived from difference in their manufacturing methods. Therefore, appropriate assessment and management is required for such risk to manufacturing quality in the course of actual drug development and manufacturing. Further, quality risk of pharmaceuticals should be re-evaluated on a regular basis during their lifecycle, i.e. from their initial development through commercialization to the end of manufacturing and sales, and it is required to take appropriate measures based on the results.

About a relationship between QRM and Japanese Pharmacopoeia, it may be said additionally as follows. In addition to conduction of the standard tests of Japanese Pharmacopoeia, it is important to plan and carry out measures to properly control elusive risk, which derived from alterations of manufacturing and quality management such as changes of raw materials and resources, in order to properly hold the pharmaceutical quality. Besides, depending on the results of risk re-evaluation, it may become necessary to revise specification tests specified by Japanese Pharmacopoeia.

1. Significance of QRM

It is commonly understood that risk is defined as the combination of the probability of occurrence of harm and the severity of that harm. However, achieving a shared understanding of the application of risk management among diverse stakeholders is difficult because of a large gap between stakeholders in type and size of risk recognized. In relation to pharmaceuticals, although there are a variety of stakeholders, including patients and medical practitioners as well as government and industry, the protection of the patient by applying QRM should be considered of prime importance.

The manufacturing and use of a drug (medicinal) product, including its components, necessarily entail some degree of risk. The risk to its quality is just one component of the

overall risk. The product quality should be maintained throughout the product lifecycle such that the attributes that are important to the quality of the drug (medicinal) product remain consistent with those used in the clinical studies. An effective QRM approach can further ensure the high quality of the drug (medicinal) product to the patient by providing a proactive means to identify and control potential quality issues during development and manufacturing. Additionally, use of QRM can improve the quality of measures and the speed of decision making if a quality problem arises. Effective QRM can provide regulators with greater assurance of a company's ability to deal with potential risks and can beneficially affect the extent and level of direct regulatory oversight.

As for QRM, it is neither always appropriate nor always necessary to use a formal risk management process. The use of informal risk management processes can also be considered acceptable. Appropriate use of QRM can facilitate but does not obviate industry's obligation to comply with regulatory requirements and does not replace appropriate communications between industry and regulators.

2. Scope of Application

QRM can be applied to every aspects of pharmaceutical quality. These aspects include development, manufacturing, distribution, and the inspection and submission/review processes throughout the lifecycle of drug substances, drug (medicinal) products, and biological and biotechnological products (including the use of raw materials, solvents, excipients, packaging and labeling materials in drug (medicinal) products, biological and biotechnological products).

3. Principle of QRM

Two primary principles of QRM are:

- Evaluation of the risk to quality should be based on scientific knowledge and ultimately link to the protection of the patient.
- Level of effort, formality and documentation of the QRM process should be commensurate with the level of risk.

4. General QRM Process

QRM is a systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle. A model for QRM is outlined in the diagram (Figure 1). The emphasis on each component of the framework might differ from case to case but a robust process will incorporate consideration of all the elements at a level of detail that is commensurate with the specific risk. Decision nodes are not shown in the diagram because decisions can occur at any point in the process. These decisions might be to return to the previous step and seek further information, to adjust the risk models or even to terminate the risk management process based upon information that supports such a decision.

4.1. Initiation of QRM Process

QRM should include systematic processes designed to coordinate, facilitate and improve science-based decision making with respect to risk. Possible steps used to initiate and plan a QRM process might include the following:

- Define the problem and/or risk question, including pertinent assumptions identifying the potential for risk;
- Assemble background information and/or data on the potential hazard, harm or human health impact relevant to the risk assessment;
- Identify a leader and necessary resources;
- Specify a timeline, deliverables and appropriate level of decision making for the risk management process.




Fig. 1 Overview of a typical quality risk management process

In the process described above, persons in charge (decision makers) should take responsibility for coordinating quality risk management across various functions and departments of their organization; and assure that a QRM process is defined, deployed and reviewed and that adequate resources are available.

4.2. Risk Assessment

Risk assessment consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards. The step includes "risk identification", "risk analysis" and "risk evaluation".

As an assist to define risk clearly for purposes of risk assessment, the following three basic questions are often helpful.

1. What might go wrong?
2. What is the likelihood (probability) it will go wrong?
3. What are the consequences (severity)?

Risk identification is a systematic use of information to identify hazards referring to the risk question or problem description. Information can include historical data, theoretical analysis, informed opinions, and the concerns of stakeholders. Risk identification addresses the "What might go wrong?" question, including identifying the possible consequences. This provides the basis for further steps in the quality risk management process.

Risk analysis is the estimation of the risk associated with the identified hazards. It is the qualitative or quantitative process of linking the likelihood of occurrence and severity of harms. In some risk management tools, the ability to detect the harm (detectability) also factors in the estimation of risk.

Risk evaluation compares the identified and analyzed risk against given risk criteria. Risk evaluations consider the strength of evidence for all three of the fundamental questions.

The output of a risk assessment is either a quantitative estimate of risk or a qualitative description of a range of risk. When risk is expressed quantitatively, a numerical probability is used. Alternatively, risk can be expressed using qualitative descriptors, such as "high", "medium", or "low", which should be defined in as much detail as possible. Some-

times a “risk score” is used to further define descriptors in risk ranking. In quantitative risk assessments, a risk estimate provides the likelihood of a specific consequence, given a set of risk-generating circumstances. Thus, quantitative risk estimation is useful for one particular consequence at a time. Alternatively, some risk management tools use a relative risk measure to combine multiple levels of severity and probability into an overall estimate of relative risk. The intermediate steps within a scoring process can sometimes employ quantitative risk estimation.

4.3. Risk Control

Risk control includes decision making to reduce and/or accept risks. The purpose of risk control is to reduce the risk to an acceptable level. The amount of effort used for risk control should be proportional to the significance of the risk. Decision makers might use different processes, including benefit-cost analysis, for understanding the optimal level of risk control.

Risk control might focus on the following questions:

- Is the risk above an acceptable level?
- What can be done to reduce or eliminate risks?
- What is the appropriate balance among benefits, risks and resources?
- Are new risks introduced as a result of the identified risks being controlled?

Risk reduction focuses on processes for mitigation or avoidance of quality risk when it exceeds a specified (acceptable) level (see Fig. 1). Risk reduction might include actions taken to mitigate the severity and probability of harm. Processes that improve the detectability of hazards and quality risks might also be used as part of a risk control strategy. The implementation of risk reduction measures can introduce new risks into the system or increase the significance of other existing risks. Hence, it might be appropriate to revisit the risk assessment to identify and evaluate any possible change in risk after implementing a risk reduction process.

Risk acceptance is a decision to accept risk. Risk acceptance can be a formal decision to accept the residual risk or it can be a passive decision in which residual risks are not specified. For some types of harms, even the best quality risk management practices might not entirely eliminate risk. In these circumstances, it might be agreed that an appropriate quality risk management strategy has been applied and that quality risk is reduced to a specified (acceptable) level. This (specified) acceptable level will depend on many parameters and should be decided on a case-by-case basis.

4.4. Risk Communication

Risk communication is the sharing of information about risk and risk management between the decision makers and others. Parties can communicate at any stage of the risk management process (see Fig. 1: dashed arrows). The output/result of the quality risk management process should be appropriately communicated and documented (see Fig. 1: solid arrows). Communications might include those among interested parties; e.g., regulators and industry, industry and the patient, within a company, industry or regulatory authority, etc. The included information might relate to the existence, nature, form, probability, severity, acceptability, control, treatment, detectability or other aspects of risks to quality. Communication need not be carried out for each and every risk acceptance. Between the industry and regulatory authorities, communication concerning quality risk management decisions might be effected through existing channels as specified in regulations and guidances.

4.5. Risk Review

Risk management should be an ongoing part of the quality

management process. A mechanism to review or monitor events should be implemented.

The output/results of the risk management process should be reviewed to take into account new knowledge and experience. Once a quality risk management process has been initiated, that process should continue to be utilized for events that might impact the original quality risk management decision, whether these events are planned (e.g., results of product review, inspections, audits, change control) or unplanned (e.g., root cause from failure investigations, recall). The frequency of any review should be based upon the level of risk. Risk review might include reconsideration of risk acceptance decisions (section 4.3).

5. Summary

The degree of rigor and formality of quality risk management should reflect available knowledge and be commensurate with the complexity and/ or criticality of the issue to be addressed.

Quality risk management is a process that supports science-based and practical decisions when integrated into quality systems. Appropriate use of QRM, however, does not obviate industry’s obligation to comply with regulatory requirements.

6. Definitions

Decision Maker(s): Person(s) with the competence and authority to make appropriate and timely quality risk management decisions.

Detectability: The ability to discover or determine the existence, presence, or fact of a hazard.

Harm: Damage to health, including the damage that can occur from loss of product quality or availability.

Hazard: The potential source of harm (ISO/IEC Guide 51).

Product Lifecycle: All phases in the life of the product from the initial development through marketing until the product’s discontinuation.

Quality: The degree to which a set of inherent properties of a product, system or process fulfills requirements (see ICH Q6A definition specifically for “quality” of drug substance and drug (medicinal) products.)

Quality Risk Management: A systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle.

Quality System: The sum of all aspects of a system that implements quality policy and ensures that quality objectives are met.

Requirements: The explicit or implicit needs or expectations of the patients or their surrogates (e.g., health-care professionals, regulators and legislators). In this document, “requirements” refers not only to statutory, legislative, or regulatory requirements, but also to such needs and expectations.

Risk: The combination of the probability of occurrence of harm and the severity of that harm (ISO/IEC Guide 51).

Risk Acceptance: The decision to accept risk (ISO Guide 73).

Risk Analysis: The estimation of the risk associated with the identified hazards.

Risk Assessment: A systematic process of organizing information to support a risk decision to be made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards.

Risk Communication: The sharing of information about risk and risk management between the decision maker and other stakeholders.

Risk Control: Actions implementing risk management decisions (ISO Guide 73).

Risk Evaluation: The comparison of the estimated risk to given risk criteria using a quantitative or qualitative scale to determine the significance of the risk.

Risk Identification: The systematic use of information to identify potential sources of harm (hazards) referring to the risk question or problem description.

Risk Management: The systematic application of quality management policies, procedures, and practices to the tasks of assessing, controlling, communicating and reviewing risk.

Risk Reduction: Actions taken to lessen the probability of occurrence of harm and the severity of that harm.

Risk Review: Review or monitoring of output/results of the risk management process considering (if appropriate) new knowledge and experience about the risk.

Severity: A measure of the possible consequences of a hazard.

Stakeholder: Any individual, group or organization that can affect, be affected by, or perceive itself to be affected by a risk. Decision makers might also be stakeholders. For the purposes of this guideline, the primary stakeholders are the patient, healthcare professional, regulatory authority, and industry.

International Harmonization Implemented in the Japanese Pharmacopoeia Seventeenth Edition

Items for which harmonization has been agreed among the European Pharmacopoeia, the United States Pharmacopeia and the Japanese Pharmacopoeia are implemented in the Japanese Pharmacopoeia Seventeenth Edition (JP 17). They are shown in the tables below.

The column headed Harmonized items shows the harmonized items written in the Pharmacopoeial Harmonization Agreement Document, and the column headed JP 17 shows the items as they appear in JP 17. In the Remarks column, notes on any differences between JP 17 and the agreement are shown as occasion demands.

The date on which the agreement has been signed is shown on the top of each table. In the case where the harmonized items have been revised and/or corrected, this is indicated in parenthesis.

Aug. 2005 (Rev. 2)

Harmonized items	JP 17	Remarks
Residue on Ignition/Sulphated Ash Test (Introduction)	2.44 Residue on Ignition Test (Introduction)	JP's particular description: Explanation on this test. Explanation of the description in monograph, etc.
Procedure	1. Procedure	

June 2014

Harmonized items	JP 17	Remarks
Thermal Analysis (Introduction)	2.52 Thermal Analysis (Introduction)	JP's particular description: Explanation of the case where thermogravimetry is used as an alternative method of loss on drying or water determination.
Thermogravimetry	1. Thermogravimetry	
Instrument	1.1. Instrument	
Temperature calibration	1.2. Temperature calibration	
Calibration of the electrobalance	1.3. Calibration of the electrobalance	JP's particular description: Setting of Calcium Oxalate Monohydrate RS for Calibration of Apparatus.
Method	1.4. Method	
Differential scanning calorimetry	2. Differential scanning calorimetry	
Instrument	2.1. Instrument	
Calibration of the instrument	2.2. Calibration of the instrument	
Temperature calibration	2.2.1. Temperature calibration	
Heat-quantity calibration	2.2.2. Heat-quantity calibration	
Operating procedure	2.3. Operating procedure	
Applications	2.4. Applications	
Phase changes	2.4.1. Phase changes	
Changes in chemical composition	2.4.2. Changes in chemical composition	
Application to phase diagrams	2.4.3. Application to phase diagrams	
Determination of purity	2.4.4. Determination of purity	
Figure 1 Thermogram	Fig. 1 Thermogram	
Figure 2 Thermal diagrams according to purity	Fig. 2 Thermal diagrams according to purity	
Table 1	Table 1	

Oct. 2007

Harmonized items	JP 17	Remarks
Characterisation of Crystalline and Partially Crystalline Solids by X-ray Powder Diffraction (XRPD) (Introduction)	2.58 X-Ray Powder Diffraction Method (Introduction)	JP's particular description: Explanation on this method.
Principle	1. Principle	
Instrument	2. Instrument	
Instrument set-up	2.1 Instrument set-up	

X-ray radiation	2.2 X-ray radiation	
Radiation protection	2.3 Radiation protection	
Specimen preparation and mounting	3. Specimen preparation and mounting	
Specimen preparation	3.1 Specimen preparation	
Specimen mounting		“Specimen mounting” is not stipulated.
Effect of specimen displacement		
Effect of specimen thickness and transparency		
Control of the instrument performance	4. Control of the instrument performance	
Qualitative phase analysis (Identification of phases)	5. Qualitative phase analysis (Identification of phases)	
Quantitative phase analysis	6. Quantitative phase analysis	
Polymorphic samples	6.1 Polymorphic samples	
Methods using a standard	6.2 Methods using a standard	
Estimate of the amorphous and crystalline fractions	7. Estimate of the amorphous and crystalline fractions	
Single crystal structure	8. Single crystal structure	
Figure 1 Diffraction of X-rays by a crystal according to Bragg's law	Fig. 1 Diffraction of X-rays by a crystal according to Bragg's law	
Figure 2 X-ray powder diffraction patterns collected for 5 different solid phases of a substance (the intensities are normalized)	Fig. 2 X-ray powder diffraction patterns collected for 5 different solid phases of a substance (the intensities are normalized)	
Figure 3 Geometric arrangement of the Bragg-Brentano parafocusing geometry	Fig. 3 Geometric arrangement of the Bragg-Brentano parafocusing geometry	

Nov. 2013 (Rev. 3)

Harmonized items	JP 17	Remarks
Bulk Density and Tapped Density of Powders	3.01 Determination of Bulk and Tapped Densities (Introduction)	JP's particular description: Explanation of the test method.
Bulk density	1. Bulk density	
Method 1: Measurement in a graduated cylinder	1.1. Method 1: Measurement in a graduated cylinder	
Procedure	1.1.1. Procedure	
Method 2: Measurement in a volumeter	1.2. Method 2: Measurement in a volumeter	
Apparatus	1.2.1. Apparatus	
Procedure	1.2.2. Procedure	
Method 3: Measurement in a vessel	1.3. Method 3: Measurement in a vessel	
Apparatus	1.3.1. Apparatus	
Procedure	1.3.2. Procedure	
Tapped density	2. Tapped density	
Method 1	2.1. Method 1	
Apparatus	2.1.1. Apparatus	
Procedure	2.1.2. Procedure	

Method 2	2.2. Method 2	
Procedure	2.2.1. Procedure	
Method 3	2.3. Method 3	
Procedure	2.3.1. Procedure	
Measures of powder compressibility	3. Measures of powder compressibility	
Figure 1 Volumeter	Fig. 1 Volumeter	
Figure 2 Measuring vessel (left) and cap (right)	Fig. 2 Measuring vessel (left) and cap (right)	
Figure 3	Fig. 3 Tapping apparatus	

Nov. 2003

Harmonized items	JP 17	Remarks
Specific Surface Area (Introduction) Multi-point measurement Single-point measurement Sample preparation Outgassing Adsorbate Quantity of sample Measurements Method 1: The dynamic flow method Method 2: The volumetric method Reference materials Figure 1 Schematic diagram of the dynamic flow method apparatus Figure 2 Schematic diagram of the volumetric method apparatus	3.02 Specific Surface Area by Gas Adsorption (Introduction) 1. Measurements 1.1. Multi-point measurement 1.2. Single-point measurement 2. Sample preparation 3. Methods 3.1. Method 1: The dynamic flow method 3.2. Method 2: The volumetric method 4. Reference materials Fig. 1 Schematic diagram of the dynamic flow method apparatus Fig. 2 Schematic diagram of the volumetric method apparatus	JP's particular description: Explanation on this test.

May 2007

Harmonized items	JP 17	Remarks
Gas Pycnometric Density of Solids (Introduction) Apparatus Method Expression of the results Figure 1 Schematic diagram of a gas pycnometer	3.03 Powder Particle Density Determination (Introduction) 1. Apparatus 2. Calibration of apparatus 3. Procedure Fig. 1 Schematic diagram of a gas pycnometer	JP's particular description: Objects to be measured by this method. The range of temperature during the measurement is described in the Procedure.

June 2004 (Method 1)/May 2007 (Rev. 1) (Method 2)

Harmonized items	JP 17	Remarks
Particle Size Determination	3.04 Particle Size Determination (Introduction)	JP's particular description: Explanation on this test.
Optical microscopy	1. Method 1. Optical microscopy	JP's particular description: Explanation on this test.
Apparatus	1.1. Apparatus	
Adjustment	1.1.1. Adjustment	
Illumination	1.1.1.1. Illumination	
Visual characterization	1.1.1.2. Visual characterization	
Photographic characterization	1.1.1.3. Photographic characterization	JP's particular description: Explanation on the method of particle size measurement.
Preparation of the mount	1.2. Preparation of the mount	
Crystallinity characterization	1.3. Characterization	
Limit test of particle size by microscopy	1.3.1. Crystallinity characterization	
Particle size characterization	1.3.2. Limit test of particle size by microscopy	
Particle shape characterization	1.3.3. Particle size characterization	
General observations	1.3.4. Particle shape characterization	
Figure 1 Commonly used measurements of particle size	1.3.5. General observations	
Figure 2 Commonly used descriptions of particle shape	Fig. 1 Commonly used measurements of particle size	
Analytical sieving	2. Method 2. Analytical sieving method	JP's particular description: Explanation on this method.
Principles of analytical sieving	Principles of analytical sieving	
Test sieves	2.1. Procedure	
Test specimen	2.1.1. Test sieves	
Agitation methods	2.1.2. Test specimen	
Endpoint determination	2.1.3. Agitation methods	
Sieving methods	2.1.4. Endpoint determination	
1) Mechanical agitation dry sieving method	2.2. Sieving methods	
2) Air entrainment methods air jet and sonic sifter sieving	2.2.1. Mechanical agitation (Dry sieving method)	
Interpretation	2.2.2. Air entrainment methods (Air jet and sonic shifter sieving)	
Figure 1 Commonly used measurements of particle size	2.3. Interpretation	
Figure 2 Commonly used descriptions of particle shape	Fig. 1 Commonly used measurements of particle size	
Table 1 Size of standard sieve series in range of interest	Fig. 2 Commonly used descriptions of particle shape	
	Table 1 Size of standard sieve series in range of interest	

Oct. 2009

Harmonized items	JP 17	Remarks
Water-Solid Interactions	3.05 Water-Solid Interactions: Determinations of Sorption-Desorption Isotherms and the Water Activity (Introduction)	
Introduction	not specified	JP's particular description: Explanation on the relevant methods.
Physical states of sorbed water	not specified	
Rates of water uptake	not specified	
Determination of Sorption-Desorption Isotherms	1. Determination of Sorption-Desorption Isotherms	
Principle	1.1. Principle	
Methods	1.2. Methods	
Report and interpretation of the data	1.3. Report and interpretation of the data	
Determination of the water activity	2. Determination of the water activity	
Principle	2.1. Principle	
Method	2.2. Method	
Figure 1 Example of an apparatus for the determination of the water sorption (other designs are possible)	Fig. 1 Example of an apparatus for the determination of the water sorption (other designs are possible)	
Table 1 Standard saturated salt solutions	Table 1 Standard saturated salt solutions	

June 2011 (Rev. 2)

Harmonized items	JP 17	Remarks
Bacterial Endotoxins Test (Introduction)	4.01 Bacterial Endotoxins Test (Introduction)	
Apparatus	1. Apparatus	
Preparation of standard endotoxin stock solution	2. Preparation of solutions 2.1. Standard endotoxin stock solution	
Preparation of standard endotoxin solution	2.2. Standard endotoxin solution	
Preparation of sample solutions	2.3. Sample solutions	
Determination of maximum valid dilution	3. Determination of maximum valid dilution	
Gel-clot technique	4. Gel-clot techniques	
(1) Preparatory testing	4.1. Preparatory testing	
(i) Test for confirmation of labeled lysate sensitivity	4.1.1. Test for confirmation of labeled lysate reagent sensitivity	
(ii) Test for interfering factors	4.1.2. Test for interfering factors	
(2) Limit test	4.2. Limit test	
(i) Procedure	4.2.1. Procedure	
(ii) Interpretation	4.2.2. Interpretation	
(3) Quantitative test	4.3. Quantitative test	
(i) Procedure	4.3.1. Procedure	
(ii) Calculation and interpretation	4.3.2. Calculation and interpretation	

Photometric quantitative techniques	5. Photometric quantitative techniques	
(1) Turbidimetric technique	5.1. Turbidimetric technique	
(2) Chromogenic technique	5.2. Chromogenic technique	
(3) Preparatory testing	5.3. Preparatory testing	
(i) Assurance of criteria for the standard curve	5.3.1. Test for assurance of criteria for the standard curve	
(ii) Test for interfering factors	5.3.2. Test for interfering factors	
(4) Test	5.4. Quantitative test	
(i) Procedure	5.4.1. Procedure	
(ii) Calculation	5.4.2. Calculation of endotoxin concentration	
(iii) Interpretation	5.4.3. Interpretation	
Reagents, test solutions		These reagents and test solutions are being defined in "9.41 Reagents, Test Solutions".
Amoebocyte lysate		
Lysate TS		
Water for bacterial endotoxins test (BET)		
Table 1	Table 1	
Table 2	Table 2	
Table 3	Table 3	
Table 4	Table 4	

June 2009 (Rev. 1 – Corr. 1) (I. Microbial Enumeration Tests)/Jun. 2008 (Rev. 1) (II. Test for Specified Micro-organisms)

Harmonized items	JP 17	Remarks
Microbial Limit Test	4.05 Microbiological Examination of Non-Sterile Products	
Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests <ul style="list-style-type: none"> 1 Introduction 2 General procedures 3 Enumeration methods 4 Growth promotion test, suitability of the counting method and negative controls <ul style="list-style-type: none"> 4-1 General considerations 4-2 Preparation of test strains 4-3 Negative control 4-4 Growth promotion of the media 4-5 Suitability of the counting method in the presence of product 4-6 Results and interpretation 5 Testing of products <ul style="list-style-type: none"> 5-1 Amount used for the test 5-2 Examination of the product 5-3 Interpretation of the results 	I. Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests (Introduction) <ul style="list-style-type: none"> 1. General procedures 2. Enumeration methods 3. Growth promotion test, suitability of the counting method and negative controls <ul style="list-style-type: none"> 3.1. Preparation of test strains 3.2. Negative control 3.3. Growth promotion of the media 3.4. Suitability of the counting method in the presence of product 3.5. Results and interpretation 4. Testing of products <ul style="list-style-type: none"> 4.1. Amount used for the test 4.2. Examination of the product 4.3. Interpretation of the results 	

Table 1 Preparation and use of test micro-organisms	Table I-1 Preparation and use of test micro-organisms
Table 2 Common neutralising agents for interfering substances	Table I-2 Common neutralizing agents for interfering substances
Table 3 Most-probable-number values of micro-organisms	Table I-3 Most-probable-number values of micro-organisms
Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms	II. Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms
1 Introduction	(Introduction)
2 General procedures	1. General procedures
3 Growth promoting and inhibitory properties of the media, suitability of the test and negative controls	2. Growth promoting and inhibitory properties of the media, suitability of the test and negative controls
3-1 Preparation of test strains	2.1. Preparation of test strains
3-2 Negative control	2.2. Negative control
3-3 Growth promotion and inhibitory properties of the media	2.3. Growth promotion and inhibitory properties of the media
3-4 Suitability of the test method	2.4. Suitability of the test method
4 Testing of products	3. Testing of products
4-1 Bile-tolerant gram-negative bacteria	3.1. Bile-tolerant gram-negative bacteria
4-2 <i>Escherichia coli</i>	3.2. <i>Escherichia coli</i>
4-3 <i>Salmonella</i>	3.3. <i>Salmonella</i>
4-4 <i>Pseudomonas aeruginosa</i>	3.4. <i>Pseudomonas aeruginosa</i>
4-5 <i>Staphylococcus aureus</i>	3.5. <i>Staphylococcus aureus</i>
4-6 <i>Clostridia</i>	3.6. <i>Clostridia</i>
4-7 <i>Candida albicans</i>	3.7. <i>Candida albicans</i>
5 Recommended solutions and culture media	4. Recommended solutions and culture media
Table II-1 Growth promoting, inhibitory and indicative properties of media	Table II-1 Growth promoting, inhibitory and indicative properties of media
Table II-2 Interpretation of results	Table II-2 Interpretation of results

June 2009 (Rev. 1 – Corr. 3)

Harmonized items	JP 17	Remarks
<p>Sterility (Introduction)</p> <p>Precautions against microbial contamination</p> <p>Culture media and incubation temperatures</p> <p>Media for the test may be prepared as described below, or equivalent commercial media may be used provided that they comply with the growth promotion test.</p> <p>Fluid thioglycollate medium</p> <p>Soya-bean casein digest medium</p>	<p>4.06 Sterility Test (Introduction)</p> <p>1. Precautions against microbial contamination</p> <p>2. Culture media and incubation temperatures</p> <p>(i) Fluid thioglycollate medium</p> <p>(ii) Soya-bean casein digest medium</p>	

<p>The media used comply with the following tests, carried out before or in parallel with the test on the product to be examined</p>	<p>3. Suitability of the culture medium</p> <p>3.1. Sterility</p> <p>3.2. Growth promotion test of aerobes, anaerobes and fungi</p> <p>4. Method suitability test</p> <p>(i) Membrane filtration</p> <p>(ii) Direct inoculation</p> <p>5. Test for sterility of the product to be examined</p>	
<p>Sterility</p> <p>Growth promotion test of aerobes, anaerobes and fungi</p>		
<p>Method suitability test</p> <p>Membrane filtration</p> <p>Direct inoculation</p>	<p>4. Method suitability test</p> <p>(i) Membrane filtration</p> <p>(ii) Direct inoculation</p>	
<p>Test for sterility of the product to be examined</p>		
<p>The test may be carried out using the technique of membrane filtration or by direct inoculation of the culture media with the product to be examined</p>		
<p>Membrane filtration</p> <p>Aqueous solutions</p> <p>Soluble solids</p> <p>Oils and oily solutions</p> <p>Ointments and creams</p> <p>Direct inoculation of the culture medium</p> <p>Oily liquids</p> <p>Ointments and creams</p> <p>Catgut and other surgical sutures for veterinary use</p>	<p>5.1. Membrane filtration</p> <p>(i) Aqueous solutions</p> <p>(ii) Soluble solids</p> <p>(iii) Oils and oily solutions</p> <p>(iv) Ointments and creams</p> <p>5.2. Direct inoculation of the culture medium</p> <p>(i) Oily liquids</p> <p>(ii) Ointments and creams</p>	
<p>Observation and interpretation of results</p>	<p>6. Observation and interpretation of results</p>	
<p>Application of the test to parenteral preparations, ophthalmic and other non-injectable preparations required to comply with the test for sterility</p>	<p>7. Application of the test to parenteral preparations, ophthalmic and other non-injectable preparations required to comply with the test for sterility</p>	
<p>Minimum number of items to be tested</p>	<p>8. Minimum number of items to be tested</p>	
<p>Table 1. Strains of the test micro-organisms suitable for use in the growth promotion test and the method suitability test</p>	<p>Table 1. Strains of the test micro-organisms suitable for use in the growth promotion test and the method suitability test</p>	
<p>Table 2. Minimum quantity to be used for each medium</p>	<p>Table 2. Minimum quantity to be used for each medium</p>	
<p>Table 3. Minimum number of items to be tested</p>	<p>Table 3. Minimum number of items to be tested</p>	<p>JP's particular description: A 100 mL or more of the labeled amount of preparation is defined as the large volume preparation.</p>

Nov. 2010 (Rev. 1)

Harmonized items	JP 17	Remarks
<p>Uniformity of Dosage Units (Introduction)</p>	<p>6.02 Uniformity of Dosage Units (Introduction)</p>	<p>JP's particular description: Additional explanation on Liquids. Additional explanation for the part not containing drug substance.</p>

Content uniformity Solid dosage forms Liquid or Semi-Solid dosage forms Calculation of acceptance value Mass variation	1. Content uniformity (i) Solid dosage forms (ii) Liquid or semi-solid dosage forms 1.1. Calculation of acceptance value 2. Mass variation	JP's particular description: Assuming that the concentration of drug substance is uniform in each lot.
Uncoated or film-coated tablets Hard capsules Soft capsules Solid dosage forms other than tablets and capsules Liquid dosage forms	(i) Uncoated or film-coated tablets (ii) Hard capsules (iii) Soft capsules (iv) Solid dosage forms other than tablets and capsules (v) Liquid dosage forms	The phrase "in conditions of normal use. If necessary, compute the equivalent volume after determining the density." is deleted.
Calculation of acceptance value Criteria Solid, Semi-Solid and Liquid dosage forms Table 1 Application of content uniformity (CU) and mass variation (MV) test for dosage forms Table 2	2.1. Calculation of acceptance value 3. Criteria (i) Solid, semi-solid and liquid dosage forms Table 1 Application of content uniformity (CU) and mass variation (MV) test for dosage forms Table 2	JP's particular description: Addition of "(divided forms, lyophilized forms)" and "(true solution)".

June 2004 (Rev. 1)

Harmonized items	JP 17	Remarks
Test for Extractable Volume of Parenteral Preparations (Introduction) Single-dose containers Multi-dose containers Cartridges and prefilled syringes Parenteral infusions	6.05 Test for Extractable Volume of Parenteral Preparations (Introduction) 1. Single-dose containers 2. Multi-dose containers 3. Cartridges and pre-filled syringes 4. Parenteral infusions	JP's particular description: Explanation on this Test

June 2004 (Rev. 1)

General precautions	1.1.4. Sensor	JP's particular description
Method	1.1.4.1. Sensor resolution (Particle size resolution of apparatus)	JP's particular description
Evaluation	1.1.4.2. Particle counting accuracy	JP's particular description
	1.1.4.3. Threshold accuracy	JP's particular description
Method 2.	1.2. General precautions	
Microscopic particle count test	1.3. Method	
	1.4. Evaluation	JP's particular description: Being classified into "equal to or more than 100 mL" and "less than 100 mL".
General precautions	2. Method 2. Microscopic particle count test	
Method	2.1. Apparatus	
Evaluation	2.2. General precautions	
	2.3. Method	
	2.4. Evaluation	JP's particular description: Being classified into "equal to or more than 100 mL" and "less than 100 mL".
1. Circular diameter graticule	3. Reagents	JP's particular description
	Fig. 1 Circular diameter graticule	

Oct. 2007 (Rev. 1)

Harmonized items	JP 17	Remarks
Disintegration	6.09 Disintegration Test	JP's particular description: This test is applied to Granules, Dry Syrups and Pills.
Apparatus	1. Apparatus	
Basket-rack assembly	(i) Basket-rack assembly	JP's particular description: The apparatus may be varied somewhat provided the specifications.
Disks	(ii) Disks	
	(iii) Auxiliary tube	
Procedure	2. Procedure	
	2.1. Immediate-release preparations	JP's particular description: Setting of a test for Granules, Dry Syrups and Pills. Allowing use of water as the test fluid. Setting of each intervals of the immersion.
	2.2. Enteric coated preparations	Setting of a definition of complete disintegration.
Figure 1 Disintegration apparatus	Fig. 1 Disintegration apparatus	Setting of a procedure for Granules. JP's particular description: Setting of a test for delayed-release preparations.
	Fig. 2 Auxiliary tube	JP's particular description.

June 2010 (Rev. 3)

Harmonized items	JP 17	Remarks
Dissolution	6.10 Dissolution Test	JP's particular description: The test also aims at preventing significant bioinequivalence.

Apparatus	1. Apparatus	JP's particular description: The sinker is allowed to use in the case only when specified in the monograph.
Apparatus 1 (Basket apparatus)	1.1. Apparatus for Basket Method (Apparatus 1)	
Apparatus 2 (Paddle apparatus)	1.2. Apparatus for Paddle Method (Apparatus 2)	
Apparatus 3 (Reciprocating cylinder)	not specified	
Apparatus 4 (Flow-through cell)	1.3. Apparatus for Flow-Through Cell Method (Apparatus 3)	
Apparatus suitability	2. Apparatus Suitability	
Procedure	3. Procedure	
Apparatus 1 or 2	3.1. Basket Method or Paddle Method	
Immediate-release dosage forms	3.1.1. Immediate-release Dosage Forms	
Procedure	(i) Procedure	
Dissolution medium	(ii) Dissolution Medium	Non-harmonized item: Alternative usage of Method A or B.
Time	(iii) Time	
Extended-release dosage forms	3.1.2. Extended-release Dosage Forms	
Procedure	(i) Procedure	JP's particular description.
Dissolution medium	(ii) Dissolution Medium	
Time	(iii) Time	
Delayed-release dosage forms	3.1.3. Delayed-release Dosage Forms	JP's particular description: Time is specified each for the 1st and 2nd fluids.
Procedure	(i) Procedure	
Method A	not specified	
Method B	not specified	JP's particular description: Time is specified each for the 1st and 2nd fluids.
Time	(ii) Dissolution Medium	
Apparatus 3	(iii) Time	
Immediate-release dosage forms	not specified	
Procedure		
Dissolution medium		
Time		
Extended-release dosage forms		
Procedure		
Dissolution medium		
Time		
Delayed-release dosage forms		
Procedure		
Time		
Apparatus 4	3.2. Flow-Through Cell Method	
Immediate-release dosage forms	3.2.1. Immediate-release Dosage Forms	
Procedure	(i) Procedure	
Dissolution medium	(ii) Dissolution Medium	
Time	(iii) Time	

Extended-release dosage forms	3.2.2. Extended-release Dosage Forms	
Procedure	(i) Procedure	
Dissolution medium	(ii) Dissolution Medium	
Time	(iii) Time	
Delayed-release dosage forms	not specified	
Procedure	not specified	
Time	not specified	
Interpretation	4. Interpretation	JP's particular description: Follow Interpretation 1 when the value Q is specified in the individual monograph, otherwise follow Interpretation 2.
Immediate-release dosage forms	4.1. Immediate-release Dosage Forms	JP's particular description: Setting of Interpretation 2.
Extended-release dosage forms	4.2. Extended-release Dosage Forms	JP's particular description: Setting of Interpretation 2.
Delayed-release dosage forms	4.3. Delayed-release Dosage Forms	Non-harmonized items: Different dissolution medium. Deletion of disharmonized part on the value Q. JP's particular description: Setting of Interpretation 2.
Acceptance Table 1	Acceptance Table 1	JP's particular description: The value Q is specified in the individual monograph.
Acceptance Table 2	Acceptance Table 2	
Acceptance Table 3	Acceptance Table 3	
Acceptance Table 4	Acceptance Table 4	
Figure 1 Apparatus1 Basket stirring element	Fig. 1 Apparatus 1, Basket stirring element	
Figure 2 Paddle stirring element	Fig. 2 Apparatus 2, Paddle stirring element	
Figure 2a Alternative sinker	Fig. 2a Alternative sinker	
Figure 3 Apparatus 3	not specified	
Figure 4 Apparatus 4 (top) large cell for tablets and capsules (bottom) tablet holder for the large cell	Fig. 3 Apparatus 3 (top) large cell for tablets and capsules (bottom) tablet holder for the large cell	
Figure 5 Apparatus 4 (top) small cell for tablets and capsules (bottom) tablet holder for the small cell	Fig. 4 Apparatus 3 (top) small cell for tablets and capsules (bottom) tablet holder for the small cell	

June 2013

Harmonized items	JP 17	Remarks
Isomalt	Isomalt Hydrate	
Definition	limits of content	
Identification	Identification (1) (2)	JP's particular description: Color reaction, Standard solution.
Conductivity	Conductivity	
Reducing sugars	Purity (4) Reducing sugars	
Related substances	Purity (3) Related substances	JP's particular description: Test for required detectability, System repeatability.
Nickel	Purity (2) Nickel	
Water	Water	
Assay	Assay	JP's particular description: Standard solution, System repeatability.
Labelling	origin	

June 2014 (Rev. 2, Corr. 2)

Harmonized items	JP 17	Remarks
Ethanol	Ethanol	
Definition	limits of content	Setting of specific gravity at 15°C.
Identification A	not specified as Identification	Setting of Specific gravity as the specification.
Identification B	Identification	
Appearance	Purity (1) Clarity and color of solution	
Acidity or alkalinity	Purity (2) Acidity or alkalinity	
Relative density	Specific gravity	Setting of specific gravity at 15°C.
Absorbance	Purity (4) Other impurities (absorbance)	
Volatile impurities	Purity (3) Volatile impurities	
Residue on evaporation	Purity (5) Residue on evaporation	
Storage	Containers and storage	

June 2014 (Rev. 2, Corr. 2)

Harmonized items	JP 17	Remarks
Ethanol, Anhydrous	Anhydrous Ethanol	
Definition	limits of content	Setting of specific gravity at 15°C.
Identification A	not specified as Identification	Setting of Specific gravity as the specification.
Identification B	Identification	
Appearance	Purity (1) Clarity and color of solution	
Acidity or alkalinity	Purity (2) Acidity or alkalinity	
Relative density	Specific gravity	Setting of specific gravity at 15°C.
Absorbance	Purity (4) Other impurities (absorbance)	
Volatile impurities	Purity (3) Volatile impurities	
Residue on evaporation	Purity (5) Residue on evaporation	
Storage	Containers and storage	

Nov. 2005

Harmonized items	JP 17	Remarks
Calcium Disodium Edetate	Calcium Sodium Edetate Hydrate	
Definition	limits of content	
Identification (1)	Identification (1)	
Identification (2)	Identification (3)	
pH	pH	
Purity (1) Chloride	Purity (2) Chloride	
Purity (2) Disodium edetate	Purity (4) Disodium edetate	
Water	Water	
Assay	Assay	

Nov. 2013 (Rev. 3)

Harmonized items	JP 17	Remarks
Sodium Chloride	Sodium Chloride	
Definition	limits of the content	
Identification A	Identification (1)	
Identification B	Identification (2)	
Acidity or alkalinity	Purity (2) Acidity or alkalinity	
Bromides	Purity (5) Bromides	
Ferrocyanides	Purity (7) Ferrocyanides	
Iodides	Purity (6) Iodides	
Nitrites	not specified	
Phosphates	Purity (4) Phosphates	
Sulphates	Purity (3) Sulfates	
Aluminium	not specified	
Barium	Purity (10) Barium	
Iron	Purity (9) Iron	
Magnesium and alkaline-earth metals	Purity (11) Magnesium and alkaline-earth materials	
Potassium	not specified	
Loss on drying	Loss on drying	
Assay	Assay	

Nov. 2011 (Rev. 1)

Harmonized items	JP 17	Remarks
Carmellose	Carmellose	
Definition	origin	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
Purity (1) Chloride	Purity (1) Chloride	
Purity (2) Sulfate	Purity (2) Sulfate	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	

July 2003 (Rev. 1)

Harmonized items	JP 17	Remarks
Carboxymethylcellulose Calcium	Carmellose Calcium	
Definition	origin	
Identification A	Identification (1)	
Identification B	Identification (2)	
Identification C	Identification (3)	
Identification D	Identification (4)	
Alkalinity	Purity (1) Alkalinity	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	
Limit of chloride	Purity (2) Chloride	
Limit of sulfate	Purity (3) Sulfate	

Oct. 2001

Harmonized items	JP 17	Remarks
Croscarmellose Sodium	Croscarmellose Sodium	
Definition	origin	
Identification A	Identification (1)	
Identification B	Identification (2)	
Identification C	Identification (3)	
pH	pH	
Settling volume	Precipitation test	
Degree of substitution	Degree of substitution	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	
Packaging and storage	Containers and storate	

June 2010 (Rev. 2)

Harmonized items	JP 17	Remarks
Citric Acid, Anhydrous	Anhydrous Citric Acid	
Definition	limits of content	
Identification	Identification	
Appearance of solution	Purity (1) Clarity and color of solution	
Readily carbonisable substances	Purity (5) Readily carbonizable substances	
Oxalic acid	Purity (3) Oxalic acid	
Sulphates	Purity (2) Sulfates	
Aluminium	not specified	
Water	Water	
Sulphated ash	Residue on ignition	
Assay	Assay	

June 2010 (Rev. 2)

Harmonized items	JP 17	Remarks
Citric Acid Monohydrate	Citric Acid Hydrate	
Definition	limits of content	

Identification	Identification	
Appearance of solution	Purity (1) Clarity and color of solution	
Readily carbonisable substances	Purity (5) Readily carbonizable substances	
Oxalic acid	Purity (3) Oxalic acid	
Sulphates	Purity (2) Sulfates	
Aluminium	not specified	
Water	Water	
Sulphated ash	Residue on ignition	
Assay	Assay	

Nov. 2010

Harmonized items	JP 17	Remarks
Crospovidone	Crospovidone	
Definition	limits of content	
Identification A	Identification (1)	
Identification B	Identification (2)	
Identification C	Particle size	
Peroxides	Purity (4) Peroxides	
Water-soluble substances	Purity (2) Water-soluble substances	
Impurity A	Purity (3) 1-Vinyl-2-pyrrolidone	
Loss on drying	Loss on drying	
Sulphated ash	Residue on ignition	
Assay	Assay	
Storage	Containers and storage	

June 2013 (Rev. 1)

Harmonized items	JP 17	Remarks
Saccharin	Saccharin	
Definition	limits of content	
Identification	Identification	
Color and clarity of solution	Purity (1)	
Loss on drying	Loss on drying	
Readily carbonisable substances	Purity (5) Readily carbonizable substances	
Residue on ignition	Residue on ignition	
Limit of benzoate and salicylate	Purity (3) Benzoate and salicylate	
Assay	Assay	

Feb. 2004 (Rev. 1)

Harmonized items	JP 17	Remarks
Saccharin Sodium	Saccharin Sodium Hydrate	
Definition	limits of content	
Identification B, C	Identification (2)	
Acidity or alkalinity	Purity (2) Acid or alkali	
Limit of benzoate and salicylate	Purity (4) Benzoate and salicylate	

Readily carbonisable substances	Purity (6) Readily carbonizable substances	
Water	Water	
Assay	Assay	

Nov. 2014 (Rev. 1, Corr. 1)

Harmonized items	JP 17	Remarks
Stearic Acid	Stearic Acid	
Definition	limits of content	
Identification A	not specified as Identification	
Identification B	not specified as Identification	Being specified as Acid value
Identification C	not specified as Identification	
Acidity	Purity (1) Acidity	
Iodine value	Iodine value	
Freezing point	Congealing point	JP's particular description: Apparatus
Assay	Assay	JP's particular description: Split ratio, Time span of measurement, Test for required detectability.
Labelling (type of stearic acid)	origin	

June 2013 (Corr. 3)

Harmonized items	JP 17	Remarks
Magnesium Stearate	Magnesium Stearate	
Definition	limits of content	
Identification A	Identification	
Identification B		Not specified because of a part of "Relative content of stearic acid and palmitic acid".
Acidity or alkalinity	Purity (1) Acidity or alkalinity	
Loss on drying	Loss on drying	
Limit of chloride	Purity (2) Chloride	
Limit of sulfate	Purity (3) Sulfate	
Limit of cadmium	not specified	
Limit of lead	not specified	
Limit of nickel	not specified	
Relative content of stearic acid and palmitic acid	Relative content of stearic acid and palmitic acid	JP's particular description: Time span of measurement, Test for required detectability.
Assay	Assay	

June 2012 (Rev. 1, Corr.1)

Harmonized items	JP 17	Remarks
Cellacefate	Cellacefate	
Definition	Content of the acetyl and carboxybenzoyl groups	
Identification	Identification	
Identification B	Identification	
Viscosity	Viscosity	
Water	Water	

Residue on ignition	Residue on ignition	
Limit of free acid	Purity (2) Free acids	
Phthalyl content	Assay (1) Carboxybenzoyl group	
Content of acetyl	Assay (2) Acetyl group	

June 2014 (Corr. 2)

Harmonized items	JP 17	Remarks
Gelatin (Gelling Grade)	Gelatin	
Definition	origin	In JP, gelatin prepared by enzymatic degradation is not included in the origin.
Identification A	Identification (1)	
Identification B	Identification (2)	
pH	pH	
Conductivity	Conductivity	
Sulphur dioxide	Purity (7) Sulfur dioxide	
Peroxides	Purity (6) Peroxides	
Gel strength (Bloom value)	Gel strength (Bloom value)	
Iron	Purity (2) Iron	
Chromium	Purity (3) Chromium	
Zinc	Purity (4) Zinc	
Loss on drying	Loss on drying	
Microbial contamination	Microbial limit	
Storage	Containers and storage	
Labelling	origin	

May 2005 (Rev. 1)

Harmonized items	JP 17	Remarks
Microcrystalline Cellulose	Microcrystalline Cellulose	
Definition	origin	
Identification A	Identification (1)	
Identification B	Identification (3)	
pH	pH	
Water-soluble substances	Purity (2) Water- soluble substances	
Ether-soluble substances	Purity(3) Diethyl ether-soluble substances	
Conductivity	Conductivity	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	
Bulk density	Bulk density	

May 2005 (Rev. 1)

Harmonized items	JP 17	Remarks
Powdered Cellulose	Powdered Cellulose	
Definition	origin	
Labeling	Labeling of mean degree of polymerization	
Identification A	Identification (1)	

Identification B	Identification (3)	
pH	pH	
Water-soluble substances	Purity (2) Water-soluble substances	
Ether-soluble substances	Purity (3) Diethyl ether- soluble substances	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	

June 2008 (Rev. 1)

Harmonized items	JP 17	Remarks
Talc	Talc	
Definition	origin, content of magnesium	
Identification	Identification	
Acidity and alkalinity	Purity (1) Acidity or alkalinity	
Aluminium	Purity (5) Aluminum	
Calcium	Purity (7) Calcium	
Iron	Purity (4) Iron	
Lead	Purity (6) Lead	
Magnesium	Assay	
Loss on ignition	Loss on ignition	

June 2011 (Rev. 2)

Harmonized items	JP 17	Remarks
Wheat Starch	Wheat Starch	
Definition	origin	
Identification A	Identification (1)	
Identification B	Identification (2)	
Identification C	Identification (3)	
pH	pH	
Iron	Purity (1) Iron	
Total protein	Purity (5) Total protein	Non-harmonized item: Decomposition accelerator
Oxidising substances	Purity (2) Oxidizing substances	
Sulphur dioxide	Purity (3) Sulfur dioxide	
Loss on drying	Loss on drying	
Sulphated ash	Residue on ignition	
Microbial contamination	not specified	

Nov. 2013 (Rev. 1)

Harmonized items	JP 17	Remarks
Rice Starch	Rice Starch	
Definition	Origin	
Identification A	Identification (1)	
Identification B	Identification (2)	
Identification C	Identification (3)	
pH	pH	
Iron	Purity (1) Iron	
Oxidising substances	Purity (2) Oxidizing substances	

Sulphur dioxide	Purity (3) Sulfur dioxide	
Loss on drying	Loss on drying	
Sulphated ash	Residue on ignition	
Microbial contamination	not specified	

June 2012 (Rev. 3)

Harmonized items	JP 17	Remarks
Corn Starch	Corn Starch	
Definition	origin	
Identification A	Identification (1)	
Identification B	Identification (2)	
Identification C	Identification (3)	
pH	pH	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	
Limit of iron	Purity (1) Iron	
Limit of oxidizing substances	Purity (2) Oxidizing substances	
Limit of sulfur dioxide	Purity (3) Sulfur dioxide	
Microbial limits	not specified	

June 2011 (Rev. 2)

Harmonized items	JP 17	Remarks
Potato Starch	Potato Starch	
Definition	origin	
Identification A	Identification (1)	
Identification B	Identification (2)	
Identification C	Identification (3)	
pH	pH	
Iron	Purity (1) Iron	
Oxidising substances	Purity (2) Oxidizing substances	
Sulphur dioxide	Purity (3) Sulfur dioxide	
Loss on drying	Loss on drying	
Sulphated ash	Residue on ignition	
Microbial contamination	not specified	

June 2013 (Rev. 3)

Harmonized items	JP 17	Remarks
Sodium Starch Glycolate	Sodium Starch Glycolate	
Definition	origin, limit of sodium	
Identification A	Identification (1)	
Identification B	Identification (3)	
pH	pH	
Loss on drying	Loss on drying	
Limit of iron	Purity (2) Iron	
Limit of sodium chloride	Purity (4) Sodium chloride	
Limit of sodium glycolate	Purity (3) Sodium glycolate	

Assay	Assay
Microbial Contamination	Microbial limits

Nov. 2010 (Rev. 4)

Harmonized items	JP 17	Remarks
Anhydrous Lactose Definition Identification Clarity and color of solution Specific rotation Acidity or alkalinity Loss on drying Residue on ignition Water Protein and light-absorbing impurities Content of alpha and beta anomers Microbial contamination	Anhydrous Lactose origin Identification Purity (1) Clarity and color of solution Optical rotation Purity (2) Acidity or alkalinity Loss on drying Residue on ignition Water Purity (4) Protein and light absorbing substances Isomer ratio Microbial limit	No use of the reference suspension I JP's particular description: System repeatability. JP's particular description: TYMC, <i>Salmonella</i> .

June 2008 (Rev. 2)

Harmonized items	JP 17	Remarks
Lactose Monohydrate Definition Clarity and color of solution Identification Specific rotation Acidity or alkalinity Residue on ignition Water Protein and light-absorbing impurities	Lactose Hydrate origin Purity (1) Clarity and color of solution Identification Optical rotation Purity (2) Acid and alkali Residue on ignition Water Purity (4) Protein and light absorbing substances	

Oct. 2007

Harmonized items	JP 17	Remarks
Sucrose Definition Appearance of solution Conductivity Specific optical rotation Dextrins Reducing sugars Sulphite Loss on drying Bacterial endotoxins Labelling	Sucrose origin Purity (2) Clarity of solution Conductivity Optical rotation Dextrins Purity (4) Reducing sugars Purity (3) Sulfite Loss on drying Bacterial endotoxins origin	

Nov. 2011 (Rev. 1, Corr.1)

Harmonized items	JP 17	Remarks
Ethyl Parahydroxybenzoate	Ethyl Parahydroxybenzoate	
Definition	limits of content	
Identification A	Melting point	
Identification B	Identification	
Appearance of solution	Purity (1) Clarity and color of solution	
Acidity	Purity (2) Acidity	
Related substances	Purity (4) Related substances	JP's particular description: Test for required detectability, System repeatability.
Sulphated ash	Residue on ignition	
Assay	Assay	

June 2010 (Rev. 1)

Harmonized items	JP 17	Remarks
Butyl Parahydroxybenzoate	Butyl Parahydroxybenzoate	
Definition	limits of content	
Identification A	Melting point	
Identification B	Identification	
Appearance of solution	Purity (1) Clarity and color of solution	
Acidity	Purity (2) Acidity	
Related substances	Purity (4) Related substances	JP's particular description: Test for required detectability, System repeatability.
Sulphated ash	Residue on ignition	
Assay	Assay	

Nov. 2011 (Rev. 1, Corr.1)

Harmonized items	JP 17	Remarks
Propyl Parahydroxybenzoate	Propyl Parahydroxybenzoate	
Definition	limits of content	
Identification A	Melting point	
Identification B	Identification	
Appearance of solution	Purity (1) Clarity and color of solution	
Acidity	Purity (2) Acidity	
Related substances	Purity (4) Related substances	JP's particular description: Test for required detectability, System repeatability.
Sulphated ash	Residue on ignition	
Assay	Assay	

Nov. 2011 (Rev. 1, Corr.1)

Harmonized items	JP 17	Remarks
Methyl Parahydroxybenzoate	Methyl Parahydroxybenzoate	
Definition	limits of content	

Identification A	Melting point	
Identification B	Identification	
Appearance of solution	Purity (1) Clarity and color of solution	
Acidity	Purity (2) Acidity	
Related substances	Purity (4) Related substances	JP's particular description: Test for required detectability, System repeatability.
Sulphated ash	Residue on ignition	
Assay	Assay	

June 2013

Harmonized items	JP 17	Remarks
Hydroxypropylcellulose	Hydroxypropylcellulose	
Definition	origin, limits of hydroxypropoxy group	
Identification A	Identification (1)	
Identification B	Identification (2)	
pH	pH	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	
Silica	Purity (2) Silicon dioxide	
Assay for hydroxypropoxy groups	Assay	

June 2014 (Rev. 1, Corr. 1)

Harmonized items	JP 17	Remarks
Hypromellose	Hypromellose	
Definition	limits of content of methoxy group and hydroxypropoxy group	
Labeling	labeling of viscosity	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
Identification (3)	Identification (3)	
Identification (4)	Identification (4)	
Identification (5)	Identification (5)	
Viscosity	Viscosity	
Method 1	Method I	
Method 2	Method II	
pH	pH	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	
Assay	Assay	

June 2006

Harmonized items	JP 17	Remarks
Hypromellose Phthalate	Hypromellose Phthalate	
Definition	origin, limit of carboxybenzoyl	
Packaging and storage	Containers and storage	

Viscosity	Viscosity	
Water	Water	
Residue on ignition	Residue on ignition	
Chloride	Purity (1) Chloride	
Limit of free phthalic acid	Purity (3) Phthalic acid	JP's particular description: System performance.
Phthalyl content	Assay	

June 2011 (Rev. 2, Corr.1)

Harmonized items	JP 17	Remarks
Benzyl Alcohol	Benzyl Alcohol	
Definition	limits of content	
Refractive index	Refractive index	
Acidity	Purity (2) Acidity	
Benzaldehyde and other related substances	Purity (3) Benzaldehyde and other related substances	
Peroxide value	Purity (4) Peroxide value	
Residue on evaporation	Purity (5) Residue on evaporation	
Assay	Assay	

Nov. 2015 (Rev. 1, Corr. 1)

Harmonized items	JP 17	Remarks
Povidone	Povidone	
Definition	origin, limits of content	
Labelling	origin	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
pH	pH	
Purity (1) Aldehydes	Purity (3) Aldehydes	
Purity (2) 1-Vinyl-2-pyrrolidone	Purity (4) 1-Vinyl-2-pyrrolidone	
Purity (3) Peroxides	Purity (5) Peroxides	
Purity (4) Hydrazine	Purity (6) Hydrazine	
Purity (5) Formic acid	Purity (7) Formic acid	
Purity (6) 2-Pyrrolidone	Purity (8) 2-Pyrrolidone	
Water	Water	
Residue on ignition	Residue on ignition	
K-value	K-value	
Assay	Assay	

Nov. 2014 (Corr. 2)

Harmonized items	JP 17	Remarks
Polysorbate 80	Polysorbate 80	
Definition	origin	
Identification (Composition of fatty acids)	Identification	
Acid value	Acid value	JP's particular description: Applying Fats and Fatty Oils Test 1.13, using ethanol (95) as the solvent.

Hydroxyl value	Hydroxyl value
Peroxide value	Purity (3) Peroxide value
Saponification value	Saponification value
Composition of fatty acids	Composition of fatty acid
Ethylene oxide and dioxan	Purity (2) Ethylene oxide and 1,4-dioxane
Water	Water
Total ash	Residue on ignition
Storage	Containers and storage

June 2014 (Corr. 1)

Harmonized items	JP 17	Remarks
Mannitol	D-Mannitol	
Definition	limits of content	
Identification by IR	Identification	
Appearance of solution	Purity (1) Clarity and color of solution	
Conductivity	Conductivity	
Melting point	Melting point	
Reducing sugars	Purity (5) Glucose	
Related substances	Purity (4) Related substances	JP's particular description: Test for required detectability System repeatability
Nickel	Purity (3) Nickel	
Loss on drying	Loss on drying	
Microbial contamination	not specified	
Bacterial endotoxins	not specified	
Assay	Assay	JP's particular description: System repeatability
Labelling	not specified	

July 2015 (Rev. 2, Corr. 2)

Harmonized items	JP 17	Remarks
Methylcellulose	Methylcellulose	
Definition	limits of content of methoxy group	
Labeling	labeling of viscosity	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
Identification (3)	Identification (3)	
Identification (4)	Identification (4)	
Identification (5)	Identification (5)	
Viscosity	Viscosity	
Method 1	Method I	
Method 2	Method II	
pH	pH	
Loss on drying	Loss on drying	
Residue on ignition	Residue on ignition	
Assay	Assay	

June 2011 (Rev. 1)

Harmonized items	JP 17	Remarks
Anhydrous Dibasic Calcium Phosphate	Anhydrous Dibasic Calcium Phosphate	
Definition	limits of content	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
Acid-insoluble substances	Purity (1) Acid-insoluble substances	
Chloride	Purity (2) Chloride	
Sulfate	Purity (3) Sulfates	
Carbonate	Purity (4) Carbonate	
Barium	Purity (6) Barium	
Loss on ignition	Loss on ignition	
Assay	Assay	

June 2011 (Rev. 1)

Harmonized items	JP 17	Remarks
Dibasic Calcium Phosphate	Dibasic Calcium Phosphate Hydrate	
Definition	limits of content	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
Acid-insoluble substances	Purity (1) Acid-insoluble substances	
Chloride	Purity (2) Chloride	
Sulfate	Purity (3) Sulfates	
Carbonate	Purity (4) Carbonate	
Barium	Purity (6) Barium	
Loss on ignition	Loss on ignition	
Assay	Assay	

May 2007

Harmonized items	JP 17	Remarks
Powder Fineness	General Information Powder Fineness	

June 2004

Harmonized items	JP 17	Remarks
Powder Flow (Introduction) Angel of repose Basic methods for angel of repose Variations in angel of repose methods Angel of repose general scale of flowability Experimental considerations for an- gle of repose Recommended procedure for angle of repose	General Information Powder Flow (Introduction) 1. Angel of repose 1.1 Basic methods for angel of repose 1.2 Variations in angel of repose methods 1.3 Angel of repose general scale of flowability 1.4 Experimental considerations for angle of repose 1.5 Recommended procedure for an- gle of repose	

Compressibility index and Hausner ratio	2. Compressibility index and Hausner ratio
Basic methods for compressibility index and Hausner ratio	2.1 Basic methods for compressibility index and Hausner ratio
Experimental considerations for the compressibility index and Hausner ratio	2.2 Experimental considerations for the compressibility index and Hausner ratio
Recommended procedure for compressibility index and Hausner ratio	2.3 Recommended procedure for compressibility index and Hausner ratio
Flow through an orifice	3. Flow through an orifice
Basic methods for flow through an orifice	3.1 Basic methods for flow through an orifice
Variations in methods for flow through an orifice	3.2 Variations in methods for flow through an orifice
General scale of flowability for flow through an orifice	3.3 General scale of flowability for flow through an orifice
Experimental considerations for flow through an orifice	3.4 Experimental considerations for flow through an orifice
Recommended procedure for flow through an orifice	3.5 Recommended procedure for flow through an orifice
Shear cell methods	4. Shear cell methods
Basic methods for shear cell	4.1 Basic methods for shear cell
Recommendations for shear cell	4.2 Recommendations for shear cell
Table 1 Flow properties and corresponding angle of repose	Table 1 Flow properties and corresponding angle of repose
Table 2 Scale of flowability	Table 2 Scale of flowability

Nov. 2008

Harmonized items	JP 17	Remarks
Particle-size Analysis by Laser Light Diffraction <ul style="list-style-type: none"> Introduction Principle Instrument Development of the method <ul style="list-style-type: none"> Sampling Evaluation of the dispersion procedure Optimisation of the liquid dispersion Optimisation of the gas dispersion Determination of the concentration range Determination of the measuring time Selection of an appropriate optical model Validation Measurement Precautions 	General Information <p>Laser Diffraction Measurement of Particle Size</p> <ul style="list-style-type: none"> Introduction 1. Principle 2. Instrument 3. Development of the method <ul style="list-style-type: none"> 3.1. Sampling 3.2. Evaluation of the dispersion procedure 3.3. Optimization of the liquid dispersion 3.4. Optimization of the gas dispersion 3.5. Determination of the concentration range 3.6. Determination of the measuring time 3.7. Selection of an appropriate optical model 3.8. Validation 4. Measurement 4.1. Precautions 	

Measurement of the light scattering of dispersed sample(s)	4.2. Measurement of the light scattering of dispersed sample(s)	
Conversion of scattering pattern into particle-size distribution	4.3. Conversion of scattering pattern into particle-size distribution	
Replicates	4.4. Replicates	
Reporting of results	5. Reporting of results	
Control of the instrument performance	6. Control of the instrument performance	
Calibration	6.1. Calibration	
Qualification of the system	6.2. Qualification of the system	
Figure 1 Example of a set-up of laser light diffraction instrument	Fig. 1 Example of a set-up of laser light diffraction instrument	
<i>Note</i>	<i>Note 1</i>	
	<i>Note 2</i>	The first sentence of the harmonized text is described as Note 2.

Sep. 2002

Harmonized items	JP 17	Remarks
Amino Acid Analysis	General Information	
Apparatus	Amino Acid Analysis	
General precautions	Apparatus	
Reference standard material	General precautions	
Calibration of instrumentation	Reference standard material	
Repeatability	Calibration of instrumentation	
Sample preparation	Repeatability	
Internal standards	Sample preparation	
Protein hydrolysis	Internal standards	
Method 1	Protein hydrolysis	
Hydrolysis solution	Method 1	
Procedure	Hydrolysis solution	
Liquid phase hydrolysis	Procedure	
Vapor phase hydrolysis	Liquid phase hydrolysis	
Method 2	Vapor phase hydrolysis	
Hydrolysis solution	Method 2	
Vapor phase hydrolysis	Hydrolysis solution	
Method 3	Vapor phase hydrolysis	
Hydrolysis solution	Method 3	
Vapor phase hydrolysis	Hydrolysis solution	
Method 4	Vapor phase hydrolysis	
Oxidation solution	Method 4	
Procedure	Oxidation solution	
Method 5	Procedure	
Hydrolysis solution	Method 5	
Liquid phase hydrolysis	Hydrolysis solution	
Method 6	Liquid phase hydrolysis	
Hydrolysis solution	Method 6	
Vapor phase hydrolysis	Hydrolysis solution	
Method 7	Vapor phase hydrolysis	
	Method 7	

Reducing solution	Reducing solution
Procedure	Procedure
Method 8	Method 8
Stock solutions	Stock solutions
Reducing solution	Reducing solution
Procedure	Procedure
Method 9	Method 9
Stock solutions	Stock solutions
Carboxymethylation solution	Carboxymethylation solution
Buffer solution	Buffer solution
Procedure	Procedure
Method 10	Method 10
Reducing solution	Reducing solution
Procedure	Procedure
Method 11	Method 11
Reducing solutions	Reducing solutions
Procedure	Procedure
Methodologies of amino acid analysis general principles	Methodologies of amino acid analysis general principles
Method 1-Postcolumn ninhydrin detection general principle	Method 1-Postcolumn ninhydrin detection general principle
Method 2-Postcolumn OPA fluorometric detection general principle	Method 2-Postcolumn OPA fluorometric detection general principle
Method 3-Precolumn PITC derivatization general principle	Method 3-Precolumn PITC derivatization general principle
Method 4-Precolumn AQC derivatization general principle	Method 4-Precolumn AQC derivatization general principle
Method 5-Precolumn OPA derivatization general principle	Method 5-Precolumn OPA derivatization general principle
Method 6-Precolumn DABS-Cl derivatization general principle	Method 6-Precolumn DABS-Cl derivatization general principle
Method 7-Precolumn FMOCl derivatization general principle	Method 7-Precolumn FMOCl derivatization general principle
Method 8-Precolumn NBD-F derivatization general principle	Method 8-Precolumn NBD-F derivatization general principle
Data calculation and analysis	Data calculation and analysis
Calculations	Calculations
Amino acid mole percent	Amino acid mole percent
Unknown protein samples	Unknown protein samples
Known protein samples	Known protein samples

June 2014 (Rev. 1)

Harmonized items	JP 17	Remarks
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) Characteristics of polyacrylamide gels Denaturing polyacrylamide gel electrophoresis	General Information SDS-Polyacrylamide Gel Electrophoresis <ol style="list-style-type: none"> 1. Characteristics of polyacrylamide gels 2. Denaturing polyacrylamide gel electrophoresis 	

Reducing conditions	2.1. Reducing conditions
Non-reducing conditions	2.2. Non-reducing conditions
Characteristics of discontinuous buffer system gel electrophoresis	3. Characteristics of discontinuous buffer system gel electrophoresis
Preparing vertical discontinuous buffer SDS-polyacrylamide gels	4. Preparing vertical discontinuous buffer SDS polyacrylamide gels
Assembling of the gel moulding cassette	4.1. Assembling the gel moulding cassette
Preparation of the gel	4.2. Preparation of the gel
Preparation of the resolving gel	4.2.1. Preparation of the resolving gel
Preparation of the stacking gel	4.2.2. Preparation of the stacking gel
Preparation of the sample	4.3. Preparation of the sample
Mounting the gel in the electrophoresis apparatus and electrophoretic separation	4.4. Mounting the gel in the electrophoresis apparatus and electrophoretic separation
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) — Gradient concentration gels	4.5. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) — Gradient concentration gels
Detection of protein in gels	4.6. Detection of proteins in gels
Coomassie staining	4.6.1. Coomassie staining
Silver staining	4.6.2. Silver staining
Recording of the results	4.7. Recording of the results
Molecular-mass determination	4.8. Molecular-mass determination
Validation of the test	4.9. Validation of the test
Quantification of impurities	4.10. Quantification of impurities
Reagents	5. Reagents
30 per cent acrylamide/bisacrylamide (29:1) solution	(i) 30% acrylamide/bisacrylamide (29:1) solution
1.5 M tris-hydrochloride buffer solution pH 8.8	(x) 1.5 M tris-hydrochloride buffer solution (pH 8.8)
SDS-PAGE sample buffer (concentrated)	(iii) SDS-PAGE sample buffer (concentrated)
SDS-PAGE sample buffer for reducing conditions (concentrated)	(iv) SDS-PAGE sample buffer for reducing conditions (concentrated)
SDS-PAGE running buffer	(ii) SDS-PAGE running buffer
Coomassie staining solution	(v) Coomassie staining solution
Destaining solution	(ix) Destaining solution
Fixing solution	(vii) Fixing solution
Silver nitrate reagent	(viii) Silver nitrate reagent
Developer solution	(vi) Developer solution
Blocking solution	(xi) Blocking solution
Table 1 Preparation of resolving gel	Table 1 Preparation of resolving gel
Table 2 Preparation of stacking gel	Table 2 Preparation of stacking gel

June 2010 (Corr. 2)

Harmonized items	JP 17	Remarks
Capillary Electrophoresis	General Information	
General principles	Capillary Electrophoresis (General principles)	
Apparatus	Apparatus	

Capillary zone electrophoresis	1. Capillary Zone Electrophoresis
Optimisation	Optimization
Instrumental parameters	Instrumental parameters
Voltage	(1) Voltage
Polarity	(2) Polarity
Temperature	(3) Temperature
Capillary	(4) Capillary
Electrolytic solution parameters	Electrolytic solution parameters
Buffer type and concentration	(1) Buffer type and concentration
Buffer pH	(2) Buffer pH
Organic solvents	(3) Organic solvents
Additives for chiral separations	(4) Additives for chiral separations
Capillary gel electrophoresis	2. Capillary Gel Electrophoresis
Characteristics of gels	Characteristics of Gels
Capillary isoelectric focusing	3. Capillary Isoelectric Focusing
Loading step	(1) Loading step
loading in one step	(i) loading in one step
sequential loading	(ii) sequential loading
Focusing step	(2) Focusing step
Mobilisation step	(3) Mobilization step
Optimisation	Optimization
Voltage	(1) Voltage
Capillary	(2) Capillary
Solutions	(3) Solutions
Micellar electrokinetic chromatography (MEKC)	4. Micellar Electrokinetic Chromatography (MEKC)
Optimisation	Optimization
Instrumental parameters	Instrumental parameters
Voltage	(1) Voltage
Temperature	(2) Temperature
Capillary	(3) Capillary
Electrolytic solution parameters	Electrolytic solution parameters
Surfactant type and concentration	(1) Surfactant type and concentration
Buffer pH	(2) Buffer pH
Organic solvents	(3) Organic solvents
Additives for chiral separations	(4) Additives for chiral separations
Other additives	(5) Other additives
Quantification	Quantification
Calculations	Calculations
System Suitability	System Suitability
Apparent number of theoretical plates	Apparent Number of Theoretical Plates
Resolution	Resolution
Symmetry factor	Symmetry Factor
Signal-to-noise ratio	Signal-to-noise Ratio

Sep. 2002

Harmonized items	JP 17	Remarks
Total Protein Assay	General Information	
Method 1	Total Protein Assay	
Standard solution	Method 1 (UV method)	
Test solution	Standard Solution	
Procedure	Test Solution	
Light-scattering	Procedure	
Calculations	Light-Scattering	
Method 2	Calculations	
Standard solutions	Method 2 (Lowry method)	JP's particular description: Explanatory footnote "Example: the Minimum Requirements for Biological Products and individual monograph of JP" is added.
Test solution	Standard Solutions	
Blank	Test Solution	
Reagents and solutions	Blank	
Copper sulfate reagent	Reagents and Solutions	
SDS Solution	Copper Sulfate Reagent	
Sodium hydroxide solution	5% SDS TS	
Alkaline copper reagent	Sodium Hydroxide Solution	
Diluted folin-ciocalteu's phenol reagent	Alkaline Copper Reagent	
Procedure	Diluted Folin's TS	
Calculations	Procedure	
Interfering substances	Calculations	
Sodium deoxycholate reagent	Interfering Substances	
Trichloroacetic acid reagent	Sodium Deoxycholate Reagent	
Procedure	Trichloroacetic Acid Reagent	
Method 3	Procedure	
Standard solutions	Method 3 (Bradford method)	
Test solution	Standard Solutions	
Blank	Test Solution	
Coomassie reagent	Blank	
Procedure	Coomassie Reagent	
Calculations	Procedure	
Method 4	Calculations	
Standard solutions	Method 4 (Bicinchoninic acid method)	
Test solution	Standard Solutions	
Blank	Test Solution	
Reagents	Blank	
BCA Reagent	Reagents and Solutions	
Copper sulfate reagent	BCA Reagent	
Copper-BCA reagent	Copper Sulfate Reagent	
Procedure	Copper-BCA Reagent	
Calculations	Procedure	
Method 5	Calculations	
Standard solutions	Method 5 (Biuret method)	
Test solution	Standard Solutions	
Blank	Test Solution	
	Blank	

Biuret reagent	Biuret Reagent
Procedure	Procedure
Calculations	Calculations
Interfering substances	Interfering Substances
Comments	Comments
Method 6	Method 6 (Fluorometric method)
Standard solutions	Standard Solutions
Test solution	Test Solution
Blank	Blank
Reagents	Reagents and Solutions
Borate buffer	Borate Buffer
Stock OPA reagent	Stock OPA Reagent
OPA reagent	OPA Reagent
Procedure	Procedure
Calculations	Calculations
Method 7	Method 7 (Nitrogen method)
Procedure A	Procedure A
Procedure B	Procedure B
Calculations	Calculations

Sep. 2002

Harmonized items	JP 17	Remarks
Isoelectric Focusing General principles Theoretical aspects Practical aspects Apparatus Isoelectric focusing in polyacrylamide gels: detailed procedure Preparation of the gels 1) Mould 2) 7.5 per cent polyacrylamide gel 3) Preparation of the mould Method Variations to the detailed procedure (subject to validation) Validation of iso-electric focusing procedures Specified variation to the general method Point to consider Reagents Fixing solution for isoelectric focusing in polyacrylamide gel	General Information Isoelectric Focusing (General principles) Theoretical Aspects Practical Aspects Apparatus Isoelectric Focusing in Polyacrylamide Gels: Detailed Procedure Preparation of the Gels Mould 7.5% Polyacrylamide gel Preparation of the mould Method Variations to the Detailed Procedure (Subject to Validation) Validation of Iso-Electric Focusing Procedures Specified Variations to the General Method Points to Consider Reagents and Solutions Fixing solution for isoelectric focusing in polyacrylamide gel Coomassie staining TS Destaining solution	JP's particular description JP's particular description

Sep. 2002

Harmonized items	JP 17	Remarks
Peptide Mapping Purpose and scope The peptide map Isolation and purification Selective cleavage of peptide bonds Pretreatment of sample Pretreatment of the cleavage agent Pretreatment of the protein Establishment of optimal digestion conditions pH Temperature Time Amount of cleavage agent Chromatographic separation Chromatographic column solvent Mobile phase Gradient selection Isocratic selection Other parameters Validation Analysis and identification of peptides Table 1 Examples of cleavage agents Table 2 Techniques used for the separation of peptides	General Information Peptide Mapping Purpose and scope 1. The peptide map 2. Isolation and purification 3. Selective cleavage of peptide bonds 3.1. Pretreatment of sample 3.2. Pretreatment of the cleavage agent 3.3. Pretreatment of the protein 3.4. Establishment of optimal digestion conditions (i) pH (ii) Temperature (iii) Time (iv) Amount of cleavage agent 4. Chromatographic separation 4.1. Chromatographic column 4.2. Solvent 4.3. Mobile phase 4.4. Gradient selection 4.5. Isocratic selection 4.6. Other parameters 4.7. Validation 5. Analysis and identification of peptides Table 1 Examples of cleavage agents Table 2 Techniques used for the separation of peptides	

Nov. 2005

Harmonized items	JP 17	Remarks
Microbiological Examination of Non-Sterile Products: Acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use	General Information Microbial Attributes of Non-Sterile Pharmaceutical Products 5. Microbial acceptance criteria for non-sterile pharmaceutical products	JP's particular description: 1. Definitions 2. Scope 3. Sampling plan and frequency of testing 4. Microbial control program JP's particular description: Explanation of the microbial acceptance criteria JP's particular description: 6. Acceptance criteria for crude drugs and crude drug preparations

Table 2. Acceptance criteria for microbiological quality of non-sterile substances for pharmaceutical use

Table 1. Acceptance criteria for microbiological quality of non-sterile dosage forms

Table 1. Acceptance criteria for microbiological quality of non-sterile substances for pharmaceutical use

Table 2. Acceptance criteria for microbiological quality of non-sterile dosage forms

Table 3. Acceptance criteria for crude drugs and crude drug preparations

JP's particular description

Feb. 2004

Harmonized items	JP 17	Remarks
Tablet Friability	General Information Tablet Friability Test	

Appendix

Atomic Weight Table (2010)

In 1961 it was decided that the atomic weights of the elements would be based on values relative to the mass number of 12 (no fractions) for carbon (^{12}C). Ever since, there has been a marked improvement in the quality and quantity of data on the nuclide masses and isotope ratios of the elements using physical methods such as mass spectrometry. The Commission on Isotope Abundances and Atomic Weights (CIAAW) of the International Union of Pure and Applied Chemistry (IUPAC) collected and examined newly measured data and publishes a new atomic weight table every two years (in the odd years). Based on this table, in April of each year the Atomic Weight Subcommittee of the Chemical Society of Japan also publishes an atomic weight table. The numbers of the following Atomic Weight Table (2010) is based on the numbers published by the IUPAC in 2007¹⁾. For a more detailed explanation, the user is referred to a report²⁾ and a review³⁾ published by the CIAAW.

The atomic weight values of each of the elements shown in the atomic weight tables are, as stated in the preface to the table, for elements that originate on Earth and are present in substances that exist naturally. Atomic weights are, with the exception of single nuclide elements (elements consisting of one stable nuclide), not natural constants like the speed of light, but rather change depending on a variety of factors, such as the method of treatment or the origin of the substance containing that element. This is because the atomic weight is dependent on the relative frequency (isotope ratio) of the stable nuclides comprising each of the respective elements. Due to advancements in measurement techniques, the isotopic frequencies of each of the elements are not necessarily constant, and fluctuate due to a variety of processes that occur on the Earth. We have come to learn that this is reflected in the atomic weights. The result of this is that differences have arisen in the accuracy of the atomic weights between elements. The figures in parentheses that follow the atomic weight values in the atomic weight tables represent the uncertainty with respect to the last digit in the atomic weight. For example, in the case of hydrogen, 1.00794(7) means 1.00794 ± 0.00007 .

The atomic weight of a single nuclide element is the most accurate and the precision is also high. This is because it is not necessary to consider the isotope ratio since single nuclide elements do not possess a multiple number of stable isotopes. The atomic weights of such elements are determined based on the mass⁴⁾ of each nuclide determined by physical techniques, taking into consideration the uncertainty with constant criteria.

Among the elements, the majority of samples gathered on Earth exhibit a constant isotope composition, however, some specific samples have isotope compositions that are different to these. These kinds of elements are indicated by a “g”, which means the value in the atomic weight table cannot be used as is, depending on the sample, as the atomic weight of these elements. In relation to this, oxygen for example exists in a number of forms on Earth, such as in air, salt water, fresh water, and in rocks, and because the isotope compositions fluctuate among these substances, oxygen is not an element for which only one value can be used. Thus, an “r” is attached to an element for which a precise atomic weight cannot be given, no matter how much progress is made in techniques for measuring the isotope composition. On the other hand, it is also possible, depending on the element, to use an isotope that has undergone artificial fractionation as a reagent. Typical elements that are representative include hydrogen, lithium, boron, and uranium. This type of element is identified by an “m”, and particularly in cases where the atomic weight is a problem, it is necessary to be careful by referring to the label of the reagent.

- 1) IUPAC Inorganic Chemistry Division, CIAAW: Standard Atomic Weights Revised. *Chem. Int.*, **29**, 18 (2007).
- 2) IUPAC Inorganic Chemistry Division, CIAAW: Atomic Weights of the Elements 2007. *Pure Appl. Chem.*, **81**, 2131 (2009).
- 3) J. R. De Laeter *et al.*: Atomic Weights of the Elements: Review 2000. *Pure Appl. Chem.*, **75**, 683 (2003).
- 4) G. Audi *et al.*: The A_{ME} 2003 Atomic Mass Evaluation (II). Tables, graphs and references. *Nucl. Phys. A*, **729**, 337 (2003).

Standard Atomic Weights 2010

(Scaled to $A_r(^{12}\text{C}) = 12$, where ^{12}C is a neutral atom in its nuclear and electronic ground state)

The atomic weights of many elements are not invariant but depend on the origin and treatment of the material. The standard values of $A_r(E)$ and the uncertainties (in parentheses, following the last significant figure to which they are attributed) apply to elements of natural terrestrial origin. The footnotes to this table elaborate the types of variation which may occur for individual elements and which may be larger than the listed uncertainties of values of $A_r(E)$. Names of elements with atomic number 112 to 118 are provisional.

Name	Symbol	Atomic Number	Atomic Weight	Footnotes
Hydrogen	H	1	1.00794 (7)	g m r
Helium	He	2	4.002602 (2)	g r
Lithium	Li	3	[6.941 (2)] ^f	g m r
Beryllium	Be	4	9.012182 (3)	
Boron	B	5	10.811 (7)	g m r
Carbon	C	6	12.0107 (8)	g r
Nitrogen	N	7	14.0067 (2)	g r
Oxygen	O	8	15.9994 (3)	g r
Fluorine	F	9	18.9984032 (5)	
Neon	Ne	10	20.1797 (6)	g m
Sodium	Na	11	22.98976928 (2)	
Magnesium	Mg	12	24.3050 (6)	
Aluminium	Al	13	26.9815386 (8)	
Silicon	Si	14	28.0855 (3)	r
Phosphorus	P	15	30.973762 (2)	
Sulfur	S	16	32.065 (5)	g r
Chlorine	Cl	17	35.453 (2)	g m r
Argon	Ar	18	39.948 (1)	g r
Potassium	K	19	39.0983 (1)	
Calcium	Ca	20	40.078 (4)	g
Scandium	Sc	21	44.955912 (6)	
Titanium	Ti	22	47.867 (1)	
Vanadium	V	23	50.9415 (1)	
Chromium	Cr	24	51.9961 (6)	
Manganese	Mn	25	54.938045 (5)	
Iron	Fe	26	55.845 (2)	
Cobalt	Co	27	58.933195 (5)	
Nickel	Ni	28	58.6934 (4)	r
Copper	Cu	29	63.546 (3)	r
Zinc	Zn	30	65.38 (2)	r
Gallium	Ga	31	69.723 (1)	
Germanium	Ge	32	72.64 (1)	
Arsenic	As	33	74.92160 (2)	
Selenium	Se	34	78.96 (3)	r
Bromine	Br	35	79.904 (1)	
Krypton	Kr	36	83.798 (2)	g m
Rubidium	Rb	37	85.4678 (3)	g
Strontium	Sr	38	87.62 (1)	g r
Yttrium	Y	39	88.90585 (2)	
Zirconium	Zr	40	91.224 (2)	g
Niobium	Nb	41	92.90638 (2)	
Molybdenum	Mo	42	95.96 (2)	g r
Technetium*	Tc	43		
Ruthenium	Ru	44	101.07 (2)	g
Rhodium	Rh	45	102.90550 (2)	

Name	Symbol	Atomic Number	Atomic Weight	Footnotes
Palladium	Pd	46	106.42 (1)	g
Silver	Ag	47	107.8682 (2)	g
Cadmium	Cd	48	112.411 (8)	g
Indium	In	49	114.818 (3)	
Tin	Sn	50	118.710 (7)	g
Antimony	Sb	51	121.760 (1)	g
Tellurium	Te	52	127.60 (3)	g
Iodine	I	53	126.90447 (3)	
Xenon	Xe	54	131.293 (6)	g m
Caesium (Cesium)	Cs	55	132.9054519 (2)	
Barium	Ba	56	137.327 (7)	
Lanthanum	La	57	138.90547 (7)	g
Cerium	Ce	58	140.116 (1)	g
Praseodymium	Pr	59	140.90765 (2)	
Neodymium	Nd	60	144.242 (3)	g
Promethium*	Pm	61		
Samarium	Sm	62	150.36 (2)	g
Europium	Eu	63	151.964 (1)	g
Gadolinium	Gd	64	157.25 (3)	g
Terbium	Tb	65	158.92535 (2)	
Dysprosium	Dy	66	162.500 (1)	g
Holmium	Ho	67	164.93032 (2)	
Erbium	Er	68	167.259 (3)	g
Thulium	Tm	69	168.93421 (2)	
Ytterbium	Yb	70	173.054 (5)	g
Lutetium	Lu	71	174.9668 (1)	g
Hafnium	Hf	72	178.49 (2)	
Tantalum	Ta	73	180.94788 (2)	
Tungsten	W	74	183.84 (1)	
Rhenium	Re	75	186.207 (1)	
Osmium	Os	76	190.23 (3)	g
Iridium	Ir	77	192.217 (3)	
Platinum	Pt	78	195.084 (9)	
Gold	Au	79	196.966569 (4)	
Mercury	Hg	80	200.59 (2)	
Thallium	Tl	81	204.3833 (2)	
Lead	Pb	82	207.2 (1)	g r
Bismuth*	Bi	83	208.98040 (1)	
Polonium*	Po	84		
Astatine*	At	85		
Radon*	Rn	86		
Francium*	Fr	87		
Radium*	Ra	88		
Actinium*	Ac	89		
Thorium*	Th	90	232.03806 (2)	g
Protactinium*	Pa	91	231.03588 (2)	
Uranium*	U	92	238.02891 (3)	g m
Neptunium*	Np	93		
Plutonium*	Pu	94		
Americium*	Am	95		
Curium*	Cm	96		
Berkelium*	Bk	97		
Californium*	Cf	98		
Einsteinium*	Es	99		
Fermium*	Fm	100		
Mendelevium*	Md	101		
Nobelium*	No	102		
Lawrencium*	Lr	103		
Rutherfordium*	Rf	104		
Dubnium*	Db	105		
Seaborgium*	Sg	106		
Bohrium*	Bh	107		
Hassium*	Hs	108		
Meitnerium*	Mt	109		
Darmstadtium*	Ds	110		
Roentgenium	Rg	111		
Copernicium*	Cn	112		

Name	Symbol	Atomic Number	Atomic Weight	Footnotes
Ununtrium*	Uut	113		
Ununquadium*	Uuq	114		
Ununpentium*	Uup	115		
Ununhexium*	Uuh	116		
Ununoctium*	Uuo	118		

* : Element has no stable isotopes.

† : Commercially available Li materials have atomic weights that range between 6.939 and 6.996 ; if a more accurate value is required, it must be determined for the specific material.

g : Geological specimens are known in which the element has an isotopic composition outside the limits for normal material. The difference between the atomic weight of the element in such specimens and that given in the table may exceed the stated uncertainty.

m : Modified isotopic compositions may be found in commercially available material because it has been subjected to an undisclosed or inadvertent isotopic fractionation. Substantial deviations in atomic weight of the element from that given in the table can occur.

r : Range in isotopic composition of normal terrestrial material prevents a more precise $A_r(E)$ being given ; the tabulated $A_r(E)$ value should be applicable to any normal material.

©2010 Atomic Weights Subcommittee of the Chemical Society of Japan

INDEX

A

Absorptive Cream, 755
Acacia, 1791
 Powdered, 1791
Acetobutol Hydrochloride, 359
Aceglutamide Aluminum, 359
Acemetacin, 361
 Capsules, 361
 Tablets, 362
Acetaminophen, 363
Acetazolamide, 364
Acetic Acid, 365
 Glacial, 365
Acetohexamide, 366
Acetylcholine Chloride for Injection, 367
Acetylcysteine, 368
Acetylsalicylic Acid, 449
 Tablets, 450
Achyranthes Root, 1792
Aciclovir, 369
 for Injection, 371
 for Syrup, 373
 Granules, 370
 Injection, 371
 Ointment, 372
 Ophthalmic Ointment, 372
 Syrup, 372
 Tablets, 374
Aclarubicin Hydrochloride, 375
Acrinol
 and Zinc Oxide Oil, 377
 and Zinc Oxide Oil, Compound, 377
 and Zinc Oxide Ointment, 378
 Hydrate, 376
Actinomycin D, 378
Adrenaline, 379
 Injection, 379
 Solution, 380
Adsorbed
 Diphtheria-Purified Pertussis-Tetanus Combined Vaccine, 816
 Diphtheria-Tetanus Combined Toxoid, 816
 Diphtheria Toxoid for Adult Use, 816
 Habu-venom Toxoid, 1004
 Hepatitis B Vaccine, 1018
 Purified Pertussis Vaccine, 1384
 Tetanus Toxoid, 1670
Afloqualone, 380
Agar, 1792
 Powdered, 1793
Ajmaline, 381
 Tablets, 382
Akebia Stem, 1793
Alacepril, 382

Tablets, 383
L-Alanine, 384
Albumin Tannate, 386
Alcohol, 895
 Dehydrated, 896
 for Disinfection, 897
Aldioxa, 386
 Granules, 387
 Tablets, 387
Alendronate
 Sodium Hydrate, 388
 Sodium Injection, 389
 Sodium Tablets, 390
Alimemazine Tartrate, 391
Alisma Tuber, 1793
 Powdered, 1794
Allopurinol, 392
 Tablets, 392
Alminoprofen, 393
 Tablets, 394
Aloe, 1794
 Powdered, 1795
Alpinia Officinarum Rhizome, 1796
Alprazolam, 395
Alprenolol Hydrochloride, 396
Alprostadiol, 396
 Alfadex, 400
 Injection, 398
Alum, 403
 Solution, 401
 Powder, Salicylated, 1542
Aluminum
 Acetylsalicylate, 450
 Monostearate, 402
 Potassium Sulfate Hydrate, 403
 Silicate Hydrate with Silicon Dioxide, 1796
 Silicate, Natural, 404
 Silicate, Synthetic, 405
 Sucrose Sulfate Ester, 1609
Amantadine Hydrochloride, 405
Ambenonium Chloride, 406
Amidotrizoic Acid, 407
Amikacin Sulfate, 408
 for Injection, 409
 Injection, 409
Aminoacetic Acid, 995
Aminobenzylpenicillin, 430
 Anhydrous, 429
 Sodium, 431
Aminophylline
 Hydrate, 410
 Injection, 410
Amiodarone Hydrochloride, 411
 Tablets, 412
Amitriptyline Hydrochloride, 414
 Tablets, 414
Amlexanox, 415
 Tablets, 416
Amlodipine Besilate, 417
Orally Disintegrating Tablets, 418
Tablets, 420
Ammonia Water, 420
Amobarbital, 421
Amomum Seed, 1797
 Powdered, 1797
Amosulalol Hydrochloride, 421
 Tablets, 422
Amoxapine, 424
Amoxicillin
 Capsules, 425
 Hydrate, 424
Amphotericin B, 426
 for Injection, 427
 Syrup, 428
 Tablets, 428
Ampicillin
 Anhydrous, 429
 Ethoxycarbonyloxyethyl Hydrochloride, 468
 Hydrate, 430
 Sodium, 431
 Sodium and Sulbactam Sodium for Injection, 433
 Sodium for Injection, 432
Ampicillinphthalidyl Hydrochloride, 1633
Ampiroxicam, 434
 Capsules, 435
Amyl Nitrite, 436
Anemarrhena Rhizome, 1797
Anesthamine, 901
Anesthetic Ether, 898
Angelica Dahurica Root, 1798
Anhydrous
 Aminobenzylpenicillin, 429
 Ampicillin, 429
 Caffeine, 543
 Citric Acid, 716
 Dibasic Calcium Phosphate, 557
 Ethanol, 896
 Lactose, 1132
 Light, Silicic Acid, 1552
 Sodium Sulfate, 1994
Antipyrine, 437
Apricot Kernel, 1798
 Water, 1799
Aprindine Hydrochloride, 437
 Capsules, 438
Aralia Rhizome, 1800
Arbekacin Sulfate, 439
 Injection, 440
Areca, 1800
Argatroban Hydrate, 441
L-Arginine, 442
 Hydrochloride, 443
 Hydrochloride Injection, 443
Aromatic Castor Oil, 1826
Arotinolol Hydrochloride, 444
Arsenic Trioxide, 445

Arsenical Paste, 445
 Arsenous Acid, 445
 Artemesia
 Capillaris Flower, 1800
 Leaf, 1801
 Ascorbic Acid, 445
 and Calcium Pantothenate Tablets, 447
 Injection, 446
 Powder, 446
 Asiasarum Root, 1801
 Asparagus Root, 1802
 L-Aspartic Acid, 449
 Aspirin, 449
 Aluminum, 450
 Tablets, 450
 Aspoxicillin Hydrate, 451
 Astragalus Root, 1803
 Atenolol, 452
 Atorvastatin Calcium
 Hydrate, 453
 Tablets, 454
 Atractylodes
 Lancea Rhizome, 1803
 Lancea Rhizome, Powdered, 1804
 Rhizome, 1804
 Rhizome, Powdered, 1805
 Atropine Sulfate
 Hydrate, 456
 Injection, 456
 Auranofin, 457
 Tablets, 458
 Azathioprine, 459
 Tablets, 460
 Azelastine Hydrochloride, 461
 Granules, 462
 Azelnidipine, 463
 Tablets, 464
 Azithromycin Hydrate, 465
 Aztreonam, 466
 for Injection, 467

B

Bacampicillin Hydrochloride, 468
 Bacitracin, 469
 Baclofen, 470
 Tablets, 470
 Bakumondoto Extract, 1805
 Bamethan Sulfate, 471
 Barbital, 472
 Barium Sulfate, 473
 Bear Bile, 1807
 Bearberry Leaf, 1807
 Beclometasone Dipropionate, 473
 Beef Tallow, 1808
 Beeswax
 White, 1808
 Yellow, 1809
 Bekanamycin Sulfate, 474
 Belladonna
 Extract, 1810
 Root, 1809
 Total Alkaloids, 1810
 Benidipine Hydrochloride, 475
 Tablets, 476
 Benincasa Seed, 1811

Benoxinate Hydrochloride, 1345
 Benserazide Hydrochloride, 478
 Bentonite, 478
 Benzalkonium Chloride, 479
 Solution, 480
 Solution 50, Concentrated, 480
 Benz bromarone, 481
 Benzethonium Chloride, 481
 Solution, 482
 Benzocaine, 901
 Benzoic Acid, 482
 Benzoin, 1812
 Benzyl
 Alcohol, 483
 Benzoate, 484
 Benzylpenicillin
 Benzathine Hydrate, 485
 Potassium, 486
 Potassium for Injection, 487
 Bepotastine Besilate, 488
 Tablets, 489
 Beraprost Sodium, 490
 Tablets, 492
 Berberine
 Chloride Hydrate, 493
 Tannate, 494
 Betahistine Mesilate, 495
 Tablets, 496
 Betamethasone, 497
 Dipropionate, 499
 Sodium Phosphate, 500
 Tablets, 498
 Valerate, 502
 Valerate and Gentamicin Sulfate
 Cream, 502
 Valerate and Gentamicin Sulfate
 Ointment, 504
 Betamipron, 505
 Betaxolol Hydrochloride, 506
 Bethanechol Chloride, 507
 Bezafibrate, 507
 Extended-release Tablets, 508
 Bifonazole, 509
 Biotin, 510
 Biperiden Hydrochloride, 510
 Bisacodyl, 511
 Suppositories, 512
 Bismuth
 Subgallate, 512
 Subnitrate, 513
 Bisoprolol Fumarate, 514
 Tablets, 515
 Bitter
 Cardamon, 1812
 Orange Peel, 1812
 Tincture, 1813
 Bleomycin
 Hydrochloride, 516
 Sulfate, 518
 Bofutsushosan Extract, 1813
 Boiogito Extract, 1817
 Boric Acid, 520
 Bromazepam, 520
 Bromhexine Hydrochloride, 521
 Bromocriptine Mesilate, 522
 Bromovalerylurea, 523
 Brotizolam, 523
 Tablets, 524
 Brown Rice, 1820
 Bucillamine, 525
 Tablets, 526
 Bucumolol Hydrochloride, 527
 Bufetolol Hydrochloride, 528
 Buformin Hydrochloride, 529
 Delayed-release Tablets, 529
 Tablets, 531
 Bumetanide, 531
 Bunazosin Hydrochloride, 532
 Bupivacaine Hydrochloride Hydrate, 533
 Bupleurum Root, 1820
 Bupranolol Hydrochloride, 534
 Buprenorphine Hydrochloride, 535
 Burdock Fruit, 1821
 Burnt Alum, 403
 Busulfan, 536
 Butenafine Hydrochloride, 536
 Cream, 537
 Solution, 538
 Spray, 538
 Butropium Bromide, 539
 Butyl Parahydroxybenzoate, 540

C

Cacao Butter, 1821
 Cadralazine, 541
 Tablets, 542
 Caffeine
 and Sodium Benzoate, 544
 Anhydrous, 543
 Hydrate, 543
 Calciferol, 882
 Calcitonin Salmon, 545
 Calcium
 Chloride Hydrate, 550
 Chloride Injection, 551
 Folinate, 551
 Gluconate Hydrate, 552
 Hydroxide, 553
 Lactate Hydrate, 553
 Leucovorin, 551
 Oxide, 554
 Pantothenate, 554
 Paraaminosalicylate Granules, 556
 Paraaminosalicylate Hydrate, 555
 Polystyrene Sulfonate, 559
 Sodium Eddetate Hydrate, 561
 Stearate, 562
 Calumba, 1821
 Powdered, 1822
 Camellia Oil, 1822
 Camostat Mesilate, 562
 d-Camphor, 563
 dl-Camphor, 564
 Candesartan Cilexetil, 565
 and Amlodipine Besylate Tablets, 567
 and Hydrochlorothiazide Tablets, 570
 Tablets, 566
 Capsicum, 1822
 and Salicylic Acid Spirit, 1824
 Powdered, 1823

- Tincture, 1824
- Capsules, 574
- Capsules**
- Acemetacin, 361
 - Amoxicillin, 425
 - Ampiroxicam, 435
 - Aprindine Hydrochloride, 438
 - Cefaclor, 593
 - Cefadroxil, 598
 - Cefalexin, 601
 - Cefdinir, 617
 - Cefixime, 624
 - Cinoxacin, 710
 - Clindamycin Hydrochloride, 722
 - Clofibrate, 729
 - Clorazepate Dipotassium, 740
 - Diltiazem Hydrochloride Extended-release, 807
 - Doxifluridine, 835
 - Droxidopa, 842
 - Emedastine Fumarate Extended-release, 858
 - Ethyl Icosapentate, 904
 - Flopropione, 939
 - Fluconazole, 941
 - Hypromellose, 574
 - Indometacin, 1063
 - Lansoprazole Delayed-release, 1140
 - Methotrexate, 1225
 - Nifedipine Extended-release, 1310
 - Nizatidine, 1320
 - Pilsicainide Hydrochloride, 1402
 - Pullulan, 574
 - Ribavirin, 1512
 - Rifampicin, 1519
 - Roxatidine Acetate Hydrochloride Extended-release, 1531
 - Sodium Iodide (¹²³I), 1579
 - Sodium Iodide (¹³¹I), 1580
 - Sulpiride, 1621
 - Tacrolimus, 1633
 - Teprenone, 1661
 - Tranexamic Acid, 1709
 - Tranilast, 1712
 - Trientine Hydrochloride, 1727
 - Ubenimex, 1742
 - Captopril, 575
 - Carbamazepine, 575
 - Carbazochrome Sodium Sulfonate Hydrate, 576
 - Carbetapentane Citrate, 1378
 - Carbetapentene Citrate, 1378
 - Carbidopa Hydrate, 577
 - L-Carbocisteine, 578
 - Tablets, 579
 - Carbolic Acid, 1390
 - Carbon Dioxide, 580
 - Carboplatin, 580
 - Injection, 582
 - Carboxymethylcellulose, 583
 - Calcium, 583
 - Sodium, 584
 - Cardamon, 1825
 - Carmellose, 583
 - Calcium, 583
 - Sodium, 584
 - Carmofur, 586
 - Carnauba Wax, 1825
 - Carteolol Hydrochloride, 587
 - Carumonam Sodium, 587
 - Carvedilol, 589
 - Tablets, 590
 - Cassia Seed, 1825
 - Castor Oil, 1826
 - Aromatic, 1826
 - Catalpa Fruit, 1826
 - Cefaclor, 592
 - Capsules, 593
 - Combination Granules, 594
 - Fine Granules, 596
 - Cefadroxil, 597
 - Capsules, 598
 - for Syrup, 599
 - Cefalexin, 599
 - Capsules, 601
 - Combination Granules, 602
 - for Syrup, 603
 - Cefalotin Sodium, 604
 - Cefatrizine Propylene Glycolate, 605
 - for Syrup, 606
 - Cefazolin Sodium, 607
 - for Injection, 608
 - Hydrate, 609
 - Cefbuperazone Sodium, 610
 - Cefcapene Pivoxil Hydrochloride
 - Fine Granules, 613
 - Hydrate, 612
 - Tablets, 614
 - Cefdinir, 615
 - Capsules, 617
 - Fine Granules, 617
 - Cefditoren Pivoxil, 618
 - Fine Granules, 619
 - Tablets, 620
 - Cefepime Dihydrochloride
 - for Injection, 622
 - Hydrate, 621
 - Cefixime
 - Capsules, 624
 - Hydrate, 623
 - Cefmenoxime Hydrochloride, 625
 - Cefmetazole Sodium, 627
 - for Injection, 628
 - Cefminox Sodium Hydrate, 629
 - Cefodizime Sodium, 629
 - Cefoperazone Sodium, 631
 - and Sulbactam Sodium for Injection, 632
 - Cefotaxime Sodium, 634
 - Cefotetan, 635
 - Cefotiam
 - Hexetil Hydrochloride, 637
 - Hydrochloride, 639
 - Hydrochloride for Injection, 640
 - Cefozopran Hydrochloride, 640
 - for Injection, 641
 - Cefpiramide Sodium, 642
 - Cefpirome Sulfate, 643
 - Cefpodoxime Proxetil, 644
 - for Syrup, 646
 - Tablets, 647
 - Cefroxadine
 - for Syrup, 649
 - Hydrate, 648
 - Cefusulodin Sodium, 650
 - Ceftazidime
 - for Injection, 653
 - Hydrate, 652
 - Cefteram Pivoxil, 654
 - Fine Granules, 655
 - Tablets, 656
 - Ceftibuten Hydrate, 657
 - Ceftizoxime Sodium, 658
 - Ceftriaxone Sodium Hydrate, 660
 - Cefuroxime Axetil, 662
 - Cellacefate, 663
 - Cellulose
 - 2-hydroxypropyl ether, 1033
 - Acetate Phthalate, 663
 - Microcrystalline, 664
 - Powdered, 667
 - Celmoleukin (Genetical Recombination), 668
 - Cetanol, 671
 - Cetirizine Hydrochloride, 671
 - Tablets, 672
 - Cetotiamine Hydrochloride Hydrate, 673
 - Cetraxate Hydrochloride, 674
 - Chenodeoxycholic Acid, 675
 - Cherry Bark, 1826
 - Chloral Hydrate, 676
 - Chloramphenicol, 677
 - Palmitate, 677
 - Sodium Succinate, 678
 - Chlordiazepoxide, 679
 - Powder, 680
 - Tablets, 681
 - Chlorhexidine
 - Gluconate Solution, 682
 - Hydrochloride, 683
 - Chlorinated Lime, 683
 - Chlormadinone Acetate, 684
 - Chlorobutanol, 685
 - Chlorphenesin Carbamate, 685
 - Tablets, 686
 - Chlorpheniramine Maleate, 687
 - Injection, 688
 - Powder, 689
 - Tablets, 690
 - d-Chlorpheniramine Maleate, 691
 - Chlorpromazine Hydrochloride, 692
 - Injection, 692
 - Tablets, 693
 - Chlorpropamide, 694
 - Tablets, 695
 - Cholecalciferol, 696
 - Cholera Vaccine, 696
 - Cholesterol, 697
 - Chorionic Gonadotrophin, 997
 - for Injection, 999
 - Chotosan Extract, 1827
 - Chrysanthemum Flower, 1829
 - Cibenzoline Succinate, 697
 - Tablets, 698
 - Ciclacillin, 699
 - Ciclosporin, 700
 - A, 700
 - Cilastatin Sodium, 701
 - Cilazapril

Hydrate, 702
 Tablets, 703
 Cilnidipine, 704
 Tablets, 705
 Cilostazol, 707
 Tablets, 708
 Cimetidine, 709
 Cimicifuga Rhizome, 1830
 Cinchocaine Hydrochloride, 786
 Cinnamon
 Bark, 1830
 Bark, Powdered, 1831
 Oil, 1831
 Cinoxacin, 709
 Capsules, 710
 Ciprofloxacin, 711
 Hydrochloride Hydrate, 712
 Cisplatin, 714
 Cistanche Herb, 1831
 Citicoline, 715
 Citric Acid
 Anhydrous, 716
 Hydrate, 717
 Citrus Unshiu Peel, 1832
 Clarithromycin, 717
 Tablets, 719
 Clebopride Malate, 720
 Clemastine Fumarate, 721
 Clematis Root, 1833
 Clindamycin
 Hydrochloride, 721
 Hydrochloride Capsules, 722
 Phosphate, 724
 Phosphate Injection, 725
 Clinofibrate, 725
 Clobetasol Propionate, 726
 Clocapramine Hydrochloride Hydrate, 727
 Clofedanol Hydrochloride, 728
 Clofibrate, 728
 Capsules, 729
 Clomifene Citrate, 730
 Tablets, 731
 Clomipramine Hydrochloride, 731
 Clonazepam, 732
 Fine Granules, 733
 Tablets, 733
 Clonidine Hydrochloride, 734
 Cloperastine Hydrochloride, 735
 Clopidogrel
 Sulfate, 736
 Sulfate Tablets, 738
 Clorazepate Dipotassium, 739
 Capsules, 740
 Clotiazepam, 741
 Clotrimazole, 742
 Clove, 1833
 Oil, 1834
 Powdered, 1833
 Cloxacillin Sodium Hydrate, 743
 Cloxazolam, 744
 Cnidium
 Monnier Fruit, 1834
 Rhizome, 1835
 Rhizome, Powdered, 1835
 Cocaine Hydrochloride, 745
 Coconut Oil, 1835

Codeine Phosphate
 Hydrate, 746
 Powder, 1%, 746
 Powder, 10%, 747
 Tablets, 748
 Cod Liver Oil, 745
 Codonopsis Root, 1835
 Coix Seed, 1836
 Powdered, 1836
 Colchicine, 749
 Colestimide, 750
 Granules, 751
 Tablets, 752
 Colistin
 Sodium Methanesulfonate, 752
 Sulfate, 753
 Compound
 Acrinol and Zinc Oxide Oil, 377
 Diastase and Sodium Bicarbonate
 Powder, 783
 Hycodenone Injection, 1347
 Iodine Glycerin, 1077
 Methyl Salicylate Spirit, 1238
 Oxycodone and Atropine Injection, 1348
 Oxycodone Injection, 1347
 Phellodendron Powder for
 Cataplasma, 1940
 Rhubarb and Senna Powder, 1957
 Salicylic Acid Spirit, 1541
 Scopolia Extract and Diastase Pow-
 der, 1976
 Thianthol and Salicylic Acid Solu-
 tion, 1679
 Vitamin B Powder, 1765
 Concentrated
 Glycerin, 993
 Glycerol, 993
 Condurango, 1836
 Fluidextract, 1837
 Coptis Rhizome, 1837
 Powdered, 1838
 Corn
 Oil, 1839
 Starch, 1601
 Cornus Fruit, 1839
 Cortisone Acetate, 754
 Corydalis Tuber, 1840
 Powdered, 1841
 Crataegus Fruit, 1842
 Creams
 Absorptive, 755
 Betamethasone Valerate and Gen-
 tamicin Sulfate, 502
 Butenafine Hydrochloride, 537
 Hydrophilic, 756
 Ibuprofen Piconol, 1044
 Ketoconazole, 1122
 Terbinafine Hydrochloride, 1663
 Cresol, 756
 Solution, 756
 Solution, Saponated, 757
 Croconazole Hydrochloride, 757
 Croscarmellose Sodium, 585
 Crospovidone, 758
 Crude Glycyrrhiza Extract, 1864
 Crystal Violet, 1237

Cyanamide, 759
 Cyanocobalamin, 760
 Injection, 761
 Cyclopentolate Hydrochloride, 761
 Cyclophosphamide
 Hydrate, 762
 Tablets, 762
 Cycloserine, 763
 Cyperus Rhizome, 1842
 Powdered, 1843
 Cyproheptadine Hydrochloride Hy-
 drate, 764
 L-Cysteine, 765
 Hydrochloride Hydrate, 766
 L-Cystine, 766
 Cytarabine, 767

D

Daiokanzoto Extract, 1843
 Daisaikoto Extract, 1844
 Danazol, 768
 Dantrolene Sodium Hydrate, 768
 Daunorubicin Hydrochloride, 769
 Deferoxamine Mesilate, 771
 Dehydrated Alcohol, 896
 Dehydrocholate Sodium Injection,
 773
 Dehydrocholic Acid, 772
 Injection, 773
 Purified, 772
 Demethylchlortetracycline Hydrochlo-
 ride, 774
 Dental
 Antiformin, 436
 Iodine Glycerin, 1078
 Paraformaldehyde Paste, 1367
 Phenol with Camphor, 1392
 Sodium Hypochlorite Solution, 436
 Trio zinc Paste, 1734
 Dermatol, 512
 Deslanoside, 775
 Injection, 776
 Dexamethasone, 776
 Dextran
 40, 777
 40 Injection, 778
 70, 779
 Sulfate Sodium Sulfur 5, 780
 Sulfate Sodium Sulfur 18, 780
 Dextrin, 781
 Dextromethorphan Hydrobromide Hy-
 drate, 782
 Diagnostic Sodium Citrate Solution,
 1572
 Diastase, 782
 and Sodium Bicarbonate Powder,
 783
 and Sodium Bicarbonate Powder,
 Compound, 783
 Diazepam, 783
 Tablets, 784
 Dibasic
 Calcium Phosphate, Anhydrous,
 557
 Calcium Phosphate Hydrate, 558
 Sodium Phosphate Hydrate, 1585

Dibekacin Sulfate, 785
 Ophthalmic Solution, 785
 Dibucaine Hydrochloride, 786
 Dichlorphenamide, 787
 Tablets, 789
 Diclofenac Sodium, 787
 Diclofenamide, 787
 Tablets, 789
 Dicloxacillin Sodium Hydrate, 789
 Diethylcarbamazine Citrate, 790
 Tablets, 790
 Difenidol Hydrochloride, 791
 Diflorasone Diacetate, 792
 Diflucortolone Valerate, 793
 Digenea, 1846
 Digitoxin, 794
 Tablets, 795
 Digoxin, 796
 Injection, 797
 Tablets, 798
 Dihydrocodeine Phosphate, 800
 Powder, 1%, 800
 Powder, 10%, 801
 Dihydroergotamine Mesilate, 802
 Dihydroergotoxine Mesilate, 803
 Dilazep Hydrochloride Hydrate, 805
 Diltiazem Hydrochloride, 806
 Extended-release Capsules, 807
 Dilute
 Hydrochloric Acid, 1024
 Iodine Tincture, 1076
 Diluted Opium Powder, 1924
 Dimemorfan Phosphate, 808
 Dimenhydrinate, 809
 Tablets, 809
 Dimercaprol, 810
 Injection, 811
 Dimorpholamine, 811
 Injection, 812
 Dinoprost, 812
 Dionin, 905
 Dioscorea Rhizome, 1847
 Powdered, 1847
 Diphenhydramine, 813
 and Bromovalerylurea Powder, 814
 Hydrochloride, 814
 , Phenol and Zinc Oxide Liniment, 815
 Tannate, 815
 Diphenylhydantoin, 1396
 Powder, 1396
 Sodium for Injection, 1398
 Tablets, 1397
 Diphtheria
 Antitoxin, Equine, Freeze-dried, 816
 -Purified Pertussis-Tetanus Combined Vaccine, Absorbed, 816
 -Tetanus Combined Toxoid, 816
 -Tetanus Combined Toxoid, Absorbed, 816
 Toxoid, 816
 Toxoid for Adult Use, Absorbed, 816
 Dipyridamole, 817
 Disodium Eddate Hydrate, 1573
 Disopyramide, 818

Distigmine Bromide, 818
 Tablets, 819
 Disulfiram, 820
 Dobutamine Hydrochloride, 820
 Docetaxel
 for Injection, 823
 Hydrate, 821
 Injection, 822
 Dolichos Seed, 1848
 Domperidone, 824
 Donepezil Hydrochloride, 825
 Fine Granules, 826
 Tablets, 827
 Dopamine Hydrochloride, 829
 Injection, 829
 Dorzolamide Hydrochloride, 830
 Ophthalmic Solution, 831
 Doxapram Hydrochloride Hydrate, 832
 Doxazosin Mesilate, 823
 Tablets, 834
 Doxifluridine, 835
 Capsules, 835
 Doxorubicin Hydrochloride, 836
 for Injection, 837
 Doxycycline Hydrochloride
 Hydrate, 838
 Tablets, 840
 Dried
 Aluminum Hydroxide Gel, 401
 Aluminum Hydroxide Gel Fine
 Granules, 402
 Aluminum Potassium Sulfate, 403
 Sodium Carbonate, 1568
 Sodium Sulfite, 1592
 Thyroid, 1684
 Yeast, 1779
 Droperidol, 841
 Droxidopa, 842
 Capsules, 842
 Fine Granules, 843
 Dydrogesterone, 844
 Tablets, 845

E

Ebastine, 845
 Orally Disintegrating Tablets, 846
 Tablets, 847
 Ecabet Sodium
 Granules, 849
 Hydrate, 849
 Ecarazine Hydrochloride, 1700
 Eclothiopate Iodide, 851
 Edaravone, 851
 Injection, 852
 Edrophonium Chloride, 853
 Injection, 854
 EDTA Sodium Hydrate, 1573
 Elcatonin, 854
 Eleutherococcus Senticosus Rhizome, 1848
 Emedastine Fumarate, 857
 Extended-release Capsules, 858
 Emorfazone, 858
 Tablets, 859
 Enalapril Maleate, 860

Tablets, 861
 Enflurane, 863
 Enoxacin Hydrate, 863
 Enviomycin Sulfate, 864
 Epalrestat, 865
 Tablets, 866
 Eperisone Hydrochloride, 867
 Ephedra Herb, 1849
 Ephedrine Hydrochloride, 868
 Injection, 869
 Powder, 870
 Powder, 10%, 870
 Tablets, 870
 Epimedium Herb, 1850
 Epinephrine, 379
 Injection, 379
 Solution, 380
 Epirizole, 871
 Epirubicin Hydrochloride, 872
 Eplerenone, 874
 Tablets, 875
 Epoetin
 Alfa (Genetical Recombination), 876
 Beta (Genetical Recombination), 879
 Ergocalciferol, 882
 Ergometrine Maleate, 883
 Injection, 883
 Tablets, 884
 Ergotamine Tartrate, 884
 Erythromycin, 885
 Delayed-release Tablets, 886
 Ethylsuccinate, 887
 Lactobionate, 887
 Stearate, 888
 Estazolam, 889
 Estradiol Benzoate, 889
 Injection (Aqueous Suspension), 890
 Estriol, 891
 Injection (Aqueous Suspension), 892
 Tablets, 892
 Etacrynic Acid, 893
 Tablets, 893
 Ethacridine Lactate, 376
 Ethambutol Hydrochloride, 894
 Ethanol, 895
 Anhydrous, 896
 for Disinfection, 897
 Ethenzamide, 897
 Ether, 898
 Anesthetic, 898
 Guaiacol Glyceryl, 1002
 Polyoxyethylene Lauryl Alcohol, 1144
 Ethinylestradiol, 899
 Tablets, 899
 Ethionamide, 900
 Ethosuximide, 901
 Ethoxybenzamide, 897
 Ethyl
 Aminobenzoate, 901
 Cysteine Hydrochloride, 902
 L-Cysteine Hydrochloride, 902
 Icosapentate, 903

Icosapentate Capsules, 904
 Parahydroxybenzoate, 906
 Ethylenediamine, 903
 Ethylmorphine Hydrochloride Hydrate, 905
 Etidronate Disodium, 907
 Tablets, 908
 Etilefrine Hydrochloride, 909
 Tablets, 909
 Etizolam, 910
 Fine Granules, 911
 Tablets, 912
 Etodolac, 913
 Etoposide, 914
 Eucalyptus Oil, 1850
 Eucommia Bark, 1851
 Euodia Fruit, 1851
 Exsiccated Gypsum, 1868
Extracts
 Bakumondoto, 1805
 Belladonna, 1810
 Bofutsushosan, 1813
 Boiogito, 1817
 Chotosan, 1827
 Crude Glycyrrhiza, 1864
 Daiokanzoto, 1843
 Daisaikoto, 1844
 Glycyrrhiza, 1863
 Goshajinkigan, 1865
 Hachimijiogan, 1868
 Hangekobokuto, 1871
 Hangeshashinto, 1873
 Hochuekkito, 1876
 Juzentaihoto, 1887
 Kakkonto, 1889
 Kakkontokasenkyushin'i, 1892
 Kamikihi, 1895
 Kamishoyosan, 1898
 Keishibukuryogan, 1901
 Maoto, 1912
 Mukoi-Daikenchuto, 1917
 Nux Vomica, 1921
 Orendokuto, 1926
 Otsujito, 1929
 Rikkunshito, 1957
 Ryokeijutsukanto, 1961
 Saibokuto, 1963
 Saikokeishito, 1965
 Saireito, 1968
 Scopolia, 1975
 Shakuyakukanzoto, 1984
 Shimbuto, 1985
 Shosaikoto, 1988
 Shoseiryuto, 1990
 Tokakujokito, 1999
 Tokishakuyakusan, 2002
 Yokukansan, 2010

F

Famotidine, 915
 for Injection, 917
 Injection, 915
 Powder, 918
 Tablets, 919
 Faropenem Sodium
 for Syrup, 920

Hydrate, 919
 Tablets, 921
 Felbinac, 923
 Cataplasma, 923
 Tape, 924
 Fenbufen, 924
 Fennel, 1851
 Oil, 1852
 Powdered, 1852
 Fentanyl Citrate, 925
 Ferrous Sulfate Hydrate, 926
 Fexofenadine Hydrochloride, 926
 Tablets, 927
Filgrastim (Genetical Recombination), 929
 Injection, 931
Fine Granules
 Cefaclor, 596
 Cefcapene Pivoxil Hydrochloride, 613
 Cefdinir, 617
 Cefditoren Pivoxil, 619
 Ceferam Pivoxil, 655
 Clonazepam, 733
 Donepezil Hydrochloride, 826
 Dried Aluminum Hydroxide Gel, 402
 Droxidopa, 843
 Etizolam, 911
 Haloperidol, 1005
 Ifenprodil Tartrate, 1050
 Irsogladine Maleate, 1090
 Levofloxacin, 1155
 Nifedipine, 1311
 Nifedipine Delayed-release, 1309
 Pravastatin Sodium, 1446
 Precipitated Calcium Carbonate, 548
 Probuclol, 1461
 Quetiapine Fumarate, 1493
 Risperidone, 1522
 Sarpogrelate Hydrochloride, 1544
 Tranilast, 1713
 Troxipide, 1735
 Flavin Adenine Dinucleotide Sodium, 932
 Flavoxate Hydrochloride, 934
 Flecainide Acetate, 934
 Tablets, 935
 Flomoxef Sodium, 936
 for Injection, 938
 Flopropione, 939
 Capsules, 939
 Fluconazole, 940
 Capsules, 941
 Injection, 942
 Flucytosine, 943
 Fludiazepam, 944
 Fludrocortisone Acetate, 944
Fluidextracts
 Condurango, 1837
 Platycodon, 1943
 Uva Ursi, 2008
 Flunitrazepam, 945
 Fluocinolone Acetonide, 946
 Fluocinonide, 947
 Fluorescein Sodium, 948
 Fluorometholone, 949
 Fluorouracil, 950
 Fluoxymesterone, 950
 Fluphenazine Enanthate, 951
 Flurazepam Hydrochloride, 952
 Flurbiprofen, 953
 Flutamide, 954
 Flutoprazepam, 955
 Tablets, 955
 Fluvoxamine Maleate, 956
 Tablets, 958
 Foeniculated Ammonia Spirit, 1852
Folic Acid, 959
 Injection, 959
 Tablets, 960
Formalin, 961
 Water, 961
Formoterol Fumarate Hydrate, 962
Forsythia Fruit, 1852
Fosfomycin
 Calcium
 Calcium for Syrup, 963
 Calcium Hydrate, 962
 Sodium, 964
 Sodium for Injection, 965
Fradiomycin Sulfate, 966
Freeze-dried
 BCG Vaccine (for Percutaneous Use), 473
 Botulism Antitoxin, Equine, 520
 Diphtheria Antitoxin, Equine, 816
 Habu Antivenom, Equine, 1004
 Inactivated Tissue Culture Rabies Vaccine, 1503
 Japanese Encephalitis Vaccine, 1111
 Live Attenuated Measles Vaccine, 1196
 Live Attenuated Mumps Vaccine, 1278
 Live Attenuated Rubella Vaccine, 1535
 Mamushi Antivenom, Equine, 1191
 Smallpox Vaccine, 1563
 Smallpox Vaccine Prepared in Cell Culture, 1563
 Tetanus Antitoxin, Equine, 1670
Fritillaria Bulb, 1853
Fructose, 967
 Injection, 968
Fudosteine, 968
 Tablets, 969
Furosemide, 970
 Injection, 971
 Tablets, 972
Fursultiamine Hydrochloride, 973
G
 Gabexate Mesilate, 974
β-Galactosidase
 (Aspergillus), 975
 (Penicillium), 975
Gallium (67Ga) Citrate Injection, 976
Gambir, 1853
 Powdered, 1853
Gardenia Fruit, 1854

Powdered, 1854
 Gas Gangrene Antitoxin, Equine, 977
 Gastrodia Tuber, 1855
 Gefarnate, 977
 Gelatin, 978
 Purified, 980
 Gentamicin Sulfate, 982
 Ophthalmic Solution, 983
 Gentian, 1856
 and Sodium Bicarbonate Powder, 1857
 Powdered, 1856
 Geranium Herb, 1857
 Powdered, 1857
 Ginger, 1857
 Powdered, 1858
 Processed, 1951
 Ginseng, 1859
 Powdered, 1860
 Glacial Acetic Acid, 365
 Glehnia Root and Rhizome, 1861
 Glibenclamide, 984
 Gliclazide, 984
 Glimepiride, 985
 Tablets, 986
 Glucose, 988
 Injection, 989
 L-Glutamic Acid, 989
 L-Glutamine, 990
 Glutathione, 991
 Glycerin, 992
 and Potash Solution, 994
 Concentrated, 993
 Glycerol, 992
 Concentrated, 993
 Glyceryl Monostearate, 995
 Glycine, 995
 Glycyrrhiza, 1862
 Extract, 1863
 Extract, Crude, 1864
 Powdered, 1863
 Prepared, 1947
 Gonadorelin Acetate, 996
 Goshajinkigan Extract, 1865
 Gramicidin, 1001
Granules
 Aciclovir, 370
 Aldioxa, 387
 Azelastine Hydrochloride, 462
 Calcium Paraaminosalicylate, 556
 Cefaclor Combination, 594
 Cefalexin Combination, 602
 Colestimide, 751
 Ecabet Sodium, 849
 L-Isoleucine, L-Leucine and L-Valine, 1096
 Pas-calcium, 556
 Ursodeoxycholic Acid, 1749
 Guaiacol Glyceryl Ether, 1002
 Guafenesin, 1002
 Guanabenz Acetate, 1003
 Guanethidine Sulfate, 1003
 Gypsum, 1868

H

Hachimijiogan Extract, 1868

Haloperidol, 1004
 Fine Granules, 1005
 Injection, 1006
 Tablets, 1006
 Halothane, 1007
 Haloxazolam, 1008
 Hangekobokuto Extract, 1871
 Hangeshashinto Extract, 1873
 Hedysarum Root, 1875
 Hemp Fruit, 1876
Heparin
 Calcium, 1009
 Sodium, 1013
 Sodium Injection, 1017
L-Histidine, 1018
 Hydrochloride Hydrate, 1019
 Hochuekkito Extract, 1876
 Homatropine Hydrobromide, 1020
 Homochlorcyclizine Hydrochloride, 1020
 Honey, 1879
 Houttuynia Herb, 1880
Human
 Chorionic Gonadotrophin, 997
 Chorionic Gonadotrophin for Injection, 999
 Menopausal Gonadotrophin, 999
 Normal Immunoglobulin, 1021
 Hycoato Injection, 1348
 Hydralazine Hydrochloride, 1021
 for Injection, 1022
 Powder, 1022
 Tablets, 1022
 Hydrochloric Acid, 1023
 Dilute, 1024
 Lemonade, 1024
 Hydrochlorothiazide, 1024
 Hydrocortisone, 1025
 Acetate, 1026
 and Diphenhydramine Ointment, 1027
 Butyrate, 1028
 Sodium Phosphate, 1028
 Sodium Succinate, 1030
 Succinate, 1031
 Hydrocotarnine Hydrochloride Hydrate, 1031
 Hydrogenated Oil, 1032
Hydrophilic
 Cream, 756
 Petrolatum, 1387
 Hydrous Lanolin, 1903
 Hydroxocobalamin Acetate, 1033
 Hydroxypropylcellulose, 1033
 Hydroxypropylmethylcellulose, 1038
 Hydroxyzine
 Hydrochloride, 1036
 Pamoate, 1036
 Hymecromone, 1037
 Hypromellose, 1038
 Acetate Succinate, 1040
 Capsules, 574
 Phthalate, 1041

I

Ibudilast, 1042

Ibuprofen, 1043
 Piconol, 1044
 Piconol Cream, 1044
 Piconol Ointment, 1045
 Ichthammol, 1046
 Idarubicin Hydrochloride, 1046
 for Injection, 1047
 Idoxuridine, 1048
 Ophthalmic Solution, 1049
 Ifenprodil Tartrate, 1050
 Fine Granules, 1050
 Tablets, 1051
 Imidapril Hydrochloride, 1052
 Tablets, 1053
Imipenem
 and Cilastatin Sodium for Injection, 1056
 Hydrate, 1054
 Imipramine Hydrochloride, 1057
 Tablets, 1057
 Immature Orange, 1880
 Imperata Rhizome, 1880
 Indapamide, 1058
 Tablets, 1059
 Indenolol Hydrochloride, 1060
 Indigocarmine, 1061
 Injection, 1062
 Indium (¹¹¹In) Chloride Injection, 1062
 Indometacin, 1062
 Capsules, 1063
 Suppositories, 1064
 Influenza HA Vaccine, 1065
Injection
 Acetylcholine Chloride for, 367
 Aciclovir, 371
 Aciclovir for, 371
 Adrenaline, 379
 Alendronate Sodium, 389
 Alprostadil, 398
 Amikacin Sulfate, 409
 Amikacin Sulfate for, 409
 Aminophylline, 410
 Amphotericin B for, 427
 Ampicillin Sodium and Sulbactam Sodium for, 433
 Ampicillin Sodium for, 432
 Arbekacin Sulfate, 440
 L-Arginine Hydrochloride, 443
 Ascorbic Acid, 446
 Atropine Sulfate, 456
 Aztreonam for, 467
 Benzylpenicillin Potassium for, 487
 Calcium Chloride, 551
 Carboplatin, 582
 Cefazolin Sodium for, 608
 Cefepime Dihydrochloride for, 622
 Cefmetazole Sodium for, 628
 Cefoperazone Sodium and Sulbactam Sodium for, 632
 Cefotiam Hydrochloride for, 640
 Cefozopran Hydrochloride for, 641
 Ceftazidime for, 653
 Chlorpheniramine Maleate, 688
 Chlorpromazine Hydrochloride, 692
 Chorionic Gonadotrophin for, 999

Injection (continued)

Clindamycin Phosphate, 725
 Compound Hydrocodone, 1347
 Compound Oxycodone, 1347
 Compound Oxycodone and Atropine, 1348
 Cyanocobalamin, 761
 Dehydrocholate Sodium, 773
 Dehydrocholic Acid, 773
 Deslanoside, 776
 Dextran 40, 778
 Digoxin, 797
 Dimercaprol, 811
 Dimorpholamine, 812
 Diphenylhydantoin Sodium for, 1398
 Docetaxel, 822
 Docetaxel for, 823
 Dopamine Hydrochloride, 829
 Doxorubicin Hydrochloride for, 837
 Edaravone, 852
 Edrophonium Chloride, 854
 Ephedrine Hydrochloride, 869
 Epinephrine, 379
 Ergometrine Maleate, 883
 Estradiol Benzoate (Aqueous Suspension), 890
 Estriol (Aqueous Suspension), 892
 Famotidine, 915
 Famotidine for, 917
 Filgrastim (Genetical Recombination), 931
 Flomoxef Sodium for, 938
 Fluconazole, 942
 Folic Acid, 959
 Fosfomycin Sodium for, 965
 Fructose, 968
 Furosemide, 971
 Gallium (⁶⁷Ga) Citrate, 976
 Glucose, 989
 Haloperidol, 1006
 Heparin Sodium, 1017
 Human Chorionic Gonadotrophin for, 999
 Hycoato, 1348
 Hydralazine Hydrochloride for, 1022
 Idarubicin Hydrochloride for, 1047
 Imipenem and Cilastatin Sodium for, 1056
 Indigocarmine, 1062
 Indium (¹¹¹In) Chloride, 1062
 Insulin Glargine (Genetical Recombination), 1067
 Insulin Human (Genetical Recombination), 1070
 Interferon Alfa (NAMALWA), 1074
 Iodinated (¹³¹I) Human Serum Albumin, 1075
 Iohexol, 1082
 Iopamidol, 1084
 Isopamycin Sulfate, 1094
 Isoniazid, 1100
 Isotonic Sodium Chloride, 1571
 Levallorphan Tartrate, 1152

Levofloxacin, 1156
 Lidocaine, 1162
 Lidocaine Hydrochloride, 1162
 Lincomycin Hydrochloride, 1164
 Magnesium Sulfate, 1190
 D-Mannite, 1195
 D-Mannitol, 1195
 Meglumine Iotalamate, 1206
 Meglumine Sodium Amidotrizoate, 1207
 Mepivacaine Hydrochloride, 1213
 Meropenem for, 1219
 Metenolone Enanthate, 1222
 Minocycline Hydrochloride for, 1256
 Mitomycin C for, 1262
 Morphine and Atropine, 1273
 Morphine Hydrochloride, 1271
 Nartograstim for (Genetical Recombination), 1293
 Neostigmine Methylsulfate, 1297
 Nicardipine Hydrochloride, 1299
 Nicotinic Acid, 1307
 Noradrenaline, 1322
 Noradrenaline Hydrochloride, 1322
 Norepinephrine, 1322
 Norepinephrine Hydrochloride, 1322
 Operidine, 1385
 Opium Alkaloids and Atropine, 1338
 Opium Alkaloids and Scopolamine, 1339
 Opium Alkaloids Hydrochlorides, 1337
 Oxytocin, 1355
 Ozagrel Sodium, 1357
 Ozagrel Sodium for, 1357
 Panipenem and Betamipron for, 1361
 Papaverine Hydrochloride, 1364
 Peplomycin Sulfate for, 1380
 Pethidine Hydrochloride, 1385
 Phenolsulfonphthalein, 1393
 Phenytoin Sodium for, 1398
 Piperacillin Sodium for, 1418
 Prednisolone Sodium Succinate for, 1456
 Procainamide Hydrochloride, 1463
 Procaine Hydrochloride, 1465
 Progesterone, 1470
 Protamine Sulfate, 1484
 Purified Sodium Hyaluronate, 1576
 Pyridoxine Hydrochloride, 1490
 Reserpine, 1508
 Riboflavin Phosphate, 1516
 Riboflavin Sodium Phosphate, 1516
 Roxatidine Acetate Hydrochloride for, 1533
 Sivelestat Sodium for, 1562
 Sodium Bicarbonate, 1566
 Sodium Chloride, 0.9%, 1571
 Sodium Chloride, 10%, 1570
 Sodium Chromate (⁵¹Cr), 1571
 Sodium Citrate for Transfusion, 1572
 Sodium Iodohippurate (¹³¹I), 1580
 Sodium Iotalamate, 1580
 Sodium Pertechnetate (^{99m}Tc), 1585
 Sodium Thiosulfate, 1593
 Spectinomycin Hydrochloride for, 1598
 Sterile Water for, in Containers, 1775
 Streptomycin Sulfate for, 1609
 Sulfonylomphthalein Sodium, 1619
 Sulpirine, 1623
 Suxamethonium Chloride, 1628
 Suxamethonium Chloride for, 1628
 Tazobactam and Piperacillin for, 1645
 Teceleukin for (Genetical Recombination), 1652
 Testosterone Enanthate, 1668
 Testosterone Propionate, 1669
 Thallium (²⁰¹Tl) Chloride, 1672
 Thiamine Chloride Hydrochloride, 1675
 Thiamylal Sodium for, 1678
 Thiopental Sodium for, 1681
 Tobramycin, 1696
 Tranexamic Acid, 1710
 Vancomycin Hydrochloride for, 1758
 Vasopressin, 1759
 Vinblastine Sulfate for, 1763
 Vitamin B₁ Hydrochloride, 1675
 Vitamin B₂ Phosphate Ester, 1516
 Vitamin B₆, 1490
 Vitamin B₁₂, 761
 Vitamin C, 446
 Water for, 1774
 Weak Opium Alkaloids and Scopolamine, 1340
 Xylitol, 1778
 Insulin
 Glargine (Genetical Recombination), 1065
 Glargine (Genetical Recombination) Injection, 1067
 Human (Genetical Recombination), 1068
 Human (Genetical Recombination) Injection, 1070
 Interferon Alfa (NAMALWA), 1071
 Injection, 1074
 Iodinated (¹³¹I) Human Serum Albumin Injection, 1075
 Iodine, 1075
 Glycerin, Compound, 1077
 Glycerin, Dental, 1078
 , Salicylic Acid and Phenol Spirit, 1079
 Tincture, 1076
 Tincture, Dilute, 1076
 Iodoform, 1080
 Iohexol, 1080
 Injection, 1082
 Iopamidol, 1083
 Injection, 1084

Iotalamic Acid, 1085
 Iototoxic Acid, 1086
 Ipecac, 1881
 Powdered, 1881
 Syrup, 1882
 Ipratropium Bromide Hydrate, 1086
 Ipriflavone, 1087
 Tablets, 1088
 Iproveratril Hydrochloride, 1761
 Irbesartan, 1089
 Irsogladine Maleate, 1090
 Fine Granules, 1090
 Tablets, 1091
 Isepamicin Sulfate, 1093
 Injection, 1094
 Isoflurane, 1094
 L-Isoleucine, 1096
 L-Leucine and L-Valine Granules, 1096
 Isomalt, 1098
 Hydrate, 1098
 Isoniazid, 1099
 Injection, 1100
 Tablets, 1101
 l-Isoprenaline Hydrochloride, 1102
 Isopropanol, 1102
 Isopropyl Alcohol, 1102
 Isopropylantipyrine, 1103
 Isosorbide, 1103
 Dinitrate, 1104
 Dinitrate Tablets, 1105
 Mononitrate 70%/Lactose 30%, 1105
 Mononitrate Tablets, 1107
 Isotonic
 Salt Solution, 1571
 Sodium Chloride Injection, 1571
 Sodium Chloride Solution, 1571
 Isoxsuprine Hydrochloride, 1108
 Tablets, 1109
 Itraconazole, 1110

J

Japanese
 Angelica Root, 1883
 Angelica Root, Powdered, 1883
 Encephalitis Vaccine, 1111
 Gentian, 1884
 Gentian, Powdered, 1884
 Valerian, 1884
 Valerian, Powdered, 1885
 Zanthoxylum Peel, 1885
 Zanthoxylum Peel, Powdered, 1886
 Josamycin, 1112
 Propionate, 1113
 Tablets, 1113
 Jujube, 1886
 Seed, 1886
 Juzentaihoto Extract, 1887

K

Kainic Acid
 and Santonin Powder, 1115
 Hydrate, 1114

Kakkonto Extract, 1889
 Kakkontokasenkyushin'i Extract, 1892
 Kallidinogenase, 1116
 Kamikihito Extract, 1895
 Kamishoyosan Extract, 1898
 Kanamycin
 Monosulfate, 1118
 Sulfate, 1119
 Kaolin, 1120
 Keishibukuryogan Extract, 1901
 Ketamine Hydrochloride, 1120
 Ketoconazole, 1121
 Cream, 1122
 Lotion, 1123
 Solution, 1123
 Ketoprofen, 1124
 Ketotifen Fumarate, 1125
 Kitasamycin, 1126
 Acetate, 1127
 Tartrate, 1128
 Koi, 1903

L

Labetalol Hydrochloride, 1129
 Tablets, 1130
 Lactic Acid, 1131
 L-Lactic Acid, 1131
 Lactose, 1133
 Hydrate, 1133
 Lactulose, 1134
 Anhydrous, 1132
 Lafutidine, 1135
 Tablets, 1136
 Lanatoside C, 1137
 Tablets, 1138
 Lanolin
 Hydrous, 1903
 Purified, 1904
 Lansoprazole, 1139
 Delayed-release Capsules, 1140
 Delayed-release Orally Disintegrating Tablets, 1141
 Lard, 1905
 Latamoxef Sodium, 1143
 Lauromacrogol, 1144
Lemonades
 Hydrochloric Acid, 1024

Lenampicillin Hydrochloride, 1144
 Lenograstim (Genetical Recombination), 1146
 Leonurus Herb, 1905
 L-Leucine, 1149
 Leucomycin, 1126
 Acetate, 1127
 Tartrate, 1128
 Leuprorelin Acetate, 1150
 Levallorphan Tartrate, 1152
 Injection, 1152
 Levodopa, 1153
 Levofloxacin
 Fine Granules, 1155
 Hydrate, 1154
 Injection, 1156
 Ophthalmic Solution, 1156
 Tablets, 1157

Levomepromazine Maleate, 1159
 Levothyroxine Sodium

 Hydrate, 1159
 Tablets, 1160
 Lidocaine, 1161
 Hydrochloride Injection, 1162
 Injection, 1162

Light

 Anhydrous Silicic Acid, 1552
 Liquid Paraffin, 1365

Lilium Bulb, 1906

Limaprost Alfadex, 1162

Lincomycin Hydrochloride

 Hydrate, 1164
 Injection, 1164

Lindera Root, 1906

Liniments

 Diphenhydramine, Phenol and Zinc Oxide, 815

 Phenol and Zinc Oxide, 1392

Liothyronine Sodium, 1165

 Tablets, 1166

Liquefied Phenol, 1391

Liquid Paraffin, 1365

Lisinopril

 Hydrate, 1167

 Tablets, 1168

Lithium Carbonate, 1169

Lithospermum Root, 1907

Live Oral Poliomyelitis Vaccine, 1428

Lobenzarit Sodium, 1171

Longan Aril, 1907

Longgu, 1907

 Powdered, 1908

Lonicera Leaf and Stem, 1908

Loquat Leaf, 1909

Lorazepam, 1171

Losartan Potassium, 1172

 and Hydrochlorothiazide Tablets, 1174

 Tablets, 1173

Lotions

 Ketoconazole, 1123

 Sulfur and Camphor, 1619

 Tacalcitol, 1630

Low Substituted Hydroxypropylcellulose, 1035

Loxoprofen Sodium

 Hydrate, 1177

 Tablets, 1178

Lycium

 Bark, 1909

 Fruit, 1909

Lysine Hydrochloride, 1180

L-Lysine

 Acetate, 1179

 Hydrochloride, 1180

Lysozyme Hydrochloride, 1181

M

Macrogol

 400, 1182

 1500, 1182

 4000, 1183

 6000, 1183

 20000, 1184

- Ointment, 1184
- Magnesium
- Carbonate, 1185
 - Oxide, 1186
 - Silicate, 1187
 - Stearate, 1188
 - Sulfate Hydrate, 1189
 - Sulfate Injection, 1190
 - Sulfate Mixture, 1190
- Magnolia
- Bark, 1910
 - Bark, Powdered, 1910
 - Flower, 1911
- Mallotus Bark, 1911
- Malt, 1912
- Maltose Hydrate, 1190
- Manidipine Hydrochloride, 1192
- Tablets, 1193
- D-Mannite Injection, 1195
- D-Mannitol, 1194
- Injection, 1195
- Maoto Extract, 1912
- Maprotiline Hydrochloride, 1196
- Meclofenoxate Hydrochloride, 1197
- Mecobalamin, 1197
- Tablets, 1198
- Medazepam, 1200
- Medicinal
- Carbon, 1200
 - Soap, 1201
- Medroxyprogesterone Acetate, 1202
- Mefenamic Acid, 1203
- Mefloquine Hydrochloride, 1203
- Mefruside, 1204
- Tablets, 1205
- Meglumine, 1206
- Iotalamate Injection, 1206
 - Sodium Amidotrizoate Injection, 1207
- Melphalan, 1208
- Menatetrenone, 1209
- Mentha
- Herb, 1914
 - Oil, 1915
 - Water, 1915
- dl-Menthol, 1210
- l-Menthol, 1211
- Mepenzolate Bromide, 1211
- Mepirizole, 871
- Mepitostane, 1212
- Mepivacaine Hydrochloride, 1213
- Injection, 1213
- Mequitazine, 1214
- Tablets, 1215
- Merbromin, 1216
- Solution, 1217
- Mercaptopurine Hydrate, 1215
- Mercurochrome, 1216
- Solution, 1217
- Meropenem
- for Injection, 1219
 - Hydrate, 1217
- Mestranol, 1220
- Metenolone
- Acetate, 1220
 - Enanthate, 1221
 - Enanthate Injection, 1222
- Metformin Hydrochloride, 1222
- Tablets, 1223
- Methamphetamine Hydrochloride, 1223
- L-Methionine, 1224
- Methotrexate, 1225
- Capsules, 1225
- Methoxsalen, 1227
- Methyl
- Parahydroxybenzoate, 1235
 - Salicylate, 1238
 - Salicylate Spirit, Compound, 1238
- Methylbenactyzium Bromide, 1227
- Methylcellulose, 1228
- Methyldopa
- Hydrate, 1229
 - Tablets, 1230
- dl-Methylephedrine Hydrochloride, 1231
- Powder, 1232
 - Powder, 10%, 1232
- Methylergometrine Maleate, 1233
- Tablets, 1233
- Methylprednisolone, 1236
- Succinate, 1236
- Methylrosanilinium Chloride, 1237
- Methyltestosterone, 1239
- Tablets, 1240
- Meticrane, 1241
- Metildigoxin, 1242
- Metoclopramide, 1243
- Tablets, 1243
- Metoprolol Tartrate, 1244
- Tablets, 1245
- Metronidazole, 1246
- Tablets, 1246
- Metyrapone, 1247
- Mexiletine Hydrochloride, 1248
- Miconazole, 1249
- Nitrate, 1249
- Microcrystalline Cellulose, 664
- Micronomicin Sulfate, 1250
- Midecamycin, 1251
- Acetate, 1252
- Miglitol, 1253
- Migrenin, 1254
- Minocycline Hydrochloride, 1255
- for Injection, 1256
 - Tablets, 1256
- Mitiglinide Calcium
- Hydrate, 1258
 - Tablets, 1259
- Mitomycin C, 1261
- for Injection, 1262
- Mizoribine, 1262
- Tablets, 1263
- Monobasic Calcium Phosphate Hydrate, 558
- Monosodium Trichloroethyl Phosphate, 1725
- Syrup, 1726
- Montelukast Sodium, 1264
- Chewable Tablets, 1267
 - Tablets, 1269
- Morphine
- and Atropine Injection, 1273
 - Hydrochloride Hydrate, 1270
- Hydrochloride Injection, 1271
- Hydrochloride Tablets, 1272
- Sulfate Hydrate, 1274
- Mosapride Citrate
- Hydrate, 1275
 - Powder, 1276
 - Tablets, 1277
- Moutan Bark, 1915
- Powdered, 1916
- Mukoi-Daikenchuto Extract, 1917
- Mulberry Bark, 1918
- Mupirocin Calcium
- Hydrate, 1279
 - Ointment, 1280
- N**
- Nabumetone, 1281
- Tablets, 1282
- Nadolol, 1283
- Nafamostat Mesilate, 1283
- Naftopidil, 1284
- Orally Disintegrating Tablets, 1285
 - Tablets, 1286
- Nalidixic Acid, 1287
- Naloxone Hydrochloride, 1288
- Naphazoline
- and Chlorpheniramine Solution, 1290
 - Hydrochloride, 1289
 - Nitrate, 1289
- Naproxen, 1291
- Narcotine, 1326
- Hydrochloride, 1327
- Nartograstim (Genetical Recombination), 1291
- for Injection, 1293
- Natamycin, 1404
- Nateglinide, 1294
- Tablets, 1295
- Natural Aluminum Silicate, 404
- Nelumbo Seed, 1919
- Neomycin Sulfate, 966
- Neostigmine Methylsulfate, 1297
- Injection, 1297
- Nicardipine Hydrochloride, 1298
- Injection, 1299
- Nicergoline, 1300
- Powder, 1301
 - Tablets, 1302
- Niceritrol, 1303
- Nicomol, 1304
- Tablets, 1304
- Nicorandil, 1305
- Nicotinamide, 1306
- Nicotinic Acid, 1307
- Injection, 1307
- Nifedipine, 1308
- Delayed-release Fine Granules, 1309
 - Extended-release Capsules, 1310
 - Fine Granules, 1311
- Nilvadipine, 1312
- Tablets, 1313
- Nitrazepam, 1314
- Nitrendipine, 1314
- Tablets, 1315

Nitrogen, 1316
 Nitroglycerin Tablets, 1317
 Nitrous Oxide, 1318
 Nizatidine, 1319
 Capsules, 1320
 Noradrenaline, 1321
 Hydrochloride Injection, 1322
 Injection, 1322
 Norepinephrine, 1321
 Hydrochloride Injection, 1322
 Injection, 1322
 Norethisterone, 1322
 Norfloxacin, 1323
 Norgestrel, 1324
 and Ethinylestradiol Tablets, 1324
 Nortriptyline Hydrochloride, 1326
 Noscapine, 1326
 Hydrochloride Hydrate, 1327
 Notopterygium, 1919
 Nuphar Rhizome, 1919
 Nutmeg, 1920
 Nux Vomica, 1920
 Extract, 1921
 Extract Powder, 1922
 Tincture, 1922
 Nystatin, 1328

O

Ofloxacin, 1328
Ointments
 Aciclovir, 372
 Aciclovir Ophthalmic, 372
 Acrinol and Zinc Oxide, 378
 Betamethasone Valerate and Gentamicin Sulfate, 504
 Hydrocortisone and Diphenhydramine, 1027
 Ibuprofen Piconol, 1045
 Macrogol, 1184
 Mupirocin Calcium, 1280
 Polyethylene Glycol, 1184
 Simple, 1993
 Sulfur, Salicylic Acid and Thianthol, 1620
 Tacalcitol, 1631
 White, 1775
 Zinc Oxide, 1784
 Olive Oil, 1923
 Olmesartan Medoxomil, 1329
 Tablets, 1330
 Olopatadine Hydrochloride, 1332
 Tablets, 1333
 Omeprazole, 1334
 Delayed-release Tablets, 1335
 Operidine, 1385
 Injection, 1385
 Ophiopogon Root, 1923
Ophthalmic Solution
 Dibekacin Sulfate, 785
 Dorzolamide Hydrochloride, 831
 Gentamicin Sulfate, 983
 Idoxuridine, 1049
 Levofloxacin, 1156
 Pemirolast Potassium, 1373
 Purified Sodium Hyaluronate, 1577

Silver Nitrate, 1557
 Tranilast, 1714
 Zinc Sulfate, 1785
Ophthalmic Ointment
 Aciclovir, 372
Opium
 Ipecac Powder, 1925
 Powder, Diluted, 1924
 Powdered, 1924
 Tincture, 1925
Opium Alkaloids
 and Atropine Injection, 1338
 and Scopolamine Injection, 1339
 Hydrochlorides, 1336
 Hydrochlorides Injection, 1337
Orange
 Oil, 1925
 Peel Syrup, 1926
 Peel Tincture, 1926
 Orciprenaline Sulfate, 1341
 Orengedokuto Extract, 1926
 Oriental Bezoar, 1928
 Otsujito Extract, 1929
 Oxapium Iodide, 1342
 Oxaprozin, 1343
 Oxazolam, 1343
 Oxetacaine, 1344
 Oxethazaine, 1344
 Oxprenolol Hydrochloride, 1345
 Oxybuprocaine Hydrochloride, 1345
 Oxycodone Hydrochloride Hydrate, 1346
 Oxydol, 1349
 Oxygen, 1350
 Oxymetholone, 1351
 Oxytetracycline Hydrochloride, 1351
 Oxytocin, 1353
 Injection, 1355
 Oyster Shell, 1932
 Powdered, 1932
 Ozagrel Sodium, 1356
 for Injection, 1357
 Injection, 1357
P
 Panax Japonicus Rhizome, 1932
 Powdered, 1933
 Pancreatin, 1358
 Pancuronium Bromide, 1358
 Panipenem, 1359
 and Betamipron for Injection, 1361
 Pantethine, 1362
 Papaverine Hydrochloride, 1363
 Injection, 1364
 Paracetamol, 363
 Paraffin, 1364
 Light Liquid, 1365
 Liquid, 1365
 Paraformaldehyde, 1366
 Paste, Dental, 1367
 Parnaparin Sodium, 1367
 Paroxetine Hydrochloride
 Hydrate, 1369
 Tablets, 1371
 Pas-calcium
 Granules, 556
 Hydrate, 555
Paste
 Arsenical, 445
 Paraformaldehyde, Dental, 1367
 Triozinc, Dental, 1734
 Peach Kernel, 1933
 Powdered, 1934
 Peanut Oil, 1935
 Pemirolast Potassium, 1372
 for Syrup, 1374
 Ophthalmic Solution, 1373
 Tablets, 1375
 Penbutolol Sulfate, 1376
 Penicillin G Potassium, 486
 Pentazocine, 1376
 Pentobarbital Calcium, 1377
 Pentoxyverine Citrate, 1378
 Peony Root, 1935
 Powdered, 1936
 Peplomycin Sulfate, 1379
 for Injection, 1380
 Perilla Herb, 1937
 Perphenazine, 1381
 Maleate, 1383
 Maleate Tablets, 1383
 Tablets, 1382
 Pethidine Hydrochloride, 1385
 Injection, 1385
 Petroleum Benzin, 1387
 Peucedanum Root, 1937
 Pharbitis Seed, 1938
 Phellodendron
 , Albumin Tannate and Bismuth Subnitrate Powder, 1940
 Bark, 1938
 Bark, Powdered, 1939
 Powder for Cataplasm, Compound, 1940
 Phenazone, 437
 Phenethicillin Potassium, 1388
 Phenobarbital, 1389
 Powder, 1390
 Powder, 10%, 1390
 Phenol, 1390
 and Zinc Oxide Liniment, 1392
 for Disinfection, 1391
 Liquefied, 1391
 with Camphor, Dental, 1392
 Phenolated Water, 1392
 for Disinfection, 1392
 Phenolsulfonphthalein, 1393
 Injection, 1393
 L-Phenylalanine, 1394
 Phenylbutazone, 1395
 Phenylephrine Hydrochloride, 1395
 Phenytoin, 1396
 Powder, 1396
 Sodium for Injection, 1398
 Tablets, 1397
 Phytomenadione, 1398
 Phytonadione, 1398
 Picrasma Wood, 1941
 Powdered, 1941
 Pilocarpine Hydrochloride, 1399
 Tablets, 1400
 Pilsicainide Hydrochloride
 Capsules, 1402

Hydrate, 1402
 Pimaricin, 1404
 Pimozone, 1405
 Pindolol, 1406
 Pinellia Tuber, 1941
 Pioglitazone Hydrochloride, 1406
 and Glimepiride Tablets, 1408
 and Metformin Hydrochloride
 Tablets, 1411
 Tablets, 1407
 Pipemidic Acid Hydrate, 1414
 Piperacillin
 Hydrate, 1414
 Sodium, 1416
 Sodium for Injection, 1418
 Piperazine
 Adipate, 1418
 Phosphate Hydrate, 1419
 Phosphate Tablets, 1419
 Pirarubicin, 1420
 Piroxidine, 1421
 Pirenzepine Hydrochloride Hydrate, 1422
 Piroxicam, 1423
 Pitavastatin Calcium
 Hydrate, 1424
 Tablets, 1425
 Pivmecillinam Hydrochloride, 1427
 Tablets, 1428
 Plantago
 Herb, 1942
 Seed, 1942
 Platycodon
 Fluidextract, 1943
 Root, 1942
 Root, Powdered, 1943
 Pogostemon Herb, 1944
 Polyethylene Glycol
 400, 1182
 1500, 1182
 4000, 1183
 6000, 1183
 20000, 1184
 Ointment, 1184
 Polygala Root, 1944
 Powdered, 1944
 Polygonatum Rhizome, 1945
 Polygonum Root, 1945
 Polymixin B Sulfate, 1429
 Polyoxyethylene Lauryl Alcohol Ether, 1144
 Polyoxyl 40 Stearate, 1430
 Polyporus Sclerotium, 1946
 Powdered, 1946
 Polysorbate 80, 1430
 Polyvidone, 1439
 Polyvinylpyrrolidone, 1439
 Poria Sclerotium, 1946
 Powdered, 1947
 Potash Soap, 1432
 Potassium
 Bromide, 1432
 Canrenoate, 1433
 Carbonate, 1433
 Chloride, 1434
 Clavulanate, 1434
 Guaiacolsulfonate, 1436

Hydroxide, 1436
 Iodide, 1437
 Permanganate, 1438
 Sulfate, 1438
 Potato Starch, 1602
 Povidone, 1439
 -Iodine, 1441
Powder
 Ascorbic Acid, 446
 Chlordiazepoxide, 680
 Chlorpheniramine Maleate, 689
 Codeine Phosphate, 1%, 746
 Codeine Phosphate, 10%, 747
 Compound Diastase and Sodium Bicarbonate, 783
 Compound Phellodendron, for Cataplasma, 1940
 Compound Rhubarb and Senna, 1957
 Compound Scopolia Extract and Diastase, 1976
 Compound Vitamin B, 1765
 Diastase and Sodium Bicarbonate, 783
 Dihydrocodeine Phosphate, 1%, 800
 Dihydrocodeine Phosphate, 10%, 801
 Diluted Opium, 1924
 Diphenhydramine and Bromovalerylurea, 814
 Diphenylhydantoin, 1396
 Ephedrine Hydrochloride, 870
 Ephedrine Hydrochloride, 10%, 870
 Famotidine, 918
 Gentian and Sodium Bicarbonate, 1857
 Hydralazine Hydrochloride, 1022
 Kainic Acid and Santonin, 1115
dl-Methylephedrine Hydrochloride, 1232
dl-Methylephedrine Hydrochloride, 10%, 1232
 Mosapride Citrate, 1276
 Nicergoline, 1301
 Opium Ipecac, 1925
 Phellodendron, Albumin Tannate and Bismuth Subnitrate, 1940
 Phenobarbital, 1390
 Phenobarbital, 10%, 1390
 Phenytoin, 1396
 Reserpine, 1508
 Reserpine, 0.1%, 1508
 Riboflavin, 1514
 Scopolia Extract, 1975
 Scopolia Extract and Carbon, 1976
 Scopolia Extract and Ethyl Aminobenzoate, 1976
 Scopolia Extract, Papaverine and Ethyl Aminobenzoate, 1977
 Swertia and Sodium Bicarbonate, 1998
 Thiamine Chloride Hydrochloride, 1675
 Vitamin B₁ Hydrochloride, 1675
 Vitamin B₂, 1514
 Vitamin C, 446
 Zinc Oxide Starch, 1785
Powdered
 Acacia, 1791
 Agar, 1793
 Alisma Tuber, 1794
 Aloe, 1795
 Amomum Seed, 1797
 Atractylodes Lancea Rhizome, 1804
 Atractylodes Rhizome, 1805
 Calumba, 1822
 Capsicum, 1823
 Cellulose, 667
 Cinnamon Bark, 1831
 Clove, 1833
 Cnidium Rhizome, 1835
 Coix Seed, 1836
 Coptis Rhizome, 1838
 Corydalis Tuber, 1841
 Cyperus Rhizome, 1843
 Dioscorea Rhizome, 1847
 Fennel, 1852
 Gambir, 1853
 Gardenia Fruit, 1854
 Gentian, 1856
 Geranium Herb, 1857
 Ginger, 1858
 Ginseng, 1860
 Glycyrrhiza, 1863
 Ipecac, 1881
 Japanese Angelica Root, 1883
 Japanese Gentian, 1884
 Japanese Valerian, 1885
 Japanese Zanthoxylum Peel, 1886
 Longgu, 1908
 Magnolia Bark, 1910
 Moutan Bark, 1916
 Opium, 1924
 Oyster Shell, 1932
 Panax Japonicus Rhizome, 1933
 Peach Kernel, 1934
 Peony Root, 1936
 Phellodendron Bark, 1939
 Picrasma Wood, 1941
 Platycodon Root, 1943
 Polygala Root, 1944
 Polyporus Sclerotium, 1946
 Poria Sclerotium, 1947
 Processed Aconite Root, 1949
 Rhubarb, 1956
 Rose Fruit, 1960
 Scutellaria Root, 1979
 Senega, 1981
 Senna Leaf, 1982
 Smilax Rhizome, 1993
 Sophora Root, 1995
 Sweet Hydrangea Leaf, 1996
 Swertia Herb, 1997
 Tragacanth, 2004
 Turmeric, 2006
 Pranlukast Hydrate, 1442
 Pranoprofen, 1443
 Prasterone Sodium Sulfate Hydrate, 1444
 Pravastatin Sodium, 1444
 Fine Granules, 1446

Solution, 1447
 Tablets, 1448
 Prazepam, 1450
 Tablets, 1450
 Prazosin Hydrochloride, 1451
 Precipitated Calcium Carbonate, 548
 Fine Granules, 548
 Tablets, 549
 Prednisolone, 1452
 Acetate, 1454
 Sodium Phosphate, 1455
 Sodium Succinate for Injection, 1456
 Succinate, 1456
 Tablets, 1453
 Prepared Glycyrrhiza, 1947
 Primidone, 1458
 Probencid, 1458
 Tablets, 1459
 Probucol, 1460
 Fine Granules, 1461
 Tablets, 1462
 Procainamide Hydrochloride, 1462
 Injection, 1463
 Tablets, 1463
 Procaine Hydrochloride, 1464
 Injection, 1465
 Procabazine Hydrochloride, 1466
 Procaterol Hydrochloride Hydrate, 1466
 Processed
 Aconite Root, 1948
 Aconite Root, Powdered, 1949
 Ginger, 1951
 Prochlorperazine Maleate, 1467
 Tablets, 1468
 Progesterone, 1469
 Injection, 1470
 Proglumide, 1470
 L-Proline, 1471
 Promethazine Hydrochloride, 1472
 Propafenone Hydrochloride, 1473
 Tablets, 1474
 Propantheline Bromide, 1475
 Propiverine Hydrochloride, 1476
 Tablets, 1477
 Propranolol Hydrochloride, 1478
 Tablets, 1479
 Propylene Glycol, 1480
 Propyl Parahydroxybenzoate, 1481
 Propylthiouracil, 1482
 Tablets, 1482
 Propyphenazone, 1103
 Prostaglandin
 E₁, 396
 E₁ α -Cyclodextrin Clathrate Compound, 400
 F_{2a}, 812
 Protamine Sulfate, 1483
 Injection, 1484
 Prothionamide, 1484
 Protirelin, 1485
 Tartrate Hydrate, 1486
 Prunella Spike, 1951
 Pueraria Root, 1952
 Pullulan, 1487
 Capsules, 574

Purified
 Dehydrocholic Acid, 772
 Gelatin, 980
 Lanolin, 1904
 Shellac, 1551
 Sodium Hyaluronate, 1575
 Sodium Hyaluronate Injection, 1576
 Sodium Hyaluronate Ophthalmic Solution, 1577
 Water, 1773
 Water in Containers, 1774
 Pyrantel Pamoate, 1487
 Pyrazinamide, 1488
 Pyridostigmine Bromide, 1489
 Pyridoxine Hydrochloride, 1489
 Injection, 1490
 Pyroxylin, 1491
 Pyrrolnitrin, 1491

Q

Quercus Bark, 1952
 Quetiapine Fumarate, 1492
 Fine Granules, 1493
 Tablets, 1494
 Quick Lime, 554
 Quinapril Hydrochloride, 1496
 Tablets, 1497
 Quinidine Sulfate Hydrate, 1498
 Quinine
 Ethyl Carbonate, 1499
 Hydrochloride Hydrate, 1500
 Sulfate Hydrate, 1501

R

Rabeprazole Sodium, 1502
 Ranitidine Hydrochloride, 1503
 Rape Seed Oil, 1953
 Rebamipide, 1504
 Tablets, 1506
 Red Ginseng, 1953
 Rehmannia Root, 1954
 Reserpine, 1507
 Injection, 1508
 Powder, 1508
 Powder, 0.1%, 1508
 Tablets, 1509
 Retinol
 Acetate, 1510
 Palmitate, 1510
 Rhubarb, 1955
 and Senna Powder, Compound, 1957
 Powdered, 1956
 Ribavirin, 1511
 Capsules, 1512
 Riboflavin, 1513
 Butyrate, 1514
 Phosphate, 1515
 Phosphate Injection, 1516
 Powder, 1514
 Sodium Phosphate, 1515
 Sodium Phosphate Injection, 1516
 Ribostamycin Sulfate, 1517
 Rice Starch, 1603

Rifampicin, 1518
 Capsules, 1519
 Rikkunshito Extract, 1957
 Ringer's Solution, 1520
 Risperidone, 1521
 Fine Granules, 1522
 Oral Solution, 1523
 Tablets, 1524
 Ritodrine Hydrochloride, 1525
 Tablets, 1526
 Rokitamycin, 1528
 Tablets, 1529
 Rose Fruit, 1959
 Powdered, 1960
 Rosin, 1960
 Roxatidine Acetate Hydrochloride, 1530
 Extended-release Capsules, 1531
 Extended-release Tablets, 1532
 for Injection, 1533
 Roxithromycin, 1534
 Royal Jelly, 1960
 Ryokejutsukanto Extract, 1961

S

Saccharated Pepsin, 1535
 Saccharin, 1535
 Sodium, 1536
 Sodium Hydrate, 1536
 Safflower, 1962
 Saffron, 1963
 Saibokuto Extract, 1963
 Saikoishito Extract, 1965
 Saireito Extract, 1968
 Salazosulfapyridine, 1537
 Salbutamol Sulfate, 1538
 Salicylated Alum Powder, 1542
 Salicylic Acid, 1539
 Adhesive Plaster, 1540
 Spirit, 1540
 Spirit, Compound, 1541
 Salvia Miltiorrhiza Root, 1971
 Santonin, 1542
 Saponated Cresol Solution, 757
 Saposhnikovia Root and Rhizome, 1971
 Sappan Wood, 1972
 Sarpogrelate Hydrochloride, 1543
 Fine Granules, 1544
 Tablets, 1545
 Saussurea Root, 1972
 Schisandra Fruit, 1973
 Schizonepeta Spike, 1973
 Scopolamine
 Butylbromide, 1547
 Hydrobromide Hydrate, 1548
 Scopolia
 Extract, 1974
 Extract and Carbon Powder, 1976
 Extract and Ethyl Aminobenzoate Powder, 1976
 Extract and Tannic Acid Suppositories, 1978
 Extract, Papaverine and Ethyl Aminobenzoate Powder, 1977
 Extract Powder, 1975

Rhizome, 1973
 Scutellaria Root, 1978
 Powdered, 1979
 Senega, 1980
 Powdered, 1981
 Syrup, 1981
 Senna Leaf, 1981
 Powdered, 1982
 L-Serine, 1548
 Serrapeptase, 1549
 Sesame, 1983
 Oil, 1984
 Sevoflurane, 1550
 Shakuyakukanzoto Extract, 1984
 Shellac
 Purified, 1551
 White, 1552
 Shimbuto Extract, 1985
 Shosaikoto Extract, 1988
 Shoseiryuto Extract, 1990
 Silodosin, 1553
 Tablets, 1555
 Silver
 Nitrate, 1557
 Nitrate Ophthalmic Solution, 1557
 Protein, 1557
 Protein Solution, 1558
 Simple
 Ointment, 1993
 Syrup, 1558
 Simvastatin, 1559
 Tablets, 1560
 Sinomenium Stem and Rhizome, 1993
 Sivelestat Sodium
 for Injection, 1562
 Hydrate, 1561
 Slaked Lime, 553
 Smilax Rhizome, 1993
 Powdered, 1993
 Sodium
 Acetate Hydrate, 1563
 Aurothiomalate, 1564
 Benzoate, 1565
 Bicarbonate, 1566
 Bicarbonate and Bitter Tincture Mixture, 1994
 Bicarbonate Injection, 1566
 Bisulfite, 1567
 Borate, 1567
 Bromide, 1568
 Carbonate Hydrate, 1569
 Chloride, 1569
 Chloride Injection, 0.9%, 1571
 Chloride Injection, 10%, 1570
 Chromate (^{51}Cr) Injection, 1571
 Citrate Hydrate, 1571
 Citrate Injection for Transfusion, 1572
 Cromoglicate, 1573
 Fusidate, 1574
 Hyaluronate, Purified, 1575
 Hyaluronate Injection, Purified, 1576
 Hyaluronate Ophthalmic Solution, Purified, 1577
 Hydrogen Carbonate, 1566

Hydrogen Sulfite, 1567
 Hydroxide, 1578
 Iodide, 1579
 Iodide (^{123}I) Capsules, 1579
 Iodide (^{131}I) Capsules, 1580
 Iodide (^{131}I) Solution, 1580
 Iodohippurate (^{131}I) Injection, 1580
 Iotalamate Injection, 1580
 L-Lactate Ringer's Solution, 1582
 L-Lactate Solution, 1581
 Lauryl Sulfate, 1584
 Metabisulfite, 1587
 Pertechnetate (^{99m}Tc) Injection, 1585
 Picosulfate Hydrate, 1585
 Polystyrene Sulfonate, 1586
 Pyrosulfite, 1587
 Risedronate Hydrate, 1588
 Risedronate Tablets, 1589
 Salicylate, 1590
 Starch Glycolate, 1591
 Sulfate Hydrate, 1994
 Thiosulfate Hydrate, 1592
 Thiosulfate Injection, 1593
 Valproate, 1593
 Valproate Syrup, 1594
 Valproate Tablets, 1594
Solution
 Adrenaline, 380
 Alum, 401
 Benzalkonium Chloride, 480
 Benzethonium Chloride, 482
 Butenafine Hydrochloride, 538
 Chlorhexidine Gluconate, 682
 Compound Thianthol and Salicylic Acid, 1679
 Cresol, 756
 Dental Sodium Hypochlorite, 436
 Diagnostic Sodium Citrate, 1572
 Epinephrine, 380
 Glycerin and Potash, 994
 Isotonic Salt, 1571
 Isotonic Sodium Chloride, 1571
 Ketoconazole, 1123
 Merbromin, 1217
 Mercurochrome, 1217
 Naphazoline and Chlorpheniramine, 1290
 Pravastatin Sodium, 1447
 Ringer's, 1520
 Risperidone Oral, 1523
 Saponated Cresol, 757
 Silver Protein, 1558
 Sodium Iodide (^{131}I), 1580
 Sodium L-Lactate, 1581
 Sodium L-Lactate Ringer's, 1582
 D-Sorbitol, 1597
 Terbinafine Hydrochloride, 1664
 Tolnaftate, 1705
 Sophora Root, 1995
 Powdered, 1995
 Sorbitan Sesquioleate, 1595
 D-Sorbitol, 1596
 Solution, 1597
 Soybean Oil, 1995
 Spectinomycin Hydrochloride for Injection, 1598

Hydrate, 1597
 Spiramycin Acetate, 1599
Spirit
 Capsicum and Salicylic Acid, 1824
 Compound Methyl Salicylate, 1238
 Compound Salicylic Acid, 1541
 Foeniculated Ammonia, 1852
 Iodine, Salicylic Acid and Phenol, 1079
 Salicylic Acid, 1540
 Spironolactone, 1600
 Tablets, 1600
Spray
 Butenafine Hydrochloride, 538
 Terbinafine Hydrochloride, 1665
Starch
 Corn, 1601
 Potato, 1602
 Rice, 1603
 Wheat, 1604
 Stearic Acid, 1606
 Stearyl Alcohol, 1607
Sterile
 Purified Water in Containers, 1774
 Water for Injection in Containers, 1775
 Streptomycin Sulfate, 1608
 for Injection, 1609
 Sucralfate Hydrate, 1609
 Sucrose, 1611
 Sulbactam Sodium, 1612
 Sulbenicillin Sodium, 1613
 Sulfadiazine Silver, 1614
 Sulfafurazole, 1617
 Sulfamethizole, 1615
 Sulfamethoxazole, 1616
 Sulfamonomethoxine Hydrate, 1616
 Sulfasalazine, 1537
 Sulfisomezole, 1616
 Sulfisoxazole, 1617
 Sulfobromophthalein Sodium, 1618
 Injection, 1619
 Sulfur, 1619
 and Camphor Lotion, 1619
 , Salicylic Acid and Thianthol Ointment, 1620
 Sulindac, 1620
 Sulpiride, 1621
 Capsules, 1621
 Tablets, 1622
 Sulpyrine
 Hydrate, 1623
 Injection, 1623
 Sultamicillin Tosilate
 Hydrate, 1624
 Tablets, 1625
 Sultame, 1626
Suppositories
 Bisacodyl, 512
 Indometacin, 1064
 Scopolia Extract and Tannic Acid, 1978
 Suxamethonium Chloride
 for Injection, 1628
 Hydrate, 1627
 Injection, 1628
 Sweet Hydrangea Leaf, 1996

Powdered, 1996
Swertia
 and Sodium Bicarbonate Powder, 1998
 Herb, 1996
 Herb, Powdered, 1997
Synthetic Aluminum Silicate, 405
Syrup
 Aciclovir, 372
 Aciclovir for, 373
 Amphotericin B, 428
 Cefadroxil for, 599
 Cefalexin for, 603
 Cefatrizine Propylene Glycolate for, 606
 Cefpodoxime Proxetil for, 646
 Cefroxadine for, 649
 Faropenem Sodium for, 920
 Fosfomycin Calcium for, 963
 Ipecac, 1882
 Monosodium Trichloroethyl Phosphate, 1726
 Orange Peel, 1926
 Pemirolast Potassium for, 1374
 Senega, 1981
 Simple, 1558
 Sodium Valproate, 1594
 Tranilast for, 1715
 Triclofos Sodium, 1726

T

Tablets
 Acemetacin, 362
 Acetylsalicylic Acid, 450
 Aciclovir, 374
 Ajmaline, 382
 Alacepril, 383
 Aldioxa, 387
 Alendronate Sodium, 390
 Allopurinol, 392
 Alminoprofen, 394
 Amiodarone Hydrochloride, 412
 Amitriptyline Hydrochloride, 414
 Amlexanox, 416
 Amlodipine Besilate, 420
 Amlodipine Besilate Orally Disintegrating, 418
 Amosulalol Hydrochloride, 422
 Amphotericin B, 428
 Ascorbic Acid and Calcium Pantothenate, 447
 Aspirin, 450
 Atorvastatin Calcium, 454
 Auranofin, 458
 Azathioprine, 460
 Azelnidipine, 464
 Baclofen, 470
 Benidipine Hydrochloride, 476
 Bepotastine Besilate, 489
 Beraprost Sodium, 492
 Betahistine Mesilate, 496
 Betamethasone, 498
 Bezafibrate Extended-release, 508
 Bisoprolol Fumarate, 515
 Brotizolam, 524
 Bucillamine, 526

Buformin Hydrochloride, 531
 Buformin Hydrochloride Delayed-release, 529
 Cadralazine, 542
 Candesartan Cilexetil, 566
 Candesartan Cilexetil and Amlodipine Besylate, 567
 Candesartan Cilexetil and Hydrochlorothiazide, 570
 L-Carbocisteine, 579
 Carvedilol, 590
 Cefcapene Pivoxil Hydrochloride, 614
 Cefditoren Pivoxil, 620
 Cefpodoxime Proxetil, 647
 Ceferam Pivoxil, 656
 Cetirizine Hydrochloride, 672
 Chlordiazepoxide, 681
 Chlorphenesin Carbamate, 686
 Chlorpheniramine Maleate, 690
 Chlorpromazine Hydrochloride, 693
 Chlorpropamide, 695
 Cibenzoline Succinate, 698
 Cilazapril, 703
 Cilnidipine, 705
 Cilostazol, 708
 Clarithromycin, 719
 Clomifene Citrate, 731
 Clonazepam, 733
 Clopidogrel Sulfate, 738
 Codeine Phosphate, 748
 Colestipide, 752
 Cyclophosphamide, 762
 Diazepam, 784
 Dichlorphenamide, 789
 Diclofenamide, 789
 Diethylcarbamazine Citrate, 790
 Digitoxin, 795
 Digoxin, 798
 Dimenhydrinate, 809
 Diphenylhydantoin, 1397
 Distigmine Bromide, 819
 Donepezil Hydrochloride, 827
 Doxazosin Mesilate, 834
 Doxycycline Hydrochloride, 840
 Dydrogesterone, 845
 Ebastine, 847
 Ebastine Orally Disintegrating, 846
 Emorazole, 859
 Enalapril Maleate, 861
 Epalrestat, 866
 Ephedrine Hydrochloride, 870
 Eplerenone, 875
 Ergometrine Maleate, 884
 Erythromycin Delayed-release, 886
 Estriol, 892
 Etacrynic Acid, 893
 Ethinylestradiol, 899
 Etidronate Disodium, 908
 Etilefrine Hydrochloride, 909
 Etizolam, 912
 Famotidine, 919
 Faropenem Sodium, 921
 Fexofenadine Hydrochloride, 927
 Flecainide Acetate, 935
 Flutoprazepam, 955
 Fluvoxamine Maleate, 958
 Folic Acid, 960
 Fudosteine, 969
 Furosemide, 972
 Glimepiride, 986
 Haloperidol, 1006
 Hydralazine Hydrochloride, 1022
 Ifenprodil Tartrate, 1051
 Imidapril Hydrochloride, 1053
 Imipramine Hydrochloride, 1057
 Indapamide, 1059
 Ipriflavone, 1088
 Irsogladine Maleate, 1091
 Isoniazid, 1101
 Isosorbide Dinitrate, 1105
 Isosorbide Mononitrate, 1107
 Isoxsuprime Hydrochloride, 1109
 Josamycin, 1113
 Labetalol Hydrochloride, 1130
 Lafutidine, 1136
 Lanatoside C, 1138
 Lansoprazole Delayed-release Orally Disintegrating, 1141
 Levofloxacin, 1157
 Levothyroxine Sodium, 1160
 Lithyronine Sodium, 1166
 Lisinopril, 1168
 Losartan Potassium, 1173
 Losartan Potassium and Hydrochlorothiazide, 1174
 Loxoprofen Sodium, 1178
 Manidipine Hydrochloride, 1193
 Mecobalamin, 1198
 Mefruside, 1205
 Mequitazine, 1215
 Metformin Hydrochloride, 1223
 Methyldopa, 1230
 Methylergometrine Maleate, 1233
 Methyltestosterone, 1240
 Metoclopramide, 1243
 Metoprolol Tartrate, 1245
 Metronidazole, 1246
 Minocycline Hydrochloride, 1256
 Mitiglinide Calcium, 1259
 Mizoribine, 1263
 Montelukast Sodium, 1269
 Montelukast Sodium Chewable, 1267
 Morphine Hydrochloride, 1272
 Mosapride Citrate, 1277
 Nabumetone, 1282
 Naftopidil, 1286
 Naftopidil Orally Disintegrating, 1285
 Nateglinide, 1295
 Nicergoline, 1302
 Nicomol, 1304
 Nilvadipine, 1313
 Nitrendipine, 1315
 Nitroglycerin, 1317
 Norgestrel and Ethinylestradiol, 1324
 Olmesartan Medoxomil, 1330
 Olopatadine Hydrochloride, 1333
 Omeprazole Delayed-release, 1335
 Paroxetine Hydrochloride, 1371
 Pemirolast Potassium, 1375

Tablets (continued)

- Perphenazine, 1382
 Perphenazine Maleate, 1383
 Phenytoin, 1397
 Pilocarpine Hydrochloride, 1400
 Pioglitazone Hydrochloride, 1407
 Pioglitazone Hydrochloride and Glimepiride, 1408
 Pioglitazone Hydrochloride and Metformin Hydrochloride, 1411
 Piperazine Phosphate, 1419
 Pitavastatin Calcium, 1425
 Pivmecillinam Hydrochloride, 1428
 Pravastatin Sodium, 1448
 Prazepam, 1450
 Precipitated Calcium Carbonate, 549
 Prednisolone, 1453
 Probencid, 1459
 Probuclol, 1462
 Procainamide Hydrochloride, 1463
 Prochlorperazine Maleate, 1468
 Propafenone Hydrochloride, 1474
 Propiverine Hydrochloride, 1477
 Propranolol Hydrochloride, 1479
 Propylthiouracil, 1482
 Quetiapine Fumarate, 1494
 Quinapril Hydrochloride, 1497
 Rebamipide, 1506
 Reserpine, 1509
 Risperidone, 1524
 Ritodrine Hydrochloride, 1526
 Rokitamycin, 1529
 Roxatidine Acetate Hydrochloride Extended-release, 1532
 Sarpogrelate Hydrochloride, 1545
 Silodosin, 1555
 Simvastatin, 1560
 Sodium Risedronate, 1589
 Sodium Valproate, 1594
 Spironolactone, 1600
 Sulpiride, 1622
 Sultamicillin Tosilate, 1625
 Taltirelin, 1638
 Taltirelin Orally Disintegrating, 1637
 Tamsulosin Hydrochloride Extended-release, 1642
 Telmisartan, 1657
 Temocapril Hydrochloride, 1659
 Terbinafine Hydrochloride, 1665
 Thiamazole, 1673
 Tiapride Hydrochloride, 1685
 Tiaramide Hydrochloride, 1686
 Ticlopidine Hydrochloride, 1688
 Tipepidine Hibenzate, 1692
 Tolbutamide, 1703
 Tosufoxacin Tosilate, 1707
 Tranexamic Acid, 1711
 Trichlormethiazide, 1722
 Trihexyphenidyl Hydrochloride, 1728
 Trimetazidine Hydrochloride, 1731
 Troxipide, 1736
 Ursodeoxycholic Acid, 1750
 Valaciclovir Hydrochloride, 1753
 Valsartan, 1756
 Verapamil Hydrochloride, 1761
 Voglibose, 1767
 Voriconazole, 1770
 Warfarin Potassium, 1772
 Zaltoprofen, 1780
 Zolpidem Tartrate, 1789
 Tacalcitol
 Hydrate, 1629
 Lotion, 1630
 Ointment, 1631
 Tacrolimus
 Capsules, 1633
 Hydrate, 1632
 Talampicillin Hydrochloride, 1633
 Talc, 1634
 Taltirelin
 Hydrate, 1636
 Orally Disintegrating Tablets, 1637
 Tablets, 1638
 Tamoxifen Citrate, 1640
 Tamsulosin Hydrochloride, 1640 Extended-release Tablets, 1642
 Tannic Acid, 1643
 Tartaric Acid, 1643
 Taurine, 1643
 Tazobactam, 1644 and Piperacillin for Injection, 1645
 Teceleukin
 for Injection (Genetical Recombination), 1652
 (Genetical Recombination), 1647
 Tegafur, 1653
 Teicoplanin, 1654
 Telmisartan, 1656
 Tablets, 1657
 Temocapril Hydrochloride, 1658
 Tablets, 1659
 Teprenone, 1660
 Capsules, 1661
 Terbinafine Hydrochloride, 1662
 Cream, 1663
 Solution, 1664
 Spray, 1665
 Tablets, 1665
 Terbutaline Sulfate, 1666
 Testosterone
 Enanthate, 1667
 Enanthate Injection, 1668
 Propionate, 1668
 Propionate Injection, 1669
 Tetracaine Hydrochloride, 1670
 Tetracycline Hydrochloride, 1670
 Thallium (²⁰¹Tl) Chloride Injection, 1672
 Theophylline, 1672
 Thiamazole, 1672
 Tablets, 1673
 Thiamine Chloride Hydrochloride, 1674
 Injection, 1675
 Powder, 1675
 Thiamine Nitrate, 1676
 Thiamylal Sodium, 1677
 for Injection, 1678
 Thianthol, 1678
 and Salicylic Acid Solution, Compound, 1679
 Thiopental Sodium, 1680
 for Injection, 1681
 Thioridazine Hydrochloride, 1681
 L-Threonine, 1682
 Thrombin, 1682
 Thymol, 1683
 Tiapride Hydrochloride, 1684
 Tablets, 1685
 Tiaramide Hydrochloride, 1685
 Tablets, 1686
 Ticlopidine Hydrochloride, 1687
 Tablets, 1688
 Timepidium Bromide Hydrate, 1689
 Timolol Maleate, 1690
Tincture
 Bitter, 1813
 Capsicum, 1824
 Iodine, 1076
 Iodine, Dilute, 1076
 Nux Vomica, 1922
 Opium, 1925
 Orange Peel, 1926
 Tinidazole, 1691
 Tipepidine Hibenzate, 1691
 Tablets, 1692
 Titanium Oxide, 1693
 Tizanidine Hydrochloride, 1694
 Toad Cake, 1998
 Tobramycin, 1695
 Injection, 1696
 Tocopherol, 1697
 Acetate, 1697
 Calcium Succinate, 1698
 Nicotinate, 1699
dl- α -Tocopherol, 1697
 Acetate, 1697
 Nicotinate, 1699
 Todralazine Hydrochloride Hydrate, 1700
 Tofisopam, 1701
 Tokakujokito Extract, 1999
 Tokishakuyakusan Extract, 2002
 Tolazamide, 1702
 Tolbutamide, 1703
 Tablets, 1703
 Tolnaftate, 1704
 Solution, 1705
 Tolperisone Hydrochloride, 1705
 Tosufoxacin Tosilate
 Hydrate, 1706
 Tablets, 1707
 Tragacanth, 2004
 Powdered, 2004
 Tranexamic Acid, 1708
 Capsules, 1709
 Injection, 1710
 Tablets, 1711
 Tranilast, 1711
 Capsules, 1712
 Fine Granules, 1713
 for Syrup, 1715
 Ophthalmic Solution, 1714
 Trapidil, 1716
 Trehalose Hydrate, 1717
 Trepibutone, 1718
 Tretoquinol Hydrochloride, 1733
 Triamcinolone, 1718

Acetonide, 1719
 Triamterene, 1720
 Tribulus Fruit, 2005
 Trichlormethiazide, 1721
 Tablets, 1722
 Trichomycin, 1724
 Trichosanthes Root, 2005
 Triclofos Sodium, 1725
 Syrup, 1726
 Trientine Hydrochloride, 1726
 Capsules, 1727
 Trihexyphenidyl Hydrochloride, 1727
 Tablets, 1728
 Trimebutine Maleate, 1729
 Trimetazidine Hydrochloride, 1730
 Tablets, 1731
 Trimethadione, 1732
 Trimetoquinol Hydrochloride Hydrate, 1733
 Tropicamide, 1734
 Troxipide, 1735
 Fine Granules, 1735
 Tablets, 1736
 L-Tryptophan, 1737
 Tulobuterol, 1738
 Hydrochloride, 1740
 Transdermal Tape, 1739
 Turmeric, 2005
 Powdered, 2006
 Turpentine Oil, 2007
 L-Tyrosine, 1740

U

Ubenimex, 1741
 Capsules, 1742
 Ubidecarenone, 1743
 Ulinastatin, 1744
 Uncaria Hook, 2007
 Urapidil, 1746
 Urea, 1747
 Urokinase, 1747
 Ursodeoxycholic Acid, 1748
 Granules, 1749
 Tablets, 1750
 Ursodesoxycholic Acid, 1748
 Uva Ursi Fluidextract, 2008

V

Vaccine
 BCG, Freeze-dried, (for Percutaneous Use), 473
 Cholera, 696
 Diphtheria-Purified Pertussis-Tetanus Combined, Adsorbed, 816
 Hepatitis B, Adsorbed, 1018
 Influenza HA, 1065
 Inactivated Tissue Culture Rabies, Freeze-dried, 1503

Japanese Encephalitis, 1111
 Japanese Encephalitis, Freeze-dried, 1111
 Live Attenuated Measles, Freeze-dried, 1196
 Live Attenuated Mumps, Freeze-dried, 1278
 Live Attenuated Rubella, Freeze-dried, 1535
 Live Oral Poliomyelitis, 1428
 Purified Pertussis, Adsorbed, 1384
 Smallpox, Freeze-dried, 1563
 Smallpox, Freeze-dried, Prepared in Cell Culture, 1563
 Weil's Disease and Akiyami Combined, 1775
 Valaciclovir Hydrochloride, 1751
 Tablets, 1753
 L-Valine, 1754
 Valsartan, 1755
 Tablets, 1756
 Vancomycin Hydrochloride, 1757
 for Injection, 1758
 Vasopressin Injection, 1759
 Verapamil Hydrochloride, 1761
 Tablets, 1761
 Vinblastine Sulfate, 1762
 for Injection, 1763
 Vincristine Sulfate, 1764
 Vitamin A
 Acetate, 1510
 Oil, 1765
 Palmitate, 1510
 Vitamin B₁
 Hydrochloride, 1674
 Hydrochloride Injection, 1675
 Hydrochloride Powder, 1675
 Nitrate, 1676
 Vitamin B₂, 1513
 Phosphate Ester, 1515
 Phosphate Ester Injection, 1516
 Powder, 1514
 Vitamin B₆, 1489
 Injection, 1490
 Vitamin B₁₂, 760
 Injection, 761
 Vitamin C, 445
 Injection, 446
 Powder, 446
 Vitamin D₂, 882
 Vitamin D₃, 696
 Vitamin E, 1697
 Acetate, 1697
 Calcium Succinate, 1698
 Nicotinate, 1699
 Vitamin K₁, 1398
 Voglibose, 1766
 Tablets, 1767
 Voriconazole, 1769
 Tablets, 1770

W

Warfarin Potassium, 1771
 Tablets, 1772
 Water, 1773
 for Injection, 1774
 for Injection in Containers, Sterile, 1775
 in Containers, Purified, 1774
 in Containers, Sterile Purified, 1774
 Purified, 1773
 Weak Opium Alkaloids and Scopolamine Injection, 1340
 Weil's Disease and Akiyami Combined Vaccine, 1775
 Wheat Starch, 1604
 White
 Beeswax, 1808
 Ointment, 1775
 Petrolatum, 1386
 Shellac, 1552
 Soft Sugar, 1611
 Whole Human Blood, 1775
 Wine, 1776
 Wood Creosote, 2008

X

Xylitol, 1778
 Injection, 1778

Y

Yellow
 Beeswax, 1809
 Petrolatum, 1387
 Yokukansan Extract, 2010

Z

Zaltoprofen, 1780
 Tablets, 1780
 Zedoary, 2012
 Zidovudine, 1781
 Zinc
 Chloride, 1783
 Oxide, 1783
 Oxide Oil, 1784
 Oxide Ointment, 1784
 Oxide Starch Powder, 1785
 Sulfate Hydrate, 1785
 Sulfate Ophthalmic Solution, 1785
 Zinostatin Stimalamer, 1786
 Zolpidem Tartrate, 1788
 Tablets, 1789

INDEX IN LATIN NAME

A

Achyranthis Radix, 1792
Aconiti Radix Processa, 1948
Radix Processa et Pulverata, 1949
Adeps Lanae Purificatus, 1904
Suillus, 1905
Agar, 1792
Pulveratum, 1793
Akebiae Caulis, 1793
Alismatis Tuber, 1793
Tuber Pulveratum, 1794
Aloe, 1794
Pulverata, 1795
Alpiniae Fructus, 1812
Officinari Rhizoma, 1796
Amomi Semen, 1797
Semen Pulveratum, 1797
Anemarrhenae Rhizoma, 1797
Angelicae Acutilobae Radix, 1883
Acutilobae Radix Pulverata, 1883
Dahuricae Radix, 1798
Apilac, 1960
Araliae Cordatae Rhizoma, 1800
Arctii Fructus, 1821
Arecae Semen, 1800
Armeniacae Semen, 1798
Artemisiae Capillaris Flos, 1800
Folium, 1801
Asiasari Radix, 1801
Asparagi Radix, 1802
Astragali Radix, 1803
Atractylosis Lanceae Rhizoma, 1803
Lanceae Rhizoma Pulveratum, 1804
Rhizoma, 1804
Rhizoma Pulveratum, 1805
Aurantii Fructus Immaturus, 1880
Pericarpium, 1812

B

Belladonnae Radix, 1809
Benincasae Semen, 1811
Benzoinum, 1812
Bezoar Bovis, 1928
Bufonis Crustum, 1998
Bupleuri Radix, 1820

C

Calumbae Radix, 1821
Radix Pulverata, 1822
Cannabis Fructus, 1876
Capsici Fructus, 1822
Fructus Pulveratus, 1823
Cardamomi Fructus, 1825
Carthami Flos, 1962
Caryophylli Flos, 1833

Flos Pulveratus, 1833
Cassiae Semen, 1825
Catalpae Fructus, 1826
Cera Alba, 1808
Carnauba, 1825
Flava, 1809
Chrysanthemi Flos, 1829
Cimicifugae Rhizoma, 1830
Cinnamomi Cortex, 1830
Cortex Pulveratus, 1831
Cistanchis Herba, 1831
Citri Unshiu Pericarpium, 1832
Clematidis Radix, 1833
Cnidii Monnieris Fructus, 1834
Rhizoma, 1835
Rhizoma Pulveratum, 1835
Codonopsis Radix, 1835
Coicis Semen, 1836
Semen Pulveratum, 1836
Condurango Cortex, 1836
Coptidis Rhizoma, 1837
Rhizoma Pulveratum, 1838
Corni Fructus, 1839
Corydalis Tuber, 1840
Tuber Pulveratum, 1841
Crataegi Fructus, 1842
Creosotum Ligni, 2008
Crocus, 1963
Curcumae Rhizoma, 2005
Rhizoma Purveratum, 2006
Cyperi Rhizoma, 1842
Rhizoma Pulveratum, 1843

D

Digenea, 1846
Dioscoreae Rhizoma, 1847
Rhizoma Pulveratum, 1847
Dolichi Semen, 1848

E

Eleutherococci senticosi Rhizoma, 1848

Ephedrae Herba, 1849
Epimedii Herba, 1850
Eriobotryae Folium, 1909
Eucommiae Cortex, 1851
Euodiae Fructus, 1851

F

Fel Ursi, 1807
Foeniculi Fructus, 1851
Fructus Pulveratus, 1852
Forsythiae Fructus, 1852
Fossilia Ossis Mastodi, 1907
Ossis Mastodi Pulveratum, 1908
Fritillariae Bulbus, 1853
Fructus Hordei Germinatus, 1912

G

Gambir, 1853
Pulveratum, 1853
Gardeniae Fructus, 1854
Fructus Pulveratus, 1854
Gastrodiae Tuber, 1855
Gentianae Radix, 1856
Radix Pulverata, 1856
Scabrae Radix, 1884
Scabrae Radix Pulverata, 1884
Geranii Herba, 1857
Herba Pulverata, 1857
Ginseng Radix, 1859
Radix Pulverata, 1860
Radix Rubra, 1953
Glehniae Radix cum Rhizoma, 1861
Glycyrrhizae Radix, 1862
Radix Praeparata, 1947
Radix Pulverata, 1863
Gummi Arabicum, 1791
Arabicum Pulveratum, 1791
Gypsum Exsiccatum, 1868
Fibrosum, 1868

H

Hedysari Radix, 1875
Houttuyniae Herba, 1880
Hydrangeae Dulcis Folium, 1996
Dulcis Folium Pulveratum, 1996

I

Imperatae Rhizoma, 1880
Ipecacuanhae Radix, 1881
Radix Pulverata, 1881

K

Kasseki, 1796
Koi, 1903

L

Leonuri Herba, 1905
Lili Bulbus, 1906
Linderae Radix, 1906
Lithospermi Radix, 1907
Longan Arillus, 1907
Lonicerae Folium Cum Caulis, 1908
Lycii Cortex, 1909
Fructus, 1909

M

Magnoliae Cortex, 1910
Cortex Pulveratus, 1910
Flos, 1911

Malloti Cortex, 1911
Mel, 1879
Menthae Herba, 1914
Mori Cortex, 1918
Moutan Cortex, 1915
Cortex Pulveratus, 1916
Myristicae Semen, 1920

N

Nelumbis Semen, 1919
Notopterygii Rhizoma, 1919
Nupharis Rhizoma, 1919

O

Oleum Arachidis, 1935
Aurantii, 1925
Cacao, 1821
Camelliae, 1822
Caryophylli, 1834
Cinnamomi, 1831
Cocois, 1835
Eucalypti, 1850
Foeniculi, 1852
Maydis, 1839
Menthae Japonicae, 1915
Olivae, 1923
Rapae, 1953
Ricini, 1826
Sesami, 1984
Sojae, 1995
Terebinthinae, 2007
Ophiopogonis Radix, 1923
Opium Pulveratum, 1924
Oryzae Fructus, 1820
Ostreae Testa, 1932
Testa Pulverata, 1932

P

Paeoniae Radix, 1935
Radix Pulverata, 1936
Panacis Japonici Rhizoma, 1932
Japonici Rhizoma Pulveratum, 1933
Perillae Herba, 1937
Persicae Semen, 1933

Semen Pulveratum, 1934
Peucedani Radix, 1937
Pharbitidis Semen, 1938
Phellodendri Cortex, 1938
Cortex Pulveratus, 1939
Picrasmae Lignum, 1941
Lignum Pulveratum, 1941
Pinelliae Tuber, 1941
Plantaginis Herba, 1942
Semen, 1942
Platycodi Radix, 1942
Radix Pulverata, 1943
Pogostemoni Herba, 1944
Polygalae Radix, 1944
Radix Pulverata, 1944
Polygonati Rhizoma, 1945
Polygoni Multiflori Radix, 1945
Polyporus, 1946
Pulveratus, 1946
Poria, 1946
Pulveratum, 1947
Prunellae Spica, 1951
Pruni Cortex, 1826
Puerariae Radix, 1952

Q

Quercus Cortex, 1952

R

Rehmanniae Radix, 1954
Resina Pini, 1960
Rhei Rhizoma, 1955
Rhizoma Pulveratum, 1956
Rosae Fructus, 1959
Fructus Pulveratus, 1960

S

Sal Mirabilis, 1994
Mirabilis Anhydricus, 1994
Salviae Miltiorrhizae Radix, 1971
Saposhnikoviae Radix, 1971
Sappan Lignum, 1972
Saussureae Radix, 1972
Schisandrae Fructus, 1973
Schizonepetae Spica, 1973

Scopoliae Rhizoma, 1973
Scutellariae Radix, 1978
Radix Pulverata, 1979
Senegae Radix, 1980
Radix Pulverata, 1981
Sennae Folium, 1981
Folium Pulveratum, 1982
Sesami Semen, 1983
Sevum Bovinum, 1808
Sinomeni Caulis et Rhizoma, 1993
Smilacis Rhizoma, 1993
Rhizoma Pulveratum, 1993
Sophorae Radix, 1995
Radix Pulverata, 1995
Strychni Semen, 1920
Swertiae Herba, 1996
Herba Pulverata, 1997

T

Tinctura Amara, 1813
Tragacantha, 2004
Pulverata, 2004
Tribuli Fructus, 2005
Trichosanthis Radix, 2005

U

Uncariae Uncis Cum Ramulus, 2007
Uvae Ursi Folium, 1807

V

Valerianae Fauriei Radix, 1884
Fauriei Radix Pulverata, 1885

Z

Zanthoxyli Piperiti Pericarpium, 1885
Piperiti Pericarpium Pulveratum, 1886
Zedoariae Rhizoma, 2012
Zingiberis Rhizoma, 1857
Rhizoma Processum, 1951
Rhizoma Pulveratum, 1858
Zizyphi Fructus, 1886
Semen, 1886

INDEX IN JAPANSE

ア

亜鉛華デンプン 1785
 亜鉛華軟膏 1784
 アカメガシワ 1911
 アクチノマイシン D 378
 アクラルビシン塩酸塩 375
 アクリノール・亜鉛華軟膏 378
 アクリノール水和物 376
 アクリノール・チング油 377
 アザチオプリン 459
 アザチオプリン錠 460
 亜酸化窒素 1318
 アシクロビル 369
 アシクロビル顆粒 370
 アシクロビル眼軟膏 372
 アシクロビル錠 374
 アシクロビルシロップ 372
 アシクロビル注射液 371
 アシクロビル軟膏 372
 アジスロマイシン水和物 465
 アジマリン 381
 アジマリン錠 382
 亜硝酸アミル 436
 アスコルビン酸 445
 アスコルビン酸・パントテン酸カルシウム錠 447
 アスコルビン酸散 446
 アスコルビン酸注射液 446
 アズトレオナム 466
 L-アスパラギン酸 449
 アスピリン 449
 アスピリンアルミニウム 450
 アスピリン錠 450
 アスピロキシシリソウ水和物 451
 アセグルタミドアルミニウム 359
 アセタゾラミド 364
 アセチルシスティン 368
 アセトアミノフェン 363
 アセトヘキサミド 366
 アセブトロール塩酸塩 359
 アセメタシン 361
 アセメタシンカプセル 361
 アセメタシン錠 362
 アゼラスチン塩酸塩 461
 アゼラスチン塩酸塩顆粒 462
 アゼルニジピン 463
 アゼルニジピン錠 464
 アセンヤク 1853
 アセンヤク末 1853
 アテノロール 452
 アトルバスタチンカルシウム錠 454
 アトルバスタチンカルシウム水和物 453
 アドレナリン 379
 アドレナリン液 380
 アドレナリン注射液 379
 アトロビン硫酸塩水和物 456
 アトロビン硫酸塩注射液 456

亜ヒ酸パスタ 445
 アプリンジン塩酸塩 437
 アプリンジン塩酸塩カプセル 438
 アフロクアロン 380
 アヘン・トコノ散 1925
 アヘンアルカロイド・アトロビン注射液 1338
 アヘンアルカロイド・スコポラミン注射液 1339
 アヘンアルカロイド塩酸塩 1336
 アヘンアルカロイド塩酸塩注射液 1337
 アヘン散 1924
 アヘンチンキ 1925
 アヘン末 1924
 アマチャ 1996
 アマチャ末 1996
 アマンタジン塩酸塩 405
 アミオダロン塩酸塩 411
 アミオダロン塩酸塩錠 412
 アミカシン硫酸塩 408
 アミカシン硫酸塩注射液 409
 アミドトリゾ酸 407
 アミドトリゾ酸ナトリウムメグルミン注射液 1207
 アミトリプチリン塩酸塩 414
 アミトリプチリン塩酸塩錠 414
 アミノ安息香酸エチル 901
 アミノフィリン水和物 410
 アミノフィリン注射液 410
 アムホテリシン B 426
 アムホテリシン B 錠 428
 アムホテリシン B シロップ 428
 アムロジピンベシル酸塩 417
 アムロジピンベシル酸塩口腔内崩壊錠 418
 アムロジピンベシル酸塩錠 420
 アモキサピン 424
 アモキシシリソウカプセル 425
 アモキシシリソウ水和物 424
 アモスラロール塩酸塩 421
 アモスラロール塩酸塩錠 422
 アモバルビタール 421
 アラセプリル 382
 アラセプリル錠 383
 L-アラニン 384
 アラビアゴム 1791
 アラビアゴム末 1791
 アリメマジン酒石酸塩 391
 亜硫酸水素ナトリウム 1567
 アルガトロバン水和物 441
 L-アルギニン 442
 L-アルギニン塩酸塩 443
 L-アルギニン塩酸塩注射液 443
 アルジオキサ 386
 アルジオキサ顆粒 387
 アルジオキサ錠 387
 アルプラゾラム 395
 アルプレノロール塩酸塩 396
 アルプロスタジル 396

アルプロスタジル アルファデクス 400

アルプロスタジル注射液 398
 アルベカシン硫酸塩 439
 アルベカシン硫酸塩注射液 440
 アルミノプロフェン 393
 アルミノプロフェン錠 394
 アレンドロン酸ナトリウム錠 390
 アレンドロン酸ナトリウム水和物 388

アレンドロン酸ナトリウム注射液 389

アロエ 1794
 アロエ末 1795
 アロチノロール塩酸塩 444
 アロブリノール 392
 アロブリノール錠 392
 安息香酸 482
 安息香酸ナトリウム 1565
 安息香酸ナトリウムカフェイン 544
 安息香酸ベンジル 484
 アンソッコウ 1812
 アンチピリン 437
 アンピシリソウ水和物 430
 アンピシリソウナトリウム 431
 アンピロキシカム 434
 アンピロキシカムカプセル 435
 アンペノニウム塩化物 406
 アンモニア・ウイキョウ精 1852
 アンモニア水 420
 アンレキサノクス 415
 アンレキサノクス錠 416

イ

イオウ 1619
 イオウ・カンフルローション 1619
 イオウ・サリチル酸・チアントール軟膏 1620
 イオタラム酸 1085
 イオタラム酸ナトリウム注射液 1580
 イオタラム酸メグルミン注射液 1206
 イオトロクス酸 1086
 イオパミドール 1083
 イオパミドール注射液 1084
 イオヘキソール 1080
 イオヘキソール注射液 1082
 イクタモール 1046
 イコサペント酸エチル 903
 イコサペント酸エチルカプセル 904
 イセパマイシン硫酸塩 1093
 イセパマイシン硫酸塩注射液 1094
 イソクスプリン塩酸塩 1108
 イソクスプリン塩酸塩錠 1109
 イソソルビド 1103
 イソニアジド 1099
 イソニアジド錠 1101
 イソニアジド注射液 1100
 イソフルラン 1094
 L-イソプレナリン塩酸塩 1102

イソプロパノール 1102
 イソプロピルアンチビリン 1103
 イソマル水和物 1098
 L-イソロイシン 1096
 イソロイシン・ロイシン・バリン顆粒
 1096
 イダルビシン塩酸塩 1046
 一硝酸イソソルビド錠 1107
 70%一硝酸イソソルビド乳糖末 1105
 イドクスウリジン 1048
 イドクスウリジン点眼液 1049
 イトロカナゾール 1110
 イフェンプロジル酒石酸塩 1050
 イフェンプロジル酒石酸塩細粒 1050
 イフェンプロジル酒石酸塩錠 1051
 イブジラスト 1042
 イブプロフェン 1043
 イブプロフェンピコノール 1044
 イブプロフェンピコノールクリーム
 1044
 イブプロフェンピコノール軟膏 1045
 イプラトロピウム臭化物水和物 1086
 イプリフラボン 1087
 イプリフラボン錠 1088
 イミダブリル塩酸塩 1052
 イミダブリル塩酸塩錠 1053
 イミプラミン塩酸塩 1057
 イミプラミン塩酸塩錠 1057
 イミペネム水和物 1054
 イルソグラジンマレイン酸塩 1090
 イルソグラジンマレイン酸塩細粒
 1090
 イルソグラジンマレイン酸塩錠 1091
 イルベサルタン 1089
 イレイセン 1833
 インジゴカルミン 1061
 インジゴカルミン注射液 1062
 インスリン グラルギン(遺伝子組換
 え) 1065
 インスリン グラルギン(遺伝子組換
 え)注射液 1067
 インスリン ヒト(遺伝子組換え)
 1068
 インスリン ヒト(遺伝子組換え)注射
 液 1070
 インダパミド 1058
 インダパミド錠 1059
 インターフェロン アルファ
 (NAMALWA) 1071
 インターフェロン アルファ
 (NAMALWA)注射液 1074
 インチンコウ 1800
 インデノロール塩酸塩 1060
 インドメタシン 1062
 インドメタシンカプセル 1063
 インドメタシン坐剤 1064
 インフルエンザ HA ワクチン 1065
 インヨウカク 1850

ウ

ウイキョウ 1851
 ウイキョウ末 1852
 ウイキョウ油 1852
 ウコン 2005
 ウコン末 2006
 ウベニメクス 1741

ウベニメクスカプセル 1742
 ウヤク 1906
 ウラビジル 1746
 ウリナスタチン 1744
 ウルソデオキシコール酸 1748
 ウルソデオキシコール酸顆粒 1749
 ウルソデオキシコール酸錠 1750
 ウロキナーゼ 1747
 ウワウルシ 1807
 ウワウルシ流エキス 2008

工

エイジツ 1959
 エイジツ末 1960
 エカベトナトリウム顆粒 849
 エカベトナトリウム水和物 849
 液状フェノール 1391
 エコチオパートヨウ化物 851
 エスタグラム 889
 エストラジオール安息香酸エステル
 889
 エストラジオール安息香酸エステル水
 性懸濁注射液 890
 エストリオール 891
 エストリオール錠 892
 エストリオール水性懸濁注射液 892
 エタクリン酸 893
 エタクリン酸錠 893
 エタノール 895
 エダラボン 851
 エダラボン注射液 852
 エタンブトール塩酸塩 894
 エチオナミド 900
 エチゾラム 910
 エチゾラム細粒 911
 エチゾラム錠 912
 エチドロン酸二ナトリウム 907
 エチドロン酸二ナトリウム錠 908
 エチニルエストラジオール 899
 エチニルエストラジオール錠 899
 L-エチルシスティン塩酸塩 902
 エチルモルヒネ塩酸塩水和物 905
 エチレフリン塩酸塩 909
 エチレフリン塩酸塩錠 909
 エチレンジアミン 903
 エデト酸カルシウムナトリウム水和物
 561
 エデト酸ナトリウム水和物 1573
 エーテル 898
 エテンザミド 897
 エトスクシミド 901
 エトドラク 913
 エトボシド 914
 エドロホニウム塩化物 853
 エドロホニウム塩化物注射液 854
 エナラブリルマレイン酸塩 860
 エナラブリルマレイン酸塩錠 861
 エノキサシン水和物 863
 エバスチン 845
 エバスチン口腔内崩壊錠 846
 エバスチン錠 847
 エパルレstatt 865
 エパルレstatt錠 866
 エピリゾール 871
 エピルビシン塩酸塩 872
 エフェドリン塩酸塩 868

エフェドリン塩酸塩散10% 870
 エフェドリン塩酸塩錠 870
 エフェドリン塩酸塩注射液 869
 エプレレノン 874
 エプレレノン錠 875
 エペリゾン塩酸塩 867
 エポエチン アルファ(遺伝子組換え)
 876
 エポエチン ベータ(遺伝子組換え)
 879
 エメダスチンフマル酸塩 857
 エメダスチンフマル酸塩徐放カプセル
 858
 エモルファゾン 858
 エモルファゾン錠 859
 エリスロマイシン 885
 エリスロマイシンエチルコハク酸エス
 テル 887
 エリスロマイシンステアリン酸塩
 888
 エリスロマイシン腸溶錠 886
 エリスロマイシンラクトビオン酸塩
 887
 エルカトニン 854
 エルゴカルシフェロール 882
 エルゴタミン酒石酸塩 884
 エルゴメトリンマレイン酸塩 883
 エルゴメトリンマレイン酸塩錠 884
 エルゴメトリンマレイン酸塩注射液
 883
 塩化亜鉛 1783
 塩化インジウム(¹¹¹In)注射液 1062
 塩化カリウム 1434
 塩化カルシウム水和物 550
 塩化カルシウム注射液 551
 塩化タリウム(²⁰¹Tl)注射液 1672
 塩化ナトリウム 1569
 10%塩化ナトリウム注射液 1570
 エンゴサク 1840
 エンゴサク末 1841
 塩酸 1023
 塩酸リモナーデ 1024
 エンビオマイシン硫酸塩 864
 エンフルラン 863

才

オウギ 1803
 オウゴン 1978
 オウゴン末 1979
 黄色ワセリン 1387
 オウセイ 1945
 オウバク 1938
 オウバク・タンナルビン・ビスマス散
 1940
 オウバク末 1939
 オウヒ 1826
 オウレン 1837
 黄連解毒湯エキス 1926
 オウレン末 1838
 オキサグラム 1343
 オキサピウムヨウ化物 1342
 オキサプロジン 1343
 オキシコドン塩酸塩水和物 1346
 オキシテトラサイクリン塩酸塩 1351
 オキシトシン 1353
 オキシトシン注射液 1355

オキシドール 1349
 オキシブロカイン塩酸塩 1345
 オキシメトロン 1351
 オキセザイン 1344
 オクスプレノロール塩酸塩 1345
 オザグレルナトリウム 1356
 オザグレルナトリウム注射液 1357
 乙字湯エキス 1929
 オフロキサシン 1328
 オメプラゾール 1334
 オメプラゾール腸溶錠 1335
 オーラノフィン 457
 オーラノフィン錠 458
 オリブ油 1923
 オルシブレナリン硫酸塩 1341
 オルメサルタン メドキソミル 1329
 オルメサルタン メドキソミル錠 1330
 オレンジ油 1925
 オロパタジン塩酸塩 1332
 オロパタジン塩酸塩錠 1333
 オンジ 1944
 オンジ末 1944

力

カイニン酸・サントニン散 1115
 カイニン酸水和物 1114
 ガイヨウ 1801
 カオリン 1120
 カカオ脂 1821
 加香ヒマシ油 1826
 カゴソウ 1951
 カシュウ 1945
 ガジュツ 2012
 加水ラノリン 1903
 ガスえそウマ抗毒素 977
 カッコウ 1944
 カッコン 1952
 葛根湯エキス 1889
 葛根湯加川芎辛夷エキス 1892
 カッセキ 1796
 過テクネチウム酸ナトリウム(^{99m}Tc)注射液 1585
 果糖 967
 果糖注射液 968
 カドララジン 541
 カドララジン錠 542
 カナマイシン一硫酸塩 1118
 カナマイシン硫酸塩 1119
 カノコソウ 1884
 カノコソウ末 1885
 カフェイン水和物 543
 カプセル 574
 カプトブリル 575
 ガベキサートメシル酸塩 974
 過マンガン酸カリウム 1438
 加味帰脾湯エキス 1895
 加味逍遙散エキス 1898
 カモスタットメシル酸塩 562
 β -ガラクトシダーゼ(アスペルギルス) 975
 β -ガラクトシダーゼ(ペニシリウム) 975
 カリジノゲナーゼ 1116
 カリ石ケン 1432
 カルシトニン サケ 545

カルテオロール塩酸塩 587
 カルナウバロウ 1825
 カルバゾクロムスルホン酸ナトリウム水和物 576

カルバマゼピン 575
 カルビドパ水和物 577
 カルベジロール 589
 カルベジロール錠 590
 L-カルボシステイン 578
 L-カルボシステイン錠 579
 カルボプラチニン 580
 カルボプラチニン注射液 582
 カルメロース 583
 カルメロースカルシウム 583
 カルメロースナトリウム 584
 カルモナムナトリウム 587
 カルモール 586
 カロコン 2005
 カンキョウ 1951
 カンゾウ 1862
 乾燥亜硫酸ナトリウム 1592
 カンゾウエキス 1863
 乾燥甲状腺 1684
 乾燥酵母 1779

乾燥細胞培養痘そうワクチン 1563
 乾燥ジフテリアウマ抗毒素 816
 乾燥弱毒生おたふくかぜワクチン 1278
 乾燥弱毒生風しんワクチン 1535
 乾燥弱毒生麻しんワクチン 1196
 乾燥水酸化アルミニウムゲル 401
 乾燥水酸化アルミニウムゲル細粒 402
 カンゾウ粗エキス 1864
 乾燥組織培養不活化狂犬病ワクチン 1503

乾燥炭酸ナトリウム 1568
 乾燥痘そうワクチン 1563
 乾燥日本脳炎ワクチン 1111
 乾燥破傷風ウマ抗毒素 1670
 乾燥はぶウマ抗毒素 1004
 乾燥BCGワクチン 473
 乾燥ボツリヌスウマ抗毒素 520
 カンゾウ末 1863
 乾燥まむしウマ抗毒素 1191

乾燥硫酸アルミニウムカリウム 403
 カンデサルタン シレキセチル 565
 カンデサルタン シレキセチル・アムロジピンベシル酸塩錠 567
 カンデサルタン シレキセチル・ヒドロクロロチアジド錠 570
 カンデサルタン シレキセチル錠 566

カンテン 1792
 カンテン末 1793
 含糖ペプシン 1535
 d-カンフル 563
 dl-カンフル 564
 肝油 745
 カンレノ酸カリウム 1433

キ
 希塩酸 1024
 キキョウ 1942
 キキョウ末 1943
 キキョウ流エキス 1943

キクカ 1829
 キササゲ 1826
 キジツ 1880
 キシリトール 1778
 キシリトール注射液 1778
 キタサマイシン 1126
 キタサマイシン酢酸エステル 1127
 キタサマイシン酒石酸塩 1128
 キナブリル塩酸塩 1496
 キナブリル塩酸塩錠 1497
 キニジン硫酸塩水和物 1498
 キニーネエチル炭酸エステル 1499
 キニーネ塩酸塩水和物 1500
 キニーネ硫酸塩水和物 1501
 牛脂 1808
 吸水クリーム 755
 キョウカツ 1919
 キョウニン 1798
 キョウニン水 1799
 希ヨードチンキ 1076
 金チオリンゴ酸ナトリウム 1564

ク

グアイフェネシン 1002
 グアバベンズ酢酸塩 1003
 グアネチジン硫酸塩 1003
 グアヤコールスルホン酸カリウム 1436
 クエチアピソフマル酸塩 1492
 クエチアピソフマル酸塩細粒 1493
 クエチアピソフマル酸塩錠 1494
 クエン酸ガリウム(⁶⁷Ga)注射液 976
 クエン酸水和物 717
 クエン酸ナトリウム水和物 1571
 クコシ 1909
 クジン 1995
 クジン末 1995
 苦味重曹水 1994
 苦味チンキ 1813
 クラブラン酸カリウム 1434
 グラミシジン 1001
 クラリスロマイシン 717
 クラリスロマイシン錠 719
 グリクラジド 984
 グリシン 995
 グリセリン 992
 グリセリンカリ液 994
 クリノフィブラート 725
 グリベンクラミド 984
 グリメピリド 985
 グリメピリド錠 986
 クリンダマイシン塩酸塩 721
 クリンダマイシン塩酸塩カプセル 722
 クリンダマイシンリン酸エステル 724

クリンダマイシンリン酸エステル注射液 725
 グルコン酸カルシウム水和物 552
 グルタチオン 991
 L-グルタミン 990
 L-グルタミン酸 989
 クレゾール 756
 クレゾール水 756
 クレゾール石ケン液 757
 クレボプリドリンゴ酸塩 720

クレマスチンフル酸塩 721
 クロカブラミン塩酸塩水和物 727
 クロキサリソナトリウム水和物
 743
 クロキサゾラム 744
 クロコナゾール塩酸塩 757
 クロスカルメロースナトリウム 585
 クロスピビドン 758
 クロチアゼパム 741
 クロトリマゾール 742
 クロナゼパム 732
 クロナゼパム細粒 733
 クロナゼパム錠 733
 クロニジン塩酸塩 734
 クロピドグレル硫酸塩 736
 クロピドグレル硫酸塩錠 738
 クロフィブロート 728
 クロフィブロートカプセル 729
 クロフェダノール塩酸塩 728
 クロベタゾールプロピオノ酸エステル
 726
 クロペラスチン塩酸塩 735
 クロミフェンクエン酸塩 730
 クロミフェンクエン酸塩錠 731
 クロミラミン塩酸塩 731
 クロム酸ナトリウム(⁵¹Cr)注射液
 1571
 クロモグリク酸ナトリウム 1573
 クロラゼプ酸二カリウム 739
 クロラゼプ酸二カリウムカプセル
 740
 クロラムフェニコール 677
 クロラムフェニコールコハク酸エステ
 ルナトリウム 678
 クロラムフェニコールパルミチン酸エ
 ステル 677
 クロルジアゼポキシド 679
 クロルジアゼポキシド散 680
 クロルジアゼポキシド錠 681
 クロルフェニラミンマレイン酸塩
 687
 d-クロルフェニラミンマレイン酸塩
 691
 クロルフェニラミンマレイン酸塩散
 689
 クロルフェニラミンマレイン酸塩錠
 690
 クロルフェニラミンマレイン酸塩注射
 液 688
 クロルフェネシンカルバミン酸エステ
 ル 685
 クロルフェネシンカルバミン酸エステ
 ル錠 686
 クロルプロパミド 694
 クロルプロパミド錠 695
 クロルプロマジン塩酸塩 692
 クロルプロマジン塩酸塩錠 693
 クロルプロマジン塩酸塩注射液 692
 クロルヘキシジン塩酸塩 683
 クロルヘキシジングルコン酸塩液
 682
 クロルマジノン酢酸エステル 684
 クロロブタノール 685

ケ

ケイガイ 1973

経口生ポリオワクチン 1428
 ケイ酸マグネシウム 1187
 軽質無水ケイ酸 1552
 軽質流動パラフィン 1365
 桂枝茯苓丸エキス 1901
 ケイヒ 1830
 ケイヒ末 1831
 ケイヒ油 1831
 ケタミン塩酸塩 1120
 結晶セルロース 664
 ケツメイシ 1825
 ケトコナゾール 1121
 ケトコナゾール液 1123
 ケトコナゾールクリーム 1122
 ケトコナゾールローション 1123
 ケトチフェンフル酸塩 1125
 ケトプロフェン 1124
 ケノデオキシコール酸 675
 ゲファルナート 977
 ケンゴシ 1938
 ゲンタマイシン硫酸塩 982
 ゲンタマイシン硫酸塩点眼液 983
 ゲンチアナ 1856
 ゲンチアナ・重曹散 1857
 ゲンチアナ末 1856
 ゲンノショウコ 1857
 ゲンノショウコ末 1857

コ

コウイ 1903
 コウカ 1962
 硬化油 1032
 コウシン 1953
 合成ケイ酸アルミニウム 405
 コウブシ 1842
 コウブシ末 1843
 コウベイ 1820
 コウボク 1910
 コウボク末 1910
 ゴオウ 1928
 コカイン塩酸塩 745
 ゴシツ 1792
 牛車腎気丸エキス 1865
 ゴシユ 1851
 コデインリン酸塩散1% 746
 コデインリン酸塩散10% 747
 コデインリン酸塩錠 748
 コデインリン酸塩水和物 746
 ゴナドリリン酢酸塩 996
 ゴボウシ 1821
 ゴマ 1983
 ゴマ油 1984
 ゴミシ 1973
 コムギデンプン 1604
 コメデンプン 1603
 コリスチンメタヌスルホン酸ナトリウ
 ム 752
 コリスチン硫酸塩 753
 コルチゾン酢酸エステル 754
 コルヒチン 749
 コレカルシフェロール 696
 コレスチミド 750
 コレスチミド顆粒 751
 コレスチミド錠 752
 コlesteroール 697
 コレラワクチン 696

コロンボ 1821
 コロンボ末 1822
 コンズランゴ 1836
 コンズランゴ流エキス 1837

サ

サイクロセリン 763
 サイコ 1820
 柴胡桂枝湯エキス 1965
 サイシン 1801
 柴朴湯エキス 1963
 柴芩湯エキス 1968
 酢酸 365
 酢酸ナトリウム水和物 1563
 サッカリン 1535
 サッカリンナトリウム水和物 1536
 サフラン 1963
 サラン粉 683
 サランミツロウ 1808
 サラゾスルファピリジン 1537
 サリチル・ミョウバン散 1542
 サリチル酸 1539
 サリチル酸精 1540
 サリチル酸ナトリウム 1590
 サリチル酸鉱創膏 1540
 サリチル酸メチル 1238
 ザルトプロフェン 1780
 ザルトプロフェン錠 1780
 サルブタモール硫酸塩 1538
 サルボグレラート塩酸塩 1543
 サルボグレラート塩酸塩細粒 1544
 サルボグレラート塩酸塩錠 1545

酸化亜鉛 1783
 酸化カルシウム 554
 酸化チタン 1693
 酸化マグネシウム 1186
 サンキライ 1993
 サンキライ末 1993
 サンザシ 1842
 三酸化二ヒ素 445
 サンシシ 1854
 サンシシ末 1854
 サンシュユ 1839
 サンショウ 1885
 サンショウ末 1886
 酸素 1350
 サンソウニン 1886
 サントニン 1542
 サンヤク 1847
 サンヤク末 1847

シ

ジアスターイゼ 782
 ジアスターイゼ・重曹散 783
 ジアゼパム 783
 ジアゼパム錠 784
 シアナミド 759
 シアノコバラミン 760
 シアノコバラミン注射液 761
 ジエチルカルバマジンクエン酸塩
 790
 ジエチルカルバマジンクエン酸塩錠
 790
 ジオウ 1954
 歯科用アンチホルミン 436

歯科用トリオジンクパスタ 1734
 歯科用パラホルムパスタ 1367
 歯科用フェノール・カンフル 1392
 歯科用ヨード・グリセリン 1078
 ジギトキシン 794
 ジギトキシン錠 795
 シクラシリン 699
 ジクロキサシリソナトリウム水和物 789
 シクロスボリン 700
 ジクロフェナクナトリウム 787
 ジクロフェナミド 787
 ジクロフェナミド錠 789
 シクロペントラート塩酸塩 761
 シクロホスファミド錠 762
 シクロホスファミド水和物 762
 シゴカ 1848
 ジゴキシン 796
 ジゴキシン錠 798
 ジゴキシン注射液 797
 ジコッピ 1909
 シコン 1907
 次硝酸ビスマス 513
 ジスチグミン臭化物 818
 ジスチグミン臭化物錠 819
 L-シスチン 766
 L-システィン 765
 L-システィン塩酸塩水和物 766
 シスプラチニン 714
 ジスルフィラム 820
 ジソピラミド 818
 シタラビン 767
 シチコリン 715
 シツリシ 2005
 ジドブジン 1781
 ジドロゲステロン 844
 ジドロゲステロン錠 845
 シノキサシン 709
 シノキサシンカプセル 710
 ジノスタチニン スチマラマー 1786
 ジノプロスト 812
 ジヒドロエルゴタミンメシル酸塩 802
 ジヒドロエルゴトキシンメシル酸塩 803
 ジヒドロデインリン酸塩 800
 ジヒドロデインリン酸塩散1% 800
 ジヒドロデインリン酸塩散10% 801
 ジピリダモール 817
 ジフェニドール塩酸塩 791
 ジフェンヒドラミン 813
 ジフェンヒドラミン・バレリル尿素散 814
 ジフェンヒドラミン・フェノール・亜鉛 華リニメント 815
 ジフェンヒドラミン塩酸塩 814
 ジブカイン塩酸塩 786
 ジフテリアトキソイド 816
 ジフテリア破傷風混合トキソイド 816
 ジフルコルトロン吉草酸エステル 793
 シプロフロキサシン 711
 シプロフロキサシン塩酸塩水和物 712
 シプロヘプタジン塩酸塩水和物 764

ジフロラゾン酢酸エステル 792
 ジベカシン硫酸塩 785
 ジベカシン硫酸塩点眼液 785
 シベレスタットナトリウム水和物 1561
 シベンゾリンコハク酸塩 697
 シベンゾリンコハク酸塩錠 698
 シメチジン 709
 ジメモルファンリン酸塩 808
 ジメルカプロール 810
 ジメルカプロール注射液 811
 ジメンヒドリナート 809
 ジメンヒドリナート錠 809
 次没食子酸ビスマス 512
 ジモルホラミン 811
 ジモルホラミン注射液 812
 シャカンゾウ 1947
 弱アヘンアルカロイド・スコポラミン 注射液 1340
 シャクヤク 1935
 萹薺甘草湯エキス 1984
 シャクヤク末 1936
 ジャショウシ 1834
 シャゼンシ 1942
 シャゼンソウ 1942
 臭化カリウム 1432
 臭化ナトリウム 1568
 十全大補湯エキス 1887
 ジュウヤク 1880
 シュクシャ 1797
 シュクシャ末 1797
 酒石酸 1643
 ショウキョウ 1857
 ショウキョウ末 1858
 小柴胡湯エキス 1988
 硝酸イソソルビド 1104
 硝酸イソソルビド錠 1105
 硝酸銀 1557
 硝酸銀点眼液 1557
 常水 1773
 ショウズク 1825
 小青竜湯エキス 1990
 焼セッコウ 1868
 消毒用エタノール 897
 消毒用フェノール 1391
 消毒用フェノール水 1392
 ショウマ 1830
 ジョサマイシン 1112
 ジョサマイシン錠 1113
 ジョサマイシンプロピオニ酸エステル 1113
 シラザブリル錠 703
 シラザブリル水和物 702
 シラスタチニンナトリウム 701
 ジラゼブ塩酸塩水和物 805
 ジルチアゼム塩酸塩 806
 ジルチアゼム塩酸塩徐放カプセル 807
 シルニジピン 704
 シルニジピン錠 705
 シロスタゾール 707
 シロスタゾール錠 708
 シロップ用アシクロビル 373
 シロップ用セファトリジンプロピレン グリコール 606
 シロップ用セファドロキシル 599
 シロップ用セファレキシン 603

シロップ用セフポドキシム プロキセチル 646
 シロップ用セフロキサジン 649
 シロップ用トラニラスト 1715
 シロップ用ファロペネムナトリウム 920
 シロップ用ペミロラストカリウム 1374
 シロップ用ホスホマイシンカルシウム 963
 シロドシン 1553
 シロドシン錠 1555
 シンイ 1911
 シンギ 1875
 親水クリーム 756
 親水ワセリン 1387
 診断用クエン酸ナトリウム液 1572
 シンバスタチン 1559
 シンバスタチン錠 1560
 真武湯エキス 1985

又

水酸化カリウム 1436
 水酸化カルシウム 553
 水酸化ナトリウム 1578
 スキサメトニウム塩化物水和物 1627
 スキサメトニウム塩化物注射液 1628
 スクラルファート水和物 1609
 スコポラミン臭化水素酸塩水和物 1548
 ステアリルアルコール 1607
 ステアリン酸 1606
 ステアリン酸カルシウム 562
 ステアリン酸ポリオキシル40 1430
 ステアリン酸マグネシウム 1188
 ストレプトマイシン硫酸塩 1608
 スピラマイシン酢酸エステル 1599
 スピロノラクトン 1600
 スピロノラクトン錠 1600
 スペクチノマイシン塩酸塩水和物 1597
 スリングダク 1620
 スルタミシリントシル酸塩錠 1625
 スルタミシリントシル酸塩水和物 1624
 スルチアム 1626
 スルバクタムナトリウム 1612
 スルピリド 1621
 スルピリドカプセル 1621
 スルピリド錠 1622
 スルピリン水和物 1623
 スルピリン注射液 1623
 スルファジアジン銀 1614
 スルファメチゾール 1615
 スルファメトキサゾール 1616
 スルファモノメトキシン水和物 1616
 スルフイソキサゾール 1617
 スルベニシリンナトリウム 1613
 スルホプロモフタレインナトリウム 1618
 スルホプロモフタレインナトリウム注射液 1619

七

成人用沈降ジフテリアトキソイド

816
 精製水 1773
 精製水(容器入り) 1774
 精製ゼラチン 980
 精製セラック 1551
 精製デヒドロコール酸 772
 精製白糖 1611
 精製ヒアルロン酸ナトリウム 1575
 精製ヒアルロン酸ナトリウム注射液 1576
 精製ヒアルロン酸ナトリウム点眼液 1577
 精製ラノリン 1904
 生理食塩液 1571
 石油ベンジン 1387
 セタノール 671
 セチリジン塩酸塩 671
 セチリジン塩酸塩錠 672
 セッコウ 1868
 セトチアミン塩酸塩水和物 673
 セトラキサート塩酸塩 674
 セネガ 1980
 セネガシロップ 1981
 セネガ末 1981
 セファクロル 592
 セファクロルカプセル 593
 セファクロル細粒 596
 セファクロル複合顆粒 594
 セファゾリンナトリウム 607
 セファゾリンナトリウム水和物 609
 セファトリジンプロピレングリコール 605
 セファドロキシル 597
 セファドロキシルカプセル 598
 セファレキシン 599
 セファレキシンカプセル 601
 セファレキシン複合顆粒 602
 セファロチンナトリウム 604
 セフィキシムカプセル 624
 セフィキシム水和物 623
 セフェピム塩酸塩水和物 621
 セフォジジムナトリウム 629
 セフォゾプラン塩酸塩 640
 セフォタキシムナトリウム 634
 セフォチアム塩酸塩 639
 セフォチアム ヘキセチル塩酸塩 637
 セフォテタン 635
 セフォペラゾンナトリウム 631
 セフカペン ピボキシル塩酸塩細粒 613
 セフカペン ピボキシル塩酸塩錠 614
 セフカペン ピボキシル塩酸塩水和物 612
 セフジトレーン ピボキシル 618
 セフジトレーン ピボキシル細粒 619
 セフジトレーン ピボキシル錠 620
 セフジニル 615
 セフジニルカプセル 617
 セフジニル細粒 617
 セフスロジンナトリウム 650
 セフタジジム水和物 652
 セフチゾキシムナトリウム 658
 セフチブテン水和物 657
 セフテラム ピボキシル 654
 セフテラム ピボキシル細粒 655

セフテラム ピボキシル錠 656
 セフトリアキソンナトリウム水和物 660
 セフビラミドナトリウム 642
 セフビロム硫酸塩 643
 セフペラゾンナトリウム 610
 セフポドキシム プロキセチル 644
 セフポドキシム プロキセチル錠 647
 セフミノクスナトリウム水和物 629
 セフメタゾールナトリウム 627
 セフメノキシム塩酸塩 625
 セフロキサジン水和物 648
 セフロキシム アキセチル 662
 セボフルラン 1550
 セラセフェート 663
 ゼラチン 978
 セラペプターゼ 1549
 L-セリン 1548
 セルモロイキン(遺伝子組換え) 668
 センキュウ 1835
 センキュウ末 1835
 ゼンコ 1937
 センコツ 1919
 センソ 1998
 センナ 1981
 センナ末 1982
 センブリ 1996
 センブリ・重曹散 1998
 センブリ末 1997

ソ
 ソウジュツ 1803
 ソウジュツ末 1804
 ソウハクヒ 1918
 ソボク 1972
 ソヨウ 1937
 ソルビタンセスキオレイン酸エステル 1595
 ソルビデム酒石酸塩 1788
 ソルビデム酒石酸塩錠 1789
 D-ソルビトール 1596
 D-ソルビトール液 1597

タ
 ダイオウ 1955
 大黄甘草湯エキス 1843
 ダイオウ末 1956
 大柴胡湯エキス 1844
 ダイズ油 1995
 タイソウ 1886
 ダウノルビシン塩酸塩 769
 タウリン 1643
 タカルシトール水和物 1629
 タカルシトール軟膏 1631
 タカルシトールローション 1630
 タクシャ 1793
 タクシャ末 1794
 タクロリムスカプセル 1633
 タクロリムス水和物 1632
 タゾバクタム 1644
 ダナゾール 768
 タムスロシン塩酸塩 1640
 タムスロシン塩酸塩徐放錠 1642
 タモキシフェンクエン酸塩 1640

タランピシリン塩酸塩 1633
 タルク 1634
 タルチレリン口腔内崩壊錠 1637
 タルチレリン錠 1638
 タルチレリン水和物 1636
 炭酸カリウム 1433
 炭酸水素ナトリウム 1566
 炭酸水素ナトリウム注射液 1566
 炭酸ナトリウム水和物 1569
 炭酸マグネシウム 1185
 炭酸リチウム 1169
 单シロップ 1558
 タンジン 1971
 ダントロレンナトリウム水和物 768
 单軟膏 1993
 タンニン酸 1643
 タンニン酸アルブミン 386
 タンニン酸ジフェンヒドラミン 815
 タンニン酸ペルベリン 494

チ

チアブリド塩酸塩 1684
 チアブリド塩酸塩錠 1685
 チアマゾール 1672
 チアマゾール錠 1673
 チアミラールナトリウム 1677
 チアミン塩化物塩酸塩 1674
 チアミン塩化物塩酸塩散 1675
 チアミン塩化物塩酸塩注射液 1675
 チアミン硝化物 1676
 チアラミド塩酸塩 1685
 チアラミド塩酸塩錠 1686
 チアントール 1678
 チオペンタールナトリウム 1680
 チオリダジン塩酸塩 1681
 チオ硫酸ナトリウム水和物 1592
 チオ硫酸ナトリウム注射液 1593
 チクセツニンジン 1932
 チクセツニンジン末 1933
 チクロピジン塩酸塩 1687
 チクロピジン塩酸塩錠 1688
 チザニジン塩酸塩 1694
 窒素 1316
 チニダゾール 1691
 チペピジンヒベンズ酸塩 1691
 チペピジンヒベンズ酸塩錠 1692
 チメピジウム臭化物水和物 1689
 チモ 1797
 チモール 1683
 チモールマレイン酸塩 1690
 注射用アシクロビル 371
 注射用アズトレオナム 467
 注射用アセチルコリン塩化物 367
 注射用アミカシン硫酸塩 409
 注射用アムホテリシンB 427
 注射用アンピシリンナトリウム 432
 注射用アンピシリンナトリウム・スルバクタムナトリウム 433
 注射用イダルビシン塩酸塩 1047
 注射用イミペネム・シラスタチンナトリウム 1056
 注射用オザグレルナトリウム 1357
 注射用シベレスタットナトリウム 1562
 注射用水 1774
 注射用水(容器入り) 1775

注射用スキサメトニウム塩化物 1628
 注射用ストレプトマイシン硫酸塩
 1609
 注射用スペクチノマイシン塩酸塩
 1598
 注射用セファゾリンナトリウム 608
 注射用セフェピム塩酸塩 622
 注射用セフォゾプラン塩酸塩 641
 注射用セフォチアム塩酸塩 640
 注射用セフォペラゾンナトリウム・ス
 ルバクタムナトリウム 632
 注射用セフタジジム 653
 注射用セフメタゾールナトリウム
 628
 注射用タゾバクタム・ピペラシリン
 1645
 注射用チアミラールナトリウム 1678
 注射用チオペンタールナトリウム
 1681
 注射用テセロイキン(遺伝子組換え)
 1652
 注射用ドキソルビシン塩酸塩 837
 注射用ドセタキセル 823
 注射用ナルトグラスチム(遺伝子組換
 え) 1293
 注射用パニペネム・ベタミプロン
 1361
 注射用パンコマイシン塩酸塩 1758
 注射用ヒト絨毛性性腺刺激ホルモン
 999
 注射用ヒドララジン塩酸塩 1022
 注射用ビペラシリンナトリウム 1418
 注射用ビンプラスチニン硫酸塩 1763
 注射用ファモチジン 917
 注射用フェニトイントナトリウム 1398
 注射用ブレドニゾロンコハク酸エステ
 ルナトリウム 1456
 注射用フロモキセフナトリウム 938
 注射用ペプロマイシン硫酸塩 1380
 注射用ベンジルペニシリンカリウム
 487
 注射用ホスホマイシンナトリウム
 965
 注射用マイトイシンC 1262
 注射用ミノサイクリン塩酸塩 1256
 注射用メロペネム 1219
 注射用ロキサチジン酢酸エステル塩酸
 塩 1533
 チョウジ 1833
 チョウジ末 1833
 チョウジ油 1834
 チョウトウコウ 2007
 釣藤散エキス 1827
 チョレイ 1946
 チョレイ末 1946
 L-チロシン 1740
 チンク油 1784
 沈降ジフテリア破傷風混合トキソイド
 816
 沈降精製百日せきジフテリア破傷風混
 合ワクチン 816
 沈降精製百日せきワクチン 1384
 沈降炭酸カルシウム 548
 沈降炭酸カルシウム細粒 548
 沈降炭酸カルシウム錠 549
 沈降破傷風トキソイド 1670
 沈降はぶトキソイド 1004

沈降B型肝炎ワクチン 1018
 チンピ 1832

ツ

ツバキ油 1822
 ツロブテロール 1738
 ツロブテロール塩酸塩 1740
 ツロブテロール経皮吸収型テープ
 1739

テ

ティコプラニン 1654
 低置換度ヒドロキシプロピルセルロー
 ス 1035
 テオフィリン 1672
 テガフル 1653
 デキサメタゾン 776
 デキストラン40 777
 デキストラン40注射液 778
 デキストラン70 779
 デキストラン硫酸エステルナトリウム
 イオウ5 780
 デキストラン硫酸エステルナトリウム
 イオウ18 780
 デキストリン 781
 デキストロメトルファン臭化水素酸塩
 水和物 782
 テストステロンエナント酸エステル
 1667
 テストステロンエナント酸エステル注
 射液 1668
 テストステロンプロピオニ酸エステル
 1668
 テストステロンプロピオニ酸エステル
 注射液 1669
 デスラノシド 775
 デスラノシド注射液 776
 テセロイキン(遺伝子組換え) 1647
 テトラカイン塩酸塩 1670
 テトラサイクリン塩酸塩 1670
 デヒドロコール酸 772
 デヒドロコール酸注射液 773
 デフェロキサミンメシル酸塩 771
 テプレノン 1660
 テプレノンカプセル 1661
 デメチルクロルテトラサイクリン塩酸
 塩 774
 テモカブリル塩酸塩 1658
 テモカブリル塩酸塩錠 1659
 テルビナフィン塩酸塩 1662
 テルビナフィン塩酸塩液 1664
 テルビナフィン塩酸塩クリーム 1663
 テルビナフィン塩酸塩錠 1665
 テルビナフィン塩酸塩スプレー 1665
 テルブタリン硫酸塩 1666
 テルミサルタン 1656
 テルミサルタン錠 1657
 テレビン油 2007
 天然ケイ酸アルミニウム 404
 デンブングリコール酸ナトリウム
 1591
 テンマ 1855
 テンモンドウ 1802

ト

桃核承気湯エキス 1999
 トウガシ 1811
 トウガラシ 1822
 トウガラシ・サリチル酸精 1824
 トウガラシチンキ 1824
 トウガラシ末 1823
 トウキ 1883
 当帰芍薬散エキス 2002
 トウキ末 1883
 トウジン 1835
 トウニン 1933
 トウニン末 1934
 トウヒ 1812
 トウヒシロップ 1926
 トウヒチンキ 1926
 トウモロコシデンプン 1601
 トウモロコシ油 1839
 ドキサゾシンメシル酸塩 833
 ドキサゾシンメシル酸塩錠 834
 ドキサラム塩酸塩水和物 832
 ドキサイクリン塩酸塩錠 840
 ドキサイクリン塩酸塩水和物 838
 ドキフルリジン 835
 ドキフルリジンカプセル 835
 ドキソルビシン塩酸塩 836
 ドクカツ 1800
 トコフェロール 1697
 トコフェロールコハク酸エステルカル
 シウム 1698
 トコフェロール酢酸エステル 1697
 トコフェロールニコチン酸エステル
 1699
 トコン 1881
 トコンシロップ 1882
 トコン末 1881
 トスフロキサシントシル酸塩錠 1707
 トスフロキサシントシル酸塩水和物
 1706
 ドセタキセル水和物 821
 ドセタキセル注射液 822
 トチュウ 1851
 トドララジン塩酸塩水和物 1700
 ドネペジル塩酸塩 825
 ドネペジル塩酸塩細粒 826
 ドネペジル塩酸塩錠 827
 ドパミン塩酸塩 829
 ドパミン塩酸塩注射液 829
 トフィソパム 1701
 ドブタミン塩酸塩 820
 トブライマイシン 1695
 トブライマイシン注射液 1696
 トランガント 2004
 トランガント末 2004
 トランザミド 1702
 トランニラスト 1711
 トランニラストカプセル 1712
 トランニラスト細粒 1713
 トランニラスト点眼液 1714
 トランネキサム酸 1708
 トランネキサム酸カプセル 1709
 トランネキサム酸錠 1711
 トランネキサム酸注射液 1710
 トランピジル 1716
 トリアムシノロン 1718

トリアムシノロンアセトニド 1719
 トリアムテレン 1720
 トリエンチン塩酸塩 1726
 トリエンチン塩酸塩カプセル 1727
 トリクロホスナトリウム 1725
 トリクロホスナトリウムシロップ
 1726
 トリクロルメチアジド 1721
 トリクロルメチアジド錠 1722
 トリコマイシン 1724
 L-トリプトファン 1737
 トリヘキシフェニジル塩酸塩 1727
 トリヘキシフェニジル塩酸塩錠 1728
 トリメタジオン 1732
 トリメタジジン塩酸塩 1730
 トリメタジジン塩酸塩錠 1731
 トリメトキノール塩酸塩水和物 1733
 トリメチチルマレイン酸塩 1729
 ドルゾラミド塩酸塩 830
 ドルゾラミド塩酸塩眼液 831
 トルナフタート 1704
 トルナフタート液 1705
 トルブタミド 1703
 トルブタミド錠 1703
 トルペリゾン塩酸塩 1705
 L-トレオニン 1682
 トレハロース水和物 1717
 トレピブトン 1718
 ドロキシドパ 842
 ドロキシドパカプセル 842
 ドロキシドパ細粒 843
 トロキシピド 1735
 トロキシピド細粒 1735
 トロキシピド錠 1736
 トロピカミド 1734
 ドロペリドール 841
 トロンビン 1682
 豚脂 1905
 ドンペリドン 824

ナ

ナイスタチン 1328
 ナタネ油 1953
 ナテグリニド 1294
 ナテグリニド錠 1295
 ナドロール 1283
 ナファゾリン・クロルフェニラミン液
 1290
 ナファゾリン塩酸塩 1289
 ナファゾリン硝酸塩 1289
 ナファモスタットメシリ酸塩 1283
 ナフトビジル 1284
 ナフトビジル口腔内崩壊錠 1285
 ナフトビジル錠 1286
 ナブメトン 1281
 ナブメトン錠 1282
 ナプロキセン 1291
 ナリジクス酸 1287
 ナルトグラスチム(遺伝子組換え)
 1291
 ナロキゾン塩酸塩 1288

ニ

ニガキ 1941
 ニガキ末 1941

ニカルジピン塩酸塩 1298
 ニカルジピン塩酸塩注射液 1299
 ニクジュヨウ 1831
 ニクズク 1920
 ニコチニ酸 1307
 ニコチニ酸アミド 1306
 ニコチニ酸注射液 1307
 ニコモール 1304
 ニコモール錠 1304
 ニコランジル 1305
 ニザチジン 1319
 ニザチジンカプセル 1320
 二酸化炭素 580
 ニセリトロール 1303
 ニセルゴリン 1300
 ニセルゴリン散 1301
 ニセルゴリン錠 1302
 ニトラゼパム 1314
 ニトレニジピン 1314
 ニトレニジピン錠 1315
 ニトログリセリン錠 1317
 ニフェジピン 1308
 ニフェジピン細粒 1311
 ニフェジピン徐放カプセル 1310
 ニフェジピン腸溶細粒 1309
 日本脳炎ワクチン 1111
 乳酸 1131
 L-乳酸 1131
 乳酸カルシウム水和物 553
 L-乳酸ナトリウム液 1581
 L-乳酸ナトリウムリンゲル液 1582
 乳糖水和物 1133
 尿素 1747
 ニルバジピン 1312
 ニルバジピン錠 1313
 ニンジン 1859
 ニンジン末 1860
 ニンドウ 1908

ネ

ネオスチグミンメチル硫酸塩 1297
 ネオスチグミンメチル硫酸塩注射液
 1297

ノ

濃グリセリン 993
 濃ベンザルコニウム塩化物液 50 480
 ノスカピン 1326
 ノスカピン塩酸塩水和物 1327
 ノルアドレナリン 1321
 ノルアドレナリン注射液 1322
 ノルエチステロン 1322
 ノルゲストレル 1324
 ノルゲストレル・エチニルエストラジ
 オール錠 1324
 ノルトリプチリン塩酸塩 1326
 ノルフロキサシン 1323

ハ

バイモ 1853
 バカンピシリソウ塩酸塩 468
 バクガ 1912
 白色セラック 1552
 白色軟膏 1775

白色ワセリン 1386
 白糖 1611
 バクモンドウ 1923
 麦門冬湯エキス 1805
 バクロフェン 470
 バクロフェン錠 470
 バシトラシン 469
 バソプレシン注射液 1759
 八味地黄丸エキス 1868
 ハチミツ 1879
 ハッカ 1914
 ハッカ水 1915
 ハッカ油 1915
 パップ用複方オウバク散 1940
 パニペネム 1359
 パパパベリン塩酸塩 1363
 パパパベリン塩酸塩注射液 1364
 ハマボウフウ 1861
 バメタン硫酸塩 471
 パラアミノサリチル酸カルシウム顆粒
 556
 パラアミノサリチル酸カルシウム水和
 物 555
 パラオキシ安息香酸エチル 906
 パラオキシ安息香酸ブチル 540
 パラオキシ安息香酸プロピル 1481
 パラオキシ安息香酸メチル 1235
 バラシクロビル塩酸塩 1751
 バラシクロビル塩酸塩錠 1753
 パラフィン 1364
 パラホルムアルデヒド 1366
 L-バリン 1754
 バルサルタン 1755
 バルサルタン錠 1756
 パルナパリンナトリウム 1367
 バルビタール 472
 バルプロ酸ナトリウム 1593
 バルプロ酸ナトリウム錠 1594
 バルプロ酸ナトリウムシロップ 1594
 バレイショデンプン 1602
 ハロキサゾラム 1008
 パロキセチン塩酸塩錠 1371
 パロキセチン塩酸塩水和物 1369
 ハロタン 1007
 ハロペリドール 1004
 ハロペリドール細粒 1005
 ハロペリドール錠 1006
 ハロペリドール注射液 1006
 パンクレアチン 1358
 パンクロニウム臭化物 1358
 ハンゲ 1941
 半夏厚朴湯エキス 1871
 半夏瀉心湯エキス 1873
 バンコマイシン塩酸塩 1757
 バンテチン 1362
 パントテン酸カルシウム 554

ヒ

ピオグリタゾン塩酸塩 1406
 ピオグリタゾン塩酸塩・グリメピリド
 錠 1408
 ピオグリタゾン塩酸塩・メトホルミン
 塩酸塩錠 1411
 ピオグリタゾン塩酸塩錠 1407
 ピオチン 510
 ピコスルファートナトリウム水和物

1585
 ピサコジル 511
 ピサコジル坐剤 512
 L-ヒスチジン 1018
 L-ヒスチジン塩酸塩水和物 1019
 ピソプロロールフマル酸塩 514
 ピソプロロールフマル酸塩錠 515
 ピタバスタチンカルシウム錠 1425
 ピタバスタチンカルシウム水和物 1424
 ビタミンA油 1765
 ヒト下垂体性性腺刺激ホルモン 999
 ヒト絨毛性性腺刺激ホルモン 997
 人全血液 1775
 人免疫グロブリン 1021
 ヒドララジン塩酸塩 1021
 ヒドララジン塩酸塩散 1022
 ヒドララジン塩酸塩錠 1022
 ヒドロキシジン塩酸塩 1036
 ヒドロキシジンパモ酸塩 1036
 ヒドロキシプロピルセルロース 1033
 ヒドロキソコバラミン酢酸塩 1033
 ヒドロクロロチアジド 1024
 ヒドロコタルニン塩酸塩水和物 1031
 ヒドロコルチゾン 1025
 ヒドロコルチゾン・ジフェンヒドラミン軟膏 1027
 ヒドロコルチゾンコハク酸エステル 1031
 ヒドロコルチゾンコハク酸エステルナトリウム 1030
 ヒドロコルチゾン酢酸エステル 1026
 ヒドロコルチゾン酪酸エステル 1028
 ヒドロコルチゾンリン酸エステルナトリウム 1028
 ピブメシリナム塩酸塩 1427
 ピブメシリナム塩酸塩錠 1428
 ヒプロメロース 1038
 ヒプロメロースカプセル 574
 ヒプロメロース酢酸エステルコハク酸エステル 1040
 ヒプロメロースタル酸エステル 1041
 ピペミド酸水和物 1414
 ピペラシリン水和物 1414
 ピペラシリンナトリウム 1416
 ピペラジンアジピン酸塩 1418
 ピペラジンリン酸塩錠 1419
 ピペラジンリン酸塩水和物 1419
 ピペリデン塩酸塩 510
 ピホナゾール 509
 ヒマシ油 1826
 ピマリシン 1404
 ヒメクロモン 1037
 ピモジド 1405
 ピャクゴウ 1906
 ピャクシ 1798
 ピャクジュツ 1804
 ピャクジュツ末 1805
 水酢酸 365
 ピラジナミド 1488
 ピラルビシン 1420
 ピランテルパモ酸塩 1487
 ピリドキシン塩酸塩 1489
 ピリドキシン塩酸塩注射液 1490
 ピリドスチグミン臭化物 1489
 ピルシカイニド塩酸塩カプセル 1402

ピレノキシン 1421
 ピレンゼピン塩酸塩水和物 1422
 ピロ亜硫酸ナトリウム 1587
 ピロカルピン塩酸塩 1399
 ピロカルピン塩酸塩錠 1400
 ピロキシカム 1423
 ピロキシリソウ 1491
 ピロールニトリン 1491
 ピワヨウ 1909
 ピンクリスチン硫酸塩 1764
 ピンドロール 1406
 ピンプラスチン硫酸塩 1762
 ピンロウジ 1800

フ

ファモチジン 915
 ファモチジン散 918
 ファモチジン錠 919
 ファモチジン注射液 915
 ファロペネムナトリウム錠 921
 ファロペネムナトリウム水和物 919
 フィトナジオン 1398
 フィルグラスチム(遺伝子組換え) 929
 フィルグラスチム(遺伝子組換え)注射液 931
 フェキソフェナジン塩酸塩 926
 フェキソフェナジン塩酸塩錠 927
 フェニトイン 1396
 フェニトイン散 1396
 フェニトイン錠 1397
 L-フェニルアラニン 1394
 フェニルブタゾン 1395
 フェニレフリン塩酸塩 1395
 フェネチシリソウカリウム 1388
 フェノバルビタール 1389
 フェノバルビタール散10% 1390
 フェノール 1390
 フェノール・亜鉛華リニメント 1392
 フェノール水 1392
 フェノールスルホンフタレイン 1393
 フェノールスルホンフタレイン注射液 1393
 フェルビナク 923
 フェルビナクテープ 924
 フェルビナクパップ 923
 フェンタニルクエン酸塩 925
 フェンブフェン 924
 複方アクリノール・チンク油 377
 複方オキシコドン・アトロピン注射液 1348
 複方オキシコドン注射液 1347
 複方サリチル酸精 1541
 複方サリチル酸メチル精 1238
 複方ジアスターゼ・重曹散 783
 複方ダイオウ・センナ散 1957
 複方チアントール・サリチル酸液 1679
 複方ビタミンB散 1765
 複方ヨード・グリセリン 1077
 複方ロートエキス・ジアスターゼ散 1976
 ブクモロール塩酸塩 527
 ブクリヨウ 1946
 ブクリヨウ末 1947

ブシ 1948
 フシジン酸ナトリウム 1574
 ブシ末 1949
 ブシラミン 525
 ブシラミン錠 526
 ブスルファン 536
 ブチルスコポラミン臭化物 1547
 ブテナフィン塩酸塩 536
 ブテナフィン塩酸塩液 538
 ブテナフィン塩酸塩クリーム 537
 ブテナフィン塩酸塩スプレー 538
 ブドウ酒 1776
 ブドウ糖 988
 ブドウ糖注射液 989
 フドステイン 968
 フドステイン錠 969
 ブトロピウム臭化物 539
 ブナゾシン塩酸塩 532
 ブピバカイン塩酸塩水和物 533
 ブフェトロール塩酸塩 528
 ブプラノロール塩酸塩 534
 ブプレノルフィン塩酸塩 535
 ブホルミン塩酸塩 529
 ブホルミン塩酸塩錠 531
 ブホルミン塩酸塩腸溶錠 529
 ブメタニド 531
 ブラジオマイシン硫酸塩 966
 ブラステロン硫酸エステルナトリウム水和物 1444
 ブラゼパム 1450
 ブラゼパム錠 1450
 ブラゾシン塩酸塩 1451
 ブラノプロフェン 1443
 ブラバスタチンナトリウム 1444
 ブラバスタチンナトリウム液 1447
 ブラバスタチンナトリウム細粒 1446
 ブラバスタチンナトリウム錠 1448
 ブラビンアデニンジスクレオチドナトリウム 932
 ブラボキサート塩酸塩 934
 ブランルカスト水和物 1442
 ブリミドン 1458
 ブルオキシメステロン 950
 ブルオシノニド 947
 ブルオシノロンアセトニド 946
 ブルオレセインナトリウム 948
 ブルオロウラシル 950
 ブルオロメトロン 949
 ブルコナゾール 940
 ブルコナゾールカプセル 941
 ブルコナゾール注射液 942
 ブルジアゼパム 944
 ブルシトシン 943
 ブルスルチアミン塩酸塩 973
 ブルタミド 954
 ブルトブラゼパム 955
 ブルトブラゼパム錠 955
 ブルドコルチゾン酢酸エステル 944
 ブルニトラゼパム 945
 ブルフェナジンエナント酸エステル 951
 ブルボキサミンマレイン酸塩 956
 ブルボキサミンマレイン酸塩錠 958
 ブルラゼパム塩酸塩 952
 ブルラン 1487
 ブルランカプセル 574

フルルビプロフェン 953
 ブレオマイシン塩酸塩 516
 ブレオマイシン硫酸塩 518
 フレカイニド酢酸塩 934
 フレカイニド酢酸塩錠 935
 プレドニゾロン 1452
 プレドニゾロンコハク酸エステル 1456
 プレドニゾロン酢酸エステル 1454
 プレドニゾロン錠 1453
 プレドニゾロンリソルビド酸エステルナトリウム 1455
 プロカインアミド塩酸塩 1462
 プロカインアミド塩酸塩錠 1463
 プロカインアミド塩酸塩注射液 1463
 プロカイン塩酸塩 1464
 プロカイン塩酸塩注射液 1465
 プロカテロール塩酸塩水和物 1466
 プロカルバジン塩酸塩 1466
 プログルミド 1470
 プロクロルペラジンマレイン酸塩 1467
 プロクロルペラジンマレイン酸塩錠 1468
 プロゲステロン 1469
 プロゲステロン注射液 1470
 フロセミド 970
 フロセミド錠 972
 フロセミド注射液 971
 プロタミン硫酸塩 1483
 プロタミン硫酸塩注射液 1484
 プロチオナミド 1484
 プロチゾラム 523
 プロチゾラム錠 524
 プロチレリン 1485
 プロチレリン酒石酸塩水和物 1486
 プロテイン銀 1557
 プロテイン銀液 1558
 プロパフェノン塩酸塩 1473
 プロパフェノン塩酸塩錠 1474
 プロパンテリン臭化物 1475
 プロビペリン塩酸塩 1476
 プロビペリン塩酸塩錠 1477
 プロピルチオウラシル 1482
 プロピルチオウラシル錠 1482
 プロピレングリコール 1480
 プロブコール 1460
 プロブコール細粒 1461
 プロブコール錠 1462
 プロプラノロール塩酸塩 1478
 プロプラノロール塩酸塩錠 1479
 フロプロピオン 939
 フロプロピオンカプセル 939
 プロベネシド 1458
 プロベネシド錠 1459
 プロマゼパム 520
 プロムヘキシン塩酸塩 521
 プロメタジン塩酸塩 1472
 フロモキセフナトリウム 936
 プロモクリプチンメシル酸塩 522
 プロモバレリル尿素 523
 L-プロリン 1471
 粉末セルロース 667

^

ベカナマイシン硫酸塩 474

ベクロメタゾンプロピオニ酸エステル 473
 ベザフィブラーート 507
 ベザフィブラーート徐放錠 508
 ベタキソロール塩酸塩 506
 ベタネコール塩化物 507
 ベタヒスチジンメシル酸塩 495
 ベタヒスチジンメシル酸塩錠 496
 ベタミプロン 505
 ベタメタゾン 497
 ベタメタゾン吉草酸エステル 502
 ベタメタゾン吉草酸エステル・ゲンタマイシン硫酸塩クリーム 502
 ベタメタゾン吉草酸エステル・ゲンタマイシン硫酸塩軟膏 504
 ベタメタゾンジプロピオニ酸エステル 499
 ベタメタゾン錠 498
 ベタメタゾンリソルビド酸エステルナトリウム 500
 ペチジン塩酸塩 1385
 ペチジン塩酸塩注射液 1385
 ベニジピン塩酸塩 475
 ベニジピン塩酸塩錠 476
 ヘパリンカルシウム 1009
 ヘパリンナトリウム 1013
 ヘパリンナトリウム注射液 1017
 ペプロマイシン硫酸塩 1379
 ペポタスチジンベシル酸塩 488
 ペポタスチジンベシル酸塩錠 489
 ペミロラストカリウム 1372
 ペミロラストカリウム錠 1375
 ペミロラストカリウム点眼液 1373
 ベラドンナエキス 1810
 ベラドンナコーン 1809
 ベラドンナ総アルカロイド 1810
 ベラパミル塩酸塩 1761
 ベラパミル塩酸塩錠 1761
 ベラプロストナトリウム 490
 ベラプロストナトリウム錠 492
 ペルフェナジン 1381
 ペルフェナジン錠 1382
 ペルフェナジンマレイン酸塩 1383
 ペルフェナジンマレイン酸塩錠 1383
 ベルベリン塩化物水和物 493
 ベンザルコニウム塩化物 479
 ベンザルコニウム塩化物液 480
 ベンジルアルコール 483
 ベンジルペニシリンカリウム 486
 ベンジルペニシリンベンザチニン水和物 485
 ヘンズ 1848
 ベンズプロマロン 481
 ベンゼトニウム塩化物 481
 ベンゼトニウム塩化物液 482
 ベンセラジド塩酸塩 478
 ペンタゾシン 1376
 ペントキシベリンクエン酸塩 1378
 ペントナイト 478
 ペントバルビタールカルシウム 1377
 ペンブトロール硫酸塩 1376

木

ボウイ 1993
 防已黃耆湯エキス 1817
 ボウコン 1880

ホウ酸 520
 ホウ砂 1567
 ボウショウ 1994
 抱水クロラール 676
 ボウフウ 1971
 防風通聖散エキス 1813
 ボクソク 1952
 ボグリボース 1766
 ボグリボース錠 1767
 ホスホマイシンカルシウム水和物 962

ホスホマイシンナトリウム 964
 ボタンピ 1915
 ボタンピ末 1916
 補中益氣湯エキス 1876
 ポビドン 1439
 ポビドンヨード 1441
 ホマトロピン臭化水素酸塩 1020
 ホミカ 1920
 ホミカエキス 1921
 ホミカエキス散 1922
 ホミカチンキ 1922
 ホモクロルシクリジン塩酸塩 1020
 ボリコナゾール 1769
 ボリコナゾール錠 1770
 ポリスチレンスルホン酸カルシウム 559
 ポリスチレンスルホン酸ナトリウム 1586
 ポリソルベート80 1430
 ホリナートカルシウム 551
 ポリミキシンB硫酸塩 1429
 ホルマリン 961
 ホルマリン水 961
 ホルモテロールフマル酸塩水和物 962

ボレイ 1932

ボレイ末 1932

マ

マイトイマイシンC 1261
 マオウ 1849
 麻黄湯エキス 1912
 マーキュロクロム 1216
 マーキュロクロム液 1217
 マクリ 1846
 マクロゴール400 1182
 マクロゴール1500 1182
 マクロゴール4000 1183
 マクロゴール6000 1183
 マクロゴール20000 1184
 マクロゴール軟膏 1184
 マシニン 1876
 麻酔用エーテル 898
 マニジピン塩酸塩 1192
 マニジピン塩酸塩錠 1193
 マプロチリン塩酸塩 1196
 マルトース水和物 1190
 D-マンニトール 1194
 D-マンニトール注射液 1195

ミ

ミグリトール 1253
 ミグレニン 1254
 ミクロノマイシン硫酸塩 1250

ミコナゾール 1249
 ミコナゾール硝酸塩 1249
 ミゾリビン 1262
 ミゾリビン錠 1263
 ミチグリニドカルシウム錠 1259
 ミチグリニドカルシウム水和物 1258
 ミツロウ 1809
 ミデカマイシン 1251
 ミデカマイシン酢酸エステル 1252
 ミノサイクリン塩酸塩 1255
 ミノサイクリン塩酸塩錠 1256
 ミョウバン水 401

ム

無コウイ大建中湯エキス 1917
 無水アンピシリソ 429
 無水エタノール 896
 無水カフェイン 543
 無水クエン酸 716
 無水乳糖 1132
 無水ボウショウウ 1994
 無水リソ酸水素カルシウム 557
 ムピロシンカルシウム水和物 1279
 ムピロシンカルシウム軟膏 1280

メ

メキシレチン塩酸塩 1248
 メキタジン 1214
 メキタジン錠 1215
 メグルミン 1206
 メクロフェノキサート塩酸塩 1197
 メコバラミン 1197
 メコバラミン錠 1198
 メストラノール 1220
 メダゼバム 1200
 メタンフェタミン塩酸塩 1223
 L-メチオニン 1224
 メチクラン 1241
 メチラボン 1247
 dl-メチルエフェドリン塩酸塩 1231
 dl-メチルエフェドリン塩酸塩散10%
 1232
 メチルエルゴメトリンマレイン酸塩
 1233
 メチルエルゴメトリンマレイン酸塩錠
 1233
 メチルジゴキシン 1242
 メチセルロース 1228
 メチルテストステロン 1239
 メチルテストステロン錠 1240
 メチルドバ錠 1230
 メチルドバ水和物 1229
 メチルプレドニゾロン 1236
 メチルプレドニゾロンコハク酸エステ
 ル 1236
 メチルベナクチジウム臭化物 1227
 メチルロザニリン塩化物 1237
 減菌精製水(容器入り) 1774
 メテノロンエナント酸エステル 1221
 メテノロンエナント酸エステル注射液
 1222
 メテノロン酢酸エステル 1220
 メトキサレン 1227
 メトクロプラミド 1243
 メトクロプラミド錠 1243

メトレキサート 1225
 メトレキサートカプセル 1225
 メトプロロール酒石酸塩 1244
 メトプロロール酒石酸塩錠 1245
 メトホルミン塩酸塩 1222
 メトホルミン塩酸塩錠 1223
 メドロキシプロゲステロン酢酸エステ
 ル 1202
 メトロニダゾール 1246
 メトロニダゾール錠 1246
 メナトレノン 1209
 メピチオスタン 1212
 メピバカイン塩酸塩 1213
 メピバカイン塩酸塩注射液 1213
 メフェナム酸 1203
 メフルシド 1204
 メフルシド錠 1205
 メフロキン塩酸塩 1203
 メペンゾラート臭化物 1211
 メルカプトプリン水和物 1215
 メルファラン 1208
 メロペネム水和物 1217
 dl-メントール 1210
 L-メントール 1211

モ

木クレオソート 2008
 モクツウ 1793
 モサブリドクエン酸塩散 1276
 モサブリドクエン酸塩錠 1277
 モサブリドクエン酸塩水和物 1275
 モッコウ 1972
 モノステアリン酸アルミニウム 402
 モノステアリン酸グリセリン 995
 モルヒネ・アトロビン注射液 1273
 モルヒネ塩酸塩錠 1272
 モルヒネ塩酸塩水和物 1270
 モルヒネ塩酸塩注射液 1271
 モルヒネ硫酸塩水和物 1274
 モンテルカストナトリウム 1264
 モンテルカストナトリウム錠 1269
 モンテルカストナトリウムチュアブル
 錠 1267

ヤ

ヤクチ 1812
 ヤクモソウ 1905
 薬用石ケン 1201
 薬用炭 1200
 ヤシ油 1835

ユ

ユウタン 1807
 ユーカリ油 1850
 輸血用クエン酸ナトリウム注射液
 1572
 ユビデカレノン 1743

ヨ

ヨウ化カリウム 1437
 ヨウ化ナトリウム 1579
 ヨウ化ナトリウム(¹²³I)カプセル
 1579

ヨウ化ナトリウム(¹³¹I)液 1580
 ヨウ化ナトリウム(¹³¹I)カプセル
 1580
 ヨウ化人血清アルブミン(¹³¹I)注射液
 1075
 ヨウ化ヒブル酸ナトリウム(¹³¹I)注射
 液 1580

葉酸 959
 葉酸錠 960
 葉酸注射液 959
 ヨウ素 1075
 ヨクイニン 1836
 ヨクイニン末 1836
 抑肝散エキス 2010
 ヨード・サリチル酸・フェノール精
 1079
 ヨードチンキ 1076
 ヨードホルム 1080

ラ

ラウリル硫酸ナトリウム 1584
 ラウロマクロゴール 1144
 ラクソロース 1134
 ラタモキセフナトリウム 1143
 ラッカセイ油 1935
 ラナトシドC 1137
 ラナトシドC錠 1138
 ラニチジン塩酸塩 1503
 ラフチジン 1135
 ラフチジン錠 1136
 ラベタロール塩酸塩 1129
 ラベタロール塩酸塩錠 1130
 ラベラゾールナトリウム 1502
 ランソプラゾール 1139
 ランソプラゾール腸溶カプセル 1140
 ランソプラゾール腸溶性口腔内崩壊錠
 1141

リ

リオチロニンナトリウム 1165
 リオチロニンナトリウム錠 1166
 リシノプリル錠 1168
 リシノプリル水和物 1167
 L-リシン塩酸塩 1180
 L-リシン酢酸塩 1179
 リスペリドン 1521
 リスペリドン細粒 1522
 リスペリドン錠 1524
 リスペリドン内服液 1523
 リセドロン酸ナトリウム錠 1589
 リセドロン酸ナトリウム水和物 1588
 リゾチーム塩酸塩 1181
 六君子湯エキス 1957
 リドカイン 1161
 リドカイン注射液 1162
 リトドリン塩酸塩 1525
 リトドリン塩酸塩錠 1526
 リバビリン 1511
 リバビリンカプセル 1512
 リファンピシン 1518
 リファンピシンカプセル 1519
 リボスママイシン硫酸塩 1517
 リボフラビン 1513
 リボフラビン散 1514
 リボフラビン酪酸エステル 1514

リボフラビンリン酸エステルナトリウム 1515
 リボフラビンリン酸エステルナトリウム注射液 1516
 リマプロスト アルファデクス 1162
 リュウガニク 1907
 リュウコツ 1907
 リュウコツ末 1908
 硫酸亜鉛水和物 1785
 硫酸亜鉛点眼液 1785
 硫酸アルミニウムカリウム水和物 403
 硫酸カリウム 1438
 硫酸鉄水和物 926
 硫酸バリウム 473
 硫酸マグネシウム水 1190
 硫酸マグネシウム水和物 1189
 硫酸マグネシウム注射液 1190
 リュウタン 1884
 リュウタン末 1884
 流動パラフィン 1365
 リューブロレリン酢酸塩 1150
 リョウキョウ 1796
 荚桂朮甘湯エキス 1961
 リンゲル液 1520
 リンコマイシン塩酸塩水和物 1164
 リンコマイシン塩酸塩注射液 1164
 リン酸水素カルシウム水和物 558
 リン酸水素ナトリウム水和物 1585
 リン酸二水素カルシウム水和物 558

レ

レセルピン 1507
 レセルピン散0.1% 1508
 レセルピン錠 1509
 レセルピン注射液 1508
 レチノール酢酸エステル 1510
 レチノールパルミチン酸エステル 1510
 レナンピシリン塩酸塩 1144
 レノグラスチム(遺伝子組換え) 1146
 レバミピド 1504
 レバミピド錠 1506
 レバロルファン酒石酸塩 1152
 レバロルファン酒石酸塩注射液 1152
 レボチロキシンナトリウム錠 1160
 レボチロキシンナトリウム水和物 1159
 レボドバ 1153
 レボフロキサシン細粒 1155
 レボフロキサシン錠 1157
 レボフロキサシン水和物 1154
 レボフロキサシン注射液 1156
 レボフロキサシン点眼液 1156
 レボメプロマジンマレイン酸塩 1159
 レンギョウ 1852
 レンニク 1919

ロ

L-ロイシン 1149
 ロキサチジン酢酸エステル塩酸塩

1530

ロキサチジン酢酸エステル塩酸塩徐放カプセル 1531
 ロキサチジン酢酸エステル塩酸塩徐放錠 1532
 ロキシスロマイシン 1534
 ロキソプロフェンナトリウム錠 1178
 ロキソプロフェンナトリウム水和物 1177
 ロキタマイシン 1528
 ロキタマイシン錠 1529
 ロサルタンカリウム 1172
 ロサルタンカリウム・ヒドロクロロチアジド錠 1174
 ロサルタンカリウム錠 1173
 ロジン 1960
 ロートエキス 1974
 ロートエキス・アネスタミン散 1976
 ロートエキス・カーボン散 1976
 ロートエキス・タンニン坐剤 1978
 ロートエキス・パパベリン・アネスタミン散 1977
 ロートエキス散 1975
 ロートコン 1973
 ロベンザリットナトリウム 1171
 ローヤルゼリー 1960
 ロラゼバム 1171

ワ

ワイル病秋やみ混合ワクチン 1775
 ワルファリンカリウム 1771
 ワルファリンカリウム錠 1772